VAERS_ID,SYMPTOM_TEXT,AGE_YRS,AGE_GROUP,ADE_LABEL,DRUG_LABEL
913745,"Fever (100.8 F), chills, body aches, headache, patient feels rapid heart rate",57.0,Adults,1,0
897442,"Overall pain; Fever; Stomach issue; This case was reported by a consumer via interactive digital media and described the occurrence of general body pain in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 9th November 2020, the patient received the 1st dose of Shingrix. In November 2020, less than a week after receiving Shingrix, the patient experienced general body pain, fever and stomach discomfort. On an unknown date, the outcome of the general body pain, fever and stomach discomfort were not recovered/not resolved.   It was unknown if the reporter considered the general body pain, fever and stomach discomfort to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age at vaccination was not reported but was captured as an adult as per vaccine indication. The patient was curious how long overall pain, fever and stomach issue might last.",,Unknown,0,0
895787,"Approx 4"" raised, red, welt around injection site.  Lasted for several days post injection.  Note:  I photographed the welt 2 days after the injection, so am happy to share if desired.  Also slight fever on day following injection (100 degrees).  Pharmacist asked me to share reaction with VAERS.",56.0,Adults,1,0
904557,Soreness at site of injection,30.0,Adults,0,0
882386,"My baby woke up having a seizure at 7:20 AM. She was sweating, she was blue and shaking with her hands by her face. Her eyes were rolling and I had to turn her on her side to calm her down. I then drove her to the ER. Spent two the first two days in the ICU. My baby had two more seizures when we arrived in the ER.",0.42,Kids,0,0
867647,"received vaccines on 3/30/20-.  Parents reported Fevers, rash and diarrhea starting  4/2/2020.  Rash was on trunk and extremities.  They were seen at an ER on 4/4/2020.  Fever ( up to 103) persisted  until into the night of 4/6 (now resolved)  but rash appeared to be fading and diarrhea continued.  They had a telehealth visit on 4/7 and an office visit on 4/8.  The visit  on 4/8 was due to worsening or change in rash parents had seen and child acting like he did not feel as well and threw up twice in the morning.  In the office on 4/8-- the rash appeared to be c/w  urticaria and responded to oral benadryl in office.  As the rash faded the child's temperament in the office improved as well.  Currently treating w/ combination of kids Zyrtec  daily and benadryl for breakthrough rash. .    Vital signs were stable and lungs were clear.",1.0,Kids,0,0
857287,"Developed a non- itchy macular red rash on her chest; This case was reported by a pharmacist via call center representative and described the occurrence of erythromacular rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced erythromacular rash. On an unknown date, the outcome of the erythromacular rash was unknown.   It was unknown if the reporter considered the erythromacular rash to be related to Shingrix.  Additional details were provided as follows: The age at administration was not reported. The patient developed a non- itchy macular red rash but stated that it was not hive located on her chest. The reporter consented to follow up.",,Unknown,1,0
893622,"The PHN came back twicw since the last booster; This case was reported by a consumer via call center representative and described the occurrence of post herpetic neuralgia in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on an unknown date). Concurrent medical conditions included hearing impaired.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced post herpetic neuralgia. On an unknown date, the outcome of the post herpetic neuralgia was unknown.   It was unknown if the reporter considered the post herpetic neuralgia to be related to Shingrix.  Additional details were reported as follows: This case was reported by the patient. The age at vaccination was not reported. The patient received Shingrix and the booster 5 years later. After receiving the last dose (booster) of Shingrix, the patient experienced post herpetic neuralgia (PHN) which came back twice since the last booster in the summer and goes away in the fall. The patient asked could I get a third booster. The patient's only concern was if Shingrix could prevent a 2nd round why could not it be used for a 3rd. After all the booster kept the PHN away for almost 5 years. The patient stated no phone call hearing impaired.",,Unknown,0,0
879092,"States the left injection site developed redness and swelling approx. size of a 50 cent piece. There is also a quarter sized whelp on the back of his left arm close to the axilla. There was a third red, raised whelp on his left side that is approx. 6 inches long and 1.5 inches wide. Has itching with these areas. Has taken Benadryl which helped with the itching, but whelps remained at the time. Provider had recommended to continue Benadryl q6h and apply cool compresses and follow up in office if no improvement by 8/12/2020.",18.0,Adults,0,0
914317,"Patient reported he started feeling funny.  Wasn't able to describe it, but that he felt funny.  His heart started racing at approx. 120 beats a minute.  It lasted about 2 minutes and then he felt ok.  He reported this to me (I was the one who gave him his shot) after the incident.",46.0,Adults,0,0
909066,"Day 1. Queasy nausea, some soreness at injection site. Day 2  runny nose, itchy throat some cough, day3  muscle cramps up into shoulder a and back. Later day 3 muscle cramps in both calfs and some nerve pain. Left side face. Day 4 bowel cramps, fatigue, congestion  and some loose stools. Day 5 symptoms subsiding.",49.0,Adults,1,0
885153,Patient reported of having chill and pain on both side of her ribcage.,78.0,Seniors,1,0
863527,"Vaccines were administered in room without complication. Staff left the room with patient safely with parents. Within 2-3 minutes after leaving the room, Mom came running out with patient in her arms asking for help. She was shaking him trying to wake him up saying she needed help. Said he just went limp in room(was not visualized by staff). Patient was limp but breathing. I asked mom to not shake him. Other staff member gently grabbed him and patient awoke upon transfer. Was acting fine and responding appropriately.",0.75,Kids,0,1
874846,"First Shangrix Shot/Dose given on 4/15/2020. No immediate side affects. Beginning on May, 2020 started experiencing all body neuropathy, pain, burning feet. Went away on it's own in 6 weeks. Received second dose on 6/20/2020. Woke the next day with a high fever, body aches, chills, and swollen glands. Lasted two days, then went into cold symptoms. By Saturday 6/27/2020, started experiencing all body neuropathy. On Monday, 6/29/2020, the neuropathy became worse and by night time, my legs were achy and fatigued, along with knee joint pain. During my sleep, I awoke with burning feet and a tremendous amount of pain. on Tuesday, 6/30/2020, I called my pharmacist to report and he told me it is a very low percentage but that gout and neuropathy were two adverse side affects of the vaccine. He advised me to call my doctor. I went to see a Nurse Practitioner, because my doctor was unavailable. She indicated she didn't know much about the vaccine and wasn't sure how to treat, other than to wait it out and see if it goes away. In the meantime, I am in excruciating pain. I never thought this vaccine would do this to me and I sure hope I don't have any long term issues with neuropathy because of this shingles vaccine.",58.0,Adults,0,0
878155,"Patient received the second dose of Prevnar-13 on July 28, 2020. He received this in the Right Vastus Lateralis.  The patient experienced significant redness and  swelling of the right thigh the  following day on July 29, 2020. The patient did not have a fever or experience any breathing difficulties.",3.0,Kids,1,0
873952,"Loca site induration (About 8 cm diameter), redness and localized pain associated with low grade fever started about 6 hours post vaccination, continued to worsen (to above size) on Day 2 and started to resolve on D3 post vaccination.",35.0,Adults,1,0
900583,"flu; so sick; Initial information was received on 27-Oct-2020 regarding an unsolicited valid non-serious social media case from a consumer via social media.  This case involves patient (unknown demography) who had flu (influenza) and was sick (illness), while the patient received INFLUENZA VACCINE.  Medical history, medical treatment(s), concomitant medications, vaccination(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious had flu (influenza) and was ""so sick"" (illness) (unknown latency) following the administration of INFLUENZA VACCINE.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of report, the outcome was unknown for the event.  There will be no information available on the batch number for this case.",,Unknown,0,1
906506,"Burning in throat, flushed face and neck. Developed stridor. Benadryl 25 mg PO given, Epinephrine 0.5mg given IM, albuterol inhaler 4 puffs. Transferred to the Emergency department and admitted to the hospital.",38.0,Adults,0,0
864301,"expired Dapacel vaccine was administered to the patient, No AE; Initial information was received on 02-Mar-2020 regarding an unsolicited valid non-serious case from a nurse.  This case is linked to cases 2020SA058732 and 2020SA058733.  This case involves a 22 months old male patient who was vaccinated with 0.5 ml fourth dose of expired vaccine DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL] (lot number: C5611BA and expiry date: 07-Feb-2020) via intramuscular route in the left arm on 17-Feb-2020 for prophylactic vaccination (PT Expired product administered).  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant vaccination included INFLUENZA VACCINE INACT SPLIT VIRION 4V (FLUZONE QUADRIVALENT).  It was actual medication error due to expired vaccine used.  At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",1.83,Kids,0,1
888630,Patient reported a dusty red color wityh swelling and hardness at injection site 2 days post immunization. Patient is a physician herself and believes that the injection site is infected.,50.0,Adults,0,0
855893,Pt. C/O pain Next day From vaccine. State excruciating pain for 20+ days. Pt. complained of excruciating pain in (L) Deltoid after receiving her flu vaccine. Pt C/O pain for 15-20 days - which has improved throughout that time. Pt now states she has some slight pain at injection site.,61.0,Adults,0,0
913327,"Swelling, pain, and heat at injection site beginning last night (12/29/20) around 9:00 pm.   Woke this morning with same plus very swollen and painful axilla to the same side.",40.0,Adults,1,0
898550,"Patient had received Flu vaccine on 9/30/20, and when in office on 11/25/20 she received flu vaccine when requested to have one. Due to short staffing chart was not reviewed to see if pt already received before administration and pt accidently received 2 doses of flu vaccine. This was caught right away and physician notified, patient was notified as well. Physician reports that pt should be ok, pt notified if she has any problem to call physician office.",,Unknown,0,1
868042,"DID NOT SKIP A DAY BETWEEN SECOND AND THIRD DOSE; This spontaneous case report (PVX2019-2855) was received from a pharmacist on 19-Nov-2019. It described a female consumer who ""did not skip a day between second and third dose"" (PT: Inappropriate schedule of product administration), while being on oral Vivotif for typhoid fever prophylaxis.  Case report: It was reported that consumer did not skip a day between the second and the third dose of Vivotif. She took doses on days 1, 3, and 4.  Action taken with Vivotif with respect to reported event was not applicable.  The clinical outcome of the reported event was unknown.  Company Comment: A patient did not skip a day between second and third dose of Vivotif (Inappropriate schedule of product administration). Considering the nature of the event, the causality of the event is assessed as not related.; Sender's Comments: A patient did not skip a day between second and third dose of Vivotif (Inappropriate schedule of product administration). Considering the nature of the event, the causality of the event is assessed as not related.",,Unknown,1,0
916362,"9:44 AM vaccine  9:48 AM Fingers begin curling backwards, noticed slight twitching in butt cheeks, throat felt hot and tight, felt like someone had a hand around my throat, felt chills, began sweating, legs, arms, jaw began spasming violently, tachycardia reaching 163, unable to walk due to severe spasms, symptoms continued and worsened  10:30 Needed to be transported to the emergency room  Could not walk needed to be lifted into a wheelchair, lifted into a vehicle, lifted out of the vehicle and transported into emergency room with symptoms worsening and the beginning of a severe headache  11:50 in emergency room symptoms continued",22.0,Adults,0,0
908004,"swollen lymph node extends from injection site toward breast, shooting pain down side",46.0,Adults,1,0
915423,"& PAIN IN EYE, PUPILLARY CONSTRICTION UNILATERAL",58.0,Adults,1,0
860198,"slurred speech/dysarthria/Moderate dysarthria; Bilateral facial weakness/R facial weakness; dysphagia/difficulty swallowing; difficulty speaking/gargled speech; difficulty chewing; difficulty closing his eyes; eyes feel heavy; unable to raise eyebrows; numb lips; lower extremity weakness; facial neuritis; Bell's palsy/left sided facial droop/Facial droop; Guillain-Barre syndrome; This case was reported by a lawyer and described the occurrence of bell's palsy in a male patient who received Herpes zoster (Shingrix) for herpes zoster.   The initial information was received on 23 January 2020, via medical records(The case was medically confirmed). As per medical records, the patient had ingested Shingrix RZV 50MCG/0.5Ml (the new shingles vaccine 2 shots) for Zoster (shingles) on 22 March 2018. As per medical records, on 20 September 2019 the patient had acute onset left sided facial droop, lower extremity weakness and slurred speech. Bilateral linear enhancement of the facial nerves, probable facial neuritis, slight left facial droop on left side compared to right although the patient states that his entire face is weak and that is difficult for him to close his eyes and moderate dysarthria. As per progress note dated on 25 September 2019 the patient recommended to be addressed at the follow up visit for Bilateral facial weakness, dysarthria and dysphagia and the patient was diagnosis with Bell's palsy. The patient had bilateral linear enhancement at the fundus of the internal auditory canals bilaterally extending into the labyrinthine portions of the facial nerves bilaterally and geniculate ganglia on both sides. The evening prior to admission he noticed a Left facial droop, had difficulty speaking, chewing and swallowing. During his stay in the ER he developed R facial weakness and bilateral idiopathic Bell's palsy. He was still experiencing left sided facial droop with gargled speech. He has difficulty closing his eyes fully and complains that his eyes feel heavy when he tries to open them. Because of recent shingles vaccination 5 days ago, early Guillain-Barre syndrome would be on the differential. The patient was unable to raise eyebrows or smile, numb lips. The patient had difficulty with movement of lips, smiling, scrunching forehead, moving nose and raising eyebrows. The patient was unable to move facial muscles, unable to smile, puff cheeks, raise eyebrows could only move lower lip. The patient had difficulty talking with frozen face, tongue mid line, sensation was intact, left pupil greater than the right and moving all extremities equally. The patient had MRI on 29 September 2019 with impression Bilateral linear enhancement of the facial nerves. Probable facial neuritis.      Lab Comments: The patient had MRI on 29 September 2019 with impression Bilateral linear enhancement of the facial nerves. Probable facial neuritis.",63.0,Adults,0,1
906393,"1st day-  started to have left arm pain, sore, heavy at around 6PM 2nd day - started at 5 am noted my left arm was swollen, still sore & painful,  having chills, headache muscle aches and later on having fever 99.8F-100.2F.  Took Tylenol  x 3. 3rd day - still having muscle aches and left arm pain & soreness. 4th day - still having  mild left arm pain.",51.0,Adults,0,0
856974,"improperly stored vaccine administered; no adverse effect; This spontaneous report as received from an office manager refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.       On an unknown date, the patient was vaccinated with improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) (lot # S021925, expiry date : 15-JUL-2021) for prophylaxis. Other suspect therapies included sterile diluent(MERCK STERILE DILUENT). It was unknown if diluent used to reconstitute was stored at proper temperature.    It was reported that the vaccine experienced a temperature excursion total time in the range of 6 degrees Fahrenheit (F) to 14 degrees F (-14 degrees Celsius (C) to - 10 degrees C) for 30 minutes, 15 degrees F to 46 degrees F (-9 degrees C to 8 degrees C) for 7 hours and 47 degrees F to 77 degrees F (9 degrees C to 25 degrees C) for 9 hours (product storage error). There was no previous temperature excursion and it was reported that this call was due to a digital data logger. The patient had no adverse events. There was no product quality compliant involved.   This is one of the several reports received from the same reporter.; Sender's Comments:  US-009507513-2001USA005586:Original Case : 2001USA005586",,Unknown,0,1
855397,"popped and a lot of liquid went out of the syringe. More of the vaccine got on her arm and her face / no AE; popped and a lot of liquid went out of the syringe. More of the vaccine got on her arm and her face; cracked syringe; Initial information received on 22-Nov-2019 regarding an unsolicited valid non-serious case received from a consumer/non-hcp.  This case involves unknown demography patient who had an incomplete vaccination of INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE [FLUZONE] lot UJ273AB (Expiry date unknown) via intramuscular route in unknown administration site.  It was an actual medication error case due to vaccine underdose.  It was also a case of syringe leak and Exposure via skin contact.  At the time of reporting no adverse reaction was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
901983,"caught the flu of another strain of flu; was so sick; Initial information was received on 11-Nov-2020 regarding an unsolicited valid non-serious case received from a consumer (patient) via social media.   This case involves a patient (unknown demographics) who got sick (illness) and caught the flu of another strain(influenza), after the patient received INFLUENZA VACCINE (flu shot).  The patient's medical history, past medical treatment(s), concomitant therapy, past vaccination(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, (Unknown latency) the patient caught the flu (illness) and was so sick (illness) from the INFLUENZA VACCINE (non serious events). The patient reported that flu was of another strain and patient did not got one since then.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, the outcome was unknown for the reported event.  There will be no information available on batch number for this case.",,Unknown,0,1
905510,"tingling in throat, rapid heart rate, flushing",22.0,Adults,0,0
889685,"patient received of IMOVAX RABIES vaccine 45 minutes to 1 hour after reconstitution/ NO AE; Initial information received on 24-Sep-2020 regarding an unsolicited valid non-serious case from a consumer or non-healthcare professional.  This case involves male patient who received vaccine  in rabies series first dose of suspect RABIES (HDC) VACCINE [IMOVAX RABIES] and IMMUNOGLOBULIN ANTI-RABIES on 16-Sep-2020, second dose of suspect RABIES VACCINE INACT (CHICK EMBRYO) [RABAVERT] and third dose of suspect IMOVAX RABIES (administered 45 minutes to 1 hour after reconstitution on 23-Sep-2020) (wrong technique in product usage process) batch number, expiry date not reported via an unknown route at an unknown administration site for post-exposure immunization.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.  It was an actual medication error case due to wrong technique in product usage process (latency: same day).   At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information available on the batch number for this case.",,Unknown,0,1
895911,Patient called on 11/10/2020 around 3:15pm and mentioned that she broke out in rashes in her back. Upon further asking she stated that she stared seeing them on Monday morning (11/9/2020) and the rashes were in the middle of her back and spread on one side of her back. Rashes were red and blistery.,73.0,Seniors,1,0
877747,Rash at injection site that spread to inner arm,67.0,Seniors,1,0
884563,"Right supraclavicular swollen lymph node, sore under right side of mandible",0.25,Kids,0,0
899484,"received 2 Flublock vaccinations in one flu season with no adverse event; Initial information received on 27-Oct-2020 regarding an unsolicited valid non-serious case received from the other healthcare professional from the agency via email at call center (reference number: US-SANOFI-00334210).  This case involved a 66-year old male patient who received 2 INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] vaccinations in one flu season with no adverse event (extra dose administered).  Medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.  It was an actual medication error due to extra dose administered.  On 21-Sep-2020, the patient received a dose of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE with an unknown batch number via unknown route in unknown administration site for prophylactic vaccination.  On 16-Oct-2020, the patient again received a dose of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE (lot number: UJ455AA) via unknown route in the left arm for prophylactic vaccination.   On 16-Oct-2020, it was reported that the patient received two Flublok vaccinations in one flu season with no adverse event (extra dose administered.).  At the time of reporting, the patient had no adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",66.0,Seniors,0,1
873423,"No symptoms or adverse effects reported; patient received unspecified dose ofVARIVAX that was improperly stored; This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender. The patient's pertinent medical history and drug reactions/allergies were not reported. Concomitant therapy included sterile diluent  On 01-OCT-2019, the patient was vaccinated an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) (lot # S003447, expiration date 04-FEB-2021; strength, dose, route were not provided) for prophylaxis (product storage error).  Temperature excursion of this vaccine was -12.8 degree Celsius for 2 hours and 38 minutes. There was previous temperature excursion and the worst previous temperature excursion was -9.8 degree Celsius for about 112 minutes. No symptoms or adverse effects reported. Data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2006USA000010:",,Unknown,0,1
871640,"Lot was expired, expired 3/10/2020 and provider ordered Hepatitis B vaccine.  Called patient to inform, no tenderness or other s/s noted.  Will provide Hepatitis B vaccination next week.",52.0,Adults,0,1
908086,"Female  2/27/2020 Boostrix TDAP at Pharmacy NDC: 58160-0842-52 A little tired than usual over the weekend 3/9/2020 MMR II Inj Merc at Pharmacy (3 prior to this did not have it) NDC: 00006-4681-00 Engerix-B 20 MCG/ml Inj Glax NDC: 58160-0821-52 3/11/2020 After taking Vitamin D liquid drops, abdominal pain and diarrhea Spinal manipulation in evening 3/12/2020 Tired, complained of aching all over, emotional and weepy, anxiety, diarrhea continued 3/14/2020 Completed 3 hours of taekwondo advanced belt testing, including breaking wood boards Entire body shaky and weak Knees began to feel hot and painful Spinal manipulation in evening 3/18/2020 Entire body sweaty, complained of aching body ? especially of legs and back Had her take small dose of magnesium supplement, thinking it was related to physical exertion.   3/19/2020 Sleepy at all times, malaise, red and swollen eyes (blood vessels in eyes), feverish (warm and sweaty) inability to concentrate.  We had a language lesson and she could not remember words after everyone repeated them several times, and was misspelling words she knew.  Complained of a headache.   3/20/2020 ? 3/23/2020 Body and forehead very hot to touch (no thermometer, deep muscle and ?close to bone? pain in legs and lumbar region, feet numb.  Complained of inability (too much pain and weakness) to get out of bed to use the bathroom on 3/20/2020. Slept most of the time, waking for 30 minutes to drink water, very sensitive to sound and light (she stayed in bed in a dark room), could not complete tasks requiring thought or remembering sequence of actions, and needed prompting to follow them. Not hungry, but ate some fruit cooked in water, and one fruit and spinach/plain yogurt smoothie.  Complained of diarrhea and abdominal pain. Drank fresh ginger and turmeric tea with cinnamon and cardamom and honey. Took Vitamin B, D, and Vitamin C supplements Rubbed Arnica gel and menthol rub on legs and low back to help relieve pain. 3/22/2020 Began menstrual cycle Body and forehead very hot to touch (no thermometer, deep muscle and ?close to bone? pain in legs and lumbar region, feet numb.  Hallucinations of people walking on the roof.  Weepy and concerned she was going to get everyone sick. 3/23/2020 Broke out in rash over entire back, buttocks, shoulders, and upper back.  (see Figure 1). Was hungry for the first time in a week, and ate some pasta and baked apple (just apple and water).  Complained of diarrhea and headache. That evening, used photography darkroom thermometer to document lowered temperature (forehead warm and body slightly warmer): 100 degrees F. Needed assistance to compose coherent email to instructors, and turn in one past assignment. Took a small dose of Thuja occidentalis 30c and a mix of the following herbs: Xiao Feng San, Huo Xiang Zheng Qi San, Huang Qin Along with ginger, turmeric, cardamom, and cinnamon with honey              3/24/2020 After sleeping 11 hours, eyes were clear and could handle slightly more sunlight in room.  Hearing sensitivity.  Temperature dropped to 98.9 degrees F.  Rash on body trunk and chest reduced (see Figure 2), but bright red rash spread to extremities. Does not recall events or conversations from the past week. Was hungry and ate some fresh fruit, vegetable broth, and bread. Administered dose of Thuja occidentalis 30c and Chinese herbs of: Xiao Feng San, Huo Xiang Zheng Qi San, Huang Qin Drank ginger, turmeric, cardamom, and cinnamon with honey.      12/23/2020 She has recovered from the rash without noticeable scarring, and has not complained of pain, however she has complained of stiffness. There has been a marked personality change since the event.",16.0,Kids,1,0
858946,"Pounding/pressure headache started within a few hours.  It worsened as the day went on.  By evening, I was chilled and shivering with no relief from multiple blankets.  Fever was likely 103 that night, although I didn't take my temperature until the next morning after the chills subsided. Then, it was 102.5 -- the highest I've ever had aside from the flu over a decade ago.  I slept ALL day that day -- the day after the vaccine, with my temperature gradually lowering to only 99 by the 3rd morning.  During that time, my left arm was extremely sore, and my whole body was weak and achy (just like the flu).  I did not, (thank you, Jesus) have an gastro-intestinal distress.  According to the internet, only 1 in 6 patients have this reaction.  This was my 2nd dose and I had no reaction to the 1st one, 12 months prior. A friend of mine who is a doctor said that 9 out of 10 of her patients taking this vaccine DO have this reaction.  I do believe that the public should be made aware so they can plan ahead for this debilitating shot.  I would do it all over again to avoid shingles in the future, but it would be nice to be able to plan ahead.  Thank you!",62.0,Adults,0,0
858918,"patient reported hives on her chest that started several days after receiving the vaccine. It persisted for about a month, but she had not tried Benadryl or more consistent use of a topical steroid.",63.0,Adults,0,1
900130,"Swelling  of upper R arm; pain, warmth, itchiness",4.0,Kids,1,0
884831,"an expired dose of Menactra was administered to the patient, no AE; Initial information was received on 03-Sep-2020 regarding an unsolicited valid non-serious case from a nurse.  This case involves a 17 year old female patient who was administered an expired dose of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] (expired product administered).  Medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient was not pregnant.  Concomitant medications included VARICELLA ZOSTER VACCINE (VARICELLA VACCINE) for prophylactic vaccination.  On 03-Sep-2020, the patient received a 0.5 ml dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE (lot U6208AD, expiry date 08-Jul-2020, vial) once via unknown route in the left deltoid for prophylactic vaccination.  It was reported that the clinician may vaccinate right away and another clinician wanted to wait on her second dose of Varicella in a month.  It was a case of an actual medication error due to expired vaccine used (latency same day).  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",17.0,Kids,0,1
882568,"Post injection site Reaction, Redness, heat Swelling, achiness",66.0,Seniors,0,0
878189,Arm swollen and red from bicep to pit of the elbow and extremely itchy.  Very sore to use but with full range of mobility.,69.0,Seniors,0,0
907986,"mild left upper arm swelling, quarter to half dollar sized lump under skin; sore tight muscle that interferes with daily activity; area is warm to the touch Symptoms started within 3 hours of dose and have continued to progress for 20 hours.",47.0,Adults,0,0
911820,Injection Site Pain,63.0,Adults,1,0
883489,"swelling near eye and down arm; redness and swelling near eye and down arm; inability to get warm; reports waking up at 2 AM; hive noticed on ear and other unspecified places; Redness at the injection site; developing hives around injection site; staying in bed all day [fatigue]; fever in 101 range; Headache; unable to get muscles to relax and unclench; Chills; Sore arm; become sicker; This case was reported by a consumer via call center representative and described the occurrence of swelling in a 69-year-old female patient who received Herpes zoster (Shingrix) (batch number ZR979, expiry date unknown) for prophylaxis.   Co-suspect products included QUADRIVALENT INFLUENZA VACCINES (FLUAD QUADRIVALENT) for prophylaxis.   Previously administered products included Angioedema and Epipen (received on unknown date  Illness at Vaccination).   On 27th August 2020, the patient received the 1st dose of Shingrix and the 1st dose of FLUAD QUADRIVALENT (intramuscular) .5 ml. On 27th August 2020, less than a day after receiving Shingrix and an unknown time after receiving FLUAD QUADRIVALENT, the patient experienced chills, pain in arm and malaise. On 28th August 2020, the patient experienced fatigue, fever, headache and muscle stiffness. On 29th August 2020, the patient experienced injection site hives and injection site erythema. On an unknown date, the patient experienced swelling, erythema, feeling cold, insomnia and injection site urticaria. On an unknown date, the outcome of the swelling, erythema, injection site hives, pain in arm and injection site erythema were not recovered/not resolved and the outcome of the fatigue, fever, headache, muscle stiffness, chills, malaise, feeling cold, insomnia and injection site urticaria were unknown.   It was unknown if the reporter considered the swelling, erythema, injection site hives, fatigue, fever, headache, muscle stiffness, chills, pain in arm, malaise, feeling cold, insomnia, injection site urticaria and injection site erythema to be related to Shingrix.  Additional details were provided as follows: The patient receiving 1st dose Shingrix last in left arm and Fluad Quadravalent flu vaccine in right arm.  The reporter reported first having a sore arm from Shingrix vaccine, and later that evening began to become sicker, notably developing chills and inability to get warm although it was a hot day outside. During bedtime, The reporter reported waking up at 2 AM putting on quilts and unable to get muscles to relax and unclench. At 2:30 AM The reporter reported going to kitchen to take temperature and notes a fever in 101 range although normal basal temperature usually runs in 96-97 range. The reporter reported also developing a headache that would not get better for a couple of days. That day The reporter reported staying in bed all day (fatigue) except for one hour. Halfway into the following day, the patient reported finally getting up and starting to do light activities.  The reporter reported developing hives around injection site extending down arm. Later, hive noticed on ear and other unspecified places. The reporter stated due to history of developing angioedema as a delayed response, she took Zyrtec twice a day because once a day was not stopping the hives from spreading. She stated having an epipen since the age of 18 due to an unspecified condition.  The reporter reported Monday was her first attempt at having a normal day, and today redness and swelling near eye and down arm, but not anywhere else.  The reporter consent to follow up. This case has been linked with case US2020176983 reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020176983:same reporter",69.0,Seniors,0,0
878971,"Red, swollen, painful, warm to touch. Patient diagnosed with cellulitis of upper, left arm.",11.0,Kids,1,0
909645,"Diarrhea, severe cramping, lighter stools, 24 hours duration, improved after loperamide",50.0,Adults,0,0
909977,Throat itching and light headedness; symptom duration 20 minutes.,24.0,Adults,0,0
896062,"16 year old patient received FLUBLOK QI/ NO AE; Initial information was received on 23-Oct-2020 regarding an unsolicited valid non-serious case received from a pharmacist (Reference number- 00329784) and transmitted to Sanofi on 23-Oct-2020.  This case is linked with case 2020SA300754 (same reporter).  This case involves a 16-year-old male patient who was vaccinated with 0.5 ml dose of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] (lot QFAA2029 and expiry date 30-Jun-2021) via an intramuscular route in the left deltoid on 16-OCT-2020 for prophylactic vaccination (Product administered to patient of inappropriate age).  The patient's medical history, past medical treatment, concomitant medication and family history were not provided.  No other vaccines were given.  It was a case of actual medication error due to inappropriate age at vaccine administration (latency was on same day).  At the time of reporting, patient had no adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",17.0,Kids,0,1
727017,"42 3/7 weeks born; Prolonged labor; induction of labor; Maternal fever was greater than 100.4 degrees F.; ultrasound antenatal screen normal; human chorionic gonadotropin positive/blood HCG was positive in office; pregnancy test positive/ patient returned on 09-NOV-2017 reporting positive home pregnancy test; exposure during pregnancy; This report was identified from a line listing obtained on request by the Company from the FDA under the Act (VAERS ID 727017) on 21-FEB-2018, referring to a 17-year-old pregnant female patient. None current illness, medical history, other medications nor prior vaccinations were reported.  On 16-AUG-2017, the patient was vaccinated with her first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), 0.5 ml, intramuscularly in the right arm (lot # M040412, expiration date was not reported but upon internal validation established as 30-JUN-2019) for prophylaxis. On the same day, she also received meningococcal acyw conj vaccine (dip toxoid) (MENACTRA), 0.5 ml (lot # U5539AA, expiration date and strength were not provided) and meningococcal b rfhbp vaccine (e. coli) (TRUMENBA), 0.5 ml (lot # S26985, expiration date and strength were not provided) both intramuscularly, in the left arm.   On the same day, the patient requested oral birth contraceptive (OBC), denied being sexually active and stated that her last menstrual period was on 28-JUL-2017. Therefore, she was given the OBC which she took during September and October in 2018.  On 25-OCT-2017, the patient returned for the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9).  Furthermore, on an unspecified date in 2017, the patient had a positive home pregnancy test; so she returned to the physician office on 09-NOV-2017 and informed about it; subsequently a blood human chorionic gonadotropin (HCG) test was performed there and was positive. The patient was sent to ultrasound and measured 38 weeks plus 3 days. The patient's estimated LMP was on 14-FEB-2017 and her estimated date of delivery would be 21-NOV-2017. At the time of this report, the outcome of the exposure during pregnancy, ultrasound antenatal screen normal, pregnancy test positive and human chorionic gonadotropin positive was unknown; as well as the pregnancy outcome which remained pending.  The agency considered this case as non-serious. The agency did not give the causality assessment between the events and suspect vaccines.  Follow-up was identified from a line listing obtained on request by the Company from the FDA under the Act (VAERS ID 727017) on 20-JUN-2019. Information was received from a medical assistant. The patient's was a female and her allergies included orange juice (hives). She received her vaccines in deltoids.  Follow up information has been received on 25-JUN-2019 and stated that the aware date of the previous version was corrected to 19-JUN-2019.  Follow up information has been received from a physician on 02-DEC-2020. The patient's date of birth was provided. Her historical vaccines included meningococcal acyw conj vaccine (dip toxoid) (MENACTRA). She was a non-smoker. Her blood type was 0+. On 16-AUG-2017, the patient was vaccinated with the first dose of meningococcal b rfhbp vaccine (e. coli) (TRUMENBA). The patient was never pregnant before. She was unaware of being pregnant. She claimed she had a bleeding on 28-JUL-2017 (also reported as 3 weeks early July 2017) and she reported it was the date of her last menstrual period. She had her first prenatal visit on 14-NOV-2017 (she was tested for human immunodeficiency virus (HIV) and Syphilis then) and her last prenatal visit on 06-DEC-2017. There were not risk factors in this pregnancy. She had no infections during pregnancy. She had antibody screen negative, Hepatitis B surface antigen (HBsAg) negative, serology non-reactive, HIV negative,  group B streptococcus (GBS) negative, gonorrhea test (GC) negative and Chlamydia negative. She was Rubella immune. She had no obstetric procedures performed.  On an unknown date in December 2017, the patient was admitted to the hospital. Tocolysis occurred. On 07-DEC-2017, she had an induction of labor, her membranes were raptured on 07-DEC-2017 at 08:23 AM. Fluid was clear. The fetus was monitored externally. Maternal fever was greater than 100.4 degrees Fahrenheit. The mother received oxytocin (PITOCIN) during labor and epidural anesthesia. Also, she received three doses of ampicillin and one dose of gentamicin. Presentation of fetus was vertex. The labor was prolonged and it took 22 hours and 36 minutes. the male infant was born vaginally, spontaneously. It was 42 weeks and 3 days of pregnancy. The infant had initial respiratory distress but transitioned quickly post delivery. In the delivery room the baby was stimulated. Suctioned with a bulb. The patient had Apgar score 8 at one minute and 9 at five minutes. His birthweight was 3700 grams. His head circuit (circ) was 36.00 cm, his body temperature was 36.33 Celsius degrees; pulse rate was 134 (unit not provided), respiratory (Resp) rate was 46 (unit not provided), glucose was 61 (unit not provided), ""Dia"" was 41 (unit not provided), pulse oximetry (Ox) was 100 (unit not provided). On the same day, the infant was admitted to newborn intensive care unit (NICU) from newborn nursery as he had suspected sepsis and required intensive monitoring and observation for signs/symptoms of clinical sepsis. He was transferred to NICU in crib and placed on pre-warm radiant warmer (RW). His admission physical exam on 08-DEC-2017 at 15:14 showed: GENERAL: awake, alert, responsive; in no acute distress; no dysmorphic features; exam consistent with gestational age assessment; HEAD/FACE: normocephalic; sutures opposed; anterior fontanel flat; EYES: red reflex present bilaterally; EARS: normally set; internal ear exam not performed; NOSE/MOUTH/THROAT: no nasal flaring; nares patent bilaterally; no cleft; gag reflex present; NECK/THYROID: supple; LYMPHATIC: no adenopathy noted; BREAST: normal for gestational age; RESPIRATORY: no retractions noted; breath sounds clear and equal with good air exchange; CARDIO/VASCULAR: S1, S2 normal; no murmur appreciated; regular rate and rhythm; pulses equal; ABDOMEN: bowel sounds present; soft, non-tender without masses; no hepatosplenomegaly; GASTROINTESTINAL (GU)/RECTAL: testes descended bilaterally; anus patent; SKIN/HAIR: large port wine stain to right leg; BACK/SPINE: no abnormalities noted; no sacral dimple; MUSCULOSKELETAL/EXTREMITIES: no deformities noted; hips stable; moves all extremities symmetrically; NEUROLOGICAL: reflexes 2+ and symmetric; muscle tone appropriate for gestational age; White Blood Cells (WBC): 14.6 (unit not provided); Hemoglobin/Hematocrit (H/H): 16.1/48 (unit not provided); Platelet (Plt): 349000 (unit not provided); ""I:T"": 0.14 (unit not provided); C-reactive protein (CRP): 10.1(unit not provided), increased. At the admission, the infant's temperature was 36.2 Celsius degrees. The diagnosis was hypothermia, newborn. The infant was at risk for hypoglycaemia and required intensive monitoring and observation for need for continued thermoregulation. He received fluid administration (reported as sweetease) through peripheral intravenous catheter (right hand) and he tolerated procedure well with good pain management. RW was maintained for thermoregulation. Since 08-DEC-2017, the infant had feeding problems (unspecified). The patient was breastfeeding the infant on demand and he was doing well with nipple shield. On 08-DEC-2017, the infant started receiving gentamycin and ampicillin. On 10-DEC-2017, the patient had hearing screening (Automated Auditory Brainstem Response (AABR)) performed and he passed the test.  Upon internal review, the event of puerperal pyrexia was considered to be medically significant.  All available medical records will be provided upon request.  This case is cross referenced with the child's case MSRRS # 2012USA001391.; Sender's Comments:  US-009507513-2012USA001391:",17.0,Kids,0,0
865554,& Rash,73.0,Seniors,1,0
872804,"No patients experienced symptoms.; Impropertly stored doses of varivax were administered; This spontaneous report was received from a nurse, referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, previous drug allergies or reactions and concomitant medications were not reported.  On 02-JUN-2020, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (Oka/Merck)(VARIVAX), subcutaneous (dose and frequency were not provided; Lot number reported as S032357 has been verified to be valid; expiration date reported and validated as 14-OCT-2021) for prophylaxis. The vaccine was reconstituted using a properly stored sterile diluent (MERCK STERILE DILUENT).  The vaccine underwent a temperature excursion of -17.2 Fahrenheit for a period of 14 hours and 2 minutes. The vaccine did not underwent a previous temperature excursion. The excursion was called by a digital data logger. The nurse reported that the patient did not experience any adverse event.  This is one of several reports received from the same source; Sender's Comments:  US-009507513-2006USA001641: US-009507513-2006USA001819: US-009507513-2006USA001817: US-009507513-2006USA001816: US-009507513-2006USA001818:",,Unknown,0,1
895749,"I had the flu shot at noon, we returned home and I ate a snack, then aright around the 2:00pm hour I started to have severe stomach pain, I was very short of breath, I started having chills, then sweats, then my hips hurt so bad I couldn?t get comfortable.  I took 3 advil for the pain, and about 4:00 I became with vomiting.  The chills continued, followed by sweating, then about 7:00pm I started having diarrhea and vomiting.  The pain in  my hips and chest eased about 8:30pm and I showered then went to bed, waking occasionally to drink water.",67.0,Seniors,0,0
888582,"Myalgias, Fever, Neck Pain Headache, Arthralgias, Chills, Diarrhea",55.0,Adults,1,0
785711,"DIARRHOEA; VOMITING; NAUSEA; This spontaneous case report was extracted through VAERS database (785711-1) on 15-Feb-19. The case was reported by a consumer via health authority. The report describes a female consumer who had diarrhea, nausea, and vomiting following the intake of oral Vivotif (one dose every other day) (lot no: 3003215) for an unknown indication.  The consumer was allergic to amoxicillin.  The consumer's concomitant medications included Flonase (fluticasone) and Zyrtec (cetirizine and pseudoephedrine) for unknown indications. The consumer also taking Lillow (levonorgestre and ethinyl estradiol) as oral contraceptive.  It was reported that the consumer took the first dose of Vivotif on Monday (05-Nov-2018) and at 1 pm same day she experienced nausea and vomited one time and diarrhea two time between 3 to 5 pm. Next day there was no side effect. On Wednesday, the consumer took the second dose and again experienced nausea which resolved on Thursday. On Friday, she took the third dose and nausea began at noon and worsened throughout afternoon and she had diarrhea two times in early evening. Then on Saturday, she experienced diarrhea six plus times from late morning to early afternoon. On Sunday, she took the last dose and there were no side effects. On the days with side effects she ate only cheerios, noodle soup, saltines, bananas, and ginger ale.  The action taken with Vivotif with respect to the events diarrhea, nausea, and vomiting was dosage maintained.  The clinical outcome of the event diarrhea, nausea, and vomiting was resolved.  Company's Comment: In this case, it was reported that a female consumer had diarrhea, nausea, and vomiting following the intake of oral Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Also, diarrhea, nausea, and vomiting are labelled as per CCDS. Hence, the causality of the events with Vivotif is assessed as possible.; Sender's Comments: Company's Comment: In this case, it was reported that a female consumer had diarrhea, nausea, and vomiting following the intake of oral Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Also, diarrhea, nausea, and vomiting are labelled as per CCDS. Hence, the causality of the events with Vivotif is assessed as possible.",,Unknown,0,0
890962,"Upon vaccination the patient exhibited marked swelling and bleeding at the injection site.  The patient was monitored for signs/symptoms of allergic reaction.  The patient did not exhibit redness at the injection site, itching, or difficulty breathing.  The injection site swelling was most likely pooling of blood post arterial laceration.",62.0,Adults,0,0
894631,"itchy around entire the body, especially around the eyes and lips; a large red itchy welt on arm where patient received vaccination also 3 -4 inches down from the injection site; entire arm was red; entire arm was red; Initial information was received on 05-Oct-2020 regarding an unsolicited valid non-serious case from an other health professional.  This case involves patient with unknown demographics who experienced itchy around entire the body (pruritus), especially around the eyes and lips, a large red itchy welt on arm where patient received vaccination also 3 -4 inches down from the injection site (urticaria) and entire arm was red (erythema and vaccination site reaction), while patient received vaccine INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV].  Medical history, medical treatment, vaccination concomitant medication and family history were not provided.  On 02-Oct-2020 at 10:45 am, the patient received a dose of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination.  On 02-Oct-2020 at 02:00 pm, the patient developed a non-serious itchy around entire the body (pruritus), especially around the eyes and lips, a large red itchy welt on arm where patient received vaccination also 3-4 inches down from the injection site (urticaria) and entire arm was red (erythema and vaccination site reaction) 3 hours 15 minutes following the administration of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE.   Details of laboratory data not reported.   On same day, the patient was treated with LORATADINE (CLARITINE) also It was reported that, patient could not take Benadryl due to other health conditions.  Event outcome was unknown as it was not reported at the time of reporting.  There will be no information available on the batch number for this case.",,Unknown,0,1
874998,"now shingles has become a part of pain; now shingles has become a part of pain; rash on left side y ribs and under left breast.; Suspected vaccination failure; This case was reported by a consumer and described the occurrence of suspected vaccination failure in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Concurrent medical conditions included rheumatoid arthritis (received now Olumiant for three weeks). Concomitant products included baricitinib (Olumiant).   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, pain and rash. On an unknown date, the outcome of the vaccination failure, shingles, pain and rash were unknown.   It was unknown if the reporter considered the vaccination failure, shingles, pain and rash to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication. The patient received Olumiant for three weeks for rheumatoid arthritis.  The patient reported now the patient had shingles. The patient had all the vaccines but now shingles had become a part of pain and rash on left side of ribs and under left breast. This case was considered as suspected vaccination failure, since the details regarding completion of primary vaccination schedule, time to onset for event and laboratory confirmation for herpes zoster were not provided.",,Unknown,0,0
913932,"Itchy face that lasted 2 mins; tightness in the throat lasted about 2 minutes; complete facial numbness; pressure behind right eye.; sore throat possibly swollen lymph nodes; sore throat possibly swollen lymph nodes; This is a spontaneous report from a contactable other health professional (patient). A 35-years-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: EK5730), intramuscularly on 22Dec2020 13:00 at single dose on left arm for COVID-19 immunization in hospital. The patient medical history and concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient known allergy included hydrocodone. The patient experienced itchy face that lasted 2 mins followed by tightness in the throat lasted about 2 minutes, 10 minutes of no other reactions then complete facial numbness and pressure behind right eye, slight pressure still and sore throat possibly swollen lymph nodes. Adverse event started from 22Dec2020 13:30. No treatment received for the adverse events. The outcome of events itchy face and tightness in the throat was recovered on 22Dec2020, of the other events was recovering. No COVID prior vaccination, since the vaccination the patient hadn't been tested for COVID-19. It was not reported as serious.",35.0,Adults,0,1
889242,Patient says she developed swelling and a rash at about 7 PM the day of vaccine. The next day it started to itch all around the area. She applied ice and took Benadryl.,74.0,Seniors,0,0
893763,"a 16 years old patient received FLUBLOK vaccine with no adverse event; Initial information received on 09-Oct-2020 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 16 years old male who received a 0.5 mL dose of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] (Lot number- UJ448AA, expiration date- 22-Mar-2021) via unknown route in the left deltoid for prophylactic vaccination (product administered to patient of inappropriate age) on 26-Sep-2020.  The patient's medical history, medical treatments, vaccinations and family history were not provided.   No concomitant vaccines given to the patient.   It was a case of an actual medication error due to inappropriate age at vaccine administration (latency: same day).  The patient experienced no adverse events.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",16.0,Kids,0,1
908088,"Patient received the vaccine at 0816 and then did some errands/shopping.  Patient returned home around 11 am and noticed she had a funny feeling in her throat.  Patient took Benadryl 50 mg and slept for at least 3 hours or longer.  When patient woke up she noticed that feeling in her throat had returned but had spread from back of her tongue to down her throat.  Patient described that it felt like her throat was swelling and she had swelling in her nose as well.  Patient went to ED for further evaluation and treatment on 12/21.  ED provider note described patient felt like her throat and nose were swollen and her chest was tight.  Patient was given solumedrol 125mg IM at 1825 and a written prescription for prednisone 20 mg bid for 5 days.  Symptoms improved after solumedrol was given.  ED provider had neck imagine done.  Impression from imaging ""the superficial soft tissues appear grossly normal. No prevertebral soft tissue swelling.  The airways appear widely patent.  No evidence for epiglottitis""",33.0,Adults,0,1
862957,Rash,49.0,Adults,1,0
864445,Right ear fullness Right ear hearing loss Extreme dizziness Brain fog Vertigo Lightheadedness Fatigue,55.0,Adults,1,0
861035,"Nausea; Stomach Cramps; Chills; Itching; Initial Report Received 30-Jan-2020 and 31-Jan-2020  A physician reported a 42-year-old female employee received her first injection of HEPLISAV-B (Lot #933621) in Jan-2020. No concomitant vaccinations were administered. Two to three hours after injection, the employee experienced nausea, stomach cramps, chills, and itching. No treatment was administered, and all events resolved within a day.     None of the events were reported as serious.    Company comment. The company assessed the events as non-serious.; Sender's Comments: The company assessed the events as non-serious.",,Unknown,1,0
915428,"Required code to be called and short MICU admission for observation, including neurology and psychiatry services. Seizures & PNEA (Psychogenic Non-Epileptic Attack)",62.0,Adults,0,0
908744,"at 8:40 am patient felt dizzy and flushed, she asked for extra attention and indicated she felt embarrassed, but denied difficulty breathing, no trouble speaking in full sentences, no rash, no change of vision;  BP was 158/108 with pulse of 95 and then patient was brought to a more quiet area and seated in a wheelchair.   She was able to ambulate, a nd speak normally, but she said she felt very strange and shaky.  she was visibly tremulous.  She was seated, and vitals reassessed and her shakiness increased and she felt panicky.  She was taken by stretcher to the Emergency room for further observation .   in the emergency room, her symptoms gradually subsided.  She was able to return to work after an hour of observation.",56.0,Adults,1,0
914880,"Nausea, Headache, Vomitting",26.0,Adults,1,0
886293,"Patient noted on vaccine administration record, a previous reaction after vaccine and she stated her mother told her to ""to always bring a companion for vaccinations"". I asked her to further expand on her reaction and if this was her first shot, she explained she may faint and this was her first flu shot. I requested she sit for the vaccine and stay seated for about 15 mins or more after so I can monitor her. I gave her flu shot and she seemed fine but within 2-3 mins she asked her friend for water because she was feeling odd, in which her friend swiftly went to store for ice water. When i came around the counter to observe her she had fainted in a seated position over the consultation counter, eyes rolled back and unresponsive. I immediately called 911 to explain the situation and while on phone with 911 she regained consciousness and  I asked if she wanted to go to hospital via ambulance. She declined, stating she was coming back and reassuring me she was going to be okay. I hung up with 911, she drank the water and I fanned her with clipboard. She sat for an additional 30 mins until she was okay, I continously asked if she was feeling better and to contact us if she had any concerns.",26.0,Adults,0,1
903184,tingling in lips no treatment,50.0,Adults,0,0
912460,"Employee started exhibiting sx 10 minutes after vaccine administration.  She started having chest heaviness, difficulty breathing and became tachycardic.  Employee was sent to the emergency room.",52.0,Adults,0,1
901009,"Low grade fever 99.9-100.4, body aches, muscle aches, sore right arm, tiredness, sleepiness, headache",62.0,Adults,1,0
867403,"Took one dose of unrefrigerated Vivotif; Spontaneous report received on 24DEC2019.  A male consumer reported that he ""took one dose of unrefrigerated Vivotif"" (PT: Product storage error), while being on oral Vivotif (lot number: 3003303) for typhoid fever prophylaxis. It was reported that the consumer was advised to take one dose every other day and complete Vivotif course at least 1 week prior to potential exposure. On 23DEC2019, the consumer took first dose of Vivotif which was left unrefrigerated for a week. Action taken with Vivotif with respect to the reported event was not applicable. The outcome of the reported event was unknown.  Company Comment: A consumer took one dose of Vivotif which was left unrefrigerated for a week (Incorrect product storage). The causality of the event is assessed as not related to Vivotif due to the nature of the event.; Sender's Comments: A consumer took one dose of Vivotif which was left unrefrigerated for a week (Incorrect product storage). The causality of the event is assessed as not related to Vivotif due to the nature of the event.",,Unknown,1,0
900938,"Patient called and said he had soreness, redness, swelling at the site of injection.  It also looked discolored at the site of injection.  He had a fever, body aches and a headache.  He received the flu shot on friday and showed all of the above symptoms overy saturday/sunday.  The brusing around the site of injection was still there on monday.",64.0,Adults,0,0
883822,"Patient was talking as shot was administered, but after completed he became quiet, his eyes rolled up into his head, his body was completely tense. Father and pharmacist moved him to a lying position, and the seizure was over in about 20 seconds. Pharmacist asked for a technician to call 911. He began to ask what happened. He was very pale and his lips were blue. His stomach was not feeling well, but he did not throw up. Father reports patient has had flu shots in the past with no issues. Patient has never had a seizure in the past. First responders arrived and checked him out. They told dad that he could wait for ambulance to arrive or transport him to the ER himself. Dad chose to take him to the er himself. He carried the child to his car and drove to the ER. The ER checked him out and did a CT. Everything was normal so he went home. They will follow up with a specialist this week. I also reported the incident to the Primacy Care Physician. I spoke with employee at Dr's office on 9/15/20.",12.0,Kids,0,1
884105,"zoster related immune inflammatory disease; zoster related immune inflammatory disease; Information has been received from a lawyer concerning a case in litigation and refers to a patient of an unknown age and gender. No information regarding the pt's medical history, concurrent conditions and concomitant medications was reported. On or about 11-DEC-2012, the pt was inoculated with zoster vaccine live (ZOSTAVAX) vaccine (dose, route, vaccination site, lot # and expiry date were not specified) for the long-term prevention of shingles and zoster-related conditions, as prescribed and/or administered by a pharmacist. On an unknown date, subsequent to zoster vaccine live (ZOSTAVAX) inoculation, the pt was treated by a healthcare provider for zoster related immune inflammatory disease. As a direct and proximate result of the pt's use of the zoster vaccine live (ZOSTAVAX) vaccine, the pt has and would continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of the events was unknown. The causality was related.",,Unknown,0,0
888761,3 x 3.5cm induration,40.0,Adults,0,0
878327,"Patient receives Menveo in Left Deltoid and Bexsero in R Deltoid at 10:45 am. Walks to front to checkout with mother. Patient collapses into wall and lands on laminate floor @ 10:50. 911 called immediately.  Mother stays at patient side. Patient eyes are dilated and arms stiff for approximately 1 min 30 seconds, patient looses bladder control. EMT arrives. Patient arouses. Ambulance takes patient to ER for further evaluation per mother's request.",18.0,Adults,0,0
891064,"Influenza vaccine but not sure which one.  AEs include swelling, spreading redness up to 7-8in circle, warm to touch, very itchy",8.0,Kids,0,1
873021,"No additional adverse effects were reported; The patient received both PROQUAD and VARIVAX; This spontaneous report was received from a medical assistant concerning to a 12 months old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not provided.   On 08-JUN-2020, the patient was vaccinated with a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) lot# S030205, expiration date 25-MAR-2021 (dose, frequency and route were not provided); and with varicella virus vaccine live (oka/merck)(VARIVAX) lot# S025910, expiration date 20-AUG-2021 (dose, frequency and route were not provided), both administered for prophylaxis (inappropriate schedule of product administration). The vaccine was reconstituted using a properly stored sterile diluent (MERCK STERILE DILUENT). No additional adverse effects were reported.",,Unknown,0,1
891433,"No further AE; temperature excursion involving multiple lot numbers for GARDASIL 9, MMR II, ROTATEQ, and RECOMBIV AX. Many of the vaccines have been administered to patients; This spontaneous report was received from a practice manager who was reporting on patient of unknown age and gender. There was no information about the patient's concurrent conditions, medical history, drug reactions or allergies and concomitant therapies provided.  On 10-AUG-2020, the patient was vaccinated with an improperly stored dose of Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) lot number S008153 was confirmed to be valid, expiration date 31-OCT-2021 (dose, route and site of administration were not provided), for prophylaxis. On 04-AUG-2020, the administered dose of vaccine was stored in a temperature of 1.1 degrees Celsius for 27 hour and 45 minutes and at temperature of 9 degrees Celsius for 1 hour and 15 minutes. A digital data logger was involved. There were no previous excursions reported. There were no further adverse events reported.  This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: RECOMBIVAX HB SYRINGE (DEVICE); commondevicename: Hepatitis B Vaccine (Recombinant); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: S022583; expirationdate: 31-OCT-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2010USA001083:",,Unknown,0,1
858720,"sick; This case was reported by a consumer via call center representative and described the occurrence of sickness in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced sickness. On an unknown date, the outcome of the sickness was recovered/resolved.   It was unknown if the reporter considered the sickness to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. After receiving Shingrix, the patient was sick for 4 days.",,Unknown,0,0
907056,"Red hives under chin, on neck, and on chest beginning 30 minutes after dose and lasting  approximately 1 hour.",23.0,Adults,0,0
897413,"Shingles; This case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 2 days after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received first shot and 2 days later got Shingles.  The patient asked if he or she should decline 2nd Shot.",,Unknown,0,0
858722,"large red ""circle"" at injection site; This case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a 69-year-old female patient who received Herpes zoster (Shingrix) (batch number 5JX9Z, expiry date 5th November 2021) for prophylaxis.   On 20th January 2020, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 22nd January 2020, 2 days after receiving Shingrix, the patient experienced injection site erythema. On an unknown date, the outcome of the injection site erythema was recovering/resolving.   It was unknown if the reporter considered the injection site erythema to be related to Shingrix.  Additional details were reported as follows: The patient received a dose of Shingrix on the left deltoid. The patient developed a large red circle at her injection site after vaccination. The reporter consented to follow up.",69.0,Seniors,0,0
874223,"Fever to 101.7, approx. 24 hours afterwards lasting x 1 day with spreading erythema around site of injection.",5.0,Kids,1,0
900071,"Pain and numbness, weakness of bilateral extremities.  Presented with numbness and burning of bilateral lower extremities which began 4 days after receiving flu vaccine and progressively worsened.  Hospital admission- CT head and brain MRI was unremarkable except for possible sinusitis with mucosal thickening that was incidentally noted.  She was treated for possible sinus infection during admission as well.  She had a cervical MRI showing increased T2 of C6-C7.  This was thought to be transverse myelitis triggered by her flu shot and she was treated by neurologist with steroids and IVIG treatment.  She is on gabapentin 100 mg 3 times daily to be decreased after 2 weeks to twice daily and eventually stopped once paresthesias resolve and Klonopin at night for insomnia.  She developed urinary incontinence during her stay and lumbar MRI was unremarkable, treated with Diflucan for possible yeast adenitis/vulvitis.",36.0,Adults,0,0
884734,"miserable for several days; not sleeping well; The patient was injected in the wrong area of her shoulder; Initial information was received on 08-Sep-2020 regarding an unsolicited valid non-serious case from a consumer/non-health care professional .  This case involves an 81 year old female patient who was miserable for several days (depressed mood) and not sleeping well (poor quality sleep) while she received vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  The patient's medical history included a bleed above her brain. The patient's past medical treatment(s), vaccination(s), concomitant medications and family history were not provided. At the time of the event, the patient had ongoing multiple sclerosis (for 32 years), had a lot of fluid in her shoulder, immune system not good with having multiple health problems.   On 08-Sep-2020, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot number not reported) once via unknown route in the shoulder NOS for prophylactic vaccination.  On an unknown date, the patient had been miserable for several days (depressed mood) and was not sleeping well (poor quality sleep) (unknown latency, non-serious) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  It was a case of an actual medication error due to wrong technique in product usage process as the pharmacist gave the patient an injection too high on her shoulder which did not go into the deltoid because the band aid was on the top of her shoulder (latency same day).  No laboratory data was reported.  It was not reported if the patient received a corrective treatment.  At the time of report, the outcome of clinical events was unknown.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information available on lot number.",81.0,Seniors,0,1
892299,"10/15: flut shot given, patient developed pain and a knot at the injection site 10/16: knot resolved however pain continued 10/17: knot and pain resolved 10/18: pain returned with an intense throbbing sensation 10/24: sought medical care",72.0,Seniors,1,0
878114,Vaccine was given at a different location.  Given at a Pharmacy.  We just gave aftercare for reaction.  Pt had rash all over body and fever.   Given Prednisone.  Still waiting to see recovery results.,52.0,Adults,0,0
872901,"injection site swelling; headache; This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a 66-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st June 2020, the patient received the 2nd dose of Shingrix. In June 2020, less than a day after receiving Shingrix, the patient experienced injection site swelling and headache. On an unknown date, the outcome of the injection site swelling and headache were not recovered/not resolved.   It was unknown if the reporter considered the injection site swelling and headache to be related to Shingrix.  Additional details were provided as follows On 1st June 2020 around 5.30 PM, the patient received the vaccine. On 2nd June 2020, the patient woke up in the morning with swelling at the injection site and a headache.  The reporter consented to follow up.",65.0,Adults,0,0
884118,"A patient who received Pentacel vaccine, was inadvertently administered a dose of IPOL as well, hence received 2 polio vaccine doses in the same day, no AE; Initial information received on 13-Aug-2020 regarding an unsolicited valid non-serious case from other health professional (clinical manager).  This case involves a 4-year-old female patient who was vaccinated with a dose of DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL], was inadvertently administered a dose of IPV (VERO) [IPOL] as well, hence received 2 polio vaccine doses in the same day (extra dose administered).  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  Patient had received no other vaccines or concomitant medication.   On 13-Aug-2020, the patient received fifth dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (lot UJ329AAA and expiration date: 04-Apr-2021) via unknown route in unknown administration site and on also received a 0.5 ml dose of suspect IPV (VERO) (multi dose vial, lot P1F541M and expiration date:07-Dec-2020 ) via unknown route in unknown administration site as prophylactic vaccination.  It was an actual medication error due to extra dose administered (same day latency).   Reporter stated that the Pentacel was given, so that the patient received an extra Hib vaccine dose by getting the Pentacel.  No adverse event reported at the time of reporting.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",4.0,Kids,0,1
882573,"Bicep became swollen 3-4 "" away from injection site and red. Swelling into forearm.",69.0,Seniors,0,0
902492,About 25 minutes after receiving vaccine complained of dizziness and being hot and nauseated. No difficulty breathing. No chest pain. B/P was 130/90 and was monitored. It went down to 124/80 after he started feeling better. He was wearing sweater over shirt and it was warm in building. Took sweater off. Cool wet cloth applied to back of neck. States he had only had a donut and cup of hot chocolate before receiving vaccine. Sprite and peanut butter crackers given. Became nauseated after eating peanut butter crackers Blood pressure monitored monitored. He laid on exam table for about 15 minutes. He felt better. Stood up and walked to conference room for another 15 minutes. Stated he felt much better and was ready to leave. Coworker drove him back. Received email from him letting us know he had made it back and they had stopped and eaten pizza on the way. Received text from coworker that he was dizzy and seeing spots and that his blood pressure had been 120/80 and then spiked to 160/100. Coworkers taking him to ER at Hospital for evaluation.,44.0,Adults,0,0
908261,"Hot; Cold sweats/having night sweats, like she was hot and cold; Cold sweats/having night sweats, like she was hot and cold; Chills; Shakes; intense nausea/ nauseous; just feels nauseous and depleted; it feels like she has the flu; she didn't know if maybe her body was low on oxygen, she didn't feel out of breath, but she just didn't feel well overall; This is a spontaneous report from a contactable other healthcare professional. A 27-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EH9899, expiry: Mar2021), via intramuscular route of administration (left deltoid) on 17Dec2020 17:40 at a single dose for COVID-19 immunisation. The patient's medical history included sulfa drug allergies. There were no concomitant medications used. The patient was having some intense nausea, and throughout the night, she had night sweats. It was further stated that she woke up a 12AM, today (18Dec2020), and she just felt like she had the flu. She was nauseous, and she was having night sweats, like she was hot and cold, and she tried to go back to sleep, but then she had an episode of chills and the shakes, and every time she was about to fall asleep, it was like her body would wake her up. Patient stated that in her mind, she didn't know if maybe her body was low on oxygen, she didn't feel out of breath, but she just didn't feel well overall. All these persisted until about 3AM, and then she went back to sleep. She woke up for the day around 530AM, and she feels a little better now, like she doesn't have the hot and cold fever feeling anymore, she just feels nauseous and depleted. She stated that she sees on her information sheet that these are possible side effects to getting the vaccine, but it feels like she has the flu. Outcome of the events was unknown.  Follow-up attempts are completed. The following information on the batch number has been requested.",27.0,Adults,0,0
906289,This patient received last year's (2019-20) influenza Vaccine on 9/26/20 due to oversight in the supply management process. The patient was notified and had not experienced any adverse effects from that vaccine. The patient did return to the office and received the appropriate Fluad Quadrivalent (2020-21) Influenza Vaccine.,78.0,Seniors,0,1
893305,"Temperature excursion; This spontaneous report as received from a registered nurse and refers to a patient of unknown age and gender. Medical history, concurrent conditions and concomitant medications were not reported.  On 20-OCT-2020, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) (Route, anatomical location were not provided, lot # S038700 expiration date 01-DEC-2021) for prophylaxis.        The vaccine had temperature excursion of -6.6 C during 1 hour 45 min. There were not previous excursions. Digital data logger was involved.",,Unknown,0,1
900702,"Nurse calling from HCP office to report that a dose of ROTATEQ was given on 12/1/2020 and had expired on 11/26/2020.; This spontaneous report was received from a registered nurse, referring to a patient of unknown age and gender. The patient's pertinent medical history, current conditions, previous drug reactions or allergies and concomitant medications were not reported.   On 01-DEC-2020, the patient was vaccinated with an expired dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ), administered by oral route, as prophylaxis (formulation, strength and vaccination scheme were not provided; lot number S005876, which has been verified to be valid, expiration date reported as 26-NOV-2020, but upon internal review was established as 25-NOV-2020). The vaccine administered did no experience previous temperature excursion.",,Unknown,0,1
864632,Underlying hardened skin induration at site of injection  of size 5x3cm by day 3 Improving and decreased in size to 2x1cm by day 7 Pt seen at clinic on both  the above days,20.0,Adults,0,0
908899,"Difficulty breathing, palpitations, feeling like she is developing hives",33.0,Adults,0,0
874345,"two patients was given ""diluent versus the vaccine"" for Pentacel/no ae; Initial information was received on 22-Jun-2020 regarding an unsolicited valid non-serious case from a other health professional.  This case is linked to case 2020SA162258. (same reporter)  This case involves a one year old male patient who had received ""diluent versus the vaccine"" for DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL] (product preparation error).   Medical history, medical treatment, vaccination and family history were not provided.  On an unknown date, the patient received concomitant medication as HEPATITIS A VACCINE (HEPATITIS A).  On 19-Jun-2020, the patient received a 0.5 mL fourth dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [carton: UJ230AAA, lot UJ315AA, expiry date: 04-Apr-2021] via an intramuscular route in the right thigh for prophylactic vaccination.  It was a case of actual medication error due to Active ingredient not added to diluent.  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",1.0,Kids,0,1
880490,"- Redness in area: upper part of arm = elbow to the top arm (red band) that is ""itchy and painful"" - Administered on 8/20/20 and pain began on Friday approx. in AM and still persisting on 8/24/20 - Ibuprofen provides relief (pain tolerable & only to the touch)",60.0,Adults,1,0
909171,"Headache, mild pain at injection site, lymphadenopathy, fatigue, nausea, malaise",40.0,Adults,1,0
868633,"FORGOT TO TAKE LAST DOSE; This spontaneous case report (PVX2019-2513) was received from a consumer on 08-Oct-2019. It described a female consumer who ""forgot to take last dose"" (PT: Product dose omission), while being on Vivotif for typhoid prophylaxis.  Case report: The consumer took first three doses of Vivotif, but forgot to take the fourth dose, which was due on 07-Oct-2019.  Action taken with Vivotif with respect to the event was not applicable.  The clinical outcome of the reported event was unknown.  Company's Comment: The causality of the event ""forgot to take last dose"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""forgot to take last dose"" was considered as not applicable.",,Unknown,0,0
888856,"Patient presents to clinic on 10/8/2020 for another reason and mentioned to me that he has a tennis ball size lump in his left armpit after receiving the shinrix vaccine on 10/1/2020.  He also notes that he felt unwell for a couple of days, but was warned that he may feel unwell, the lump was unexpected and he wonders if it is normal.  He notes that it became large on the day the vaccine was given, but has not changed since then.  It is no longer getting bigger and is only painful if he uses the arm too much or pushes on it.",61.0,Adults,0,0
862252,UNMONITORED TEMP FOR 63H,9.0,Kids,0,0
906171,"Patient became slightly tachycardic (HR 145, BP 140/75) and light-headed.  Described as anxiety attack.  Patient laid down and feet were elevated and heart rate and blood pressure returned to normal.  Patient was observed for another 30 minutes and released",23.0,Adults,0,0
901498,11/7/2020  after vaccine patient experience some pain in the arm with a slight headache about 4pm.  At 8:30 pm caller went to bed and callers husband  found caller to be confused with fever 107. Callers husband called ambulance and caller was taken hospital. O2 stats were 40 and blood sugar was 50.Caller stayed in hospital for 48 hours and was released on Tuesday.,0.08,Kids,0,0
889671,"Temperature 35.6 F; This spontaneous report was received from a medical assistant referring to a patient of unknown age and unknown gender. Information about medical history, concurrent conditions and concomitant therapies was not provided.  On 24-SEP-2020, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (lot# 1637651 with expiration date 09-JUN-2022, dose detail and route were not reported) for prophylaxis.  The vaccine was stored at 35.6 Fahrenheit degrees (F) for 3 hours and 15 minutes (product storage error). There was a previous temperature excursion and the call was because of a data logger involved.   This is one of two reports received from the same reporter. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. devicelotnumber: 1637651; expirationdate: 09-JUN-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2010USA003213:",,Unknown,0,1
890048,"Swelling of lips and eyes, patient took Benadryl, swelling has stopped",72.0,Seniors,0,0
890248,"pt presented back to office on 10-16-20 with quite large local reaction with redness, warmth, and local itching, but no tenderness, no fever, no systemic s/s of allergic reaction, I placed pt on hydroxyzine as needed for itching and a 3 day course of oral steroid for swelling, advised family to apply cool compress as tolerated and monitor for worsening s/s, advised family that this looks to be a local reaction and not an allergic reaction to the vaccine, antibiotic is not indicated at this time, family to call if worsening or concerns",4.0,Kids,0,0
905355,"sniffles; Initial information received on 10-Dec-2020 regarding an unsolicited valid non-serious social media case from a consumer (patient).  This case involved a patient with unknown demographics who experienced sniffles (rhinorrhea), while he/she received vaccine INFLUENZA VACCINE.  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via an unknown route at an unknown administration site.    On an unknown date, the patient developed a non-serious sniffles (rhinorrhea) (Unknown latency) following the administration of INFLUENZA VACCINE.  Details of laboratory data not reported.  It was not reported if the patient received a corrective treatment.  The event outcome was reported as unknown, at the time of reporting.  There will be no information available on the batch number for this case.",,Unknown,0,1
875390,"Donor reports of weakness about an hour after shot and felt Nausea, vomiting, and feverish for 24 hours. Donor  reports of taking Tylenol and Ibuprofen and a good night of rest and felt back to her normal self.",29.0,Adults,0,0
907879,"benign accrural papulovesicular eruption, onset about 3 weeks post-injection. Similar reaction within two weeks of his influenza immunization 31 OCT 2019.",22.0,Adults,0,0
856409,"Fever, chills, rash. I developed a rash, fever and chills starting the evening after receiving my second shingrix vaccine on Friday, 1/3/2020. Symptoms developed approx. 12 hours after receiving the shot. The rash was a 3"" diameter red spot around the injection site (left arm). The fever measured around 99.8F, and I developed chills requiring blankets all over me. I took aspirin, the fever came down, and the next day I was better but sore all over. I was much better on Sunday. I received the shot at Pharmacy.",58.0,Adults,0,0
884123,"80 year old female patient inadvertently received the fluzone quadrivalent instead of fluzone high dose, no AE; Initial information received on 25-Aug-2020 regarding an unsolicited valid non-serious case received from a pharmacist.  This case is linked to case 2020SA228800.  This case involves a 88 year old female patient who inadvertently administered INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT] instead of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (wrong product administered).  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  At the time of the event, the patient had ongoing has cancer and receives chemo.   On 24-Aug-2020, the patient received a 0.5 ml dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (lot UJ428AA and expiry date: 30-Jun-2021) via an intramuscular route in the left arm for prophylactic vaccination.  It was a case of actual medication error due to wrong product administered and product administered (same day latency).  At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",88.0,Seniors,0,1
890235,"Pain at the shoulder; Swelling at the shoulder; 1st dose March 10, 2020 and 2nd dose on October 1, 2020; Limitied range of motion at shoulder; Injection site Pain; Swelling; Hardness (Induration); Hot temperature (at injection site); Diarrhea; Fatigue; This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a 80-year-old female patient who received Herpes zoster (Shingrix) (batch number 453S4, expiry date 19th March 2022) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 10th March 2020).   On 1st October 2020, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 1st October 2020, less than a day after receiving Shingrix, the patient experienced injection site pain, injection site swelling, injection site induration, injection site warmth, diarrhea, fatigue and mobility decreased. On an unknown date, the patient experienced shoulder pain, swollen joints and drug dose administration interval too long. On an unknown date, the outcome of the injection site pain, injection site swelling, fatigue and mobility decreased were not recovered/not resolved and the outcome of the injection site induration, injection site warmth, diarrhea and drug dose administration interval too long were recovered/resolved and the outcome of the shoulder pain and swollen joints were unknown.   It was unknown if the reporter considered the injection site pain, injection site swelling, injection site induration, injection site warmth, diarrhea, fatigue, shoulder pain, swollen joints and mobility decreased to be related to Shingrix.  Additional details were provided as follows: The pharmacist was reporting numerous adverse events that were reported by the patient.  The patient received Shingrix and experienced, injection site pain, swelling, induration and hot temperature at injection site.  The pharmacist reported that the patient experienced diarrhea 6 hours after vaccine administration which has resolved.  The pharmacist added, the patient continues to complain of fatigue, pain and swelling at the shoulder as well as limited range of motion of the shoulder.  Additionally, the pharmacist noted the patient has been to her doctor and they have ordered an MRI of her shoulder.  The patient received 2nd dose late, which led to lengthening of vaccination schedule. The reporter did not consent to follow up.",80.0,Seniors,0,0
895556,"1-1 1/2 week after shot, arm started  to ached & stabbing pain certain movements hurt, like pulling off a shirt, or rotating  arm. Pain is still going on Also experience soreness in Rt shoulder blade & cont'd to rt side neck area. This has dimenses",65.0,Adults,1,0
858133,"Employee had constantly watering eyes, cough and felt like throat was swollen.",57.0,Adults,0,0
902477,"Swelling, rash, pain , headache, shivering all night, fever next day started in the afternoon. Rash spreading  Talked to a medical assistant and the dr. Pharmacist. Used Benadryl cream and liquid Benadryl. Advised to use my triamcinolone ointment, that helped the rash. Took 2 Tylenol at w different times. That helped. Fever gone on Friday, rash receding. No more side effects.",73.0,Seniors,0,0
889459,"Patient arm was red and swollen from the shot from Saturday afternoon. She went to the doctor on Tuesday morning as swelling and red did not go down. Doctor told her it was a localized infection from a flu shot, for her to take benadryl, ice the area, and rest. If the area expanded or patient developed fever she was to return to the doctor. We called the patient back on Thursday 10/8 and she was doing much better and did not need to return to the doctor.",66.0,Seniors,0,0
910871,Tightening in face/jaw after vaccine.  Subsided on its own with no treatment necessary.  Somewhat red cheeks.,33.0,Adults,0,1
873542,"Patient developed 1 inch sized redness day after vaccination to right upper thigh and grew daily until contact office on 6/15/20 late afternoon. Office visit on 6/16/20 found to have red, swollen area to right upper thigh measuring 28 x 14 cm. Patient denies any pain, fever or other symptoms. Dx: Cellulitis  Tx: Keflex and Prednisone",5.0,Kids,1,0
882079,"Large 3in x 2 in reddened area, hard, tender, hot to the touch.",11.0,Kids,0,0
909119,Massive headache 7/10 take came on after I woke up from a 5hr nap after I got my vaccine I am also feeling tired. My arm is feeling a bit sore (esp if I raise it) but not worried about that. My headache really hurts more then my usual post covid headaches which I've recently gotten under control I took sumatriptan to see if it will help. Will eat and probably go back to sleep. (it's 3pm for reference),30.0,Adults,0,0
905424,"I get sick every time; Initial information regarding this unsolicited valid non-serious social media case received from a consumer on 16-Dec-2020.  This case involved a patient who get sick every time, after receiving vaccine INFLUENZA VACCINE.  Relevant medical history, concomitant medications and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route in unknown administration site.   On an unknown date, the patient get sick every time (Illness), unknown latency following the administration of INFLUENZA VACCINE.  Relevant laboratory test was not reported.  Final diagnosis was get sick every time.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome was unknown for the reported event.  There would be no information available on batch number for this case.",,Unknown,0,1
910130,"On 12/24/20  I received the vaccine at Pharmacy, later that night I woke up feeling very cold. My temperature for the first 2 days of 103.1, chills, body aches, veins in my eyes busted. The fever has continued, today 12/28/20, 100.8, I feel dizzy, tired. Due to the holiday, will be seeing my PCP today.",35.0,Adults,0,0
885734,"Rash around her trunk area of the; Chills; This case was reported by a other health professional via sales rep and described the occurrence of rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, less than 4 months after receiving Shingrix, the patient experienced rash and chills. On an unknown date, the outcome of the rash and chills were unknown.   It was unknown if the reporter considered the rash and chills to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix injection to a local pharmacy and did not know if it was 1st or 2nd dose 3 to 4 months ago and reported a rash with chills around her trunk area of the body.  The Doctor had just left the office but took her laptop with her that had more information such as date of birth, patient initials and maybe if other Vaccinations were recommended that day.",,Unknown,1,0
905918,tingling in arm & chest directly after vaccine given.  Tightness in throat and a little feeling of short of breath.    Went to emergency dept and received bendaryl & solumedrol - symptoms resolved except arm tingling.,42.0,Adults,0,1
911665,"expired IPOL administered to patient; Initial information regarding an unsolicited valid non-serious case was received from an other health professional. This case involved a 4 year old female patient who received a dose of IPV (VERO) [IPOL] (lot number: P1F541 and Expiry date: 07-Dec-2020) via an unknown route in left arm for prophylactic vaccination (Expired product administered).  Medical history, medical treatment, vaccination and family history were not provided.  Concomitant medications included DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID (DTAP) for Immunisation; and MEASLES VACCINE, MUMPS VACCINE, RUBELLA VACCINE (MMR) for Immunisation.  It was an actual medication error case due to expired vaccine used (latency same day).   At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",4.0,Kids,0,1
883095,"patient received a 0.05 ml invalid dose of Adacel ,No AE; Adacel was administered after being exposed to 30 Farenheit, No AE; Initial information received on 11-Aug-2020 regarding an unsolicited valid non-serious case from the other health care professional.  The case is linked to the cases 2020SA209621 and 2020SA210303 (same reporter).  This case involves a 33 years old female patient who received a 0.05 mL invalid dose of  DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] (batch number and expiration date were not reported), after being exposed to 30 Fahrenheit via unknown route in the right deltoid as prophylactic vaccination on 09-Aug-2020.  Medical history, medical treatment and family history were not provided.  No other medication or vaccinations were received on this visit.   It was an actual medication error case due to product storage error temperature too low.  It was also a case of vaccine underdose.  No adverse event reported at the time of reporting.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information on the batch number for this case.",33.0,Adults,0,1
886634,patient received vaccine that morning and later that evening around 5pm called the pharmacy and said her arm had begun to swell and was red and a little warm to touch. No difficulty breathing or swelling of face or throat. Just in the arm where vaccine was given.,75.0,Seniors,0,1
855303,"The patient is not experiencing any symptoms. No additional adverse effect reported; The patient was administered the live VARIVAX vaccine less than 28 days after she received the live influenza vaccine, FLUMIST; This spontaneous report was received from a nurse referring to a female patient of unknown age. The patient pertinent medical history, concurrent conditions, drug reactions or allergies were not reported.   On 26-AUG-2019, The patient was vaccinated with first dose of varicella virus vaccine live (oka/merck)(VARIVAX), subcutaneous for prophylaxis (strength, dose, frequency, lot number and expiration date were not provided).   On 27-NOV-2019, the patient was vaccinated with second dose of varicella virus vaccine live (oka/merck)(VARIVAX), subcutaneous for prophylaxis (strength, dose, frequency were not provided) (Lot number S005085 is an invalid lot number for varicella virus vaccine live (oka/merck)(VARIVAX), expiration date 19-FEB-2021), less than 28 days after received the live influenza vaccine, influenza virus 3v reassortant vaccine live intranasal (cold adapted ann arbor master strain) (FLUMIST) who was administered on 05-NOV-2019 (inappropriate schedule of product administration). The patient not experienced any symptoms, no additional adverse effect reported.",,Unknown,0,1
862039,"currently had a pap with positive HPV; currently had a pap with positive HPV; This spontaneous report was received from a registered nurse referring to a female patient of unknown age.  Information about medical history, concurrent conditions and concomitant therapies was not provided.      On an unknown date, the patient was vaccinated with quadrivalent human papillomavirus (types 6,11,16,18) recomb. Vaccine (GARDASIL) (strength, dose details, route, lot # and expiration date were not reported) for prophylaxis. On an unknown date, the patient currently had a pap with positive human papilloma virus (HPV). The outcome of the events was unknown. The causality assessment was not reported.",,Unknown,0,1
882273,"Vomiting, trembling, headache, weakness, tiredness and unusual swelling at injection site.",64.0,Adults,1,0
912672,"Patient developed persistent nausea one day after vaccination with Pfizer COVID-19 vaccine.   Nausea is ongoing 7 days post vaccination.  Patient has not had any vomiting, diarrhea, myalgias, fever, and endorses no pain or tenderness in her abdomen.  She has taken promethazine oral with minimal relief of nausea.",50.0,Adults,0,0
867671,"Pentacel dose was given sooner than intended to the patient; the injection site quickly turned a little red; Initial information received on 24-Mar-2020 regarding an unsolicited valid non-serious case received from a consumer/non-healthcare professional.  This case involves a 15 months old male patient who developed the injection site quickly turned a little red (vaccination site erythema), while he received vaccine DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL].  Medical history, medical treatment, vaccination and family history were not provided.   On 07-Jan-2020, the patient received a dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (lot number not reported) via unknown route at an unknown administration site. On 24-Mar-2020 he also received a dose of the same vaccine with an unknown batch number via unknown route at left hip area.  On 24-Mar-2020, the patient's injection site quickly turned a little red (vaccination site erythema) (non-serious), 2 months 17 days following the initial dose and on the same day following the last dose administration of DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE.  The reporter stated that her physician called her after her son's visit today and informed her that Pentacel was given sooner than intended. He had a dose of Pentacel on 07-Jan-2020 and again today on 24-Mar-2020. Today's dose was given in the left hip area. The reporter reported that her son does not follow the typical schedule of vaccinations. Reporter was unsure which dose this was for her son. Today when it was given, the injection site quickly turned ""a little red"". The doctor told her this is common with vaccines which contain tetanus. Patient was fine otherwise. Patient had no fever.  It was also a case of actual medication error due to Drug dose administration interval too short.  No laboratory data were reported.  Final diagnosis was vaccination site erythema.   It was not reported if the patient received a corrective treatment.  Event outcome was not reported for vaccination site erythema.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information available on the batch number for this case.",,Unknown,0,0
892171,"On the ride home after receiving the vaccination, the patients mother noted his pulse ox to be low (88%). She reports that he had a weak cry, looked purple, and was limp. She also notes that his eyes rolled to the back of his head. The mother did not notice any abnormal body movements associated with the episode. The mother took the patient out of the car seat and his coloration improved. She brought him to the ER.",0.33,Kids,0,0
898417,Patient was administered full dose of oral rotavirus vaccine. She spit up vaccine and it splashed into her eye. Eye was washed out F/u call without mom showed no effect,0.33,Kids,0,1
875657,"Within a week of the vaccine, arm started to feel tender below the shoulder. Pain then radiated down the arm. Felt like a numbness and tingling, similar to nerve pain. Now the numbness has moved to all parts of the body. Patient no longer able to do day to day physical activities.",70.0,Seniors,0,0
890094,"redness and swelling at site, benadryl was ordered",3.0,Kids,0,0
874924,"Patient Received Combo vaccine of Dtap & IPV (Quadracel) and called our office the next day to report a fever of 102.1'F. Gave tepid Bath & Tylenol, Fever down to 99'F. Mom states he vomited that night but no longer having any sx.",48.0,Adults,0,0
887206,Approx. 6 hours after injection I started feeling soreness in my R eye. Mild swelling developed and has persisted. Feels like I have a black eye. Swelling mostly above the eye on the inside-side. There is no excess mucus production or fluid being produced by the eye.,,Unknown,0,0
905768,"Left facial nerve tingling; discomfort especially around orbital area and cheek; discomfort especially around orbital area and cheek; Left posterior neck and head discomfort; Left posterior neck and head discomfort; This is a spontaneous report from a contactable Nurse reporting for herself.   A 54-years-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK5730), intramuscular in left deltoid at hospital on 16Dec2020 08:45 at single dose for COVID-19 immunization. The patient was not pregnant at the time of vaccination. Medical history included colitis ulcerative as a child, colectomy total 27 years before. The patient previously experienced allergy to IV contrast as hives. Concomitant medication included loperamide hydrochloride (LOMOTIL) and bifidobacterium breve, bifidobacterium infantis, bifidobacterium longum, lactobacillus acidophilus, lactobacillus bulgaricus, lactobacillus paracasei, lactobacillus plantarum, streptococcus thermophilus (VSL#3).  The patient experienced left facial nerve tingling, discomfort especially around orbital area and cheek; left posterior neck and head discomfort lasting 60-90 minutes on 16Dec2020 18:00 with outcome of recovered on 16Dec2020. The events resolved on own, no medications taken. Prior to vaccination the patient was not diagnosed with COVID-19 and has not been tested for COVID-19.",54.0,Adults,0,1
913289,"very sore arm, woke up very bloated, diarrhea, dizziness (slight), night before a little more asthma than usual nothing serious",29.0,Adults,1,0
876931,"No additional adverse effects reported; one patient was administered a dose of improperly stored VARIVAX; This spontaneous report was received from a physician, referring to a 3-year-old patient of unknown gender. The patient's pertinent medical history, concurrent conditions, concomitant medications, previous drug reactions, or allergies were not reported.  On 30-JUN-2020, the patient was administered a dose of improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) injection (strength, dose, vaccination scheme, anatomical site of injection and route of administration were not reported; lot number S012036, expiration date: 17-APR-2021) as prophylaxis (product storage error). The vaccine was reconstituted with properly stored sterile diluent (DILUENT MRK) (lot number S033779, expiration date: 16-JUN-2022; lot number S030249, expiration date: 02-JUN-2022 or lot number S036204, which has been verified to be valid, expiration date reported and validated as 03-JUL-2022). No additional adverse effects reported.  On an unknown date, the vaccine experienced a temperature excursion between 15 degrees Fahrenheit (F) to 46F (32.9F) for 5 hours, as recorded by a data logger. There was no previous temperature excursion.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2007USA005592: US-009507513-2007USA005952:",3.0,Kids,0,1
900980,"lack of appetite; dizziness; energy ever since; Initial information regarding an unsolicited valid non-serious case was received from a other health professional via regulatory authority (Reference number- US-SANOFI-00336223) and transmitted to Sanofi on 28-Oct-2020.  This case involves a 71 year old female patient who had lack of appetite (decreased appetite), dizziness (dizziness) and energy ever since (asthenia), while she received INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  Medical history, medical treatment(s), vaccination(s) and family history were not provided.   Concomitant medications was not applicable.  On 20-Oct-2020, the patient received a 0.7 ml dose of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] (lot UJ512AA, expiry date 30-Jun-2021) once (standard) via intramuscular route in the right deltoid for prophylactic vaccination.  On 20-Oct-2020, the patient developed a non-serious lack of appetite (decreased appetite), dizziness(dizziness) and energy ever since (asthenia) (same day) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  No laboratory data was provided.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome of event was unknown.",,Unknown,0,0
882124,"experiencing  fever, chest pain  and has rash all over her left arm",65.0,Adults,1,0
889039,"Patient's arm began to get red and swell a few hours after vaccine was administered. She took Benadryl and applied cold compress. Pharmacist checked back in with her in a few hours and patient's symptoms were better but still present. When contacted two days later she was still having symptoms. She did not wish to get medical care, but will continue to take Benadryl and ibuprofen. Will seek medical if necessary.",66.0,Seniors,0,1
884719,extreme body aches starting around 7 hours after vaccine. Low grade fever also.  Lasted for approximately 48 hours after vaccine.,58.0,Adults,0,0
902448,"stroke; neuropathy; post herpetic neuralgia; cardiovascular event; vision problems; hearing problems; balance problems; herpes zoster; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. Information on the patient's concurrent conditions, medical history or concomitant therapy was not reported.  On or about 10-AUG-2015, the patient was inoculated with zoster vaccine live(ZOSTAVAX) (lot#, expiration date, dose, route of administration and anatomical location were not reported) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster).  On an unknown date, shortly after receiving zoster vaccine live(ZOSTAVAX), the patient suffered multiple outbreaks of herpes zoster, post herpetic neuralgia, stroke, cardiovascular event, vision problems, hearing problems, balance problems and neuropathy. As a result of these symptoms, patient was seen and treated by medical providers and was still under their care. As a direct and proximate result of zoster vaccine live(ZOSTAVAX), patient's symptoms have resulted in physical limitations not present prior to using zoster vaccine live(ZOSTAVAX). Patient also experienced mental and emotional distress due to resulting physical limitations and seriousness of patient's condition. As a result of zoster vaccine live(ZOSTAVAX), patient sustained severe and permanent personal injuries. Further, as a tragic consequence of Company's wrongful conduct, patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of Company's conduct, patient suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages.  The reporter considered all events to be disabling and related to Zoster Vaccine Live(ZOSTAVAX).  Upon internal review, the events of stroke and neuropathy were considered to be medically significant.",,Unknown,0,1
864345,"pt came in for flu shot and blood draw in afternoon. several hours later, at dinner, felt lightheaded (had eaten some, drank 1 glass alcohol), got up to go to the bathroom and syncopal event. came to in a chair, witnessed and witnesses had helped her into chair",31.0,Adults,0,1
898505,"four children including my son went in with this illness; Suspected vaccination failure; This case was reported by a consumer via interactive digital media and described the occurrence of bacterial meningitis in a child patient who received Men B NVS (Meningococcal B vaccine) for prophylaxis.   On an unknown date, the patient received Meningococcal B vaccine. On an unknown date, unknown after receiving Meningococcal B vaccine, the patient experienced bacterial meningitis (serious criteria death and GSK medically significant) and vaccination failure (serious criteria GSK medically significant). On an unknown date, the outcome of the bacterial meningitis was fatal and the outcome of the vaccination failure was unknown. The reported cause of death was bacterial meningitis.   The reporter considered the bacterial meningitis and vaccination failure to be related to Meningococcal B vaccine.  Additional details were provided as follows: Age at vaccination was not reported. It was reported that vaccine meningitis B, did not protect from bacterial meningitis. The patient went in with this illness and did not survive. This case was considered as vaccination failure, since the details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation were not provided.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR232424:same reporter US-GLAXOSMITHKLINE-US2020AMR232426:same reporter US-GLAXOSMITHKLINE-US2020AMR232267:same reporter; Reported Cause(s) of Death: Meningitis bacterial",,Unknown,0,1
855674,"Patient given TD and Tdap at same visit. TD to right deltoid and Tdap to left deltoid. No adverse reaction noted, no fever, no rash, no pain, no streaking, no shortness of breath, no syncopal episode, no swelling at site of injection. Pt left facility in no acute distress.",,Unknown,1,0
857082,"Pt experiencing redness, swelling, itching, heat and pain at injection site.  Itching started Wednesday evening  (1/15) followed by rest of symptoms on Thursday (1/16)",72.0,Seniors,1,0
900719,"Patient started feeling her finger tips numb about 3 days after taking her vaccination. Consulted with her PCP that did not do anything at the time. In the beginning of September the symptoms got worse. Her fingers she can not move then or do anything. Then her arms started getting numb, and painful. It is from her fingers up to her neck. Her fingers are mostly numb. After some weeks she started having problems walking. Her daughter had to buy her a wheelchair. She can't move her head very well and she can't take care of her primary daily activities by herself as taking a shower, going to the bathroom, she can't dress herself without help, wash dishes doing nothing. She also got depressed, crying a lot and a family family member told her to talk to her PCP who referred her to a specialist and she does not remember her name. She said the specialist prescribed her some pills that are helping her with depression. Patient said the pain at the injection site is so severe she can't wear long sleeves. A Sleeve touching the site is very painful to her. She also says her fingers are swollen and she said she does not feel them anymore. She states she does not have any mobility in both arms. She was prescribed physical therapy but she does not believe it is helping.",70.0,Seniors,1,0
879021,"Pt called on call service with ""severe joint pain"" throughout entire body.  OTC product instructions given via Dr.",17.0,Kids,1,0
904767,"got sick years ago when had the last one; Initial information received on 23-Nov-2020 regarding an unsolicited valid non-serious case from a consumer via Social media from the .  This case involves an Adult patient who experienced got sick years ago when had the last one (illness), while the patient received INFLUENZA VACCINE [INFLUENZA VACCINE].  Medical history, medical treatment, vaccination and family history were not provided.    On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number: not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, after started vaccine, the patient reported that no shot here and got sick years ago when had the last one (illness) (Unknown latency) following the administration of INFLUENZA VACCINE.  No laboratory data was provided.  Final diagnosis was illness.   It was not reported if the patient received a corrective treatment.  The outcome was reported as Unknown for illness.",,Unknown,0,1
890196,"Soreness; This case was reported by a other health professional via interactive digital media and described the occurrence of pain in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 5th October 2020, the patient received the 1st dose of Shingrix. In October 2020, less than a week after receiving Shingrix, the patient experienced pain. On an unknown date, the outcome of the pain was unknown.   It was unknown if the reporter considered the pain to be related to Shingrix.  Additional deatils were provided as follows: The age at vaccination was not reported. The age group of patient was not provided but captured as adult as per vaccine indication. The patient was vaccinated with 1st dose of Shingrix on past Monday afternoon of reporting day. After vaccination patient had soreness.",,Unknown,0,0
880272,Patient reported that he had a 102 degree fever the night of 8/14/20 after receiving the Fluad Quadravalent vaccine on 8/13/20. The fever worsened to 105 degrees the night of 8/15/20. He treated at home with Tylenol and his temperature returned to normal on 8/16/20.,66.0,Seniors,0,0
877585,"Side effects; This case was reported by a consumer via interactive digital media and described the occurrence of adverse drug reaction in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 21st July 2020 16:00, the patient received the 2nd dose of Shingrix. In July 2020, less than a week after receiving Shingrix, the patient experienced adverse drug reaction. On an unknown date, the outcome of the adverse drug reaction was not recovered/not resolved.   It was unknown if the reporter considered the adverse drug reaction to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The age group was not reported but was selected as an adult as per vaccine indication. The patient received Shingrix and experienced most of the side effects listed but not severely. The patient asked how long the side effects lasts.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR133646:same reporter",,Unknown,0,1
912765,"Headache, nausea, stomach cramps, diarrhea",49.0,Adults,1,0
890574,Patient reports soreness under arm and slight swelling/tenderness on left side near breast but no soreness/swelling at injection site. Unsure if related to vaccine. Patient is contacting her primary care doctor.,71.0,Seniors,0,1
899998,"Narrative:  Per note dated 5/8/20: -Anaphylactic protocol immediately initiated. EpiPen administered, 50 mg Benadryl IV, 20 mg famotidine IV, Solu-Medrol 125 mg IM stat issued. 500 mL normal saline started. EKG obtained which demonstrated normal sinus rhythm. Within 5 minutes of medications administration, patient states all symptoms are resolved however now complaining of some diffuse abdominal cramping and some nausea. Zofran 4 mg by mouth administered, CBC, CMP, UA and culture, hCG test ordered Symptoms:  Dizziness, SkinRash, Rash, UrticariaPruritus, NauseaVomiting, HYPERtension & Tachycardia Treatment:",38.0,Adults,1,0
881374,"Muscle pain, fatigue, headache, fever, shivering, diarrhea, starting mid-afternoon after I received the injection, continued for approximately 36 hours.",53.0,Adults,1,0
894355,Woke up vomiting and have vomited twice more since waking.,28.0,Adults,0,0
911913,Injected into tricep instead of deltoid,33.0,Adults,0,0
872672,"frozen shoulder; a partial tear of her right rotator cuff; not able to raise her arm above her head/ she was unable to move her hand and arm; right shoulder pain/ pain at the injection site/ her right arm was burning and throbbing; swelling; This spontaneous report has been received from a lawyer, regarding a case in litigation and refers to a female patient of unknown age. The patient's concurrent conditions, medical history and concomitant medications were not reported. On 03-APR-2018, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) lot# N005597 (expiry date not provided but upon internal validation established as 19-OCT-2018) and diphtheria toxoid, pertussis acellular 5-component vaccine, tetanus toxoid (ADACEL) lot# C5446AA, both administered in right shoulder (dose, route of administration were not provided) for prophylaxis at medical clinic. On or about 04-APR-2018, less than 48 hours after receiving her vaccinations, the patient returned to medical clinic with right shoulder pain. She stated that she had pain at the injection site where the vaccinations were administered. The patient's shoulder pain was so substantial that she was unable to move her hand and arm. Her physician's plan of care for the patient included taking ibuprofen and icing her arm for the next 48 hours and she advised the patient to stay home for 24 to 48 hours and not go to work. On or about, 09-APR-2018, the patient again returned to her physician because her right shoulder pain had not diminished. The patient stated that the pain in her right shoulder was constant and that she was able to obtain some relief from ibuprofen, but that the pain was still an 8 on a scale of 1-10 and that her right arm was burning and throbbing. Physician advised the patient to avoid lifting with the affected arm and to put ice or a cold pack on the sore joint for 10 to 20 minutes at a time every 1 to 2 hours for the next 3 days or until the swelling went down. Further, the physician ordered a magnetic resonance imaging (MRI) of the patient's right shoulder, which was completed on 18-APR-2019 (conflicting information). On or about, 19-APR-2018, the patient again visited her physician to follow-up on her right shoulder pain. She had then regained some range of motion in her shoulder but was still not able to raise her arm above her head. During this visit, physician extended patient's disability until 19-JUN-2018. On or about, 31-MAY-2018, the patient established care with physician for an evaluation of her MRI as well as a diagnosis of her shoulder pain. Physician informed the patient that she had a partial tear of her right rotator cuff and what he referred to as ""frozen shoulder."" Prior to 03-APR-2018, the patient was not suffering from any shoulder pain or injury on the date that she received the vaccinations. The patient continued to suffer residual effects and complications from the shoulder injury she received as a result of the vaccinations. She was unable to work from 04-APR-2018, until 28-FEB-2019, due to the residual effects and complications from the shoulder injury she received as a result of the vaccinations. As set forth fully above, the patient sustained personal injuries as a result of the vaccines. As a direct and proximate result, the patient suffered personal injuries and damages, including, but not limited to, past and future medical expenses, past and future loss of earnings, and pain and suffering. The outcome of the events was unknown. The reporter considered the events to be related to pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) and diphtheria toxoid, pertussis acellular 5-component vaccine, tetanus toxoid (ADACEL).  The events were considered to be disabling by the reporter. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: N005597; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent",,Unknown,0,0
860774,"At 6am today (2/7/20) patient complained of not feeling well, was dizzy all night and his temp at that time was 101 F. He stayed home from school all day and his Mother checked his temp at 2.15 pm it was 99.7 F He did take Tylenol during the day. I advised Mom to monitor patient and if he did not recover or if synptoms got worse to go to ER or call PCP",11.0,Kids,0,1
902669,"Immediately after the vaccine, I got severely nauseaed, got a yucky metal taste in my mouth and got super lightheaded and hadnt even gotten up.  The agent helped walk me to a chair and I felt really loopy in the head.  After the 15 minutes, I got up and immediately felt the whole room was spinning causing me to have to sit back down another 15 minutes.  Closing my eyes made the dizziness much worse.  I was given juice, my sugar was checked at was 115.  After about 30 minutes I stood and felt alot better.  I went back to my assigned duties but was feeling super bad and my supervisor sent me home because they states I didnt look good.  On the drive home I threw up and my PCP called in Zopran to help with the nausea.",35.0,Adults,0,0
880436,"urticaria; body turns red; Initial information was received on 12-Aug-2020 regarding an unsolicited valid non-serious case from the physician.  This case involves a female patient of unknown age who experienced urticaria and her body turns red (erythema), while she received vaccine TETANUS TOXOID.  The patient's medical history, past medical treatment, vaccination, family history and concomitant medication were not provided.   On an unknown date, the patient received a dose of suspect TETANUS TOXOID produced by unknown manufacturer for prophylactic vaccination (batch number and other dosing details were not reported).  On an unknown date, the patient developed non-serious urticaria (urticaria) and her body turns red (erythema), (unknown latency) following the administration of TETANUS TOXOID.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, the event outcome was not reported.  There will be no information available on the batch number for this case.",,Unknown,0,1
885243,"an injection of MMR II vaccine was given IM instead of SQ; This spontaneous report was received from a pharmacist and refers to a 63-year-old male patient. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.     On 16-SEP-2020, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) recombinant human albumin (rHA), lot # S035356, expiration date 05-NOV-2021, intramuscularly instead of subcutaneously for prophylaxis (exact dose was not reported).",,Unknown,0,1
910131,"I exp sore arm, fatigue, body ache and  after taking Ibuprofen was gone. The fatigue is still lingering not entirely sure if this is due to vaccine.",26.0,Adults,0,0
860681,"experienced vomiting after 1st dose; This case was reported by a pharmacist via call center representative and described the occurrence of vomiting in a 73-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included gluten intolerance.   On 18th January 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced vomiting. On an unknown date, the outcome of the vomiting was unknown.   It was unknown if the reporter considered the vomiting to be related to Shingrix.  Additional details were provided as follows: The patient experienced vomiting after 1st dose of Shingrix. The reporter asked if gluten present in Shingrix, as patient had gluten intolerance. The healthcare professional (HCP) unable to provide full details of vaccine. The reporter asked howto proceed over 6 months for 2nd dose of Shingrix. The reporter Did not consent to follow up.",73.0,Seniors,0,1
867917,"Patient received fluzone high dose vaccine on October 1, 2019. Patient called pharmacy where she received flu vaccine on April 11, 2020 to ask when she had received the vaccine and was stating that her arm was still very sore at the injection site. Patient was asked what she had tried to help with soreness and asked if she had seen a doctor and she had not at this time. We showed our concern and recommended she reach out to her PCP to see about getting her arm checked out and to let us know if she had any further questions.",66.0,Seniors,0,1
869189,"shingles after dose 1 of Shingrix; This case was reported by a physician via call center representative and described the occurrence of shingles in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient had shingles after 1st dose of Shingrix. The reporter consented to follow up. This case has been linked with US2020045152, reported by same reporter.",,Unknown,0,0
913868,"Started the symptoms the next day 12/24: worn down, cough, weak, chill, difficulty breathing.  On Sunday got worse 12/27:  Staff used inhaler.  Went to work and was sent home by his boss. slightly better today, still using inhaler.",53.0,Adults,0,0
887305,"Nausea, dizziness, extreme fatigue, extreme muscle weakness (arms and shoulders, primarily), severe headache, stomach upset, overall feeling of being ""unwell"", slight facial swelling with associated itchiness.  Symptoms presented approx. 3 days after vaccinations received and have thus far persisted to present day.",65.0,Adults,1,0
893727,"Patient describe shoulder discomfort starting 15 minutes after injection. As of today 10/30/2020, is still reporting  shoulder soreness/tenderness. I am reporting to ensure if bursitis or shoulder discomfort continues long term.",79.0,Seniors,0,0
883228,Hives 1.5 days later,70.0,Seniors,0,0
881238,"Swelling of upper arm, Red area about 3 fingers wide 2 inches below from injection site, very, very tender to the touch.",52.0,Adults,0,0
913916,"rash at edge of her face, edge of eyebrow all the way down to her cheek area; Psoriasis; itch at base of her neck/she had an itch at the base of her neck palm size on both sides; This is a spontaneous report from a contactable nurse. A 66-year-old female patient received the first dose of BNT162B2 (Pfizer-BIONTECH Covid-19 Vaccine), via an unspecified route of administration on 19Dec2020 at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient stated that she had a COVID-19 vaccine on Saturday morning and on Sunday (20Dec2020), she had an itch at the base of her neck palm size on both sides. Stated that the rash was on edge of her face, edge of eyebrow all way down to her cheek area. The patient took Benadryl but stated that it still bothered her. She was not sure if it was from the injection or not. Also stated that she did have psoriasis and had treatment for it. Stated that she was okay. She wanted to know if the rash was from the COVID vaccine. Stated that it was her first dose and if she had any other issues than she will call back. Outcome of the events was unknown.  Information on the Lot/batch number has been requested.",66.0,Seniors,0,0
885528,"got the flu shot one year I was so sick; This case was reported by a consumer via interactive digital media and described the occurrence of sickness in a patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis.   On an unknown date, the patient received Influenza vaccine Quadrivalent unspecified season. On an unknown date, less than a year after receiving Influenza vaccine Quadrivalent unspecified season, the patient experienced sickness. On an unknown date, the outcome of the sickness was unknown.   It was unknown if the reporter considered the sickness to be related to Influenza vaccine Quadrivalent unspecified season.  Additional details were reported as follows: The age at vaccination was not reported. The patient reported that got the flu soht 1 year and was so sick, never again and doing great without no thanks. No further information was available.",,Unknown,0,1
885419,"Patient reported cold sores to her right and central upper lip, under her tongue, and into the back of her throat that started a day after receiving the two vaccines.  She reports that today (5 days after vaccines and 4 days after onset of sores) that the pain is improving and she feels she is through the worst of it.  She experienced pain and problems being able to tolerate eating.  Prescribed viscous lidocaine to help with pain.  Denied fevers and body aches.",61.0,Adults,0,0
905954,"Pt states that ~ 20 minutes after receiving the COVID-19 vaccine on her right deltoid, the R side of her face felt numbness and tingling on the R-side of her face. States her muscles felt weaker. Improved after waiting another 10-15 minutes. Advised to monitor and record her symptoms, speak with her doctor if necessary, and enroll in the V-safe reporting app.",32.0,Adults,0,1
878382,"12 year old male patient received Dapatcel instead of Adacel, no AE; 12 year old male patient received Dapatcel vaccine, no AE; Initial information received on 30-Jul-2020 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 12 year old male patient who received a DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL] instead of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] (wrong product administered and product administered to patient of inappropriate age).  Medical history, medical treatment, vaccination and family history were not provided.  Concomitant medication was not reported.   On 27-Jul-2020, the patient received a sixth dose of suspect DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE (lot 2032420 and expiry date: 23-May-2021) via an unknown route at an unknown administration site for prophylactic vaccination.  It was a case of actual medication error due to wrong vaccine administered and inappropriate age at vaccine administration.  At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information available on the batch number of Adacel for this case (it was not administered).",12.0,Kids,0,1
877618,"an expired diluent for ActHIB was used for vaccine administration to a patient, no AE; Initial information received on 23-Jul-2020 regarding an unsolicited valid non-serious case from a health care professional.  This case involves a patient (age and gender not reported) who received 0.5 mL an expired diluent for HIB (PRP/T) VACCINE [ACT-HIB] vial, (Lot Number:UJ112AA, Expiration Date : 21-Jun-2020; Lot Number:UJ112AAC, Expiration Date :21-Jun-2020) once via an unknown route at an unknown administration site for prophylactic vaccination on 23-Jul-2020. It was also reported (Local Trade Name: Act-Hib Lot Number:U6573AD,Expiration Date :2021-03-22)  The patient's medical history, past medical treatment, past vaccination and family history were not provided.  Concomitant medication were not reported.  It was an actual medication error due to expired medical agent used (expired product administered). It was reported there was confusion with the expiration dates printed on the vaccines which gave room for misinterpretation thus expired component of vaccine was given.  At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
913534,Pfizer-BioNTech COVID-19 Vaccine  dizziness upon receiving vaccine,36.0,Adults,0,0
874919,"diarrhea; vomiting; sweats; This case was reported by a consumer via call center representative and described the occurrence of diarrhea in a 65-year-old patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 23rd June 2020, the patient received the 1st dose of Shingles vaccine. On 23rd June 2020, less than a day after receiving Shingles vaccine, the patient experienced diarrhea, vomiting and sweating. On an unknown date, the outcome of the diarrhea, vomiting and sweating were unknown.   It was unknown if the reporter considered the diarrhea, vomiting and sweating to be related to Shingles vaccine.  Additional case details were reported as follows: At 11am, the patient received shingles vaccination. The patient was very ill during the night with diarrhea, vomiting and sweats.  The patient did not recover until approximately noon today. The patient asked was it advisable not to get the 2nd shot in this case.",65.0,Adults,0,1
899035,"Sick; Initial information received on 09-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer or non-healthcare professional.  This case involves 70-years-old patient (unknown demographics) who got sick (sickness), when received INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer, lot number not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious sick (sickness) unknown latency following the administration of INFLUENZA VACCINE.  Laboratory details were not reported.   It was not reported if the patient received any corrective treatment.  The event outcome was unknown for sickness.  There will be no information available on the batch number for this case.",,Unknown,0,1
864463,"severe intermittent pain in the left arm from injection site deltoid; severe intermittent pain in the left arm from injection site deltoid to wrist; This case was reported by a pharmacist via call center representative and described the occurrence of pain in arm in a 76-year-old female patient who received Herpes zoster (Shingrix) (batch number K9M5N, expiry date 7th November 2021) for prophylaxis.   On 28th August 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 6 months after receiving Shingrix, the patient experienced pain in arm and wrist pain. On an unknown date, the outcome of the pain in arm and wrist pain were not recovered/not resolved.   It was unknown if the reporter considered the pain in arm and wrist pain to be related to Shingrix.  Additional case details were reported as follows: The patient received vaccine in left deltoid. The patient experienced severe intermittent pain in the left arm from injection site deltoid to wrist for 6 months and till the time of reporting experiencing it. The reporter did not consent to follow up",75.0,Seniors,0,0
893425,Tic - Blinking eyes due to  DRY EYES,14.0,Kids,0,0
887383,"Because of flu-like symptoms after 1st Shingrix, I took 400 mg Ibuprofen 2 hrs before this 2nd vaccination (per MD). 14 hrs after vaccine, had onset of flu-like symptoms same as before: headache, fever up to 100.8, SEVERE chills (worse than with first vaccination), muscle aches. Took Ibuprofen q 12 hrs per MD and symptoms only lasted about 2 days instead of 3 days.  Injection site was sore but not nearly as swollen and inflamed as first time.  (Filed separate VAERS Report about reaction to 1st vaccination).  PLEASE NOTE: Pharmacy records state 2nd Shingrix was given on August 7, 2020.  It was NOT.  It was definitely given to me on August 10, 2020.",69.0,Seniors,0,0
879631,"Severe headache starting about 8-10 hours after vaccination and lasting about 30 hours  Vomiting- starting about 8 hours after vaccination, lasting about four hours  Shivers/aches/chills/sweats first night after vaccination. Extreme fatigue lasting two days after vaccination.",59.0,Adults,1,0
913249,"30 seconds following IM injection, felt warm, flushed, lightheaded, vision dimming., near syncope. Symptoms improved lying supine. Blood pressure measured to be 90's systolic, Heart Rate 60's. NO RASH, NO ANGIOEDEMA, NO Shortness of breath. Symptoms resolved completely within in 3 minutes.",35.0,Adults,1,0
867832,"reconstituted the vaccine ACT-HIB with sterile water instead of the provided saline/ no AE; Initial information received on 30-Mar-2020 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a two month old female patient who was vaccinated with a 0.5 mL first dose of vaccine HIB (PRP/T) VACCINE [ACT-HIB] (lot UJ161AAA and expiry date 26-Nov-2020) via an intramuscular route in the left thigh for prophylactic vaccination on 26-Mar-2020.  Medical history, medical treatment, vaccination and family history were not provided.  Concomitant medications included DIPHTHERIA VACCINE TOXOID, HEPATITIS B VACCINE RHBSAG (YEAST), PERTUSSIS VACCINE ACELLULAR 3-COMPONENT, POLIO VACCINE INACT 3V (VERO), TETANUS VACCINE TOXOID (PEDIARIX); PNEUMOCOCCAL VACCINE CONJ (PNEUMOCOCCAL CONJUGATE VACCINE); and ROTAVIRUS VACCINE (ROTAVIRUS VACCINE) for prophylactic vaccination.  It is an actual medication error due to wrong solution used in drug reconstitution. it was reported that a dose of ACT-HIB was reconstituted with sterile water instead of the provided saline.  At the time of this report, no adverse event was reported.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",0.17,Kids,0,1
895126,"redness and swelling about 2 and 1/2 inches below injection site (described as 3 inches long, 2 inches wide); patient currently applying ice pack",67.0,Seniors,0,0
877474,PAtient developed significant swellinf of the arm and redness,64.0,Adults,0,0
904185,FACIAL/NECK ERYTHEMA WITH FLUSHING NAUSEA,46.0,Adults,1,0
863652,1st symptom was red spot at site for 4 days with frequent bowel movement resolved after 4 days. 2nd symptoms was lesions on roof of mouth that started 4 days after 1 or 2 and continued until time of report. PATIENT hAs follow-up appt. on 3/9/20 to assess the unresolved oral lesions on roof of mouth.,,Unknown,0,0
901650,"Associate received the vaccine and was sitting in waiting area. Approximately 20 minutes after she received the vaccine she stated she was having Chest tightness and mild SOB. A MET call was started and the team arrived. BP 160/102, no known history of  HBP.  Associate was taken to the ED  per MD at the scene.",30.0,Adults,0,1
904831,PT DESCRIBES PAIN WHEN MOVING ARM. NO BRUISING OR SWELLING. NOTICED A LIMITED RANGE IN MOTION. WILL F/U W/DOCTOR,26.0,Adults,1,0
865417,"Girl vomited after administration; This spontaneous report was received from a physician and refers to a female patient (reported as a girl) of unknown age. There was no information about the patient's concurrent conditions, allergies, drug reactions, concomitant therapies or medical history provided. Family history included brother's vomiting after administration of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) in approximately 2015 (captured in case MARRS# 2002USA007623). On unknown date in approximately 2017 (reported as 2 or 3 years later after brother's vaccination), the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (dose, dose number, lot #, expiration date, route of administration was not reported) for prophylaxis. On unknown date, after the vaccine administration the girl vomited. The outcome of the event was unknown.  The causality assessment between vomiting and suspect therapy was not provided.  This is one of the three cases received from the same reporter.; Sender's Comments:  US-009507513-2002USA009379: US-009507513-2002USA007623:",,Unknown,0,1
887140,"Within 4 days I got the Shingles  on left upper arm & left shoulder near my neck   The rash disappeared within a month, but it's  over a year and I have pain ever day where the rash was on arm & shoulder.  Note ( Had the Shingles vaccine about 15 years ago with no adverse problems )",82.0,Seniors,0,0
892315,Patient developed Rash on the left arm and having some pain.  The symptoms began few days after the immunization was administered.   Patient had notified their Doctor's office and have suggested the patient to follow up with the doctor if the symptoms continues to persist.,66.0,Seniors,1,0
912498,"Tenderness in injection site; This is a spontaneous report from a non-contactable Other HCP (patient). A 34-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) Lot number EJ1685, via Intramuscular route of administration on 23Dec2020 11:15 at single dose on left arm for COVID-19 immunization. Medical history included Gastrooesophageal reflux disease (GERD), Postpartum Depression. Concomitant medication included sertraline. The patient previously received nickel, amoxicillin, penicilline, hepatitis b vaccine and had allergies. The patient had not received other vaccine in four weeks. The patient had no covid prior vaccination. The patient had no covid tested post vaccination. The patient experienced Tenderness in injection site on 24Dec2020. The outcome of the event was resolving.  No follow-up attempts are possible. No further information is expected.",34.0,Adults,0,1
889518,Fever of 99.2 as of 10:30 a.m. on 10/13/2020.,53.0,Adults,1,0
865668,"No additional adverse symptoms reported; patient was inadvertently administered one dose of VARIVAX four days past its labeled expiry; This spontaneous report was received from a nurse and refers to a 12 month old patient of unknown gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On 18-MAR-2020, the patient was inadvertently vaccinated with one dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot # R007695, expiration date 14-MAR-2020, subcutaneous (dose was not reported) for prophylaxis. Concomitant therapies included sterile diluent. The suspect vaccine was four days past its labeled expiry. No additional adverse symptoms reported. The outcome of expired product administered and was unknown.",,Unknown,0,1
883835,"She felt awful,legs felt warm,chills,leg pain.The next day after the vaccination.She vomited once. She then felt slightly better until 9/04/2020 when she had a headache,nausea and fatigue.Found to have an extremely elevated WBC. Sent to ED for admission .Admitted to the PICU on 9/11/2020 ,Diagnosed with T cell ALL .Currently in the hospital.",10.0,Kids,1,0
911279,"headache; take BP. My usual normal is 125/80. 164/93 just mow; This is a spontaneous report from two contactable pharmacists. A 53-year-old female patient received BNT162B2 (lot number: EJ1685), via an unspecified route of administration on left arm on 21Dec2020 07:00 at single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. Patient began getting a headache (H) on 21Dec2020 09:00 (around 9:30), felt like a different kind of headache that progressed. At 2:30, patient went back to monitoring area and asked them to take blood pressure (BP). Her usual normal was 125/80, but 164/93 just now (21Dec2020 09:00). COVID-19 vaccine was administered in the hospital. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Outcome of the events was resolving.",53.0,Adults,0,0
876613,"No additional adverse effects reported.; patients have been administered improperly stored vaccines; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. There was no information about the patient's pertinent medical history, concomitant therapies or drug reactions and allergies provided. The case concerns 1 patient and 1 combination product. On 29-JUN-2020, the patient was vaccinated with improperly stored hepatitis a vaccine, inactivated (VAQTA) prefilled syringe injection, lot # S026003, expiration date 17-OCT-2020 (exact dose and injection site were not reported) for prophylaxis.  Administered dose of vaccine experienced the temperature excursion of below 36 degrees Fahrenheit (29.5 degrees Fahrenheit) for 10 minutes. The digital data logger was involved in recording the temperature excursion details. No previous temperature excursion had occurred. No additional adverse effects were reported. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: S026003; expirationdate: 17-OCT-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2007USA001777: US-009507513-2007USA001779: US-009507513-2007USA001780: US-009507513-2007USA001781: US-009507513-2007USA001782: US-009507513-2007USA001783: US-009507513-2007USA001137:",,Unknown,0,1
885815,"mild headache; mild shivering; 99.5 fever; slight tiredness; This case was reported by a consumer via call center representative and described the occurrence of headache in a 56-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of injection site pain (1st dose received on unknown date. Please refer the case US2020AMR187682.).   On 16th September 2020, the patient received the 2nd dose of Shingrix. On 17th September 2020, 1 days after receiving Shingrix, the patient experienced headache, shivering, fever and tiredness. On an unknown date, the outcome of the headache, shivering, fever and tiredness were not recovered/not resolved.   It was unknown if the reporter considered the headache, shivering, fever and tiredness to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. After receiving 2nd dose the patient experienced the mild headache, mild shivering, 99.5 fever and slight tiredness.  The reporter consent to follow up; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR187682:same reporter",56.0,Adults,1,0
913448,"Started immediately light headed, muscle and joint aches, fever, chills, nausea, headache",37.0,Adults,1,0
887630,"Medical assistant calling to report a temperature excursion that occurred 8/14/2020 which involved the following products: GARDASIL9, PEDVAXHIB, RECOMBIVAX, ROTATEQ. Per caller, ""it would be possible that at least 100 patients have received vaccines; This spontaneous report was received from a medical assistant, concerning a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies or concomitant medications were not reported.  On 15-SEP-2020, the patient was vaccinated with an improperly stored dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) as prophylaxis (lot # T011167 with expiration date 27-MAY-2022) (strength, frequency, route of administration and anatomical location were not reported).  The improperly stored dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) experienced a temperature excursion of 35.4 Fahrenheit degrees (F) for the time frame of 20 minutes without previous temperature excursions. It was confirmed that a digital data logger was involved.  This is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2009USA006106:",,Unknown,0,1
870357,Medication was 1 month out of date when given to patient.,11.0,Kids,0,0
888949,"Patient experienced pain and rash on the arm from the shoulder to the elbow. It started on 10/07 at night. On 10/10, the patient came to reported and she said that it is getting better. Advice her to take Ibuprofen and Benadryl and let her PCP know.",62.0,Adults,1,0
889244,left arm at site of injection was warm and painful to touch that progressively got worse after 2 days,56.0,Adults,1,0
907628,"Employee received vaccine, stayed 15 minutes and left ?. came back within 5-10 minutes c/o throat tightness and difficulty breathing",50.0,Adults,0,1
904353,"Coughing, chest tightness, decreased saturation, itching forehead and back, rash on upper back",52.0,Adults,1,0
884579,patient received injection and started not feeling well. Hisface turned deep red and he planked his body (possible anxiety attack). Patient never lost consciousness but then he started shaking and sweating heavily. Blood pressure was 121/73 pulse 70 and breathing was normal.  Store manager called 911 and paramedics arrived -- checked vitals and patient stated he felt better and did not want to go to the hospital.,24.0,Adults,0,0
904892,"got sick every year; Initial information regarding an unsolicited valid non-serious social media case received from consumer (patient) on 29-Nov-2020.  This case involved patient with unknown demographics who got sick (illness) when received INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concurrent condition, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer, lot number not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date (unknown latency) after the administration of INFLUENZA VACCINE, the patient got sick every year (illness) and for the last 4 years.  Laboratory details were not reported.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome of event was unknown.  There will be no information available on the batch number for this case.",,Unknown,0,1
867402,"Took fourth dose of Vivotif 12 hours late; Spontaneous report received on 24DEC2019.  A female consumer reported that she took fourth dose of Vivotif 12 hours late (PT: Inappropriate schedule of product administration), while being on Vivotif for immunisation. The consumer reported that she took her first three doses of Vivotif according to the schedule, but took the last dose 12 hours late. She stated that instead of taking the last dose at night of 23DEC2019, she took it the next morning on 24DEC2019. Action taken with Vivotif with respect to the reported event was not applicable. The outcome of the reported event was unknown.  Company Comment: A consumer took fourth dose of Vivotif 12 hours late (Inappropriate schedule of vaccine administered). The causality of the event is assessed as not related to Vivotif due to the nature of the event. ; Sender's Comments: A consumer took fourth dose of Vivotif 12 hours late (Inappropriate schedule of vaccine administered). The causality of the event is assessed as not related to Vivotif due to the nature of the event.",,Unknown,0,1
875653,"Flu like symptoms.  Body aches, nausea",65.0,Adults,1,0
862190,"Provider ordered Dtap, nurse gave Kinrix. Patient's mother was called with med error. Patient not having any adverse reactions at this time.",3.0,Kids,0,0
863344,"Patient took the Vivotif on 1/22/20, 1/24/20/, 1/26/20, and 1/28/20. On approximately 2/18/20, she began to develop a rash on her arms.  The rash/ hives continue to develop on her arms, hands, neck, back and as of today 2/27/20 continue to appear.  She has had one on her ankle, but mostly arms and back trunk.  They are raised, red, and extremely itchy.  They seem to have a whitish center that ""crusts"" or ""scabs"" as it heals.  But so far, new spots appear, but none have gone away completely.  She has no fever or trouble breathing.",18.0,Adults,1,0
916590,Hives,42.0,Adults,0,0
867103,"ACHING; FEVER; This spontaneous case report (PVX2019-2483) was received from a consumer on 01-Oct-2019. It described a male consumer who experienced ""aching"" (PT: Pain) and ""fever"" (PT: Pyrexia), while being on oral Vivotif for typhoid fever prophylaxis.  Case report: The consumer took third dose of oral Vivotif (one dose every other day) on 30-Sep-2019 and experienced aching with high fever of 101.5 degrees. He reported that he had a low fever all day around 100 and felt like his fever was coming back again. He also reported that the aching was more exacerbated at the night and the morning. He stated that this felt like the symptoms of a mild flu. He also reported that aching and fever was ongoing at the time of the report.   The consumer took Aleve (200 mg; every 5 hours) as treatment medication for the events. The consumer also received travel vaccines last week of Hepatitis A, yellow fever, and tetanus.  Action taken with Vivotif with respect to the event was unknown.  The consumer had not recovered from the reported events.  Company's Comment: In this case, it was reported that the consumer had ""aching"" and ""fever"" after intake of Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Hence, the causality of the events with Vivotif is assessed as possible. Also, fever and abdominal pain are labelled as per CCDS.; Sender's Comments: Company's Comment: In this case, it was reported that the consumer had ""aching"" and ""fever"" after intake of Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Hence, the causality of the events with Vivotif is assessed as possible. Also, fever and abdominal pain are labelled as per CCDS.",,Unknown,0,0
905409,"Flu; Initial information regarding an unsolicited valid non-serious case received from a consumer (patient) via social media on 15-Dec-2020.  This case involves a patient of unknown demographics who got flu (Influenza ), while the patient received Influenza vaccine.  The patient's medical history, medical treatment(s), vaccination(s), concomitant medication and family history were not provided.  On an unknown date, the patients received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number not reported) via unknown route in unknown administration site as prophylactic vaccination.  On an unknown date (unknown latency), the patient got flu (Influenza) every time when received influenza vaccine.   It was not reported if the patient received a corrective treatment.  Outcome of the event was unknown, at the time of reporting.  There will be no information available on the batch number for this case.",,Unknown,0,1
911836,"developed fever,chills, shaking and body aches. Very sore arm",57.0,Adults,1,0
886114,"bad rash; her eyes felt swollen; felt like her throat was closing up; there was pressure in her neck and face; there was pressure in her neck and face; itchy skin; limp-nodes were swollen; some swelling; This spontaneous report was received from a consumer referring to a 40 years old female patient. The patient's drug reactions/ allergies included sulfacetamide sodium (+) sulfadiazine (+) sulfamethazine (SULFA), sulfamethoxazole (+) trimethoprim (BACKTRUM), acetaminophen (+) oxycodone hydrochloride (PERCOCET). The patient's medical history and concomitant therapy were not reported.   On an unknown date in 2010 (reported as 10 years ago), the patient received the regular quadrivalent human papillomavirus (types 6,11,16,18) recomb. Vaccine (GARDASIL) vaccine, all 3 shots (strength, dose, route, lot number and expiration date were not reported) for prophylaxis. On 24-JUN-2020, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) to gain more immunity (strength, dose, route, lot number and expiration date were not reported). on an unknown date in 2020, the patient experienced some swelling.   On 27-AUG-2020, the patient was vaccinated with the second of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) to gain more immunity (strength, dose, route, lot number and expiration date were not reported). At the same time, the patient got influenza virus vaccine (unspecified) (strength, dose, route, lot number, expiration date and indication were not reported).  On 03-SEP-2020 (reported as a week after getting the second shot), the patient experienced limp-nodes were swollen and bad rash, her eyes felt swollen, she also felt like her throat was closing up and there was pressure in her neck and face and she stated she had itchy skin. The patient spoke with her primary care and went to an ear and throat doctor. The patient was given diphenhydramine (BENADRYL) and acetaminophen (TYLENOL) for the events. The outcome of the events was not recovered. The causality between the events and all the suspect therapies was not provided.",30.0,Adults,0,0
856739,patient experienced tennis elbow the next day and said it spread to her other arm within a month and a half. rash on inject site arm appeared within a week,50.0,Adults,1,0
886853,vesicular rash to trunk of body 4 days after immunizations.  No fever or URI symptoms,12.0,Kids,1,0
871667,"Patient given Menactra, MMR, Varicella and Tdap. Unsure of vaccine lot numbers.  swelling of left deltoid. Pain with lifting the left arm",16.0,Kids,0,0
858421,Patient received Prevnar 13 instead of Prevnar 23-report attached,,Unknown,0,0
888379,Itchy Rash on arm and leg,55.0,Adults,1,0
899803,Flu vaccine was not administered correctly. the dose was not injected into the muscle of the arm as recommend.,69.0,Seniors,0,1
915300,"Fever, chills and body aches",30.0,Adults,1,0
863712,"Reaction is localized to the injection site.  It is tender and hot to the touch. Redness and swollen area is a large welt: 18 hours after injection it measured = 3 inches by 1.25 inches and was elevated about 1/8th of an inch from surrounding skin.  41 hours after injection it is less raised but the red, swollen welt area has grown to 4 inches by 1.75 inches in area.",57.0,Adults,0,0
894306,"patient was given RECOMBIVAX HB that was recalled; Administration of improperly stored vaccine; This spontaneous report has been received from a nurse referring to a 9 weeks old patient of unknown gender. Information about medical history, concurrent conditions, concomitant therapies and drug allergies was not provided.      On 23-OCT-2020, the patient was vaccinated with hepatitis b vaccine (recombinant) (RECOMBIVAX HB) (lot #: T007984, expiration date not reported, but upon internal validation established as 01-NOV-2022; 0.5 ml) via unknown route for prophylaxis. The vaccine was incorrectly stored and administered to the patient before being recalled (recalled product administered and product storage error).",,Unknown,0,1
882968,"Suddenly stopped breathing, brain damage",,Unknown,0,0
876293,SkinRash & Nausea Vomiting,65.0,Adults,1,0
858482,"1/25/2020  -  Fever, arm pain, nauseous, weak, headaches, tiredness, chills, body pain. 1/26/2020  -  now  -  Arm pain, headaches, tongue blisters and swollen gums",54.0,Adults,1,0
856755,"Second night it felt like my shoulder dislocated when lifting arm. Had to support my arm as if it were in a sling. It took almost an hour before it returned to normal. The pain was excruciating.  One week later, the same event happened. Now I have intermittent pain shooting down left arm. The pain is bad.",64.0,Adults,1,0
912161,Left arm had tingling feeling down to fingertips,56.0,Adults,0,0
904490,"Thurs 12/17 :  aching in left arm infection site.          Later evening : ?flu-like ? symptoms Fri 12/18 :  04:30 am : vomiting , headache,              Started work at 06:00 am.  - continued nausea, chills/ warmth ( but no fever)      Around 1:00 -small pupils ( but dilating) , increased weakness, & dizziness begins.  No appetite.    Slept all evening. All vitals normal range. Took 2 capsules (200 mg) q 6 hr. Sat Dec. 20 : weakness in am . Increased appetite.",56.0,Adults,1,0
860430,"Patient received Daptacel vaccine that expired on 1/30/2020.  Patient has not had an adverse effects, but will need to be revaccinated.  I called patients mother, patient has an appointment on 2/20/2020 and will receive Daptacel vaccine at that time.",1.25,Kids,0,1
870763,Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far,0.08,Kids,0,1
862472,"Had pain at the injection site for about 2 months; This is a spontaneous report from a contactable pharmacist via Pfizer Sales Representative, who reported events for two patients. This is one of the two reports. A patient of unspecified age and gender received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13) on an unspecified date at single dose for immunisation .The patient medical history and concomitant medications were not reported. On an unspecified date the patient had pain at the injection site for about 2 months; event is non-serious and recovered on an unknown date. Information on the lot/batch number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2020076440 same reporter/drug, different patient",,Unknown,0,0
865690,"vesicular rash, which was diagnosed as severe herpes zoster or shingles; The vaccine did not prevent shingles as intended; Information has been received from a lawyer regarding a case in litigation concerning a patient of unknown age or gender. The patient's medical history, concurrent conditions and concomitant medication use were not provided.   In 2015, the patient was vaccinated with a dose of zoster vaccine live (ZOSTAVAX) (dose, strength, administration route, anatomical location, lot number and expiration date were not reported) for routine adult health maintenance and for the long-term prevention of shingles at a clinic.The reporter stated that the vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster or shingles. Later in 2015, the patient was treated in a health center, for the onset of a vesicular rash, which was diagnosed as severe herpes zoster or shingles. As a direct and proximate result of the zoster vaccine live (ZOSTAVAX), and/or despite receiving zoster vaccine live (ZOSTAVAX) for long-term prevention of shingles. The patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and would continue to suffer significant medical expenses, and pain and suffering, and other damages.",,Unknown,0,0
877988,"Uncontrollable itchiness / on the area she receive the vaccination; Rash on her arm, on the area she receive the vaccination; This case was reported by a nurse via sales rep and described the occurrence of injection site itching in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   In July 2020, the patient received the 1st dose of Shingrix. In July 2020, less than a week after receiving Shingrix, the patient experienced injection site itching and injection site rash. The patient was treated with benadryl (nos) (Benadryl). On an unknown date, the outcome of the injection site itching and injection site rash were unknown.   It was unknown if the reporter considered the injection site itching and injection site rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix and experienced uncontrollable itchiness and rash on her arm, on the area she received the vaccination.  Benadryl was administered to this patient. No further details were reported. This case linked with US2020146794, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020146794:same reporter",,Unknown,1,0
898900,"shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of an unknown age and gender. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On an unspecified date in 2012, the patient was vaccinated with zoster vaccine live(ZOSTAVAX)(lot #, expiration date, dose, dose # and route not specified) for the long-term prevention of singles and zoster-related conditions. Subsequently on an unknown date, the patient was treated for singles. As a direct and proximate result of the patient's receipt of zoster vaccine live (ZOSTAVAX), the patient continued suffer ongoing injuries including but not limited to mental and physical pain and suffering, medical care and treatment for these injuries; significant medical and related expenses as medical losses and costs included care for hospitalization, physical care, monitoring, treatment, medications and supplies, diminished capacity for the enjoyment of life, diminished quality of life, increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of singles was not recovered. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).",,Unknown,0,0
907611,"Rash on face and neck, redness, itching, rash",38.0,Adults,1,0
889453,"afib attack; several palpitations; Initial information received on 30-Sep-2020 regarding an unsolicited valid serious case from a consumer or non-health care professional.  This case is linked to case 2020SA270423 (reporter friend).  This case involves a female patient (age not reported) who experienced afib attack (atrial fibrillation) and several palpitations (palpitations), after she received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a serious afib attack (atrial fibrillation) and several palpitations (palpitations) unknown latency following the administration of INFLUENZA VACCINE. This event was assessed as medically significant.  Caller wanted to know the uncommon side effects listed for both Fluzone Quad and High Dose.  Laboratory details were not reported.  It was not reported if the patient received a corrective treatment.  The event outcome was unknown for atrial fibrillation and palpitations.  There will be no information available on the batch number for this case.; Sender's Comments: The female patient (age not reported) who presented with atrial fibrillation following the vaccination with INFLUENZA VACCINE (unknown manufacturer). Time to onset is not clearly defined. Medical history, concomitant medication, precise final diagnosis and lab data ruling out alternative etiologies would be needed for complete assessment of the case. Based upon the reported information, role the vaccine cannot be assessed.",,Unknown,0,1
890362,"pt experienced slurred speech, confusion, weakness, trembing directly after immunization; continuing for a hour after, before slowly subsiding",88.0,Seniors,0,0
879526,"Quite sore arm, aching muscles/joints, slight nausea, general fatigue, slight dizziness",72.0,Seniors,1,0
751086,"Abdominal pain; Blanching of skin; Conjunctivitis; Cough; Edema hands; Edematous feet; Erythematous rash; Joint pain; Maculopapular rash; Mucosal dryness; Oral intake reduced; Painful rash; Pharyngeal erythema; Pruritic rash; Serum sickness-like reaction; Throat pain; Neutrophil count increased; Osmolality decreased; Protein total decreased; C-reactive protein increased; Haematocrit normal; Haemoglobin normal; Red blood cell sedimentation rate normal; Platelet count normal; White blood cell count increased; Pyrexia; Rash; Respiratory viral panel; Streptococcus test negative; Throat tightness; Viral test negative; Lymphocyte percentage decreased; Monocyte percentage decreased; Mononucleosis heterophile test negative; Mycoplasma test negative; Neutrophil percentage increased; Carbon dioxide normal; Culture throat negative; Dyspnoea; Glycosylated haemoglobin decreased; ALANINE  AMINOTRANSFERASE NORMAL; Aspartate aminotransferase normal; Blood alkaline phosphatase normal; Blood bilirubin normal; Blood calcium decreased; Blood chloride normal; Blood creatinine normal; Blood culture negative; Blood glucose normal; Blood potassium normal; Blood sodium normal; Blood urea normal; This report was identified from a line listing obtained on request by the Company from the FDA (agency# 751086) under the Freedom of Information Act, referring to an 11 year old female patient. Information about the patient's medical history, current illness was unknown.     On 23-MAY-2018, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) (dose 2, in left arm, lot # N022728 with expiration date auto-populated as 31-MAY-2020; strength and dose were not reported) intramuscular for prophylaxis.  Other suspect therapies included diphtheria toxoid, pertussis acellular 3-component vaccine, tetanus toxoid (BOOSTRIX) (dose 2, in right arm, lot # 7Y29Z; strength and dose were not reported) and meningococcal acyw conj vaccine (crm197) (MENVEO) (dose 2, in left arm, lot # M17023; strength and dose were not reported).      On 24-MAY-2018, the patient experienced rash, sensation of throat tightness/difficulty breathing and fever. Then she was treated with diphenhydramine hydrochloride (BENADRYL), hydroxyzine, prednisone, intravenous fluids, topical steroids.  The tests on 24-MAY-2018 included: alanine aminotransferase 8(unit not provided) (normal), aspartate aminotransferase 13(unit not provided) (normal), viral test negative, streptococcus test negative, Viral respiratory panel negative, neutrophil percentage 93% (increased), mycoplasma test negative, mononucleosis heterophile test negative, monocyte percentage 1% (decreased), lymphocyte percentage 6% (decreased), glycosylated haemoglobin 3.7(unit not provided) (decreased), dyspnoea, culture throat negative, carbon dioxide 24(unit not provided) (normal), blood urea 11(unit not provided) (normal), blood sodium 136 (unit not provided) (normal), blood potassium 3.8 (unit not provided) (normal), blood glucose 133(unit not provided) (normal), blood culture negative, blood creatinine 0.59(unit not provided)normal, blood chloride 103 (unit not provided) (normal), blood calcium  8.1(unit not provided) (decreased), blood bilirubin  0.7(unit not provided) (normal), blood alkaline phosphatase  113(unit not provided) (normal).  The Complete Blood Count (CBC) tests included: white blood cell count (27-MAY-2018): 17.3(unit not provided) (increased); Hemoglobin (27-MAY-2018): 14.9(unit not provided) (normal); Hematocrit (27-MAY-2018): 43.7(unit not provided) (normal); Platelet count (27-MAY-2018): 375.4(unit not provided) (normal);  Other tests included Sedimentation Rate (27-MAY-2018): 2 (unit not provided), Sedimentation Rate (28-MAY-2018): 10 (unit not provided) (normal); C-reactive protein (27-MAY-2018): 50.7 (unit not provided), C-reactive protein (28-MAY-2018): 101.2 (unit not provided)(increased).  The patient was hospitalized due to events. At the reporting time, the outcome of the events was not recovered. The causality between the vaccines and the events was not reported.  Follow-up information has been received from a physician on 29-OCT-2019. According to the nurse follow up on 04-JUN-2018, the hospital records of discharge (D/c) indicated that the patient was diagnosed as serum sickness-like reaction. The patient developed rash. Presented to outside emergency room (ER). Discharged with hydrocortisone cream and oral steroids. Rash worsened, the patient returned to ER. Treated with ""IVF"" and diphenhydramine (BENADRYL) with improvement of rash, the patient was recommended stopping steroids and she was discharged home. The patient developed shortness of breath (SOB), cough, diffuse maculopapular painful rash, fever to 105 Fahrenheit, joint pain. On an unknown date the patient presented to this ER. Physical Examination (PE): tacky mucous membranes, conjunctivitis, difficulty taking full deep breath, diffuse maculopapular pruritic blanching erythematous rash to face/torso/back/arm/legs/palms/soles with distinct borders. The patient was admitted and treated with ""IVF"", prednisone, diphenhydramine (BENADRYL). The patient had diffused abdominal pain, throat pain, not tolerating oral (PO). hands and feet mildly edematous with erythema, mild posterior pharyngeal erythema, possible white strawberry tongue consulted with the Infectious Disease (ID) doctor, diphenhydramine (BENADRYL) was changed to hydroxyzine (VISTARIL), which was more effective. Tolerating oral fluids. The medical prescriptions included prednisone, hydrocortisone cream, hydroxyzine (VISTARIL), the patient was discharged home in improved condition with the medical prescriptions, lab/ diagnostic records included: White blood cell count 17.3 K/mm3 (H), lymphocyte percentage 6% (L), monocyte percentage 1% (L), neutrophil percentage 93% and 16.1 K/mm3 (H). albumin 3.7 g/dL (N), protein 6.1 g/dL (L). C-reactive protein test 50.7 (H). Ca 8.1 mg/dL (L), osmolality 273 mOsm/kg (L). It was also reported that the patient went to doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care and hospitalized for 2 days, due to events. At the reporting time, the outcome of the events was not recovered. The causality between the vaccines and the events was not reported.  Follow up information was received via telephone call stating that as of 17-JAN-2020, a telephone call was placed to the reporting physician who at the time, was not available.",11.0,Kids,0,0
910655,"101.5 Fever, HR 155, SOB",25.0,Adults,1,0
907857,"Tachycardia, light headed,very dry mouth, numbing of tongue",51.0,Adults,0,0
895301,"She got shots on 11/05/2020 she was perfectly healthy that day although they did not check her temperature at that check up before shots. The next day she started crying a ton, acting in pain so I was giving her tylonal.1.25 ml every 4 hours. She felt warm so I checked her temp rectal and it was 102. That was with tylonal given less than 2 hours ago. She started coughing all day and having breathing issues. Not drinking her bottles. So that night of 11/06/2020 i took her to hospital because something didn't seem right. They diagnosed her with upper respiratory infection. When we got discharged her temp was still 100.4",0.33,Kids,1,0
875528,"Within 5 days of my son being vaccinated, he began to exhibit welts upon his torso and upper leg/groin region. Initially, these welts varied in size ranging approximately 6-12 inches in length & diameter. Twelve hours after these welts initially appeared, they began to grow in number and in extreme size, ultimately covering his entire body. The welts would also consistently disappear and reappear in different locations on his entire body. Per his explanation, these welts burned and itched immensely. He also experienced light-headedness, weakness and moderate fatigue. In addition to this, he experienced numbness & tingling in his lower extremities and they were cold to the touch.  He was seen at an urgent care the same day as the reaction and then ultimately the emergency 16 hours later when his body was covered in welts. He received a diagnosis of both urticaria and rash. I was given the instruction for him to take antihistamines and he was prescribed hydrocortisone cream to apply topically. We implemented the prescribed regimen, and followed up with his pediatrician?s office the next day. 24 hours since the reaction, the welts have diminished moderately. They are still somewhat visible, but per his demeanor, he seems to be feeling somewhat better.  To our surprise, no further medical tests and or labs were performed to determine a proper diagnosis by the urgent care, emergency room or the pediatrician?s office. Additionally, no further medical investigation was ordered to determine if this reaction could be due to any other condition or reaction to any environmental source.",11.0,Kids,1,0
855230,"1 day after recieving vaccine, at emergency department pt arrives febrile, tachycardic, normotensive. Well appearing overall.  R shoulder vaccine site is erythematous, warm, tender, and indurated. Feel he is septic from R shoulder cellulitis, low concern for septic arthritis given full ROM and no pain with short arc ROM.",58.0,Adults,0,0
875480,The kinrix was given to early for the pt.  The DTap and the polio immunizations should have been given separately.  Pt did not have any adverse effects.,1.0,Kids,0,0
863271,"some sort of reaction; Serum sickness; This spontaneous report was received from a physician via company representative referring to a 20 year old female patient. The patient's historical condition included reaction to meningitis shot. The patient's concurrent conditions and concomitant medications were unknown.     On 31-JAN-2020, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) for prophylaxis (strength, dose, anatomical location, route, lot # and expiry date not reported). On an unknown date in 2020, the patient developed serum sickness. On 03-FEB-2020, the patient called physician's office and she claimed that she had experienced some sort of reaction (adverse reaction). The patient received treatment for the events. The treatment drugs included dexamethasone (DECADRON), depo-medrol and hydroxyzine. The reporter also stated that the physician had anticipated a reaction after the hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) shot. On an unknown date in February 2020, the events of serum sickness and adverse reaction were recovered. The reporter's causality assessment was not provided.",20.0,Adults,0,1
897173,"The doctor determined that patient had ""skin necrosis""; Injection site became sensitive and a thin film developed on the skin; Injection site swelling; Injection site was hard; consumer started having headaches and body chills; consumer started having headaches and body chills; This spontaneous report was received from a 60 year old, former smoker female patient reporting on herself. The patient's concurrent conditions included allergy to sulfamethoxazole, trimethoprim (BACTRIM), the patient developed rash due to ""antibiotics ointment"". The patient's pertinent medial history was not reported.  On 31-AUG-2020, the patient was vaccinated with a dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) lot # S029542, expiration date reported as 06-OCT-2021, but upon internal validation established as 10-JUN-2021 (dose and route were not reported)  for prophylaxis. Concomitant therapies included potassium citrate, atorvastatin, thyroid (ARMOUR THYROID TABLETS), hydrochlorothiazide and ""Duprofidon"".     On 01-SEP-2020, the patient started having headaches and body chills (chills). The patient took ibuprofen (ADVIL). The next day on 02-SEP-2020, the injection site was hard (injection site induration) and swollen (injection site swelling). The patient contact with her doctor who prescribed her ""PREDNOSONE"" for 5 days. The swelling went down, but then on 07-SEP-2020 the skin at the injection site became sensitive (injection site hyperaesthesia) and a thin film developed on the skin. The patient stated that her doctor prescribed an unspecified antibiotic and did a biopsy of the skin. The doctor determined that she had ""skin necrosis"" (injection site necrosis) and then sent the patient to a surgeon who on 11-SEP-2020 removed the skin.  At the time of the report, the patient was recovering from the events. The relationship between the events and pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) was not reported.  ""Skin necrosis"" and then sent the patient to a surgeon who on 11-SEP-2020 removed the skin was considered to be medically significant by the reporter. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. devicelotnumber: S029542; expirationdate: 10-JUN-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent",60.0,Adults,0,0
875975,"has been sleeping all day; warm to touch (but had not checked temperature); significant headache; fatigue; This is a spontaneous report from contactable nurse via Pfizer Sales Representative. This nurse reported events for three patients. This is the third of 3 reports.    A 19-year-old male patient received the 1st dose of meningococcal group b rlp2086 (TRUMENBA) (lot # CM1497), via an unspecified route of administration at single dose on 08Jul2020 for immunisation. The patient medical history and concomitant medications were not reported.   On 08Jul2020, the patient experienced warm to touch (but had not checked temperature), significant headache, fatigue. On 09Jul2020, he has been sleeping all day. The outcome of the events was unknown.    No follow-up attempts are needed. No further information is expected.",19.0,Adults,0,0
894266,"The entire upper left arm bright red, swollen, and somewhat painful.  Iced the area.",82.0,Seniors,1,0
875604,"still hurting; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 30th June 2020, the patient received the 1st dose of Shingrix (injection). On 30th June 2020, less than a day after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was not recovered/not resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional details were provided as follows: The patient had his first Shingrix injection in the right arm this morning and it was still hurting.  The patient wanted to know if he could still use his right arm.  No HCP information provided. The patient would call his doctor himself and talk to him. The reporter did not consent to follow-up.",75.0,Seniors,1,0
906903,"28 HOURS AFTER INJECTION, DEVELOPED BODY ACHES AND PAINS, 99.5 FEVER, CHILLS, SIGNIFICANT FATIGUE REQUIRING ME TO GO TO BED - SLEPT 12 HOURS",56.0,Adults,1,0
896582,Pt stated that a couple days later he had a headache and it felt like some one had stuck his eyeball from behind with needles,69.0,Seniors,1,0
872245,"Continued fever  from 11 p.m. of the date of injection all the way until midnight the following night.  The first time i took my temperature , in the morning on 05/30/20, it was 101.3 and it had already gone down from the hottest I felt.  I continued to take Tylenol which lowered my fever to 99.6.  When the Tylenol wore off, it returned back to 101.0.  The glands in my neck are still painful to the touch and it spread from one nodule to 2 nodules in my right neck and also to a node in my right armpit.  My neck is still visibly swollen on 5/31/20 on the right side and still hurts, although when i awoke on 05/31/20, my fever was gone.",54.0,Adults,0,0
896588,"Pt reports severe arm pain and lack of mobility at injection which increased over the rest of the day. She used over the counter products and we advised her seek medical help instead of self help. She went to the doctor, but pain medication did not relieve her pain. She was referred to the ER, where Xray was performed. Patient was not clear about what was revealed in the Xray, if anything. She reported to us on 11/11/20 the events of the last few weeks since the initial conversation. It is now 6 weeks later, she is feeling some improvement, but still can not sleep or fully lift the arm without pain.",39.0,Adults,1,0
880202,"Feel sick; Severe nausea; Fever; Recieved half a dose; This case was reported by a other health professional via call center representative and described the occurrence of sickness in a 10-year-old female patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis.   On an unknown date, the patient received Boostrix. On an unknown date, immediately after receiving Boostrix, the patient experienced sickness, nausea, fever and underdose. On an unknown date, the outcome of the sickness, nausea, fever and underdose were unknown.   It was unknown if the reporter considered the sickness, nausea and fever to be related to Boostrix.  Additional information was provided as follows: The patient was about 10 years old. The patient received Boostrix but she received half a dose at the time because it made her feel sick with severe nausea and fever. The patient received hald dose, which led to underdose. The reporter consented to follow up.",10.0,Kids,1,0
856893,"Pt mother reported ""red blotches all over her face, pink on her eyebrows, eyelids and she had a big huge blotch of red on the side of head""",0.75,Kids,0,0
886855,patient starting get a red arm from her wrist up.  Her caregiver said she needed to get to the doctor.  Doctor states pt has a skin irritation and gave her an antiobiotic.,82.0,Seniors,0,0
906358,"MMR vaccine diluent was added to the mix and administered to a patient.; MMR vaccine diluent was added to the mix and administered to a patient.; Wrong solution used in drug reconstitution; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   On 1st December 2020, the patient received Menveo. On 1st December 2020, unknown after receiving Menveo, the patient experienced inappropriate preparation of medication, incorrect dose administered and wrong solution used in drug reconstitution. On an unknown date, the outcome of the inappropriate preparation of medication, incorrect dose administered and wrong solution used in drug reconstitution were unknown.  Additional information received as follows: The age at vaccination was not reported.  Menveo vaccine was reconstituted using the powder and the approved diluent and then an MMR vaccine diluent was added to the mix and administered to a patient. Addition of another diluent to the Menveo vaccine. This led to inappropriate preparation of medication, incorrect dose administered and wrong solution used in drug reconstitution. The reporter did not consent to follow-up.",,Unknown,0,1
891429,"A patient received the MMR vaccine on 07/09/20 at 16:19. Unit RN called  doctor at 18:38 reporting itching from the patient. Vitals were within normal limits. Patient was given 50 mg diphenhydramine, which patient noted was effective. Doctor followed up with patient on 07/10/20. Left ventral forearm had no visible rash, and patient noted rash on right forearm was gone. Abdomen was also free of rash. Patient noted rash on their forehead and chin/neck area. The chin/neck area was affected by wearing a face mask and sweating. Their forehead was erythematous and had acne present. Patient noted the rash arose after receiving the vaccine and was not present before the injection. Patient denied any shortness of breath with rash. Rash was presumed to be due to MMR vaccine. Hydroxyzine was increased to 50 mg TID and 50 mg hydroxyzine 50 mg q24h PRN itching was added to help with further itching. Patient was marked with MMR vaccine allergy. One dose PRN hydroxyzine given 07/11/20, symptoms improved. Per the product insert, M-M-R II vaccine has skin-related adverse effects listed as SJS, erythema multiforme, urticarial, rash, measles-like rash, pruritus, injection site reactions (pain, erythema, swelling and vesiculation). No percentages accompany these adverse effects. This was rated as possible.",50.0,Adults,0,0
856802,"Warm, raised circle with knot on right arm.  4 inches in diameter.  Steroid shot at doctor's office and antibiotics called in to pharmacy",45.0,Adults,0,0
873490,"local swelling on the left deltoid area, red and itchy, no pus",78.0,Seniors,0,0
905657,She was sore  at injection site later on day of injection (12/20) that developed into whole body muscle aches the next day (12/21). She also reported a cough started on 12/20 and this has persisted and slight Shortness of breath started 12/20 that has become worse today 12/21 where if she is moving around she needs to stop and take a few breaths.  She denied any feeling of life threatening shortness or breath or need to go to ER.  She has been instructed to contact employee health prior to coming back to work given cough/SOB not typically a reaction to vaccine.,19.0,Adults,0,1
871645,"Aching beyond injection site, fever, fatigue, loss  of appetite, malaise",51.0,Adults,1,0
884305,"Unusually stiff and sore at injection site (left shoulder) shortly after injection; felt like shoulder had received a very strong punch unlike other years' flu injections. The stiffness and soreness then spread to the forearm (left) and hand starting at 4:30 pm (90 minutes after injection.) Thirty minutes later, stiffness and soreness spread to left leg (top). Was difficult and very uncomfortable to fully raise left arm overhead. Noted that I was not able to do so until some time later that evening. Stiffness/soreness in mentioned sites continued eight hours later until I went to sleep at midnight. Soreness/stiffness had lessened some by morning, but remained noticeable at all sites mentioned. Soreness did not abate until later that day. Injection site remains lightly sore at touch today, five days later.",31.0,Adults,0,0
876484,"Morning after vaccine, woke up with severe hearing loss in my left ear. On 12/18/2019, I started on a course of Prednisone, and then on 12/20/2019 I had the first of 3 Intratympanic  Dexamethasone injections. On 12/24/2019 I had my 2nd injection and my word recognition went from 4% to 64% on hearing test. On 12/30/2019, I had my 3rd injection. My hearing gradually improved.  My hearing test on 01/06/2020 showed my hearing was back to where it had been before the vaccine.",76.0,Seniors,0,1
895739,"The shipment of vaccine was received outside 72 hour guideline and was potentially compromised, no AE; The shipment of vaccine was received outside 72 hour guideline and was potentially compromised, no AE; Initial information regarding an unsolicited valid non-serious case was received from a other health professional via The Agency (Reference number- 00303291) and transmitted to Sanofi on 06-Oct-2020.  This case is linked to cases 2020SA310350, 2020SA310351, 2020SA310352, 2020SA310901, 2020SA310354, 2020SA310460, 2020SA277871, 2020SA310462, 2020SA310463, 2020SA310464, 2020SA310555, 2020SA310556, 2020SA310557, 2020SA310558, 2020SA310559, 2020SA310704, 2020SA310705, 2020SA310706, 2020SA310707, 2020SA310708, 2020SA310759, 2020SA310760, 2020SA310761, 2020SA310762, 2020SA310763, 2020SA310764, 2020SA310765, 2020SA310766, 2020SA310767, 2020SA310768, 2020SA310769 and 2020SA310770 (same reporter).  This case involves a patient (demographics unknown) who was administered a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] (lot UJ505AA, expiry date: 30-Jun-2021, form: prefilled syringe) via unknown route in unknown administration site for prophylactic vaccination on 05-Oct-2020, whose shipment was received outside the 72 hour guideline and was potentially compromised (product storage error and product distribution issue)  It was a case of an actual medication error due to incorrect product storage.  It was also a case of product shipment delay.  The shipment of vaccines was received outside the 72 hour guideline for standard shipping. It was received in 76 hours. The practice was advised not to use any remaining stock as new stock will be replenished and to return the remaining stock. It was also advised to re-vaccinate the patients who had received a dose of the potentially compromised product. No thermometer was in packaging and product was cold when they received it.  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
879248,"shingles; This case was reported by a consumer via call center representative and described the occurrence of shingles in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient was over the age of 65 and had a prior history of shingles outbreaks.  The patient received the first dose of Shingrix and experienced shingles and never went back for the second dose. This case is one of the 3 cases reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020153380:same reporter US-GLAXOSMITHKLINE-US2020153378:same reporter",,Unknown,0,0
895451,arm pain  cannot lift arm past elbow radiating pain difficulty range of motion,39.0,Adults,1,0
861959,none,60.0,Adults,0,0
891941,After influenza vaccine given on 10/8/2020 clients arm progressively became more and more sore to the point where the client could not lift their arm. Pain keeps client up at night.  Saw their PCP on 10/20/20 when a red spot was noticed and it was warm to the touch.  Client was told that the site is infected.,39.0,Adults,0,0
887865,"Fever for three days averaging 100 degrees. Extremely bad body aches,  weakness.  Swelling , redness and hot to the touch at the injection sit Nasea  No appetite",53.0,Adults,1,0
868134,"MISSED TO TAKE LAST DOSE OF VIVOTIF ACCORDING TO SCHEDULE; This spontaneous case report (PVX2019-2779) was received from a consumer on 11-Nov-2019. It described a female consumer who ""missed to take last dose of Vivotif according to schedule"" (PT: Product dose omission), while being on oral Vivotif for typhoid fever.  Case report: The consumer missed to take the last dose of Vivotif, which was due on 10-Nov-2019.  Action taken with Vivotif with respect to reported event was not applicable.  The clinical outcome of the reported event was unknown.  Company's Comment: The causality of the event ""missed to take last dose of Vivotif according to schedule"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""missed to take last dose of Vivotif according to schedule"" was considered as not applicable.",,Unknown,1,0
872737,Patient presented 2 days post vaccine with swelling in arm and elbow region. Patient saw a doctor and received a prednisone order to help. There was no bruising or adverse signs of vaccine not being administered correctly. It was very evident that it was a reaction to the shot itself. Patient had no reactions to prevnar 13 vaccine given a year ago.,66.0,Seniors,0,1
886919,Pt had fever of 101 Turned purple and flaccid for few seconds 911 was called it took few minutes for pt to be completely back  to normal,0.42,Kids,1,0
863036,"SHE HAD A FEVER AND SWEATING ON THE EVENING THE DAY OF RECEIVING THE SHOT WHICH SHE TREATED WITH IBUPROFEN. CURRENTLY (TWO DAYS AFTER THE IMMUNIZATION), PATIENT REPORTS A VERY SORE RIGHT UPPER ARM WITH  REDNESS, WARMTH, AND PAIN.",65.0,Adults,1,0
903892,"Light headed, Itchy Chest, Chest tightness, Heart racing, Throat tightness, Tingling legs",44.0,Adults,0,0
872407,"Fever, Chills, Muscle Soreness, Headache, Fatigue",40.0,Adults,1,0
867582,"DID NOT TAKE THE FOURTH DOSE ON TIME; This spontaneous case (PVX2019-835) was received from a consumer on 08-Apr-2019. It describes a female consumer who ""did not take the fourth dose on time"", while taking of oral Vivotif (lot number: 3003242; one dose every other day) for typhoid fever prophylaxis.  Case report: The consumer took the third dose of Vivotif on 05-Apr-2019 and did not take her last dose, which was due on 07-Apr-2019.  Action taken with Vivotif with the event ""did not take the fourth dose on time"" was not applicable.  The clinical outcome of the event ""did not take the fourth dose on time"" was unknown.  Company's Comment: The causality of the event ""did not take the fourth dose on time"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""did not take the fourth dose on time"" was considered as not applicable.",,Unknown,1,0
886289,"28 hours following flu vaccine, she developed irregular heart beat, palpitations, then dizziness, nausea vomiting, sweating episode.  Had to lay down.",46.0,Adults,0,0
864929,"The day after receiving injection, the patient called to notify us of feeling pretty bad with flu like symptoms, cold and headache. Patient was counseled these are potential side effects and can be expected after receiving Prevnar 13. Patient was counseled to take OTC Tylenol or ibuprofen to help with the pain and fever.",52.0,Adults,0,0
886426,Rt Arm - Proquad Red bump/lump (local) Lt Deltoid - Kinrix Red swelling travled,5.0,Kids,0,0
855362,"3 hours after receiving the vaccine, the patient had radiating pain from the injection site down to her hand and up to her head causing a headache. She was in bed for 2 days after receiving the vaccine, unable to get up to do anything other than go to the bathroom. She felt like she had an increased urge to urinate, going about every 2 hours. When she woke up on the third day after receiving the vaccine, she was feeling much better.",83.0,Seniors,0,0
889632,"Fever (about 101.5) for day and a half; lethargy, achy; weak.",14.0,Kids,1,0
886583,"Deathly ill with chills, fever, hot/cold flashes, abdominal pain, nausea, muscle aches",70.0,Seniors,1,0
896584,Patient reported soreness in her arm and that it was hard to lift. I told her to ice her arm and take a otc pain medication. She will call back with any issues.,71.0,Seniors,1,0
894533,"No additional AE; Patient was administered Improperly Stored ROTATEQ and PEDVAX HIB; This spontaneous report was received from a nurse referring to a 4-month-old patient on unknown gender. The patient's medical history, historical drugs, concurrent conditions and concomitant medications were not provided.       On 29-OCT-2020, the patient was vaccinated with improperly stored rotavirus vaccine, live, oral, pentavalent(ROTATEQ) 1 dosage form, lot number S040483, expiration date 19-JUN-2021 and haemophilus b conjugate vaccine (meningococcal protein conjugate)(LIQUID PEDVAXHIB) 1 dosage form, lot number T000886, expiration date 29-MAY-2022 (route of administration was not provided for the vaccines). Both for prophylaxis.      The vaccines underwent a temperature excursion above 9 degrees Celsius (C), with an average of 9.7C for 45 minutes. There were no previous temperature excursions. The call was due to digital data logger. ; Sender's Comments:  US-009507513-2010USA012181:",0.33,Kids,0,1
856536,"allergic reaction to Shingrix; red blotchy rash over her legs, arms chest torso and neck; red blotchy rash over her legs, arms chest torso and neck; fever; felt lethargic all day; headache; didn't feel well; This case was reported by a consumer via call center representative and described the occurrence of allergic reaction in a 76-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Allergy shot. Concurrent medical conditions included allergic to dogs and allergy to plants.   On 2nd January 2020, the patient received the 1st dose of Shingrix. On 3rd January 2020, 1 days after receiving Shingrix, the patient experienced fever, lethargy, headache and feeling unwell. On 4th January 2020, the patient experienced allergic reaction, blotchy rash and red rash. The patient was treated with prednisone. On 4th January 2020, the outcome of the fever, lethargy, headache and feeling unwell were recovered/resolved. On an unknown date, the outcome of the allergic reaction was recovering/resolving and the outcome of the blotchy rash and red rash were unknown.   The reporter considered the allergic reaction to be related to Shingrix. It was unknown if the reporter considered the fever, lethargy, headache, feeling unwell, blotchy rash and red rash to be related to Shingrix.  Additional case details were reported as follows: The patient got her first dose of Shingrix last Thursday.  The patient had allergies to dogs and trees, she takes allergy shots for that. On friday morning the patient had a fever, felt lethargic all day, headache and didn't feel well. On saturday she felt fine, those issues had resolved but late in the day she noticed red blotchy rash over her legs and then on her arms, that she had noticed earlier. On sunday the rash was all over her chest, torso and neck. The patient was seen at Clinic and the physician diagnosed her with Stephen's Johnson Syndrome. The patient was sent to the Emergency Room, who changed the diagnosis to an allergic reaction to the Shingrix.  She was started on prednisone. The patient went to her primary physician office, who confirmed the reaction to Shingrix diagnosis. The patient noted things are looking better, but her legs are the worst and remain with the rash. The patient had referred to a Dermatologist for the continued rash on her legs. She noted no allergy to any ingredients in Shingrix. The reported consented to follow up.",76.0,Seniors,1,0
888672,Patient got both shots in her left arm and now she can no longer lift her left arm. She went to the doctor and the doctor told her that she has muscle damage from the shot.patient is still in pain from the shot.,85.0,Seniors,1,0
874697,"pre anaphylactic reaction; injection site was bruised; wheel"" formed under the vaccine site / area felt raised; wheel"" formed under the vaccine site / area felt raised; area felt raised and was little itchy; muscle fatigue; malaise; isn't sure it was given IM / unsure if the needle ever reached the muscle; used a  5/8 in 25 gauge needle; This case was reported by a nurse via call center representative and described the occurrence of anaphylactic reaction in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of muscle fatigue (received 1st dose on March 2020, refer Case ID:US2020AMR108337).   On an unknown date, the patient received the 2nd dose of Shingrix .5 ml. On an unknown date, less than a day after receiving Shingrix, the patient experienced anaphylactic reaction (serious criteria GSK medically significant), injection site bruising, injection site wheal, injection site swelling, injection site itching, muscle fatigue, malaise, intramuscular formulation administered by other route and wrong technique in device usage process. The patient was treated with benadryl (nos) (Benadryl) and medication unknown (Inhaler (Nos)). On an unknown date, the outcome of the anaphylactic reaction, injection site bruising, injection site wheal, injection site swelling, injection site itching, muscle fatigue, malaise, intramuscular formulation administered by other route and wrong technique in device usage process were unknown.   It was unknown if the reporter considered the anaphylactic reaction, injection site bruising, injection site wheal, injection site swelling, injection site itching, muscle fatigue and malaise to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient was received the first dose of Shingrix in March of 2020. The patient received the 2nd dose on 18th June 2020, in the left arm but was not sure it was given intramuscular.  The reporter said it was a quick injection without resistance. The pharmacist used a 5/8 in 25 gauge needle so she was unsure if the needle ever reached the muscle. Within four to five hours later on the same day, the patient noticed the injection site was bruised , and the wheel was formed under the vaccine site. It was more oblong in shape and began to spread until it was three to four inches vertical and two inches horizontally. The area felt raised and was little itchy. She also had a pre anaphylactic reaction so she took Benadryl and used an inhaler. The patient had some muscle fatigue as well as malaise. The reporter consented to follow up.",,Unknown,0,0
889474,"no other adverse events; vaccine that was expired and administered to a patient; Proquad had 1 prior temperature excursion; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided.  On 08-OCT-2020, the patient was vaccinated with an improperly stored and expired dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (recombinant human albumin(rHa)) (PROQUAD) 0.5 ml, lot # S009760 was confirmed to be valid, expiration date 27-SEP-2020 (route of administration and anatomical location were not reported) for prophylaxis. On 13-APR-2020, administered dose of vaccine experienced temperature excursion. The product reached temperature 39.9 degrees Fahrenheit for 9 hours.  The reporter confirmed there was no other adverse events.",,Unknown,0,1
901089,"flu symptoms; Initial information was received on 07-Nov-2020 regarding an unsolicited valid non-serious case from a social media via consumer or non-health care professional (Patient).  This case involves patient [age and gender unspecified] who had flu symptoms [influenza], while patient received vaccine INFLUENZA VACCINE [Flu shot].  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacture) [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious flu symptoms (influenza) unknown latency following the administration of INFLUENZA VACCINE.  Details of laboratory data not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, the event outcome reported as unknown for event.  There will be no information available on the batch number for this case.",,Unknown,0,1
913513,body aches-next day  fever 103-104   took ibuprofen fever went down fatigue,31.0,Adults,1,0
915702,"A  hive at the injection site, 2 smaller hives adjacent, and some itching . . . s/p 7 days after vaccination.",24.0,Adults,0,0
891547,"fever; pain / body aches; nausea; fatigue; could not get out of bed; This case was reported by a physician via sales rep and described the occurrence of fever in a 58-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included methotrexate for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix and methotrexate at an unknown dose and frequency. On an unknown date, unknown after receiving Shingrix, the patient experienced fever, general body pain, nausea, fatigue and mobility decreased. The action taken with methotrexate was unknown. On an unknown date, the outcome of the fever, general body pain, nausea and fatigue were unknown and the outcome of the mobility decreased was recovered/resolved.   It was unknown if the reporter considered the fever, general body pain, nausea, fatigue and mobility decreased to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient got Shingrix at pharmacy, so the reporter did not knew the lot number, but patient only had 1 dose. The patient had pain, fever, body aches, nausea, fatigue that was 100 times the normal. For 4 days the patient could not get out of bed. The patient was on methotrexate and the reporter wondered if that drug caused the adverse event.",,Unknown,1,0
902613,& CHILLS,81.0,Seniors,1,0
897853,"patient reported the arm being soar, some injection site hives that were raised and warm to touch. Reaction possibly started on 11/20/2020 but patient was unsure",43.0,Adults,0,0
871064,Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far,0.33,Kids,0,1
861923,"patient inadvertently received doses of both VARIVAX and PROQUAD; patient inadvertently received doses of both VARIVAX and PROQUAD; patient inadvertently received doses of both VARIVAX and PROQUAD; This spontaneous report as received from an office manager refers to a 12-month-old. No information was provided regarding the patient's medical history, concurrent conditions or concomitant medications. On 07-FEB-2020 the patient received doses of both varicella virus vaccine live (oka/merck)(VARIVAX)  and varicella (oka-merck) virus vaccine live(PROQUAD) for prophylaxis (dose, route of administration, lot number and expiration date were not reported). Suspect therapy included: included sterile diluent(STERILE DILUENT).",1.0,Kids,0,1
872380,"Received a dose of GARDASIL 9 on 22-5-20 after previously receiving 2 doses of GARDASIL  on unspecified dates ""about 2 to 3 years ago""; Received a dose of GARDASIL 9 on 22-5-20 after previously receiving 2 doses of GARDASIL  on unspecified dates ""about 2 to 3 years ago""; This spontaneous report was received from a physician referring to a patient of unknown age and gender. The patient's current conditions, medical history and concomitant therapies were not reported. On an unknown date in 2017 (reported as 2 or 3 years ago), the patient was vaccinated with one dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. Vaccine (GARDASIL) and then on an unspecified date, the patient was vaccinated with second dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. Vaccine (GARDASIL) (routes, anatomical positions, lot numbers and expiration dates were not reported) as prophylaxis. On 22-MAY-2020, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (route, anatomical position, lot number and expiration date were not reported) as prophylaxis (interchange of vaccine products and inappropriate schedule of product administration). The outcome of the events was unknown. Causality assessment for the event of interchange of vaccine products was not reported. No additional information was provided. No product quality complaint was involved.",,Unknown,0,1
882145,"Chills all night, fever of 100.3 the next morning at 8 am. Extreme headache, stomach pain and nausea, very sore arm at injection site, but not swollen.",64.0,Adults,1,0
863234,"2/22/2020 6:30 p.m. arm pain, chills evening 2/23/2020 3:00 a.m. fever, little nausea, chills all night chills all night, poor sleep 2/23/2020  5:00 a.m. aches and fever, took aspirin, felt more comfortable within an hour. 2/23/2020  felt weak and tired until 4:00 p.m.  Arm very sore and red. 2/24/202 until 2/25/2020 arm sore",61.0,Adults,1,0
856871,pt said her arm was swollen and red with a tingling pain- she went to her doctors office and got a shot of steroid. Her arm is still swollen at this time.,52.0,Adults,1,0
899169,"a 38 years old patient received a dose of Fluzone High Dose with no AE; a 38 years old patient received an expired dose of Fluzone High Dose by mistake with no AE; Initial information received on 14-Oct-2020 regarding an unsolicited valid non-serious case received from a pharmacist via Medical Information (Reference number: 00315664) .  This case involves a 38 years old male patient who received an expired 0.5 mL dose of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE] by mistake (lot: UJ268AA, expiry date: 10-May-2020), via intramuscular route in left deltoid on an unknown date for prophylactic vaccination (product administered to patient of inappropriate age) and (expired product administered).  The patient's medical treatments, vaccinations and family history were not provided.   The patient's medical history included transplant.  No Concomitant medications were given.  It was a case of an actual medication error due to the expired vaccine used and inappropriate age at vaccine administration (latency same day on the day of vaccination).   Reporter wants to know if there are any known adverse effects. The Fluzone High Dose that was give was the 2019-2020 formula. They have already given the patient Fluad.  At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",38.0,Adults,0,1
878428,"Vaccine given was past expiration date. Expired on 7/8/2020, was given 7/20/2020. Called vaccine manufacturer and confirmed that dose would not be valid. Called Dad. No signs or symptoms of any adverse reaction to vaccine.",16.0,Kids,0,1
883928,"September 3, 2020 feverbetween 100.2 and 100.8 for approximately 12 hours. Redness of injection site for one week.  Sept. 3, 2020, mid afernoon, one brief dizzy spell and wave of nausea.  No vomiting.",75.0,Seniors,1,0
894444,"Flublok Quadrivalent was accidentally administered to an 11 year old patient with no adverse event; Initial information regarding this valid unsolicited non-serious case was received from pharmacist on 04-Oct-2020.  This case involved a 11-year-old male patient who received INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] accidently (Product administered to patient of inappropriate age) .  The patient's medical history, medical treatments, vaccinations and family history were not provided.   No concomitant vaccine was given.  On 01-Oct-2020, the patient received a 0.5 ml dose of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] (Lot number- UJ448AB, expiration date- 22-Mar-2021) via intramuscular route in the left arm for prophylactic vaccination.  It was a case of actual medication error due to Inappropriate age at vaccine administration (Latency: same day).  At the time of reporting, the patient was doing well and had no reaction .  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",11.0,Kids,0,1
889305,"Patient received first Shingrix injection on Friday, 10/9/20 and developed fever, chills, and shingles-like lesions on Saturday, 10/10/20.  The patient reported several lesions developed on her scalp and forehead, one lesion on each breast, 2-3 lesions on abdomen, and left palm was itchy.  The patient called her doctor Monday morning, 10/12/20, who advised her to notify the pharmacy.  The patient received no treatment for the lesions.  As of Monday, 10/12/20, the lesions were reportedly fading.",63.0,Adults,1,0
879954,"didn't feel well; the vaccine was out of stock; This case was reported by a consumer via call center representative and described the occurrence of feeling unwell in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of malaise (Refer linked case US2020156565 for 1st dose.).   On 3rd August 2020, the patient received the 2nd dose of Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced feeling unwell and product supply issue. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the feeling unwell was recovered/resolved and the outcome of the product supply issue was unknown.   It was unknown if the reporter considered the feeling unwell to be related to Shingrix.  Additional details were reported as follows: The patient received 2nd dose of Shingrix because the vaccine was out of stock which led to product supply issue and patient didn't feel well for 24 hours, after the 24 hours period, she felt fine. The reporter consented to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020156568:same reporter US-GLAXOSMITHKLINE-US2020156565:same patient",62.0,Adults,0,1
872477,"1 week after receiving simultaneous Menactra, Inactivated Polio and Hep A, the patient developed positional dizziness followed by progressive lower extremity weakness and in-coordination.  He has poor tandem walking and a borderline Rhomberg test Over an additional 10 days his motor weakness has become a primary complaint",39.0,Adults,1,0
868686,"rash; allergic reaction; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a 68 year old female patient. Information on the patient's concurrent conditions, medical history or concomitant therapy was not reported. On 04-APR-2017, the patient was administered zoster vaccine live (ZOSTAVAX) (dose, route of administration, lot# and expiration date were not reported). As a result of her receipt of zoster vaccine live (ZOSTAVAX), on 11-APR-2017, patient was caused to suffer an allergic reaction and rash, including any and all of its sequelae. As a result of her receipt of zoster vaccine live (ZOSTAVAX), patient has been caused to suffer severe personal injuries, pain, suffering, and emotional distress, as well as to incur substantial economic damages. As a result of the foregoing acts and omissions, patient was caused to suffer serious and dangerous side effects including an allergic reaction and rash, as well as other severe and personal injuries which are permanent and lasting in nature, physical pain and mental anguish, including diminished enjoyment of life, as well as the need for lifelong medical treatment, monitoring and/or medications. As a result of the foregoing acts and omissions, patient requires and/or will require more health care and services and did incur medical, health, she will in the future be required to obtain further medical and/or hospital care, attention, and services. As a foreseeable, direct, and proximate consequence of Company's actions, omissions, and misrepresentations, patient suffered an allergic reaction and rash and other related health complications. In addition, patient requires and will continue to require healthcare and services. Patient has incurred and will continue to incur medical and related expenses. Patient also has suffered and will continue to suffer diminished capacity for the enjoyment of life, a diminished quality of life, increased risk of premature death, aggravation of preexisting conditions, activation of latent conditions, and other losses and damages. Patient's direct medical losses and costs include physician care, monitoring, and treatment. Patient has incurred and will continue to incur mental and physical pain and suffering. The outcome of rash and hypersensitivity was reported as not recovered/not resolved. The reporter considered rash and hypersensitivity to be related to Zoster Vaccine Live (ZOSTAVAX).     Allergic reaction and rash were considered to be disabling.",68.0,Seniors,0,0
908973,"15 min after receiving  Covid 19 vaccine patient started to feel like her heart was racing / felt faint. Burning feeling in upper thigh and pelvic area.  BP 180/100  HR 130. Rapid Response called / transported to ER.  Admitted for 24 hr observation.. Solu -medrol, Benadryl and Ativan given in ER. Released home the next day. 72 hrs  later patient states she has numbness and tingling in hands and feet. 12/24/2020 patient reports she is feeling better today / no symptoms noted.",48.0,Adults,0,1
915765,Patient had an anaphylactic reaction to the vaccine the day after it was given and went to the nearest ER.,46.0,Adults,0,1
886989,Patient states last night she was experiencing dizziness and chills.  This caused her to have trouble with balance as she is blind.  She stated that she felt fine today though.,79.0,Seniors,1,0
910133,"Noted tongue starting to swell on 12/24 at 1030. Started on left side, then progressed to right side. No SOB, difficulty swallowing or breathing, but staff noted difficulty understanding her speech. Presented to ED at 1300. 50mg Benadryl given IV on 12/24 at 1328 and 125mg solumedrol given IV at 1327. Pt reported improvement in tongue swelling at 1630.",64.0,Adults,0,0
882232,"Patient was administered immunizations on 9/2/20. Mother states she noticed a red spot and bump at injection site. She states by the next day the redness has spread down the arm. She called today (9/4/20) to report redness spreading, hot to touch, and temperature 99.6 F. She was advised to come in to see the pediatrician. she agreed. Doctor assessed the site, diagnosed as cellulitis and patient was started on antibiotics. A call was placed to the immunization program coordinator. She will reach out for further advisement.",11.0,Kids,0,0
916331,"12/22- SORENESS AND HEAT AROUND PUNCTURE SITE, FEELS LIKE A BP CUFF ON HER ARM, 12/30- ARM/FINGER TINGLING, WITH HEAT STILL PRESENT.",24.0,Adults,0,0
904921,"he caught the flu; Initial information received on 30-Nov-2020 regarding an unsolicited valid non-serious case received from a consumer/ non-healthcare professional via social media.  This case involves male patient (unspecified age) who he caught the flu (influenza) while he received vaccine Influenza Vaccine.  Medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.   On an unknown date, the patient received influenza vaccine [lot number: unknown and expiration date: unknown] at an unknown dose via unknown route in an unknown administration site for prophylactic vaccination.  On an unknown date, (latency: unknown) after starting the suspect vaccine therapy, patient had a shot, he caught the flu (influenza) (non-serious).  No laboratory data was reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event was unknown.  There will be no information available regarding batch number in this case.",,Unknown,0,1
915302,"After first 12 hrs:  headache (migraine like) for 10-12 hrs After fist 30-36hrs:  increase local pain at site on injection, some muscle pain on the arm, numbness on upper lip, chills without fever 3rd-4th  days post vaccine:  no headache, extreme pain to light skin touch at the site of infection and muscle pain (significant more after rest; after arm was not being used for a while);  lip numbness had gone away x 24 hrs and came back 6-7th day post vaccine:  tender enlarged nodes on left axilla (same arm of injection) with some mild tenderness on arm movement and light upper lip numbness.",48.0,Adults,0,0
898717,"Immediately upon completion of vaccination, pt lost consciousness for approximately 30 seconds, followed by vomiting, lethargy, low BP, sweating. This continued for about 20 minutes.",18.0,Adults,0,0
898615,"He started feeling nauseated right after the injection but could eat with no problem. Within 1 hour, he started feeling cold with chills and then the mild fever over 100 degrees followed by vomit and eyes swollen. Fever went away the next morning. He had stomachaches and couldn't eat for 24 hours. And as soon as he took Benadryl the next day, he got better within 30 minutes, while his eyes are still swollen.",16.0,Kids,1,0
865642,"Pt had vaccines on 3/9 approximately 1:30 pm. Approx 5.00 her right arm & right trunk had welts. Gave Benadryl & helped. Next day, welts still on right arm. On 3/12, pt had hives on right elbow & right hand went numb for a little bit. * Pt had dental work on same side on same day*",16.0,Kids,0,1
907854,"Just a tiny red mark; This is a spontaneous report from a Pfizer-sponsored program Corporate (Pfizer) Social Media Platforms. A contactable consumer (patient) of unspecified age and gender received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at single dose for Covid-19 immunisation. The medical history and concomitant medications were not reported. The patient did not have pain, swelling or anything. Just a tiny red mark. The outcome of the event was unknown.  No follow-up attempts are possible. Information about batch number cannot be obtained.",,Unknown,0,0
903868,"About 5 minutes after receiving the vaccine, recipient reported tightness in the arm he received the vaccine. Five minutes later reported feeling light headed and tightness in his throat. Blood pressure taken--142/80 with 102 pulse. Reports  no difficulty with breathing.  Respirations easy and nonlabored. SaO2 99%.   After reporting to healthcare provider, instructed to give Benadryl and call 911. Vital signs @ 3:30pm 139/81 with 79 pulse, temp 97.6   SaO2 100%  Paramedics arrived at 3:35pm  Recipient refused transport.  Agreed to be escorted to ER via shuttle. Arrived at ER @ 3:53pm",36.0,Adults,0,1
909678,Diarrhea stomach cramps on Sunday afternoon  Very sore arm Saturday to now Feeling like my nose is stuffy or tender but no congestion or mucus,31.0,Adults,0,0
892598,"Soreness at the injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 15th October 2020, the patient received Shingrix. On 15th October 2020, less than a day after receiving Shingrix, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was unknown.   It was unknown if the reporter considered the injection site pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. Age group was selected as adult as per product indication. Consumer states that they received a dose of Shingrix yesterday from the day of reporting and that they had soreness at the injection site. Did not consent to follow-up. The case had been linked with US2020206901 reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020206901:same reporter",,Unknown,1,0
913343,"Patient developed injection site reaction of redness, warmth, pain and inflammation around injection site, day 1 following injection. Area was marked. Day 2, redness extended beyond markings. Day 3 redness extended minimally beyond new markings. Level of warmth, pain and inflammation has remained the same at this time.",51.0,Adults,1,0
908491,None stated.,44.0,Adults,0,0
909779,"IM shot received at 0750. Went to sleep for the day since I work nights. I work up at noon with severe headache and numb bilateral hands. I took Tylenol 1000mg and went back to sleep. I woke up for work at 1630 feeling flushed. I took naproxen and went to work(in the ER). I developed a rash on my chest that evening. Over the next 3 days the rash progressively worsened across torso, back, and extremities. Since I received the vaccine on Christmas eve, employee health has not answered my calls or messages with the holiday. I also am scheduled to see PCP for this after the holiday weekend. I have been medicating with Zyertec BID, Benadry Q4hr, Pepcid BID, Tylenol TID since 12/24. I started a prednisone taper on 12/27.",31.0,Adults,0,0
901554,"Patient stated she started to notice some pain in her left shoulder at some time after her shot.  She did not seem to attribute pain to the shot as she was not able to pinpoint a start date, she made a best guess.  She said she thought pain would go away, but it has not resolved with heat or ibuprofen, which is all she has tried to this point.  She has lost range of motion in left shoulder as well.",67.0,Seniors,1,0
896837,"Shingles; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 1 week after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was not recovered/not resolved.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient receive dthe vaccine and one week later developed shingles.  He was still an active case of shingles.  No additional details were available. The reporter consented to follow up. This case has been linked with US2020220495, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020220495:same reporter",,Unknown,0,1
857446,"Patient's body broke out in welts and hives mainly to bilateral arms and legs. Left leg (thigh) at the site of the vaccine injection was identified as reaction vs. cellulitis. Area was marked and parents were advised if it spreds, gets warm to the touch to return for evaluation. Mom was instructed to give the child 2ml of children's Benadryl q8'prn",1.0,Kids,0,1
860165,"Arm soreness; Diarrhea; Itching of scalp and limbs; Headache; tenderness and swelling at injection site; tenderness and swelling at injection site; This is a spontaneous report from a contactable nurse via Pfizer Sales Representative. A 62-year-old female patient received pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) (PREVNAR 13) via an unspecified route of administration on an unspecified date at a single dose for immunization. Medical history included diabetes, blood pressure and cholesterol, all from an unknown date and unknown if ongoing. Concomitant medications include many medications (unspecified) for diabetes, blood pressure and cholesterol, all from an unknown date and unknown if ongoing. The patient received pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) and reported the following adverse events the following day: diarrhea, itching of scalp and limbs, headache, tenderness and swelling at injection site as well as arm soreness. The patient had not recovered from the arm soreness at the time of reporting; while recovered for the rest of the events.  Information on the batch number has been requested.",,Unknown,0,0
861042,"soreness all over body; difficulty sleeping; This case was reported by a other health professional via sales rep and described the occurrence of generalized aching in a 63-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 11th November 2019, the patient received the 1st dose of Shingrix (intramuscular). On 12th November 2019, 1 days after receiving Shingrix, the patient experienced generalized aching and insomnia. On an unknown date, the outcome of the generalized aching and insomnia were unknown.   It was unknown if the reporter considered the generalized aching and insomnia to be related to Shingrix.  Additional details were provided as follows:  The age at vaccination was not reported but could be 62 or 63 years. Post vaccination the patient developed soreness all over body and difficulty sleeping. The reporter consented to follow up.",,Unknown,0,0
867928,"Shingles after the first dose; This case was reported by a pharmacist via sales rep and described the occurrence of shingles in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as adult as per vaccine indication. No patients or vaccine data was available. The pharmacist did not want provide the patient's data. The pharmacist did not consent to follow-up. This case has been linked to US2020062452, reported by the same reporter.",,Unknown,0,1
912772,"828a- covid injection left arm 836a- itchiness at site of injection in left arm 839a-hives at site of injection left arm physician notified 840a-benadryl 50 mg PO liquid given, zyrtec 10 mg given po 852a-symptoms resolving, pt feeling fine, no difficulty breathing or swallowing, no further increase in hives",40.0,Adults,0,0
858594,"put her to sleep. She slept for a full day and night; Adverse reaction; This case was reported by a consumer via call center representative and described the occurrence of sleepiness in a 79-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included hip discomfort and sulfonamide allergy.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced sleepiness and adverse reaction. On an unknown date, the outcome of the sleepiness and adverse reaction were recovered/resolved.   It was unknown if the reporter considered the sleepiness and adverse reaction to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient experienced slight reaction on the 1st doseof Shingrix.  The first dose put her to sleep. She slept for a full day and night. Consent to follow up was provided. For tolerance with 2nd dose of Shingrix refer case US2020AMR012125.",,Unknown,0,0
868159,"TOOK VIVOTIF EVERY DAY; This spontaneous case report (PVX2019-2964) was received from a nurse on 03-Dec-2019. It described a male consumer who ""took Vivotif every day"" (PT: Inappropriate schedule of product administration), while being on oral Vivotif for typhoid fever prophylaxis.  Case report: The consumer took all four doses of Vivotif on every day instead of every other day. The doses were taken on 23-Oct-2019, 24-Oct-2019, 25-Oct-2019, and 26-Oct-2019.  The action taken with Vivotif with respect to reported event was not applicable.  The clinical outcome of reported event was unknown.  Company Comment: A consumer took one dose of Vivotif every day for four days instead of every other day (Inappropriate schedule of product administration). Considering the nature of the event, the causality of the event is assessed as not related to Vivotif.; Sender's Comments: A consumer took one dose of Vivotif every day for four days instead of every other day (Inappropriate schedule of product administration). Considering the nature of the event, the causality of the event is assessed as not related to Vivotif.",,Unknown,1,0
861965,"After getting the SECOND dose of the shingrix on 2/1, she developed fever blisters on 2/3 that the Dr identieifed on 2/18 to be ""Vaccine-associated zoster"", to which they prescribed Valtrex and Gabapentin",62.0,Adults,0,0
883659,"I didn't see maker, lot # of the Shingrix shot that I received.  This was the 2nd dose in 2 months.  About 12 hr after the shot, I had chills, headache, body aches and weak muscles.   Later while laying down, I had stomach pain - center of stomach area and fever.    The next morning, I was fine as well as my arm.  But later in the afternoon, I was extremely tired and took a 3-hr nap.   That evening I had same stomach pain - short while, while laying down.",58.0,Adults,1,0
910958,"Flushing, heart beating  fast,  pulse ox 96% hr 13-114 .  kept for observation 45 min felt well when left  pulse ox 99% hr 110.",39.0,Adults,0,0
863361,"Preterm birth (birth prior to 37 weeks of gestation); Foetal exposure during pregnancy; This is a literature case, initially received on 19-Feb-2020, concerning a neonate patient of unspecified gender.   The Project was a multi-site, prospective cohort study of pregnant women who were members of medical group during the 20102011 influenza season. Women and their newborns were followed until six months post-delivery. Potential participants were pregnant women identified through electronic health records (EHR) and were contacted for recruitment between Dec-2010 and May-2011.  The maternal demographics, behavioural characteristics and medical conditions included: maternal race/ethnicity, age (less than 30, 3034, more than 35 years), education (high school or less, some college/college graduate, Master's degree or higher), prenatal vitamin use (unspecified minerals and vitamins) (yes/no), alcohol use during pregnancy (yes/no), smoking during pregnancy (yes/no), parity (0, 1+), and month of conception during typical wintertime flu season (Nov-Mar) or not during flu season (Apr-Oct). Influenza vaccination status in the year prior to pregnancy was also ascertained from the EHR.  On an unspecified date, during 2010-2011 influenza season, the patient's mother was administered trivalent inactivated influenza vaccine (IIV3) [influenza virus vaccine polyvalent; dose, route od administration, anatomical location, batch number and expiry date: not reported] (explicitly coded as Foetal exposure during pregnancy') for influenza vaccination.   On an unspecified date, the patient was born prior to 37 weeks of gestation.  The outcome of premature birth' was not reported.   The event of premature birth' was assessed as serious due to the criterion of medical significance.   The reporter did not provide causality assessment to influenza vaccine.  The study results found no association between IIV3 exposure during pregnancy and infant development at six months.  This case is linked to cases: 202001895, 202001904, 202001915, 202001916, 202001917, 202001918, 202001919, 202001920, 202001921, 202001922, 202001923, 202001924, 202001925, 202001926, 202001927, 202001928, 202001929, 202001930, 202001932, 202001933, 202001934, 202001935, 202001936, 202001937 and 202001938 (same literature article).   Company comment: A neonate subject was delivered as premature baby after foetal exposure to the suspect product trivalent inactivated influenza vaccine (IIV3). Multiple pregnant patients were administered vaccine during pregnancy. Of these women, 40% received the IIV3 during the first trimester, 44% in the second trimester and 16% in the third trimester. Chronology needs more clarification. Some of these patients had medical history of advanced maternal age, smoking and alcohol use during pregnancy which may have contributed to development of the event. Causal role of the suspect vaccine cannot be totally excluded and is assessed as unlikely related (defaults to ""related"" in the safety database for reporting purposes). Foetal exposure during pregnancy is assessed as unrelated per company's conventions.; Sender's Comments: A neonate subject was delivered as premature baby after foetal exposure to the suspect product trivalent inactivated influenza vaccine (IIV3). Multiple pregnant patients were administered vaccine during pregnancy. Of these women, 40% received the IIV3 during the first trimester, 44% in the second trimester and 16% in the third trimester. Chronology needs more clarification. Some of these patients had medical history of advanced maternal age, smoking and alcohol use during pregnancy which may have contributed to development of the event. Causal role of the suspect vaccine cannot be totally excluded and is assessed as unlikely related (defaults to ""related"" in the safety database for reporting purposes). Foetal exposure during pregnancy is assessed as unrelated per company's conventions.",,Unknown,0,1
883413,Rash with red bumps,82.0,Seniors,1,0
867473,"EAR INFECTION; WALKING PNEUMONIA; This spontaneous case report (PVX2019-2529) was received from a nurse on 09-Oct-2019. It described a male consumer who developed walking pneumonia (PT: Atypical pneumonia) and an ear infection (PT: Ear infection), while being on oral Vivotif one dose every other day for typhoid fever.  Case report: The consumer took three doses of Vivotif as per schedule.  On an unknown date, he was diagnosed with walking pneumonia and an ear infection and it was getting worse. He was prescribed an antibiotic, but he did not started it.   Action taken with Vivotif with respect to reported events was unknown.  The clinical outcome of the reported events was unknown.  Company's Comment: In this case, the patient developed walking pneumonia and an ear infection after receiving Vivotif vaccine. Due to the fact that walking pneumonia and an ear infection are infectious in etiology the causality of the event was assessed as unlikely with Vivotif. ; Sender's Comments: Company's Comment: In this case, the patient developed walking pneumonia and an ear infection after receiving Vivotif vaccine. Due to the fact that walking pneumonia and an ear infection are infectious in etiology the causality of the event was assessed as unlikely with Vivotif.",,Unknown,0,0
874287,"Vaccine given 6/2/2020. Guillain-Barre Syndrome diagnosed on 6/19/2020 Admitted to ICU, intubated and started on plasma exchange therapy. Planned to stay inpatient ongoing at least thru next week",25.0,Adults,0,1
908716,"Patient had hives on right side of neck to the nape of neck, bilateral elbow creases, bottoms of bilateral feet.  Redness and swelling of mouth.  Patient was prescribed 80mg Depo-Medrol IM, 50 mg Benedryl IM, and sent out with 6 day Medrol Dose pack with OTC benedryl and pepcid.",35.0,Adults,0,0
905384,"Patient got Covid; Initial information was received on 14-Dec-2020 regarding an unsolicited valid non-serious case received from a consumer (patient) via social media.  This case involved an unknown age patient who patient got Covid (corona virus disease) (COVID-19), after receiving vaccine INFLUENZA VACCINE.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination.   On an unknown date, it was reported that patient got Covid (corona virus disease) (COVID-19), unknown latency following the administration of INFLUENZA VACCINE.   Laboratory test included COVID-19 test.   It was not reported if the patient received a corrective treatment.   At the time of reporting, the outcome was unknown for the reported event.   There would be no information available on batch number for this case.",,Unknown,0,1
900981,"patient administered an expired dose of Pentacel/ NO AE; Initial information regarding an unsolicited valid non-serious case was received from a nurse via Agency via call-center (Reference number- 00339146) and transmitted to Sanofi on 30-Oct-2020.  This case involves a 6-months-old female patient who received expired 0.5 mL DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL] (frequency: once, strength: standard, lot number: UJ065AAA and expiry date: 16-Oct-2020) (expired vaccine used) on 23-Oct-2020 for prophylactic vaccination.  The patient's medical history, past medical treatment, vaccination and family history were not provided.  Concomitant medications included ROTAVIRUS VACCINE (ROTAVIRUS VACCINE), PNEUMOCOCCAL VACCINE CONJ 13V (CRM197) (PREVNAR 13), HEPATITIS B VACCINE RHBSAG (YEAST) (ENGERIX B) and Menvale (study drug) for prophylactic vaccination.  This site is part of the vaccine study.  It was an actual medication error case due to due expired vaccine used (latency: same day).  At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",0.5,Kids,0,1
882691,"Recurring Herpes Zoster/ occurs on the mandibular branch of his face, no other location/ His HZ was ""never severe, just recurrent""; This spontaneous report was received from a physician via company representative concerning a 55-year-old male patient. The patient's medical history included natural varicella and it was reported that the patient presented herpes zoster every time he ran a marathon; the reporter confirmed that the patient had been on valacyclovir hydrochloride (VALTREX) prophylaxis for years and it was doing fine. The patient's concurrent conditions were not provided.  On an unknown date, approximately in 2010, the patient was vaccinated with zoster vaccine live(ZOSTAVAX) (Strength, dosage regimen, lot number and expiration date were not provided) due to his recurring herpes zoster episodes.   On an unknown date, approximately 3 years post-vaccination, the patient experienced Herpes Zoster on the mandibular branch of his face, no other location. Per the physician PCR testing was not performed; since it was assumed a wild type virus. The reporter did not considered the herpes zoster post vaccination to be an adverse event.   At the time of the report it was unknown if the patient had recovered from the herpes zoster reactivation. The causal relationship between zoster vaccine live(ZOSTAVAX) and the event was not reported.",,Unknown,0,1
879349,"Patient was feeling dizzy, turned pale and had a blank stare for a couple minutes. Patient was kept and monitored for 45 minutes in the office. Apple juice was given before the vaccine. BP was taken 4 times before discharged. Doctor's kept monitoring the patient.",11.0,Kids,0,1
880455,"aches all over, glands hurt, really tired, localized pain where shot was given.  Felt like really bad 24 hour virus.  I was in bed all day",59.0,Adults,1,0
878038,Pt came in for his 2nd dose of Shingrix. He said he was delayed to get the second dose because he has partial loss of his left eye vision after a week received the shingrix. He still loss his vision now. He said he cant see anything below. He sees thing in front or upper are fine.,59.0,Adults,0,0
908205,"Patient experienced chills, lethargy, and soreness the first couple days after administration. Patient stated that he started to have itchy skin on Monday (12/21) and now it looks like he has hives (redness and itchy) mostly on right arm, back, and chest. Patient has been using hydrocortisone. It was advised he take Benadryl orally to help with the hives.",68.0,Seniors,1,0
889731,"patient Felt dizzy and nausea, unable to stand up.",9.0,Kids,1,0
904704,"Patient report itching and rash of the neck, upper arm and upper back  on Saturday 12/19/20 .  50 mg of Benadryl  taken on 12/19/20 and symptoms resolved on 12/19/20.",60.0,Adults,1,0
916407,24 hrs after experienced fatigue a headache. 48 hrs later fatigue and headache increased. Ibuprofen was taken with no results.,67.0,Seniors,1,0
880401,"no adverse effects; patient have been administered doses of improperly stored vaccines; This spontaneous report was received from a nurse and refers to an unspecified number of patients of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical histories provided. On 23-MAR-2020, the patient was vaccinated with improrperly stored doses of  haemophilus b conjugate vaccine (meningococcal protein conjugate)(LIQUID PEDVAXHIB) lot # S030965 with expiration date of 03-APR-2022(upon internal validation) 0.5 milliliter, intramuscular in the right thigh for prophylaxis; pneumococcal vaccine (unspecified)(PNEUMOCOCCAL VACCINE (UNSPECIFIED)) and diphtheria toxoid, hepatitis b virus vaccine rhbsag (yeast), pertussis acellular 3-component vaccine, poliovirus vaccine inactivated (vero), tetanus toxoid(PEDIARIX). No adverse events were reported.     This is one of several reports from the same reporter ; Sender's Comments:  US-009507513-2003USA002275:Original Case : 2003USA002275 US-009507513-2008USA008883:Original Case : 2003USA002275 US-009507513-2008USA008876:Original Case : 2003USA002275 US-009507513-2008USA008875:Original Case : 2003USA002275 US-009507513-2008USA008877:Original Case : 2003USA002275 US-009507513-2008USA008878:Original Case : 2003USA002275 US-009507513-2008USA008879:Original Case : 2003USA002275 US-009507513-2008USA008880:Original Case : 2003USA002275 US-009507513-2008USA008881:Original Case : 2003USA002275 US-009507513-2008USA008884:Original Case : 2003USA002275 US-009507513-2008USA008886:Original Case : 2003USA002275 US-009507513-2008USA008887:Original Case : 2003USA002275 US-009507513-2008USA008888:Original Case : 2003USA002275 US-009507513-2008USA008889:Original Case : 2003USA002275 US-009507513-2008USA008890:Original Case : 2003USA002275 US-009507513-2008USA008891:Original Case : 2003USA002275 US-009507513-2008USA008892:Original Case : 2003USA002275 US-009507513-2008USA008893: US-009507513-2008USA008894: US-009507513-2008USA008895: US-009507513-2008USA008896: US-009507513-2008USA008897: US-009507513-2008USA008898: US-009507513-2008USA008899: US-009507513-2008USA008900: US-009507513-2008USA008901: US-009507513-2008USA008902: US-009507513-2008USA008903: US-009507513-2008USA008904: US-009507513-2008USA008905: US-009507513-2008USA008906: US-009507513-2008USA008907: US-009507513-2008USA008908: US-009507513-2008USA008909: US-009507513-2008USA008910: US-009507513-2008USA008911: US-009507513-2008USA008912: US-009507513-2008USA008913: US-009507513-2008USA008914: US-009507513-2008USA008915: US-009507513-2008USA008916: US-009507513-2008USA008917: US-009507513-2008USA008918: US-009507513-2008USA008919: US-009507513-2008USA008920: US-009507513-2008USA008921: US-009507513-2008USA008922: US-009507513-2008USA008923: US-009507513-2008USA008924: US-009507513-2008USA008925: US-009507513-2008USA008926: US-009507513-2008USA008927: US-009507513-2008USA008928: US-009507513-2008USA008929: US-009507513-2008USA008930: US-009507513-2008USA008931: US-009507513-2008USA008931: US-009507513-2008USA008932: US-009507513-2008USA008933: US-009507513-2008USA008886:",,Unknown,0,1
900317,"Fever, muscle ache, tiredness, headache",62.0,Adults,1,0
868548,"subcutaneous lump, redness and pain started 3 days after vaccine was given, pain still present 4.5 weeks after vaccine was given, and child reports pain in arm with movement (not in shoulder joint), subcutaneous mass measures 1.5 cm and mom reported this has increased in size since the initial lump appeared 3 days after the vaccine.",11.0,Kids,0,0
906975,"Hot Flashes and headache, patient reports that she feels weird and not herself.  No spike in actual temperature reported.",37.0,Adults,1,0
902469,"pt had radiating pain from middle of left arm up to spine the first night following dose.  for the last 3 months, pt has reported having a coming and going pulsating pain around middle of left upper arm.  Pain is described to be more common in the morning upon wakening but distinctly different from her typical arthritis pain.  She has not seeked medical attention at this time",65.0,Adults,1,0
893307,"Fever 101.5; arm pain; neck / pain; should pain; tiredness; cold; headache; This case was reported by a consumer via call center representative and described the occurrence of fever in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on an unknown date, no reaction).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than a day after receiving Shingrix, the patient experienced fever, pain in arm, neck pain, shoulder pain, tiredness, cold and headache. On an unknown date, the outcome of the fever, pain in arm, neck pain, shoulder pain, tiredness, cold and headache were recovered/resolved.   It was unknown if the reporter considered the fever, pain in arm, neck pain, shoulder pain, tiredness, cold and headache to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. Patient received 2nd dose of Shingrix and within 10 hours, experienced awful reaction included fever 101.5, arm pain, neck pain, shoulder pain, tiredness, cold and headache and all their events got resolved within 24 hours. Patient wondered why there was a reaction to the 2nd dose and not to 1st dose of Shingrix. The reporter did not consented to follow up.",,Unknown,1,0
883522,"patient stated she felt faint and was going to go ""out"". Patient went unconscious continued to breath, flushed on arms and chest ems called patient awoke EMT arrived and spoke with patient taking blood pressure and oxygen level. Patient stated she did not want to go to hospital and EMTs escorted her to her car and she was driven home",73.0,Seniors,0,0
912633,"Day of vaccine- extreme fatigue, pain at injection site Day 1- scratchy throat, extreme fatigue, muscle pain Day 2 - scratchy throat, extreme fatigue, chest tightness, muscle pain, headache Day 3 all symptoms as above with sore throat and fever",31.0,Adults,0,0
897830,"Nausea, fatigue, muscular weakness, loss of bladder control",74.0,Seniors,1,0
898671,"horrible rash all over the body, in the ears, on the scalp with terrible itching",69.0,Seniors,1,0
871303,"Lower Back Issue; This case was reported by a pharmacist via call center representative and described the occurrence of back pain in a 64-year-old female patient who received Herpes zoster (Shingrix) (batch number HE2P5, expiry date 22nd February 2022) for prophylaxis.   On 3rd January 2020, the patient received the 1st dose of Shingrix. On an unknown date, less than 3 months after receiving Shingrix, the patient experienced back pain. The patient was treated with prednisone. On an unknown date, the outcome of the back pain was unknown.   It was unknown if the reporter considered the back pain to be related to Shingrix.  Additional information was provided as follows: The patient received Shingrix and started with a Prednisone therapy for a lower back issue. The pharmacist was not sure of the patients clinical condition. He also clarified to the second line agent that the therapy consisted on 60 mg of Prednisone for 3 days, 40 mg for 3 days, 20 mg for 3 days and 10 mg for 3 days. The reporter consented to follow up.",64.0,Adults,1,0
907179,"erythematous papular rash scattered throughout abdomen, torso, neck with areas Onset of symptoms noticed 6hrs from vaccine, rash has continued to spread 4 days from time of vaccination sparing most of the extremities.",28.0,Adults,0,0
883459,Pt's arm was red and swollen from Deltoid down to elbow. Pt used Cortizone Cream which she stated helped.,68.0,Seniors,0,0
889874,Patient slumped to her right while sitting. She jerked twice while mother tried to sit her up.  She then was alert but skin was damp and clammy.  She also experienced nausea a few minutes later and tried to vomit but did not,20.0,Adults,1,0
886355,"Patient began having trouble sleeping and starting showing signs of not acting herself 10/13/2018.  10/17/2018 her fever started extremely warm, 7 am (101) 9:40 (100.8 ) 11:45 am  (102.4) 4:30 pm 102.1, walking off balance (more than usual)  I called into our Dr's office, took her to urgent care and tested for a UTI.  This continued on and 10/18/2020 she became extremely lethargic falling asleep when she otherwise would not have, called Dr office again, also rash on eyelids. By 10/19/2020 her eyes were red, swollen and she was congested and uncomfortable, and not her self and made a Dr appointment, ma 10/20/2018 After hours call 10/21/2018 Called + visit after hours clinic, saw 2  doctors, then  sent us to ER",1.08,Kids,1,0
912643,"5-10 minutes after vaccine got mild numbness/heaviness feeling corner of left side of mouth (very pinpoint without migration) that 1-2 hours after vaccine progressed to similar feeling on lateral left side of face and corner of left eye-no motor weakness in face, facial drooping or clinical change in sensation on palpation of skin, intermittent  gritty/sandy feeling  on tongue/mouth that started about 30 minutes or so after received the vaccine.  Intermittent very mild scratchy/sore throat that start 30+ minutes after vaccine, frontal  pressure-like headache-forehead/temples/cheeks on face-started within about 30 mins-1 hr of getting vaccine-can get extremely strong at times.  Approximately 12-14 hrs after vaccine got  tingling/burning sensation  on  tongue with complete  100% loss of taste that was transient and 1-2 hours after started has slowly been  improving and taste is slowly returning since then. no loss of smell. no tongue  swelling or throat closing up sensation.  all symptoms improve with taking over the counter antistamines-Zyrtec or benadryl, but haven't resolved yet.  all symptoms overall mild (except headache at time) and  are waxing and waning in severity (including headache) the entire time since receiving the vaccine.  I feel completely fine otherwise.",38.0,Adults,0,0
876561,"Flu like symptoms; This case was reported by a other health professional via call center representative and described the occurrence of influenza-like symptoms in a 22-year-old female patient who received Rabies NVS (RabAvert) (batch number ARBA651B, expiry date 20th March 2023) for prophylaxis.   Co-suspect products included LIVE VARICELLA VIRUS VACCINE (CHICKEN POX VACCINE) for prophylaxis.   On 23rd June 2020, the patient received the 2nd dose of RabAvert. On 22nd June 2020, the patient received CHICKEN POX VACCINE. On an unknown date, less than 3 weeks after receiving RabAvert, the patient experienced influenza-like symptoms. On an unknown date, the outcome of the influenza-like symptoms was unknown.   It was unknown if the reporter considered the influenza-like symptoms to be related to RabAvert.  Additional details were provided as follows: The reporter stated that, the patient received pre-exposure schedule for Rabavert and experienced flu-like symptoms. The patient received  dose of a chicken pox vaccine just the day before receiving Rabavert 2nd dose. It was unknown if the reporter considered the influenza-like symptoms to be related to Chicken pox vaccine. The reporter consented to follow up.",22.0,Adults,0,1
860885,"Constant headache since 1/17. Intensity comes and goes. It sometimes feels like a migraine and sometime feels dull. She had tried caffeine, motrin, alka seltzer, vics with no relief. She says it sometimes feels like her sinuses. She had a runny nose. No sore throat. Imitrex rx'd. Followed by allergist. Toradol 60mgxl. Follow up with PCP on 02/20/20.",27.0,Adults,1,0
913362,"general achiness; This case was reported by a consumer via call center representative and described the occurrence of general body pain in a 62-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 30th November 2020, the patient received the 1st dose of Shingrix. On 30th November 2020, less than a day after receiving Shingrix, the patient experienced general body pain. On an unknown date, the outcome of the general body pain was not recovered/not resolved.   It was unknown if the reporter considered the general body pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received dose of shingrix in left arm and experienced general achiness. The reporter was calling for management information. The reporter consented to follow up.",62.0,Adults,1,0
880756,"five doses of the VARIVAX that underwent the temperature excursion were administered; This spontaneous report has been received from a physician  concerning a 12 months- old patient of unknown gender. The patient's concomitant therapies, concurrent conditions, historical drugs and medical history were not reported.  On 09-AUG-2020,  the patient was vaccinated with one of the five doses of varicella virus vaccine live (oka/merck)(VARIVAX) subcutaneous injection 0.5 milliliter once for prophylaxis, that underwent temperature excursion.  Lot # reported as S026925 (Patient route of administration and expiration date was not reported).  The storage temperature was reported  to have been at -9.2 celsius degrees (C) and in between  -14 celsius degrees (C) to -10 celsius degrees (C) (-14.3) for 30 minutes.  There was digital data logger involved and  no previous temperature excursion was reported.  Lot #  S026925 is an invalid lot number for varicella virus vaccine live (oka/merck)  This is one of many reports received from the same reporter about related temperature excursion cases.; Sender's Comments:  US-009507513-2008USA011215: US-009507513-2008USA011215: US-009507513-2008USA011596: US-009507513-2008USA011473:",1.0,Kids,0,1
887583,"Medical assistant calling to report a temperature excursion that occurred 8/14/2020 which involved the following products: GARDASIL9, PEDVAXHIB, RECOMBIVAX, ROTATEQ. Per caller, ""it would be possible that at least 100 patients have received vaccines; This spontaneous report was received from a medical assistant, concerning a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies or concomitant medications were not reported.  On 11-AUG-2020, the patient was vaccinated with an improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) 0.5 ml orally as prophylaxis (lot # 1660974 with expiration date 20-APR-2021) (strength and frequency were not reported).  The improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) experienced a temperature excursion of 35.4 Fahrenheit degrees (F) for the time frame of 20 minutes without previous temperature excursions. It was confirmed that a digital data logger was involved.  This is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2009USA006106:",,Unknown,0,1
861291,"Vaccine was administered 3 cm from the elbow. Per provider's note: ""Patient presents 2 days after receiving 4 year old immunizations. Patient's mother states that immunization was administrated near the elbow. Mom states over past 48 hours the immunization site has become red and swollen. Patient with some pain overnight, none currently. No fever. No loss of mobility of left arm/elbow""",4.0,Kids,0,0
915945,"As soon as patient received the vaccine, she noticed a flushed feeling and then her right hand was tingling. She then felt a rush of heat up her right arm into her right ear and then a subsequent tingling of the lips. She became flushed on her chest and diaphoretic.  After a dose of 10mg Benadryl and consumption of peanut butter crackers, ginger ale, and an orange, patient stated that she felt much better despite some heat in her right ear and tingling in her right thumb still.",50.0,Adults,0,1
906721,"Patient developed dizziness shortly after receiving Pfizer Covid-19 vaccine on 12/21/2020.  Patient was brought to the Emergency Department.  SBP initially in 70's, rapidly improved to 90's without intervention.  Patient denied SOB.  No e/o angioedema on exam.  SBP improved to 110's after 500cc of NS.",63.0,Adults,0,0
882715,"FLUBLOK QUADRIVALENT was administered to a 17 year old male/no AE; Initial information received on 03-Sep-2020 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 17 years old male patient who was vaccinated with 0.5 mL INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] (batch number and expiry date not reported) via unknown route in unknown administration site on an unknown date for prophylactic vaccination (product administered to patient of inappropriate age).  Medical history, concomitant therapy, medical treatment(s), vaccination(s) and family history were not provided.   It was an actual medication error case due to inappropriate age at vaccine administration.  At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information available on batch number for this case.",17.0,Kids,0,1
881803,"Daptacel was given to a patient instead of Adacel, no AE; Initial information received on 26-Aug-2020 regarding an unsolicited valid non-serious case from other health professional.  This case involves a 11 years old female patient who was vaccinated with 0.5 ml DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL] (lot number :C5732AA  and expiration date:24-Apr-2022) instead of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] (lot number and expiration date were not reported) via intramuscular route in the right deltoid as prophylactic vaccination on 26-Aug-2020.  The patient's medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.  It was an actual medication error case due to wrong vaccine administered .  No adverse event reported at the time of reporting.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
867936,"fever; body aches; Still doesn't feel well; Arm is also sore; This case was reported by a consumer via call center representative and described the occurrence of fever in a 58-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of malaise (received 1st dose at least 6 months ago, refer case US2020AMR062690). Concurrent medical conditions included nasal stuffiness (had a stuffy nose for the past few days before vaccination).   On 8th April 2020, the patient received the 2nd dose of Shingrix (intramuscular). On 8th April 2020, less than a day after receiving Shingrix, the patient experienced fever and general body pain. In April 2020, the patient experienced feeling unwell and pain in arm. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the fever, general body pain and pain in arm were not recovered/not resolved and the outcome of the feeling unwell was recovered/resolved.   It was unknown if the reporter considered the fever, general body pain, feeling unwell and pain in arm to be related to Shingrix.  Additional details were provided as follows: In the evening of vaccination day, the patient started experiencing fever and body aches. Less than a week after vaccination, the patient experienced feeling unwell and sore arm. The patient stated he still did not feel well in the morning of reporting day. The patient's arm was sore. The reporter consented to follow up.",58.0,Adults,1,0
905574,"After 15 minutes of monitoring post injection, I developed itching to left shoulder with diffue hives to shoulder and chest",51.0,Adults,0,0
880084,"when the needle was removed, the injection site bled.; when the needle was removed, the injection site bled.; when the needle was removed, the injection site bled./hard to determine if the patient got a full dose; injection site bled; This case was reported by a other health professional via call center representative and described the occurrence of injection site hemorrhage in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 27th August 2019).   On 14th January 2020, the patient received the 2nd dose of Shingrix. On 14th January 2020, immediately after receiving Shingrix, the patient experienced injection site hemorrhage, inadvertent exposure to vaccine, accidental underdose and exposure via skin contact. On an unknown date, the outcome of the injection site hemorrhage, inadvertent exposure to vaccine, accidental underdose and exposure via skin contact were unknown.   It was unknown if the reporter considered the injection site hemorrhage to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The Other health professional reported that a patient got first dose of Shingrix on 27th August 2019 The patient got the second dose on 14th January 2020. However, when the needle was removed, the injection site bleed. It was hard to determine if the patient got a full dose or not. The HCP was considering giving a 3rd dose or re-starting the complete series. This led to product administration error, accidental underdose and exposure via skin contact. The reporter consented to follow up.",,Unknown,0,1
874628,"Pt states 5-6 flat red spots, ~1/2"" wide, with ""microblisters"" in the center of each one that have bruise-like soreness only upon depression of the area, slowly developed below the injection site starting about 18 hours after the injection. Pt states no similar reaction after 1st injection, and no other issues with this 2nd injection. Pt denies exposure to anything else (ex: poison ivy, etc) that could have caused a similar type of response.  Recommended a dose of Benadryl and watch for any resolution. If rash started to resolve, recommended a 2nd dose of Benadryl. If rash continued or worsened, advised ER or paging PCP.",62.0,Adults,1,0
890790,"got sick / didn't feel good; This case was reported by a pharmacist via call center representative and described the occurrence of sickness in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, immediately after receiving Shingrix, the patient experienced sickness. The patient was treated with methylprednisolone (Medrol Dosepak). On an unknown date, the outcome of the sickness was unknown.   It was unknown if the reporter considered the sickness to be related to Shingrix.  Additional details were provided as follows: The age group was not reported, however it was captured as an adult as per vaccine indication. The age at vaccination was not reported. The patient got sick and did not feel good right after receiving the first dose of Shingrix. The patient was given Medrol Dosepak. No additional details were available. The reporter did not consent to follow up. The reporter could not clarify further what got sick entailed and did not remember any further details. The reporter does not wish to be contacted because she had nothing more to provide.",,Unknown,0,1
903641,"Tingling in lips and left side of face felt numb 20 minutes after vaccine.  No treatment, resolved in 3 hours.",28.0,Adults,0,1
878281,"symptoms like having the flu but without a fever; extreme Tiredness; Headache; muscle aches throughout entire body; This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on unknown date).   On 29th July 2020, the patient received the 2nd dose of Shingrix (intramuscular). On 30th July 2020, 1 days after receiving Shingrix, the patient experienced influenza-like symptoms, tiredness, headache and muscle pain. On an unknown date, the outcome of the influenza-like symptoms, tiredness, headache and muscle pain were not recovered/not resolved.   It was unknown if the reporter considered the influenza-like symptoms, tiredness, headache and muscle pain to be related to Shingrix.  Additional case details were reported as follows: The patient experienced next day after vaccination headache followed by muscle aches throughout entire body and then extreme tiredness towards the end of the day.  The patient described symptoms like having the flu but without a fever. The reporter consent to follow up.",50.0,Adults,1,0
888189,"swelling and knot the size of a goose egg at the injection site; knot / at the injection site which was very red; knot / at the injection site which was / slightly itchy.; her arm was sore for a couple of weeks; knot the size of a goose egg at the injection site; was not able to move her arm for 2 to 3 days; This case was reported by a nurse via call center representative and described the occurrence of injection site swelling in a 50-year-old female patient who received Herpes zoster (Shingrix) (batch number H4H34, expiry date 30th November 2021) for prophylaxis.   Concurrent medical conditions included allergy.   On 23rd July 2020, the patient received the 1st dose of Shingrix. On an unknown date, less than 3 months after receiving Shingrix, the patient experienced injection site swelling, injection site erythema, injection site itching, mobility decreased, pain in extremity and injection site lump. On an unknown date, the outcome of the injection site swelling and injection site lump were not recovered/not resolved and the outcome of the injection site erythema and injection site itching were unknown and the outcome of the mobility decreased and pain in extremity were recovered/resolved.   It was unknown if the reporter considered the injection site swelling, injection site erythema, injection site itching, mobility decreased, pain in extremity and injection site lump to be related to Shingrix.  Additional details were provided as follows: The patient received Singrix and she experienced injection site swelling, injection site knot the size of a goose egg, injection site redness, injection site slightly itchy, unable to move her arm for two to three days and sore arm for a couple of weeks. Till the time of reporting patient had a knot and swelling at injection site. The physician was wait for the swelling to resolve before administering the second dose. The reporter consented to follow up.",50.0,Adults,1,0
875752,She is having pain on the inside of her left ankle. She does not have the pain when she elevates her leg.  She also is having trouble standing on her left foot.,73.0,Seniors,1,0
904348,"Pain in the injection site for several hours (probably 5 hours or less), with a pain scale of 3/10. Pain is manageable, can still use the affected arm, no pain medication taken.",41.0,Adults,1,0
892686,"PATIENT STATES SMALL, ITCHING FLUID FILLED 'BLISTERS' OR BUMPS FORMED NEAR INJECTION SITE AFTER ADMINISTRATION. AS OF 10/26/20, THOSE BUMPS WERE GONE AROUND INJECTION SITE BUT NOW PRESENTED ON LEG.  PATIENT STATES BUMPS ONLY ITCH, NO PAIN ASSOCIATED WITH BUMPS.",82.0,Seniors,1,0
858751,"fever 100.2 F; sore arm; This case was reported by a nurse via call center representative and described the occurrence of fever in a 3-year-old female patient who received Rabies NVS (RabAvert) (batch number ARBA51YA, expiry date 31st March 2023) for prophylaxis.   On 17th January 2020, the patient received the 1st dose of RabAvert. In January 2020, less than a week after receiving RabAvert, the patient experienced fever and pain in arm. On an unknown date, the outcome of the fever and pain in arm were unknown.   It was unknown if the reporter considered the fever and pain in arm to be related to RabAvert.  Additional details were provided as follows: The patient developed a fever of 100.2 degree fahrenheit and a sore arm.  It was unknown if the events were ongoing at the time of this report. The reporter consented to follow up.",3.0,Kids,1,0
893920,"Developed left arm redness, pain, swelling, warmth induration one day after injection. Symptoms persisted one week later without improvement. Diagnosed with left arm cellulitis.",60.0,Adults,1,0
872133,patient complained of soreness in his left shoulder the evening of the day he got the vaccine and it was swollen a little. the next evening  his left bicep was turning red and started to swell.  The next day he stated the lymph nodes under his arm hurt badly and he didn't feel well.,66.0,Seniors,0,1
868774,"TOOK SECOND DOSE A DAY LATE; This spontaneous case report (PVX2019-1762) was received from a pharmacist on 08-Jul-2019. It describes a female consumer who ""took second dose a day late"" (PT: Inappropriate schedule of product administration), while being on oral Vivotif (one dose every other day) (lot number: 3003279) for typhoid fever prophylaxis.  Case report: The consumer took the first dose of Vivotif on 03-Jul-2019. Then, she took the second dose on 06-Jul-2019 instead of 05-Jul-2019.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event ""took second dose a day late"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took second dose a day late"" was considered as not applicable.",,Unknown,1,0
883001,Left arm swelling plus redness st vaccination site,4.0,Kids,0,0
911937,severe vertigo,51.0,Adults,1,0
906180,"12/21/2020 3:00PM Abdominal  l quad pain, nausea sore arm, headache, fever 101.9 with chills -- tylenol, ibuprofen some relief. 12/22/20 tylenol in  AM-- low grade fever persists with headache, some nausea.",59.0,Adults,0,0
856267,"shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unspecified age. Information about the patient's concurrent condition, concomitant medication or medical history was not provided. In 2016 the patient was vaccinated with zoster vaccine live(ZOSTAVAX) (strength, dose, route, lot # and expiration date were not reported) as prescribed and/or administered by a healthcare provider for the long-term prevention of shingles and/or zoster-related conditions. At the time of patient's vaccination, patient relied on the warning label affixed to zoster vaccine live(ZOSTAVAX), and the information relayed through patient's healthcare provider(s) that zoster vaccine live(ZOSTAVAX) was effective in preventing shingles on a permanent basis and did not carry any significant risk of adverse effects, which induced patient to be vaccinated. On an unspecified date (reported as subsequent to zoster vaccine live(ZOSTAVAX) inoculation), patient was treated a doctor for shingles. As a direct and proximate result of patient's use of the zoster vaccine live(ZOSTAVAX) vaccine, patient has and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of shingles was not provided. The lawyer considered shingles to be related to zoster vaccine live(ZOSTAVAX).",,Unknown,0,0
901087,"flu; Initial information received on 27-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer or non-healthcare professional.  This case involve a patient (unknown age) who experienced flu (influenza) , when received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.  On an unknown date, the patient received a  dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious flu (influenza) unknown latency following the administration of INFLUENZA VACCINE.  Laboratory details were not reported.  It was not reported if the patient received a corrective treatment.  The event outcome was unknown for influenza.  There will be no information available on the batch number for this case.",,Unknown,0,1
911638,"muscle pain in both arms, R worse than L. Slight dizziness for first 4 hours after vaccine. On and off minor headaches for the first 48 hours post vaccine",39.0,Adults,0,0
898476,Patient reported soreness at the injection site (deltoid) beginning the day after receiving the vaccine,58.0,Adults,0,1
798713,"FATIGUE; HEADACHE; ABDOMINAL DISCOMFORT; STOMACH PAIN; VOMITING; LOOSE STOOLS; This spontaneous case (798713-1) was extracted through VAERS database on 26-Apr-2019. The case was reported by a consumer. It describes a 53-year-old female consumer who had fatigue, headache, abdominal discomfort, stomach pain, vomiting, and loose stools, after the administration of oral Vivotif (company suspect) (lot no: 3003220) for an unknown indication. She also received intramuscular Engerix-B (non-company suspect) (lot number: 2KJ42) for an unknown indication.  Case report: The consumer took the first dose of Vivotif on 24-Jan-2019 and Engerix-B. After 1 hour, she had a headache and abdominal discomfort. She took Tylenol (paracetamol) for it but got no relief. Approximately three hours later, she had a massive headache and severe stomach pain. In the late morning, she had vomiting and loose stools, which persist for hours. Next morning, she felt fatigued but condition was improved.   The consumer's past medical history included stomach bug (December 2018). She had no allergy.   The consumer had no concomitant medication.  The consumer had no laboratory tests.  Action taken with Vivotif was unknown.  The consumer had recovered from the events of fatigue, headache, abdominal discomfort, stomach pain, vomiting, and loose stools on 25-Jan-2019.  Company's Comment: In this case, the consumer experienced ""sore throat"", ""headache"", ""influenza like symptoms"", ""high fever"" and ""body pain"" following administration of Vivotif and intramuscular Engerix-B. There seems to be a temporal association between the intake of Vivotif and the events. Hence, the causality of the events with Vivotif was assessed as possible. Additionally, co-administration of multiple vaccines also provides a plausible explanation for the reported events.; Sender's Comments: Company's Comment: In this case, the consumer experienced ""sore throat"", ""headache"", ""influenza like symptoms"", ""high fever"" and ""body pain"" following administration of Vivotif and intramuscular Engerix-B. There seems to be a temporal association between the intake of Vivotif and the events. Hence, the causality of the events with Vivotif was assessed as possible. Additionally, co-administration of multiple vaccines also provides a plausible explanation for the reported events.",,Unknown,0,0
915259,"""About an hour after receiving the Pfizer covid vaccine, I developed a red itchy area on my opposite scapula/back. It went away after roughly 30min and then reappeared on a small part of my neck. I went to employee health, notified them, and was given a Claritin. While waiting for it to work, the top of my head and bottom of my feet itches for just a minute. The employee health nurse thought my reaction could have been from the latex on the top of the vial. In the past I've gotten mild localized rashes from latex bandaids. Perhaps if the vial was made of something other than latex that may have prevented or minimized my reaction. Or reaction could be from something else, as I've never gotten this reaction from other vaccines before. However, I much prefer this reaction to getting covid and it's side effects, and am thankful to have received this vaccine.""",39.0,Adults,0,0
914987,"Within 24 hours a rash developed on right forearm and left leg.  Patient waited for it to go away but didn't.  He had regular appointment with his doctor on 12-24-2020 and asked him about it.  Doctor said it was not shingles, but not sure if it was associated with either vaccine.  Gave him a prescription for Triamcinolone Cream.  Patient reports the itch has gone away as of 12-30-2020 but still has a rash.",63.0,Adults,0,0
892537,"No additional AE/PQC.; improperly stored vaccine of PROQUAD was administered; This spontaneous report was received from a medical assistant and refers to a 5-year-old patient of unknown gender. The patient's pertinent medical history, drug reactions, allergies and concomitant medication were not reported.  On 19-OCT-2020, the patient was vaccinated with improperly stored dose of with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, 0.5 ml (frequency reported as ""once"", lot # reported as T01691 with expiration date reported as 11-NOV-2021, anatomical location was not provided) for prophylaxis.  The temperature excursion was 30.1 Fahrenheit (F) for 40 hours and 40 minutes. There were no previous excursions reported. The digital data logger was not involved. No adverse effects were reported.",5.0,Kids,0,1
860402,"ichy; sore; uncomfortable; This case was reported by a consumer via call center representative and described the occurrence of pruritus in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included tremor (mild tremor) and red face. Previously administered products included Cortisone (years ago) and Epinephrine (years ago). Concomitant products included simvastatin, etanercept (Enbrel) and potassium nos (Potassium).   On 12th November 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 3 months after receiving Shingrix and an unknown time after starting simvastatin, the patient experienced pruritus, pain and discomfort. On an unknown date, the outcome of the pruritus, pain and discomfort were unknown.   It was unknown if the reporter considered the pruritus, pain and discomfort to be related to Shingrix.  Additional details were received as follows: The patient after vaccination experienced little achy, sore and uncomfortable. The patient consented to follow up. For tolerance to 2nd dose, refer case US2020012242.",67.0,Seniors,1,0
883798,"VARIVAX administered post temperature excursion; This spontaneous report was received from a nurse and refers to a patient of unknown gender and age. The patient's pertinent medical history, concurrent conditions, previous drug reactions, allergies, or concomitant medications were not reported.  On 27-AUG-2020, the patient was vaccinated with an improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) injection, 0.5 milliliter (lot number S032355 which has been verified to be valid, expiration date 14-OCT-2021) (route of administration and anatomical location were not reported), for prophylaxis. The vaccine was reconstituted with sterile diluent (dose reported as 0.5 milliliter, frequency reported as once and it was unknown if it was improperly stored as well). The vaccine was exposed to temperature of -2.8 degrees Celsius for 5 hours 2 minutes. Digital data logger was involved. There was no previous temperature excursion.",,Unknown,0,1
887250,Immediate burning and soreness that developed into SIRVA,33.0,Adults,0,0
889952,"Less than 48 hours after flu vaccine I began to experience shoulder pain and limited range of motion that gradually worsened over the course of 2-3 weeks.  Simple tasks that required me to lift my arm up, such as getting dressed and combing my hair became very difficult and painful.  I have also had difficulty sleeping due to shoulder pain at night.  My family doctor diagnosed me with subacromial bursitis caused by improper administration of the flu vaccine.  He explained that the vaccine was administered too high on my arm and entered the joint rather than my deltoid muscle.  At present my family doctor has prescribed Voltaren cream to reduce inflammation and pain.  As of today, 10/15/2020, symptoms have not yet subsided and treatment with Voltaren continues.",36.0,Adults,0,0
899764,"Soreness in arm for 3 days. Headache for 2nd and 3rd days (still experiencing slight headache). Took Tylenol both days. Swelling at the injection site about 3"" in diameter still after 3 days.",57.0,Adults,0,0
870548,"no adverse event; administered an impropery stored dose of PEDVAX HIB; This spontaneous report was received from a nurse regarding a patient of unknown age and gender. Patient's pertinent medical history, concurrent conditions, past drugs, allergies and concomitant therapies were not reported. On 03-APR-2020, the patient was vaccinated with improperly stored haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (strength, dose and route were not reported) (lot number S023645 and expiration date 10-MAR-2022) for prophylaxis (product storage error). The temperature excursion was noted with a temperature of 51.5 Fahrenheit (F) for 45 minutes. There was no previous temperature excursion. No adverse effects were reported. The call was because of digital data logger. No product quality complaint was reported.  This is one of the several reports received from the same reporter.; Sender's Comments:  US-009507513-2005USA002553:",,Unknown,0,1
896903,"Fever next day of 101. Lot of pain all over. Skin felt like it was burning. Left arm was swollen and red. Felt nausea, achy, feverish and nausea for five days. Had fever for three days. Lasted for six days.  Had 2nd Shingrix on 11/7/2020. Still does not fell great. It's been nine days. Had fever of 101, had severe pain, right arm swollen ans itchy rash, nausea, diarrhea and headache. Rash moved everyday from outside of arm to inside of arm. Now it's under the arm and itchy. Feel like she does not have energy. Feels like she has the flu.",69.0,Seniors,1,0
874582,"patient was adminitered vaccine which was exposed at below 30-32 F for one hour due to opening and closing of refrigerator door/No AE; Initial information was received on 19-Jun-2020 regarding an unsolicited valid non-serious case from a physician.  This case is linked to cases 2020SA161064, 2020SA161182, 2020SA161183, 2020SA161184 and 2020SA161203 (same reporter).  This case involves a six month and twenty days old male patient who was vaccinated with DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL] which was exposed at below 30-32 Fahrenheit for one hour due to opening and closing of refrigerator door (product storage error).  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included PNEUMOCOCCAL VACCINE CONJ 7V (CRM197) (PREVNAR) and ROTAVIRUS VACCINE (ROTAVIRUS VACCINE) for prophylactic vaccination.  On 10-Jun-2020, the patient received 0.5 ml third dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (lot UJ015AAA and expiry date 26-OCT-2020) via intramuscular route in the left thigh for prophylactic vaccination.  It was a case of an actual medication error due to product storage error temperature too low.  At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",0.5,Kids,0,1
890118,lower back pain,51.0,Adults,1,0
915487,"About 5 minutes after I got the shot, I felt as though someone poured warm liquid starting at my head to toes, I also began to tingle. My mouth got hot and tingly. Elevated Blood pressure, and felt like I was going to pass out. I was laid down, and was very clammy. The really severe tingling and hot feeling passed in about 3-5 minutes, but it lasted for about 1.5 hours in a much more mild fashion.",32.0,Adults,0,0
886893,"Fever, chills, body aches, sore arm",54.0,Adults,1,0
897430,"she had been suffered with pain at the injection site at her left shoulder; Initial information was received on 19-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer (patient) via call center.  This case involves a 69-year-old female patient who had been suffered with pain at the injection site at her left shoulder (injection site pain), while on influenza quadrival a-b high dose hv vaccine [Fluzone High-Dose Quadrivalent].  The patient's medical history, concomitant therapy, past medical treatment(s), vaccination(s) and family history were not provided.   On 28-Sep-2020 (3 weeks ago), the patient received on influenza quadrival a-b high dose hv vaccine, (formulation, strength, dose, frequency, batch number, expiration date, route of administration was unknown) at a 1 time dose in the right arm for prophylactic vaccination.  On 19-Oct-2020, 22 days after starting the suspect vaccine therapy it was reported that she had been suffering with pain at the injection site at her left shoulder. She contacted her HCP who advised her to treat it with interchanging heat and ice. Because the patient was still hurting today.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event was not resolved.  There will be no information available regarding batch number in this case.  No further relevant information was reported.",69.0,Seniors,0,0
884722,Staff member received influenza vaccine from employee health nurse.  Received flu vaccine in right deltoid on 9/11/20. Later in the day developed enlarged painful lymph node. Tenderness & swelling persisted for 2-3 days and gradually subsided.,57.0,Adults,0,0
913519,"Headache, Vomiting, 99.6 Temp",25.0,Adults,1,0
873761,"About 2 hours after I received the vaccination, I noticed that my shoulder was extremely stiff and painful. I could not raise my arm without severe pain. There was swelling and redness from my shoulder to my elbow. My left arm is about twice its normal size and very hot to the touch.",66.0,Seniors,1,0
908741,"1915: associate had left facility, associate started feeling generalized itchiness. Associate took a dose of Zyrtec. Associate states she woke up feeling body aches that Saturday and Sunday. Itchiness had resolved. As of Monday morning, all symptoms had resolved.",52.0,Adults,0,0
892012,"Fainting, Ems dispatched. She awoke and was transported for observation",17.0,Kids,0,0
904254,"severe flu symptoms occurring on date of second dose (11/20/2020) and for three days after, patient experienced severe nausea, headache fatigue, and full body soreness to the point that she could not move her arms or legs. patient also experienced sever joint pain in hands and feet. injection site has extreme swelling (size of a baseball) and experienced pain, erythema, and swelling for 5 days around injection site. she experienced the same adverse effects from the first dose in July of 2020, but they were not as extreme and only lasted around 2 days",50.0,Adults,1,0
905637,"Patient became dizzy, vital signs -10:32 am  162/101, P-96, sat 98% on room air, hot clammy, blurry vision, heart palpitations, repeat vitals 1036- 171/102 P-85 sat 98% on room air, transferred to Emergency Room 10:43 am",57.0,Adults,0,0
880502,"Redness in arm Headache Nausea aches, Body pain exhaustion",52.0,Adults,1,0
861010,"Soreness at injection site almost immediately and worsened over next 25 hours.  10-12 hours after shot joint and muscle aches (feels like flu without the fever), 8 hours after shot and continuing for remainder of day diarrhea, fatigue.",51.0,Adults,1,0
899017,"welts; was feeling flu-ish; arm was sore; raised rash about 2x3 inches in size near the injection site; welts are red; welts are / hot; welts are / itchy; This case was reported by a consumer via call center representative and described the occurrence of influenza like illness in a 66-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 16th November 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. In November 2020, less than a week after receiving Shingrix, the patient experienced raised rash, erythema, skin warm and itchy rash. On 17th November 2020, the patient experienced influenza like illness and pain in arm. On 18th November 2020, the patient experienced welts. On 19th November 2020, the outcome of the influenza like illness was recovered/resolved and the outcome of the pain in arm and welts were not recovered/not resolved. On an unknown date, the outcome of the raised rash, erythema, skin warm and itchy rash were unknown.   It was unknown if the reporter considered the influenza like illness, pain in arm, welts, raised rash, erythema, skin warm and itchy rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The next day, her arm was sore and she reports that she was feeling flu-ish.  On 18th November 2020, the patient had welts or raised rash about 2 by 3 inches in size near the injection site.  The welts are red, hot and itchy.  The patient was still experiencing the welts but that they seem to be improving and look less red. The reporter did not consent to follow up.",66.0,Seniors,1,0
909397,Metallic taste  after around 20 mins after the shot Muscle pain around the injection site - 20 mins after  Mild headache after around 4 hours after the shot Mild headache on and of until two days after the shot Mild sore throat until two days after  No treatment done,58.0,Adults,1,0
891193,"Symptoms of type 1 diabetes; Sickest ever been; This spontaneous case was received on 12-Oct-2020 from other non-health professional via Novartis (reference number: NUS2019US228530) and concerned patient of an unknown age and gender.  The patient's medical history and concomitant medications were not reported.  On an unknown date, the patient was vaccinated with influenza virus vaccine polyvalent (brand not specified, dose, anatomical location, route of administration and indication: not reported). The batch number was not reported.   On an unknown date, ten days after receiving influenza virus vaccine polyvalent, the patient was sickest than ever been.  On an unknown date, another ten days after receiving influenza virus vaccine polyvalent symptoms of type 1 diabetes showed up immediately.  The outcome of the events was not reported.   The reporter did not provide a causality assessment.  The event of 'Type 1 diabetes mellitus' was considered to be medically significant by a Physician within Risk Management Department.  Company comment: A patient of an unknown age and gender was administered influenza virus vaccine polyvalent. The patient developed malaise, ten days after receiving vaccine. Another ten days after receiving influenza virus vaccine polyvalent symptoms of type 1 diabetes. The patient's medical history and concomitant medications were not reported. Causal role of suspect vaccine is assessed as not related for type 1 diabetes, due to biological implausibility. For the event malaise, causality is assessed as not related due to implausible chronology.; Sender's Comments: A patient of an unknown age and gender was administered influenza virus vaccine polyvalent. The patient developed malaise, ten days after receiving vaccine. Another ten days after receiving influenza virus vaccine polyvalent symptoms of type 1 diabetes. The patient's medical history and concomitant medications were not reported. Causal role of suspect vaccine is assessed as not related for type 1 diabetes, due to biological implausibility. For the event malaise, causality is assessed as not related due to implausible chronology.",,Unknown,0,1
894208,"Flu Like symptoms   achy, sweating, headache, redness and swelling at injection site.",71.0,Seniors,1,0
884454,"It is reported that appx 10 minutes after receiving vaccine, client complained of shortness of breath, was diaphoretic, and complained of nausea before vomiting. BP was reported to be apprx 172/95 with pulse in 90's. Patient continued to be short of breath. Nurse administered 0.5 mg of epinephrine and called 911. It is reported that near immediately, the client began to breathe easier, color returned and while a bit shaky called her family. Client was at medical facility so oxygen at 2 liter/min was applied. Supervisor had a portable pulse oxyimeter and reported that O2 sats were 98/99 during the entire event. It is reported that BP dropped down a bit but exact number were not provided. EMS arrived and took client to the hospital. It is reported that she was in no apparent distress when leaving the clinic.",41.0,Adults,0,0
861482,"None adverse reaction or side effects; pneumococcal 23v polysaccharide vaccine (PNEUMOVAX) (16-JAN-2013 and 13-JUL-2017); Information received from a case in litigation (# 1705USA006337) referring to a 69 year old male patient(pt). The pt's medical history, concurrent conditions and concomitant medications were not provided. On 16-JAN-2013 and 13-JUL-2017, the pt was vaccinated with pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23)(reported as PNEUMOVAX; dose, route of administration, anatomical location, lot#, expiration date were unknown) for prophylaxis (inappropriate schedule of product administration). The pt did not experience any adverse event or side effects.; Sender's Comments:  US-009507513-1705USA006337: US-009507513-2002USA005475:",65.0,Adults,0,1
889772,"Within 30-60 minutes post injection, I started feeling nauseated, became pale and dizzy with a rapid heart rate, B/P elevated, shaky, weak and developed a headache.  I drove myself home leaving work at approximately 1 hour 20 minutes.  Took acetaminophen 1000mg  was able to sleep fairly well through the night.  Awoke the next morning with a headache, runny nose and minor difficulty breathing.",50.0,Adults,1,0
884902,"Patient developed shakiness, chills, and headache apx. 12 hours after the flu vaccine.  They overall improved.  No s/s of anaphylactic reaction.",69.0,Seniors,0,0
893103,Was fine after getting the shot walked out got to car went down looked like seizure then stopped breathing/no hart beat did CPR police/ems came took over got him back took to hospital.,73.0,Seniors,0,0
863168,"Headache, fever, chills, muscle ache, nausea for 36 hours",66.0,Seniors,1,0
895481,The patient receives 1 mL instead of 0.5 mL,69.0,Seniors,0,0
890367,"redness, warmth, swelling",13.0,Kids,0,0
887429,"nausea, dizziness, breathing isue",20.0,Adults,1,0
894969,"myalgia, subjective fever, slight diarrhea, joint pain inability to lift hand.",53.0,Adults,1,0
880102,"Pt started having redness and warmth at injection site the morning after injection given, developed rapidly. seen in MD office 28 hours later -dx large local reaction. continued to worsen and went to ED 34 hours after. noticed some blistering/fluid filled lesions. redness spreading. no fever. dx with cellulitis and put on clindamycin. seen back in our office the next day after 2 days of clindamycin. continued to have increasing redness/induration. no fever still. dx with arthur reaction",4.0,Kids,1,0
895205,"Pt tolerated well, then few minutes after injections reported dizziness, feeling faint. Pt emesis x1. Vital signs were taken, BP/temp/heart rate all stable. Pt laid down x15 mins and RN and charge RN assessed. Pt provided juice to drink. Pt stable to leave office. No previous rxs to vaccines.",16.0,Kids,0,0
869326,"rash; cough; This case was reported by a nurse via call center representative and described the occurrence of rash in a 73-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2019-2020 season) for prophylaxis.   The patient's past medical history included shingles.   On 23rd October 2019, the patient received the 1st dose of Shingrix (intramuscular) and Influenza vaccine Quadrivalent 2019-2020 season. On an unknown date, less than 6 months after receiving Shingrix and not applicable after receiving Influenza vaccine Quadrivalent 2019-2020 season, the patient experienced rash and cough. On an unknown date, the outcome of the rash was recovered/resolved and the outcome of the cough was unknown.   The reporter considered the rash to be related to Shingrix. It was unknown if the reporter considered the cough to be related to Shingrix and Influenza vaccine Quadrivalent 2019-2020 season.  Additional details were reported as follows: The 1st shot was given intramuscularly in his right deltoid. The flu shot [brand name unspecified] was given in his left arm at the same time. Reporter was not at home therefore the Shingrix paperwork was not available to look for the lot number or expiry date however reporter did provide the name or location of the pharmacy where the shot was administered. Caller stated that husband developed a rash on the same arm where the Shingrix was injected.  The rash was not at the injection site (deltoid) but it was down by his elbow. It resolved.  About 3 weeks ago the patient had his second shot of Shingrix.  The second injection was given intramuscularly in the left arm. He received the injection even though he had a cough at the time. (The reporter was said she does not know the cough may have been Covid-19 related as he has not been tested). The cough has since resolved. [The patient did NOT experience a rash after the second Shingrix shot].  Negative history of live shingles vaccine (Zostavax). The reporter consented to follow up. This is 1 out of 3 cases reported by the same reporter.",73.0,Seniors,0,0
883355,"Within 5 minutes of receiving the flu shot, I started experiencing dizziness and disorientation. Within an hour, the far left side of my face lost some sensation. Then excessive sleepiness set in, as though I had taken a drug like Nyquil. Two hours later, I called the nurse hotline who then called 911. The following morning I woke with a sore throat, followed by tightness in my throat lasting all day. The third day I noticed a painful, swollen lymph node under my left arm.",42.0,Adults,0,0
873213,"The patients did not experience any symptoms; patient was vaccinated with improperly stored varivax; This spontaneous report as received from a medical assistant refers to a 21 months old female patient. The patient's pertinent medical history and drug reactions or allergies were not reported. The patient's concomitant therapy included sterile diluent. On 11-FEB-2020, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck)(VARIVAX) for prophylaxis (strength, dose, route of administration and anatomical location were not reported) of lot # S006647 is an invalid lot number, expiry date reported as 05-MAR-2021 for prophylaxis (product storage error). The patient did not experience any symptoms. The outcome of product storage error was unknown. The temperature excursion for varicella virus vaccine live (oka/merck) (VARIVAX) was reported as -9 degrees Celsius (C) to 8 degrees Celsius (3.3 C) for 53 hours. There was no previous temperature excursion reported. Data logger was involved. No product quality complaint (PQC) was associated with this report.  This is one of the multiple reports from the same reporter.; Sender's Comments:  US-009507513-1911USA011629:",1.75,Kids,0,1
864310,Pt developed benign acral papulovesicular eruption on day 20 after vaccination.,23.0,Adults,0,0
908645,"Fever, Chills, Muscle aches, joint pain, headache",45.0,Adults,1,0
877325,"No a loss of motion in the affected arm; Worsening arm pain; Injection site pain; This case was reported by a pharmacist via call center representative and described the occurrence of pain in arm in a 79-year-old female patient who received Herpes zoster (Shingrix) (batch number 47D2Z, expiry date 24th April 2022) for prophylaxis.   On 3rd July 2020, the patient received the 2nd dose of Shingrix. In July 2020, less than 3 weeks after receiving Shingrix, the patient experienced pain in arm and injection site pain. On an unknown date, the patient experienced injected limb mobility decreased. On an unknown date, the outcome of the pain in arm, injection site pain and injected limb mobility decreased were unknown.   It was unknown if the reporter considered the pain in arm, injection site pain and injected limb mobility decreased to be related to Shingrix.  Additional case details were reported as follows: After receiving the 2nd dose of Shingrix on left deltoid the patient experience worsening arm pain that progressed from left side injection site pain to no a loss of motion in the affected arm. The reporter consent to follow up.  The reported batch number 4702Z for Shingrix did not exist and was updated to 47D2Z as per the sales database.",79.0,Seniors,1,0
904363,Left arm pain.,44.0,Adults,1,0
895240,PT RECIEVED INJECTION ON 9-16; REPORTED ARM SORNESS AT INJECTION SITE AND SYNCOPE ON 9-17. PT PASSED OUT AND INJURED LEG DURING FALL. PT WAS TAKEN TO THE HOSPITAL WHERE TESTS WERE RUN.,78.0,Seniors,0,0
858744,"No aditional adverse events reported; improperly stored vaccines may have been administered to patients; This spontaneous report has been received from a nurse, referring to a patient of unknown gender and age. Information about the patient's pertinent medical history, concurrent conditions, and previous drugs reactions or allergies were not provided.  On 30-DEC-2019, the patient was vaccinated with an improperly stored (product storage error), pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) (Therapy type: Digital Data Logger), lot number S006210 and expiration date 22-DEC-2020 for prophylaxis (strength, dose, dose number, frequency, route of administration, and anatomical location, were not provided).  The vaccine was stored at a temperature above 47 degree Fahrenheit (47.1 Fahrenheit), for a timeframe of 8 to 16 minutes, with no previous temperature excursion. The call was due to a Digital Data Logger.  No additional adverse events were reported.  This case is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2001USA009007:",,Unknown,0,1
860581,"I received a flu vaccine at my doctor's office.  Later that evening my arm was really sore, to be expected, but the pain got worse, it felt liked I had been punched in the arm along with a large, red, hot, rash around the injection site.  It was about the size of sliced kiwi.   The pain was worse at night and I had to sleep with a cold compress on my arm.... it took about 5 days for the redness to fade and the pain to subside.  It's now 2/6... there is a shadow of the rash on my arm still and a tolerable soreness that when I'm still and quiet am aware of its presence.   I did report this to my doctor and was told to keep an eye on it and let them know if it got worse.  I never called back as it did get better.  Last year I received a flu vaccine at a pharmacy and had no reaction at all.",53.0,Adults,0,0
912545,"Severe headache; fever; chills; fatigue; This is a spontaneous report from a contactable nurse, the patient. A 40-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), intramuscularly on 23Dec2020 at 18:15 (at the age of 40-years-old) as a single dose in the left arm for COVID-19 immunization. Medical history included multiple sclerosis and hypothyroidism. The patient had no known allergies. The patient was not pregnant at the time of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medication included duloxetine hydrochloride (CYMBALTA), gabapentin, cefixime (FLEXERIL), tolterodine, levothyroxine, liothyronine; all for unknown indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. The patient experienced severe headache, fever, chills, and fatigue on 23Dec2020 at 18:30. No treatment was received for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcomes of the severe headache, fever, chills, and fatigue were recovering.   Information on the lot/batch number has been requested.",40.0,Adults,0,0
855432,"Inadvertent exposure to vaccine; Exposure via skin contact; Product Complaint; Cut her finger; some blood on the ring; This case was reported by a pharmacist via call center representative and described the occurrence of laceration of finger in a female patient who received Herpes zoster (Shingrix) (batch number 3B33N, expiry date 9th April 2022) and (batch number 2K9T2, expiry date 9th April 2022) for prophylaxis. This case was associated with a product complaint.   On 22nd November 2019, the patient received Shingrix. On 22nd November 2019, the dose was an unknown dose. On 22nd November 2019, immediately after receiving Shingrix, the patient experienced laceration of finger and wound bleeding. On an unknown date, the patient experienced inadvertent exposure to vaccine, exposure via skin contact and pharmaceutical product complaint. On an unknown date, the outcome of the laceration of finger, wound bleeding, inadvertent exposure to vaccine, exposure via skin contact and pharmaceutical product complaint were unknown.   It was unknown if the reporter considered the laceration of finger and wound bleeding to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The pharmacist was preparing to reconstitute a Shingrix vaccine and when she removed the blue-green cap from the adjuvant vial and the red ring also came off and it cut her finger which led to inadvertent exposure to vaccine and exposure via skin contact. The pharmacist just cleaned the wound and put a bandage on the wound. The reporter stated that there was some blood on the ring, so that adjuvant was discarded. There was no picture of the defect and antigen vial would be discarded. Conclusions of the QA statement were received as follows: GlaxoSmithKline Biologicals considered this complaint as unsubstantiated. The reporter consented to follow up.",,Unknown,0,1
904182,"performed 30 min observation, left to go back to work, said he felt like his heart was racing and looked at his smart watch and HR was 168. Upon arriving back at clinic, denies dyspnea or resp concerns. Reports feeling hot, anxious, heart racing, pt was sweating. HR 152 BP 150/100, Pulse ox 99%. Patient taken to ED to be evaluated.",28.0,Adults,0,0
897421,"anaphylactic reaction; This case was reported by a nurse via call center representative and described the occurrence of anaphylactic reaction in a 60-year-old female patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2020-2021 season) for prophylaxis.   On 26th October 2020, the patient received Influenza vaccine Quadrivalent 2020-2021 season. In October 2020, less than a week after receiving Influenza vaccine Quadrivalent 2020-2021 season, the patient experienced anaphylactic reaction (serious criteria GSK medically significant). On an unknown date, the outcome of the anaphylactic reaction was unknown.   It was unknown if the reporter considered the anaphylactic reaction to be related to Influenza vaccine Quadrivalent 2020-2021 season.  Additional details were provided as follows: The age at vaccination was not reported, but could be 59 or 60 years. The patient received Flu vaccine approximately on 26th October 2020. The patient presented an anaphylactic reaction after administration of Flu vaccine approximately two weeks ago from the time of reporting. The reporter did not consent to follow up.",,Unknown,0,1
876210,"pt felt Light headed after vaccination + laid down x 10"" then felt better. Dangled Legs For a few minutes then Left office. In car w/Mother started to ""not feel well, felt numb"" the had LOC x 3-4 minutes per Mom w/Rigidity, jerking at waste. After event pt. started to cry, stated she felt heavy and needed 2 people to assist her out of car into home. Pt continued to state her ""body felt heavy + tingly + Remembered shaking."" Mother Report ~ 4' after event patient was speaking as if ""she were drunk (like after having her wisdom teeth pulled) legs were weak + she needed help with ambulating upstairs. Slept well overnight but did report initially feeling ""weird"" Upon waking but felt better later in The morning. Hx of anxiety and vasovagal w/Blood work + orthotactic changes subjectively w/ position changes.",18.0,Adults,0,0
863029,"Migraine, fever, chills. Nausea, vomiting. Dehydration, diarrhea, swelling at the injection site ?tomato sized? per ER doctor, extreme pain, dizziness. Body aches And a white blood cell count of 23.",53.0,Adults,1,0
885156,Experiencing pain in right arm 2 weeks after receiving flu shot.,29.0,Adults,0,0
914309,"Within 3 minutes of vaccination patient became fully flushed head and neck, with rapid heart rate (112), and feeling like her airways were tightening.. Nurse immediately called for response, administered Epipen, when response arrived applied oxygen and transported to ED. Solumedrol 125 mg, Bendadryl 25 mg, and Famotidine 20 mg, she responded well and was released home with Rx Prednisone 40 mg x 3 days.  Only residual effect was a dry/sore throat.",46.0,Adults,0,0
897000,"8-17-20: sore throat 8-18-20: sore muscles (thigh, buttox, hips, calves, lower back).  Progressed to seveRe pain for 4 weeks; also Chills. Insomnia due to pain - 4+ weeks; also severe muscle weakness. Pain felt like P.M.R pain experienced 11 yrs ago from Lipitor Rxed mega dose (80mg) Muscle pain & weakness still present (11-5-20) muscle pain & weakness (Lower body) still present but improving with time, Rest, and physical therapy. I was in great physical shape until flu vaccination - swam 50 laps per day, walked 1.6 miles 3x/week, worked out 2/week, at a gym, and have 26 flower beds that I maintain. Something very serious happened to me, and its not over! Please Cross reference: (A) High Dose influenza vaccine with history of Polymyalgia Rheumatica. (B) High Dose influenza vaccine with history of BCG infusion of T.B (tuberculin) immunotherapy treatment for transitional cell carcinoma (early stage) of the Bladder. (C) High dose influenza vaccine with Bladder Cancer. I would appreciate a reply.",76.0,Seniors,0,0
916578,"Swelling, itching, rash, pain, lymph node underarm pain",48.0,Adults,1,0
879708,Pt had mild generalised rash over body.,70.0,Seniors,1,0
881824,"Sore, swollen, hot red arm,  sleepless, no appetite, Fever (101.5), Body Aches, Nausea, Stomach Pain, No Appetite, Dizzy, Sweats especially at night, Headache, Diarrhea, Fatigue, Nervousness, Shortness of breath",69.0,Seniors,1,0
911081,1600 reported petechiae to both upper arms and abdomen  1611  took 25 mg bendryl  waiting for 15 min. didn't get any worse  went home,38.0,Adults,0,0
911927,"Sore arm, Joint Aches",58.0,Adults,0,0
908093,Left arm injection site soreness started about 4 hours after administration. Left full arm tingling lasted about 12 hours then resolved. Left arm soreness lasted for about 36-48 hours with some mild nasal congestion and shortness of breath.,31.0,Adults,0,0
908427,Had headache fatigue  and sinus pressure,40.0,Adults,1,0
855877,"acute cystitis with hematuria; hematuria; neuralgic pain; periorbital cellulitis; 6th nerve palsy of the left eye; high suspicion of shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female of unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications.   In or around 12-OCT-2017, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, lot # and expiration date were not specified) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX) vaccine, the patient suffered a painful burning sensation to the right lateral mid and right mid anterior torso. The patient was diagnosed with acute cystitis with hematuria and neuralgic pain, with high suspicion of shingles. Shortly thereafter, the patient's left eye started to have pain and swelling and she was diagnosed with periorbital cellulitis and 6th nerve palsy of the left eye.   As a direct and proximate result of zoster vaccine live (ZOSTAVAX)  vaccine, patient symptoms have resulted in physical limitations not present prior to using this product. Patient also experienced mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), patient sustained severe and permanent personal injuries, further, as a tragic consequence of this wrongful conduct, patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of Defendants' conduct, patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages.  Upon internal review, 6th nerve paralysis and periorbital cellulitis were determined to be medically significant.",,Unknown,0,1
897443,"Fever; This case was reported by a consumer via call center representative and described the occurrence of fever in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, 7 days after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was unknown.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional details were reported as follows: The reporter was patient's husband. The age at vaccination was not reported. The reporter did not consent to follow-up. The case has been linked to US2020222174, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020222174:same reporter",,Unknown,1,0
896738,"Throat swelling after Fluarix injection; Mouth swelling after Fluarix injection; This case was reported by a other health professional via sales rep and described the occurrence of throat swelling in a female patient who received Flu Seasonal QIV Dresden (Fluarix Tetra) for prophylaxis.   Co-suspect products included flu seasonal qiv dresden pre-filled syringe device (Fluarix Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   On an unknown date, the patient received Fluarix Tetra and Fluarix Tetra Pre-Filled Syringe Device. On an unknown date, unknown after receiving Fluarix Tetra and Fluarix Tetra Pre-Filled Syringe Device, the patient experienced throat swelling and swollen mouth. On an unknown date, the outcome of the throat swelling and swollen mouth were unknown.   It was unknown if the reporter considered the throat swelling and swollen mouth to be related to Fluarix Tetra and Fluarix Tetra Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not reported. The patient experienced both throat and mouth swelling after Fluarix injection.",,Unknown,0,0
867428,"TOOK FIRST DOSE OF VIVOTIF IMMEDIATELY AFTER EATING; This spontaneous case (PVX2019-1138) was received from a pharmacist on 07-May-2019. It describes a 34-year-old male consumer who ""took first dose of Vivotif immediately after eating"". The consumer was receiving oral Vivotif (one dose every other day) for typhoid fever prophylaxis.  Case report: The consumer took the first dose of Vivotif immediately after eating on either 06-May-2019 or 07-May-2019.  Action taken with Vivotif was not applicable.  The clinical outcome of the event ""took first dose of Vivotif immediately after eating"" was unknown.  Company's Comment: The causality of the event ""took first dose of Vivotif immediately after eating"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took first dose of Vivotif immediately after eating"" was considered as not applicable.",,Unknown,1,0
910066,"1.  Injection site pain - more than typical with a flu shot - awakened in the middle of night with aching - took acetaminophine which remedied the problem.  Continued general body achiness for 24-36 hours, again resolved withacetaminophine. 2.  Next day, December 24 - (a very active day for me) - experienced fatigue as day progressed - had to stop in mid-afternoon and sleep - very uncommon for me. NOTE:  The above symptoms were unpleasant but did not prevent me from playing the organ for 3 church services on the 24 and 25.",70.0,Seniors,0,0
884790,"lhe patient was administered an improperly stored dose of PROQUAD; This spontaneous report was received from a medical assistant and refers to a patient of an unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On an 08-SEP-2020, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD), rHA, lot # S031706 has been verified to be a valid lot number, expiration date 06-APR-2021 (exact dose, route of administration and anatomical location were not provided) for prophylaxis. The vaccine was reconstituted with properly stored sterile diluent (STERILE DILUENT). Administered dose of vaccine experienced the temperature excursion of -11  degrees Celsiust (C) for 5 hours and 20 minutes. Data logger was not involved. There were no previous excursions reported.",,Unknown,0,1
866257,"diagnosis of diabetes.; having a heart murmur; right knee replacement; aortic valve stopped working, the valve was replaced with a bovine valve; having stents put in in 2000; This spontaneous report was received from a currently 91 years old female patient referring to herself. The patient's pertinent medical history included rheumatic fever as a child. The patient's concomitant medication and drug reactions/allergies was not reported.     On an unknown date (reported as long ago), the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown) (reported as pneumonia vaccine) (strength, dose, route, lot # and expiration date were not reported) for prophylaxis.         On an unknown date, the patient was having a heart murmur, having stents put in in 2000, as well as right knee replacement, during which her aortic valve stopped working, the valve was replaced with a bovine valve; diagnosed of diabetes. The outcome of the events was unknown. The causality assessment was not reported.     Upon internal review, diabetes was determined to be medically significant.",,Unknown,0,0
888539,"Patient started feeling very lethargic the morning after receiving the vaccine. He denied having a fever. He stated that he is now feeling better (10/8/2020) and not as lethargic, but he has developed a rash on the side of the arm the size of a baseball.",48.0,Adults,0,0
865746,"The patient experienced no symptoms; there was no diluent available for use; the patient was unable to receive the dose of M-M-R II; Information has been received from a pharmacist referring to a patient of unknown age and gender. The patient's concomitant medication, pertinent medical history and drug reactions/allergies were not reported.  On 17-MAR-2020, the patient came into the pharmacy for administration of a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live rHA (M-M-R II) (strength, dose detail and route were not reported) (lot # S009753, expiration date 31-MAR-2021) and sterile diluent (STERILE DILUENT) for prophylaxis.  The patient was unable to receive the dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) on 17-MAR-2020 because the sterile diluent (STERILE DILUENT) used for administration of the measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) dose had expired and there was no sterile diluent (STERILE DILUENT) available for use at that time (circumstance or information capable of leading to medication error and product availability issue). The patient experienced no symptoms.",,Unknown,0,1
905041,"made me horribly sick; Initial information received on 03-Dec-2020 regarding an unsolicited valid non-serious social media case received from non-health care professional.  This case involves a patient of unknown demographics who made horribly sick (Illness), while he/she received INFLUENZA VACCINE.  The patient's medical history, medical treatments, vaccinations, family history and concurrent condition were not provided. Concomitant medication was not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number and expiration date not reported) via an unknown route on unknown site of administration for prophylactic vaccination.   On an unknown date, the patient reported that made horribly sick (Illness, non-serious) (Unknown latency) following the administration of INFLUENZA VACCINE.  No relevant laboratory data was reported.  It was not reported if the patient received a corrective treatment.  Event outcome was reported as unknown for sickness, at the time of reporting.  There will be no information available on the batch number for this case. No further information was reported.",,Unknown,0,1
890077,"I have never had a reaction to any drug or injection.   I had the shot around 10:00 a.m. and started taking Advil immediately when I got home.  10 hours after this shot, I began to feel weak, sore all over and a little nauseous.  It came on quickly and only intensified.   I also had a loud ringing in my ears.  About 1/2 hour later, I began shaking uncontrollably.  I went to bed immediately and continued to shake in bed for 5 minutes.  My sleep was fitful with many nightmares.  The next day I still felt weak and  sore and had a headache with ringing in my ears.   It has now been over 48 hours and I till have body aches, possibly from all the shivering and shaking.",67.0,Seniors,1,0
856138,"Pt received IPV at 4:00pm on 01/08/2020.  Pt started vomiting at 4:30pm on 01/08/2020.  Mom states she seemed ""out of sorts"" wanted to be held.  Mom states pt fell asleep from 6:00 to 6:30pm.  She woke up again ""out of sorts"" fussy.  Stated she slept on the way home from church from 800pm to 830pm.  She stated she was hungry, ate some crackers.  At 9:00pm mom was getting her ready for bed and she had a massive diarrhea stool per mom and with an extremely terrible odor.  Mom cleaned her up and she fell asleep only to wake again with that same odor at 2:00am on 01/09/2020.  Massive diarrhea.  Mom states she cleaned her up and she fell back asleep and did not wake until 9:00am.  She told mom she was hungry and before mom could finish fixing breakfast, she fell back to sleep and woke up at 11:30.  She ate an egg at that time.  Mom states she fell asleep again from 1230pm until 5:00pm.  After waking she ate some carrots and went back to bed at 8:00 and slept until 7:00am this morning , 01/10/2020.  When she woke up, she again had a diarrhea stool.  She stated that she fell asleep on the way to our office for a visit today for about 15 to 20 minutes.  After her visit at 11:00, she ate a small amount for lunch and is now napping again at 2:00pm 01/10/2020.",2.0,Kids,0,0
911526,"Swelling reported around mouth and eyes; Swelling reported around mouth and eyes; rash; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received bnt162b2 (Pfizer-BIONTECH COVID-19 vaccine), via an unspecified route of administration on 22Dec2020 16:30 at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously took doxycycline in 2019 and experienced swelling reported around mouth and eyes and rash. On an unspecified date in Dec2020, the patient experienced swelling reported around mouth and eyes and rash. The outcome of the events was unknown.  Information on the lot/Batch number has been requested.",,Unknown,0,0
892018,"Aside from the pain in the arm, which is pretty normal,  I woke up at 3a.m. (12 hours after the injection) with a fever, dizziness, nausea, a splitting headache and I vomited. The headache lasted until  early Thursday morning,  and my fever finally broke on Wednesday afternoon (went up to 101.8) A rash started to appear below the injection site on Tuesday afternoon and is currently still on my body (as of 8pm PST on 10/22/2020).  The rash does not itch or burn but it is quite warm to the touch, as though it had its own little fever.  I took photos and sent them to my doctor today (10/22).  I did contact my doctor on  Wednesday and had a Telemed meeting with her.  I did forget to mention the rash until today; I simply overlooked it.   That?s why I sent a photo over, called her office to take a look at it and hope to hear from her by 10/23.   My physician had me call the pharmacy to see what dose of the flu vaccine I was given and it was the super one (ones given to the elderly).  My physician believes it was too strong for me and noted it on my chart.  I then contacted the pharmacy and had them note it as well.  Last of all, I did have this vaccine along with a PPSV23.  I have done the pneumonia and flu before in the past without any issues.",66.0,Seniors,0,0
893049,"having a fever; Pain at injection site; developed redness at the injection site; heat at the injection site; hardness at the injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 66-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st August 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 1st August 2020, immediately after receiving Shingrix, the patient experienced injection site pain, injection site erythema, injection site warmth and injection site induration. On 2nd August 2020, the patient experienced fever. The patient was treated with benadryl (nos) (Benadryl). On 4th August 2020, the outcome of the injection site pain, injection site erythema, injection site warmth, injection site induration and fever were recovered/resolved.   It was unknown if the reporter considered the injection site pain, injection site erythema, injection site warmth, injection site induration and fever to be related to Shingrix.  Additional details were reported as follows: The patient received 1st dose of Shingrix and immediately after vaccination had a pain at the injection site. Later that evening, the patient developed redness, heat and hardness at the injection site. The next day after vaccination, patient reportes fever. The patient took a Benedryl for symptoms and they cleared up within 2 and half days. The patient asked about receiving the 2nd vaccine. The reporter did not consent to follow up.",66.0,Seniors,0,0
913886,"my armpit is swollen; my armpit is / tender; This case was reported by a consumer and described the occurrence of local swelling in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 4th December 2020, the patient received Shingles vaccine. In December 2020, less than a week after receiving Shingles vaccine, the patient experienced local swelling and axillary pain. On an unknown date, the outcome of the local swelling and axillary pain were unknown.   It was unknown if the reporter considered the local swelling and axillary pain to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was captured as an adult as per vaccine indication. It was reported that patient received the Shingles vaccine and after that experienced swollen armpit with tenderness.",,Unknown,0,0
885260,Redness and swollen right thigh.,4.0,Kids,0,0
913889,"inflamed gums from eye tooth to eye tooth; This case was reported by a consumer via call center representative and described the occurrence of gingival inflammation in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 24th September 2020, the patient received Shingrix. On an unknown date, between 1 and 3 weeks after receiving Shingrix, the patient experienced gingival inflammation. On an unknown date, the outcome of the gingival inflammation was not recovered/not resolved.   It was unknown if the reporter considered the gingival inflammation to be related to Shingrix.  Additional details were reported as follows: The reporter was the patient.  The age at vaccination was not reported. She reported that she got the Shingrix shot and about a week or two later, she got all inflamed gums from eye tooth to eye tooth. She visited her doctor regarding this and neither she nor her doctor knows if the Shingrix was responsible for causing the gum inflammation. She told that her doctor took bloodwork to help determine the cause.",,Unknown,0,0
878344,"she was doing okay and had not experienced any side effects from receiving the expired vaccination; On 29Jul2020, she received a Proquad vaccine that expired 23Jul2020; This spontaneous report was received from a certified medical assistant referring to a 5-year-old female patient. Information regarding the patient's concurrent conditions, medical history, historical drugs and concomitant therapies was not provided.   On an unspecified date in 2016 (reported as ""when she was 1 year old""), the patient was vaccinated with the first dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) for prophylaxis (dose, route of administration, lot number and expiration date were not reported). On 29-JUL-2020, she received the second dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (recombinant human albumin (rHA)) (PROQUAD) 0.5 milliliter subcutaneous injection for vaccination, lot# S002490, expiration date 23-JUL-2020.  The second dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) was expired at the time of administration. At the time of the call, the patient was ""doing okay"" and had not experienced any side effects from receiving an expired vaccine. As of 29-JUL-2020, it was unknown if she would receive another measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) injection.  This is one of two cases received from the same reporter.; Sender's Comments:  US-009507513-2008USA000238:",1.0,Kids,0,1
870742,"Patient and guardian were both with dialect different. Patient was asked to verify DOB, she reported another DOB with a document to support it. Then upon checking out after receiving vaccines, the guardian presented another document that reported a different DOB, which was finally confirmed the actual correct DOB. Patient was given extra dose of MMR and Polio vaccine not needed for her correct age and immunization record. No adverse effects from the vaccines given.",11.0,Kids,0,1
884625,Patient experiencing pain in eyebrow radiating down to lip on right side of face. No pain on or near injection site or left side. Does not believe it is associated with vaccine technique but is afraid it is an adverse effect of the vaccine.,72.0,Seniors,0,0
882168,"Within 20 minutes of receiving the vaccine, he developed red, hot cheeks, with red splotches around mouth and neck. Low-grade fever.",5.0,Kids,0,0
890441,"At first arm was sore, then entire upper arm became red, swollen and hot to the touch.  Then I developed hives, headache, nausea and fatigue.",66.0,Seniors,1,0
880242,"Family returned at 11:30 am.  Infant's face was swollen and appears urticarial.  She has bulbar conjunctival swelling.  On exam, there were no wheezes or respiratory distress.  No tongue swelling or vomiting.  She was given Benadryl 3.75 p.o. in office and within 15 minutes she is sleepy and swelling is markedly improved.  She had no prior issues with her 2 month and 4 month vaccines.  Of note, mom fed the infant a small piece of egg for the 1st time, but mom says her face was already starting to turn red at theat point.  2:00 p., the father called stating she woke up and vomited x1.  Advised not to give egg again.  No other issues noted.",0.5,Kids,0,1
867749,"No adverse effect; an unspecified number of patients may have been administered an improperly stored doses of MMRII; This spontaneous report was received from a physician referring to an unspecified number of patients of unknown age and gender. The patient's pertinent medical history and drug reaction/allergies were unknown. Concomitant therapies included sterile diluent. On an unknown dates, the patients may have been administered an improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) of lot # S005249  with expiry date 20-FEB-2021 (dose, strength, dose number, route of administration unspecified) for prophylaxis (product storage error). On an unknown date, the vaccines were exposed to the temperature of 11.73 Celsius for 4 hours and 30 minutes. There was no previous temperature excursion and digital data logger was involved. No adverse effects were reported.   Follow up information was received from physician on 07-NOV-2019.     No vaccine adverse reaction were reported. The only had to recall patients because no data available for temperature excursion. On 23-OCT-2019, during office site visit temperature excursion were noted. 10, measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) doses (Lot # R000550, expiry date: 08-JAN-2020) were stored to 24.08 degree Celsius. Since no data exists were (illegible doc) to revaccinate. No adverse reaction noted.    This is a non-valid case due to lack of patient identifiers.  Follow up information was received from the physician on 08-APR-2020.   This information refers to a 11-year-old male patient. On 18-JUN-2019, the patient was administered with an improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) with Lot number R000550.  This is one of several cases received from the same reporter.  This case was previously considered non-valid, but upon receipt of follow-up it was determined that the case is now valid as the patient demographics were obtained.; Sender's Comments:  US-009507513-2004USA002896: US-009507513-2004USA002897: US-009507513-2004USA002898: US-009507513-2004USA002899: US-009507513-2004USA002900: US-009507513-2004USA002901: US-009507513-2004USA002902: US-009507513-2004USA002903: US-009507513-2004USA002904:",11.0,Kids,0,1
862216,UNMONITORED TEMP FOR 63H,9.0,Kids,0,0
863578,"Fever, chills, headache, body ache, achy. Jaw pain (don?t know if that related or not)",55.0,Adults,1,0
863621,"flu-like symptions (fever, muscle pain, headache, fatigue) and injection site pain.  Fever occurred during the night but went away in the morning (8 hrs).  Muscle pain about12 hours.  Headache about 3 hours.  Fatigue over 2 days.  Injection site pain 36 hours (decreased each day).  After injection, site ached constantly.  After 36 hours, only hurts if touched.  Took ibuprofen 200 mg twice a day over two days helped lessen symptoms.",63.0,Adults,1,0
905890,After vaccine became dizzy and had a brief episode of syncope,10.0,Kids,0,1
893068,"Patient experienced fatigue, and was not able to sleep the night of the vaccination;  Arms and back were sore.  This morning when patient woke up,  legs were  sensitive and scratchy. Patient took aleve this morning",50.0,Adults,1,0
868350,"MISSED TO TAKE LAST DOSE OF VIVOTIF ON TIME; This spontaneous case (PVX2019-2275) was received form a nurse on 05-Sep-2019. It described a female consumer who ""missed to take last dose of Vivotif on time"" (PT: Product dose omission), while being on oral Vivotif for typhoid fever prophylaxis.  Case report: The consumer took three doses of Vivotif every other day but missed to take fourth dose on time. She had not taken the fourth dose till the time of the report.  Action taken with Vivotif with respect to the event was not applicable.  The clinical outcome of the reported event was unknown.  Company's Comment: The causality of the event ""missed to take last dose of Vivotif on time"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""missed to take last dose of Vivotif on time"" was considered as not applicable.",,Unknown,1,0
862868,"Aura migraines lasting 3+ days, GI issues including diarrhea and nausea, extreme tiredness, excessive sleeping (12+ hours for 3 days consecutively), loss of appetite, inability to focus, feelings of depression and helplessness",30.0,Adults,1,0
895502,"It was sore that night; red patch that surrounded the injection site; body temperature went up to 100.7 F; cannot pick up my left arm; red patch that surrounded the injection site, went under my left arm toward my arm pit and around on the other side of my arm.; She advised me I had a severe reaction; This spontaneous report was received from a 62 year old female patient with hypertension and allergy to penicillin and amlodipine which caused her hives and edema of feet hand legs swell respectively. The patient was vaccinated with pneumococcal 13v conj vaccine in 2018. Concomitant therapies included potassium, vitamins, calcium, biotin and fish oil.  On 12-OCT-2020, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) in the left arm for prophylaxis. The patient reported that it was sore that night and by the next morning there was a red patch that surrounded the injection site, went under my left arm toward my arm pit and around on the other side of my arm. The red spot was 4 inches up and down my arm and 6 to 7 inches across my arm. It was very painful, and my body temperature went up to 100.7 degrees Fahrenheit. She called her doctor and went in to see her on that Thursday 15-OCT-2020. She tested her for COVID, but she was negative. She advised her she had a severe reaction. A treatment the patient apply ice and acetaminophen (TYLENOL) every 4 hours , and now acetaminophen (TYLENOL) every 6 hours. Told to rub it but was to painful, but now I can rub it.   At the reporting time, the outcome of the events was reported as recovering, but still cannot pick up my left arm, or pick up anything that weighs more than a pound or two.  Causality was not provided.",,Unknown,0,0
914613,"swollen, warm arm body aches fatigue",80.0,Seniors,1,0
865062,"On 3/10 I woke up with a rash on the arm where I had the injection.  About 6:00 that evening I felt a tingling sensation in my upper lip.  As the evening progressed it seemed to start to swell.  About 9:00 my throat started to feel as though it was closing. I took 50 mg of Benadryl.  We went to the hospital and my blood pressure was 180/81.  They gave me an IV with Benadryl, Prednisone and Pepcid.  I was released about 1:00 with a prescription for Prednisone for 5 days.",65.0,Adults,1,0
903162,"Allergic reaction to vaccine +1 more Dx Referred by MD Reason for Visit Progress Notes PA-C (Physician Assistant) ? ? Physician Assistant Cosign Needed      Patient was seen at COVID Vaccine Clinic today for her first dose of the COVID 19 vaccination.  She denied any history of previous adverse reactions to vaccines.   She was given the Pfizer-Biontech (lot:  EH9899) vaccination in the left deltoid muscle.   During her 15 minute waiting period after the injection, the patient began to experience oral tingling (upper lip and then into the lower lib)  It then progressed to the tongue and she reported tingling to the tip of the tongue and further back to the middle of tongue.  She thought there might be some mild swelling to the tip of the tongue.  She denied rash, hives, welts, difficulty breathing, difficulty swallowing, wheezing, throat tightness, hoarseness, stridor, itching, lightheadedness, dizziness, facial swelling and lip swelling.   This Staff member was notified of patient reaction and she was then assessed in the emergency bay area.   PMH:  Hx hypertension but did not take her medication today.  Patient had recovered from the COVID-19 virus about 2 weeks ago.   Vitals Time 1130 BP 170/90 HR 86 s/r RR 14 nl O2 97 %   Physical Exam  Constitutional: She is oriented to person, place, and time. She appears well-developed and well-nourished. No distress.  HENT:  Head: Normocephalic and atraumatic.  Right Ear: Hearing and external ear normal.  Left Ear: Hearing and external ear normal.  Eyes: Conjunctivae are normal. Right eye exhibits no discharge. Left eye exhibits no discharge. No scleral icterus.  Neck: Normal range of motion.  Cardiovascular: Normal rate, regular rhythm and normal heart sounds.  Pulmonary/Chest: Effort normal and breath sounds normal. No stridor. No respiratory distress. She has no wheezes. She has no rales.  Musculoskeletal: Normal range of motion.  Neurological: She is alert and oriented to person, place, and time. No sensory deficit. Gait normal.  Skin: Skin is warm and dry. She is not diaphoretic.  Psychiatric: She has a normal mood and affect. Her behavior is normal. Judgment and thought content normal. Cognition and memory are normal.  Vitals reviewed.     Treatment included antihistamines.  Patient was given 50 mg of benadryl at 1138.   Vitals Time 1147 BP 160/100 HR 90 S/R RR 14 nl O2 98%   Response to care:  Patient states the upper lip resolved but the lower lip and tongue sensations remained but did not worsen.  Patient was recommended to go to the hospital given her sudden response with concern of tongue swelling.  Patient did agree to this.  COVID staff was made aware that the patient would be leaving her SUV in the parking lot.   Patient was transfer by Response team to the hospital at 11:53 AM.",51.0,Adults,0,0
875501,"Patient reported redness, swelling, inflammation and pain around injection site. She stated this also happened with her first Varivax injection as well. She had been given an antibiotic for cellulitus after her first Varivax injection because the correlation with the injection site reaction was not made at that time by another provider.",19.0,Adults,1,0
907244,"Employee administered vaccine at 0725.  At about 0740 he began to feel lightheaded, dizzy, and nauseous.  He also became pale and diaphoretic.  Gave some water and monitored for several more minutes.  He stood up at 0747 as he stated that he was feeling much better.  When he stood up, he became dizzy and lightheaded again.  Had him sit down, cool down, had a few sips of water.  BP 148/95, HR 83, O2 sat was 99%.  He did state that the vaccine burned for about 2-3 minutes when administered.  Had him sit for 10 more minutes and he stated that he was feeling much better.  He stood up and was feeling much better.  He was offered to go to the emergency room and refused.  He was escorted to his department by an RN observer.  At this time, he has no symptoms and states he is feeling good.",30.0,Adults,0,1
891767,It started with migraines and overall feeling of being unwell on 10/17/2020. On 10/20/2020 I broke out in a rash. It started on my arms then it travel throughout my body. The itch was uncontrollable. I spoke with my doctor's office on 10/21/2020 (provided them photos) and they asked I go to urgent care immediately.   I was told to take Claritin asap and was prescribed steroids.,42.0,Adults,1,0
914898,Patient felt a tingling sensation on the tip of her tongue. Continued to observe her for an hour and the sensation progressed to her entire tongue. Escorted her to emergency department.,66.0,Seniors,0,0
863934,"two years old patien was receiving routine vaccines and inadvertently received Quadracel/ No AE; Initial information was received on 28-Feb-2020 regarding an unsolicited valid non-serious case received from an  other health care professional.  This case involves a 24 months 27 days old male patient who inadvertently received DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/IPV (MRC5) VACCINE [QUADRACEL] (lot C5532AA) via intramuscular route in the right thigh for prophylactic vaccination while receiving routine vaccines (product administered to patient of inappropriate age).  Medical history, past medical treatment(s), vaccination(s) and family history were not provided.   Concomitant medications included HIB VACCINE CONJ (TET TOX) (ACT HIB) and HEPATITIS A VACCINE (HEPATITIS A) for prophylactic vaccination.  It was also a case of actual medication error due to inappropriate age at vaccine administration.  At the time of reporting no adverse reaction was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",2.0,Kids,0,1
907883,general warmth and dry throat,46.0,Adults,0,0
913586,"Itching all over, Arms, legs, feet and hands with no Rash. Swelling of Hand and Feet. Started 12/29 and progressively worsened over the evening.",36.0,Adults,1,0
876015,"Increased blood pressure; This case was reported by a consumer via call center representative and described the occurrence of increased blood pressure in a 82-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included hypertension. Concomitant products included lisinopril.   On 4th July 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 6th July 2020, 2 days after receiving Shingrix, the patient experienced increased blood pressure. On an unknown date, the outcome of the increased blood pressure was recovering/resolving.   It was unknown if the reporter considered the increased blood pressure to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient reporting blood pressure elevation of 20 points following vaccination with Shingrix.  The patient also added, his blood pressure appeared to be declining towards normal.  Limited information was available.  Lot and expiration date unavailable. The reporter did not consent to follow up.",82.0,Seniors,0,0
896599,"November 2019. Back/legs, aching/fatigue commenced early mid-month, as did erratic bowel movements. Culminated with hospitalization on 11/25 after an extended period of constipation and fatigue resulted in a severe bowel attack, walking difficulty and spasmodic body shaking. Initial thought was a paralytic ileum which was subsequently discounted. Discharged on 11/26 and directed to get a colonoscopy.  December 2019. Colonoscopy on 12/5  uneventful, no ileus. Walking/balance/gait continued to deteriorate. Unable to get a neurologist appointment.  January 2020. Saw neurologist on 1/3. He prescribed a brain MRI which demonstrated no signs of MS. He wasn't available to see me again until March 23, 2020. Went to Urgent care clinic on 1/13 and given a prescription for doxycycline to rule out possible Lyme disease as a cause. No positive effect. Saw an osteopath for an EMG test on 1/22 and he indicated the need for neurology treatment and also prescribed a lumbar MRI, which demonstrated no inflammation, just stenosis. Saw a peripheral nerve disease doctor on 1/28 who upon receipt of MRI's of my thoracic region of the spine, referred me to colleague who specialized in spinal disorders.  February 2020. On Feb 5th, after being diagnosed with transverse myelitis, commenced a 5 day steroid infusion. It provided limited, short term relief and then I continued to deteriorate, worse than before the steroid infusion. Doctor consulted with an infectious disease doctor and together they decided to put me on a 3 week infusion of ceftriaxone to take Lyme disease off the table  that started about 2/20. It had no effect on my walking issues and I continued using a walker or wheelchair. I started PT in February in effort to hold on to some muscle strength. Bowel issues continued with extensive periods of constipation followed by explosive movements.  March 2020. Ended my ceftriaxone infusion on 3/10 and diagnosed with Covid on 3/17. All Covid symptoms gone by 3/28, however, body very weak and unable to walk without wheelchair or walker. PT stopped with onset of Covid. Bowel issues continue.  April/May 2020. Doctors unsure what treatment to pursue so I started a second round of 5 day steroids infusion on 5/20. CT scan on 5/22 ruled out cancer as the myelitis cause. Legs very achy, feet, lower legs numb and tingly. Bowel issues continue.  June 2020. The steroids were more effective than the first infusion and I could detect some improvement in my walking, so I was able to move from the wheelchair to the walker and a cane towards the end of June. Knees remained painful, as did feet, which were numb and tingling. Recommenced PT after visiting rehab doctor on 6/15who had xrays taken of knees and hips due to my complaining about soreness. Xrays established nothing more than normal deterioration. Had another thoracic spine MRI on 6/26 which demonstrated that inflammation had abated. Bowel issues continue.  July/August 2020. Continued PT. Slow but steady walking improvement. Balance better but still not stable. Gait, awkward. Using predominantly cane, exclusively in August. Bowel issues continue.  September 2020. MRI on 9/17. Shows inflammation dormant with some residual scarring. Walking slightly better. Continued PT. Knees achy, feet numb/tingly/freezing at night. Bowel issues continue.  October 2020. More stamina, but marginal improvement in balance, gait and discomfort. Knees and feet bothersome. Balance mediocre. PT ended. Bowel issues continue.",76.0,Seniors,1,0
860785,"muscle pain fever headache fatigue chills nausea all very bad, except for the nausea and headache",67.0,Seniors,1,0
903164,Very sore and red arm from shoulder to elbow. Chills and sweats. Max fever reached 102.7 with Tylenol Body aches Extreme fatigue. Started about 24 hours after i got the shot and the worst part lasted about 48 hours. fever of 100.2 lingered for another day or so. Arm is still a bit red and now itches like crazy.,64.0,Adults,0,0
915338,5 minutes after receiving vaccine patient started getting nauseous. Reports waves of nausea every couple of minutes.,36.0,Adults,0,0
893532,Sterile abscess developed at site of injection,0.67,Kids,0,0
858780,"flu like symptoms for 3 days; Had to be in bed; This case was reported by a pharmacist and described the occurrence of influenza-like symptoms in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced influenza-like symptoms and bedridden. On an unknown date, the outcome of the influenza-like symptoms and bedridden were recovered/resolved.   It was unknown if the reporter considered the influenza-like symptoms and bedridden to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The reporter stated that, after vaccination with 1st dose of shingrix, the patient experienced bad reaction to be in bed with flu like symptoms for 3 days. The patient asked, if there was any statistical studies that proved to have less side effects if wait till 6 months versus 2 months to get 2nd dose of Shingrix.",,Unknown,0,0
898039,patient's arm has a red circle around injection site and is a little swollen,75.0,Seniors,0,0
894781,Dose was given very high on the shoulder I have had pinching pain limited muscle mobility and muscle weakness ever since.,35.0,Adults,1,0
869955,"incorrect product storage; No additional adverse effects reported; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.  On 30-DEC-2020, the patient was vaccinated with improperly stored hepatitis b vaccine (recombinant)(RECOMBIVAX HB) lot# R028529, expiration date 09-JUN-2021 (formulation, strength, dose and route of administration were not reported) for prophylaxis.  The administered doses of the vaccines were stored with the lowest temperature of 34.3 Fahrenheit during 4 hours. There was a digital data logger involved, but there was no previous temperature excursion. No additional adverse effects were reported.  This is one of several reports received from the same reporter. Additional information is not expected.",,Unknown,0,1
862891,"When drawing up the vaccines, the Rotovirus was drawn up into Pedarix, before it was given to the patient. New vaccines were drawn and given to the patient.",0.17,Kids,0,1
883169,patient sought medical attention from ambulance due to cardiac distress.  she was taken to Hospital and stated the physician there does not feel this was related to the flu shot.,77.0,Seniors,0,1
866220,"Arm very sore, muscles weak, horrible terrible headaches,  sore throat, cough upper respiratory infection, hair loss in patches (alopecia areata)  later uncontrollable nausea, diarrhea later a lump was found in her right breast they said it was benign but it was painful and grew rapidly so they had to surgically remove it.  Temporary VAERS E report No. 190325 has more details of everything she experienced And everything she is still going through",18.0,Adults,1,0
914988,about 45 min after injection my face felt numb for about 20 min,68.0,Seniors,0,0
864591,"difficult to move the arm up and down; swelling at the injection site; This spontaneous report as received from a medical assistant refers to a 69-year-old male patient. This report concerns 1 patient and 1 combination product. The patient's concurrent conditions included diabetes, hypertension and latex allergy. His concomitant therapies included lisinopril (manufacturer unknown), metformin and insulin human (HUMULIN). No information about the patient's past medical history was provided. On 03-MAR-2020, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) intramuscularly, lot # S029542, expiration date 10-JUN-2021 (dose was not reported) for prophylaxis. On 04-MAR-2020, the patient experienced swelling at the injection site and difficulty to move the arm up and down. The patient sought for medical attention by scheduling appointment with a physician. The outcome of the events was reported as not recovered/not resolved. The relatedness between the events and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was not provided. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; manufactureraddress:; manufacturercity:; manufacturerstate:; manufacturercountry:; devicelotnumber: S029542; expirationdate: 10-JUN-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",,Unknown,0,1
900999,"pt experienced a tender, palm sized raised bump next day. looks like it is resolving today (day 2)",52.0,Adults,0,0
856241,"pt reported pain and discomfort at injection site, since 9/15/2019. she has been feeling sick ever since, also presenting with small bump",77.0,Seniors,1,0
883778,"Mom reports that patient developed a red, raised area below injection site about 31 hours after receiving the flu vaccine. The area was very itchy. Mom gave Zyrtec and the area returned to normal about 30 minutes later. Patient has not experienced a reaction to other vaccines and has no known allergies.",6.0,Kids,0,1
885413,large red area that is warm and tender to the touch,58.0,Adults,0,0
875039,"1:15 dizzy and light headed  & arm hurt really bad, painful not like most shots 8-9pm that night was starting feel nauseous and had some diarrhea but not a lot ..  6am, had a fever, diarrhea and vomiting,, the vomiting was so long and violent he burst blood vessel in his left eye and emptied his stomach. By 7am he was dry heaving and just some neon/ bright yellow greenish maybe bile was coming up and said his stomach hurt so bad.",16.0,Kids,1,0
904264,"Patient presented to the emergency department at 8:45pm on 12/18/20 with lower abdominal pain, nausea, vomiting, and constipation that started approximately 2 hours prior to presentation, at approximately 6:45pm. Her labs were significant for a lipase of > 6000 IU/L, and a CT scan of her abdomen/pelvis was done that demonstrated evidence of acute pancreatitis. Given the fact that she does not have a history of heavy alcohol use, with normal triglycerides and no evidence of gallstones on her current admission, and no recent gastroenterology procedures, there is no clear etiology of her pancreatitis; concern for post-vaccination pancreatitis. The patient is currently admitted to the hospital, on hospital day #1 of her current condition.",46.0,Adults,1,0
913191,"can't raise her arm up; pain at the site of the injection; During the night she couldn't sleep; This is a spontaneous report from a contactable nurse (patient herself) via the Pfizer Sponsored Program. A 69-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), lot number: EK9231, via an unspecified route of administration on left arm from 23Dec2020 10:10 to 23Dec2020 10:10 as single dose for COVID-19 immunization. The patient medical history was not reported. There were no concomitant medications. The patient previously took tetanus toxoid and got red and was itching (clarified she had a reaction to a tetanus shot several years ago). Reports she received the first dose of COVID 19 vaccine at the hospital where she works on 23Dec2020 at 10:10AM in left upper arm. She started having pain at the site of the injection in the afternoon at around 3PM or 4PM 23Dec2020. During the night she couldn't sleep because of the pain no matter where she turned. The patient states the pain was probably 8 out of 10 on the pain scale. Adds she had no redness or swelling. The pain today (24Dec2020) is still the same and now she can't raise her arm up. No treatment has been applied. No cold or heat applied. The outcome of the event pain at the site of the injection was not recovered; while the other events was unknown.   Information about lot/batch number and expiration date requested.",69.0,Seniors,0,0
862193,"Upper right arm erythema and induration (1.5in x 2in); Upper right arm erythema and induration (1.5in x 2in); This is a spontaneous report from a contactable physician. This physician reported non serious events. A patient of unspecified age and gender received meningococcal group b rlp2086 (TRUMENBA), via an unspecified route of administration, on an unspecified date, at 0.5 ml single, for immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced upper right arm erythema and induration (1.5in x 2in) on an unspecified date with outcome of unknown.",,Unknown,0,0
864919,swollen left upper arm/cellulitis,,Unknown,0,0
886920,Mom spoke to provider had fever last eve 102 & vomited x1 today. Afebrile now,4.0,Kids,1,0
868954,"TOOK LAST DOSE ON DAY 9; TOOK AN UNREFRIGERATED DOSE; This spontaneous case report was received from a nurse (PVX2019-383) on 11-Feb-2019. The report describes a male consumer who ""took an unrefrigerated dose"" and ""took last dose on day 9"". The consumer was receiving Vivotif for an unknown indication.   It was reported that the consumer put Vivotif in his luggage while traveling  and his luggage got lost for two days. He took his last dose on day 9 (08-Feb-2019). His first three doses had been taken appropriately. He was unsure of the temperature that Vivotif was exposed to while the luggage was lost.  The action taken with Vivotif with respect to the events ""took an unrefrigerated dose"" and ""took last dose on day 9"" was not applicable.  The clinical outcome of the events ""took an unrefrigerated dose"" and ""took last dose on day 9"" was unknown.  Company's Comment: The causality of the event ""took an unrefrigerated dose"" and ""took last dose on day 9"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took an unrefrigerated dose"" and ""took last dose on day 9"" was considered as not applicable.",,Unknown,0,0
900872,"always get the flu after the shot, once H1N1; I always get the flu after the shot; Initial information regarding this unsolicited valid non-serious social media case was received from a consumer (patient) and transmitted to Sanofi on 27-Oct-2020.  This case was linked to cases 2020SA305170, 2020SA305222, 2020SA305230, 2020SA305270, 2020SA305371, 2020SA305401, 2020SA305420, 2020SA305444, 2020SA305474, 2020SA305488, 2020SA305527, 2020SA305545, 2020SA305591, 2020SA305629, 2020SA305651 and 2020SA305230.  This case involves a patient with unknown demographics who always get the flu (influenza), once H1N1 (H1N1 influenza), after the shot of vaccine INFLUENZA VACCINE.  Relevant medical history, past medical treatment, vaccination, concomitant medications and family history were not provided   On an unknown date, the patients received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious flu (influenza) and once H1N1 (H1N1 influenza) unknown latency following the administration of INFLUENZA VACCINE.  Relevant laboratory test was nor reported. Final diagnosis was the patient always get the flu after the shot and always get the flu after the shot, once H1N1.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome was unknown for the reported events.  There will be no information available on batch number for this case.",,Unknown,0,1
892525,"Redness, swelling from under deltoid to above elbow.  Referred patient to clinic",67.0,Seniors,0,0
895010,"Shoulder injury. noted red and raised, hot to touch. Painful when touched.  Staff was evaluated by the attending emergency department MD and was provided with a steroid to take by mouth.  Approximately at 5:00PM, employee health nurse looked at left upper arm and the swelling had decreased very little. Still red and warm to touch.",45.0,Adults,1,0
912426,"He was diagnosed with COVID 19; He was diagnosed with COVID 19; This is a spontaneous report from a contactable consumer (front line hospital worker) reporting for himself, received via a Pfizer sales representative. This male patient of unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on an unspecified date in Dec2020, at single dose, for COVID-19 immunization. Medical history and concomitant medications were not reported. On an unspecified date in Dec2020, after vaccination, the patient was diagnosed with COVID 19 with unknown outcome.  Information on the lot/batch number has been requested.",,Unknown,0,1
865388,"warm rash around the injection site; warm rash around the injection site; I am itchy all over; sore achy joints; achy muscle/ sore achy muscle; chills; headache; This case was reported by a consumer via call center representative and described the occurrence of joint pain in a 64-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on unknown date).   On 24th February 2020, the patient received the 2nd dose of Shingrix. In February 2020, less than a week after receiving Shingrix, the patient experienced joint pain, myalgia, chills and headache. On 27th February 2020, the patient experienced injection site rash, injection site warmth and generalized pruritus. On an unknown date, the outcome of the joint pain, myalgia, chills and headache were recovered/resolved and the outcome of the injection site rash, injection site warmth and generalized pruritus were unknown.   It was unknown if the reporter considered the joint pain, myalgia, chills, headache, injection site rash, injection site warmth and generalized pruritus to be related to Shingrix.  Additional details were reported as follows: The patient received 2nd dose of shingrix vaccine 72 hours ago from reporting date and experienced sore achy joints and muscles, chills, headache, which subsided after 48 hours. On 27th February 2020, in morning patient also discovered a warm rash around the injection site and patient felt itchy all over. The patient wanted to know how long these side effects might last",64.0,Adults,0,0
906461,"Severe headache for four days after vaccine, trouble keeping temperature below 100, extreme fatigue, shortness of breath, chills, nausea, loss of appetite, body aches, chest pain.",20.0,Adults,0,0
865580,stiffening with crying immediately after injection (per Mom),0.08,Kids,0,0
913741,"received vaccine 7:30 am.   Began to have some discomfort in right hand and wrist around 4:00pm.  I have arthritis in that area as well as in the left  hand/wrist along with other joints.  I had knee replacement several years ago.   I also had some recent bursitis in the right elbow.   The injection was in the left arm.   By 8 or 9pm, my right hand and wrist were so painful, especially with any movement, I was almost screaming with pain.    I am not one to complain much, but this was terrible pain.   The pain was gone by 10 or 11 am this morning.",65.0,Adults,0,0
868622,"TOOK TWO DOSES IN A ROW; This case (PVX2019-2196) was received form a pharmacist on 28-Aug-2019. It described an adult male consumer (age in between 18 to 64 years), who ""took two doses in a row"" (PT: Inappropriate schedule of product administration), while being on Vivotif for an unknown indication.  Case report: The consumer took the first there doses as directed. However, the third and the fourth dose of Vivotif were taken in a row.  Action taken with Vivotif with respect to the event was not applicable.  The clinical outcome of the reported event was unknown.  Company's Comment: The causality of the event ""took two doses in a row"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took two doses in a row"" was considered as not applicable.",,Unknown,0,0
916401,Patient had potential SIRVA from Fluzone HD.  Being examined by an neurologist now.,71.0,Seniors,0,0
858977,"he was diagnosed with dissection of his internal carotid artery; Initial information received on 27-Jan-2020 regarding an unsolicited valid serious case received from a physician.  This case involves a male patient (of unknown age) who was diagnosed with dissection of his internal carotid artery (carotid artery dissection), while he received vaccine INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE].  Medical history, concomitant, medical treatment, vaccination and family history were not provided.  On 06-Dec-2019, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE (lot number not reported, of unknown Expiration date) via unknown route at an unknown administration site for prophylactic vaccination.  On 13-DEC-2019, the patient underwent (serious) dissection of his internal carotid artery (carotid artery dissection) 7 days following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE. This event was assessed as medically significant.  Laboratory data was not provided.  Final diagnosis was carotid artery dissection.   It was not reported if the patient received any corrective treatment.  The patient outcome is reported as Unknown for dissection of his internal carotid artery.  Information on the batch number was requested.; Sender's Comments: This case concerns a male patient (of unknown age) who was diagnosed with carotid artery dissection after vaccination with FLUZONE HIGH DOSE. The time to onset is compatible. However, patient's medical history, medical condition at time of vaccination and lab test ruling out alternate etiologies were not reported. Based upon the reported information, the role of the suspect vaccine cannot be assessed.",,Unknown,0,1
895549,"Shoulder pain mimicking a shoulder injury, shoulder pain with movement getting progressively worse over time after the shot. Pain prevalent when moving arm above shoulder level, using arm/hand to apply pressure, and when turning arm.",39.0,Adults,1,0
867679,"The patient experienced no symptoms; a patient was administered a dose of improperly stored VARIVAX; This spontaneous report was received from a licensed practical nurse, referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, previous drug allergies or reactions and concomitant medications were not reported.       On 07-APR-2020, the patient was vaccinated with a dose of improperly stored varicella virus vaccine live (oka/merck)(VARIVAX) injection administered by subcutaneous route as prophylaxis (dosage regimen, strength, and anatomical location were not reported; lot number and expiration date were unknown by the reporter) (product storage error). The patient experienced no symptoms. It was unknown if the sterile diluent (MERCK STERILE DILUENT) used for administration was stored properly.      The vaccine underwent a temperature excursion of -14.3 degrees Celcius for 12 minutes, with a previous unspecified temperature excursion as captured by a data logger.",,Unknown,0,1
857737,None stated.,,Unknown,0,0
862872,18 days post reaction patient exhibited a varicella like rash.,7.0,Kids,1,0
891541,"No further AE; temperature excursion; This spontaneous report was received from a practice manager and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On 02-SEP-2020, the patient was vaccinated with an improperly stored dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 1 injection, lot # R025726, expiration date: 26-MAY-2021 (injection site and route of administration were not provided) for prophylaxis.  On 04-AUG-2020, the administered dose experienced the temperature excursions of below 2 degrees Celsius (C) (1.1 C) for 27 hours and 45 minutes and above 9 degrees Celsius (9 C) for 1 hour and 15 minutes. The digital data logger was involved. No previous temperature excursion had occurred. No further adverse events (AE) were reported.  This is one of multiple reports received from the same reporter. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. devicelotnumber: R025726; expirationdate: 26-MAY-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2010USA001083:Same Reporter",,Unknown,0,1
868161,Fever & Rash,68.0,Seniors,1,0
906573,"After I ate lunch I had watery stool, Next day I had hot flashes , body aches, eyes watering, chills,",41.0,Adults,1,0
889172,"Rash; First dose of Shingrix on 07-May-2018; This case was reported by a pharmacist via call center representative and described the occurrence of rash in a 76-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 7th May 2018, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, the patient experienced rash and incomplete course of vaccination. On an unknown date, the outcome of the rash and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix and developed rash. The reporter asked could receive second dose and how to continue with the schedule as was going to be late for second dose, which led to incomplete course of vaccination. The reporter consented to follow up. The reporter did not had further vaccine details. No further information provided.",76.0,Seniors,0,0
908366,"Pt. developed a typical (for her) migraine headache about 5-10 minutes after vaccination. She also described significant flushing and feeling hot, quickly removing her head covering and scarf. She took her regular dose of aspirin which she carries with her and we applied cold compresses to her neck which relieved the flushing and hot flash. We turned the lights low above the cot, she rested and symptoms all resolved over about 20 minutes and she left feeling relieved her headache did not progress.",37.0,Adults,1,0
867082,"Shingles; Information has been received from a lawyer and a female patient of unknown age regarding a case in litigation. Information about concurrent condition, medical history and concomitant medication was not reported. In 2015, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (strength, dose, lot# and route unknown) for the long-term prevention of shingles and/or zoster-related conditions. Subsequent to the inoculation (date not reported), the patient was treated by a health care provider for shingles. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient has and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of the event shingles was not recovered. The causality assessment was considered as related by the lawyer.",,Unknown,0,0
871043,"fever; Injection site has a ring; This case was reported by a consumer via call center representative and described the occurrence of fever in a female patient who received Men B NVS (Bexsero) for prophylaxis.   On 12th May 2020, the patient received Bexsero. In May 2020, less than a week after receiving Bexsero, the patient experienced fever and injection site reaction. On an unknown date, the outcome of the fever and injection site reaction were unknown.   It was unknown if the reporter considered the fever and injection site reaction to be related to Bexsero.  Additional details were reported as follows: The age at vaccination was not reported. The patient received vaccine and developed fever and the injection site had a ring around it. No other information was reported.",,Unknown,0,0
857066,"* ITEM 17: I DO NOT KNOW WHAT TYPE OF FLU SHOT I REVIEVED, I am required by my employer (a hospital) to get the flu shot  Severe and debilitating arthritis starting in fingers and hands and eventually in ankles and toes.  I have seen my doctor 2x about this issue.  MD has ruled out gout and believe it is related to flu shot. See following for timeline of these flares. I have never experienced any type of arthritis or gout prior to this flu shot.  October 3rd- Flu Shot  October 5th- extreme joint stiffness in fingers and wrists  lasting through 10/6 October 24th flare starting with right middle finger and eventually wrists November 2nd - extreme flare starting in R  wrist  moving to fingers and eventually ankles, making it impossible to walk  this worsened through November 4th and slow dissipated through November 6th  November 24th -slight flare in wrists -bilateral  December 6th- bilateral wrists and ankles-  December 21st- wrists, ankles dissipating Dec. 22nd  December 24th- bilateral writs only Jan. 1st - bi lateral wrists and R. ankle Jan. 8th - bi-lateral writs and ankles  Jan.12th- slight flare- with continued joint discomfort to present",34.0,Adults,0,1
875318,Patient states he has had arm pain for 5 months since his injection,54.0,Adults,1,0
914708,"5 days after receiving the vaccine, I noticed neck swelling( lump) in front of my neck, not sure if it is related but showed up all of a sudden.Was not there the day before. Had a neck/thyroid US shows bilateral cervical lymph nodes. Nodule  on the isthmus 1.9 cms in height moderately suspicious. Will need an FNA",57.0,Adults,0,1
898172,In the middle of the night patient experienced increased heart rate (>100bpm) and almost went to the ER.,64.0,Adults,0,0
888762,red warm raised area at injection site,85.0,Seniors,0,0
877984,"Soreness at injection site/Pain at injection site; red area at the injection site; Nausea; Body Ache; Fatigue; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 63-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of injection site pain (received 1st dose on unknown date, refer case US2020AMR142892).   On 22nd July 2020, the patient received the 2nd dose of Shingrix. On 23rd July 2020, 1 days after receiving Shingrix, the patient experienced injection site pain, injection site erythema, nausea, general body pain and fatigue. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the injection site pain, injection site erythema, nausea, general body pain and fatigue were recovered/resolved.   It was unknown if the reporter considered the injection site pain, injection site erythema, nausea, general body pain and fatigue to be related to Shingrix.  Additional details were reported as follows: The patient received Shingrix in left arm and had a red area at the injection site of his left arm.  The area was about the size of the palm of a man's hand and about 3 inches in diameter. The patient had soreness and pain at the injection site, fatigue, body ache, and nausea. The reporter consented to follow up. Lot and expiration date was unknown. The reporter stated that patient consent to follow up. This case linked with US2020141485, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020141485:same reporter US-GLAXOSMITHKLINE-US2020AMR142892:same patient",63.0,Adults,1,0
881016,Skin reaction ~5cm of induration/erythema and edema,17.0,Kids,0,0
879562,Pain on shoulder and fever,18.0,Adults,1,0
877239,"flu like symptoms/side effects; side effects; This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of influenza like illness (1st dose received on unknown date. Please refer the case US2020092721).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced influenza-like symptoms and adverse drug reaction. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the influenza-like symptoms and adverse drug reaction were unknown.   It was unknown if the reporter considered the influenza-like symptoms and adverse drug reaction to be related to Shingrix.  Additional details were provided as follows: The patient had not elaborated beyond the flu like symptoms. the caller did not wish to participate in a safety report and would not elaborated on flu like symptoms, or other side effects. The reporter did not consent to follow up.   Follow up information received from consumer on 25th June 2020: The patient's flu-like symptoms lasted approximately 48 hours.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020092721:",,Unknown,0,0
907876,"Shortly after receiving the Moderna COVID-19 Vaccine (Within minutes) she complained of the injection site and that arm of feeling warm.  Upon further inspection, her arm was warm to the touch and was red.  Patient could feel warmth from inside and we could also feel the warmth  with touch.  She stayed 15 minutes and we monitored the site.  There was no further reaction.  The patient had been offered Benadryl and declined.  This will be  notated for her second dose and will pre-treat with benadryl if needed.",26.0,Adults,0,1
855960,"tingle - nerve sensation;  in left arm from shoulder to fingers- stronger in fore arm and arm, over all surface of the arm. Also a little sore up left side on neck and left shoulder blade but No tingling in these two locations.",63.0,Adults,0,0
912418,"Patient  received the vaccine, waited 15 minutes and had no difficulties.  He presented back to the injection area with complaints of dizziness, slight chest and neck tightness. BP was slightly elevated.  He was given 2 benadryl an taken to the ED where they monitored him. No further medication intervention needed.",55.0,Adults,0,0
915843,"Fever to 102, malaise, body aches",50.0,Adults,1,0
888986,"Hives in mouth and over body, swollen throat, itchy skin and eyes lasting about 1 hour resolving on own.",34.0,Adults,0,0
914951,"Patient reported ""not feeling right"" shortly after receiving vaccine. Patient experiencing audible wheezing, mild cyanosis, and was nonverbal. pharmacist responded with epi-pen at 2:48pm. Patient immediately responded to epi-pen (no wheezing, lips/nailbeds pink, verbalizing ""I'm ok"" after 15-30 seconds. Patient was monitored and experienced no further distress.",54.0,Adults,0,1
872224,"Pt sat for vaccine, admin into L deltoid, bandaid and ice pack put on arm, pt walked out to car and stumbled upon minivan then rollder and fell and dad and I caught him, he complained that the arm was ok but his legs felt funny and his ears felt funny(reported to parent ringing in the ears for few minutes). Pulse ox gotten and was 97% pulse:67(earlier @beginning of visit pulse was 104), bp 110/70 pt felt funny sat for few minutes drank some water then helped to front seat of van, felt better and temp taken was 98.8, pt stated felt ok so family left, will plan to check on pt later",12.0,Kids,0,1
886060,Patient Fainted,19.0,Adults,0,0
898080,"Continues to have pain around the injection site in her right arm; Continues to have pain around the injection site in her right arm; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 73-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included shingrix with an associated reaction of pain in extremity (first dose received around Spring 2019.refer linked case US2020166806).   In July 2019, the patient received the 2nd dose of Shingrix. In July 2019, immediately after receiving Shingrix, the patient experienced injection site pain and pain in arm. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the injection site pain and pain in arm were not recovered/not resolved.   It was unknown if the reporter considered the injection site pain and pain in arm to be related to Shingrix.  Additional details were provided as follows: The patient had pain around the injection site in her arm. The pain was not on the injection site.  The pain was off and on and pain was there mostly when she wakes up from her sleep. The follow up consent was granted; Sender's Comments:  US-GLAXOSMITHKLINE-US2020166806:1st dose",72.0,Seniors,1,0
891750,No adverse event. Vaccine error reporting.,1.08,Kids,0,1
891886,upon adminsitration a little leaked from injection site no adverse effect noted,56.0,Adults,0,0
872071,"Varivax following temperature excursion; no adverse event; This spontaneous report was received from a nurse and refers to unknown number of patients of  unknown age and gender. The patient's medical history, historical drugs and concurrent conditions were not reported.   On unknown dates, the patients were vaccinated with incorrect storage doses of varicella virus vaccine live (oka/merck) (VARIVAX) dose and route were not reported, (lot # S020965, expiration date 07-JUL-2021) for prophylaxis. Concomitant therapies included sterile diluent. The temperature was in the range of 15 degrees F to 46 degrees F (-9 degrees C to 8 degrees C) (-2.5 C) for 4 hours. A data logger was involved.",,Unknown,0,1
856061,"Fever, headache, arm soreness, general malaise persisted overnight into the next day",56.0,Adults,1,0
873698,"Gestational diabetes; Anemia; Vaccine exposure during pregnancy; This is an observational study case, initially received from other health professional on 09-Jun-2020, concerning a 33-year-old, pregnant female subject of body weight: 194 lbs, height: 63 inches and body mass index (BMI): 34.4, enrolled in, a prospective observational study.  The subject's medical history included body mass index high (BMI 34.4) and chronic hypertension.   The subject's concomitant medication included Prenatal vitamin (unspecified vitamins and minerals) for pregnancy.   The subject's obstetrical history included no previous pregnancies. The subject did not have a history of offspring with major congenital malformation (MCM). Also, the subject had no maternal or paternal history with MCMs. The subject did not use tobacco, alcohol or illicit drugs during pregnancy.  The subject's last menstrual period (LMP) date was 29-Jun-2019. Estimated delivery date (EDD) was reported as 04-Apr-2020 and corrected estimated date of delivery (CEDD) was reported as 13-Apr-2020. The type of pregnancy was singleton.  On 27-Aug-2019, the subject underwent cystic fibrosis mutation analysis and spinal muscular atrophy test and no MCM was noted.  On 24-Sep-2019, the subject underwent ultrasound scan and no MCM was noted.   On 30-Oct-2019, the subject underwent panorama test and ultrasound scan and no MCM was noted.    On 13-Nov-2019, at approximately 19 weeks of gestation (calculated per LMP), the subject was administered Flucelvax QIV (Flu Vaccine Cell Subunit QIV NVD) [influenza vaccine, subunit influenza virus vaccine polyvalent; dose: 0.5 ml, batch number: 261218, route of administration, anatomical location and expiry date: not reported] (explicitly coded as Vaccine exposure during pregnancy') for influenza immunisation.   On 04-Jan-2020, the subject underwent ultrasound scan and no MCM was noted.   On 29-Jan-2020, two months and 16 days after vaccination, the subject developed anemia and started treatment with ferrous sulfate, at a dose of 325 mg, twice a day, administered via oral route.   On the same date, the subject underwent ultrasound scan and no MCM was noted.   On 06-Feb-2020, two months and 24 days after vaccination, the subject developed gestational diabetes.   On 13-Feb-2020, 19-Feb-2020, 04-Mar-2020, 11-Mar-2020 and 25-Mar-2020, the subject underwent ultrasound scans and no MCMs were noted.    at 39.3 weeks of gestation (as reported), the subject delivered live birth female neonate, by caesarean method of delivery. The neonate's birth weight was 3140 grams, head circumference was 34.3 cm and body length 48.3 cm. The appearance, pulse, grimace, activity, and respiration (APGAR) scores were 3 at one minute, 8 at five minutes and 8 at ten minutes. There was no MCM identified at birth.   On the same date, the subject recovered from anemia and treatment with ferrous sulfate was completed.   At the time of this report, the subject did not recover from gestational diabetes.   The event of gestational diabetes was assessed as serious due to the criterion of medical significance, per company.   The reporter did not provide causality assessment to Flucelvax QIV.  This case is linked to 202003799 (corresponding baby case).  Company comment: A pregnant subject experienced gestational diabetes and anaemia more than two months after receiving Flucelvax QIV. The subject's medical history included body mass index high (BMI 34.4) and chronic hypertension, therefore causality was highly confounded for gestational diabetes. Anaemia is frequent during pregnancy and treatment with ferrous sulphate suggests iron-deficiency etiology. Causal role of the suspect vaccine is assessed as not related for both events. Vaccine exposure during pregnancy assessed as not related per company's conventions.; Sender's Comments: A pregnant subject experienced gestational diabetes and anaemia more than two months after receiving Flucelvax QIV. The subject's medical history included body mass index high (BMI 34.4) and chronic hypertension, therefore causality was highly confounded for gestational diabetes. Anaemia is frequent during pregnancy and treatment with ferrous sulphate suggests iron-deficiency etiology. Causal role of the suspect vaccine is assessed as not related for both events. Vaccine exposure during pregnancy assessed as not related per company's conventions.",33.0,Adults,0,1
883619,Arm swollen and red below deltoid.,77.0,Seniors,0,0
898347,My upper arm has been painful ever since I got the injection. Can barely lift anything heavy.  Interferes with my sleep since I cannot place weight on my arm.  Cannot lift my arm w/o pain.  Can only get my arm over my head by using my left arm to lift it.  Shame on our government for approving something like this and not caring at all how it could horribly affect people's lives.  I have had a flu shot for countless years and have NEVER experienced something like this.  I do not think I will ever regain normal use of my arm.  It has been 2 months now.,65.0,Adults,0,0
881624,"A patient was administered an improperly stored dose of VAQTA; This spontaneous report was received from a Licensed Practical Nurse referring to a 3 year old female patient. The patient's medical history, concurrent conditions, concomitant medications, and historical drugs were not reported.  On 14-AUG-2020, the patient was vaccinated with an improperly stored dose of  hepatitis a vaccine, inactivated(VAQTA) (strength, dose, frequency, and anatomical location were unknown) with lot # S032358, and expiration date 11-JAN-2021, intramuscular for prophylaxis.    The administered dose of hepatitis a vaccine, inactivated(VAQTA) experienced the temperature excursion above of  47 F degrees Fahrenheit  / 9C (8.9 C) Celsius degrees for 33 minutes. There was a digital data logger invloved, but there was no previous temperature excursion. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.  manufactureraddress:  manufacturercity:  manufacturerstate: ; manufacturercountry: ; devicelotnumber: S032358; expirationdate: 11-JAN-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",3.0,Kids,0,1
870041,"Side effects; Nausea; This case was reported by a consumer and described the occurrence of adverse event in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced adverse event and nausea. On an unknown date, the outcome of the adverse event and nausea were not recovered/not resolved.   It was unknown if the reporter considered the adverse event and nausea to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The patient had all but the nausea. The reporter asked how long would the common side effects of Shingrix last.",,Unknown,1,0
865939,"Stomach ache, headache, fever, exhausted for a week, hallucinations or ""crazy"" dreaming.",54.0,Adults,1,0
886491,"Redness on legs, swelling. Treated with Tylenol q 6 hr",1.33,Kids,0,1
915786,Sore arm Sore throat Severe fatigue Itching,61.0,Adults,1,0
911358,"really uncomfortable, my stomach is alarming; This is a spontaneous report from a contactable consumer (patient). A 57-year-old female patient received BNT162B2 (COVID Vaccine, manufacturer not clarified), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunisation. Medical history included hypertension, diabetes, atrial fibrillation. The patient had some concomitant medications. When probed for any concomitant, patient stated, that was her other concern. She was seeing there was an issue with if you won't blood thinner (further not clarified). Patient stated, she got her own injection (COVID Vaccine) on Friday and It was not been major but she had been to the bathroom since Friday and she was change her diet or anything. This was really uncomfortable, her stomach was alarming. Patient asked if that was normal. Outcome of the event was not reported.   Pfizer is a marketing authorization holder of COVID Vaccine in the country of incidence or the country where the product was purchased (if different). This may be a duplicate report if another marketing authorization holder of COVID Vaccine has submitted the same report to the regulatory authorities.  Information on the lot/batch number has been requested.",57.0,Adults,0,1
916495,"Headache, SOB but 99% O2, vitals okay, talked to NP and told to monitor. Felt better the next day. COVID + in the past",77.0,Seniors,1,0
906824,"Hard lump and redness at injection site on right deltoid almost immediately after injection. Patient describes a ""fireball"" in her throat. Denies swelling. No difficulty swallowing, maintaining airway independently. Headache.  In E.D., patient received NS 1000 ml at 2000 ml/hr at 19:34, Diphenhydramine 25 mg IV x1 at 19:36, Methylprednisolone 125 mg IV at 19:38, Ketorolac 30 mg IV at 19:41, Famotidine 20 mg IV at 19:42.  Forty minutes post injection, all symptoms gone. Discharged from E.D. at 20:52 with prescription for prednisone 50 mg po daily x4 days, diphenhydramine 25 mg po q6h prn, and famotidine 20 mg po nightly prn.",47.0,Adults,1,0
861233,"I started feeling feverish and pain in my left arm which spread to shoulder and back. Shooting pain and swelling which was not responsive to pain Ibuprofen. For the next 2 days the symptoms worsened with chills, giddiness and nausea. No fever but just the feeling. A lot of sweating. This subsided by day 3.  I tried to handle this with Ibuprofen and Pantoprazole.",36.0,Adults,1,0
880353,"Patient received both vaccines in right arm separated by an inch apart on Friday 8/21/20. Patient returned to pharmacy on Sunday 8/23/20 with complaints of being unable to move arm, very sore, and warm to the touch. She had three small welts that were pink and raised and irritated that were not at the site of injection but around it. She explained that she did not have the same effect with the first dose of Shingrix but she did not have any other vaccine at the same time as that one. This was her first Pneumonia vaccine however.",67.0,Seniors,0,1
855938,"sore arm; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   In August 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 6 months after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovered/resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional details were provided as follows: The case was reported by patient's husband. Post vaccination the patient had sore arm. This case was linked to another case US2020AMR003672 reported for the same patient (2nd dose).",70.0,Seniors,1,0
914310,Fever of 103 F for 5 days. Negative for covid. Cellulitis of lower extremities worsened. Infection occurred prior to vaccine.,73.0,Seniors,0,0
855020,"sore arm,  fever 101 , chills, and aching muscles, flu like symptons",67.0,Seniors,1,0
911391,"I had severe body rigors/Chills; I threw up; I had a 101.8 fever; I was pretty much out all day yesterday, like I was out sleeping with a fever; pretty much out; This is a spontaneous report from a contactable Nurse. A 59-year-old female patient started to receive first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot/batch number: EJ1685, Expiry Date: 31Mar2021) intramuscular on 19Dec2020 at 0.3 mL, single for covid-19 immunization from her work. Patient history was reported as no. The patient didn't have really anything. Concomitant medication included paracetamol (TYLENOL), the patient had been taking some Tylenol. The patient had a vaccination Saturday morning on 19Dec2020 and had a very bad reaction during the night. The patient had severe body rigors and chills. She threw up. She had a 101.8 fever. She was pretty much out all day yesterday, like was out sleeping with a fever. Investigation assessment was no. The patient just would like to know if she can get the second injection. Outcome of the events was unknown. The events were considered as related by the reporter via global introspection (Method of assessment).",59.0,Adults,0,0
896305,"Patient states for about she had facial swelling, her skin turned red, she was hot and itchy for about 3 days after receiving the FLUAD vaccination.",71.0,Seniors,0,0
912341,"Extreme body aches, has to stay in be, severe headache, eyes hurt, swollen lymph nodes under right arm, fever to 99.2",49.0,Adults,1,0
890218,Became ridgid and had jerking muscular movements noted on 10/10/2019,0.17,Kids,0,0
887203,Vaccine was given in upper left deltoid. Upon withdrawal of the needle the patient started bleeding heavily. We cleaned him up and band aid was applied and he left. Patient seemed coherent and lucid when he left from the clinic. He is concerned that the vaccine came out when he was bleeding. He wants to get another Flu vaccination.,70.0,Seniors,0,1
880587,"received the first dose of the GARDSIL 9 series on an unspecified date in 2/2020 and the second dose of the series on 8/10/2020; This spontaneous report was received from a pharmacist, concerning an adult male patient in his mid 20's. Information regarding concomitant medications, pertinent medical history and drug reactions/allergies was not reported.   On an unspecified day in February 2020, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) for prophylaxis (dose, route of administration, anatomical location, lot # and expiration date were not reported= On 10-AUG-2020, the patient received the second dose of the series (Inappropriate schedule of product administration).",,Unknown,0,1
879184,Painful left arm at site of injection at depth muscle and bone for 4+ months.  I?m concerned about bone infection because injection might have been too deep.,65.0,Adults,1,0
911525,"the injection site is extremely painful; bleed a lot; there was lot of blood, it was more than usual; I could barely move; Rest of the arm feels cold like really cold; This is a spontaneous report from a contactable nurse (patient). This 48-year-old female patient (weight 68.04 kg, height 160 cm) received BNT162B2 (Pfizer-Biontech Covid-19 Vaccine) on 22Dec2020, at single dose, for COVID-19 immunisation. Relevant medical history included asthma and allergy from an unspecified date and ongoing. Concomitant medications were none. On 22Dec2020, the injection site was extremely painful and bleed a lot; there was lot of blood, it was more than usual. She could barely move and rest of the arm felt cold like really cold. Patient put 3 band aids on injection site. Clinical outcome of the events was unknown at time of this report.   Information on the lot/batch number has been requested.",48.0,Adults,0,0
916101,"15 minutes after injection patient reported feeling lightheaded and nervous. Patient denies chest pain, difficulty breathings, itchiness or pain. Patient was evaluated by EMS at 11:19 am Blood Pressure 168/95 at 11:29 am Blood pressure 148/92 O2sat 100% Patient is drinking water and feeling better. 11:35 am Patient reports her symptoms have resolved, and wishes to leave.  Patient was advised to follow up with her PCP or to ED if symptoms return.",41.0,Adults,1,0
907929,Staff member started to feel fatigue and chills the evening he received the vaccine. Symptoms continued the following day and a half. Fever was as high as 101.4. He had COVID nine months ago. Symptoms have resolved.,49.0,Adults,0,0
862343,UNMONITORED TEMP FOR 63H,6.0,Kids,0,0
915390,"Shortness of breath, Lethargic.  Takin to ED and given Epinephrine IM.  symptoms resolved",58.0,Adults,0,0
892398,Seizure like activity to right side of body with elevated temp. Event lasted a few minutes. Body started to cool down and seizure like activity stopped.,0.92,Kids,0,0
897051,No adveRse reactions,41.0,Adults,0,0
886849,"Severe ache in all  joints and muscles from torso to lower limbs; lethargy; weakness.  No elevation of temperature. No nausea, vomiting, but definite loss of appetite.",72.0,Seniors,1,0
886223,"Patient reported localized swelling, redness, tenderness, and heat in her right shoulder which started almost immediately following immunization and has gotten progressively worse over the last three days.  It has extended down to the right elbow and over to the right underarm and breast.  Patient using ice and acetaminophen to manage the symptoms, and she is planning on seeking further medical attention if the condition worsens significantly or does not improve within 24 hours.",62.0,Adults,0,0
864896,raised swelling and redness at the injection site after administration of Prevnar 13; raised swelling and redness at the injection site after administration of Prevnar 13; This is a spontaneous report from contactable Physician via Pfizer Sales Representative. A patient of unspecified age and gender received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13) via an unspecified route of administration on an unspecified date at single dose for immunization. The patient's medical history and concomitant medications were not reported.  The patient experienced raised swelling and redness at the injection site after administration of Prevnar 13. Event took place after use of product. The outcome of the event was unknown. Information on the lot/batch number has been requested.,,Unknown,0,1
897881,"Achy , tired, head heavy,",60.0,Adults,0,0
907992,Patient monitored x 15 min per guidelines. Returned within 10 mins c/o itching hands. 25 mg diphenhydramine given IM per order. Post adm VS stable. Symptoms resolved within 15 min.,58.0,Adults,0,0
887854,"I received the seasonal flu vaccine, I don't know what particular name it has.  My symptoms started that night and went through the next day. They included: fever, great fatigue, headache, and a little diarhhea.",59.0,Adults,0,0
857382,"Hives, rash all over entire body. Started the night of the vaccine and continued for a week. Then had eczema.",0.5,Kids,0,0
911626,"After having covid 4 weeks ago, I got the covid vax. After an hour, arm was sore. I went through my work day. Got home and was tired, showered, and was tired. I woke up at 1am and was shivering and shaking . It was intense. I had a better reaction with the actual virus. The CDC stated that I should be 10 days out from having covid, to get the vaccine, and I did so. My arm is swollen, there is a lump where the injection was. I did not take any thing for pain or symptoms.",52.0,Adults,0,0
885195,"Fluzone pre-filled syringe was apparently leaked while patient was receiving the vaccine/ NO AE; Fluzone pre-filled syringe was apparently leaked while patient was receiving the vaccine/ NO AE; Initial information received on 02-Sep-2020 regarding an unsolicited valid non-serious case from a consumer or non-healthcare professional.  This case involves a female patient (age unknown) who while receiving 0.5 mL INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT] (prefilled syringe) (batch number, expiry date, route and site of administration not reported) was apparently leaked (syringe issue and underdose) on an unknown date for prophylactic vaccination.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.  It was a case of syringe leak and vaccine underdose.  At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information available on the batch number for this case.",,Unknown,0,1
898994,"blisters on back, arms and legs; rash; This case was reported by a nurse via call center representative and described the occurrence of blister in a 81-year-old male patient who received Herpes zoster (Shingrix) (batch number 24DP5, expiry date 8th April 2022) for prophylaxis.   On 28th August 2020, the patient received the 1st dose of Shingrix. In September 2020, 1 week after receiving Shingrix, the patient experienced blister and rash. On an unknown date, the outcome of the blister and rash were not recovered/not resolved.   It was unknown if the reporter considered the blister and rash to be related to Shingrix.  Additional details were provided as follows: The patient received the 1st dose of Shingrix and experienced rash and blisters. The patient experienced rash and blisters on back ,arms and legs. The patient reported they would come and go. The patent was not recovered. The reporter consented to follow up. No further information was available.",81.0,Seniors,1,0
887682,"left arm pain; red rash with itching around the injection; red rash itching around the injection site; itching around the injection site; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 79-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 10th August 2020, the patient received the 1st dose of Shingrix. On 10th August 2020, less than a week after receiving Shingrix, the patient experienced pain in arm, injection site rash, injection site erythema and injection site itching. On an unknown date, the outcome of the pain in arm was unknown and the outcome of the injection site rash, injection site erythema and injection site itching were recovered/resolved.   It was unknown if the reporter considered the pain in arm, injection site rash, injection site erythema and injection site itching to be related to Shingrix.  Additional details were provided as follows: The patient received 1st dose of Shingrix in left deltoid. On the same of vaccination or the next day, the patient had left arm pain and also red rash with itching around the injection site, which took about 1 week to resolve. The reporter consented to follow up.",79.0,Seniors,1,0
875567,2 dose shot  vaccine administered.  The site of injection is swollen and red.  I had body chills and pain on the arm  plus fatigue and didn?t  feel  well  over all .  Today I don?t have chills but still pain on site and is still swollen plus fatigued on today  second  day.,50.0,Adults,0,0
863908,fever sore arm chills muscle ache,58.0,Adults,1,0
881938,"temperature excursion that was intermittent/involving PROQUAD states that there have been administered doses; This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, concurrent conditions, drug reactions or allergies and concomitant therapy was not reported.   On 21-AUG-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live rHA (PROQUAD) (0.5ml, route of administration and anatomical location were not reported, lot # S031882 with an expiry date of 07-APR-2021 or lot# T009929 with an expiry date of 16-AEP-2021), for prophylaxis. Beginning from 28-JUL-2020, the temperature excursion of measles, mumps, rubella and varicella (oka-merck) virus vaccine live rHA (PROQUAD) was between -14 Celsius degrees and -10 Celsius degrees (max -9.5 Celsius degrees) for a total of 38 hours and 30 minutes and was assessed as intermittent. There had not been previous temperature excursion. Digital data logger was used.",,Unknown,0,1
902286,"On approximately October 12, after receiving the Gardasil 9 vaccine on September 30, I noticed that my ""sore"" left arm was not just sore but had a nodule in the tissue. I measured the nodule, and it was about 2 cm in diameter. I applied heat and massaged it, but it did not help. I messaged my provider's office on October 18 to ask if this was abnormal and if I should do anything else. My provider replied that I should continue to apply heat and that this was normal. I did apply heat as often as possible, and I even slept with heat for several hours at a time. This did not seem to speed up the resolution of the nodule. The nodule increased in size to 3 cm and swelled up to a round knot. I would say that it was 3 cm diameter by the end of October and increasingly sore and heavy. It gradually decreased in size in the latter half of November. Today I have no nodule but my left arm is still slightly sore. I still do not feel that I could receive another vaccine in the left arm without anxiety because of the soreness.",41.0,Adults,0,1
856737,Soreness at vaccination site and diarrhea,68.0,Seniors,0,0
906310,Hives at day 2 treated with OTC medication like benadry.  Day 4 reported shortness of breath and patient being seen in the ED.,53.0,Adults,0,0
901662,Rach & UrticariaPruritus,61.0,Adults,0,0
877516,"Erythema, swelling and pruritus just inferior to injection site beginning 24-36 hours after injection. No treatment given, watchful waiting.",18.0,Adults,0,0
863511,"hydrocephalus; cranial bleed; no bladder control; rash on back; shingles on back; pain; confusion; difficulty walking; encephalitis; severe muscle pain (left leg); redness at injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 2nd November 2019, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 2nd November 2019, less than a day after receiving Shingrix, the patient experienced injection site erythema (serious criteria hospitalization). On 8th November 2019, the patient experienced muscle pain (serious criteria hospitalization). On 12th November 2019, the patient experienced rash (serious criteria hospitalization), shingles (serious criteria hospitalization), pain (serious criteria hospitalization), confusion (serious criteria hospitalization), walking difficulty (serious criteria hospitalization) and encephalitis (serious criteria hospitalization and GSK medically significant). On 15th November 2019, the patient experienced bladder incontinence (serious criteria hospitalization). On 30th November 2019, the patient experienced intracranial hemorrhage (serious criteria hospitalization and GSK medically significant). On 13th January 2020, the patient experienced hydrocephalus (serious criteria hospitalization and GSK medically significant). On an unknown date, the outcome of the injection site erythema, muscle pain, rash, shingles, pain, confusion, walking difficulty, encephalitis, bladder incontinence, intracranial hemorrhage and hydrocephalus were unknown.   It was unknown if the reporter considered the injection site erythema, muscle pain, rash, shingles, pain, confusion, walking difficulty, encephalitis, bladder incontinence, intracranial hemorrhage and hydrocephalus to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix and experinced injection site erythema, muscle pain in left leg, rash, shingles, pain, confusion, walking difficulty, encephalitis, no bladder control, intracranial hemorrhage and hydrocephalus. The patient went to the emergency room on on 15th November 2019 and was admitted to the hospital the same day. on 5th February 2020 the patient was discharged from the hospital.  Reporter consented to follow up",75.0,Seniors,1,0
907835,"Fever; Mild headache; Fatigue; This is a spontaneous report from the Pfizer-Sponsored program received by a contactable consumer.  A 55-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number EH9899 with Expiration Date Mar2021), via intramuscular, on 17Dec2020 at single dose for COVID-19 immunisation. The patient did not have a relevant medical history and concomitant medications.. On 19Dec2020, the patient developed mild headache and fatigue.  On 20Dec2020, the patient experienced fever. She stated ''I will take some paracetamol (TYLENOL) whatever for next couple days, if it is not then I need to get COVID Test''. The outcome of the events was unknown.",55.0,Adults,0,0
887422,"mom came in on 10/03/2020 stating that that around 6 hours after patient recieved vaccine her arm and face started to swell, she then went to the doctors office and was told it was likely from the flu shot- patient was then treated and is doing fine today per mom. allergy in patients profile has been listed- she has never had a reaction to a vaccine before",31.0,Adults,0,1
860663,"No additional adverse symptoms reported.; an expired dose of PROQUAD (ROl 1216, 10/15/2019) was administered to a patient; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. No information regarding the patient's concurrent conditions, medical history or concomitant medications was provided. On 29-JAN-2020, the patient was vaccinated with a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (exact dose, frequency and route of administration were not reported) lot # R011216 and expiration date: 15-OCT-2019, for prophylaxis. The vaccine was reconstituted with sterile diluent. No additional adverse symptoms reported.",,Unknown,0,1
883401,redness and soreness at injection site warm to touch,67.0,Seniors,0,0
908338,5 minutes post-injection onset of nausea.  10 minutes post-injection retching.  1 hour post injection intense abdominal pain.  2 hours post injection onset of full body itching with no rash or hives.  Itching responded to 50 mg Benadryl po and 20 mg po pepcid.  Next day light itching; no other symptoms,31.0,Adults,1,0
888620,"Within moments after receiving  vaccinations, patient started exhibiting shortness of breath, shakiness and felt cold (subjective), patient was alert and responsive. Patient was asked to lay down and take slow/deep breathes until she felt calm. Patients vital signs were assisted and normal. Provider assisted patient, gave one 25 mg capsule of diphenhydramine which per patients mother; patient tolerates fine. Pt was asked to stay seated until calm and was released per Provider.",16.0,Kids,0,0
915434,"Swollen lymph node on injected site started 5 days after injection Area from injection site getting red, swelling, and pain 7 days after injection",39.0,Adults,1,0
870298,"No adverse effects; unspecified patients received improperly stored doses of PNEUMOVAX 23; This spontaneous report was received from a medical assistant, referring to a 68-year-old patient of unknown gender. No information regarding the patient's pertinent medical histories, concurrent conditions, concomitant therapies, drug reactions or allergies.  It was reported that on 09-OCT-2019, the vaccine pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was exposed to a temperature excursion with a lowest temperature below 36 Fahrenheit (F) degrees (30.5 F degrees) for 10 hours. There was no previous temperature excursions.  On 01-NOV-2019, the patient was vaccinated with the improperly stored pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) lot # S029265, expiration date 31-MAR-2021 (dose, dose number, route of administration and anatomical injection site were not reported) for prophylaxis. The call was placed because of the Digital Data logger report. No adverse effects reported.  This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: S029265; expirationdate: 31-MAR-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-1911USA001801: US-009507513-2005USA002426: US-009507513-2005USA002452: US-009507513-2005USA002453: US-009507513-2005USA002454: US-009507513-2005USA002456: US-009507513-2005USA002457:",68.0,Seniors,0,1
908471,"I was very tired at 18:30 after receiving the vaccine at 14:29.  I went to bed at 18:30 that night awoke at 3 am for work and was still very tired and body aches.  I was driving to work and notice that I was having a delayed reaction to such things as I was looking at Christmas lights and had to remind myself I was driving.  The drive to work otherwise I do not remember.  I felt as if I was just not processing things around me correctly.  At work the symptoms were intermittent.  The thought process or lack of continued.  I began to have stomach pain felt like diarrhea coming on however I never had it.  Then nauseated and thought I was going to throw up and felt like I was going to pass out.   The passing out feeling continued until I had my coworker call a rapid because I knew my blood pressure was dropping and my hear rate became  slow and I was passing out.   I was then taken to the emergency room to where I continued to experience orthostatic blood pressure changes and bradycardia and hypotension.   I was given fluids and potassium IV and was feeling slightly better.   I went home and slept for the next 18 hours.   When I did briefly awaken through the evening I had an elevated temperature 102, chills and an extreme headache and body aches.    Today I awoke at 6 am and still sluggish with a slight headache and absolutely no appetite.",51.0,Adults,0,0
857175,Started vomiting within an hour....with no warning followed by uncontrollable diahrea over a few hours.  Contacted doc office at 4:45 PM; I was told that nurse may not call me back until next day.  Got a nurse to call back about 6 PM who thought my symptoms were 24 stomach virus or flu; no mention was made of allergic reaction to the shot....or possibly nurse wearing possible latex gloves.,65.0,Adults,0,0
916057,Nausea and lightheadedness  is what the patient is reporting,46.0,Adults,1,0
892353,"Symptoms: fatigue, body aches, headache, sore throat, nausea, diarrhea, dizziness",26.0,Adults,1,0
874044,on 5/7 patient called to report ongoing pain in the left arm with inability to lift the arm. She states the pain is ongoing since the vaccine was administered on 4/28.  On 6/18 with PCP visit continues to report soreness of the right arm.,32.0,Adults,0,0
863300,"HPV vaccine for right foot warts (plantar warts); This literature marketed report has been received from the authors of the published article, concerning a 63 year old male patient. The patient's pertinent medical history include therapy with liquid nitrogen, salicylic acid, candida albicans, duct tape and zinc (unspecified). The patient's current conditions and concomitant medications were not reported.  On an unspecified date, the patient was vaccinated with quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (manufacturer unknown) for right foot warts (plantar warts) (product use in unappoved indication) (strength, dose, frequency, route of administration, lot number and expiration date were not reported).  This is one of several reports received from the same literature.  Sender's Comments:  US-009507513-1912USA001729:",,Unknown,0,1
892522,Erythema that hasn't resolved after approximately 3 days.  Patient took antihistamine without improvement. Patient also had 101 fever and some arm pain.,60.0,Adults,1,0
878906,"2 complex febrile seizures. First one lasted 9 minutes and resolved by itself. Second one was inside the ambulance, lasted 2 minutes and it was treated with .4mL of Versed. She was taken to Hospital.",1.0,Kids,0,0
858450,"Chills; Headache; This is a spontaneous report from a contactable physician via Pfizer sales representative. A patient of unspecified age and gender received pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) (PREVNAR 13), via an unspecified route of administration on an unspecified date at a single dose for immunisation. The patient's medical history and concomitant medications were not reported. Patient was described to have gotten chills and a headache after receiving the vaccine. Outcome of the events was unknown.   Information on the lot/batch number has been requested.",,Unknown,0,0
887966,"began to bleed from the injection site; This case was reported by a pharmacist via call center representative and described the occurrence of injection site hemorrhage in a 64-year-old female patient who received Herpes zoster (Shingrix) (batch number Y7JL5, expiry date 13th May 2022) for prophylaxis.   On 26th September 2020, the patient received the 1st dose of Shingrix (intramuscular). On 26th September 2020, immediately after receiving Shingrix, the patient experienced injection site hemorrhage. On 26th September 2020, the outcome of the injection site hemorrhage was recovered/resolved.   It was unknown if the reporter considered the injection site hemorrhage to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient received dose of Shingrix via intramuscular in the left deltoid. Immediately after the needle was withdrawn the patient began to bleed from the injections site, a band aid was applied and the bleeding had stopped by the time the patient returned to home. The reporter did not consent to follow up.",,Unknown,0,0
861418,"Fetal ventricular septal defect; Foetal exposure during pregnancy; Echogenic bowel; This is an observational study case, initially received from other health professional on 06-Feb-2020, concerning a foetal subject whose mother was 20-year-old, female, pregnant subject, of body weight: 185 lbs, height: 67 inches and body mass index (BMI): 29, enrolled in, a prospective observational safety study.  The subject's mother current conditions included increased BMI, bundle branch block, seasonal allergies and acid reflux.  The subject's mother's concomitant medications included Prenatal vitamins (unspecified vitamins and minerals) for pregnancy, Zantac (ranitidine hydrochloride) for acid reflux and Zyrtec (cetirizine hydrochloride) for allergies.  The subject's mother obstetrical history noted that the mother had no previous pregnancies. The subject's mother had no maternal or paternal history with major congenital malformations (MCMs). Also, the subject's mother had no history of offspring with MCM. The subject's mother did not use tobacco, alcohol or illicit drugs during pregnancy.   The subject's mother's last menstrual period (LMP) date was on 30-Jul-2019. The subject's mother's estimated delivery date (EDD) was reported as 05-May-2020, while corrected estimated delivery date (CEDD) was reported as 12-May-2020. The type of pregnancy was singleton. The subject's father age was not reported.  On 25-Sep-2019, the subject's mother underwent ultrasound and no MCMs were noted.  On 23-Oct-2019, the subject's mother underwent non-invasive prenatal testing and nuchal translucency. No MCMs were noted.   On 20-Nov-2019, at approximately 16 weeks of gestation, the subject's mother was administered Afluria QIV [influenza vaccine, subunit influenza virus vaccine polyvalent, cell cultured derived; batch number: P100112488, dose, route of administration, anatomical location and expiration date: not reported] (explicitly coded as Foetal exposure during pregnancy') for an influenza immunisation.   On the same day, the subject's mother underwent maternal serum alpha fetoprotein screening (MSAFP) and no MCMs were noted.  On an unspecified date in 2019, echogenic bowel was noted.  On 30-Dec-2019, the subject's mother underwent 20-week anatomy ultrasound, foetal ventricular septal defect was noted as MCM and echogenic bowel was ongoing.  At the time of this report, the subject did not recover from the event of foetal gastrointestinal tract imaging abnormal', while the outcome for the event of foetal cardiac disorder' was not reported.  The events of foetal gastrointestinal tract imaging abnormal' was considered as serious due to criterion of medical significance, per company.  The events of foetal cardiac disorder' was considered as serious due to criterion of medical significance and congenital anomaly, per company.  The causality assessment was not provided.  This case is linked to case number 202001666, corresponding mother case.  Company comment: A foetal subject developed foetal cardiac disorder (reported as ventricular septal defect) and foetal gastrointestinal tract imaging abnormal after his mother was vaccinated (on 20-Nov-2019) with the suspect product Flu Vaccine Egg Split QIV CSL for an influenza immunisation. Reportedly, on an unspecified date in 2019, echogenic bowel was noted. Chronology needs more clarification. The subject's mother current conditions included increased BMI, bundle branch block, seasonal allergies and acid reflux. The subject's mother's concomitant medications included Prenatal vitamins (unspecified vitamins and minerals) for pregnancy, Zantac (ranitidine hydrochloride) for acid reflux and Zyrtec (cetirizine hydrochloride) for allergies. Both reported concomitant drugs are on B1 list. According to FDA regulations cetirizine should not be used during pregnancy unless the benefit outweighs the risk to the fetus. With information presented, causality is assessed as unlikely related for both events considering provided confounders (mothers medical history, reported concomitant drugs and unclarified temporal relationship) Foetal exposure during pregnancy is considered unrelated per labelling conventions. (''unlikely related'' defaults to ""related"" in the safety database for reporting purposes); Sender's Comments: A foetal subject developed foetal cardiac disorder (reported as ventricular septal defect) and foetal gastrointestinal tract imaging abnormal after his mother was vaccinated (on 20-Nov-2019) with the suspect product Flu Vaccine Egg Split QIV CSL for an influenza immunisation. Reportedly, on an unspecified date in 2019, echogenic bowel was noted. Chronology needs more clarification. The subject's mother current conditions included increased BMI, bundle branch block, seasonal allergies and acid reflux. The subject's mother's concomitant medications included Prenatal vitamins (unspecified vitamins and minerals) for pregnancy, Zantac (ranitidine hydrochloride) for acid reflux and Zyrtec (cetirizine hydrochloride) for allergies. Both reported concomitant drugs are on B1 list. According to FDA regulations cetirizine should not be used during pregnancy unless the benefit outweighs the risk to the fetus. With information presented, causality is assessed as unlikely related for both events considering provided confounders (mothers medical history, reported concomitant drugs and unclarified temporal relationship) Foetal exposure during pregnancy is considered unrelated per labelling conventions. (''unlikely related'' defaults to ""related"" in the safety database for reporting purposes)",,Unknown,0,1
905609,"Dry Cough, Fatigue, Arthralgia, Low Grade Fever.",48.0,Adults,1,0
879160,"Vomiting; Fever; This is spontaneous report from a contactable consumer. A 11-month-old male patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13) on 15Nov2019 at single dose, diphtheria vaccine toxoid/pertussis vaccine acellular/tetanus vaccine toxoid (DTAP) on 15Nov2019 at unknown dose, hepatitis b vaccine on 30Aug2019 at unknown dose, hib vaccine on 15Nov2019 at unknown dose, polio vaccine inact (IPV VACCINE) on 15Nov2019 at unknown dose, rotavirus vaccine (ROTAVIRUS PENTAVALENT) on 15Nov2019 at unknown dose; all via an unspecified route of administration for immunization. Medical history included having feeding tube. Concomitant medications were none. The patient had vomiting. Due to the vaccines he had fever. He did not had any conditions before the vaccines, he was healthy. The patient underwent lab tests and procedures which included X rays, blood transfusions, abdominal ultrasounds, blood test. They had extracted his blood and ran for normal test and the reporter was still trying to receive the medical reports for the blood test. Outcome of the events was unknown. The lot number has been requested.",0.17,Kids,0,0
906628,"Red raised rash 48 hours after Extreme nausea and dizziness; Red raised rash 48 hours after Extreme nausea and dizziness; Red raised rash 48 hours after Extreme nausea and dizziness; This is a spontaneous report from a contactable healthcare professional.  A non-pregnant 45-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), intramuscularly on 15Dec2020 15:45 at a single dose for COVID-19 immunization.  Medical history included ulcerative colitis, hypothyroidism, allergies: sulfites. sulfa.  Concomitant medication included amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL), dhea (MANUFACTURER UNKNOWN), levothyroxine, liothyronine (NP THYROID), progesterone (MANUFACTURER UNKNOWN), fluoxetine hydrochloride (PROZAC), levothyroxine sodium (SYNTHROID), bupropion hydrochloride (WELLBUTRIN).  On 15Dec2020, the patient experienced red raised rash 48 hours after extreme nausea and dizziness.  No treatment was received from the events.  The outcome of the events was not recovered.     The batch/lot number for the vaccine, BNT162B2, was not provided and will be requested during follow-up.",45.0,Adults,0,0
901205,"was turned up sick; Initial information was received on 08-Nov-2020 regarding an unsolicited valid non-serious social media case from a consumer via Social media.  This case involves patient (unknown demography) who was turned up sick (illness), while the patient received vaccine INFLUENZA VACCINE.  Medical history, medical treatment(s), concomitant medications, vaccination(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious was turned up sick (illness) (unknown latency) following the administration of INFLUENZA VACCINE.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of report, the outcome was unknown for the event.  There will be no information available on the batch number for this case.",,Unknown,0,1
886657,"Patient called and said at night she had pain and couldn?t move her hand even for 10 degrees, she searched online and believes she has frozen shoulder. Advised her to contact her doctor or emergency room ASAP to be evaluated and treated and completed the report.",66.0,Seniors,1,0
883755,"No additional adverse effects reported; administered an improperly stored dose ofROTATEQ; This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On 01-SEP-2020, the patient was administered a dose of inappropriately stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (orally, lot # S038691, expiration date 12-MAY-2021 (also reported as 20-MAY-2021) (dose number not reported.) No additional adverse effects reported.  The reported temperature excursion was below ""36 degree of Fahrenheit: 35 degree of Fahrenheit"" through 20 minutes. There was no previous temperature excursion. The temperature excursions were detected by a Data Logger.",,Unknown,0,1
887684,lab confirmed hematochezia.  historically first on 9/28/2020.  lab + hemoccult 10/2/2020.  seen in office on 9/30/2020.  three neg hemoccult stool prior to the + one on 10/2/2020 and coinciding with grossly visible blood,0.17,Kids,0,0
905010,"Pain at injection site. 24hrs after injection site, my left arm started hurting and painful to the touch. At 48 hours, the injection site is very raised and red. It's approximately 3inches long by 2inches wide. It's very sensitive to the touch and very hot.  I went back to the medical clinic and was told to draw a circle around the site, and watch for further spreading, apply an ice pack, and submit this reaction to Vaers.",28.0,Adults,1,0
879241,"15 days post vaccination states he developed a large bruise, approx. 2.5"" x 2.5"" on the anterior aspect of his L upper arm. Denies pain, no swelling noted, area non tender and soft to touch. States he takes ""blood thinners"". Referred him to his PCP.",76.0,Seniors,1,0
911709,"On December 19th, I started feeling dizzy, having body aches, chills and was febrile. I had a temp of 103.7. I took a cool shower and Tylenol and my temperature decreased to 101.1 within 30 minutes. I drank a lot of fluids-water and sprite. I went to bed. In the morning, I felt a lot better. Still weak and tired and low grade fever. I took Tylenol and then was afebrile. I was just tired on December 20th. I have felt fine since.",47.0,Adults,0,0
887898,"the patient had inflammation redness from shoulder to elbow. it was difficult to move. pt said it started the afternoon/evening of imz.  she did not call us until today. she had a planned office visit with her md the friday after the imz , and it was better by that time. the imz was given 9-26-2020 and the office visit was 10-2-2020. the md stated that he felt it was due to the imz given in the same arm.",76.0,Seniors,0,0
2760384,"vaccines exposed at 30-32 degrees F for one hour due to opening and closing of refrigerator door/no AE; Initial information received on 19-Jun-2020 regarding an unsolicited valid non-serious case received from a physician.  This case is linked to cases 2020SA161183, 2020SA161064, 2020SA161181, 2020SA161182 and 2020SA161184(same reporter)  This case involves a 12 years old male patient who was vaccinated with MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] and DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] which was exposed at 30-32 degrees Fahrenheit for one hour due to opening and closing of refrigerator door(product storage error).  Medical history, concomitant therapy, medical treatment(s), vaccination(s) and family history were not provided.   On 10-Jun-2020, the patient received first dose 0.5 ml of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE (lot U6543AB and expiry date 23-Feb-2021) via intramuscular route in the right arm and first dose 0.5 ml of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (lot C5602AA and expiry date 19-Mar-2021) via intramuscular route in the left arm for prophylactic vaccination.  It was a case of an actual medication error due to product storage error temperature too low.  At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",12.0,Kids,0,1
878415,Swollen reddened l deltoid,11.0,Kids,0,0
901935,"flu; sick; Based on the additional information received on 08-Oct-2020, the case was initially assessed as non-valid was amended to valid since the suspect vaccine was incorrectly selected as Sanofi Product NOs in the initial version.    Initial information received on 02-Oct-2020 regarding an unsolicited non-valid non-serious social media case through global digital media received from a consumer (Patient).  This case is linked to case 2020SA297232, 2020SA297338, 2020SA297344, 2020SA297203, 2020SA297183, 2020SA297189, 2020SA297215, 2020SA297267, 2020SA297198, 2020SA297259, 2020SA297264, 2020SA297224, 2020SA297197, 2020SA297275, 2020SA297193, 2020SA297278, 2020SA297301, 2020SA297294, 2020SA295993, 2020SA290234, 2020SA285105, 2020SA289150, 2020SA297267 and 2020SA297164 (same source, cluster)  This case involved a 17 years old patient of unknown gender who was sick for two weeks (illness) with flu (influenza) while patient had received INFLUENZA VACCINE.  The patient's medical history, medical treatment(s), vaccination(s), concomitant medication and family history were not provided.  On an unknown date in 1969, the patient had a blood test done and the doctor said that the patient needed to be vaccinated with the flu vaccine.   On an unknown date in 1969, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number and expiry date not reported via unknown route at unknown administration site for prophylactic vaccination.  On an unknown date in 1969, reported 3 days post-vaccination the patient was sick (illness) due to flu (influenza) for two weeks. The patient also said that since then the patient had never received the INFLUENZA VACCINE again and thus never suffered from flu also.   It was not reported if the patient received a corrective treatment.  The event outcome was resolved at the time of reporting.  There will be no information available on the batch number for this case.  Additional information received on 08-Oct-2020.   The case amended as valid as company suspect product was added. new event flu was added. The lowest level term coding for event sickness was amended. Age of the patient was updated. the year of vaccination and the year of event was also updated. The event outcome was updated to recovered.   Corresponding fields and narrative updated accordingly.",17.0,Kids,0,1
871719,"Your child received a vaccination at our clinic during the period between February 28 and April 16, 2020. During the period between February 28th, 2020 and March 2nd, 2020, our data logger had a technical malfunction that we were not aware of and it stopped sending its temperature recordings to the system. During that period the fridge never stopped working. The temperature logs of the fridge before and after the incident were always within required range. Our fridge has been always in a perfect new condition and never had any temperature problems previously. There was no power outage in the area or inside the office during that period as well.    The CDC requires continuous temperature monitoring of all VFC vaccines and due to lack of continuous temperature data documentation, the vaccine manufacturers have determined that the doses administered on these dates should be re-administered to ensure proper effectiveness.",0.5,Kids,0,1
865621,"The vaccine did not prevent shingles as intended; herpes zoster or shingles; Information has been received from a lawyer regarding a case in litigation referring to a female patient of unknown age. Information about concurrent condition, medical history and concomitant therapy was not reported. In 2011, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dose, route, lot# and expiration date not reported) at a pharmacy, as recommended for routine adult health maintenance and for the long-term prevention of shingles. The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain of herpes zoster or shingles. In 2012, the patient was treated by a physician, for the onset of a severe vesicular rash, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the zoster vaccine live (ZOSTAVAX), and/or despite receiving zoster vaccine live (ZOSTAVAX) for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events herpes zoster and vaccination failure was not reported. The lawyer considered the events to be related to zoster vaccine live (ZOSTAVAX).",,Unknown,0,0
905867,"She c/o of numbness and tingling on left side of entire body.  98.8, 92,142/84, o2 sat 99, rr 16. denied other compliant. emerenccy response team called.  taken to ED",41.0,Adults,0,0
911249,"arm started to feel sore; injection site pain; This is a spontaneous report from a contactable consumer (patient). A 76-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number E9899, expiry date Mar2021) intramuscular on left arm on 17Dec2020 at single dose for COVID-19 immunization. The patient has no prior vaccinations within 4 weeks. Medical history included and concomitant medications were none. The patient got the COVID vaccine on Thursday (17Dec2020), her arm was still really sore (17Dec2020). The patient asked on how long will this last and was referred to healthcare professional. Full EUA PI, discussed incidence of injection site pain. No information on duration after 1st dose. The patient received the Covid vaccine around 10:30 on Thursday morning and her arm started to feel sore Thursday evening. The patient clarified that the vaccine was administered around 10:30AM to 11:00AM. The patient was advised to follow up with healthcare professional. The patient did not receive treatment for the events. The outcome of the events arm started to feel sore and injection site pain was recovering. The reporter informed that the vaccination facility type was a hospital and was not administered at a military facility.",76.0,Seniors,0,0
900110,"Fever of 101.3 for 12 hours--second day, fever of 99.8; third day, no fever.  Soreness, redness (Red patch on arm 4""x6"".  Still presenting on third day), swelling.  Flu-like symptoms with brain fog, body aches, fatigue, loss of appetite, nausea, strong headache, strong muscle pain--day one.  Second day--fatigue, low grade fever, nausea, and brain fog remained.  Third day--brain fog, fatigue, loss of appetite.  Experienced same with Shot 1.  Full recovery occurred after 7 days.  Brain fog presented as serious confusion--making wrong turns when driving, not recognizing surroundings, getting lost, not comprehending instructions and information.  No previous brain issues or reduced cognitive ability.  ER administered Vertigo medication to address brain fog after Shot 1.",62.0,Adults,1,0
862371,"Woke up 6 am went to the bathroom had dizziness, lightheadedness, anxiety, difficulty breathing,  stomach pain, sweating  and chilling, Nausea, and fainted.  Both hand were tingling and  fingers were closing unable to open. Called 911.  Fire and paramedics came took to hospital",58.0,Adults,1,0
889454,"Swelling, cellulitis L arm",17.0,Kids,0,0
867463,"DID NOT COMPLETE HER IMMUNIZATION ONE WEEK PRIOR TO TRAVEL; TOOK TWO UNREFRIGERATED DOSES; This spontaneous case (PVX2019-1443) was received from a consumer on 02-Jun-2019. It describes a 50-year-old adult female consumer who ""took two unrefrigerated doses"" and ""did not complete her immunization one week prior to travel "", while being on oral Vivotif (one capsule every other day) for typhoid prophylaxis.  Case report: The consumer did not refrigerate Vivotif doses and took two doses on 31-May-2019 and 02-Jun-2019, respectively. She had a planned trip on 09-Jun-2019.  Action taken with Vivotif was not applicable.  The clinical outcome of the events was unknown.  Company's Comment: The causality of the event ""took unrefrigerated doses"" and ""did not complete her immunization one week prior to travel"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took unrefrigerated doses"" and ""did not complete her immunization one week prior to travel"" was considered as not applicable.",,Unknown,0,0
883760,"reaction to pneumovax; pain from her arm to her chest after getting vaccine, having serious pain and swollen arm and headaches pain traveled up to her neck; pain from her arm to her chest after getting vaccine, having serious pain and swollen arm and headaches pain traveled up to her neck; pain from her arm to her chest after getting vaccine, having serious pain and swollen arm and headaches pain traveled up to her neck; pain from her arm to her chest after getting vaccine, having serious pain and swollen arm and headaches pain traveled up to her neck; pain from her arm to her chest after getting vaccine, having serious pain and swollen arm and headaches pain traveled up to her neck; This spontaneous report as received from a physician via a company representative refers to a 65-year-old female patient. The patient's medical history and concurrent conditions were not reported. However, it was reported that the patient experienced reaction to pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) on an unknown date.  On 09-SEP-2020, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (dose number, route of administration and dose volume were not reported) for pneumonia prophylaxis.        On 10-SEP-2020, after getting the vaccine, the patient experienced pain from her arm to her chest, having serious pain and swollen arm and headaches pain traveled up to her neck. The patient's outcome was not reported. Causality between the event of arm pain, chest pain, swollen arm, headache and neck pain was not reported. Causality between unspecified reaction to pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) and the vaccination with reaction to pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was assessed as related.  The reporting physician considered pain from her arm to her chest, having serious pain and swollen arm and headaches pain traveled up to her neck to be serious (medically significant).",65.0,Adults,0,0
915534,"Pt state she had one dose of Men-   B,Bex 10/05/20 and next day noted worsening skin rash on her torso and    arms worse near the site of injection, no feverhives, HA,or SOB    reported but rash spreading and very uncorfortable because of    itchiness.    SKIN/BREAST:   multiples mildly elevated erythematous patchy, very itchy    lesion both arms and torso, more intense Left lateral upper    arm near the site of the immunization.",24.0,Adults,1,0
861546,"redness at the injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 58-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced injection site erythema. On an unknown date, the outcome of the injection site erythema was not recovered/not resolved.   It was unknown if the reporter considered the injection site erythema to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient experienced injection site redness after receiving the Shingrix. The patient wanted to know how long could the redness at the injection site last.",,Unknown,0,0
909506,Brusing Pain Entire arm soreness Nerve tingling pain Fingers moving on their own,63.0,Adults,1,0
876002,"No additional AE; The nurse stated Pneumovax 23 that underwent a temperature excursion was administered; This spontaneous report was received from a nurse, concerning a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions or allergies, and concomitant medications were not reported.   On 16-JUN-2020, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) pre-filled syringe at the dose of 0.5 milliliter (ml), lot # S021740 with an expiration date reported and validated as 25-MAR-2021, for prophylaxis (dose number, route of administration and anatomical location were not reported). It was stated by the nurse that the vaccine underwent a temperature excursion (product storage error). No additional adverse events were reported, nor product quality complain involved.   It was reported that a data-logger was involved (captured in Marrs #2007USA002972).  This is one of the several reports received from the same reporter. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: S021740; expirationdate: 25-MAR-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2007USA002422:01631944 US-009507513-2007USA002972:01631948",,Unknown,0,1
866762,"arm was uncomfortable and sore; arm was uncomfortable and sore/the pain was unbearable, it felt like someone punched my arm; Indication: Covid-19; I can barely lift my arm to take off my shirt; By the time I went to bed I could barely sleep; The spot where I received it is swollen and hot to the touch; The spot where I received it is swollen and hot to the touch; This spontaneous report was received from a 47-year-old female patient reporting on herself. The patient's concurrent conditions included allergy induced asthma. Drug reactions or allergies included allergy to tetracycline. Pertinent medical history was not provided.  On 24-MAR-2020, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) one dose, administered in the right arm (exact dose, frequency, route of administration, lot# and expiration date were not provided) as she had asthma and was nervous about getting Covid-19.   After the vaccination, her arm was uncomfortable and sore. By the time she went to bed she could barely sleep, and the pain was unbearable. It felt like someone punched arm. She could barely lift her arm to take off her shirt. The spot where she received the vaccine was swollen and hot to touch. The patient took acetaminophen (TYLENOL) to treat the events. No laboratory diagnostics or studies were performed. The patient did not seek for medical attention. The outcome of the events was reported as not recovered.  The relatedness between the events and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was not reported.",,Unknown,0,0
871426,"Pain at the injection site; Swelling, hardness, redness and heat at the injection site; Immediately felt itching at the injection site; Swelling, hardness, redness and heat at the injection site; Swelling, hardness, redness and heat at the injection site; Swelling, hardness, redness and heat at the injection site; She was very upset; This is a spontaneous case initially received from other non-health professional (consumer) via agency (reference number: SEQ19-07498) on 17-Dec-2019, concerning an over 65-year-old female patient.   The patient's medical history was not provided. The patient's historical vaccine included Flucelvax (QIV) last year and the year before without any adverse reaction. The patient's concomitant medications were not provided.   On 22-Oct-2019, the patient was administered Flucelvax (QIV) [influenza vaccine, subunit influenza virus vaccine polyvalent; dose, route of administration, anatomical location, batch number and expiration date: not reported] for influenza prophylaxis.  On the same day, after vaccination, the patient immediately felt itching at the injection site. About an hour after the vaccination, the patient developed swelling, hardness, redness and heat at the injection site.   On the same day, the outcome of the event vaccination site itching was resolved.  On 23-Oct-2019, one day after vaccination, the patient developed pain at the injection site. The patient was very upset.   On 24-Oct-2019, the outcome of all events which occurred at the injection site was resolved. However, it was not reported whether the patient still was upset. It was unknown whether the patient received any corrective treatment for the events.  The reporter assessed all the events as non-serious and did not provide causality assessment to Flucelvax (QIV).  Company comment: The patient developed vaccination site warmth, anxiety, vaccination site pruritus, vaccination site swelling, vaccination site induration, vaccination site erythema, vaccination site pain on the same day after Flucelvax (QIV) was administered. Chronology is plausible. More information regarding medical history and concomitant medications is needed. Based on provided information, causal role of the suspect product is assessed as related for all events.; Sender's Comments: The patient developed vaccination site warmth, anxiety, vaccination site pruritus, vaccination site swelling, vaccination site induration, vaccination site erythema, vaccination site pain on the same day after Flucelvax (QIV) was administered. Chronology is plausible. More information regarding medical history and concomitant medications is needed. Based on provided information, causal role of the suspect product is assessed as related for all events.",,Unknown,0,0
900968,"Groin pain; Knee pain on the right side; Upper pain in his arms; Elevated c-reactive proteins; unable to move both arms; Diagnosed with Polymyalgia Rheumatica; Unable to move both arms; Myalgia; This case was reported by a nurse via call center representative and described the occurrence of polymyalgia rheumatica in a 70-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 9th September 2020, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, less than a week after receiving Shingrix, the patient experienced polymyalgia rheumatica (serious criteria GSK medically significant), paralysis of arms (serious criteria GSK medically significant), myalgia, groin pain, knee pain, pain in arm, c-reactive protein increased and mobility decreased. On an unknown date, the outcome of the polymyalgia rheumatica, paralysis of arms, c-reactive protein increased and mobility decreased were unknown and the outcome of the myalgia, groin pain, knee pain and pain in arm were not recovered/not resolved.   It was unknown if the reporter considered the polymyalgia rheumatica, paralysis of arms, myalgia, groin pain, knee pain, pain in arm, c-reactive protein increased and mobility decreased to be related to Shingrix.  Additional details were received as follows: The reporter was the wife of the patient and also a nurse.  Myalgia presented 2 to 3 days after the vaccine and continued throughout the month of October.  He visited a doctor on 15th September 20.  He had groin pain and knee pain on the right side.  He was referred to an orthopedist and had 4 appointments.  The knee pain was thought to be referred pain from the groin.  He had a shot in his knee on 2nd October 20 and 8th October 20.  On 15th Oct 20 and 28th October 20 he was seen for upper pain in his arms.  He was unable to move both arms.  He visited a rheumatologist  on 5h November 2020 and blood work showed elevated c-reactive proteins. He was diagnosed with Polymyalgia rheumatica. The reporter consented to follow up.",70.0,Seniors,0,1
828771,"double vision; and in the hospital with Transverse Myelitis; paralyzed/paralyzed waist down; loss sensation in bowel/oss sensation in her bladder and bowel/could not feel her feet/getting worse; could not lift her legs up or walk/ could not walk; could not lift her legs up or walk; super sensitivity from her elbows to her upper body/unable to take warm showers/hypersensitivity sensations; too scared; felt ill/got worse; numbness and tingling in her feet.; tingling in her feet.; feet are always cold; weakness in legs; MOG positive; ear infection/getting worse; when they took her blood pressure it was very painful; loss sensation in bladder; headache/got worse; neck pain/got worse; pressure in her ears/got worse; This case was reported by a consumer via interactive digital media and described the occurrence of myelitis transverse in a 55-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included urinary catheter insertion (placed an indwelling urinary catheter).   On 10th June 2019, the patient received the 1st dose of Shingrix. In June 2019, less than 2 weeks after receiving Shingrix, the patient experienced myelitis transverse (serious criteria hospitalization and GSK medically significant), paralysis (serious criteria hospitalization and GSK medically significant), loss of sensation (serious criteria hospitalization), unable to walk (serious criteria hospitalization), mobility decreased (serious criteria hospitalization), hypersensitivity (serious criteria hospitalization), double vision (serious criteria hospitalization), headache, neck pain, sensation of pressure in ear, loss of bladder sensation and pain. On 18th June 2019, the patient experienced ear infection. On an unknown date, the patient experienced fear, feeling unwell, numbness in feet, tingling of extremity, cold feet, lower extremities weakness of and anti-myelin-associated glycoprotein antibodies positive. The patient was treated with antibiotics nos (Antibiotic (Details Unknown)), steroids nos (Steroid (Not Specified)) and rituximab (Rituxan Infusion). On an unknown date, the outcome of the myelitis transverse, paralysis, loss of sensation, mobility decreased, double vision, fear, headache, neck pain, sensation of pressure in ear, feeling unwell, loss of bladder sensation, ear infection, pain and anti-myelin-associated glycoprotein antibodies positive were unknown and the outcome of the unable to walk was recovered/resolved and the outcome of the hypersensitivity, numbness in feet, tingling of extremity, cold feet and lower extremities weakness of were not recovered/not resolved.   It was unknown if the reporter considered the myelitis transverse, paralysis, loss of sensation, unable to walk, mobility decreased, hypersensitivity, double vision, fear, headache, neck pain, sensation of pressure in ear, feeling unwell, loss of bladder sensation, ear infection, pain, numbness in feet, tingling of extremity, cold feet, lower extremities weakness of and anti-myelin-associated glycoprotein antibodies positive to be related to Shingrix.  Additional details were reported as follows: The patient felt ill after receiving the 1st dose of vaccine, she experienced headache, neck pain and pressure in her ears. She slowly got worse and loss sensation in her bladder and bowel. On 18th June 2019, she went to urgent care and was told she had an ear infection and was given an antibiotic shot along with an antibiotic prescription. She continued getting worse, she could not lift her legs up or walk so her husband took her to the emergency room on 22nd June 2019, and they placed an indwelling urinary catheter and she was sent to home. On 23rd June 2019, patient went to her doctor who admitted her into the hospital. By then she was paralyzed waist down and could not feel her feet and was experienced super sensitivity from her elbows to her upper body, she stated that when they took her blood pressure it was very painful. The patient started to slowly recover after she received steroid treatment in the hospital. She also experienced double vision after starting steroid treatment. After 12 days of hospitalization and rehab she was discharged. The patient was able to walk but had numbness and tingling in her feet. She had computer tomography scan, which was negative, her first MRI was positive for Transverse Myelitis. After treatment her MRI came back negative for inflammation or lesions of the spinal cord. Currently she was being treated and was receiving Rituxan infusion every six months. The infusion is scheduled for 8 hours first day and 15 days later for 4 hours. She had been tested for multiple scelerosis and Lyme's Disease which were negative, but myelin oligodendrocyte glycoprotein came back positive, she was told that it might be a false positive and was still being evaluated for possible myelin oligodendrocyte glycoprotein. Currently she was working on improving sensation of her bladder and bowel, and was still experiencing numbness and tingling in feet, her feet were always cold, and weakness in legs. At the time of reporting, patient was unable to take warm showers and had to take cool showers because she was still experiencing hypersensitivity sensations and tingling. The patient stated that she was ended up paralyzed and in the hospital with Transverse Myelitis aftr vaccination and was too scared. No other vaccines were received by her. The reporter consented to follow up.",55.0,Adults,0,1
910616,"Approximately 4 hours after vaccine, noted hives/welts on arms, took cetirizine. Went to bed. ~8pm (4 hours later) was very itchy, swollen, discolored face, face felt cold/body hot. No difficulty breathing.  Lips purplish, arms swollen.  Went to ED.  Given benadryl, 2 other pills, watched for 30 minutes.   No epinephrine.  Hives improved, released,  had headache.  Next day improved, but still mild headache and groggy.  Hives gone completely 48 hours. Mild headache persists.  No prior experience like this.",30.0,Adults,0,0
898626,"ITCHY THROAT,  EYE SWOLLEN SHUT, INSIDE MOUTH SWOLLEN, COVERED IN HIVES",12.0,Kids,0,0
900789,no adverse affect at time of dosage,1.08,Kids,0,0
885050,Left arm / shoulder pain past 10-14 day,,Unknown,1,0
912661,Swelling redness and bump at injection site,27.0,Adults,0,0
877139,3 CM NODULE LEFT ARM,16.0,Kids,0,0
900676,Large round (3 inch diameter) swollen and hot red area at injection site.  Headache.,58.0,Adults,1,0
881751,"Itchiness at the injection site; swelling at the injection site; Initial information received on 26-Aug-2020 regarding an unsolicited valid non-serious case received from a nurse.  This case is linked to cases 2020SA232560, 2020SA229965 and 2020SA231710 (same reporter).  This case involves a female patient (aged 20-30 years) who experienced itchiness at the injection site (vaccination site pruritus) and swelling at the injection site (vaccination site swelling), while she received vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  No concomitant medication was given.   On an unknown date, the patient received 0.5 mL dose (once) of suspect INFLUENZA QUADRIVAL A-B VACCINE (Pre-filled syringes) (lot UJ432AB and expiry date 30-Jun-2021) via unknown route in the deltoid(not otherwise specified) for prophylactic vaccination.  On an unknown date, the patient developed non-serious itchiness at the injection site (vaccination site pruritus) and swelling at the injection site (vaccination site swelling) (Unknown latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  Details of laboratory data were not reported.   It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event was reported as unknown.",,Unknown,0,1
887624,"Medical assistant calling to report a temperature excursion that occurred 8/14/2020 which involved the following products: GARDASIL9, PEDVAXHIB, RECOMBIVAX, ROTATEQ. Per caller, ""it would be possible that at least 100 patients have received vaccines; This spontaneous report was received from a medical assistant, concerning a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies or concomitant medications were not reported.  On 11-SEP-2020, the patient was vaccinated with an improperly stored dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) as prophylaxis (lot # T011167 with expiration date 27-MAY-2022) (strength, frequency, route of administration and anatomical location were not reported).  The improperly stored dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) experienced a temperature excursion of 35.4 Fahrenheit degrees (F) for the time frame of 20 minutes without previous temperature excursions. It was confirmed that a digital data logger was involved.  This is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2009USA006106:",,Unknown,0,1
883842,"Per Son of patient - he mentioned that many hours after patient received vaccine that he called and reported shaking uncontrollably. The patient was taken to the hospital by the son and it was reported that a cardiac enzyme was elevated and patient was treated in ER for 6 hours. Son states that MD was not sure if it was a reaction to the vaccine but stated it was possible. Patient had no prior history of allergy to flu vaccine or components. Patient had a regularly scheduled appt with primary care MD on the following week and it was recommended to also let MD know to put note in chart. Per the son, not further issues or adverse reacts have come about since patient got home from hospital",87.0,Seniors,0,1
884362,"received dose 1 of Shingrix in June 2019, dose 2 in December 2019. He states he was diagnosed with shingles on August 1, 2020 / your vaccine, which didn't work in my case/ vaccination failure; shingles / having shingles; received 2nd dose after 1 month 24 days; This case was reported by a consumer via call center representative and described the occurrence of vaccination failure in a 72-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included lymphoma (non Hodgkin lymphoma).   On 21st October 2019, the patient received the 1st dose of Shingrix. On 15th December 2019, the patient received the 2nd dose of Shingrix. In December 2019, not applicable after receiving Shingrix and unknown after receiving Shingrix, the patient experienced drug dose administration interval too short. On 1st August 2020, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. The patient was treated with valaciclovir hydrochloride (Valacyclovir Hydrochloride). On 5th August 2020, the outcome of the shingles was recovered/resolved. On an unknown date, the outcome of the vaccination failure and drug dose administration interval too short were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.  Additional details were reported as follows: The patient received 2 doses of Shingrix and diagnosed with shingles on 1st August 2020. The patient started valcyclovir Hcl treatment and symptoms resolved on 5th August 2020. The date of the second vaccine was unknown, but the consumer thought it was 15th December 2019. The patient stated that vaccine did not work in his case. The patient received 2nd dose of Shingrix, before than the recommended interval, which led to shortning of vaccination schedule. The reporter consented to follow up.",71.0,Seniors,0,1
872976,"No patients experienced any adverse effects; Improperly stored dose of ROTATEQ; This spontaneous report was received from a physician concerning a patient of unknown age and gender. No information was provided regarding the patient's pertinent medical history, concomitant medications, or drug reactions/allergies.     On 04-MAY-2020, the patient was vaccinated with an improperly stored dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) vial (product storage error), by oral route (lot # 1660693, has been verified to be a valid lot number; expiration date 19-MAR-2021) as prophylaxis (dosage schedule and strength were not reported).   The administered dose of the vaccine experienced a multiple temperature excursions below highest temperature above 47 Fahrenheit degrees  to 66.6 Fahrenheit degrees for 2 hours and lowest temperature below 36 Fahrenheit degrees to 33.6 Fahrenheit degrees  for 45 minutes as recorded by a data logger. There was no previous temperature excursion. There was no adverse effect reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2006USA001703:",,Unknown,0,1
909918,"Immediately after receiving vaccine recipient stated that he felt faint. Eyes rolled back and he became limp. Two nurses laid him on floor. He came to within seconds but was diaphoretic. Vitals were checked and monitored (BP 130/70, 118/74, 120/72; pulse 57, 72, 68; pulse ox 98%, 99%, 99%). He quickly felt better (within a few minutes), was given water, chocolate and a granola bar. He stayed in observation a total of 35 minutes. He reports that he had been very nervous about getting a vaccination. He returned to his unit with a colleague. We checked in with him a few hours later and he reported that he felt well.",24.0,Adults,0,1
897039,"1. Body Aches 2-Days 24 HRS 2. Chills- 24 HRS 3. Fatique - 4-5 days 4. Temperature -99.7 - 12 Hours 5. Severe Redness, Swelling and tenderness at shot site for 5 days.  Began Oct6 @ 1:30 pm",65.0,Adults,1,0
858413,"first the legs had a sharp fire like pain,still feels in the hands and arms feels like an electric shock that travels down the arm; swelling in the hands; weakness in both leg muscles; straining to be able to stand; fallen down 4-times due to tripping or the legs giving out; allergic reaction to the vaccine; Initial information received on 14-Jan-2020 regarding an unsolicited valid non-serious case from a consumer.  This case involves a 76 years old male patient who experienced first the legs had a sharp fire like pain, still feels in the hands and arms feels like an electric shock that travels down the arm (pain), swelling in the hands (peripheral swelling), weakness in both leg muscles (muscular weakness), straining to be able to stand (muscle strain), fallen down 4-times due to tripping or the legs giving out (fall) and allergic reaction to the vaccine (allergy to vaccine), while he received INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE].  The patient's past medical history included Rotator cuff syndrome with that his symptoms did disappear for a week following steroid shots he received to treat pain in the rotator cuffs; that the pain in the rotator cuffs began prior to getting the Fluzone High dose and received three injections in the rotator cuff area with each treatment, Diabetes mellitus with mild diabetes that he has been taking pills for 10 years to treat; and Blood cholesterol decreased with lower cholesterol he was placed on simvastatin. It was reported that same weakness and pain symptoms he has had with the Fluzone HD; that he could barely walk then and it would take 5-minutes to get up; that the symptoms did go away a month after he stopped taking the simvastatin that before his mother passed away she suffered from Myasthenia gravis and had weakness; that his mother was treated with prednisone that helped her weakness; and that he has is not Myasthenia gravis like his mother due to differing symptom presentation.  Past medical treatment was not provided.  On 13-Sep-2019, the patient received a 0.5 ml dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE (lot W238AA and expiry date: 14-Apr-2020) via intramuscular route in the left arm.  On an unknown date, the patient developed a non-serious first the legs had a sharp fire like pain, still feels in the hands and arms feels like an electric shock that travels down the arm (pain), swelling in the hands (peripheral swelling), weakness in both leg muscles (muscular weakness), straining to be able to stand (muscle strain), fallen down 4-times due to tripping or the legs giving out (fall) and allergic reaction to the vaccine (allergy to vaccine) (unknown latency) following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE. It was reported that volunteering with 4 organizations; that he volunteers his services as a handyman; that he is unable to do anything but attend meeting.  Relevant laboratory test results included: Electromyogram - On an unknown date: [Electromyography (EMG) but the consumer was unable to complete the test; that he was unable to complete the test due to not being able to take the discomfort of the testing of the head area; that he did complete the test with the legs and was told the legs were okay]  Other relevant tests included 10- vials of blood drawn for testing and waiting results. It was also the neurologist is next planning to perform a muscle biopsy; that he will see the prescriber on 20Jan2020 on Monday.  Final diagnosis were pain, peripheral swelling, muscular weakness, muscle strain, fall and allergy to vaccine.  It was not reported if the patient received any corrective treatment.  On an unknown date, the patient had not recovered from the all events.",,Unknown,0,0
867935,"Social problem; This case was reported by a pharmacist via call center representative and described the occurrence of social problem in an adult patients who received Herpes zoster (Shingrix) for an unknown indication.   Previously administered products included Shingrix (received 1st dose on an unknown ).   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced social problem. The action taken with Shingrix was unknown. On an unknown date, the outcome of the social problem was unknown.  Additional details were received as follows: The age at vaccination was no applicable for this report.  The patient reported that a number of her patients would not be able to receive the second dose of Shingrix within six months after dose 1 due to the SARS-CoV-19 outbreak.",,Unknown,0,0
909902,"10 minutes after receiving vaccine patient complained of head heaviness, palpitations and feeling hot in the ears.  BP = 166/97, HR = 129, O2 SAT = 100%, Temp. = 98",45.0,Adults,0,1
900066,"losing weight; loss my sense of taste; Initial information received on 30-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer.  This case involves a patient of unknown age and gender who experienced losing weight (Weight decreased) and loss my sense of taste (Ageusia), while he/she received vaccine INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE [FLUZONE].  Past medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.   On an unknown date, the patient received a dose  dose of suspect INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE [lot number and expiry date not reported] via unknown route at an unknown administration site for vaccination.  On an unknown  date (unknown latency), the patient developed a non-serious losing weight (weight decreased) and loss my sense of taste (ageusia)following the administration of INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE.  Final diagnosis was loss my sense of taste and losing weight.   It was not reported if the patient received a corrective treatment.  The patient outcome was reported as Unknown for losing weight and for loss my sense of taste.",,Unknown,0,1
892226,"10/20/2020 Child presents to parents upon waking with localized swelling and bruised right upper arm following vaccination the previous afternoon. Reports her ?arm really hurts? rates pain 6/10 using Wong-Baker FACES scale. Child is guarded with arm, and cries when being dressed. Body temperature 97.8 F, BP and pulse within normal range. Radial pulse strong and equal bilaterally. 200mg Ibuprofen administered PO Q6h for pain.  10/21/2020 Bruising is diminished, but erythema and edema (1+) are present at injection site and immediately surrounding tissue. Firmness detected in deltoid muscle not present on opposite non-injected arm. Pain reported at 4/10. Child remains guarded with arm, will not allow parents to dress her. Winces when raising affected arm above shoulder level. Body temperature 98.1 F, BP and pulse within normal range. Radial pulse strong and equal bilaterally. 200mg ibuprofen administered Q6 h for pain. 10/22/2020 Erythema and edema (1+) extending from shoulder to elbow. Firmness in deltoid has increased, and is visible from a profile view. Swelling visible and noticeable without close inspection. Pain not reported, but child will still not allow parents to assist in dressing. Winces when arm is touched, or raised above shoulder level. Body temperature 98.1 F, BP and pulse within normal range. Radial pulse strong and equal bilaterally.  10/23/20 Erythema and edema (1+) extend from shoulder to elbow, erythema splotchy v. contiguous in nature. Firmness in deltoid has increased further. Child does not want to move arm above shoulder level, says ?it pinches.? Denies pain. Body temperature 97.9F, BP and pulse within normal range. Radial pulse strong and equal bilaterally. Pediatrician notified. Will continue to monitor for signs of infection and range of motion.",4.0,Kids,1,0
877307,Patient was given an expired vaccine. The vaccine expired on 7/7/2020. Patient was informed of the problem and knows she needs to come back for another immunization to complete the series.,31.0,Adults,0,1
913671,"Pfizer BioNTech COVID vaccine dose 1, felt lip tingling and sweating 90 minutes post vaccination Observed in ED",41.0,Adults,0,1
881563,The vaccine refrigerator went out and compromised the MMR vaccines making it invalid at time of administration. No adverse effects were reported. Patient to be revaccinated.,1.17,Kids,0,1
879993,"no adverse effects; The patient was administered doses of improperly stored vaccines; This non-valid spontaneous report as received from a nurse and refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical histories provided.  On unknown dates since 31-DEC-2019, the patients were vaccinated with improperly stored doses of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) lot # 1621931, expiration date on 26-JAN-2022, measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) rHA, lot# R008690, expiration date on 22-MAR-2020, haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) lot# S023219, expiration date on 03-MAR-2022, measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) rHA, lot# S030093, expiration date on 24-MAR-2021, and varicella virus vaccine live (oka/merck) (VARIVAX) lot# R020673, expiration date on 18-JUL-2020 (dose and route of administration were not provided for all). There was no adverse effect reported.  Administered doses of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) and haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) experienced the temperature excursion above 9 degrees Celsius (15.5C) for 4 hour and 6 minutes.  Administered doses of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) and varicella virus vaccine live (oka/merck) (VARIVAX) experienced the temperature excursion between -14 and -10 degrees Celsius (-11.2C) for 3 hour and 42 minutes.  Digital data logger was involved. There were no previous temperature excursions reported. The outcome was provided as ""supported"".  This report is non-valid due to lack of patients' identifiers.  As of 30-JUL-2020, all telephone attempts to obtain follow-up information have been unsuccessful.  Follow-up information was received by the registered nurse on 12-AUG-2020. This case refers to a specific patient (gender and age not reported). No information was provided regarding the patient's medical history, concurrent conditions, previous drug reactions, allergies and concomitant medications. It was confirmed that on 03-MAR-2020 at 08:57, the patient was vaccinated with an improperly stored dose of haemophilus b conjugate vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAXHIB) lot # S023219, at a dose of 0.5 mL intramuscularly (IM) on the left thigh (LT) and at 09:00, with an improperly stored dose of diphtheria toxoid, hepatitis B virus vaccine rHBsAg (yeast), pertussis acellular 3-component vaccine, poliovirus vaccine inactivated (Vero), tetanus toxoid (PEDIARIX) lot # YS4Z5 (expiration date not reported), at a dose of 0.5 mL IM on the right thigh (RT).  This case was previously considered non-valid but per new information received (patient identifiers) it was determined to be valid.  This is one of several cases received from the same reporter.; Sender's Comments:  US-009507513-2008USA008884: US-009507513-2008USA008879: US-009507513-2008USA008880: US-009507513-2008USA008878: US-009507513-2008USA008888: US-009507513-2008USA008881: US-009507513-2008USA008886: US-009507513-2008USA008876: US-009507513-2008USA008877: US-009507513-2008USA008882: US-009507513-2008USA008875: US-009507513-2008USA008883: US-009507513-2008USA008885: US-009507513-2008USA008887: US-009507513-2008USA008889: US-009507513-2008USA008890: US-009507513-2008USA008891: US-009507513-2008USA008892: US-009507513-2008USA008893: US-009507513-2008USA008894: US-009507513-2008USA008895: US-009507513-2008USA008896: US-009507513-2008USA008897: US-009507513-2008USA008898: US-009507513-2008USA008899: US-009507513-2008USA008900: US-009507513-2008USA008901: US-009507513-2008USA008902: US-009507513-2008USA008903: US-009507513-2008USA008904: US-009507513-2008USA008905: US-009507513-2008USA008906: US-009507513-2008USA008907: US-009507513-2008USA008908: US-009507513-2008USA008909: US-009507513-2008USA008910: US-009507513-2008USA008911: US-009507513-2008USA008912: US-009507513-2008USA008913: US-009507513-2008USA008914: US-009507513-2008USA008915: US-009507513-2008USA008916: US-009507513-2008USA008917: US-009507513-2008USA008918: US-009507513-2008USA008919: US-009507513-2008USA008920: US-009507513-2008USA008921: US-009507513-2008USA008922: US-009507513-2008USA008923: US-009507513-2008USA008924: US-009507513-2008USA008925: US-009507513-2008USA008926: US-009507513-2008USA008927: US-009507513-2008USA008928: US-009507513-2008USA008929: US-009507513-2008USA008930: US-009507513-2008USA008931: US-009507513-2008USA008932: US-009507513-2008USA008933:",,Unknown,0,1
915519,"Area of erythema approx. 10cm x8cm with satellite are approx. 2 cm beyond the inner red area.   Warm to the touch, not raised, blanches easily.   Told to monitor and take claritin or allegra OTC.",27.0,Adults,0,0
888955,"Sore arm (4-5 hrs); flu like symptoms (6-7 hrs) - full on flu symptoms, pain in muscles, joints, headache, fever (102 F) chills, insomnia (7-15 hrs).",50.0,Adults,1,0
856978,"improperly stored vaccine administered; no adverse effect; This spontaneous report as received from an office manager refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.       On an unknown date, the patient was vaccinated with improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) (lot # S021925, expiry date : 15-JUL-2021) for prophylaxis. Other suspect therapies included sterile diluent(MERCK STERILE DILUENT). It was unknown if diluent used to reconstitute was stored at proper temperature.    It was reported that the vaccine experienced a temperature excursion total time in the range of 6 degrees Fahrenheit (F) to 14 degrees F (-14 degrees Celsius (C) to - 10 degrees C) for 30 minutes, 15 degrees F to 46 degrees F (-9 degrees C to 8 degrees C) for 7 hours and 47 degrees F to 77 degrees F (9 degrees C to 25 degrees C) for 9 hours (product storage error). There was no previous temperature excursion and it was reported that this call was due to a digital data logger. The patient had no adverse events. There was no product quality compliant involved.   This is one of the several reports received from the same reporter.; Sender's Comments:  US-009507513-2001USA005586:Original Case : 2001USA005586",,Unknown,0,1
890461,"Patient woke up with a red circle near the site of injection, it was tender to the touch, and hot and swollen. Patient states it was sore only ,and no shortness of breath.",62.0,Adults,0,0
912145,Pressure in ears that started approximately 3 hours and 40 minutes after vaccination. Pressure is reported in both ears but more prominent in the left ear. Patient came back to immunization clinic under direct observation for additional 30 minutes after symptoms started. Symptoms still present.,51.0,Adults,0,0
871889,"Your child received a vaccination at our clinic during the period between February 28 and April 16, 2020. During the period between February 28th, 2020 and March 2nd, 2020, our data logger had a technical malfunction that we were not aware of and it stopped sending its temperature recordings to the system.  During that period the fridge never stopped working. The temperature logs of the fridge before and after the incident were always within required range. Our fridge has been always in a perfect new condition and never had any temperature problems previously. There was no power outage in the area or inside the office during that period as well.       The CDC requires continuous temperature monitoring of all VFC vaccines and due to lack of continuous temperature data documentation, the vaccine manufacturers have determined that the doses administered on these dates should be re-administered to ensure proper effectiveness.",0.17,Kids,0,1
857276,"girl dies hours after getting HPV vaccine; This spontaneous report as received from a journalist refers to a female patient of unknown age. No information regarding the patient's concurrent conditions, medical history and concomitant medications was provided.  On an unknown date, the patient was vaccinated with quadrivalent human papillomavirus (types 6,11,16,18) recomb. Vaccine (GARDASIL) (lot number, expiration date, dose, frequency and route of administration were not reported) for prophylaxis.  On an unknown date, hours after getting HPV vaccine, the patient died. It was unknown if an autopsy was performed.  The relatedness between the patient's death and quadrivalent human papillomavirus (types 6,11,16,18) recomb. Vaccine (GARDASIL) was not reported.",,Unknown,0,1
889735,"Patient received PPSV 23 at her visit on 10/12/2020 at 10:45am, by dinner time that day the injection site was itchy and sore with rash on inferior upper arm. The rash then continued to spread to back, abdomen and chest. Was seen in office on 10/14/2020 for evaluation.",68.0,Seniors,1,0
879298,"I am a healthy and highly active/athletic 66 woman. I had the ppsv-23 injection two days ago. Within 2 hours I began to have severe side effects. These have included extreme pain, edema, redness, and burning in the entire upper arm. I have greatly decreased arm mobility making dressing and performing even the smallest of tasks painful and nearly impossible.  I cannot lie in bed on that side thus rendering sleep tortuous. Additional side effects from this shot have included a bad headache, fatigue, myalgia, and chills. I have been taking Benadryl and Advil and have been icing the upper arm, all of which have helped somewhat. I hope these symptoms/side-effects will dissipate. I will never take this vaccine again nor can I recommend it to anyone. Merck Pharmaceutical, maker of ppsv23 should remove this money-maker from the market.",66.0,Seniors,0,0
905759,"Repetitive intense sneezing night of vaccination which ended with overnight sleep.  Arm pain the next day followed by swelling of lymph nodes with intense aching pain. Swelling lasted 24 hours, pain in lymph nodes has now lasted 36 hours.",40.0,Adults,1,0
898996,"has had nerve pain radiating the neck to the finger on the right arm; has had difficulty sleeping; This case was reported by a pharmacist via call center representative and described the occurrence of nerve pain in a 73-year-old female patient who received Herpes zoster (Shingrix) (batch number AG7M9, expiry date 6th May 2022) for prophylaxis.   On 11th November 2020, the patient received the 1st dose of Shingrix (intramuscular). On 11th November 2020, immediately after receiving Shingrix, the patient experienced nerve pain and difficulty sleeping. On an unknown date, the outcome of the nerve pain and difficulty sleeping were not recovered/not resolved.   It was unknown if the reporter considered the nerve pain and difficulty sleeping to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in the right arm. Since the vaccination, the patient had nerve pain radiating from the neck to the finger on the right arm and difficulty sleeping due to the nerve pain. Till the time of reporting nerve pain and difficulty sleeping was ongoing. No further details were provided. The reporter did not consent to follow up. This case has been linked to US2020228544, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020228544:Same Reporter",73.0,Seniors,1,0
912811,"Chills, Shortness of Breath, Chest Pain, Arm Pain",64.0,Adults,1,0
902821,"Fatigue, nausea, muscle aches",33.0,Adults,1,0
905761,"At one and a half hours after receiving her vaccine, developed tongue and throat swelling, went immediately to the ER. She was treated in the ER and was discharged to home with EPI pen. She still has the following symptoms headache, dizziness, lightheaded, fever 99.2. Difficulty concentration and talking. She is following up with her primary care physician on 12/21/2020",50.0,Adults,0,0
905938,Passed out/numb arm,19.0,Adults,0,0
879130,"a bruise on his left arm / of the bruise and she described it as pretty large; This case was reported by a pharmacist via call center representative and described the occurrence of bruising of arm in a 75-year-old male patient who received Herpes zoster (Shingrix) (batch number 453S4, expiry date 19th March 2022) for prophylaxis.   On 31st July 2020, the patient received the 2nd dose of Shingrix (intramuscular). On an unknown date, less than a week after receiving Shingrix, the patient experienced bruising of arm. On an unknown date, the outcome of the bruising of arm was not recovered/not resolved.   It was unknown if the reporter considered the bruising of arm to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in left arm and had bruise on his left arm where he received the Shingrix vaccination.   The patient could not lift his shirt for the pharmacist to see the entire bruise, however, she saw the bottom half of the bruise and she described it as pretty large in size. The reporter consented to follow up. The reporter could follow up with the Pharmacist directly.",75.0,Seniors,0,0
915254,"Moderna COVID-19 Vaccine: Arm started itching with bumps around injection site on 12/30/20 and started feel fatigued, when I woke up at 4:41 am on 12/31/2020 the rash had spread over my upper left arm, left shoulder, front chest area and under both breast. I also feel very tired, scratchy throat, runny nose and headache",50.0,Adults,0,0
856299,"Patient received a Diluent of the DTap/IPV and not the Hib of the Pentacel.; Initial information received on 16-Dec-2019 regarding an unsolicited valid non-serious case received from a nurse.  This case involves a 6 months old female patient who was vaccinated with 0.5 ml diluent of the dtap/ipv and not the hib of the vaccine DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL] via intramuscular route in the left thigh on 13-Dec-2019. The lot number U6218AA, UJ015AAA and UJ015AAA and expiry date: 26-Oct-2020.  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included PNEUMOCOCCAL VACCINE CONJ 13V (CRM197) (PREVNAR 13); INFLUENZA VACCINE INACT SPLIT VIRION 4V (FLUZONE QUADRIVALENT); and ROTAVIRUS VACCINE LIVE REASSORT ORAL 5V (ROTATEQ).  It was actual medication error due to inappropriate reconstitution technique.  At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
894496,"terrible chills, fever 102-103, uncontrollable shaking for all that night , nausea, headache, fatigue took ibuprofen, stayed in bed. fever lasted 2 days. nausea lasted thru 1st night, headache and fatigue  lasting 3 days.",65.0,Adults,1,0
864540,"I was given a flu vaccine at work on my left arm. The administering nurse gave it too high up on my shoulder. When she gave it she said ""Oh I think I got it in your bone, you are just too skinny."" She didn't pinch the muscle. I had pain for a few days and it kept getting worse and worse. I couldn't move my arm without pain. I got a steroid shot a few weeks later on 10/14/19.. It helped for about a week or two then I was seen by my work's wellness center on 10/30 and 11/6 and was referred to occupation medicine and physical therapy for bursitis/tendonitis/SIRVA (shoulder injury related to vaccine administration). I went to 7physical therapy sessions and have seen occupational therapy every 1-3 weeks since November. I am finally feeling better and am able to move my shoulder without pain.",34.0,Adults,0,0
911784,14 hours after injection woke up with swollen upper lip and extreme systemc itching. Took 50 mg Benadryl. 12/26/2020 at 0900 continued itching took claritin 10mg and 25 mg Benadryl lip still swollen.12/26/2020 @2000 took 25mg benadryl for itching lip no longer swollen. 12/27/2020 itching has now become burning sensation systemically took 25 mg benadryl and 10mg Claritin. Upper lip swollen 12/27/2020 @ 2000 took 25 mg benadryl for continue burning and itching Lip no longer swollen. 12/28/2020 @ 0600 took 10 mg claritin till itching no burning. 12/28/2020 at 2100 took benadryl 25 mg for continued itching. 12/29/2020 0600 took claritin 10 mg for itching.,60.0,Adults,0,0
903903,"Runny nose, body aches, fatigue, slight nausea",61.0,Adults,1,0
855836,"Give influenza vaccines in left deltoid on 11/4/19. Initially had localized achiness and pain but 1 week later developed redness, swelling and tenderness. The pain continued in the left deltoid area. Continues to have pain but does have decreased ROM including difficulty removing jacket. Determined to have post influenza vaccine subdeltoid bursitis. Will start Physical therapy 2-3 times per week, take Ibuprofen prn and continue to use warm packs.",57.0,Adults,0,0
869293,"DID NOT COMPLETE IMMUNIZATION ONE WEEK PRIOR TO TRAVEL; SORE THROAT; PAIN IN LYMPH NODES; CONGESTION IN HER CHEST/ COUGH; CONGESTION IN HER CHEST/ COUGH; PAIN IN JOINT; LOSE BOWELS; PAIN IN STOMACH; NAUSEA; FELT BAD; This spontaneous case report was received from a consumer (PVX2019-524) on 25-Feb-2019. The report described a female consumer (weight: 150 pounds/ 68 kg and height: 5 feet 6 inch/ 167 cm) who felt bad and also experienced sore throat, pain in joints, pain in lymph nodes, pain in stomach, congestion in chest/ cough, nausea, and lose bowels following the intake of Vivotif (lot no: 3003239 and expiry date: Oct 2019) for vaccination. The consumer ""did not complete immunization one week prior to travel"".  The consumer's concurrent medical condition included high blood pressure for which she was taking Lisinopril (10 mg; once in a day).  It was reported that the consumer took the first dose of Vivotif on 21-Feb-2019, after that she felt bad. She took the second dose on 23-Feb-2019, and after that, she experienced sore throat, pains in her joints, lymph nodes, and stomach, congestion in her chest/ cough, nausea, and lose bowels. Her third dose was due today. She stated that the vaccine made her sick.  The consumer took Tylenol (paracetamol) for treatment and she also took OTC (over the counter) medicine for cold and cough on 25-Feb-2019.  The consumer had no laboratory test.  The action taken with Vivotif with respect to the events sore throat, pain in joints, pain in lymph nodes, pain in stomach, congestion in chest/ cough, nausea, and lose bowels was unknown, while with respect to the event felt bad was vaccine maintained and with respect to event ""did not complete immunization one week prior to travel"" was not applicable.  The clinical outcome of the events sore throat, felt bad, pain in joints, pain in lymph nodes, pain in stomach, nausea, lose bowels, and ""did not complete immunization one week prior to travel"" was unknown while with respect to the event congestion in chest/ cough was resolving.  Company's Comment: In this case, a female consumer experienced the event ""felt bad"" following the administration of Vivotif. She also experienced the following events ""sore throat, pain in joints, pain in lymph nodes, pain in stomach, congestion in chest/ cough, nausea and lose bowels"". Also the consumer ""did not complete immunization one week prior to travel"". The events were reported with reasonable time relationship to intake of the vaccine. The events sore throat, pain in joints, pain in lymph nodes, congestion in chest and cough are of infectious etiology and hence the causality of these events is assessed as unlikely to vivotif. The event ""felt bad"" can be attributed to the various events experienced by the consumer. The events ""pain in stomach, nausea and lose bowels"" can be due to the infectious etiology or the suspect vaccine as it has potential to cause these events. Hence, the causality of the events ""pain in stomach, nausea and lose bowels"" with Vivotif is assessed as possible. The causality of the event ""did not complete immunization one week prior to travel"" was considered as not applicable.; Sender's Comments: Company's Comment: In this case, a female consumer experienced the event ""felt bad"" following the administration of vivotif. She also experienced the following events ""sore throat, pain in joints, pain in lymph nodes, pain in stomach, congestion in chest/ cough, nausea and lose bowels"". Also the consumer ""did not complete immunization one week prior to travel"". The events were reported with reasonable time relationship to intake of the vaccine. The events sore throat, pain in joints, pain in lymph nodes, congestion in chest and cough are of infectious etiology and hence the causality of these events is assessed as unlikely to vivotif. The event ""felt bad"" can be attributed to the various events experienced by the consumer. The events ""pain in stomach, nausea and lose bowels"" can be due to the infectious etiology or the suspect vaccine as it has potential to cause these events. Hence, the causality of the events ""pain in stomach, nausea and lose bowels"" with Vivotif is assessed as possible. The causality of the event ""did not complete immunization one week prior to travel"" was considered as not applicable.",,Unknown,0,0
913841,"Feverish, headache, earache starting in one ear then becoming in both ears, extreme fatigue, sinus pain on right side, right tonsils pain, right cervical lymph nodes pain, nausea. All the above symptoms started  24 hours after injection and currently at 42 hours slowly subsiding.  Left arm injection site swelling and redness. Started 12 hours after injection and continues to get bigger and more painful now at 42 hours post injection.",31.0,Adults,1,0
906835,"bilateral rash/itching on ear lobes, rash/itching/swelling suborbital region, diffuse rash on forehead. bump on right side cervical region.",28.0,Adults,1,0
911141,"No additional AEs reported; post-expiry stability data of an expired dose of PNEUMOVAX23; This spontaneous report was received from a registered nurse referring to a 67-year-old female patient. Information about medical history, concurrent conditions and concomitant therapies was not provided.    On 23-DEC-2020, the patient was vaccinated with an expired dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) (lot # S005856, expiration date 03-DEC-2020, 0.5 milliliter; route was not reported) for prophylaxis (expired product administered). No adverse event was reported. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); ; devicelotnumber: S005856; expirationdate: 03-DEC-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",67.0,Seniors,0,1
902473,"Morning after vaccine, I did not feel good. Had sores in mouth, low grade fever all day, aches and pain all over with nausea and diarrhea. Lasted for about a whole week. I went to dentist for sores in mouth (was prescribed mouthwash). The diarrhea finally subsided. When I saw a doctor, he gave me mouth was for the sores in mouth as well.  The initial  feeling of me not feeling well lasted for a week, but the sores and diarrhea lasted a lot longer.",77.0,Seniors,0,0
881285,patient stated she woke up next morning with rash/red bumps over torso and spread in random spots around body. she said they itched and she noticed it after working out. she had applied an anti itch cream that seemed to help. there did not seem to be anything at the sight of injection except soreness.,76.0,Seniors,1,0
901098,"8hours after he received shot, he started temperature, body aches, chills, weakness, brain fog. Thought it was covid, but had neg result. He is still having the same symptoms now. We are awaiting his second covid test results before patient can go to ER.",68.0,Seniors,1,0
871078,Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far,0.33,Kids,0,1
878243,"Right after I received vaccine I started feeling pain in my left arm.  Pain did not go away after 2 weeks. I waited with hope it will go away but instead it got worse.  I visited my doctor in January 2020 who recommended to take Advil or Alive to help with pain an the swollen.   I started Physical therapy sections but after 6 visits I contacted my doctor again because I was with the same pain and continued being unable to stretch out my arm.  The doctor recommended I get an MRI which attended to get it done.  I could not get it done.  During the time I was attending to get an MRI, the coronavirus pandemic started so I stopped pursuing medical help. I still have the pain and I cannot extend my arm.",58.0,Adults,0,0
864340,"Two minutes after administration, patient passed out. She lost consciousness and fell from a chair straight forward onto the floor, hitting her head as I (the pharmacist) caught her from the righthand side. When she came to we administered Tylenol with water. Patient does have a history of fainting with vaccines, but reported it had not happened in years.",54.0,Adults,0,1
867774,"No adverse effect; an unspecified number of patients may have been administered an improperly stored doses of MMRII; This spontaneous report was received from a physician referring to an unspecified number of patients of unknown age and gender. The patient's pertinent medical history and drug reaction/allergies were unknown. Concomitant therapies included sterile diluent. On an unknown dates, the patients may have been administered an improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) of lot # S005249  with expiry date 20-FEB-2021 (dose, strength, dose number, route of administration unspecified) for prophylaxis (product storage error). On an unknown date, the vaccines were exposed to the temperature of 11.73 Celsius for 4 hours and 30 minutes. There was no previous temperature excursion and digital data logger was involved. No adverse effects were reported.   Follow up information was received from physician on 07-NOV-2019.     No vaccine adverse reaction were reported. The only had to recall patients because no data available for temperature excursion. On 23-OCT-2019, during office site visit temperature excursion were noted. 10, measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) doses (Lot # R000550, expiry date: 08-JAN-2020) were stored to 24.08 degree Celsius. Since no data exists were (illegible doc) to revaccinate. No adverse reaction noted.    This is a non-valid case due to lack of patient identifiers.  Follow up information was received from the physician on 08-APR-2020.   This information refers to a 03-year-old female patient. On 27-MAR-2019, the patient was administered with an improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) with Lot number R000550.  This is one of several cases received from the same reporter.  This case was previously considered non-valid, but upon receipt of follow-up it was determined that the case is now valid as the patient demographics were obtained.; Sender's Comments:  US-009507513-1910USA016114:",3.0,Kids,0,1
914851,"Patient started c/o  some itching behind ears.  No rash, no respiratory complaints.  Patient monitored for 45 minutes.  No change in overall condition.  Patient offered to be seen at a higher level of care (UC/ED) but declined.",53.0,Adults,1,0
909855,"jabbing pain; had a shingles episode after first dose; Tingling to the left scapula; This case was reported by a physician via call center representative and described the occurrence of shingles in a 64-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 12th October 2020, the patient received the 1st dose of Shingrix. On 16th October 2020, 4 days after receiving Shingrix, the patient experienced shingles and tingling. On 17th October 2020, the patient experienced pain. The patient was treated with valaciclovir hydrochloride (Valtrex). On 21st October 2020, the outcome of the pain was recovered/resolved. On 30th November 2020, the outcome of the tingling was recovered/resolved. On an unknown date, the outcome of the shingles was recovered/resolved.   It was unknown if the reporter considered the shingles, tingling and pain to be related to Shingrix.  Additional details were provided as follows: The experienced shingles after receiving the 1st dose of Shingrix. The patient started to have tingling sensation on the left scapula on 16th October 2020.  From 17th October 2020 to 21st October 2020, the patient presented jabbing pain instead of tingling and on 22nd October 2020 patient went to the physician, reporter, and physician diagnosed patient with shingles and prescribed Valtrex 1 gram every 8 hours for 7 days. According to reporter, shingles symptoms had abated by time of the report. The reporter consented to follow up.",64.0,Adults,1,0
894828,"right middle lobe pneumonia; Information has been received from a lawyer referring to a male patient of unknown age. Information about concurrent condition, history condition and concomitant medication was not reported. On or around 26-OCT-2017, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (strength, dose, route, lot# and expiration date unknown) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX), the patient suffered difficulty breathing and was diagnosed with right middle lobe pneumonia. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient's symptoms have resulted in physical limitations not present prior to using the vaccine. The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of his condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of zoster vaccine live (ZOSTAVAX), the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events right middle lobe pneumonia was considered to be not recovered and causal relationship was assessed as related.    The lawyer considered the event right middle lobe pneumonia to be disability.  Upon internal review, the event right middle lobe pneumonia was considered to be medically significant.",,Unknown,0,0
871317,"Pulse increased; Feeling discomfort; Dizziness; Fever like symptoms/ aprox 37-38C; Fatigue; This is a spontaneous case, reported by other non-health professional (consumer) to Agency (Case ID: SEQ19-03067) and initially received on 23-Sep-2019, concerning a 33-year-old, adult, male patient.   The patient had no relevant medical history, drug reactions or allergies, and concomitant medications provided.  On 19-Sep-2019, the patient was administered Flucelvax QIV [influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration: intramuscular (IM), anatomical location: arm, batch number, expiration date: not reported] for influenza prophylaxis.  On 23-Sep-2019, at 8 am, the patient developed a fever-like symptoms, approximately 37-38 C. Pulse increased and the patient felt discomfort, dizziness and fatigue. During night fever got to 38.1 C (106 F). Corrective treatment has not been applied yet.  On 24-Sep-2019 in the morning, the fever stopped, the patient had no more temperature.  On 26-Sep-2019, dizziness and sweating went away as reported.  On 29-Sep-2019, the patient was feeling fatigued.  On 30-Sep-2019, the patient was better than the day before. And reported he was 80% recovered.  The outcome of the events fever-like symptoms, approximately 37-38 C and dizziness was recovered on 26-Sep-2019.  The outcome of the events pulse increased, feeling discomfort and fatigue was recovering, at the time of this report.  The reporter assessed the case as non serious and did not provide causality assessment to Flucelvax.  Follow up received on 30-Sep-2019: It was provided the outcome and stop dates of the events. Dizziness was added. The narrative was amended accordingly.; Sender's Comments: The patient experienced heart rate increased, discomfort, dizziness, pyrexia and fatigue four days after receipt of Flucelvax QIV. Chronology is plausible. More information regarding medical history and concomitant drugs is needed. Based on provided information, causal role of the suspect product is assessed as related for all events.",,Unknown,0,0
873402,"The patient did not experience any symptoms; patient was vaccinated with improperly stored varivax; This spontaneous report as received from a medical assistant refers to a 3 year old female patient. The patient's pertinent medical history and drug reactions or allergies were not reported. The patient's concomitant therapy included sterile diluent. On 03-DEC-2019, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck)(VARIVAX) (strength, dose, route of administration and anatomical location were not reported) of lot # S004119 is an invalid lot number, expiry date reported as 11-FEB-2021 for prophylaxis (product storage error). The patient did not experience any symptoms. The outcome of product storage error was unknown. The temperature excursion for varicella virus vaccine live (oka/merck) (VARIVAX) was reported as -9 degrees Celsius (C) to 8 degrees Celsius (3.3 C) for 53 hours. There was no previous temperature excursion reported. Data logger was involved. No product quality complaint (PQC) was associated with this report.  This is one of the multiple reports from the same reporter.; Sender's Comments:  US-009507513-1911USA011629:",3.0,Kids,0,1
891240,The patient called his Dr complaining of should pain following the vaccination. Dr advised him to try OTC pain remedies as the pain is expected to resolve within 1 day. The patient stated that the pain did not resolve in one day.,21.0,Adults,1,0
914534,Vomited x2 temp 101,62.0,Adults,0,0
881422,"severe headache; myalgia; severe pain; This is a spontaneous report from a contactable physician. This physician reported similar events for four patients. This is the second of four cases. A 19-year-old patient of an unspecified gender received meningococcal group b rlp2086 (TRUMENBA) ,(lot/batch# CM8296), via an unspecified route of administration, on 12Aug2020, at single dose, for immunisation. Medical history and concomitant medications were none. The patient experienced severe headache, myalgia and severe pain all in Aug2020 with outcome of unknown.    No follow-up attempts are needed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2020335485 Same reporter/event, different patient",19.0,Adults,0,0
864917,"""22 y/o F presented to clinic complaining of rash that is spreading over her entire body. PT describes the rash as feeling tight on the skin, itchy, and stinging. PT states that she received her vaccines for Hep A and HPV yesterday and attributes the rash to a reaction to on of those shots. PT denies any difficulty breathing, SOB, or wheezing. PT does not appear to be in any acute distress.""  Once seen by medical professional her skin condition was described as such: ""erythematous papules noted spread diffusely across entire body. No weeping, lesions, or open sores""",22.0,Adults,0,0
888818,Patient reported having difficulty breathing and face numbness after giving a pneumovax-23 vaccine.  An adult epinephrine 0.3 mg was given in left thigh and 911 was called. Patient felt better after the injection.  Patient delivered to hospital for further monitoring,42.0,Adults,0,1
901551,"The shot itself hurt worse than any shot I've ever had in my life. I wailed out in pain.  Within thirty minutes my left shoulder was killing me.  It has not improved at all.  It's painful to drive, to cook, to help my clients, to do anything!",51.0,Adults,1,0
904276,"10 minutes after vaccination felt lightheaded and dizzy,  pulse 64 resp 18 - given water and put feet up.   15 minutes later better but still woozy - pulse 80 resp 20. 15 minutes later walked around pulse 72 resp 18   20 minutes later - still feeling dizzy wishes to go to ER - transported via wheelchair.",25.0,Adults,0,0
864468,Hives appeared on my neck. I took Diphenhydramine for 2x a day for three days until rash was gone.,59.0,Adults,1,0
877673,"Pain and stinging at injection site/; shingles rash that looks like pimples/rash that looks like pimples on her face,scalp,ears,chest, and back; Shingles / Shingles rash that looks like pimples; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles and brain injury (had brain injury from a car accident several years ago).   On 8th June 2020, the patient received the 1st dose of Shingrix (intramuscular). On 11th June 2020, 3 days after receiving Shingrix, the patient experienced shingles and vesicular rash. On an unknown date, the patient experienced injection site pain. The patient was treated with topical steroid nos (Steroid Cream). On an unknown date, the outcome of the shingles was not recovered/not resolved and the outcome of the injection site pain was recovered/resolved and the outcome of the vesicular rash was unknown.   It was unknown if the reporter considered the shingles, injection site pain and vesicular rash to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in left arm and had outbreak of shingles that began 3 or 4 days and lasted about 3 to 4 weeks before resolving. The patient reported a second outbreak of shingles began 4 days ago and was ongoing currently.  The patient stated currently has a shingles rash that looks like pimples on her face, scalp, ears, chest, and back that began 4 days ago and has been using a steroid cream to treat this.  The patient reported pain and stinging at injection site and these had resolved.  The reporter did not consent to follow up. No lot number or expiration date information was available The reporter did not get consent to follow up with HCP.",60.0,Adults,1,0
912181,None stated.,42.0,Adults,0,0
877440,"Patient was lethargic, but no noteworthy symptoms throughout the day. I put him to sleep in his crib, on his back, without any surrounding blankets, toys, or pillows. At approx. 8:30 pm, his owlet monitor alarm went off alerting us his oxygen levels were rapidly decreasing. When I went to his room to wake him, his body was shaking. No foaming at mouth to note. After checking breathing vitals, and for fever, I put him back to sleep and monitored him all night. The next morning, the alarm did go off again, alerting us of low oxygen levels. I placed a call to the pediatrician, and I made sure the call was recorded. I was told they ""do not recommend Owlet monitors"" and he was ""probably shaking from a fever"" and this was ""normal"". They had no further concerns and did not think he should be seen for any symptoms.",0.5,Kids,1,0
911846,"muscle pain in arm, headache, fatigue",36.0,Adults,1,0
899176,"given a second dose of Adacel with no adverse event; pregnant female was ""unexpectedly, in error"" given a second dose of Adacel; Initial information was received on 15-Oct-2020 regarding an unsolicited valid non-serious case from the other health professional.  This case involves a 30 year old female patient who was pregnant and was unexpectedly, in error, given a second dose of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] (extra dose administered and Vaccine exposure during pregnancy).  Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. It was reported that the patient was exposed to the vaccine at 29 weeks of pregnancy and had given a second dose of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE on 34 weeks of pregnancy.  The date of the last menstrual period was reported as 15-Feb-2020.  The estimated due date is 21-Nov-2020.  Medical history, medical treatments, vaccinations and family history were not provided. It was a potential medication error due to an extra dose being administered. Concomitant medications included INFLUENZA VACCINE INACT SPLIT 3V (FLULAVAL) for immunisation.  On 31-Aug-2020, the patient received 1 dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (lot number U6676AA expiration date 16-May-2022) via intramuscular route in the right deltoid muscle for immunization during the 29 weeks of pregnancy (vaccine exposure during pregnancy).   On 13-Oct-2020, 1 month 15 days after the first dose of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE unexpectedly, in error, the patient was given the second dose of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE and asked if there were any possible side effects or concerns that they should look out for.   The healthcare professional stated that the 30 year old pregnant female patient was given a second DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE dose on 13-Oct-2020. The patient's first dose of vaccine was given on 31-Aug-2020. The physician, did not realize that the patient had already received the DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE and wrote a prescription for patient to receive vaccination on 13-Oct-2020.   It was discovered after DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE that this was actually the second DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE.  No relevant laboratory tests were reported.  It was not reported if the patient received a corrective treatment.  Event outcome was reported as not applicable for both the events.",,Unknown,0,1
874567,"sleeping a lot from exhaustion; sleeping a lot; spending most of each day in bed; This case was reported by a consumer and described the occurrence of bedridden in a 77-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of bedridden (1st dose received 6 months back on unknown date. Please refer the case US2020AMR106664).   On 18th June 2020, the patient received the 2nd dose of Shingrix. On 19th June 2020, 1 days after receiving Shingrix, the patient experienced bedridden. On 21st June 2020, the patient experienced exhaustion and somnolence. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the bedridden, exhaustion and somnolence were unknown.   It was unknown if the reporter considered the bedridden, exhaustion and somnolence to be related to Shingrix.  Additional case details were reported as follows: Approximately 6 months later after 21st dose on (last Thursday), the patient had booster shot.  The reaction was similar but not quite as bad.  After spending most of each day (starting Friday) in bed, in the late afternoon patient was finally up to getting out of bed. On Sunday, patient was in bed (except for the bathroom) in bed, even sleeping a lot from exhaustion.  This day was the worst of all from the booster shot. The patient was a fairly resilient person, having some very tough.  The patient did not expect to have such an exhausting reaction to the booster shot, even though patient had experienced it with the initial shot.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR106664:same patient (1st dose)",77.0,Seniors,0,0
880860,Patient reported projectile vomiting for about 1 and 1/2 hours starting at 6:30 pm the same day as vaccine (vaccine given around 1:30 pm).  Patient reports then having dry heaving and a temperature of 99.1 F. We followed up with patient the next day. She stated she was able to keep down some food and fluids and was resting. Temperature on the day after vaccine was 98.8 F,77.0,Seniors,0,1
914144,Sore site headache body ache fever of 100.02,35.0,Adults,1,0
906677,"Slight headache; sore throat; This is a spontaneous report from a contactable consumer. A 61-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number EK5730/expiration date unknown) dose number 1 via an unspecified route of administration on the left arm on 18Dec2020 11:15 for COVID-19 immunization. Medical history included polycythemia vera, high BP, and GERD (gastrooesophageal reflux disease). Concomitant medications included omeprazole, aspirin [acetylsalicylic acid], hydroxyurea, tapentadol hydrochloride (NUCYNTA), and amlodipine besilate (NORVASC). The patient experienced slight headache and sore throat on 18Dec2020 12:15. The outcome of the events was not recovered.",61.0,Adults,0,0
915525,"Wheezing, throat tightness, palpitations, headache, weakness",35.0,Adults,1,0
879662,"a dose of MMRII that was given intramuscularly instead of subcutaneous injection; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 27-JUL-2020, the registered nurse in the office was vaccinated with a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), 0.5 milliliter, once, intramuscularly instead of subcutaneously (injection site, lot # and expiration date were not reported) for prophylaxis by another registered nurse. The outcome of the event was unknown.",,Unknown,0,1
895515,"Patient is currently pregnant and followed up with her OB.  Symptoms started with scattered rash that ""spread all over body and down to her toes"" itching began on left arm then on entire body.  Physician ordered Benadryl & OTC hydrocortisone cream.  the following day after little relief she contacted her physician again and received order for steriods.",24.0,Adults,1,0
872099,"The patient experienced no symptoms; an 18 years old patient was administered an adult dose of VAQTA; This spontaneous report was received from a nurse referring to an 18 year old patient of unknown gender. Information about the patient's concurrent condition, concomitant medication, medical history and drug allergy/reaction was not reported.   On 13-MAY-2020, the patient was vaccinated with an adult dose of hepatitis a vaccine, inactivated (VAQTA) 50/1.0 Units/milliliter, lot # S007265, expiry date: 07-JUL-2020 via intramuscular route for prophylaxis (dose number and anatomical location were not reported) (incorrect dose administered). The patient experienced no symptoms (no adverse event). No product quality complaint was involved. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; manufactureraddress:; manufacturercity:; manufacturerstate:; manufacturercountry:; devicelotnumber: S007265; expirationdate: 07-JUL-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent",18.0,Adults,0,1
915135,"Vaccine received Wednesday 12/23 about 12:15-12:30 pm and arm was sore after. On Thursday 12/24: Tired in the afternoon and increasing tiredness and feeling weak.  Evening brought on headache, chills, fever of 100.7 or higher and fast heart rate of about 100 when resting heart rate is usually 55-60.",63.0,Adults,0,0
857020,"improperly stored vaccine administered; no adverse effect; This spontaneous report as received from an office manager refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.       On an unknown date, the patient was vaccinated with improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) (lot # S021925, expiry date : 15-JUL-2021) for prophylaxis. Other suspect therapies included sterile diluent(MERCK STERILE DILUENT). It was unknown if diluent used to reconstitute was stored at proper temperature.    It was reported that the vaccine experienced a temperature excursion total time in the range of 6 degrees Fahrenheit (F) to 14 degrees F (-14 degrees Celsius (C) to - 10 degrees C) for 30 minutes, 15 degrees F to 46 degrees F (-9 degrees C to 8 degrees C) for 7 hours and 47 degrees F to 77 degrees F (9 degrees C to 25 degrees C) for 9 hours (product storage error). There was no previous temperature excursion and it was reported that this call was due to a digital data logger. The patient had no adverse events. There was no product quality compliant involved.   This is one of the several reports received from the same reporter.; Sender's Comments:  US-009507513-2001USA005705:Original Case : 2001USA005586 US-009507513-2001USA005680:Original Case : 2001USA005586 US-009507513-2001USA005703:Original Case : 2001USA005586 US-009507513-2001USA005686:Original Case : 2001USA005586 US-009507513-2001USA005688:Original Case : 2001USA005586 US-009507513-2001USA005691:Original Case : 2001USA005586 US-009507513-2001USA005685:Original Case : 2001USA005586 US-009507513-2001USA005684:Original Case : 2001USA005586 US-009507513-2001USA005687:Original Case : 2001USA005586 US-009507513-2001USA005678:Original Case : 2001USA005586 US-009507513-2001USA005707:Original Case : 2001USA005586 US-009507513-2001USA005704:Original Case : 2001USA005586 US-009507513-2001USA005701:Original Case : 2001USA005586 US-009507513-2001USA005699:Original Case : 2001USA005586 US-009507513-2001USA005697:Original Case : 2001USA005586 US-009507513-2001USA005696:Original Case : 2001USA005586 US-009507513-2001USA005682:Original Case : 2001USA005586 US-009507513-2001USA005690:Original Case : 2001USA005586 US-009507513-2001USA005698:Original Case : 2001USA005586 US-009507513-2001USA005681:Original Case : 2001USA005586 US-009507513-2001USA005702:Original Case : 2001USA005586 US-009507513-2001USA005695:Original Case : 2001USA005586 US-009507513-2001USA005689:Original Case : 2001USA005586 US-009507513-2001USA005683:Original Case : 2001USA005586",,Unknown,0,1
898572,"brain fog x 2 days, muscle ache x 5 days, soreness to touch x 7 days",69.0,Seniors,0,0
891730,"Received afluria pfs 2020-21 inj 0.5 ml; 4 hours later developed chills, fever 102.9, headache. Lasted 24 hours. Day 2 had headache, fatigue, fogginess. Day 3 and Day 7 tested negative COVID.",,Unknown,1,0
904809,"got so sick with shot; Initial information received on 29-Nov-2020 regarding an unsolicited valid non-serious case received social media case through agency reported by a consumer (patient).  This case involves patient (unknown demographics) who had the patient got so sick with shot (illness), while the patient received vaccine influenza vaccine.  The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided.   Concomitant medications were not reported.  On an unknown date, the patient received a dose of suspect influenza vaccine produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for Prophylactic vaccination  On an unknown date (reported as since few years), (latency unknown) after the initiation of suspect vaccine, the patient got so sick with shot (illness) and thought he was dying. The patient stated do not trust the flu shot.  No relevant laboratory data was reported.  It was unknown if the patient received a corrective treatment. The events outcome was unknown.  There will be no information available on the batch number for this case.",,Unknown,0,1
890788,"Low grade fever; Diarrhea; Soreness; nausea; lethargy.; Dry heaves; This case was reported by a consumer via call center representative and described the occurrence of fever in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis.   In September 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml and the 1st dose of Influenza vaccine Quadrivalent unspecified season .5 ml. On 13th October 2020, less than 3 weeks after receiving Shingrix and Influenza vaccine Quadrivalent unspecified season, the patient experienced dry heaves. On an unknown date, the patient experienced fever, diarrhea, pain, nausea and lethargy. On an unknown date, the outcome of the fever, diarrhea, pain, nausea and lethargy were not recovered/not resolved and the outcome of the dry heaves was unknown.   The reporter considered the fever, diarrhea, pain, nausea and lethargy to be related to Shingrix and Influenza vaccine Quadrivalent unspecified season. It was unknown if the reporter considered the dry heaves to be related to Shingrix and Influenza vaccine Quadrivalent unspecified season.  Additional details were provided as follows: The patient received both the Shingrix and the Flu vaccine the last week of September in left arm and about 4 hours after the injections, she began to experience low grade fever, diarrhea, soreness, nausea and lethargy.   The reporter reported symptoms had gotten worse over past 3 weeks.  The patient experienced dry heaves.  The reporter provided medical disclaimer and advised her to follow up with her physician and copy of PI sent via email.  The reporter also informed could HCP follow up with GSK Medical Information department for any further questions. The reporter consented to follow up.",60.0,Adults,0,0
896879,"patient woke up the next day to soreness and weakness/heaviness in the arm,  swelling and redness at the injection site, intense itching all over the body and some hives",82.0,Seniors,0,0
913199,"In middle of night had strong headache, then day following vaccination was headache-y (mild), light-headed, tired and with body aches. Two days after had mild body aches and mild light headed-ness; day 3 I was clear.",68.0,Seniors,1,0
863539,Vaccine was not reconstituted. Only diluent was given orally.    NO ADVERSE EFFECTS. patient will need to be re-vaccinated due to error.,0.17,Kids,0,1
875062,Patient reports an itchy rash developing on her arms and knees the night she received her vaccine (at around 8:30 PM). She stated that the symptoms are being managed with Benadryl and hydrocortisone and that she has had no symptoms on her face/mouth/throat.,65.0,Adults,0,0
869510,"CHILLS; arm became sore; This case was reported by a consumer via call center representative and described the occurrence of chills in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, 1 day after receiving Shingrix, the patient experienced chills and pain in arm. On an unknown date, the outcome of the chills and pain in arm were recovered/resolved.   It was unknown if the reporter considered the chills and pain in arm to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The patient was either 63 or 64 years old. The patient's arm became sore the day after the injections and lasted a day. The patient also experienced chills the morning after receiving the shot. The reporter did not consent to follow up.",,Unknown,1,0
912825,"Rash, itching",29.0,Adults,1,0
887999,"Hospitalized for a neuromyelitis optica flareup; This case was reported by a consumer via call center representative and described the occurrence of neuromyelitis optica in a 32-year-old female patient who received Men B NVS (Bexsero) for prophylaxis.   The patient's past medical history included myelitis transverse. Concurrent medical conditions included neuromyelitis optica spectrum disorder and anti-aquaporin-4 antibody.   On 11th September 2020, the patient received the 1st dose of Bexsero. In September 2020, less than a week after receiving Bexsero, the patient experienced neuromyelitis optica (serious criteria hospitalization and GSK medically significant). On an unknown date, the outcome of the neuromyelitis optica was unknown.   It was unknown if the reporter considered the neuromyelitis optica to be related to Bexsero.  Additional case details were reported as follows: The patient reported case for herself. She stated that on Sunday, 13th September 2020, she was hospitalized for a neuromyelitis optica flareup. All information was not available. The reporter did not consent to follow up.",32.0,Adults,0,0
887622,"Medical assistant calling to report a temperature excursion that occurred 8/14/2020 which involved the following products: GARDASIL9, PEDVAXHIB, RECOMBIVAX, ROTATEQ. Per caller, ""it would be possible that at least 100 patients have received vaccines; This spontaneous report was received from a medical assistant, concerning a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies or concomitant medications were not reported.  On 11-SEP-2020, the patient was vaccinated with an improperly stored dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) as prophylaxis (lot # T011167 with expiration date 27-MAY-2022) (strength, frequency, route of administration and anatomical location were not reported).  The improperly stored dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) experienced a temperature excursion of 35.4 Fahrenheit degrees (F) for the time frame of 20 minutes without previous temperature excursions. It was confirmed that a digital data logger was involved.  This is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2009USA006106:",,Unknown,0,1
857778,"About 1/2 to 1 inch below the injection site her arm had a warm, red blotch that was a size of about a softball.",60.0,Adults,0,0
912218,"rash to both forearms, thigh and private area/developed a rash on both arms, thighs, and kind of near the private area. Areas are red and bumpy/rash now is flat, red, and pinkish; rash to both forearms, thigh and private area/developed a rash on both arms, thighs, and kind of near the private area. Areas are red and bumpy/rash now is flat, red, and pinkish; rash to both forearms, thigh and private area/developed a rash on both arms, thighs, and kind of near the private area. Areas are red and bumpy/rash now is flat, red, and pinkish; This is a spontaneous report received from a contactable nurse (who is also the patient). A 62-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EJ1685, expiry date unknown), intramuscular in left deltoid, on 19Dec2020 at single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient reported she received the COVID-19 vaccine on Saturday (19Dec2020). Everything was fine all day on Saturday and when she took a shower on Sunday morning (20Dec2020), she noticed she developed a rash on both arms, thighs, and kind of near the private area. Areas are red and bumpy, and she still has the rash on the arms. She called her primary care provider and was instructed to use Benadryl at bedtime and Zyrtec in the morning to help. She was wondering because in 20 some odd days she is to get the second shot and wants to know if she should expect this type of adverse reaction. She mentioned that the rash now is flat, red, and pinkish. She stated she has never had COVID-19 testing or symptoms. Just this rash from the vaccine. The reporter assessed the events as non-serious. The outcome of the events was not recovered (reported as ongoing).",62.0,Adults,0,0
877687,"Shingles; Extreme Pain; Increased BP; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 77-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1si dose received in April 2020).   On 2nd July 2020, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 2nd July 2020, less than a day after receiving Shingrix, the patient experienced shingles, pain and increased blood pressure. On an unknown date, the outcome of the shingles, pain and increased blood pressure were unknown.   It was unknown if the reporter considered the shingles, pain and increased blood pressure to be related to Shingrix.  Additional case details were reported as follows: The age at vaccination was not reported. The patient experienced the symptoms of extreme pain, increased blood pressure and the shingles on the same day she got her 2nd dose. The patient reported her blood pressure was so high and went to the urgent care and they sent her to the hospital and they released. The reporter consent to follow up.",77.0,Seniors,1,0
900818,"Provider ordered Kinrix to catch patient up on vaccines.  Right order was given by medical staff, but Kinrix is not formulated for 2 years old.  Off Label use --- Kinrix is used on 4 years to 6 years.  No adverse events noted.",2.0,Kids,0,1
858875,"Noticed throat felt on fire was dark red and inflamed then was told it was a bad sinus infection, mid grade fever, put on amoxicillin, then codeine for throat then clindamycin, doxycycline. After vaccination the next day she could not get out of bed. Extreme fatigue. Needed to take time off of work.",52.0,Adults,1,0
881508,"Right after I gave the shot to the patient. Patient got dizzy and have to help her to sit down. She said she is about to fall, cannot see anything and her head is spinning. I Immediately grab water from our shelf.  5minutes after drinking, pt wasn't getting better. She requested to lie down on the floor.  She  claims that she haven't eat that much so she took a chololate bar.  I stayed and watched the patient for 15 to 20 minites.  Patient tried to stand up and right after she stand up she got dizzy again, have to assist her to sit down. Wait another 15minutes and she said she is felling better. I observed her when she stood up and walked her to her car. I gave her an epipen just in case she would need it. She said she is feeling better and just live 2 blocks away.",29.0,Adults,0,0
898624,"Fever, body aches, stomach pain, lethargy, nausea",56.0,Adults,1,0
901180,"hematoma, swelling, pain in arm",55.0,Adults,1,0
898319,No Adverse Event to document - duplication of vaccine  Initial vaccine administered 08/2018 - by Dr  Duplicate Dose administered 11/17/2020 - by RPH,69.0,Seniors,0,1
913447,Tunneling in vision,28.0,Adults,0,0
914722,"Moderate generalized joint pain that affected functional activity, requiring medication of tylenol 500mg po and then ibuprofen 400mg po that finally relieved symptoms temporarily. The joint pain lasted for approximately 36 hours.",48.0,Adults,0,0
885492,"I experienced Marked swelling from the left shoulder to below the elbow and about 85-90% circumferentially. The injection site was in my left upper arm. This lasted 4-5 days and I did visit my doctor's office as well as the pharmacy regarding the swelling. I used benadryl, ice, and extra strength tylenol for the discomfort. In December, I went to an orthopedic clinic regarding the residual pain and weakness in that arm. Further studies included x-rays, PT, MRI of shoulder due to loss of posterior muscle of the left shoulder, and referral to a Dr. of Physical Medicine & Rehabilitation. He requested another MRI of the neck, then specific PT orders.",66.0,Seniors,0,0
894725,"severe allergic contact dermatitis; type iv hypersensitivity reaction; Allergy to aluminum; This case was reported by a consumer and described the occurrence of allergic contact dermatitis in a patient who received Hepatitis B vaccine for prophylaxis.   On an unknown date, the patient received Hepatitis B vaccine. On an unknown date, 1 day after receiving Hepatitis B vaccine, the patient experienced allergic contact dermatitis, type iv hypersensitivity reaction and allergy to aluminum. On an unknown date, the outcome of the allergic contact dermatitis, type iv hypersensitivity reaction and allergy to aluminum were unknown.   It was unknown if the reporter considered the allergic contact dermatitis, type iv hypersensitivity reaction and allergy to aluminum to be related to Hepatitis B vaccine.  Additional details were provided as follows: The age at vaccination was not reported. In 2014 the patient had severe allergic contact dermatitis the day after the hepatitis B vaccine.  The reporter found out this was type iv hypersensitivity reaction and reporter thought it was the aluminum.",,Unknown,0,1
908436,None stated.,37.0,Adults,0,0
872007,"no adverse affects reported; improperly stored VARIVAX was administered to patient; This spontaneous report as received from a nurse refers to a patient of unknown age and gender. No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.  On 13-MAY-2020, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot # S012036, expiration date: 17-APR-2021 (strength, dosage schedule and route of administration were not provided) for prophylaxis. Administered dose of vaccine was exposed to the temperature 48.2 (units not provided) for 4 hours- as recorded by digital data logger. No previous excursion was noted. No adverse effects reported.",,Unknown,0,1
916543,"Fever, chills, and severe fatigue lasting 12 hours",64.0,Adults,1,0
891308,"shivering 2 hours then stopped, tiredness, muscle pain, headache,  nausea all subsided after about 24 hours",71.0,Seniors,1,0
892331,"very large bruising and she states it swelled to feel like a ""golf ball"" underneath her skin. She states she also experienced significant pain in the injection site for a couple days. She states she has since recovered.",78.0,Seniors,1,0
905078,"tgeybhad the flu; Initial information regarding an unsolicited valid non-serious case received from a non health care professional via social media on 06-DEC-2020 This case involves a patient of unknown age and gender who reported tgeybhad the flu (Influenza), while he/she received vaccine Influenza Vaccine.   The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medication was unknown.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number not reported) via unknown route in unknown administration site as prophylactic vaccination.  On an unknown date, the reporter reported that then explain to why a couple I worked with got Flu shot every year and by the end odbtge week tgeybhad the flu. They then decided not to get the flu shot guess what they Dident get the flu that year or the following years.  It was not reported if the patient received a corrective treatment.  Outcome of the event was unknown, at the time of reporting.  There will be no information available on the batch number for this case.  The reporter assessed the causal relationship with suspect vaccine as related.",,Unknown,0,1
911766,"called to observation area 10:50 - report that patient passed out, was on stretcher, reported did not fall, 'came to' in less than 1 minute.  108/68, P 70 and strong, alert and oriented.  states feels anxious about flu shots.  felt lightheaded, hot, sweaty, skin pale and warm.  at 1052 rapid response arrived.  states feeling better, had had food/fluids today.   assessed that not allergic response - vaso/vagel.  1055 sat up and feeling good, skin pink.  1100 to chair.  1115 left area walking.",33.0,Adults,0,1
913828,Indigestion (heartburn) - started the evening of day vaccine received (12/29/20) around 5:00 p.m. Began again on 12/30/20 around 10:00 a.m. Extremely abnormal for this to occur with me.,31.0,Adults,0,1
903194,Patient may have received undiluted Pfizer COVID-19 vaccine 0.3 ml= ~120 mcg,57.0,Adults,0,1
912127,Lower right extremity raised rash beginning from ankle to groin. Lower left extremity raised rash localized on calf.,70.0,Seniors,1,0
882364,"Patient fainted after fluzone administration. Pt was standing with her parents while pharmacist was administering another vaccine for another family member. Patient was laid down and regained consciousness. Patient denies hitting her head or any other injuries. Pt provided water after regaining consciousness. Management notified, store incident reported. VAERs reported.",8.0,Kids,0,1
895377,"Reported by the patient on the next day: Within 20-30 minutes of vaccination patient had congestion, headache, redness and swelling of the face and felt dizzy. During next 28 hours he felt dehydrated and suffered from hot flushes and ""foggy brain"" that completely resolved in the afternoon of the next day. Pt used ORS only",36.0,Adults,1,0
877278,"A patient received an expired dose of Quadracel, no AE; Initial information received on 22-Jul-2020 regarding an unsolicited valid non-serious case from a other health professional.  This case involves a 4 years old male patient who received an expired 0.5 ml first dose of DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/IPV (MRC5) VACCINE [QUADRACEL] (lot: C5497AA, expiry date: 17-Jul-2020) once via an intramuscular route in the right leg for prophylactic vaccination on 22-Jul-2020.  The patient's medical history, past medical treatment, past vaccination and family history were not provided.  Concomitant medications included HEPATITIS A VACCINE and VARICELLA ZOSTER VACCINE LIVE (OKA/MERCK) (VARIVAX [VARICELLA ZOSTER VACCINE LIVE (OKA/MERCK)]) which were given on 22-Jul-2020 for prophylactic vaccination.  It was an actual medication error due to expired vaccine used.  At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",4.0,Kids,0,1
887886,"PATIENT IS A 4MOS OLD WHO PRESENTS FOR 4 MOS VACCINATIONS. PARENTS OPTED TO RECEIVE JEV ALONG WITH ROUTINE 4 MONTH VACCINES. ABOUT 2 -3 MINUTES POST VACCINATION, PARENTS WERE IN THE WAITING ROOM AND BROUGHT INFANT BACK TO ROOM STATING REDNESS AND PURPLE RASH.  RN ASSESSED AND GENERALIZED RASH TO BILATERAL LOWER EXTREMITIES; NOT RAISED. NO DYSPNEA NOTED. PATIENT WAS ESCORTED TO THE ACUTE CARE CLINIC FOR FURTHER ASSESSMENT BY PROVIDER.",0.33,Kids,0,0
895165,Rec. 1st shingle vax. Started getting dizzy room was spinning and then progressively got worse. Couldn't walk. Attempted to stand up but could not was stumbling. Had to catch breath. sweating profusely. Went to bathroom and was dry heaving. also had Blurry vision. Called MD next day twice and has not gotten response. All symptoms gone just feeling exsaughted.   Rec Flu shot 10/6/20  At workplace Hospital.,,Unknown,0,1
858611,"Fever, chills, dizziness, muscle aches, leg cramps, weakness, (flu-like symptoms) lasted approx 36 hours",68.0,Seniors,1,0
864620,"6 month old male patient received Quadracel vaccine, no AE; Initial information was received on 02-Mar-2020 regarding an unsolicited valid non-serious case from a other health professional.  This case involves a six month old male patient who received 0.5 mL first dose DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/IPV (MRC5) VACCINE [QUADRACEL] (lot C5656AA and expiry date: 13-Aug-2021) via an intramuscular route in the right thigh for prophylactic vaccination on 10-Feb-2020.  Medical history, medical treatment, vaccination and family history were not provided.  Concomitant medications included HIB VACCINE CONJ (TET TOX) (ACTHIB), INFLUENZA VACCINE INACT SPLIT VIRION 4V (FLUZONE QUADRIVALENT), and PNEUMOCOCCAL VACCINE CONJ 13V (CRM197) (PREVNAR 13) for Immunisation, on 10-Feb-2020.  It was actual medication error case due to inappropriate age at vaccine administration.  At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",0.5,Kids,0,1
894103,"it caused him to go deaf in one ear.; This case was reported by a consumer via interactive digital media and described the occurrence of deafness unilateral in a male patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis.   Co-suspect products included theraflu unknown unknown (batch number UNK, expiry date unknown) for flu.   On an unknown date, the patient received Influenza vaccine Quadrivalent unspecified season and theraflu unknown at an unknown dose and frequency. On an unknown date, less than a year after receiving Influenza vaccine Quadrivalent unspecified season and theraflu unknown, the patient experienced deafness unilateral (serious criteria GSK medically significant). The action taken with theraflu unknown was unknown. On an unknown date, the outcome of the deafness unilateral was unknown.   It was unknown if the reporter considered the deafness unilateral to be related to Influenza vaccine Quadrivalent unspecified season and theraflu unknown.  Additional information was provided as follows: The case was reported by patient's friend. The age at vaccination was not reported. The patient received his shot a year before reporting because he works in the medical field, it caused him to go deaf in one ear. The case had been linked with US2020AMR215313, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR215313:same reporter",,Unknown,0,1
916526,potentially a 0.3ml dose on Pfizer COVID vaccine administered without diluent. Monitor the resident q 2 hours x 72 hours. only compliant is mild soreness at injection site.,75.0,Seniors,0,1
904208,approximately 25 minutes past receiving the COVID vaccine I felt numbness in my neck and clavicle area.  This resolved on its own after about 2 hours of receiving  the vaccine,59.0,Adults,0,1
900187,"flu; Initial information was received on 19-Oct-2020 regarding an unsolicited valid non-serious case from a social media via consumer or non-health care professional.  This case is linked to cases 2020SA296404 and 2020SA296404 (same reporter).  This case involves patient (age and gender unspecified) who experienced flu (influenza), while patient received INFLUENZA VACCINE, [Flu shot].   Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.    On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) [lot number and expiry not reported] via an unknown route at an unknown administration site for prophylactic vaccination.   On an unknown date, the patient developed a non-serious flu (influenza) unknown latency following the administration of INFLUENZA VACCINE.  Details of laboratory data not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, the event outcome reported as unknown for event.  There will be no information available on the lot number for this case.",,Unknown,0,1
911152,"fatigue; Fever 103.6/fever 100.3; headache; chills/chills with fever 100.3 after ibuprofen; Sore at injection site; body aches; This is a spontaneous report from a non-contactable consumer (patient). A 36-year-old female patient (not pregnant) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number and expiration date not provided), via an unspecified route of administration on 18Dec2020 14:30 at single dose for COVID-19 immunization. Vaccine location was Left arm. Medical history included migraine, transient ischaemic attack (TIA), allergies: Penicillin, the patient had covid-19 prior to vaccination. Concomitant medication included buspirone hydrochloride (BUSPAR), cranberry, vitamin c (ascorbic acid), colecalciferol (VITAMIN D). The patient was not received other vaccine in four weeks. The patient experienced Sore at injection site, body aches, chills with fever 100.3 after ibuprofen, headache on 18Dec2020 19:00. And then the patient had Fever 103.6, headache, chills, fatigue on 18Dec2020 19:30, sore at injection site on 18Dec2020 19:00, body aches on 18Dec2020 19:00. Therapeutic measures were taken as a result of events fever and chills, no treatment was received for the other events. The outcome of the events was recovering. All events were assessed as non-serious.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.",36.0,Adults,0,0
866042,"hands and palms were also painful, itching; Sensitive to warm water; Itching; red rash on his back, buttocks, arms, hands and palms; This case was reported by a consumer via call center representative and described the occurrence of pruritus in a 69-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included meat allergy. Concomitant products included prednisone.   On 12th December 2019, the patient received the 1st dose of Shingrix (intramuscular). In December 2019, 7 days after receiving Shingrix, the patient experienced pruritus. In February 2020, the patient experienced red rash, pain in extremity and sensitization. The patient was treated with hydrocortisone (Cortisone Topical Cream) and benadryl (nos) (Benadryl). On an unknown date, the outcome of the pruritus and red rash were recovered/resolved and the outcome of the pain in extremity and sensitization were unknown.   It was unknown if the reporter considered the pruritus, red rash, pain in extremity and sensitization to be related to Shingrix.  Additional details were provided as follows: After receiving Shingrix, the patient experienced itching. The patient also experienced red rash on his back, buttocks, arms, hands and palms. His hands and palms were also painful, itching, and sensitive to warm water. The patient used topical cortisone and prescription cream. When he initially noticed the rash he took Benadryl. The day after he noticed the rash, he visited his physician assistant, and had blood work done for an allergy test. The results showed that he was allergic to alphagalactose. He also saw his allergist and was told to stop eating red meat and carry an EpiPen with him.      Lab Comments: On an unknown date, lab test was performed",69.0,Seniors,1,0
866600,"first shot made my stomach upset; if there is anything I can take that will help with my stomach ache; This case was reported by a consumer via call center representative and described the occurrence of upset stomach in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced upset stomach and stomach pain. On an unknown date, the outcome of the upset stomach and stomach pain were unknown.   It was unknown if the reporter considered the upset stomach and stomach pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The first shot made patient's stomach upset. The patient just wanted to know if there was anything he/she can take that would help with stomach ache. The patient was nervous about the 2nd dose.",,Unknown,1,0
913054,"At 1430, she received the COVID-19 vaccine and started feeling flushed, right-sided neck tightness, and throat constriction shortly afterwards. At 1435, she was given a dose of epinephrine and brought to the Emergency Department for further evaluation. Upon arrival to the Emergency Department, the patient reports feeling better. Her last menstrual period was 2 weeks ago. No rash or itching. No history of anaphylaxis to vaccines. No history of COVID-19 diagnosis. Denies pregnancy.",43.0,Adults,0,1
913222,On the second day I had a sore arm and I woke up with a headache that lasted 2 hours.,30.0,Adults,1,0
910552,"feels sluggish; had a little bit of fever yesterday; Warm feeling shooting in head; developed a warm feeling in his head that turned into a headache; This is a spontaneous report from a contactable consumer. A 57-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EM9899), via an unspecified route of administration (arm left) on 16Dec2020 at single dose for precaution for front line worker. The patient's medical history included blood pressure abnormal, blood cholesterol abnormal, diabetes, enlarged prostate, sleep disorder, on anticoagulant therapy, and migraine. Concomitant medications included lisinopril, simvastatin, metformin hcl, tamsulosin, dutasteride, zolpidem, aspirin [acetylsalicylic acid], and melatonin. It was reported that the patient experienced warm feeling shooting in head on 16Dec2020. It was further reported that the patient developed a warm feeling in his head that turned into a headache on 16Dec2020. The patient also experienced slight fever on 1Dec2020. The patient received the vaccine on Wednesday afternoon (16Dec2020). The patient stated, ""initially it felt weird; for a couple of minutes, it felt ok and then he felt a warm feeling shooting in his head, like when you take strong medications or do MRI. It gives you that strong feeling. It was cold or warm but shoots in head. He felt it, so he went to occupational health and it went away. He went home early and did not finish his shift. Then he got a headache and it did not go away and it is not severe. He feels sluggish and had a little bit of fever yesterday and took Tylenol and it went away. He still had a headache and it bothers him. He cannot remember the name of the medication that he got the warm feeling shooting in his head, but he believed it was when they did a dye for an MRI. He does not have the name and did not have a lot or expiration. He works at a hospital but not as a healthcare provider. He got the vaccine a few day ago and later stated it was Wednesday, 16Dec2020 warm feeling started an hour after getting the vaccine. As soon as he went to occupational health, it went away and improved. He did not have the headache yet. He did not work his full shift. He got home at night and felt not too bad of a headache. He has a history of migraines and he can feel somehow, he is starting to have a headache. It is not severe though. The headache started that night and it is still there. It is not so severe, but it bothers him. When he had a slight fever, it is gone after taking Tylenol. He never actually checked his temperature, he just felt warm. He takes medications every day, so he took medications the night before and did not take other medications since then. He wanted to find out if there was any interaction with the vaccine before taking them again. The outcome of event fever was recovering, events warm feeling shooting in head and headache was not recovered, and the event feels sluggish was unknown.",57.0,Adults,0,0
871926,"patient who received a possibly expired vaccine, no adverse event; Initial information was received on 22-May-2020 regarding an unsolicited valid non-serious case from a nurse  This case involves a child patient who possibly received an expired dose of DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL].  Medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.   On an unknown date, the patient received a dose of suspect DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE (lot C5202AA, expiry date 16-May-2019) via unknown route at an unknown administration site for prophylactic vaccination.  It was a case of an actual medication error due to expired vaccine used.   At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
902876,"flu; Initial information received on 19-Nov-2020 regarding an unsolicited valid non-serious case received from a consumer or non-healthcare professional via social media.  This case involves a 56-years-old patient who experienced flu (influenza), when received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious flu (influenza) unknown latency following the administration of INFLUENZA VACCINE.  Laboratory details were not reported.   It was not reported if the patient received a corrective treatment.  The event outcome was unknown for influenza.  There will be no information available on the batch number for this case.",,Unknown,0,1
899561,"No patients reported any additional adverse experiences as a result of receiving the improperly stored vaccine; Since the receipt of the late shipment, the vaccine has been administered to 6 patients; Information has been received from a medical assistant, referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 30-NOV-2020, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) lot # T014309, expiration date on 24-APR-2022, 0.5 milliliter (administration route and anatomical location were not reporter) for prophylaxis. The reporter stated when she first received the vaccines, she for some reason thought the current date of receipt was actually 27-OCT-2020 and not 29-OCT-2020 and that the product was received on time. She immediately placed the product into the freezer. Since then, the reporter stated that she let them know what happened and that the product was actually received 2 days late. Since the receipt of the late shipment, the vaccines has been administered to a 6 patients. No patients reported any additional adverse experiences as a result of receiving the improperly stored vaccine. The reporter stated that when she opened the package, the information and logger inside the package stated the product was ""ok"" but she does not have any of that paperwork at this time as when it was found ""ok"". This is one of several reports received from the same source.; Sender's Comments:  US-009507513-2011USA013293: US-009507513-2011USA013200: US-009507513-2011USA013620: US-009507513-2011USA013163: US-009507513-2011USA013851:",,Unknown,0,1
860112,"No additional adverse events reported; improperly stored vaccines may have been administered to patients; This spontaneous report has been received from a nurse, referring to patient of unknown gender and age. Information about the patient's pertinent medical history, concurrent conditions, and previous drugs reactions or allergies were not provided. Concomitant therapies included sterile diluent (MERCK STERILE DILUENT).  On 31-DEC-2019, the patient was vaccinated with an improperly stored (product storage error) varicella virus vaccine live (oka/merck) (VARIVAX) (Therapy type: Digital Data Logger), lot number S003448 and expiration date 04-FEB-2021 for prophylaxis (strength, dose, dose number, frequency, route of administration, and anatomical location, were not provided). The sterile diluent (MERCK STERILE DILUENT) used for reconstitution was properly stored (lot number S025291 had not been valid upon internal validation; expiration date 23-APR-2022).  The vaccine was stored at a temperature from 6 degree Fahrenheit to 14 degree Fahrenheit (7.2 Fahrenheit), for a timeframe of 25 minutes, with no previous temperature excursion. The call was due to a Digital Data Logger.  No additional adverse events were reported.  This case is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2001USA009007:",,Unknown,0,1
916387,"Shortly after receiving vaccine I had moderate COVID symptoms and my significant other tested positive for COVID 2 days later.  I figured I had it also, but I was just tested and my COVID-19 swab was negative.   My side effects following vaccination were fever (max 102.2), chills, fatigue and body aches.  The mild symptoms began the Saturday morning after the vaccine and included some fatigue and a headache.  By Tuesday night I was having more severe symptoms that lasted through Sunday 12/27.  My negative COVID test was performed on 12/30/20.",42.0,Adults,0,0
897777,vasovagal syncope,15.0,Kids,0,0
902989,"Headache, fatigue, temperature of 100.3. Lasted about 8 hours.",33.0,Adults,1,0
870608,"Patient reports redness and swelling from shoulder to elbow starting the day after vaccination and continuing for 10 days, followed by rash and itching",65.0,Adults,1,0
861856,Patient developed severe bruising and redness both at the injection site and in another spot below the injection site.,55.0,Adults,0,0
907777,Severe neck and spine pain. No neurological symptoms noted but severe pain. Feels muscle related.,36.0,Adults,1,0
905567,Hep A vaccine administer that was ordered,,Unknown,0,1
910309,"fainted right after taking the vaccine; This is a spontaneous report from a non-contactable consumer (Pfizer company representative).  A female patient of an unspecified age received the bnt162b2 (BNT162B2; also reported as COVID-19 vaccine; Batch/lot number, NDC number, Expiry Date: Unknown), via an unspecified route of administration on 17Dec2020 at a single dose for COVID-19 immunization.  The patient medical history was not reported.  The patient's concomitant medications were not reported.  The patient experienced fainted right after taking the vaccine (medically significant) on 17Dec2020. It was unknown if the patient received other products, and any investigation assessment was unknown. The clinical course was reported as follows: The reporter stated they had seen quite a bit on social media and on the (site name), where people have been sending around a video regarding a healthcare worker who fainted. The caller was just wondering "" if Pfizer has been made aware of this. ""Apparently, this was on the news. This healthcare worker was taking the COVID-19 vaccine and as she was talking to the press, she apparently fainted. It looks as if she fainted as one would do when taking blood tests or faint from fear of a shot or being worried. However, this video has been sent all over social media, as seen as an AE, and telling people to not take the vaccine."" The reporter further clarified the healthcare worker was in (city name) and received the COVID-19 vaccine. As the healthcare worker was talking to the press, she fainted right after taking the vaccine. The reporter further clarified she was sent a link via (site name) from the news channel where it had the video recording. The reporter did not have a specific reporter. The reporter explained it was a "" whole group that was talking about it."" The reporter clarified she was in a (state name) group on (site name) with friends and family. The reporter also saw it on social media. "" People are sending it left and right."" When probed to determine if the reporter had any patient details or further details regarding the event, the caller stated the only information she had was that on (News name), and click on (City name) news and find the video of the healthcare worker taking the vaccine and fainting. The reporter clarified the news article was dated as 17Dec2020 ""so this event must have happened yesterday."" From the reporter's understanding from the news, the patient was fine, she got up.  ""However, people are sending out on social media that she is dead"", which the reporter did not think was the outcome. According to the news, when the reporter opened the link, it was just a regular fainting, it was not a death.  The reporter felt obligated to report and make sure Pfizer was aware of this since she had been seeing it everywhere on social media. The clinical outcome of the event, fainted right after taking the vaccine, was unknown.  No follow-up attempts are possible; information about batch/lot number cannot be obtained.",,Unknown,0,1
892260,"I believe the patient stated that all three vaccines were administered in the same arm, but our documents don't specify for sure.  The patient started experiencing issues before he had even arrived home, 15 minutes after leaving the pharmacy.  It started out with an upset stomach, then a headache followed.  He said that a few hours later he noticed having chills and muscle soreness with erythema in the injection site.  Most of these adverse reactions had dissipated by the next morning except the redness and soreness which is still there today (10/23/20), three days later.",88.0,Seniors,0,0
889815,"deathly ill with the flu until it finally killed her; Initial information received on 07-Oct-2020 regarding an unsolicited valid serious social media case from a consumer/non-health care professional via public post on the Sanofi flu shot campaign.   This case involves female patient (unknown age) who was deathly ill with the flu until it finally killed her (influenza), while she received INFLUENZA VACCINE.  The patient's past vaccinations included flu shots (INFLUENZA VACCINE) every year and every year she was deathly ill with the flu.  Concomitant medication(s), medical treatment(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer lot number and expiration date were not reported) via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient was deathly ill with the flu and that it finally killed her (influenza) (serious) (Unknown latency) following the administration of INFLUENZA VACCINE. This event was leading to death.  No laboratory data reported.  It was not reported if the patient received a corrective treatment.  The outcome of the event Influenza was fatal as the patient died due to it on an unknown date.  It was not reported whether the autopsy was done or not and the cause of death was reported as Influenza.  Information on the batch number to be requested.; Sender's Comments: A case was reported which involves a female patient of unknown age who died due to influenza, after vaccination with INFLUENZA VACCINE (unknown manufacturer). Time to onset was unknown. The patient used to have flu shots every year and had got ill every time in the past. Additional information regarding patient's relevant medical history, health condition at time of vaccination, concomitant medication and Laboratory tests, autopsy results is needed for complete assessment of the case. Thus, a role of the vaccine could not be assessed.; Reported Cause(s) of Death: deathly ill with the flu until it finally killed her",,Unknown,0,1
899972,"Right arm-sever pain at injection site, swelling, redness, limited mobility. Body aches, high-grade fever 103.3, vomiting, nausea, fatigue, Decreased appetite, abdominal cramping, low back pain",40.0,Adults,1,0
880304,Severe joint pain in ALL joints just like it felt when I had interferon injections (many years ago) with a fever of 101* for about 8 hours with the chills. This was my first shot.,61.0,Adults,1,0
898099,"A 10 year old patient was vaccinated with Flublok, no AE; Initial information regarding an unsolicited valid non-serious case was received from a other health care professional via The Agency (Reference number- 00333429) and transmitted to Sanofi on 27-Oct-2020.  This case involves a 10 year old female patient who was vaccinated with INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] (lot: QFAA2053, expiry: 30-Jun-2021) once via unknown route in the right arm for prophylactic vaccination on 27-Oct-2020 (product administered to patient of inappropriate age)  Medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient did not receive any other vaccinations or medications   It was a case of an actual medication error due to inappropriate age at vaccine administration (latency same day).  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error",10.0,Kids,0,1
891845,"No further AE; temperature excursion involving multiple lot numbers for GARDASIL 9, MMR II, ROTATEQ, and RECOMBIV AX. Many of the vaccines have been administered to patients; This spontaneous report was received from a practice manger and refers to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions, allergies and concomitant medications were not reported.  On 10-SEP-2020, the patient was vaccinated with improperly stored dose of hepatitis b vaccine (recombinant) (RECOMBIVAX HB) lot #S022584, expiration date: 31-OCT-2020, dose: 1 injection (exact dose, dose #, route of administration and anatomical location were not reported) for prophylaxis.  The temperature excursion took place on 04-AUG-2020 and was as follows: below 2 Celsius degree (C) (1.1 C) for 27 hours and 45 minutes and above 9 Celsius degrees (9 C) for 1 hour and 15 minutes. There were no previous excursions reported. The digital data logger was involved. No further adverse events (AE) or product quality complain (PQC) were reported.  This is one of multiple reports received from the same reporter. combinationproductreport: Yes; brandname: RECOMBIVAX HB SYRINGE (DEVICE); commondevicename: Hepatitis B Vaccine (Recombinant); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: S022584; expirationdate: 31-OCT-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2010USA001083:Same Reporter",,Unknown,0,1
886949,"Neck swelling at dinner, feeling of swelling over entire left side by the end of the evening.  Severe pain.  I'd been told reaction may be minor, lasting 24-48 hours, nothing like what ensued.  By that evening I was unable to move or lift my head.  My husband had to hold my head and accompany me in order for me to get out of bed and go to the bathroom.  Pain severe.  Notified primary care physician.  Nothing I could take that I wasn't already taking.  Slept for 5 days with this pain.  Today, 9 days later, I still have residual neck pain and am unable to drive because of limited neck movement.  My research indicates I never should have been given this vaccine, having had RA, and telling the nurse this.  I even asked her why I needed the vaccine if I've had shingles as well as chicken pox, and she said there's a debate about that.",65.0,Adults,0,0
860442,"Large area of redness, spreading around inner thigh and almost to the back of thigh. Swollen and warm to the touch.",1.42,Kids,0,0
912279,Metallic taste in mouth.,47.0,Adults,0,0
904166,"Flushing, rash, dizziness, lightheadedness, slightly elevated BP and heart rate",53.0,Adults,1,0
871760,"Your child received a vaccination at our clinic during the period between February 28 and April 16, 2020. During the period between February 28th, 2020 and March 2nd, 2020, our data logger had a technical malfunction that we were not aware of and it stopped sending its temperature recordings to the system.  During that period the fridge never stopped working. The temperature logs of the fridge before and after the incident were always within required range. Our fridge has been always in a perfect new condition and never had any temperature problems previously. There was no power outage in the area or inside the office during that period as well.       The CDC requires continuous temperature monitoring of all vaccines and due to lack of continuous temperature data documentation, the vaccine manufacturers have determined that the doses administered on these dates should be re-administered to ensure proper effectiveness.",0.17,Kids,0,1
870813,Immediate pain from left arm after injection. Continuous pain in arm/shoulder since the day of the shot during the day and night. Limited mobility as it is painful to reach for items or hold any weight in left hand. Pain is still continuing. Birth information: Due date is July 30th 2020,32.0,Adults,1,0
916230,"Swelling in neck and behind left eye.  Note fromMD: Female who complains of swollen feeling on neck and behind eye. Now improved. No other complaints. Exam: No swelling observed, no other findings. Plan: Home with primary care provider follow up. Unlikely to be significant allergic reaction.",39.0,Adults,0,0
899838,Flu vaccine was not administered correctly. the dose was not injected into the muscle of the arm as recommend.,72.0,Seniors,0,1
906529,"When I got the vaccination I was 32weeks pregnant and on Saturday I had spontaeous rupture of the amnotic fluids and went immediately to the hospital and was immediately given steroid, magnesium for the baby.  And on Sunday around 3:45PM I got a second round of the steroids and was transferred for observation.  On Monday, at 8:06am I went into early labor I delivered my baby at 33weeks gestation and she weighed 3lb 11oz.  Expected Date of Delivery-2/8/2021.  I was a high risk patient d/t Fibroids but have experienced no issues the entire pregnancy and my last ultrasound was 12/17 and baby was healthy with no complications at that time.",34.0,Adults,0,0
863175,"My 12 year old daughter had a reaction to th HPV 9 shot. She received it 11/26/2019. Within 3 weeks, she started having low platelets. She was diagnosed with ITP 1/7/2020. This is currently an ongoing problem. Her body is continuing to make antibodies that are destroying her own platelets. She was a healthy, normal, active athlete before this shot.",,Unknown,0,0
887667,"pain and weakness in my left elbow joint and in the muscles above and below the elbow/Sore elbow joint; weakness in my left elbow joint and in the muscles above and below the elbow/weak elbow joint; pain and weakness in my left elbow joint and in the muscles above and below the elbow; weakness in my left elbow joint and in the muscles above and below the elbow; This case was reported by a consumer and described the occurrence of joint pain in a 67-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 21st September 2020, the patient received the 1st dose of Shingrix. In September 2020, less than 2 weeks after receiving Shingrix, the patient experienced joint pain, joint disorder, muscle pain and muscle weakness. On an unknown date, the outcome of the joint pain, joint disorder, muscle pain and muscle weakness were unknown.   It was unknown if the reporter considered the joint pain, joint disorder, muscle pain and muscle weakness to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient was in good health. The patient received the first Shingrix shot on 21st September 2020 in my left arm. Ever since the patient experienced continuous pain and weakness in the left elbow joint and in the muscles above and below the elbow. The patient contacted his primary care physician but did not seemed alarmed. The patient questioned what was going on and should he be concerned.",,Unknown,1,0
862027,Headache Muscle pain Chills,53.0,Adults,1,0
856924,"Vomiting (multiple times within an hour, Hives across entire body.  Due to multisystemic symptoms I would classify as mild anaphylaxis however due to no breathing difficulties attending physician did not agree.  Provider notes as follows: MD at 1/16/2020  6:37 AM Emergency Department Sign-Out Note   Time of transfer: 6AM   Care transferred from: Dr.    Condition at time of transfer: Stable   Brief HPI Patient is a 5 y.o. female pmh T1DM and DKA presented with N/V/ glucose 300s/ transient hives and was awaiting period of observation at the time of signout.   Please see Dr. and Dr.'s notes for initial evaluation, assessment, and plan.  Briefly, pt started on basal insulin yesterday.  Leading dx is immune stimulus.  Extremely low clinical suspicion for anaphylaxis. Received zofran w some improvement.     ED Course (since sign-out to me) UA remarkable for glucosuria and ketonuria.  Ordered DKA work-up which was extremely reassuring against DKA. Pt was observed in ED for several hours and continued hives primarily over her trunk remained but remained HS and comfortable wo other symptoms, playful and extremely well-appearing. Discharged home w return precautions and close f/u w pediatrician.   The patient was signed out to me by preceding ED team.  Please see their notes for full details.  I assumed the patient's care, reviewed the medical record, and discussed the patient's ED course with the previous treatment team.  Pertinent labs and studies have been reviewed.     MD Resident 01/16/20 1319   Electronically signed by, MD at 1/16/2020  1:39 PM MD at 1/16/2020  5:47 AM       Chief Complaint Patient presents with ? Emesis     HPI    5-year-old female previously healthy type I diabetic presenting to the emergency department with 2 episodes of nonbilious nonbloody emesis at home with episode of hyperglycemia.  Patient woke up and went to mother for not feeling well.  She vomited.  Mom noticed her sugar on her pump was in the 300s so gave her insulin per sliding scale. Pt in low 100s prior to bed. Pt broke out in hives to left UE, so mom called EMS. By the time EMS arrived, hives resolved so mom sent EMS away. Immediately after, pt again vomited a second time.    Transported to the ED by EMS. No hx of allergies. Sister in room with hx of allergies to nuts, hx of asthma. Pt without hx of asthma. Mom concerned about ?anaphylaxis given GI symptoms + temporary rash.    Allergies Allergen Reactions ? Other [Unclassified Drug] Hives     flinstones multivitamin      Review of Systems General: no fever Head: no headache Eyes: no vision changes Neck: no sore throat Cardiovascular: no chest pain Respiratory: no shortness of breath GI: + nausea, + vomiting GU: no dysuria   10 systems were reviewed and negative except where detailed above.      Physical Exam  Constitutional: She appears well-developed. No distress.  HENT:  Mouth/Throat: Mucous membranes are moist.  Eyes: Pupils are equal, round, and reactive to light.  Neck: Normal range of motion.  Cardiovascular: Normal rate, regular rhythm, S1 normal and S2 normal. Pulses are strong.  Pulmonary/Chest: Effort normal and breath sounds normal. There is normal air entry. No respiratory distress. Air movement is not decreased. She has no wheezes. She exhibits no retraction.  Abdominal: Soft. She exhibits no distension. There is no tenderness.  Musculoskeletal: Normal range of motion. She exhibits no tenderness or deformity.  Neurological: She is alert.  Skin: Skin is warm. Capillary refill takes less than 2 seconds. She is not diaphoretic.      Procedures   MDM   ED Course:       5-year-old female with history of type 1 diabetes presenting with episode of vomiting and temporary rash to upper extremity.  Patient had sugars in 300s this morning which have since improved with appropriate dosing of insulin.  Mom concerned about anaphylaxis however patient has no wheezes, no rash, no hypotension, no persistent GI symptoms. Will get UA to eval for ketones and monitor. Will give zofran for nausea. Will give benadryl for hives which have since resolved. No known food allergies. Doubt anaphylaxis given presentation.    Plan for UA, and monitor in ED with repeat exam. If persistent neg symptoms, will discharge home with close pcp f/u.    MD 01/16/20 0638",5.0,Kids,1,0
868043,"TOOK ONLY ONE DOSE; This spontaneous case report (PVX2019-2856) was received from a pharmacist on 19-Nov-2019. It described an adult (18 to 22-year-old) male consumer who ""took only one dose"" (PT: Product dose omission), while being on Vivotif for an unknown indication.  Case report: The consumer took only first dose of Vivotif on 14-Nov-2019.  Action taken with Vivotif with respect to the reported event was not applicable.  The clinical outcome of the reported event was unknown.  Company comment: It was reported that a patient only took one dose of Vivotif (missed dose). Further detail of the event is limited.  Considering the nature of the event, the causality of the event missed dose is assessed as not related.; Sender's Comments: It was reported that a patient only took one dose of Vivotif (missed dose). Further detail of the event is limited.  Considering the nature of the event, the causality of the event missed dose is assessed as not related.",,Unknown,0,0
897479,Patient  experience extreme pain in the left arm of the injection site for a week and  pain in the top of head immediately after injection was completed.,,Unknown,1,0
879203,Per pt she started having swelling over her body including the face about 30 minutes after receiving the vaccine. She took Benadryl and went to the emergency room where they administered more Benadryl and steroids. She was discharged 08/11. Dropped off script for a 4 day course of prednisone at 7:30pm on 08/12.,50.0,Adults,0,1
912951,"received injection at 13:04, went to observation area. reported brief dizzy spell at 13:20.  Drank water, BP right arm 184/101, BP left arm  166/90 at 13:25.  Patient reported only brief episode of dizziness and no further dizziness.  User reports they ate lunch 1.5 hours earlier.  BP 173/90 at 13:30.  User reports she feels fine and will recheck BP when she gets home and follow up with her PCP.  User waited 5 additional minutes before leaving with no further adverse effects.  Total time of observation post injection was 30 minutes.",54.0,Adults,1,0
879624,"I woke up early morning (about 4:00 a.m. but am not sure feeling achy, felt a little sick to my stomach, could not move my head or neck in bed and felt really stiff in my neck and shoulders.  I used my right hand to push myself onto myself and could then use  move my head, sat up and walked around but felt really stiff and achy and lethargic all day.  Also had chills but no fever.  Used a pulse oxy-meter and my oxygen levels were normal.  Next day still felt sick.  I did some yard work and my right hand and thumb started spasming, very painful.  lasted on and off for about an hour.  Next day the spasming was gone (three days after the shot) and then I started to feel better.  I still have a little bit of ""weirdness in my right thumb but it isn't spasming anymore.",60.0,Adults,1,0
880914,"No additional adverse events.; on 7/1/2020 an 18 year old patient was inadvertently administered PROQUAD.; This spontaneous report was received from a registered nurse, referring to an 18-year-old male patient.  The patient's pertinent medical history, previous drug reactions, or allergies, were not reported.   On 01-JUL-2020, the adult patient was inadvertently vaccinated with  measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) injection, as prophylaxis (strength, dose, vaccination scheme, route of administration, and anatomical site of vaccination were not reported; lot number S012533, which has been verified to be valid, the expiration date was unknown by the reporter, but upon internal review was determined as 20-OCT-2020) (product administered to patient of inappropriate age). As concomitant therapy, sterile diluent (MERCK STERILE DILUENT) was used to reconstitute the vaccine. No additional events were reported.",18.0,Adults,0,1
911791,developed raised red bumps on arms and legs several hours after receiving vaccine.,56.0,Adults,0,1
855559,"On 11/17/2019 Started coughing,  runny nose and itching, and red rashes on face, back, and legs.",75.0,Seniors,1,0
916083,"swelling, itching, hives began1 wk after injection and at injection site",33.0,Adults,0,0
858976,"Sizure; Initial information was received on 27-Jan-2020 regarding an unsolicited valid serious case received from a pharmacist.  This case involves adult female patient (currently 29 year old) who experienced sizure (seizure), while she received vaccine INFLUENZA VACCINE.  Medical history, past medical treatment, vaccination and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) (lot number not reported) via unknown route in an unknown administration site for prophylactic vaccination.  On an unknown date five years ago the patient developed a serious sizure (seizure) on an unknown latency following the administration of INFLUENZA VACCINE. This event was assessed as medically significant.  Laboratory details were not reported.  Final diagnosis was seizure.  It was not reported if the patient received a corrective treatment.  The outcome was unknown for the event of seizure.  Information on the batch number was requested.; Sender's Comments: This case concerns an adult female patient who experienced seizure after vaccination with INFLUENZA VACCINE from unknown manufacturer. The time to onset was unknown. Patient's medical history, medical condition at time of vaccination and lab test ruling out alternate etiologies were not reported. Based upon the reported information, the role of the vaccine cannot be assessed.",,Unknown,0,1
910049,Immediately after vaccine my face started getting hot and itching. swelling to my face and neck area  I took zyrtec for the adverse events,43.0,Adults,0,1
903505,"Issues were similar to what I have experienced with the flu vaccine but a bit more pronounced including soreness at the injection site (moderate), tiredness (moderate),  joint pain (moderate), headache (mild). The worst of the symptoms started on the first day post-vaccine and subsided about 36 hours later.",33.0,Adults,0,0
866710,"THREW UP; This spontaneous case (PVX2019-1538) was received from a pharmacist on 13-Jun-2019. It describes an 18-year-old male consumer who threw up, after the administration of Vivotif for an unknown indication.  Case report: The consumer threw up 15 minutes after taking the final dose of Vivotif.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: In this case, it was reported that the consumer  threw up after the administration of Vivotif. There seems to be a temporal association between the intake of the vaccine and the event. Hence, the causality of the event with Vivotif is assessed as possible.; Sender's Comments: Company's Comment: In this case, it was reported that the consumer  threw up after the administration of Vivotif. There seems to be a temporal association between the intake of the vaccine and the event. Hence, the causality of the event with Vivotif is assessed as possible.",,Unknown,0,1
861949,"Foetal exposure during pregnancy; Preterm birth at 36.9 gestational age; This is an observational study case  initially received on 03-Feb-2020, concerning a neonate female subject whose  mother was 33-year-old female pregnant, of body weight 243.4 lbs, height 64 inches and body mass index (BMI) 41.8, enrolled in, a prospective observational study.  The subject's mother current conditions included increased BMI, gestational diabetes mellitus (DM) and polycystic ovarian syndrome.  The subject's mother concomitant medications included prenatal vitamins (unspecified vitamins and minerals) as neonatal care and Metformin HCL ER (metformin hydrochloride) for gestational diabetes.   The subject's mother obstetrical history noted that the mother had four previous pregnancies of full-term live birth with no birth defects. The subject's mother had no maternal or paternal history with major congenital malformations (MCMs). The subject's mother had no history of offspring with MCM. The subject's mother did not use tobacco, alcohol or illicit drugs during pregnancy.   The subject's mother last menstrual period (LMP) date was on 03-Jan-2019. The mother's estimated date of delivery (EDD) was reported as 10-Oct-2019, while corrected estimated date of delivery (CEDD) was reported as 07-Nov-2019. The type of pregnancy was singleton. The subject's father was 35 years old.  On 02-Apr-2019, the subject's mother underwent ultrasound and no MCMs were noted.  On 29-Apr-2019, the subject's mother underwent first trimester screen and no MCMs were noted.  On 24-Jun-2019, the subject's mother underwent ultrasound and no MCMs were noted.  On 12-Sep-2019, at approximately 32 weeks of gestation, the subject's mother was administered Flucelvax QIVc( Flu Vaccine Cell Subunit QIV NVD) [influenza vaccine, subunit influenza virus vaccine polyvalent, batch number: 261207, dose: 0.5 mL, route of administration, anatomical location and expiration date: not reported] (explicitly coded as 'Foetal exposure during pregnancy') for influenza immunisation.  At approximately (reported as) 36.9 weeks of gestation,, the mother delivered a live female neonate via caesarean method. The characteristics of the neonate included birth weight: 3062 grams, length: 48.3 cm, while head circumference was not reported. Appearance, pulse, grimace, activity, and respiration (APGAR) scores were 7 at one minute, 8 at five minutes and 9 at ten minutes. No MCMs were identified at the time of birth.   At the time of this report, the outcome for the event of premature baby was not reported.  The event of premature baby' was considered as serious due to criterion of medical significance, per company.  The reporter did not provide causality assessment to Flucelvax QIVc.  This case is linked to case number 202001630 (corresponding mother case).  Company Comment: A female neonate was delivered as premature baby after foetal exposure during pregnancy with Flucelvax QIVc, administered at approximately 32 weeks of gestation. Chronology is compatible. The subject's mother history of polycystic ovarian syndrome, gestational diabetes mellitus and obesity (body mass index 41.8) may provide alternative aetiology for the event. Causality was also confounded by subject's mother therapy with concomitant medication, Metformin HCL ER (metformin hydrochloride). Considering all the above mentioned, causality between suspect product and the event premature baby is assessed as unlikely related (defaults to ""related"" in the safety database for reporting purposes). Foetal exposure during pregnancy is assessed as not related per company's conventions.; Sender's Comments: A female neonate was delivered as premature baby after foetal exposure during pregnancy with Flucelvax QIVc, administered at approximately 32 weeks of gestation. Chronology is compatible. The subject's mother history of polycystic ovarian syndrome, gestational diabetes mellitus and obesity (body mass index 41.8) may provide alternative aetiology for the event. Causality was also confounded by subject's mother therapy with concomitant medication, Metformin HCL ER (metformin hydrochloride). Considering all the above mentioned, causality between suspect product and the event premature baby is assessed as unlikely related (defaults to ""related"" in the safety database for reporting purposes). Foetal exposure during pregnancy is assessed as not related per company's conventions.",,Unknown,0,1
893124,Syncope probable approx. 15min after vaccination. Patient claimed she had not eaten all day. No injury when fall to floor- she slumped to floor kept patient in pharmacy for another 10-15 min. and pt wanted to leave. Most symptom resolved after hydrating with electrolytes ie Gatorade. Follow up with pt later in evening-showed no symptoms.,36.0,Adults,0,0
907846,"Little sinus pressure; may be a little bit of soreness of the throat; Little bit a soreness in throat, scratching of little bit but not too sore; or just allergies; Heart rate low/60 beats per minute; Ache in right side of my ribs; This is a spontaneous report from a contactable consumer (patient). A 53-years-old male patient received BNT162B2 (lot number: EJ1685) via an unspecified route of administration on 18Dec2020 at single dose for COVID-19 immunization. The patient medical history was not reported. Concomitant medication included fluticasone propionate. The patient was given vaccine shot (later clarified as Covid 19 vaccine) yesterday and just got a side effects of little sinus pressure, may be a little bit of soreness of the throat. About treatment, the patient took some Advil and he took some sinus pills, congestion pills a little bit earlier. It was clarified as nasal Decongestant, nasal congestion, 30mg, take 2 in 24 hours but he had taken two of them earlier along with 3 Advil pills. He deals with sinuses too but this one is like came on pretty much kind of overnight. He was wondering if doing the shot or something, he was not sure what's the matter or just allergies. It was just the sinus pressure yet. He didn't have the fever, not fever. Little bit a soreness in throat, scratching of little bit but not too sore. His heart rate is 60 per minute so it is low, 60 beats per minute, very low. He had just low heart rate though. About lab work the patient stated that went in for side pain, side ache in right side of his ribs. They did ear analysis, CBC. They all came back normal. He just wanted a report in and see he guessed just find it out if the symptoms go away or maybe he is having sinus infection going on or this sinus be going on so. Events outcome was unknown.",53.0,Adults,0,0
906217,"I got so sick; Initial information regarding an unsolicited valid non-serious case received from a consumer (patient) via social media on 04-Dec-2020.  This case involves a patient of unknown demographics reported got so sick as got the flu shot and got the flu (influenza), while the patient received Influenza Vaccine.  The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medication was unknown.  On an unknown date, the patients received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number not reported) via unknown route in unknown administration site as prophylactic vaccination.  On an unknown date, the patient reported got vaccine two times and got so sick (Illness), stayed in bed three days in misery, both times (influenza) unknown period of time after the administration of influenza vaccine.  It was not reported if the patient received a corrective treatment.  Outcome of the event was unknown, at the time of reporting.  There will be no information available on the batch number for this case.",,Unknown,0,1
882340,shortness of breath extremely fast heart rate,70.0,Seniors,0,0
884137,"fever; gastro; myalgia; This case was reported by a consumer via interactive digital media and described the occurrence of fever in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced fever, gastrointestinal disorder and myalgia. On an unknown date, the outcome of the fever, gastrointestinal disorder and myalgia were not recovered/not resolved.   It was unknown if the reporter considered the fever, gastrointestinal disorder and myalgia to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported but selected as an adult as per the vaccine indication. The patient would like to know, what to take to manage severe side effects of Shingrix that he/she had experienced like fever, gastrointestinal disroder and myalgia.",,Unknown,0,0
903695,"Headache, sweats, low grade temperature (99.3), fatigue, and myalgias. These resolved within 24 hours with two separate doses of 650mg tylenol, but the fatigue persisted for 48 hours.",29.0,Adults,0,0
899460,"Office vaccinated a 6 month old with Fluzone Quad and gave the baby 2 doses of 0.5 mL with no adverse event; Initial information received on 06-Nov-2020 regarding an unsolicited valid non-serious case received from a consumer/non-hcp.  This case involves a 6 month old who was vaccinated by an office with influenza quadrival a-b vaccine [Fluzone Qiv] and gave the baby 2 doses of 0.5 ml (extra dose administered) (batch number: UT7041JA and expiration date: 30-Jun-2021) via intramuscular route in 1 in right and 1 left unknown administration site for prophylactic vaccination.  Medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.  This was an actual medication error case due to the event extra dose administered (latency: unknown).  At the time of reporting, no adverse event was reported.  No laboratory data was reported.  Disclaimer: this suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in directive 2001/83/ec and module VI of the good Pharmacovigilance practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",0.5,Kids,0,1
916194,Pain in injection site. Red rash around injection site (Getting Bigger),26.0,Adults,1,0
878822,"Patient states 2 hours after the injection she developed Body pain, shaking, headache, nasal congestion and cough that lasted for 2 days.  While speaking to pt still have cough",66.0,Seniors,1,0
864378,"Extreme exhaustion, extreme cold, headache, dry nostrils, weakness",59.0,Adults,1,0
874648,"shingles; Information has been received from a lawyer regarding a case in litigation concerning a female patient (pt) of unknown age. The pt's medical history, concurrent conditions and concomitant medications were not provided. In or about 2013, the pt was vaccinated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, anatomical location, lot#, expiration date were unknown) by a healthcare provider at a clinic for the long-term prevention of shingles and/or zoster-related conditions. Subsequent to pt's zoster vaccine live (ZOSTAVAX) inoculation, pt was treated by a healthcare provider for shingles. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), pt had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of shingles was unknown and the causal relationship between shingles and zoster vaccine live (ZOSTAVAX) was considered related.",,Unknown,0,0
884507,"Patient received a flu shot, approximately 10 minutes later she felt light headed and fell.",71.0,Seniors,0,1
884837,"anaphylactic reaction; blood pressure went up; dizzy; could not breathe; heart raced; Initial information received on 14-Sep-2020 regarding an unsolicited valid serious case received from a (patient) consumer/non-healthcare professional.  This case involves a 80 years old female patient whose blood pressure went up (blood pressure increased) was dizzy (dizziness) and she could not breathe (dyspnoea) and her heart raced (palpitations), and it was resulted into anaphylactic reaction, while she received INFLUENZA VACCINE.  The patient's medical history, past medical treatment, past vaccination and family history were not provided. Concomitant medication were not reported.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number not reported) via an unknown route and administration site for prophylactic vaccination.  On an unknown date, the patient's blood pressure went up (blood pressure increased) was dizzy (dizziness) and she could not breathe (dyspnoea) and her heart raced (palpitations), and it was resulted into anaphylactic reaction (unknown latency) following the administration of INFLUENZA VACCINE.   These events were assessed as medically significant.   Relevant laboratory test results included: On an unknown date, the blood pressure was increased.  The patient cannot take ibuprofen, lidocaine and cortisone.  The event outcome was reported as unknown for anaphylactic reaction.  Information on the batch number was requested; Sender's Comments: This case concerns a 80 years old female patient who experienced anaphylactic reaction (unknown latency) following the administration of INFLUENZA VACCINE  produced by unknown manufacturer.  Medical history concomitant medication, lab data ruling out alternative etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of the vaccine could not be assessed.",,Unknown,0,0
881650,"Vaccine was administered subcutaneously rather than Intramuscular and  I have injection site pain, tenderness, swelling, redness and general ill-feeling.",59.0,Adults,0,0
863556,On 2/13 20 patient are became sore and she became tired after 2 hours of vaccine. the next day those symptoms were still present and she started to have body aches these symptoms lasted 24 hours.,57.0,Adults,0,1
893437,"No adverse event/ pt is fine; Caller reported administration of PROQUAD after product experienced temperature excursion.; This spontaneous report was received from a medical assistant and refers to a 5-year-old male patient. The patient had no pertinent medical history, concomitant medications and drug reactions or allergies.  On 06-OCT-2020, the patient was vaccinated with a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (rHA) subcutaneously in left vastus lateralis (LVA) (also reported as left vast laterials), lot # T015598, expiry date 02-NOV-2021 (dose was not provided) as immunization for the prevention of measles, mumps, rubella and varicella at public health clinic/ hospital. On the same day, the patient was vaccinated with diphtheria toxoid, pertussis acellular 3-component vaccine, poliovirus vaccine inactivated (vero), tetanus toxoid (KINRIX) and influenza virus split virion 3v vaccine inactivated (FLULAVAL). The dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) experienced temperature excursion of 23.7 Fahrenheit degrees (range 15 to 46 Fahrenheit degrees) for 2 hours and 19 minutes. There was no previous temperature excursion. Digital data logger was involved. The patient did not sought medical attention and did not receive any treatment (also reported as it was unknown if the patient required any treatment). The patient was fine. No adverse event was reported.",5.0,Kids,0,1
899503,Flu vaccine given twice within 10 minutes. Mom came with patient to my station.  I asked if patient needed a flu shot and if she had flu shot in the past.  Her mom replied yes to both. Vaccine was given. Nurse that gave first shot asked why I had given her another one.  The nurse said she came to me for a certificate of flu shot for school. Mother is not from here and I do not think she understood my question when she said yes. There was not reaction then and I followed up the following day with mother. The patient was fine without any reactions from shot.,6.0,Kids,0,1
915578,Sudden increase of asthma symptoms that required use of rescue inhaler. Hives appeared on right hand and hive rash appeared on both cheeks of face. Headache. Headache stared midday and continue to increase in severity till onset of asthma symptoms and hives/rash that started about 06:00pm and lasted for about 3 hours. Took rescue inhaler and dose of Benadryl.,39.0,Adults,1,0
909097,"arm soreness: started about 4-6 hours after injection and lasted 3 days; stabbing type stomach/intestinal pain (no nausea, vomiting or diarrhea): started the next day and lasted 3 days (completed this report 3 days after vaccine and still with GI symptoms) ; backache:  started the morning after the  injection and lasted 3 days.  Overall, similar to flu-like symptoms. No significant fever or chills.",60.0,Adults,0,0
876563,"Fever; Flu-like Symptoms; Aching; Chills; Insect Bites; Redness; Itchiness; This case was reported by a consumer via call center representative and described the occurrence of fever in a 67-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   In May 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On an unknown date, less than 3 months after receiving Shingrix, the patient experienced fever, influenza-like symptoms, pain, chills, insect bite nos, erythema and pruritus. On an unknown date, the outcome of the fever, influenza-like symptoms, pain, chills and erythema were recovered/resolved and the outcome of the insect bite nos and pruritus were not recovered/not resolved.   It was unknown if the reporter considered the fever, influenza-like symptoms, pain, chills, insect bite nos, erythema and pruritus to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. After receiving Shingrix, the patient experienced fever, flu-like symptoms, aching, chills, insect bites, redness, and itchiness. The reporter was consented to follow up.",,Unknown,1,0
911592,"Injection sight began to become sore around 6:30pm on 12/28, which kept me up all night with the soreness worsening. Throughout the night, I had severe chills, which is not normal for me.",27.0,Adults,1,0
889049,"PATIENT IS EXPERIENCING REDNESS, SWELLING AND SEVERE PAIN AT  THE INJECTION SITE. SHE STATES IT IS PAINFUL TO MOVE HER ARM OR SLEEP ON IT.",75.0,Seniors,1,0
869568,"Patient had a minor cold for 2-3 days prior to the vaccines.  She had a runny nose, sniffle, and mild fever one night.  She was on the mend and doing better prior to the vaccines.  The doctor told me that it would be fine if her fever was more than 24 hours prior.  It was but she was still slightly stuffy.  She got the vaccines and within 24 hours afterward was not sleeping through the night like she had been for months prior.  She was screaming nearly non-stop.  She proceeded to regress into her cold again but this time worse.  She developed an ear infection.  She received an antibiotic.  This gave her diarrhea, a topical yeast infection on her vulva and groin and did not help the infection.  She then received another antibiotic from a different pediatrician for a double ear infection and a topical nystatin for her yeast infection on her vulva/groin.  This slowly improved over 14+ days.  She now has muscle spasms in her face (eyebrows and jaw) and has ongoing diarrhea and constipation alternating since this episode.",1.0,Kids,0,0
2767778,"a 13 years old patient was inadvertently given a dose of FLUBLOK QUADRIVALENT, No AE; Initial information was received on 28-Sep-2020 regarding this unsolicited valid non-serious case from a pharmacist via phone.  This case was linked to case 2020SA267028 (same reporter).  This case involved a 13-years-old patient who was inadvertently given a dose of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV]  (lot QFAA2003 and expiration date: 19-May-2021) via an unknown route and administration site on 26-Sep-2020 for prophylactic vaccination (product administered to patient of inappropriate age).  Medical history, past medical treatment, vaccination, concomitant medications and family history were not provided.   It was a case of an actual medication error due to inappropriate age at vaccine administration (latency was same day).   Reporter wanted to know if any data available on use of Flublok quadrivalent for pediatric patients and whether the patient needed additional flu vaccines this season.   At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",13.0,Kids,0,1
882793,Patient woke up in middle of night with facial swelling and hives. Had hives throughout body and neck. He had high respiratory rate and was admitted to the hospital. He was hospitalized for 1 day and presented with low oxygen while hospitalized.,36.0,Adults,0,0
896789,"Suspected vaccination failure\Shingrix in September. Was diagnosed with Shingles for the first time last week; Shingles; This case was reported by a consumer via call center representative and described the occurrence of suspected vaccination failure in a 79-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   In September 2020, the patient received Shingrix. On an unknown date, between 1 and 3 months after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported The case has been considered as suspected vaccination failure being full schedule was unknown.",,Unknown,0,0
914925,"Left arm underneath is red under the injection site.  can move the arm, and sore",33.0,Adults,0,0
910263,"FLUSHING, HIVES, FACIAL NUMBNESS ON THE LEFT SIDE",31.0,Adults,0,0
862015,Tenderness left upper arm. Ibuprofen  600 mg every 8 hours PRN x 5 days.,42.0,Adults,0,0
893318,"sore arm. Arm soreness; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 84-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 22nd October 2020, the patient received the 1st dose of Shingrix. On 22nd October 2020, 6 hrs after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was not recovered/not resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in the left arm and experienced a sore arm.  The reporter did not consent to follow-up.",84.0,Seniors,1,0
912857,"covid vaccine given at 1030am 12/28/20 bed ridden from pain, dizziness, nausea, and lightheadedness from 2pm 12/28/20 to 4pm 12/29/20. severe muscle pain in L upper pain which peaked around 1230am generalized muscle aches dehydration even though constant fluid drinking nausea, lightheadedness, dizziness if speaking more than one sentence at a time, shortness of breath  vitals (taken 5pm 12/29/20) BP 131/87 (normal is usually 116/56) HR 95-105 (normal resting is around 70s-80s)",25.0,Adults,0,0
891635,"fever and diarrhea causing rash - treated with tylenol, nystatin. fever resolved in 2 days, Rash resolved",0.17,Kids,0,0
873045,"No patients experienced any adverse effects; Improperly stored dose of ROTATEQ; This spontaneous report was received from a physician concerning a patient of unknown age and gender. No information was provided regarding the patient's pertinent medical history, concomitant medications, or drug reactions/allergies.     On 17-APR-2020, the patient was vaccinated with an improperly stored dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) vial (product storage error), by oral route (lot # 1660693, has been verified to be a valid lot number; expiration date 19-MAR-2021) as prophylaxis (dosage schedule and strength were not reported).   The administered dose of the vaccine experienced a multiple temperature excursions below highest temperature above 47 Fahrenheit degrees  to 66.6 Fahrenheit degrees for 2 hours and lowest temperature below 36 Fahrenheit degrees to 33.6 Fahrenheit degrees  for 45 minutes as recorded by a data logger. There was no previous temperature excursion. There was no adverse effect reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2006USA001703:",,Unknown,0,1
821799,"started losing vision in left eye/was diagnosed with bilateral posterior uveitis; occular sarcoidosis; This spontaneous report was received from the patient's mother via the Agency and refers to a non-pregnant female patient of an unknown age, who was 14 years old at the time of vaccination. The patient had no concomitant medications, concurrent conditions and allergies.  On 01-JUN-2017 at 10:30, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) intramuscularly, into arm (unspecified) (exact dose, lot# and expiration date were not reported) for prophylaxis. On 01-AUG-2017 at 18:00, the patient started losing vision in the left eye. On 11-SEP-2017, the patient was diagnosed with bilateral posterior uveitis. She had many tests and diagnosis was presumed as ocular sarcoidosis. Lung computerized tomography (CT) was negative, pulmonary functions tests was normal, all sorts of bloodwork for disease, viruses and other issues were all normal. She took prednisone for several month and then was changed to 2000 mg of mycophenolate mofetil (CELLCEP), which was still ongoing at the reporting time. Since 03-JUL-2019 (reported as 7/3/3019), she saw a rheumatologist and retina specialist every 4 months. Next visits were scheduled in August. The patient's vision would not be restored. The events resulted in disability or permanent damage.  The outcome of the event was reported as not recovered. The relatedness between the events and hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) was not provided.  As of 06-AUG-2020, all telephone attempts trying to obtain additional information has been unsuccessful. A message was left requesting a call back.",14.0,Kids,0,1
905128,Accidentally gave expired Tdap (Boostrix) vaccine.  Expired 12/04/2020.  Administered 12/15/2020.  No adverse reactions or symptoms have been reported by patient since administration.,52.0,Adults,0,1
896653,"The injection site has been sore since the vaccine was administered.  Today it is red, swollen, and hot to the touch.  I used a digital thermometer, and my temp is under 98 (normal for me to be low), but the injection site is 101.2.",50.0,Adults,0,1
889224,"painful arm; difficulty moving the arm that was used for immunization; This is a spontaneous report from a contactable consumer, the patient.  A 65-year-old male patient received the first dose of pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) (PREVNAR 13), via an unspecified route of administration in the arm in 2017 (at the age of 65-years-old) as a single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient previously received pneumococcal vaccine polysacch 23V (PNEUMOVAX 23) for immunization in 2010.  In 2017, after the vaccination, the patient experienced painful arm and difficulty moving the arm that was used for immunization. The clinical outcomes of painful arm and difficulty moving the arm that was used for immunization was unknown.     No follow-up attempts are possible; information about lot number cannot be obtained.",65.0,Adults,0,0
864144,"sensory neuropathy / started in lips and inside mouth and progressed to involve; This case was reported by a physician via call center representative and described the occurrence of sensory neuropathy in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 1 month after receiving Shingrix, the patient experienced sensory neuropathy (serious criteria GSK medically significant). On an unknown date, the outcome of the sensory neuropathy was unknown.   It was unknown if the reporter considered the sensory neuropathy to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication.  The patient receved 1st dose of Shingrix and after one month experienced sensory neuropathy, lips and inside mouth and progressed to involve extremities. The follow up consent was not granted.",,Unknown,0,1
878244,"5 days later had swelling, redness + tenderness at the site of injection.",63.0,Adults,0,0
873916,"0.5mm area at injection site where the top layer of the skin appears to have been scratched off. 3.5mm x 4.0mm red, warm to touch area circled with a pen by patient's mother when she first noticed the reaction at approx 6:30 pm on 6/18/2020.  Mother states she gave the child benadryl at approx 6:30pm. Mother states child c/o mild pain at the site and itching. 6.0mm x 7.5mm red, warm to touch area circled by mother with pen at approx 11:00am 6/19/2020. Child denies pain while in clinic today @ 2:00pm 6/19/2020 for us to look at the reaction.",4.0,Kids,1,0
907587,"Acute onset nausea and abnormal throat sensation shortly after receiving  COVID vaccine.  Hemodynamically stable in ED, saturating well on RA, did receive Epi .3 mg IM for concern of throat sensation, tolerated well.",42.0,Adults,0,0
891646,Individual described lip and face redness and tongue tingling.  She stated it felt as though her throat was swelling.,35.0,Adults,0,0
887673,"Shivering; possible fever (feeling hot); Severe headache; Sore arm; This case was reported by a consumer via call center representative and described the occurrence of shivering in a 61-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2020-2021 season) for prophylaxis.   Concomitant products included bupropion hydrochloride (Wellbutrin) and sertraline hydrochloride (Zoloft).   On 23rd September 2020, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 23rd September 2020 10:00, the patient received Influenza vaccine Quadrivalent 2020-2021 season (intramuscular). On 23rd September 2020, less than a day after receiving Shingrix and Influenza vaccine Quadrivalent 2020-2021 season and an unknown time after starting Wellbutrin, the patient experienced shivering, fever, headache and pain in arm. On 24th September 2020, the outcome of the shivering, fever, headache and pain in arm were recovered/resolved.   It was unknown if the reporter considered the shivering, fever, headache and pain in arm to be related to Shingrix and Influenza vaccine Quadrivalent 2020-2021 season.  Additional information was provided as follows: The patient experienced shivering, a possible fever, severe headache and a sore arm after the 2nd dose of Shingrix, he also had administered the Flu vaccine at the same time. The patient also mentioned that, he had started taking Zoloft and Wellbutrin as new medications. The reporter did not consetnt to follow up.",61.0,Adults,0,0
858203,"4 years patient received vaccine in his left thigh; throat pain; abdominal pain; vomiting; hives on back and abdomen; Initial information received on 07-Jan-2020 regarding an unsolicited valid non-serious case received from a Nurse.  This case involves a 4 years old male patient who experienced abdominal pain (abdominal pain), vomiting (vomiting), throat pain (oropharyngeal pain) and hives on back and abdomen (urticaria), while he received vaccines DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/IPV (MRC5) VACCINE [QUADRACEL].  Medical history, medical treatment, vaccination and family history were not provided.  At the time of the event, the patient had ongoing Food allergy.  Concomitant vaccination included MEASLES VACCINE LIVE (ENDERS-EDMONSTON), MUMPS VACCINE LIVE (JERYL LYNN), RUBELLA VACCINE LIVE (WISTAR RA 27/3), VARICELLA ZOSTER VACCINE LIVE (OKA/MERCK) [PROQUAD]. The patient received this vaccine in same visit and had no adverse reactions.  On 06-Jan-2020, the patient received a dose of 0.5 mL suspect DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/IPV (MRC5) VACCINE [lot C5656AA, expiry date: 13-AUG-2021] via unknown route in the left thigh.  On 06-Jan-2020, the patient developed a non-serious abdominal pain (abdominal pain), vomiting (vomiting), throat pain (oropharyngeal pain) and hives on back and abdomen (urticaria), 5 minutes following the administration of DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/IPV (MRC5) VACCINE.  It was also the case of actual medication error due to vaccine administered at inappropriate site. Patient received vaccine in his left thigh (product administered at inappropriate site).  Details of laboratory data not reported.  Final diagnosis was urticaria, oropharyngeal pain, vomiting and abdominal pain. All events were reported as severe reaction.  It was not reported if the patient received a corrective treatment.  Outcome of the all reported events was unknown.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",4.0,Kids,0,0
889413,"Shot given 7-21-20. 10:00 A.M. - 7-22 - Dinner feeling kinda sick - 34th feeling depressed and sick again. small headache, muscle pain ithing several places. 25th feeling better"" still muscle pain - 26th - itching on same arm of shot. 27th still red on same arm - 27th Big whelp,swelled, getting hungry again  28th Noitching - a little red and real hungry -",77.0,Seniors,1,0
899983,infection at injection site. was prescribed Bactrim DS 800-160mg and cephalexin 250mg.,57.0,Adults,0,0
893891,"Chills, uncontrollable shivering, headache, body ache, mild fever set I'm the night of the vaccine. Bed rest, water, and tylenol to treat.",34.0,Adults,0,0
900355,Burning pain similar to shingles outbreak to right upper quadrant of abdomen/under right breast.,69.0,Seniors,1,0
891255,"patient experienced rash in groin area, trunk , and arms starting 48 hours after vaccine admin. patient also experienced swelling around the eyes.   patient recognized symptoms and began diphenhydramine 25mg for 4 consecutive doses starting friday 10/09/20 through sat 10/10/20. Syptoms resolved over the next 48 hours. patient came to pharmacy 10/20/20 to report adverse event",80.0,Seniors,0,0
884384,"Area of redness, mild swelling, tenderness and warmth extending halfway down upper arm. Resolved 09/18/2020.",71.0,Seniors,0,0
879789,"administrations of improperly strored vaccines; This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.  On 21-JUL-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (recombinant Human albumin (rHa)), lot # T006792, expiration date: 24-AUG-2021, 0.5 milliliter (route of administration and dosing schedule were not provided) for prophylaxis. The administered dose of vaccine was exposed to the following temperature excursions: -13.5 Celsius degrees for 24 minutes, -11.4 Celsius degrees for 27 minutes and -1.8 Celsius degrees for 2 hours and 8 minutes. There was a previous temperature excursion, as recorded by a digital data logger.   This is one of multiple reports received from the same reporter.; Sender's Comments:  US-009507513-2007USA010374: US-009507513-2007USA010361: US-009507513-2007USA010893: US-009507513-2007USA010434: US-009507513-2007USA010252: US-009507513-2007USA010001: US-009507513-2007USA010334: US-009507513-2007USA011962:",,Unknown,0,1
908363,"-Swelling, sore throat: lasted about 8 hours, exacerbated by continuous use of n95 mask. -Injection site swelling: so far, started upon injection, has stayed swollen for 3 days. Measures  ~6cm wide, still itching and tender. Redness comes and goes. -Myalgia: Lasted about 4 days, exacerbated by physical nature of job.",28.0,Adults,0,0
911060,"Chills, Fever, body aches, fatigue. Took Tylenol. Resolved in 24-36 hours.",46.0,Adults,0,0
862267,UNMONITORED TEMP FOR 63H,11.0,Kids,0,0
902436,"sick; Initial information received on 17-Nov-2020 regarding an unsolicited valid non-serious case received from a social media consumer.  This case involves patient (unknown demographics) who experienced sick (illness), while he/she received vaccine INFLUENZA VACCINE.  Past vaccination included flu shot every year.  Medical history, medical treatment, concomitant medication and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date: not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious sick (illness) (unknown latency) following the administration of INFLUENZA VACCINE.  It was also reported that from 1980 until 1992 patient was forced to get the flu shot every year. Every year patient would be down for at least a week, after I got the shot. Since 1992 patient have not gotten sick like that. Because patient stopped getting the shot.  Details of laboratory data not reported.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome of event was not reported.  There will be no information available on the batch number for this case.",,Unknown,0,1
895852,"PATIENT & MOTHER RECEIVED ANNUAL FLU VACCINE AT 8PM ON EVENING OF 11/09/2020. PATIENT RECEIVED HERS 1ST IN THE RIGHT DELTOID MUSCLE. NO SIGNS/SYMPTOMS NOTED AT THIS TIME. AS SHE WAITED APPROXIMATELY 3 MINUTES STANDING BEHIND SHE BECAME DIZZY/LIGHT HEADED AND FELL TO THE FLOOR. SHE WAS MOVED TO BENCH WHERE SYMPTOMS RETURNED 5 MINUTES LATER. SHE WAS OBSERVED FOR 15 MINUTES, GIVEN GATORADE AND CHIPS, AND LEFT WITH MOTHER ON HER OWN ACCORD.",17.0,Kids,0,1
861694,"Pt had a Vasovagal syncope response and was directed to the ground, pt lost consciousness, airway was intact and patient was breathing appropriately, blood pressure was 92/44 mmHg while lying down, heart rate was 77, pt given about 4 fluid ounces of orange juice and felt better. Pt recovered quickly and walked out of the pharmacy with her mom after waiting about 15 minutes.",13.0,Kids,0,0
909443,"Migraine with aura and pain 1 hour after injection. Laid down, took OTC migraine medicine and applied ice pack to head pain area. Migraine disappeared after 3 hours.",33.0,Adults,1,0
896257,"Her arm was swollen, red and puffy; Her arm was swollen, red and puffy; This is a spontaneous report from a contactable pharmacist. A female patient of an unspecified age received pneumococcal 13-val conj vac (dipht crm197 protein) (reported as ""the patient had unknown pneumonia vaccine shot, unknown if it was Prevnar 13 or not, lot number was unknown), via an unspecified route of administration, was given in her arm on an unspecified date in 2020 at single dose for immunization. The patient medical history and concomitant medications were not reported. It was reported that the reporter had seen another individual in the last 6 months, did not remember what the date was, but patient was female and had an unknown pneumonia vaccine shot, unknown if it was Prevnar 13 or not; but where shot was given in her arm, her arm was swollen, red and puffy and it was around the muscle and it went down like the front inside of arm and back side of her arm on an unspecified date in 2020. That patient was on the way to a doctor's office about the events when caller saw her. The outcome of the events was unknown.  Pfizer is a marketing authorization holder of pneumococcal 13-val conj vac (dipht crm197 protein) in the country of incidence or the country where the product was purchased (if different). This may be a duplicate report if another marketing authorization holder of pneumococcal 13-val conj vac (dipht crm197 protein) has submitted the same report to the regulatory authorities.  No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.",,Unknown,0,1
855262,"Patient came to see me on 1/2/2020. She is not sure exactly what vaccine she was given, but was told it was preservative free.  Within three hours of administration the patient was bedridden with high fever, chills, shivering violently, severe fatigue, vomiting  headache,  very forgetful & spacey.  Exacerbated insomnia and anxiety.  Although she no longer had a fever or vomiting, all of her symptoms were continuous since the injection. She was given a homeopathic remedy by another physician which helped temporarily.",67.0,Seniors,0,0
865452,"Pruritic rash; Herpes simplex virus I mouth; Acute bronchitis; Nausea; Vaccine exposure during pregnancy; This is an observational pregnancy study case initially received from other health professional on 09-Dec-2019, concerning a 28-year-old, adult, female pregnant subject of body weight: 213 lbs, height: 63 inches and body mass index (BMI): 37.7, enrolled in a prospective observational study.  The subject's current medical conditions included obesity (BMI 37.7), autoimmune disease causing calcium build up on kidneys, anxiety/depression, asthma and upper respiratory tract infection.  The subject also had a history of LEEP (loop electrosurgical excision procedure).   The subject's concomitant medications included folic acid as vitamin and amoxicillin for upper respiratory infection.   The subject's obstetrical history included five previous pregnancies with two full term live births, two spontaneous abortions and one stillbirth. The subject did not have a history of offspring with major congenital malformation (MCM). Also, the subject did not have maternal or paternal history with MCMs.    The subject's last menstrual period (LMP) date was 06-Sep-2019, estimated delivery date (EDD) and corrected estimated date of delivery (CEDD) were reported as 12-Jun-2020. The subject did not use tobacco, alcohol or illicit drugs during pregnancy.   On an unknown date, the pregnancy status was collected, and no pregnancy complications were noted. The type of pregnancy was singleton.  On 01-Nov-2019, the subject underwent ultrasound scan and no MCM was noted.   On 21-Nov-2019, at 10 weeks of gestation (calculated per LMP), the subject was administered Flucelvax QIVc (Flu Vaccine Cell Subunit QIV NVD) [influenza vaccine, subunit influenza virus vaccine polyvalent; dose: 0.5 ml, batch number: 261223, route of administration, anatomical location and expiration date: not reported] (explicitly coded as Vaccine exposure during pregnancy') for influenza immunisation.   On the same day, an unknown amount of time after vaccination, the subject developed nausea.   On 21-Nov-2019, the subject started corrective treatment with Diclegis (doxylamine succinate, pyridoxine hydrochloride) at a dose of 10 mg, 2 tablets at every bedtime, 1 tablet every morning, 1 tablet every evening, orally.  On 02-Dec-2019, the subject underwent first trimester screen and nuchal translucency and no MCMs were noted.   On 27-Dec-2019, the subject underwent second trimester screen and no MCM was noted.   On the same date the subject underwent ultrasound cervical length (CL) check which showed CL of 4.5. No MCM was noted.   On 30-Dec-2019, the subject developed acute bronchitis and started treatment with Zithromax (azithromycin) at a dose of 250 mg, frequency: as directed, orally.   On 05-Jan-2020, the treatment with Zithromax was stopped.   On 22-Jan-2020, the subject underwent anatomy ultrasound which was incomplete and follow up was scheduled in four weeks.   On 02-Feb-2020, the subject developed herpes simplex virus I mouth, and started treatment with Valtrex (valacyclovir) at a dose of 500 mg, twice a day (bid), orally.   On 07-Feb-2020, the subject underwent ultrasound follow-up. Anatomy was within normal limits, cervical length was 3.6 and no MCM was noted.  On the same date, the subject recovered from herpes simplex virus I mouth and treatment with Valtrex was stopped.   On 21-Feb-2020, the subject underwent ultrasound follow-up, cervical length was 3.8 and no MCM was noted.   On 28-Feb-2020, the subject developed pruritic rash and started corrective treatment with hydrocortisone cream, 2.5 percent, twice a day, administered topically and Medrol Dosepak (methylprednisolone) at a dose of 4 mg, frequency: taper dose, administered orally.   On 06-Mar-2020, the treatment with Medrol Dosepak was stopped.   At the time of this report, the subject did not recover from pruritic rash and nausea. Outcome of the event acute bronchitis was not reported.   The event of acute bronchitis was assessed as serious due to the criterion of medical significance, per company.   The reporter did not provide causality assessment.   Follow up information received from other health professional on 13-Mar-2020: New adverse events (acute bronchitis, herpes simplex virus I and pruritic rash) were received. The event of acute bronchitis was assessed as medically significant; therefore, the case was upgraded to serious. Laboratory tests added in patient's tab. Zithromax, Valtrex, hydrocortisone and Medrol Dosepak added as treatment medications. Narrative was amended accordingly.  Company comment: The patient developed nausea on the same day after vaccination, experienced the event of bronchitis after more than a month after vaccination, while herpes simplex and rash pruritic occurred after approximately three months after administrating the suspect product, Flucelvax QIV. Reportedly, the patient received vaccine at gestation age of 10 weeks (explicitly coded as Vaccine exposure during pregnancy').  Causality for the event of bronchitis was confounded by medical history of asthma and upper respiratory tract infection. Considering all the above mentioned, causal relationship between the suspect product and the event of vaccine exposure during pregnancy is assessed as not related per company conventions, for nausea is assessed as possibly related, while for the events of bronchitis, herpes simplex and rash pruritic as unlikely related. (defaults to ""related"" in the safety database for reporting purposes).; Sender's Comments: The patient developed nausea on the same day after vaccination, experienced the event of bronchitis after more than a month after vaccination, while herpes simplex and rash pruritic occurred after approximately three months after administrating the suspect product, Flucelvax QIV. Reportedly, the patient received vaccine at gestation age of 10 weeks (explicitly coded as Vaccine exposure during pregnancy').  Causality for the event of bronchitis was confounded by medical history of asthma and upper respiratory tract infection. Considering all the above mentioned, causal relationship between the suspect product and the event of vaccine exposure during pregnancy is assessed as not related per company conventions, for nausea is assessed as possibly related, while for the events of bronchitis, herpes simplex and rash pruritic as unlikely related. (defaults to ""related"" in the safety database for reporting purposes).",28.0,Adults,0,0
864693,Patient states pain since date of administration on 10/14/19. Has been to see Dr and he is having her have xrays and then steroid shot/possible physical therapy.,67.0,Seniors,1,0
887101,"Drooling; That night patient hadn't eaten and became acutely congested; felt like there were marbles in his mouth; This case was reported by a other health professional via call center representative and described the occurrence of drooling in a 4-year-old male patient who received DTPa-IPV (Kinrix) (batch number YZ97N, expiry date 26th August 2022) for prophylaxis.   Co-suspect products included PROQUAD for prophylaxis.   On 10th September 2020 16:30, the patient received the 1st dose of Kinrix .5 ml and PROQUAD. On 10th September 2020 18:00, 1 hr 30 min after receiving Kinrix, the patient experienced drooling, respiratory tract congestion and oral discomfort. The patient was treated with benadryl (nos) (Benadryl). On an unknown date, the outcome of the drooling, respiratory tract congestion and oral discomfort were recovered/resolved.   It was unknown if the reporter considered the drooling, respiratory tract congestion and oral discomfort to be related to Kinrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received a dose of Kinrix and ProQuad in right thigh.  At 6pm that night patient hadn't eaten and became acutely congested, was drooling and felt like there were marbles in his mouth.  The patient's mom gave him Bendaryl and he seemed spaced out.  The symptoms subsided immediately after receiving Benadryl.  He had no issues in the past.  Consented to follow up.",4.0,Kids,0,0
900176,"Developed pancreatitis; This case was reported by a other health professional via interactive digital media and described the occurrence of pancreatitis in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 3 weeks after receiving Shingrix, the patient experienced pancreatitis (serious criteria GSK medically significant). On an unknown date, the outcome of the pancreatitis was unknown.   It was unknown if the reporter considered the pancreatitis to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. After receiving Shingrix, the patient developed pancreatitis. The patient was wondering if he should receive his 2nd dose.",,Unknown,0,0
909952,"approx. one hour after receiving vaccine pt started having throat tightness, nausea, lips tingling, SOB and ""feeling weird"". States has had anaphylaxis in the past from nuts and uses an EPI pen. States she used her pen but did not get relief so went to ER where she received IV benadryl, tagment and steroids. EKG was abnormal. States no problems at injection site. F/U with patient appox. 7 hours after incident and pt states she is doing fine and not having any issues now.",70.0,Seniors,0,1
912525,"Sore arm; nausea; This is a spontaneous report from a contactable nurse reporting for self.  A 43-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), Lot# EH9899, via an unspecified route of administration in the right arm on 19Dec2020 at 15:30 (at the age of 43-years-old), as a single dose for COVID-19 immunization. The patient was not pregnant at the time of vaccination. The vaccine was administered in a hospital facility. There was no prior COVID-19 vaccination. The patient was not diagnosed with COVID-19 prior to vaccination & not COVID tested post vaccination. Medical history was none.  Concomitant medications were not reported; however, there were no other medications the patient received within 2 weeks of the vaccination. The patient did not receive any other vaccine within 4 weeks prior to the COVID vaccine. There were no known allergies to medication, food, or other products. The patient experienced sore arm for 24 hours, then from about 34-72 hours had nausea. The onset date and time for the events was reported as 19Dec2020 at 15:30. The events were reported as non-serious. There was no treatment for the events. The patient recovered from the sore arm  and nausea on an unspecified date.",43.0,Adults,0,0
857880,"pain, swelling at injection site. fever chills ,  tiredness,   vomiting,  upset stomach  overall soreness in muscles",72.0,Seniors,1,0
857524,Pain and discomfort at vaccination site Fever (99.6 axillary) Chills Nausea Malaise,54.0,Adults,1,0
874282,"No additional adverse event; patient received the first dose of GARDASIL 9 on 12/6/2019, and the second dose of GARDASIL 9 on 6/18/2020; 44-year-old patient received the first dose of GARDASIL 9; This spontaneous report as received from a pharmacist refers to a 44-year-old male patient. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On 06-DEC-2019, the patient was vaccinated with the first dose hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (dose, route of administration, lot # and expiration date were not reported) for prophylaxis. On 18-JUN-2020, the patient was vaccinated with the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) lot # 1602284, expiration date 26-SEP-2021 (dose and route of administration were not reported) for prophylaxis. There was no adverse event reported. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: 1602284; expirationdate: 26-SEP-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",44.0,Adults,0,1
909482,"12/23  report feeling lightheaded, anxious, body aches, fatigue, headaches, chills without fever, dry cough and nasal congestion",27.0,Adults,1,0
889590,"Several hours post vaccine I was feverish, had severe headache and arm began to become red.  I also became nauseous.  The redness on arm continued to become larger, redder and itchy.  The location of this lesion was beneath the injection site (about three inches ) .  The injection site itself was just slightly sore to the touch but the large red, swollen, itchy area continued to enlarge, my headache remained, nausea remained and I have had no appetite.  My temperature was about 100 degrees for days, it was normal last night and today.",72.0,Seniors,0,0
876553,"Cellulitis; Inflammation; interrupting his ability to work; Headache as pretty painful / interrupting his ability to work; This case was reported by a physician via call center representative and described the occurrence of cellulitis in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced cellulitis (serious criteria GSK medically significant), inflammation, headache and inability to work. On an unknown date, the outcome of the cellulitis, inflammation and inability to work were unknown and the outcome of the headache was recovered/resolved.   It was unknown if the reporter considered the cellulitis, inflammation, headache and inability to work to be related to Shingrix.  Additional details were p[rovided as follows: The age at vaccination was not reported. The reporter stated that, the patient experienced cellulitis, inflammation, headache and inability to work following dose 1 of Shingrix administration. The reporter stated that, the patient received another vaccine at the same time (name was not provided). The patient had headache as pretty painful, which lasted for 4 days. No additional details were provided. The reporter did not consent to follow up.",,Unknown,0,0
864874,"Lower left extrimiy/numbness in her entire leg/decreased sensation of lower extremitydiminished reflexes in the lower extremities/Numbness foot/numbness ascended under her breast/Left leg numbness; transverse myelitis; Stroke; hyperesthesia; uncovertebral joint spondylosis; Diminished reflexes; Pain in toe; flattening of the spinal cord; disc osteophyte complex; Mild degenerative changes are seen at the interphalangeal joint; pins and needles; facet joint arthropathy; Degeneration of cervical intervertebral disc; central spinal stenosis/neural foraminal and narrowing; Sensory loss/ decreased vibratory temperature; This case was reported by a lawyer and described the occurrence of numbness of lower extremities in a 81-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Initial information was received on 26 February 2020 via Medical record. As per medical record the patient had historical condition included spin problems and alcohol use. The patient administered shingrix vaccine on 8 May 2018. She said 1 week after getting a single sought on 19 May 2018 she developed numbness in her entire leg. On 29 May 2018 the patient visited for follow up on 29 May 23018 and patient had decreased sensation of lower extremity. The patient had numbness in her entire leg. The patient had hyperesthesia. The patient was hospitalized for Lower left extremity Numbness patient was admitted on 19 May 2018 and discharged on 21 May 2018 with diagnosis of hyperesthesia, along with decreased vibratory temperature and pinprick sensation anteriorly to T8 and posteriorly lo L3 with mildly symmetrically diminished reflexes in the lower extremities but without weakness. The patient ha d left leg numbness on 26 October 2018. Also the patient had spine problems.This was felt to represent a possible mild transverse myelitis, albeit atypical. The patient states that it started as numbness, pins and needles in her left foot and then ascended to just under her left breast. The patient does have some decreased sensation in the left lower extremity anteriorly and posteriorly. Other physician suggested that the numbness was from a shingles shot because that would be more of a peripheral nerve and there are 3 nerves that supply sensation to the leg.More likely she had a small stroke that is just not showing up on imaging studies While hopping the patient had little bit of difficulty as per discharge summery of 12 June 2018. X-ray LT toe or toes on 26 June 2019 for pain in left toe and it revealed Mild degenerative changes are seen at the interphalangeal joint with mild to moderate degeneration at the first MTP.MRI of cervical spine W/O contrast done on 13 December 2018 and it revealed Disc osteophyte complex and ligamentous buckling results in moderate central spinal stenosis and flattening of the spinal cord. Disc degeneration is moderate at C4-C5 and C5-C6 and mild in the remaining cervical spine. At C5-C6, moderate central spinal stenosis. Moderate-to-severe bilateral neural foraminal and narrowing. At C6-C7, mild right and moderate to severe left neural foraminal narrowing. At C7-Tl, mild bilateral neural foraminal narrowing. C2-C3: Shallow disc osteophyte complex. C3-C4: Disc osteophyte complex and ligamentous buckling results in mild central spinal stenosis and flattening of the dorsal spinal cord. Left-sided uncovertebral joint spondylosis and facet joint arthropathy. Mild to moderate left neural foraminal narrowing.EMG done on 13 November 2018 was normal.      Lab Comments: Xray LT toe or toes on 26 June 2019 for pain in left toe and it revealed Mild degenerative changes are seen at the interphalangeal joint with mild to moderate degeneration at the first MTP.MRI of cervical spine W/O contrast done on 13 December 2018 and it revealed Disc osteophyte complex and ligamentous buckling results in moderate central spinal stenosis and flattening of the spinal cord. Disc degeneration is moderate at C4-C5 and C5-C6 and mild in the remaining cervical spine. At C5-C6, moderate central spinal stenosis. Moderate-to-severe bilateral neural foraminal and narrowing. At C6-C7, mild right and moderate to severe left neural foraminal narrowing. At C7-Tl, mild bilateral neural foraminal narrowing. C2-C3: Shallow disc osteophyte complex. C3-C4: Disc osteophyte complex and ligamentous buckling results in mild central spinal stenosis and flattening of the dorsal spinal cord. Left-sided uncovertebral joint spondylosis and facet joint arthropathy. Mild to moderate left neural foraminal narrowing. EMG done on 13 November 2018 was normal.",,Unknown,0,1
879123,"who had a allergic reaction; rash spreading to her chest; This case was reported by a consumer via interactive digital media and described the occurrence of allergic reaction in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced allergic reaction and rash. Shingrix was discontinued. On an unknown date, the outcome of the allergic reaction and rash were unknown.   It was unknown if the reporter considered the allergic reaction and rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as adult as per the vaccine indication. The patient received Shingrix and had allergic reaction. The rash spreading to her chest. The reporter stated that they likely not pursuing a second shot because of this.",,Unknown,0,0
893899,"Patient reported insomnia  that night of vaccination. Fever developed the following morning along with headache. The headache persisted for at least 2 weeks, although it has been occasional and not constant.  Patient also reported nerve involvement with occasional shooting pain down both hands to the fingertips.  This was the first dose of two",62.0,Adults,1,0
906844,"On 12-16-20 received the vaccine. On 12/17/2020 develop Headache, Nausea, vomiting, diarrhea, chills and fever. After taking some Zofran employee improved on 12/18/2020. Symptoms have resolved.",25.0,Adults,0,0
905119,"pain and itchying over L cheekbone, HTN Solu-Medrol 125mg IVP, Benadryl 50mg IVP slowly, Lisinopril/HCTZ 10/12.5mg PO symptoms resolved in 2 hours of observation and management",55.0,Adults,1,0
873615,"Rash on arms, chest/Benadryl & Hydrocortisone  recommended seeking medical attention if no improvement",,Unknown,1,0
888377,"injection given 9/25/20 ?left deltoid- symptoms started that evening, joint pain and weakness in right arm, Saturday moved to right knee and foot, Saturday evening went to her back. Sunday left arm, shoulder and hand, Monday joint pain in right arm and hand.",39.0,Adults,1,0
886418,Low grade fever and sore arm,7.0,Kids,1,0
888929,"Patient experienced redness, heat, and pain at injection site. Pharmacist referred her to Urgent Care, where she was diagnosed with Cellulitis. Patient received antibiotic therapy.",74.0,Seniors,1,0
867112,"Neuropathic pain; This case was reported by a physician via call center representative and described the occurrence of neuropathic pain in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (episode 5 weeks before receiving Shingrix).   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced neuropathic pain. On an unknown date, the outcome of the neuropathic pain was unknown.   It was unknown if the reporter considered the neuropathic pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was captured as an adult as per vaccine indication. The reporter did not consented to follow up.",,Unknown,0,0
872926,fever to 103'F,1.0,Kids,1,0
897420,"severe fever; aches / soreness; severe nausea; dizziness; received the 1st dose of Shingrix on 29Aug2018 / the 2nd one on 25Sep2018; This case was reported by a pharmacist via call center representative and described the occurrence of fever in a 78-year-old female patient who received Herpes zoster (Shingrix) (batch number 37KL2, expiry date 12th February 2021) for prophylaxis.   Concomitant products included Herpes zoster (Shingrix).   On 25th September 2018, the patient received the 2nd dose of Shingrix. On 25th September 2018, unknown after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the patient experienced fever, general body pain, nausea and dizziness. On an unknown date, the outcome of the fever, general body pain, nausea, dizziness and drug dose administration interval too short were unknown.   It was unknown if the reporter considered the fever, general body pain, nausea and dizziness to be related to Shingrix.  Additional details were provided as follows: After receiving 2nd dose of Shingrix, the patient experienced fever, aches, soreness, nausea, dizziness and said it was the worst thing she had ever experienced in the world. The patient received 2nd dose of Shingrix, before than the recommended interval, which led to shortening of vaccination schedule. The reporter did not consent to follow up. The case was considered as medication error with harm. This case has been linked with US2020223963, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020223963:same reporter",76.0,Seniors,1,0
867894,"Burning of her skin, like it is on fire on her arms, legs, back, neck, and face; Has been sick; sore throat; dry eyes; Redness of the left arm; Pain of the left arm; Diagnosed with a UTI; Intermittent low grade fever; Arm swelling; This case was reported by a consumer via call center representative and described the occurrence of urinary tract infection in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included urinary tract infection (was previously taking Macrobid for prevention of UTI's until June 2019,) and cold sores. Previously administered products included Macrobid. Concurrent medical conditions included arthritis. Concomitant products included sulfamethoxazole + trimethoprim (Bactrim), trimethoprim, alprazolam (Xanax), phenazopyridine hydrochloride (Pyridium), ibuprofen, tylenol #1 (nos) (Tylenol Codeine #1), magnesium, cyanocobalamin (Vitamin B12), ophthalmologicals (nos) (Eye Drops (Ingredients Unknown)) and mannose (D Mannose).   In January 2020, the patient received the 1st dose of Shingrix. In January 2020, less than 2 months after receiving Shingrix and an unknown time after starting Bactrim, Keflex, Valtrex and Macrobid, the patient experienced fever. On 24th January 2020, the patient experienced urinary tract infection. On 5th April 2020, the patient experienced swelling arm, erythema of extremities and pain in extremity. On an unknown date, the patient experienced burning skin, sickness, sore throat and eye dryness. The patient was treated with cephalexin (Keflex), valaciclovir hydrochloride (Valtrex), nitrofurantoin (Macrobid), antibiotics nos (Antibiotics Therapy (Unknown)) and nystatin. On an unknown date, the outcome of the urinary tract infection, burning skin and sore throat were not recovered/not resolved and the outcome of the fever, sickness, eye dryness, erythema of extremities and pain in extremity were unknown and the outcome of the swelling arm was recovered/resolved.   It was unknown if the reporter considered the urinary tract infection, fever, burning skin, sickness, sore throat, eye dryness, swelling arm, erythema of extremities and pain in extremity to be related to Shingrix.  Additional details were reported as follows: The patient received Shingrix in mid January.      On January 24th   she was seen at a doctor visit and diagnosed with a UTI.      She states she has been placed on 5 antibiotics for the UTI and none have been successful.  She noted she hasn't completed any of the courses  of antibiotics because they weren't working.   She didn't provide any specific symptoms of UTI, other than intermittent low grade fever.    She noted  she also has burning of her skin, like it was on fire,  on her arms, legs, back, neck, and face that was worse at night when she was trying to sleep.   She was unable to provide a date of when the burning skin started.  She has been to the Emergency room twice with the UTI but hasn't stayed overnight.     She also noted she has been sick, which she described as a sore throat,  and a low grade intermittent fever.     Till the time of reporting she has the burning of her skin, the sore throat and the UTI.    She noted she has also had dry eyes, which she was using OTC eye drops for.    For 5 days, she noted she had arm swelling, redness and pain of the left arm, which was the arm of her injection.  She described the location of injection as hand width below her shoulder and on the underside/ backside of her arm.     She doesn't have documentation from the pharmacy of the vaccination route or the lot and expiration date.     She noted she has a history of cold sores in her nose and on her buttocks, she had some Valtrex for that, so she took a Valtrex 500mg today to see if it will help, she denied ever having Shingles before. She wonders if this could be shingles due to the skin burning, but denies a rash of any kind.   She was also concerned about Stephen's Johnson syndrome due to the burning of the skin and sore throat, and having been on 5 different antibiotics since 24th January2020. She noted she was placed on Macrobid intially,  500mg twice daily and took for 6 days,  it didn't improve her symptoms, so she was switched to Bactrim, twice a day, then Trimethoprim 100mg twice a day for 5 days,  it didn't work either so went to Keflex, which she also took twice a day.   Macrobid was added to Keflex initially but it didn't work, a urine culture still showed UTI.  She was placed on just on Keflex by itself, but still not working.     She wa  placed on Monoro this weekend and notes  it was a one dose drug, but not improvement still.      She has a follow up appointment with the Nurse Practitioner in the afternoon of reporting day,  on 6th March 2020, she has also been referred to Infectious Disease, but no appointment has been set up till the time of reporting.   She noted she was also seen by her physician for the sore throat and given nystatin, which helped.  She states she was told to try Xanax, pyridium,  and has also taken other vitamins and supplements that haven't helped. ER Visit Required. Reporter consented to follow up.",71.0,Seniors,0,0
879942,Had a shingles rash on her back.,60.0,Adults,1,0
878636,"Client had never received any vaccinations prior to today's visit. Immediately after administering Tdap at 0845, client's eyes rolled back, skin became pale, body went limp, and lost consciousness for 5 seconds. Client hit head on chair but did not collapse to the floor. During 5 seconds , client's upper torso went rigid and there were 2-3 involuntary muscle spasms of the shoulders. Airway patent, no signs of respiratory distress. Client returned to consciousness without medical intervention. Client alert and aware x4 after return to consciousness, sat up without assistance. Client was unaware had fainted. RN informed client about syncope episode and hitting head. Client denied pain or any change in mentation. RN remained at client's side. Water and graham crackers were provided. Fan was utilized to circulate air. Client's color returned after 2 minutes. Continued to monitor for 15 minutes. Client denied any further lightheadedness/dizziness.",19.0,Adults,1,0
905932,"monitor for vs, NO HX OF PREVIOUS REACTIONS REPORTED, code green called, throat feels like she can't swallow/shot at 1446, to ER at 1530",47.0,Adults,0,0
863345,sore muscles headache redness and swelling at injection site,61.0,Adults,1,0
895620,"received expired doses of ADACEL with no AE; Initial information received on 13-Oct-2020 regarding an unsolicited valid non-serious case received from a other health professional.  This case is linked to case 2020SA287830 (same reporter).  This case involves a 11 year old female patient who was vaccinated with expired dose of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] (expired product administered).  Medical history, medical treatment, vaccination and family history were not provided.  Concomitant medications included MENINGOCOCCAL VACCINE (MENINGOCOCCAL VACCINE).  On 15-Sep-2020, the patient received a 0.5 ml first dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (lot C5519BA and expiry date: 12-sep-2020) via an intramuscular route in the left deltoid for prophylactic vaccination.  It was a case of actual medication error due to expired vaccine used. (latency on same day).  At the time of reporting, patient had no adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",11.0,Kids,0,1
878715,Almost complete loss of appetite within 4 hours of injection. Has not had a meal in almost 48 hours from lack of appetite. Vomited within 48 hours of vaccination.,4.0,Kids,0,0
874266,"allergic reaction; rash that looks like small bumps from my side around to the middle of my front trunk; This case was reported by a other health professional via interactive digital media and described the occurrence of allergic reaction in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 30th May 2020, the patient received the 2nd dose of Shingrix. On an unknown date, less than 3 weeks after receiving Shingrix, the patient experienced allergic reaction and raised rash. On an unknown date, the outcome of the allergic reaction and raised rash were unknown.   It was unknown if the reporter considered the allergic reaction and raised rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as adult as per the vaccine indication. The patient received Shingrix and had an allergic reaction. The patient had a rash that looks like small bumps going from my side around to the middle of my front trunk.  The reporter asked what could did to help get over this.",,Unknown,0,0
904310,"Right arm burning sensation as injection was started. Right arm soreness at injection site immediately. About 45 minutes after vaccine, new onset of facial numbness and tingling (in cheeks and forehead). Symptoms went away after about 10 minutes. Facial numbness/tingling returned 3 hours post injection for >30 minutes. Woke up the next day and facial numbness/tingling was still present and also included both sides of face. This resolved around 1:00pm. Headache and significant right arm pain continued. Took 600mg of ibuprofen which reduced pain. Saturday (today) mild right arm soreness.",42.0,Adults,0,0
894703,"Subchorionic haematoma; Migraines; Vaccine exposure during pregnancy; This is an observational study case, received on 27-Oct-2020 from other health professional, concerning a 26-year-old pregnant, female subject of body weight: 143.5 lbs, height: 62.8 inches and body mass index (BMI): 25.6, who was enrolled in a prospective observational safety study.   The subject's concurrent conditions included anxiety, morning sickness and increased body mass index.  The subject's past medications included Bonjesta (doxylamine succinate, pyridoxine hydrochloride) for morning sickness. The subject's concomitant medications included Prenatal + DHA (unspecified minerals and vitamins) for pregnancy and Diclegis (doxylamine succinate, pyridoxine hydrochloride) for morning sickness.  The subject's obstetrical history noted two previous pregnancies which included one full-term live birth and one spontaneous abortion. The subject had no history of offspring with major congenital malformation (MCM) and no maternal or paternal history with MCM. The subject did not use tobacco, alcohol or illicit drugs during pregnancy.   The subject's last menstrual period (LMP) date was 08-Jun-2020, the estimated delivery date (EDD) was 15-Mar-2021 and corrected estimated date of delivery (CEDD) was reported as 30-Mar-2021. The type of pregnancy was singleton.  On 12-Aug-2020, ultrasound revealed no MCMs.  On 02-Sep-2020, ultrasound, counsyl chromosomes 13, 18, 21, Sex chromosome analysis and counsyl fundamental panel with fragile X revealed no MCMs.  On 04-Sep-2020 and 08-Sep-2020, ultrasound revealed no MCMs.   On 08-Oct-2020, at gestational age of 17 weeks (calculated per LMP), the subject was vaccinated with Afluria QIV vaccine (Flu Vaccine Egg Split QIV CSL) (Influenza vaccine, dose, route of administration and anatomical location: not reported) (explicitly coded as 'Vaccine exposure during pregnancy') for influenza immunisation. The batch number reported was P100253284.  On an unknown date, an unknown time after vaccination, the pregnancy status was collected, and it was noted that the subject had subchorionic haematoma. The subject also experienced migraines.   At the time of initial reporting on 27-Oct-2020, the subject had not recovered from the event of migraines.  The outcome for the event of subchorionic haematoma was not reported.   The event of 'subchorionic haematoma' was considered serious due to criterion of medical significance by a Physician within Seqirus' Pharmacovigilance and Risk Management Department.  The reporter did not provide a causality assessment.  Company comment:A 26-year-old female pregnant subject developed subchorionic haematoma and migraine on an unknown date after vaccination with the suspect product Afluria QIV. Chronology is unclear. The subject's medical history of anxiety and increased body mass index may have contributed to development of the events. The subject's obstetrical history noted two previous pregnancies which included one full-term live birth and one spontaneous abortion. Subchorionic bleed is a common cause of first-trimester bleeding and often occurs in uncomplicated pregnancies. Women who have already had one baby or who are older appear to be more likely to develop subchorionic hematomas. With information presented, causality for both events is assessed as not related due to confounders provided. Causal relationship for vaccine exposure during pregnancy is assessed as not related per company conventions.; Sender's Comments: A 26-year-old female pregnant subject developed subchorionic haematoma and migraine on an unknown date after vaccination with the suspect product Afluria QIV. Chronology is unclear. The subject's medical history of anxiety and increased body mass index may have contributed to development of the events. The subject's obstetrical history noted two previous pregnancies which included one full-term live birth and one spontaneous abortion. Subchorionic bleed is a common cause of first-trimester bleeding and often occurs in uncomplicated pregnancies. Women who have already had one baby or who are older appear to be more likely to develop subchorionic hematomas. With information presented, causality for both events is assessed as not related due to confounders provided. Causal relationship for vaccine exposure during pregnancy is assessed as not related per company conventions.",26.0,Adults,0,1
916557,"Fever (up to 102 F), chills, body aches, weakness, headache",29.0,Adults,1,0
860469,"Throat began to tighten up; This case was reported by a consumer via call center representative and described the occurrence of throat tightness in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than an hour after receiving Shingrix, the patient experienced throat tightness. The patient was treated with benadryl (nos) (Benadryl). On an unknown date, the outcome of the throat tightness was recovered/resolved.   It was unknown if the reporter considered the throat tightness to be related to Shingrix.  Additional details were reported as follows: The patient received her first dose of Shingrix two to three months ago from reporting date. Her throat began to tighten up 30 to 45 minutes after the vaccination. She took Benadryl and felt fine.",62.0,Adults,0,0
881425,Vaccine refrigerator went out and there  was a temperature excursion which affected  the IPOL dose. No adverse effects on  patient.,11.0,Kids,0,1
877405,"Previous to this I was told to stop Mesalamine and Meloxicam due to high kidney function. Thru this whole ordeal I have been in near constant arthritic pain. My thumbs are barely useable. Switching to Tylenol for Arthritis provided no relief. Prayed for morphine gods to have pity on me. This is dose #1 of 2.  Friday July 17, 2020  Shingles Vaccine #1: left arm sore at injection site  Monday July 20, 2020  Nuclear Stress Test: blood pressure became extremely low 52/46  Tuesday July 21, 2020  Woke up in the middle of the night wringing wet with sweat   Wednesday July 22, 2020  Blood Test 8am no fever. 9:15pm 99.6 and aching all over Temp 100.5 in afternoon Low grade nagging headache and low grade sore throat Can?t breath  Only relief is sleeping all day  Thursday July 23, 2020  Had diarrhea all day temp 98.6 to 99.3 still aching  Aching all over only relief is sleeping all day Low grade nagging headache and low grade sore throat Can?t breath  Woke up middle of night sweating still aching all over  Friday July 24, 2020  Sneezed 5xs in the am temp 98.7 saw respiratory at Hospital. Got Covid test  Aching all over only relief is sleeping all day  Low grade nagging headache and low grade sore throat Can?t breath  Woke up middle of night sweating still aching all over  Saturday July 25, 2020  Still aching all over only relief is sleeping all day  Low grade nagging headache and low grade sore throat  Temp 98.6-99.6  Can?t breath  Woke up middle of night sweating still aching all over  Sunday July 26, 2020  Still aching all over  Low grade nagging headache and low grade sore throat Temp 101.0 in am then 100.3 in pm & 100.0 by eve Still get winded and with minimal exertion Woke up middle of night sweating still aching all over  Monday July 26, 2020  Still sore all over. Get hot flashes. Temp in am 100.2 Covid test is NEGATIVE Still got very sweaty napping on sofa Still get winded and with minimal exertion Maybe not quite so achy and arthritis is a bit more tolerable Thumbs still very painful, still achy all over but not as severe Went to bed feeling like fever shivering was going to happen, it didn?t Injection site still sore   Tuesday July 27, 2020  Woke up in am drenched.  Still not 100% yet",65.0,Adults,0,0
885858,"SICK FOR A WEEK; A spontaneous report has been received from a consumer. The report concerns a female patient (age not provided) of Unknown ethnic origin.    No medical history was reported.     No concomitant products were reported.    The patient received Flumist (influenza virus vaccine live, intranasal), via nasal route, on an unknown date.     On an unknown date, the patient experienced sick for a week (preferred term: Malaise).     It is unknown if any action was taken with Flumist (influenza virus vaccine live, intranasal).     The outcome of the event was unknown.    The event was considered non-serious.",,Unknown,0,1
895956,"ill for a couple days; Initial information received on 07-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer or non-healthcare professional via social media.  This case involves female patient (age not reported) who experienced ill for a couple days (illness), while she received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) (lot number not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious ill for a couple days (illness) unknown latency following the administration of INFLUENZA VACCINE.  Laboratory details were not reported.   It was not reported if the patient received a corrective treatment.  The event outcome was unknown for illness.  There will be no information available on the batch number for this case.",,Unknown,0,1
865927,"Muscle pain; arm is not as sore and there is not as much redness and swelling; arm is not as sore and there is not as much redness and swelling, although it hurts; arm is not as sore and there is not as much redness and swelling; Shivers; Tiredness; Headaches; upset stomach; feels like she has a fever; feels like throwing up and is afraid that she can't stand up without vomiting; This case was reported by a consumer via call center representative and described the occurrence of muscle pain in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 20th February 2020, the patient received the 2nd dose of Shingrix. In February 2020, less than a week after receiving Shingrix, the patient experienced muscle pain, swelling arm, pain in arm, erythema of extremities, shivers, tiredness, headache, upset stomach, feeling hot, vomiting and difficulty in standing. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the muscle pain, swelling arm, pain in arm, erythema of extremities and shivers were not recovered/not resolved and the outcome of the tiredness, headache, upset stomach, feeling hot, vomiting and difficulty in standing were unknown.   It was unknown if the reporter considered the muscle pain, swelling arm, pain in arm, erythema of extremities, shivers, tiredness, headache, upset stomach, feeling hot, vomiting and difficulty in standing to be related to Shingrix.  Additional details were provided as follows: The reporter stated that after vaccination, the arm was not as sore and there was not as much redness and swelling, although it hurts. The patient stated that after vaccination, felt like had a fever but was not sure. the patient stated that felt like throwing up and was afraid that could not stand up without vomiting. For the tollerence of 1st dose refer case US2020032222.",60.0,Adults,1,0
916050,"At approximately 5:15 AM patient found to have temperature of 38.6 degrees C and with supraventricular tachycardia (HR 134-140- documented with EKG). Patient sent to local hospital emergency room via ambulance. (Note prior to event- patient was being for possible UTI with Macrobid and had had low grade fever on and off. The day of the vaccine 12/29/20- patient reported feeling better and desired to proceed with vaccine). Emergency room evaluation revealed clear CXR, normal WBC.   Patient was sent back to facility on 12/30/20 from the Emergency room with recommendation to continue antibiotic for possible urinary tract infection. Patient seen 12/31/20 AM and reports feeling improved.  Temperature at 7AM 12/31/20- 38.3 degrees C, HR 90, BP 124/82. Patient denies shortness of breath or cough. No headache. Patient reports mild tenderness to left upper arm at injection site. No swelling or redness to area noted. Of note urine culture sent on 12/28/20- final result reported 12/30/20- no growth.",58.0,Adults,0,0
857739,"headache, muscle ache overall. dizziness",74.0,Seniors,1,0
869253,"Swollen face and throat, difficulty breathing, light headed.  Took one Benadryl 25 mg  and slept poorly that night.  I went to work the next day because symptoms began to lessen.  Symptoms went away after 2 days.",64.0,Adults,0,0
870459,"A few hours after vaccination, patient developed fevers up to 101.5 and seizure episodes.  Parent described as irregular eye movements and foaming at the mouth.  One episode on same day of vaccinations and one approximately 24 hours after vaccinations.  Child was evaluated at the emergency department and then admitted to the hospital.  Work up done (below) and determined there was no other cause to her seizure like movements except perhaps vaccination reaction as all other tests were negative.  Since discharge from hospital, parents have observed patient to continue to have intermittent tongue thrust like movements or lip smacking episodes.  Fever resolved prior to hospital discharge.",0.17,Kids,1,0
856094,"Suspected vaccination failure; a possible adverse event of shingles in a patient after Shingrix; This case was reported by a pharmacist via call center representative and described the occurrence of suspected vaccination failure in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was selected as adult as per vaccine indication. The pharmacist reported a possible adverse event of shingles in a patient after Shingrix. The reporter asked if the patient get shingles from the Shingrix shot and conservatively recorded the adverse event. The reporter did not consent to follow-up. This case was considered as suspected vaccination failure, since the details regarding the dose number, time to onset for event and laboratory confirmation for shingles were not provided.",,Unknown,0,1
856421,"Flu, type A; Vaccination failure; Swab test/ Flu, type A; Feeling sick; Extreme fatigue; Muscle ache; Chills; Cough; Congestion; This is a spontaneous case initially received from other non-health professional (consumer) on 31-Jan-2019, concerning a 39-year-old, adult female patient.  The patient had no medical history and had not received any concomitant medications.  On 08-Nov-2018, the patient was administered INN Flu Vaccine Seasonal (influenza vaccine, influenza virus vaccine polyvalent, route of administration: intramuscular, anatomical location: deltoid, dose, batch number, expiry date, trade name and manufacturer: not reported) for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.   On 30-Jan-2019, 2 months and 22 days after vaccination, the patient started feeling sick with extreme fatigue, muscle ache, chills, cough and congestion. The patient had no fever. On the same day, the patient went to her physician's office for a consultation and a swab test was performed on the same day. The patient was diagnosed with type A flu (influenza A virus test positive) (explicitly coded as vaccination failure). The patient was treated with Tamiflu (oseltamivir phosphate) for 9 days (from 30-Jan-2019 to 08-Feb-2019).  The outcome of all the events was recovered on 07-Feb-2019.  The reporter assessed the case as non-serious.  Non-significant follow up received from the reporter on 12-Mar-2019: agency number (SEQ19-00699) was updated in the additional information tab. As there was no new information in the source document hence no changes were made in narrative.  Follow up received from other non-health professional (consumer) on 14-Mar-2019: The reporter's details (institution, email address and fax number) were added in the general tab. The patient's email address was added in the patient tab. The patient had no medical history and had not received any concomitant medications. Added new events vaccination failure, feeling sick, fatigue extreme, muscle ache, chills, cough and congestion in the event tab [start date: 30-Jan-2019 and stop date: 07-Feb-2019]. On 30-Jan-2019, swab test was performed which resulted positive for flu (influenza A virus test). Added treatment medication Tamiflu (oseltamivir phosphate) (start date: 30-Jan-2019 and stop date: 07-Feb-2019) was added in the product tab. The outcome of the event influenza A virus infection was changed from not reported to recovered in the event tab as the events resolved on 07-Feb-2019. The causality of the event influenza A virus infection was changed from 'unassessable' to 'related' in the event assessment tab. It was reported that the patient received the influenza vaccine at work and no further information was available to identify the vaccine administered. The narrative was amended accordingly.; Reporter's Comments: A 39-year-old female patient was diagnosed with type A flu (influenza), 2 months 22 days after vaccination with INN flu vaccine (considered as vaccination failure). The event influenza was confirmed as type A (positive for flu) by swab test. Time to onset is plausible following vaccination with the reported Influenza and vaccination failure events. Hence, company assessed the events as possibly related to suspect vaccine. The company assessed the case as serious (medically significant).",39.0,Adults,0,0
891910,"Indication as potential COVID prevention; He mentioned that he did not know if this was a joint issue; The HCP's wife was frustrated that she was experiencing this for over a month; And it was a prolonged injection site reaction; patient began experiencing aching pain and disconfort on and around injection site; patient began experiencing aching pain and disconfort on and around injection site; This spontaneous report was received from a pharmacist and refers to a 73 year old female patient with sulfonamide  (BACTRIM) allergy, nitrofurantoin (MACRODANTIN) allergy  and Gastrointestinal upset. Concomitant therapies included herbs (unspecified), levothyroxine sodium(SYNTHROID) and raloxifene hydrochloride(EVISTA).  Information regarding the patient's medical history and historical drugs was not provided.  On 09-SEP-2020 , the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live rHA (recombinant human albumin) (M-M-R II) lot # S023654, expiration date 30-JUL-2021, subcutaneously in her left arm for potential COVID 19 prevention (prophylaxis) (product use in unapproved indication).  On 11-SEP-2020, patient began experiencing aching pain and discomfort on and around injection site (injection site pain and injection site discomfort).  On an unknown date in October 2020, the patient  experienced a prolonged injection site reaction, she was frustrated that she was experiencing this for over a month(frustration tolerance decreased) and her husband mentioned that he did not know if this was a joint issue (Arthropathy).   On 05-OCT-2020, the patient sought medical attention due to the events.   The outcome of injection site pain, frustration tolerance decreased, injection site reaction, arthropathy and injection site discomfort was unknown.     The causality between the events and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live(M-M-R II) was not provided.",73.0,Seniors,0,0
873696,"Redness from right thigh to knee; Hives from right thigh to knee; Blanchness from right thigh to knee; This case was reported by a other health professional via call center representative and described the occurrence of erythema in a 2-month-old female patient who received DTPa-HBV-IPV (Pediarix) (batch number D93B4, expiry date 14th June 2021) for prophylaxis.   Concomitant products included HAEMOPHILUS B CONJUGATE VACCINE (MENINGOCOCCAL) (PEDVAX HIB), PNEUMOCOCCAL 13 VALENT CONJUGATE VACCINE (PREVNAR 13) and ROTAVIRUS VACCINE (ROTATEQ).   On 8th June 2020, the patient received the 1st dose of Pediarix (intramuscular) .5 ml. On 8th June 2020, 5 min after receiving Pediarix, the patient experienced erythema, hives and blanching of skin. On an unknown date, the outcome of the erythema, hives and blanching of skin were unknown.   It was unknown if the reporter considered the erythema, hives and blanching of skin to be related to Pediarix.  Additional details were provided as follows: The patient was administered Pediarix in the right thigh and was also administered Pedvax Hib and Prevnar 13 in the left thigh and Rotateq was given orally. About 5 minutes after vaccination patient experienced redness, hives and blanchness from the right thigh down to her knee. The patient described blanchness as redness turning into white area upon touching. No other details were provided.",0.17,Kids,0,1
911782,"Day 1-after immunization covid 19 moderna vaccine-headache, sneezing, low grade temp 99 when she arrived home Day 2-102F-took tylenol as needed, she continue to experience headaches, body aches Day 3- No signs or symptoms, temp 97.6F with out tylenol",52.0,Adults,0,0
863730,"Rash on the face; This case was reported by a pharmacist via call center representative and described the occurrence of rash in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 10th February 2020, the patient received the 1st dose of Shingrix. On 11th February 2020, 1 days after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The patient experienced rash on face one day after receiving the dose of Shingrix. The reporter consented to follow up. No vaccine's data provided.",,Unknown,0,0
889927,"Side effects / aches in my muscles; This case was reported by a consumer via call center representative and described the occurrence of muscle pain in a 64-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On 6th October 2020, the patient received the 1st dose of Shingrix. In October 2020, less than a week after receiving Shingrix, the patient experienced muscle pain. On an unknown date, the outcome of the muscle pain was not recovered/not resolved.   It was unknown if the reporter considered the muscle pain to be related to Shingrix.  Additional details were as follows: The age at vaccination was not reported. The patient was still feeling aches in muscles. The reporter consented to follow up.",64.0,Adults,1,0
903779,"Patient reported numbness and tingling on the tongue 5 minutes after receiving the COVID-19 vaccine, she has a history of anaphylactic reaction to sulfa, epi pen administered at 13:50pm. Took by ambulance to emergency room at 14:10pm today",40.0,Adults,0,1
908466,"fever with tmax 105, chills, tachycardia to 150, moderate headache, cough, lightheaded, dizzy, somnolence",28.0,Adults,1,0
904183,"Fevers to 104.8, myalgias, chills, rigors, fatigue, diarrhea",32.0,Adults,1,0
906857,"Fever, chills, burning rash on neck and behind ears.",67.0,Seniors,1,0
886083,"patient initially had mild fever and weakness which she took tylenol for and felt better, then the next day she started to experience all over itching hives/welts and redness.  She took 2 doses of benadryl which seemed to help",73.0,Seniors,0,0
893809,"Next day patient reports redness, warmth and swelling extending 5in x 5in below injection site. No fever or pain. MD assessed on 10/30/2020, no infection diagnosed.",16.0,Kids,1,0
862817,"10 cm indurated area; erythematous area at right upper arm; pain 1 day post injection; This case was reported by a nurse via other manufacturer and described the occurrence of pain in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 26th June 2019, the patient received the 1st dose of Shingrix. On 27th June 2019, 1 days after receiving Shingrix, the patient experienced pain. On 28th June 2019, the patient experienced erythema. On an unknown date, the patient experienced induration. On an unknown date, the outcome of the pain, erythema and induration were unknown.   It was unknown if the reporter considered the pain, erythema and induration to be related to Shingrix.  Additional details were received as follows: The age at vaccination was not reported. The nurse reported that she developed pain and erythematous at right upper arm and 10 cm indurated area after vaccination. No further information were reported.",,Unknown,1,0
878850,"sore arm; body aches; This case was reported by a consumer via interactive digital media and described the occurrence of pain in arm in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 31st July 2020, the patient received Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced pain in arm and general body pain. On an unknown date, the outcome of the pain in arm and general body pain were recovered/resolved.   It was unknown if the reporter considered the pain in arm and general body pain to be related to Shingrix.  Additional details were provided as follows: The case was reported by patient's wife. The age at vaccination was not reported. The patient had the Shingrix vaccine. He had a sore arm and body aches for two days.",,Unknown,0,0
886283,"Bell's Palsy; This spontaneous case from the Country was received on 20-Sep-2020 from a pharmacist via Agency (reference number: SEQW20-01995) and concerned an elderly, female patient.  The patient's medical history and concomitant medications were not reported.   On an unspecified date in 2017, the patient was vaccinated with Fluad (TIV) (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, MF59, dose, route of administration and anatomical location: not reported) for influenza prophylaxis. The batch number was not reported.   On an unspecified date, after receiving Fluad (TIV), the patient developed Bell's Palsy.  On an unspecified date, the patient recovered from the event of Bell's Palsy. The patient was referred by the physician to the pharmacist to see if the patient could take the Fluad this year.   The reporter did not provide a causality assessment.  The event of Bell's Palsy was considered to be medically significant by a Physician within Seqirus's Pharmacovigilance and Risk Management Department.  Company comment: A elderly, female patient experienced facial paralysis, an unknown amount of time after administration of Fluad (TIV) vaccine. Temporal relationship needs more clarification. The patient's medical history and concomitant medications were not provided. Due to lack of information, causal role of the suspect product is unassessable.; Sender's Comments: A elderly, female patient experienced facial paralysis, an unknown amount of time after administration of Fluad (TIV) vaccine. Temporal relationship needs more clarification. The patient's medical history and concomitant medications were not provided. Due to lack of information, causal role of the suspect product is unassessable.",,Unknown,0,1
867172,"Echogenic intra cardiac focus; Fetal exposure during pregnanay; This is an observational study case, initially received from other health professional on 30-Mar-2020, concerning a foetal subject, whose mother was a 25-year-old female of body weight 291 lbs, height 67 inches and body mass index (BMI) 45.6, enrolled in a prospective observational safety study.  The subject's mother's medical history included obesity, nausea and vomiting. The subject's mother was rubella non-immune.  The subject's mother's concomitant medications included Unisom (doxylamine succinate), ondansetron and pyridoxine for nausea and vomiting and Prenatal vitamins (vitamin not specified (nos), minerals nos) for pregnancy.   The subject's mother had no previous pregnancies. The subject's mother had no maternal or paternal history with major congenital malformations (MCMs). The subject's mother did not use tobacco, alcohol or illicit drugs during pregnancy.   The subject's mother's last menstrual period (LMP) was on 26-Oct-2019. Type of pregnancy was singleton. The estimated delivery date (EDD) was reported as 01-Aug-2020 and corrected estimated date of delivery (CEDD) was not reported. The subject's father age was not reported.  On 17-Dec-2019, the subject's mother underwent ultrasound scan and no MCM was noted.   On 08-Jan-2020, the subject's mother underwent non-invasive prenatal testing (NIPT) and no MCM was noted.  On 22-Jan-2020, at approximately 12 weeks of gestation (calculated per LMP), the subject's mother was administered Afluria QIV (Flu Vaccine Egg Split QIV CSL) [influenza vaccine, batch number: P100112488, dose, route of administration, anatomical location and expiration date: not reported] (explicitly coded as Foetal exposure during pregnancy') for an influenza immunization.   On 19-Feb-2020, the subject's mother underwent maternal serum alpha-fetoprotein screening (MSAFP)/serum marker and no MCM was noted.  On an unspecified date, after vaccination, the subject's mother experienced allergy.  On 19-Mar-2020, the subject's mother started treatment with Zyrtec (cetirizine hydrochloride), 10 mg, every day, orally for allergy. On the same day, the subject's mother experienced heartburn and started treatment with Protonix (omeprazole), 20 mg, every day, orally.   On the same day, the subject's mother underwent 20-week-anatomy ultrasound and echogenic intracardiac focus and normal echo of subject was noted. No MCM was noted.  At the time of this report, the outcome of the event echogenic intracardiac focus was not reported.  The event of echogenic intracardiac focus was considered serious due to the criterion of medical significance, per company.  The reporter did not provide causality assessment.  This case is linked to 202002671 (the corresponding mother case).  Company comment: Reportedly, foetal disorder (echogenic intracardiac focus - EIF) was noted in neonate subject, 1 month 26 days after subject's mother received Afluria QIV. EIFs are considered normal changes found in about 35% of normal pregnancies and cause no health problems. However, considering plausible temporal relationship, causal role of the suspect vaccine cannot be excluded and is assessed as unlikely related (defaults to ""related"" in the safety database for reporting purposes). Foetal exposure during pregnancy is assessed as unrelated per company's conventions.; Sender's Comments: Reportedly, foetal disorder (echogenic intracardiac focus - EIF) was noted in neonate subject, 1 month 26 days after subject's mother received Afluria QIV. EIFs are considered normal changes found in about 35% of normal pregnancies and cause no health problems. However, considering plausible temporal relationship, causal role of the suspect vaccine cannot be excluded and is assessed as unlikely related (defaults to ""related"" in the safety database for reporting purposes). Foetal exposure during pregnancy is assessed as unrelated per company's conventions.",,Unknown,0,0
904648,"The patient is not having adverse signs and symptoms at this time; have a patient in my office, and I gave him a PNEUMOVAX 23 vaccine that expired on 03-DEC-2020; This spontaneous report was received from a physician referring to a 66-year-old male patient. The patient's concurrent conditions included thyroid disorder, hypertension, dyslipidaemia, and lipids increased. His medical history and drug reactions/allergies were not reported. Concomitant medications included levothyroxine sodium, atorvastatin, and amlodipine.  On 04-DEC-2020, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23), 0.5 milliliter, intramuscular injection in the left arm (lot number not provided), with an expiration date reported as 03-DEC-2020 (expired product administered) for routine immunization for patients 65 and older. The reporter wanted to know if it was okay to give the pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) past the expiration date. No treatment was given, the patient did not seek medical attention, and the present status was reported as recovered. At the time of the report, the patient was not having adverse signs and symptoms. No product quality complaint reported.",,Unknown,0,1
915880,Patient died within 12 hours of receiving the vaccine.,99.0,Seniors,0,1
903967,Following COVID19 vaccine employee returned to work and began to feel dizzy/lightheaded/shakey. Went to ED for further eval.,29.0,Adults,0,1
910328,felt tired and had left elbow pain,49.0,Adults,1,0
890420,"Date of injection 9-22-20 Left shoulder pain began on 9-24-20. Decreased shoulder ROM, pain with lifting noted on 10-2-20 Evaluated at Employee Health on 10-6-20. Referred for physical therapy, given Naproxen, home exercises also given, assigned light duty. Follow-up appointment on 10-14-20: improved ROM.  PT approved, first appointment pending. Continue med, home exercises, LD. Next follow-up scheduled for 10-28-20.",25.0,Adults,1,0
856262,"a dose ofGARDASIL9 that experienced a temperatme excursion.; Patient did not experience any symptoms; This spontaneous report has been received from a nurse, referring to a patient of unknown age and gender. Information about the patient's pertinent medical history, concurrent conditions, concomitant medications and previous drug reactions and allergies were not provided.  On 06-JAN-2020, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), by intramuscular route, lot number S008154, and expiration date 20-NOV-2021 for prophylaxis (strength, dose and frequency were not provided) that experienced a temperature excursion (product storage error). The patient did not experience any symptoms.   The temperature was for 2 celsius degrees (C) (-5.7 degrees (C)) for a timeframe of 16 minutes and a previous temperature excursion of above 9 celsius degrees (C) (10.7C) for a timeframe of 45 minutes. The call was due to data logger.",,Unknown,0,1
879555,patient reported a square area around the injection site became warm to the touch and developed a small welt,66.0,Seniors,0,0
873097,"patient was given an expired dose of Adacel with no adverse event; Initial information received on 08-Jun-2020 regarding an unsolicited valid non-serious case received from a nurse.  This case involves patient (age and gender not reported) who was given an expired dose of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (ADACEL) (lot U5898AA expiry date-30-Mar-2020) for prophylactic vaccination.  The patient's past medical history, medical treatments, vaccinations and family history were not provided.  On an unknown date, the patient received a dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (lot U5898AA exp date-30-Mar-2020) for prophylactic vaccination.  It was an actual medication error due to expired vaccine used. (expired product administered).   At the time of reporting, the patient had no adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
862602,"horrible headache; Body ache; shivering; fever; oxygen was very low; This case was reported by a consumer via call center representative and described the occurrence of headache in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On 10th February 2020, the patient received Shingrix. On 11th February 2020, 1 days after receiving Shingrix, the patient experienced headache, general body pain, shivering, fever and oxygen saturation decreased. On an unknown date, the outcome of the headache was not recovered/not resolved and the outcome of the general body pain, shivering, fever and oxygen saturation decreased were unknown.   It was unknown if the reporter considered the headache, general body pain, shivering, fever and oxygen saturation decreased to be related to Shingrix.  Additional details were provided as follows: This case was reported by patient for self. The age at vaccination was not reported. The patient received Shingrix vaccine and experienced horrible headache, body ache, shivering and fever. The patient had a doctor appointment for another issue and oxygen was very low. The patient wanted to know the events were normal. Till the time of reporting the patient had headache.",,Unknown,0,0
899389,Every nerve on fire. All over body.  Lasted at extreme level for 24 hours and lingered for days.,73.0,Seniors,0,0
873654,"flu-like symptoms; Body Aches; Tiredness; arm was sore; This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, 1 day after receiving Shingrix, the patient experienced influenza-like symptoms, general body pain, fatigue and pain in arm. On an unknown date, the outcome of the influenza-like symptoms, general body pain, fatigue and pain in arm were recovered/resolved.   It was unknown if the reporter considered the influenza-like symptoms, general body pain, fatigue and pain in arm to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix in an unknown arm. The pateint expereinced flu-like symptoms which included body aches, tiredness but no fever. The reporter also stated their arm was sore.  All the symptoms began the following day of administration and lasted approximately a day.  The reporter did not consent to follow up.",,Unknown,1,0
885230,"Left deltoid red, warm to the touch, swollen and feels tight. Employee complains of pain with touch or pressure to the area.",33.0,Adults,1,0
881708,"worsens brain injury symptoms /previous brain injury felt a worsening of their brain injury condition after receiving the vaccine.; worsens brain injury symptoms; This case was reported by a consumer via call center representative and described the occurrence of brain injury in an unknown number of patients who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included brain injury (had a previous brain injury).   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced brain injury (serious criteria GSK medically significant) and condition aggravated. On an unknown date, the outcome of the brain injury and condition aggravated were unknown.   It was unknown if the reporter considered the brain injury and condition aggravated to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not applicable. The age group was not reported but it was selected as adult as per the vaccine indication. The patient who had a previous brain injury felt a worsening of their brain injury condition after receiving the vaccine. The reporter did not consent to follow up. There are no additional details for this report.",,Unknown,0,1
881550,"Flu-lik symptoms - Exhaustion, body aches, Pain at inj. site 1-2 wks This lasted about 3 days and gradually got better over the week. (Same reactions w/1st Shingrix vaccine, given at same location) My first Shingrix vaccine was given in Nov'19, but I don't know the date. I had all of the symptoms of the 2nd dose. I was planning to get the 2nd dose in March 2020, but then COVID 19...",67.0,Seniors,0,0
856505,Patient was complaining of pain to right arm,14.0,Kids,1,0
873101,"eczema-skin reaction; Eczema; This case was reported by a consumer via call center representative and described the occurrence of skin reaction in a 64-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced skin reaction and eczema. On an unknown date, the outcome of the skin reaction and eczema were unknown.   The reporter considered the skin reaction and eczema to be possibly related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient asked if Shingrix vaccine could cause eczema. The patient thought the skin reaction might be from the vaccine.",,Unknown,0,1
871450,"Patient received Flucelvax Quadrivalent after temperature excursion; Patient received Flucelvax Quadrivalent after temperature excursion; This is a spontaneous case, initially received from other health professional via Med Communications (reference number: SEQ20-00509) on 14-Feb-2020, concerning a 10-year old patient of unspecified gender.   The patient's medical history and concomitant medications were not reported.   On an unknown date in 2019, the sticker on the box that contained Flucelvax Quadrivalent vaccine [influenza vaccine, subunit influenza virus vaccine polyvalent, batch number: 261228 and expiry date: not reported] turned red and showed that storage temperature was out of range, but it did not indicate when temperature excursion happened and how long it lasted. The first temperature excursion was confirmed (explicitly coded as Product storage error').  On 10-Nov-2019, there was another excursion at 10.9 degrees Celsius for undetermined time, potentially five hours.  On 11-Nov-2019, the patient was administered Flucelvax Quadrivalent [anatomical location: left deltoid, dose and route of administration,expiration date: not reported] for an unknown indication after temperature excursion (explicitly coded as Product administration error').  It was not reported whether the patient experienced an adverse event due to Flucelvax Quadrivalent administration.   This case is linked to cases 201907258, 202001725, 202001745, 202001746, 202001747, 202001748, 202001749, 202001750, 202001752, 202001753, 202001754, 202001755, 202001756, 202001757, 202001758, 202001759, 202001760, 202001761, 202001762, 202001763, 202001764, 202001765, 202001766, 202001767, 202001768, 202001769, 202001770, 202001771 and 202001772 (the same reporter).   Company comment: Reportedly, the patient was administered the suspect product Flucelvax Quadrivalent after two temperature excursions. It was not reported whether the patient experienced an adverse event. Product storage error and product administration error are assessed as not related per company's conventions.; Sender's Comments: Reportedly, the patient was administered the suspect product Flucelvax Quadrivalent after two temperature excursions. It was not reported whether the patient experienced an adverse event. Product storage error and product administration error are assessed as not related per company's conventions.",10.0,Kids,0,1
858930,"shivering ,fever",57.0,Adults,1,0
890168,"She suspects that the batch of Shingrix caused the shingles; pain in the right abdomen; shingles; fever; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 70-year-old male patient who received Herpes zoster (Shingrix) (batch number 73T27, expiry date 9th September 2022) for prophylaxis. This case was associated with a product complaint.   On 27th July 2020, the patient received the 1st dose of Shingrix (intramuscular). On 27th July 2020, less than a day after receiving Shingrix, the patient experienced fever. On 6th August 2020, the patient experienced shingles and abdominal pain. On an unknown date, the patient experienced pharmaceutical product complaint. On an unknown date, the outcome of the shingles was not recovered/not resolved and the outcome of the fever, abdominal pain and pharmaceutical product complaint were unknown.   The reporter considered the shingles to be related to Shingrix. It was unknown if the reporter considered the fever and abdominal pain to be related to Shingrix.  Additional details were provided as follows: The daughter of the patient is the reporter.   The patient received 1st dose of Shingrix at an unspecified pharmacy. The patient reported that 10 days after receiving the Shingrix dose, he developed shingles. The reporter noted her mother received dose 1 of Shingrix, batch number EJ4NB, at the same time as the patient and she had no side effects and the lot number was different than the patient's dose. The suspected that the batch of Shingrix caused the shingles. The reporter was explained that Shingrix is not a live vaccine but the reporter was insistent. There was not product to return and the reporter obtained the lot number from the pharmacy paperwork. The patient also experienced fever and pain in the right abdomen. Emergency room visit required. There was no return or credit. The reporter did not consent to follow up.",70.0,Seniors,0,0
897388,"Maculopapular rash spreading across left anterior shoulder, left upper trunk  and right anterior shoulder then behind ears. Mild pruritus, self-limited to rash without airway involvement",40.0,Adults,1,0
882238,"Patient called and said that she has dizziness, vomits, muscular weakness and soreness, unbalance and she felt weak. she also said that she was in bed for a least 2 days. In second day, she goes to the doctor and he told her that she had a cellulitis in the arm and she was dehydrate.  He put  normal saline iv and give a prescription for antibiotics, anti-inflammatory and anti-emetic.  Until todays date she still felt weak, with unbalance and pain.",80.0,Seniors,1,0
865259,INJECTION SITE REDNESS AND SWELLING,1.5,Kids,0,0
870822,"Within 12-24 hours of my first dose of this HepB vaccination, I developed severe pain in my fingertips, palms of my hands, my face, and the bottom of my feet and toes. Walking, grimacing, coughing, sneezing, washing dishes, fastening clothing, and resting my hands on my steering wheel while driving were excruciating. This pain lasted about 3-4 weeks. My 2nd dose of the HepB vaccination was on 09/25/2019. Within 6-8 hours of this dose, I developed tingling/pins and needles feeling in my right hand, fingers, and arm. Within an hour of this numbness, I lost feeling and sensation in my right arm from my elbow to my fingertips. Overall, this lasted approximately 12 hours, but the pain from the 1st dose started again and continued for another 3-4 weeks.",30.0,Adults,1,0
915835,"Arm is red, swollen, tender, itchy. nausea, muscle pain, fever 102.3, fatigue, headache",50.0,Adults,1,0
894166,"Fatigue Fever to 101 degrees, abated by 5pm on same day",55.0,Adults,1,0
906484,extreme weakness and fever that prompted hospitalization,79.0,Seniors,1,0
867326,"received 2 doses of GARDASIL 9 by mistake; This initial spontaneous report was received from a physician and refers to a 12-year-old female patient. This report concerns 1 patient and 1 combination product. The patient's pertinent medical history, drug reactions or allergies were not reported. Concomitant therapies included diphtheria toxoid (+) pertussis acellular vaccine (unspecified) (+) tetanus toxoid, varicella virus vaccine live (oka/merck) (VARIVAX) and meningococcal acyw conj vaccine (carrier unspecified).  On 11-MAR-2020, by mistake, the patient was vaccinated with 2 doses of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection (lot # R030456; expiration date was reported as 20-JUL-2021, but upon internal validation established as 23-JUL-2021) (exact dose, route of administration and anatomical location were not reported) for prophylaxis.",12.0,Kids,0,1
899102,"patient was in tremendous pain from neck all the way down my arm to wrist and the top of thumb; patient could not raise his/her arm above waist; it frightened patient considerably; Initial information received on 15-Oct-2020 regarding an unsolicited valid non-serious Social Media case received from a consumer.  This case involves unknown demographics patient who was in tremendous pain from neck all the way down my arm to wrist and the top of thumb (pain), could not raise his/her arm above waist (hypokinesia), it frightened patient considerably (fear), while he/she received vaccine INFLUENZA VACCINE.   The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided.   Concomitant medications were unknown.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient was in tremendous pain from neck all the way down my arm to wrist and the top of thumb (pain), could not raise his/her arm above waist (hypokinesia), it frightened patient considerably (fear) (Unknown latency) following the administration of INFLUENZA VACCINE.  Relevant laboratory data was not reported.  It was not reported if the patient received a corrective treatment.  The outcome was reported as Unknown for all events.  There will be no information available on the batch number for this case.",,Unknown,0,0
875618,"Chills, muscle aches, fever",69.0,Seniors,1,0
880988,"No additional adverse effects reported; administered intramuscularly instead of subcutaneously; This spontaneous report was received from a medical assistant and refers to a patient of an unknown age and gender. No information regarding the patient's medical history, concurrent conditions, concomitant medications, drug reactions or allergies was provided.   On 13-AUG-2020, the patient was inadvertently vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) rHA, lot # S021622, expiration date 09-JAN-2021 (dose, strength and anatomical location were not reported) intramuscularly instead of subcutaneously, for prophylaxis. No additional adverse effects were reported.",,Unknown,0,1
908666,"Patient states she was receiving her COVID vaccination today, 12/23/20, in the left arm. About 5 minutes after the vaccine was administered, patient felt left arm pain that radiated into the left shoulder. About 10 minutes after the arm/shoulder pain began, she had left anterior chest tightness. She had her blood pressure taken, which was 109/104. She states the 104 diastolic is high for her.",53.0,Adults,0,0
880199,"LOST HIS VOICE; COUGHING; EXTREMELY SICK; A spontaneous report has been received from a consumer concerning a male patient (age not provided) of Unknown ethnic origin.    No medical history was reported.     No concomitant products were reported.    On an unknown date, patient received Flumist (influenza virus vaccine live, intranasal) once/single administration, via nasal route.     It was reported that reporter's son got this one time ended up extremely sick (preferred term: Malaise),  coughing (preferred term: Cough) and lost his voice (preferred term: Aphonia) took him to the doctor they said it was a reaction to the mist. He gets the shot as they said the flumist has a live virus and thats likely what he reacted to. Shots don't bother him but he was terrified of the mist now.    The outcome of the events of lost his voice, extremely sick and coughing was unknown.     The event lost his voice was considered serious due to important medical event by the company physician. The events extremely sick and coughing were considered non-serious by the company physician.     The reporter considered the events coughing, lost his voice and extremely sick as related to treatment with Flumist.; Sender's Comments: Aphonia is not listed in the company core data sheet of Quadrivalent live attenuated influenza vaccine (Q/LAIV). Reported cough could be risk factor to the event. Due to limited information on relevant medical history ,concurrent conditions, event onset date and outcome, circumstance leading to the event, concomitant medications ,detailed etiological and diagnostic workup , it is not possible to make a conclusive assessment of the causal relationship of event with suspect drug.",,Unknown,0,1
858168,"Patient came in next day with a large red, warm welt area above her elbow.  concerned on how low shot given and the intense site reaction.",64.0,Adults,0,0
882044,"Fever 100.4, chills, soreness at site of Shingrix vaccine,  flu like symptoms",62.0,Adults,0,0
887403,decribes as a mild case of hives presented on the back of both arms and across patients back.  was resolved with diphenhydramine but returned when it wore off.,67.0,Seniors,0,0
882934,"Employee came back to employee health 1.5 hours after the vaccination complaining of severe dizziness and chest heaviness.  No shortness of breath, wheezing or signs of airway restrictions.  No nausea or vomiting. No redness or bruising at injection site.  Blood pressure taken was 150/88.  Heart rate was 120.  Employee taken to facility Emergency Department  by wheelchair.",44.0,Adults,1,0
889097,"what the dosing schedule is for the vaccine; what the dosing schedule is for the vaccine; the patient had a reaction and broke out in hives; the patient had a reaction and broke out in hives; This spontaneous report was received from a consumer (the patient's parent), referring to a 17-year-old female patient. The patient's pertinent medical history, concurrent conditions and concomitant medications were not reported. It was reported that the patient had allergy to tree nuts.  On an unspecified date in 2017, the patient was vaccinated with the first dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) route of administration reported as ""injection"" (dose, anatomical site of vaccination, lot number or expiration date were not reported) as the pediatrician recommended it (prophylaxis).  On the same day, the patient had a reaction and broke out in hives (urticaria and vaccination complication). The patient sought medical attention and went to the emergency room; as treatment she was administered an unspecified steroid. As soon as she received the steroid, the patient recovered from the events. The reporter wanted to know if ""tree nut"" could be in the vaccine components,  that could have caused the reaction; she also asked what the dosing schedule for the vaccine was (circumstance or information capable of leading to medication error and inappropriate schedule of product administration).  The causality assessment between quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) and the events urticaria and vaccination complication, was not reported.",17.0,Kids,0,1
859000,"Diarrhea resolved within 3 days, redness around administration site about 12 inches in diameter still present 4 days after administration but decreasing in size",71.0,Seniors,0,0
899096,"Patient get sick every single time she got the flu shot; Initial information was received on 14-Oct-2020 regarding an unsolicited valid non-serious social media case from a consumer.  This case involves a female patient who get sick every single (illness), while she received vaccine INFLUENZA VACCINE.  Medical history, past medical treatments, vaccinations, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (Produced by unknown manufacturer, lot number and expiration date not reported) via unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient who get sick every single (illness), (unknown latency) following the administration of INFLUENZA VACCINE.  Laboratory data was not reported.   It was not reported if the patient received any corrective treatment or not.  The outcome of the event was unknown at the time of reporting.  There will be no information on the batch number for this case.",,Unknown,0,1
900178,"flu like reaction; Initial information was received on 07-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer or non-health care professional via social media.  This case involves a female patient of unknown age who experienced flu like reaction (influenza like illness), while she received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), concomitant therapy, vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious flu like reaction (influenza like illness) (Unknown latency) following the administration of INFLUENZA VACCINE.  Details of laboratory data were not reported.   It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event was unknown.  There will be information available on batch number for this case.",,Unknown,0,1
906045,"30 minutes after receiving the vaccine, I (the patient) felt tingling in my lips, nose, and feet. I then developed a non-itchy, macular rash on my chest and back, associated with flushing. No fevers,  chest pain,  shortness of breath, nausea, vomiting, or diarrhea, I was taken to the emergency department, where I had normal vital signs. I was given Benadryl 25 mg PO with complete resolution of rash and tingling sensation within one hour.",27.0,Adults,0,0
874271,Vasovagal syncope,11.0,Kids,0,0
885469,"a low grade fever; Initial information received on 02-Sep-2020 regarding an unsolicited valid non-serious case received from a consumer or non health care professional.  This case involves a patient (unknown demographics) who experienced a low grade fever (pyrexia), while received vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].  Medical history, concomitant therapy, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date (3 weeks ago), the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (lot number, dosing details and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious a low grade fever (pyrexia) (Unknown latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  No laboratory data was reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, patent had not recovered from pyrexia.  There will be no information available on batch number for this case.",,Unknown,0,0
890436,"The patient reports feeling achy all over, having arm pain, and having chills that started about 12 hours after vaccine administration. She reported no fever during that time, and did not take any supportive medications to help deal with symptoms. The patient's condition seemed to continue until she spoke with the pharmacy about 24 hours later. The patient was counseled that she could take supportive medication for aches and pains if necessary. The patient was also told to report back to us or her physician if her condition worsened or did not improve.",57.0,Adults,0,0
913294,"Dizziness, mild cough, nausea, low grade fever, and sore arm.",59.0,Adults,1,0
868656,My first dose in 12/2019 I got ulcers in my mouth. I had to go to a urgent care due to Christmas holidays. Valtrex prescribed. It helped. I received the second dose in March 2020. About 1 week later I started with lip pustules. After 2-3 days I had upper lip edema and itching to my lips. No difficulty breathing. I had a virtual visit due to the weekend and Covid. Prescribed Medtol dose pack. It did help .,56.0,Adults,0,0
857730,"Urinary tract infection; This case was reported by a consumer via call center representative and described the occurrence of urinary tract infection in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced urinary tract infection. The patient was treated with antibiotics nos (Antibiotics Therapy (Unknown)). On an unknown date, the outcome of the urinary tract infection was not recovered/not resolved.   It was unknown if the reporter considered the urinary tract infection to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient stated she was currently on an antibiotic for Urinary tract infection.   The patient was asking if she could get second dose of Shingrix. No other information was provided.  The reporter did not consent to follow up.",,Unknown,0,0
915176,"dizziness; fatigue/tired; chills; irritability; headache; weakness; This is a spontaneous report from a contactable consumer.  A 49-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on 28Dec2020 at a single dose for COVID-19 immunization.  The patient's medical history and concomitant medications were not reported.  In Dec2020, the patient experienced dizziness, fatigue/tired, chills, irritability, headache and weakness.  The outcome of dizziness, fatigue/tired, chills, irritability, headache and weakness was unknown.   The batch/lot number for the vaccine, BNT162B2, was not provided and will be requested during follow-up.",,Unknown,0,0
897353,"Cough, Runny nose followed by nausea, headache which lead to migraine lasting 2 days, 4 days of appetite changes and weight loss.",69.0,Seniors,1,0
881383,"Drug allergy for medications that she is allergic/becomes ill because the flu shot is made with a chicken protein ended with pneumonia; could not breathe; becomes ill; This case was reported by a consumer via call center representative and described the occurrence of pneumonia in a 70-year-old female patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis.   Previously administered products included Influenza vaccine with an associated reaction of pneumonia (received Influenza vaccine on an unknown date and experienced Pneumonia, refer case US2020170274). Concurrent medical conditions included lung disease and drug allergy.   On an unknown date, the patient received Influenza vaccine Quadrivalent unspecified season. On an unknown date, less than a year after receiving Influenza vaccine Quadrivalent unspecified season, the patient experienced pneumonia (serious criteria GSK medically significant), difficulty breathing and malaise. Rechallenge with Influenza vaccine Quadrivalent unspecified season was positive. On an unknown date, the outcome of the pneumonia, difficulty breathing and malaise were recovered/resolved.   The reporter considered the pneumonia and difficulty breathing to be related to Influenza vaccine Quadrivalent unspecified season. It was unknown if the reporter considered the malaise to be related to Influenza vaccine Quadrivalent unspecified season.  Additional details were provided as follows: The age at vaccination was not reported. After receiving flu vaccine, the patient became ill because the flu shot was made with a chicken protein.  The patient stated that, she would stay sick for months. She said this happened 2 years in a row and she ended up going to the emergency room by ambulance because she could not breathe.  The patient also ended up with pneumonia which she got 3 times in a year and a half after the flu shots were received.  The patient had since recovered from all of these events, but she stated, she was not going to get a flu shot again.  The patient did not know the name of the flu shots she received but said we could contact her doctor for that information.  The patient was calling GlaxoSmithKline, because she wanted to know if Shingrix had any chicken or fowl protein in it.  She stated, she had the first shot of Shingrix on Friday 21st August 2020 and the last few days she was coughing a lot.  For the tolerance of dose of Shingrix, refer the linked case US2020AMR170918. This was 1 of 3 linked cases reported for the same patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR170918:same patient (Shingrix vaccine) US-GLAXOSMITHKLINE-US2020170274:same patient",70.0,Seniors,0,1
872850,"High fever , desenes, high blood sugar , and he became diabetes",1.33,Kids,1,0
873482,"Patient received the Japanese Encephalitis Vaccine and started to don her blouse.  Pt stated that she needed to sit down and began to slouch over.  I caught the patient and gently leaned her back on the exam table and lifted her legs and placed on the exam table  foot rest.  I was speaking to the patient until she regained consciousness.  Patient was pale and sweating.  Once patient regained consciousness, the patient stayed laying down and was given a cold pack.  Patient stayed laying down for roughly five minutes and then was able to sit up and had the exam table placed into the seated position.  patient stated her fingers were tingling. Patient was given a glass of water and crackers and felt better within moments. Patient stated she did not eat breakfast and did not drink much water but had a Monster energy drink.  I sat with the patient for about 20 minutes after the episode and ensured she felt well enough to stand and walk.  I consulted a medical provider to ensure nothing else was required. Patient felt well enough to leave and did not wish to be seen by a provider was escorted to her car by another team member.",32.0,Adults,0,1
911488,"left arm soreness; extreme fatigue for 4 days; severe headache day 3,4; This is a spontaneous report from a contactable physician, who is also the patient. This 44-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration in the left arm on 18Dec2020 at 07:00 at single dose for COVID-19 immunisation. Vaccination facility type: hospital. Relevant medical history included penicillin allergy. There were no concomitant medications. On 18Dec2020 at 15:00, the patient experienced left arm soreness and extreme fatigue for 4 days and in Dec2020 she experienced severe headache day 3, 4. The patient did not receive corrective treatments. She recovered from the events in Dec2020. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, she had not been tested for COVID-19.  No follow-up attempts are possible, information about batch number cannot be obtained.",44.0,Adults,0,0
878080,"A type IV reaction is described as redness, swelling and pain from injection site down the left arm. Lasted 2 days. No treatment.",66.0,Seniors,1,0
894061,"Illness; Head ache; Body aches; This case was reported by a other health professional via call center representative and described the occurrence of feeling unwell in a female patient who received Rabies NVS (RabAvert) for prophylaxis.   On an unknown date, the patient received RabAvert. On an unknown date, unknown after receiving RabAvert, the patient experienced feeling unwell, headache and general body pain. On an unknown date, the outcome of the feeling unwell, headache and general body pain were unknown.   It was unknown if the reporter considered the feeling unwell, headache and general body pain to be related to RabAvert.  Additional details were provided as follows: It was unknown if exposure was pre or post exposure. The age at vaccination was not reported. The HCP stated that the patient had headaches, body aches and illness. The case had been linked with US2020206868 reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020206868:same reporter",,Unknown,1,0
916219,"Patient complained of numbness in left cheek. Monitored vitals; pronounced tachycardia. EMS transported patient to hospital.  MD note: 55 year old female who had numbness on left cheek and forehead after vaccination. Patient given Benadryl prior to vaccination. Patients states no prior similar allergic reaction. Patient states no change in voice or cardiopulmonary; no symptoms, wheezing, shortness of breath. Requested vitals be repeated. Patient's tachycardia persists. Patient states no history of tachycardia. Recommend transport to emergency department for possible allergic reaction and concern of tachycardia. EMS contacted to transport. Emergency Department notified about patient.",55.0,Adults,0,0
864078,"left herpetic keratitis; Information has been received from a lawyer referring to a female patient of unknown age. Information about concurrent condition, history condition and concomitant medication was not reported. On or around 07-MAR-2017, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (strength, dose, route, lot# and expiration date unknown) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX) (date not reported), the patient suffered sharp left eye pain with redness, drainage, photophobia and blurred vision. The patient was diagnosed with left herpetic keratitis. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient's symptoms have resulted in physical limitations not present prior to using the vaccine. The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of zoster vaccine live (ZOSTAVAX), the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the event left herpetic keratitis was considered to be not recovered and causal relationship was assessed as related.   The lawyer considered the event left herpetic keratitis to be disability.  Upon internal review, the event left herpetic keratitis was determined to be medically significant.",,Unknown,0,0
862013,"insomnia, disorientation, feeling ""manic"", pain and swelling at injection site, perioral pain and erythema, painful oral lesions (possible lupus flare). Present x 6 days",53.0,Adults,1,0
913399,"Paresthesias, pruritis of face, flushing described as ""hot flash""",31.0,Adults,0,0
858472,Severly reddened with blistering noted day4 after injection,73.0,Seniors,0,0
860526,"01:10 PM-Patient consented to receive Bexsero vaccine. Mother present. 01:11 PM-Patient states, ""I feel light headed like the last time."" Began to slump down in seat. Moved patient into a safe position, legs elevated and Code Blue was called. 01:13 PM-Patient Alert and oriented X 3. Cool towel placed on forehead. Blood pressure 137/82, pulse 77. 01:15 PM-Alert and oriented. Sitting in upright position. Given juice and crackers. Tolerated well. No complaints voiced.  01:17 PM-Alert and oriented. Blood pressure 125/86, pulse 76. Able to stand without difficulty. Ambulated to lobby unassisted. Denies any dizziness or difficulty. Mother present. Instructed to notify MD if symptoms return.",18.0,Adults,0,0
860762,"Summarize HPI: Review of events per patient's recall and review of available medical records:  1) 4/2/2015 Patient cleared for work   2) 7/9/2015 AVA #1 (FAV427A-Emergent) to left arm  3) 7/10-11/2015 flew to another location  reports good health.  On arrival 7/11/2015 states restaurants closed for holidays so did not eat/drink until onboard ship 7/12/2025.  4) 7/12/2015 Once on ship, patient reports urine was dark-looked like blood  medical advised and told had elevated ketones (UA machine broken).    5) Patient reports about day 3-4 post vaccination he felt weak and sluggish describing this as objects were heavy to move/lift/carry and he experienced shortness of breath climbing stairs between decks (difficult to take in deep breaths), and stated while on the bridge his vision would black out for few seconds (returned if relaxed and stood still).  6) 7/14/2015 Medical records document first medical exam with c/o increased urine color x2 days and c/o neck pain.  UA dip stick on ship suggested RBC and ketones. Was clinically dehydrated and sent to shore medical (Hospital) where diagnosed with Urinary Tract Infection, hematuria and dehydration.  Records document electrolytes, glucose, BUN/Creatinine, routine urinalysis, glycosylated hb, and Rello check 4.4 mmol/L ordered (no lab values documented) and US abdomen offered but refused as ""had to travel"".  Patient offered IV fluids but declined preferring IV on base. Patient stated was told his labs were normal.  Patient recalls 7/14/2015 or day 5 that he was hot to touch with hot/cold chills, shivering and was restricted to his room for 12 hours.  He recalls he could not eat over next 1-2 days and vomited x1.  7) Patient states he had a headache and dizziness day 7 post vaccination and still had difficulty eating and drinking due to nausea, lack of appetite.  He stated he had no veins for IV access and was encouraged to drink water/fluids.  8) 7/19/2015 (day 10 post vaccine) he reports losing about 18 pounds due to continued n/v/d.  Records document a follow up exam on base for c/o loss appetite x9 days (eats 4-5 bites then nauseated, no vomiting), cough, congestion x5 days, and peripheral vision ""blackout"" x 30 seconds with no LOC while standing still on the bridge.   Medical exam was normal with Temp 101.5-102.5F, heart rate 116, and respirations 14, BP 104/66.  Labs showed UA with ketones, small amount blood, trace proteins, color dark yellow, and specific gravity 1.030.  IV's infiltrated x 2 and 3rd try was a miss.was given oral fluids and diagnosed with Fever Unknown Origin and dehydration.  9) 7/20/2015 to 7/25/2015 he was followed by ships medical twice a day for vital signs and follow up exams (while at sea).  Patient continued to c/o poor/loss of appetite, nausea, fever, lethargy.Heart rate average 115-124 bpm. EKG not available on ship. Temperature varied from 98.9 to 100.3 on Septra and Tylenol. Mono test was negative. UA: large ketones, ph 6.5, and SP 1.015-1.025.    10) 7/25/2015 seen by shore physician with exam normal.  Abdominal ultrasound suggested questionable renal calculi vs UTI and MD diagnosed dehydration/tachycardia with UA negative for ketones/hematuria. He was cleared to fly home for further evaluation of this unknown illness.  11) Patient advised once home, he continued to feel weak, lethargic/tired, could only eat cheerio's and slept a lot. He recalls his family stating he was ashen, eyes red and irritated.   12) 7/27/2015 follow up with medical reporting he was ""better"" with records documenting ketones in UA and elevated liver enzymes (which ones?). He stated he did see his HCP about 2 days after home or early August and was put on Augmentin for an unknown illness.     13) Follow up exams by medical on 8/12/2015 patient felt better and all labs normal (specific labs tested for not recorded).  8/17/2015 patient advised was back to his normal self.",23.0,Adults,0,0
877888,"PATIENT CAME IN 8/1/20 AND REPORTED THAT AFTER GETTING THIS VACCINE ON 1/18/20 HE DEVELOPED A MILD RASH, ESPECIALLY ON HIS HANDS. I ENCOURAGED HIM TO GET EXPLICIT PERMISSION / RECOMMENDATION FROM HIS DOCTOR BEFORE GETTING SECOND SHINGRIX. HE AGREED THAT WAS A GOOD IDEA.",62.0,Adults,0,0
869324,"MILD SORE THROAT; NOT FEELING WELL/ ICKY; FEELING EXTRA RUN DOWN; MILD HEADACHES; HER STOMACH FELT FUNNY; NAUSEOUS; This spontaneous case report (PVX2019-2632) was received from a consumer on 22-Oct-2019. It described a female consumer who ""felt nauseous"" (PT: Nausea), had been feeling extra run down (PT: Fatigue), not feeling well/icky (PT: Malaise), had mild sore throat (PT: Oropharyngeal pain), her stomach felt funny (PT: abdominal discomfort) and had mild headaches (PT: Headache) while being on oral Vivotif (company suspect) in every other day.  Case report: The consumer completed all four doses of Vivotif either on 14-Oct-2019 or 15-Oct-2019. She stated that she felt nauseous only during the day of her second dose and fourth dose. Since then, had been feeling extra run down, not feeling well and icky and just wanted to sit down and take a nap. The consumer also reported a mild sore throat, but she was not coughing, and it was not unbearable. She was not eating a lot and not eating heavily, since her stomach felt funny. She also had mild headaches for which she was not worried about and thought maybe she just needed more sleep. She would take Aleve for her headache.  The consumer's medical history included occasional back aches and takes muscle relaxer.  Action taken with Vivotif with respect to the events was not applicable.  The clinical outcome of the reported event was unknown.  Company's Comment: In this case, it was reported that a female consumer ""felt nauseous"", had been feeling extra run down, not feeling well/icky, her stomach felt funny and had mild headaches while being on oral Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Hence, the causality of the events with Vivotif is assessed as possible. Owing to the nature of the event the causality of the event ""had mild sore throat"" has been assessed as unlikely.; Sender's Comments: Company's Comment: In this case, it was reported that a female consumer ""felt nauseous"", had been feeling extra run down, not feeling well/icky, her stomach felt funny and had mild headaches while being on oral Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Hence, the causality of the events with Vivotif is assessed as possible. Owing to the nature of the event, the causality of the event ""had mild sore throat"" has been assessed as unlikely.",,Unknown,0,0
873341,Pain at injection site.  Dizziness & shivers.  Slight fever.  Fatigue,66.0,Seniors,1,0
904903,"the arm felt like someone took a hammer to it for about 3 to 5 days; Initial information regarding an unsolicited valid non-serious case received from a consumer (patient) via social media on 30-Nov-2020.  This case involves a patient of unknown demographics who felt like someone took a hammer to the arm for about 3 to 5 days (pain in extremity), after receiving INFLUENZA VACCINE.  The patient's medical history, past medical treatments, past vaccinations, family history and concomitant medications were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number and expiration date not reported) via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient felt like someone took a hammer to the arm for about 3 to 5 days (pain in extremity), (non-serious event) (unknown latency) following the administration of INFLUENZA VACCINE.  No laboratory data reported.  It was not reported if the patient received a corrective treatment.  At the time of report, the outcome was unknown for the event.  There will be no information available on the batch number for this case.",,Unknown,0,0
886067,"chills, full-body pain, nausea, dry cough, severe headache, temperature of 103-104f 20 hours after injection. vomiting, extreme fatigue and weakness and light sensitive.   Nausea subsided after taking Zofran (glad we had that on hand).  Ate crackers and drank Liquid IV hydrating packets the rest of the day.  Chicken noodle soup later at night.  Two days after injection, temperature has dropped to 99f, body pain, fatigue.  Injection site is still very tender.",60.0,Adults,1,0
881036,Left arm rotator cuff bursitis/tendinitis noted 2 days post vaccine,60.0,Adults,0,1
879931,Polymyalgia Rheumatica,79.0,Seniors,0,0
865817,"rash on her arms, which has now spread to her neck.; Dose 1 of Shingrix was given 14 months prior; This case was reported by a consumer via call center representative and described the occurrence of rash in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose 14 months prior from the date of reporting ).   On 5th February 2020, the patient received the 2nd dose of Shingrix (intramuscular). On 5th February 2020, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On 12th February 2020, the patient experienced rash. On an unknown date, the outcome of the rash and drug dose administration interval too long were unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were received as follows: The patient reported that she had dose 2 of Shingrix.  no events were noted with dose 1.  The patient reports that 7 days after dose 2, she developed a rash on her arms, which has now spread to her neck. The interval was more than recommended, which led to lengthening of vaccination schedule.  The reporter consented to follow up. The reporter had no other contact information for physician at time of report.",,Unknown,1,0
914794,"Dizziness for couple hours after shot, Soreness at injection site 5 days; Headache 2 days; Nausea 1 day; Muscle and Joint aches 4 days, Tiredness 4 days",57.0,Adults,1,0
859032,"Moderate neck and shoulder pain, increasing 2-3 days after injection. Still persisting at 5 days post injection. Nightmares and difficulty sleeping, still persisting 5 days post injection.  Migraine 3-4 days post injection. Intermittent headaches.  Arm soreness at injection site, still persisting 5 days post injection. Overall muscle soreness, not limited to injection site.",31.0,Adults,1,0
875666,"He left the clinic and immediately felt dizzy.  He stumbled and fell to the ground in the parking lot, saying he couldn't see and felt dizzy. Mom helped him up to try to get him to the curb. He fell limp in my (mom's) arms. I laid him down in the parking lot & he fainted. I ran back to the door and yelled for help.  He came to and the nurses helped him back into the clinic , laid him down and gave him water and ice pack and tended to him.   He was sweating profusely and then started throwing up.  We stayed approx. 15 min, he had a small snack and started to feel like he could leave.  At home, he has had a very sore right arm and is tired.",12.0,Kids,0,0
901801,"Very sore upper left arm- to touch and while using. Chills, skin ""hurts"" all over body, headache, tired, stomach cramps.",53.0,Adults,1,0
874039,"Dizziness; This case was reported by a other health professional via call center representative and described the occurrence of dizziness in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced dizziness. On an unknown date, the outcome of the dizziness was unknown.   It was unknown if the reporter considered the dizziness to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient experienced dizziness following the Shingrix.  No additional information was provided.",,Unknown,1,0
855610,"respiratory failure; stevens johnson syndrome; toxic epidermal necrolysis; Initial information received on 31-DEC-2019 regarding an unsolicited valid serious literature case.   This case is linked to cases 2020SA001262, 2020SA001225, 2020SA001235 and 2020SA001250 (Same reporter).  The following is verbatim from the article:  Background: Since the last review of vaccine safety surveillance data for erythema multiforme (EM), Stevens Johnson syndrome (SJS), SJS/TEN, and toxic epidermal necrolysis (TEN) (EM/SJS/TEN), over 37 new vaccines have been introduced. We sought to describe reported EM/SJS/TEN after vaccines during 1999-2017.  Methods: We identified reports of EM/SJS/TEN received by the Vaccine Adverse Event Reporting System (VAERS) during 1999-2017. We stratified analysis by condition (EM, SJS, or TEN), and analyzed reports by serious or non-serious status, sex, age group, time from vaccination to symptom onset, exposure to known causes of EM/SJS/TEN, and vaccines administered. We used Empirical Bayesian data mining to detect vaccine-AE pairs reported more frequently than expected. Results: Of 466,027 reports to VAERS during 1999-017, we identified 984 reports of EM, 89 reports of SJS, 6 reports of SJS/TEN, and 7 reports of TEN. Few reports of EM (9%), and most reports of SJS (52%), SJS/TEN (100%), and TEN (100%) were serious. Overall, 55% of reports described males, 48% described children aged 4 years; 58% of EM/SJS/TEN occurred 7 days after vaccination. Few reports (5%) described exposure to known causes of EM/SJS/TEN. Overall, childhood vaccines (e.g., combined measles, mumps, and rubella vaccine) were most commonly reported. We identified 6 deaths; 4 were exposed to medications associated with EM/SJS/TEN. EM after smallpox vaccine was reported disproportionately among people aged 19 - 49 years.  Conclusions: EM/SJS/TEN were rarely reported after vaccination; data mining identified a known association between EM and smallpox vaccine.  This case involves a 43 years old female patient who experienced Stevens-Johnson syndrome (Stevens-Johnson syndrome), respiratory failure (respiratory failure) and toxic epidermal necrolysis (toxic epidermal necrolysis) while she received vaccine INFLUENZA VACCINE.  Medical history included Post herpetic neuralgia. Medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included AMOXICILLIN SODIUM (AMOXICILLIN [AMOXICILLIN SODIUM]).  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE TRIVALENT produced by unknown manufacturer lot number not reported via unknown route in unknown administration site.  On an unknown date, the patient developed serious Stevens-Johnson syndrome (Stevens-Johnson syndrome) and toxic epidermal necrolysis (toxic epidermal necrolysis) 3 days following the administration of INFLUENZA VACCINE. The patient was died due to respiratory failure (respiratory failure) on an unspecified date. All events was assessed as medically significant.  It is unknown if an autopsy was done.  Details of laboratory data not reported.  Final diagnosis was toxic epidermal necrolysis, Stevens Johnson syndrome and respiratory failure  It was not reported if the patient received a corrective treatment.  The outcome of the events toxic epidermal necrolysis, Stevens Johnson syndrome was unknown at the time of reporting.   There will be no information available on the batch number for this case.; Sender's Comments: This case involves a 43 years old female patient who experienced toxic epidermal necrolysis, respiratory failure, Stevens Johnson syndrome and reported (fatal) death after vaccination with INFLUENZA VACCINE produced by unknown manufacturer. The time to onset is compatible with the role of vaccine. Medical history included Post herpetic neuralgia. Additional information regarding condition at the time of vaccination, lab data excluding other etiologies and detailed autopsy report would be needed for complete assessment of the case. Based upon the reported information, the role of vaccine cannot be assessed.; Reported Cause(s) of Death: respiratory failure",,Unknown,0,1
861898,"Sick; This case was reported by a consumer via call center representative and described the occurrence of sickness in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of malaise (received 1st dose on an unknown date and experienced flu like symptoms).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced sickness. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the sickness was recovered/resolved.   It was unknown if the reporter considered the sickness to be related to Shingrix.  Additional details were received as follows: The age at vaccination was not reported. The reporter stated that the patient was sick after vaccination. For tolerance to 1st dose, refer case US2020025207.",,Unknown,0,0
880165,"no adverse effects; Product reported as GARDASIL but lot # valid for GARDASIL 9; patient have been administered doses of improperly stored vaccine; This spontaneous report was received from a nurse and refers to an unspecified patient of unknown age and gender. There was no information about the patients concurrent conditions, concomitant therapies or medical histories provided.  On 10-MAR-2020 at 15:51, the patient was vaccinated with improperly stored doses of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) , 0.5 milliliter, intramuscular in the right arm for prophylaxis. Reporter reported quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) with lot # 1621931 which was not valid for quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL). However, lot# 1621931, expiration date  26-JAN-2022 was valid for  hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9).No adverse event was reported. This is one of several reports from the same reporter. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: 1621931; expirationdate: 26-JAN-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2003USA002275:Original Case : 2003USA002275 US-009507513-2008USA008883:Original Case : 2003USA002275 US-009507513-2008USA008876:Original Case : 2003USA002275 US-009507513-2008USA008875:Original Case : 2003USA002275 US-009507513-2008USA008877:Original Case : 2003USA002275 US-009507513-2008USA008878:Original Case : 2003USA002275 US-009507513-2008USA008879:Original Case : 2003USA002275 US-009507513-2008USA008880:Original Case : 2003USA002275 US-009507513-2008USA008881:Original Case : 2003USA002275 US-009507513-2008USA008884:Original Case : 2003USA002275 US-009507513-2008USA008886:Original Case : 2003USA002275 US-009507513-2008USA008887:Original Case : 2003USA002275 US-009507513-2008USA008888:Original Case : 2003USA002275 US-009507513-2008USA008889:Original Case : 2003USA002275 US-009507513-2008USA008890:Original Case : 2003USA002275 US-009507513-2008USA008891:Original Case : 2003USA002275 US-009507513-2008USA008892:Original Case : 2003USA002275 US-009507513-2008USA008893: US-009507513-2008USA008894: US-009507513-2008USA008895: US-009507513-2008USA008896: US-009507513-2008USA008897: US-009507513-2008USA008898: US-009507513-2008USA008899: US-009507513-2008USA008900: US-009507513-2008USA008901: US-009507513-2008USA008902: US-009507513-2008USA008903: US-009507513-2008USA008904: US-009507513-2008USA008905: US-009507513-2008USA008906: US-009507513-2008USA008907: US-009507513-2008USA008908: US-009507513-2008USA008909: US-009507513-2008USA008910: US-009507513-2008USA008911: US-009507513-2008USA008912: US-009507513-2008USA008913: US-009507513-2008USA008914: US-009507513-2008USA008915: US-009507513-2008USA008916: US-009507513-2008USA008917: US-009507513-2008USA008918: US-009507513-2008USA008919: US-009507513-2008USA008920: US-009507513-2008USA008921: US-009507513-2008USA008922: US-009507513-2008USA008923: US-009507513-2008USA008924: US-009507513-2008USA008925: US-009507513-2008USA008926: US-009507513-2008USA008927: US-009507513-2008USA008928: US-009507513-2008USA008929: US-009507513-2008USA008930: US-009507513-2008USA008931: US-009507513-2008USA008932: US-009507513-2008USA008933:",,Unknown,0,1
889346,Pt stated they observed redness the day following administration.  The redness began to subside days following administration and then roughly a week after the redness and itching came back.,65.0,Adults,0,0
908943,"Received vaccine before shift. Within 10-15 mins bilateral back of the tongue numbness and tingling. Walked to ER (my department) and  asked charge nurse for Zyrtec. Advised to stay and be monitored, opted not to be checked in to ER. BP 146/105, 126-120 BP, abnormally high. Experienced red lips, itchy hands and feet, 'frog in throat' feeling. Convinced to check into ER. Swollen uvula, tonsils, lips red/swollen, stridorous breathing. Checked  in to ER, given IV Benadryl, fluid, prednisone, and Pepcid. Hands and feet were mottled. Confirmed anaphylactic reaction. Became nauseous, given Zofran.  Given Epi in left shoulder. Stayed for 4 hours for continued monitoring. Symptoms started to subside. Also given inhaled albuterol. Discharged w/ Benadryl, Pepcid, prednisone 5 days course, and prescription for Epi.",28.0,Adults,0,1
855736,"double vision; This case was reported by a consumer via call center representative and described the occurrence of double vision in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 31st October 2019, the patient received the 2nd dose of Shingrix. On 14th November 2019, 14 days after receiving Shingrix, the patient experienced double vision. On an unknown date, the outcome of the double vision was recovering/resolving.   It was unknown if the reporter considered the double vision to be related to Shingrix.  Additional details were provided as follows: The patient had the second dose of Shingrix and experienced double vision and eyes are out of alignment. After closing the one eye she seen ok but both eyes open she seen double, one on top of each other.",70.0,Seniors,0,0
856790,"My husband received the Pneumonia vaccine 23 on Friday January 3, 2020 at Pharmacy. Shortly after he said it was painful. Took an extra strength Tylenol. Sat. am was tired slept almost all afternoon. Said his arm hurt. Took 2 extra strength Tylenol total that day. Sunday morning went to church. Came home his arm hurt and I looked at it and it was beet red, hot to touch, swollen and went several inches across and about 12 inches long it went from above the Elbow to down close to his wrist. He looked like he was carrying a loaf of bread on his arm. We called the pharmacy and I explained the problem. He said no I never heard of that before. If it was still bad on Mon. See the family doctor. Well I was concerned. We went to Clinic and he was seen and the PA said it was Cellulitis and gave him a strong dose of antibiotics. About 2 days later it improved. Now it's almost clear. I am telling you this so you can help educate pharmacists who give the vaccine. Thank you.",66.0,Seniors,0,0
862007,none,38.0,Adults,0,0
905820,"feeling tired; achy; This is a spontaneous report from a contactable consumer. This consumer reported similar events for two patients. This is 1st of two reports. A patient of unspecified age and gender received bnt162b2 (Covid-19 vaccine) , via an unspecified route of administration on 16Dec2020 at single dose for immunization.  The patient's medical history and concomitant medications were not reported. The consumer had two friends who are health care professionals who received the Covid-19 vaccine on 16Dec2020. They just reported feeling tired and achy in Dec2020 to the consumer. The outcome of the events was unknown.   Information on the Batch/Lot number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2020501305 same reporter/drug/event, different patient",,Unknown,0,1
867842,"I was given a flu shot at work by nurse brought in to provide the shot. I am not sure which flu vaccine it was. The next morning, the site where the shot was given was very sore. I was expecting this and didn't think anything about it. This pain lasted for months and it was so bad it kept me up at night. I finally went to the doctor who gave me a steroid shot in the arm that relieved the pain. I am who has had many shots - very big shots - and I never had a problem with them. I always had a problem with the flu shot giving me flu like symptoms but never had pain at the site of the shot before. Psychologically, I never had a problem even as a child with shots because I watched my sister (Type 1 diabetic) have shots every day. The pain was very real and significant. Given that I have very prevalent autoimmune disease in my family and I have POTS which researchers have discovered may be an autoimmune disease, I have read that having a shot could be dangerous. Never being prone to getting the flu, even as a child, I have decided to not get the flu shot until more research is done on why people are reacting badly to it.",51.0,Adults,0,0
911597,40 min after vaccine was given my face turned red and tight on left side. Then something happened next day. Face on left side felt weird like tight skin and a little numbness on left side that comes and goes on left side since and a little swelling on left side of face.,50.0,Adults,0,1
867660,"flu; the patient was readmitted to the hospital from 3/9/2020 through 3/12/2020 for vomiting and and bloody diarrhea; the patient was readmitted to the hospital from 3/9/2020 through 3/12/2020 for vomiting and and bloody diarrhea; This spontaneous report was received from a physician and refers to a infant female patient who was born with congenital diaphragmatic hernia and lung hypoplasia. The patient's medical history included hospitalization for two months after birth, due to congenital anomalies. There was no information about the patient's allergies, drug reactions or concomitant therapies provided. On unknown date in 2019, while hospitalization after birth, the patient was vaccinated with first dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) orally (dose, lot # and expiration date were not reported) for prophylaxis. On unknown date in February 2020, the patient was admitted to the hospital due to the flu. The patient sought medical attention and received unspecified treatment. While hospitalization G-tube was placed as well as Nissen fundoplication procedure due to congenital anomalies. During the admission, the patient was administered all age appropriate unspecified vaccines, except the second dose ofrotavirus vaccine, live, oral, pentavalent (ROTATEQ). Since 9-MAR-2020 to 12-MAR-2020, the patient was readmitted to the hospital because of vomiting and bloody diarrhea. The patient sought medical attention and received unspecified treatment.  The outcome of flu was unknown. The physiaican reported that the event of vomiting had resolved but the patient still had blood in stool.   The causality assessment between the events and rotavirus vaccine, live, oral, pentavalent (ROTATEQ) was not provided.   Upon internal review the event of bloody diarrhea (haematochezia) was considered to be medically significant.",,Unknown,0,1
875773,"Patient was administered a dose of ROTAVIRUS intramuscularly instead of orally; The pharmacist is not sure if ROTATEQ or ROTARIX was administered; The pharmacist is not sure if ROTATEQ or ROTARIX was administered; One unspecified leg does have some redness; The parent gave Tylenol for pain; This spontaneous report was received from a pharmacist concerning a 4 month old male patient. Information regarding the patient's medical history, concurrent conditions and concomitant medications was not reported.   On an unspecified date in 2020, the patient was vaccinated with a rotavirus vaccine for prophylaxis, intramuscularly instead of orally (incorrect route of product administration), the pharmacist was not sure if was rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (strength, frequency, lot number and expiration date were not provided) or rotavirus g1 p1 vaccine live (89-12) (ROTARIX) (interchange of vaccine products and circumstance or information capable of leading to medication error) (strength, frequency, lot number and expiration date were not provided); the reporter mentioned that this was the second dose and the parents were not sure which leg the rotavirus vaccine was administered in.       On 07-JUL-2020, the patient did has some redness on an unspecified leg (erythema) and the parent gave acetaminophen (TYLENOL) for pain.    The outcome of erythema and pain was reported as not recovered. The causality assessment between the suspect drugs and the events occurrence was not reported.",0.33,Kids,0,0
890372,"Patient got a rash on her shoulders, neck and back approximately 1 hour after receiving vaccine. Patient said she was able to tolerate it while applying calamine lotion. Patient did not require further hospitalization.",66.0,Seniors,0,0
878972,Patient was given a 3rd dose of Gardasil which was not needed. Patient had previously Received 1st dose at age 12 and 2nd dose at age 13. On Saturday 8/8 patient c/o lower back pain which did not subside til Sunday (8/9) evening,16.0,Kids,1,0
887654,"Medical assistant calling to report a temperature excursion that occurred 8/14/2020 which involved the following products: GARDASIL9, PEDVAXHIB, RECOMBIVAX, ROTATEQ. Per caller, ""it would be possible that at least 100 patients have received vaccines; This spontaneous report was received from a medical assistant, concerning a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies or concomitant medications were not reported.  On 21-SEP-2020, the patient was vaccinated with an improperly stored dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) as prophylaxis (lot # T011167 with expiration date 27-MAY-2022) (strength, frequency, route of administration and anatomical location were not reported).  The improperly stored dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) experienced a temperature excursion of 35.4 Fahrenheit degrees (F) for the time frame of 20 minutes without previous temperature excursions. It was confirmed that a digital data logger was involved.  This is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2009USA006106:",,Unknown,0,1
861952,"Preterm delivery at 36.7 weeks of gestation; Vaccine exposure during pregnancy; This is an observational study case, initially received on 11-Feb-2020, concerning a 35-year-old, pregnant, female subject, of body weight 108 lbs, height 62 inches and body mass index (BMI) 19.8, enrolled in, a prospective observational safety study.   The subject's current conditions included obsessive compulsive disorder (OCD) and anxiety. It was noted that the subject had a pregnancy in advanced age.  The subject's concomitant medications included Prenatal vitamins (unspecified vitamins and minerals) for pregnancy.  The subject's obstetrical history noted that the subject had two previous full-term, live birth pregnancies with no birth defects. The subject had no history of offspring with major congenital malformation (MCM). Also, the subject had no maternal or paternal history with MCM. The subject did not use tobacco, alcohol or illicit drugs during pregnancy.   The subject's last menstrual period (LMP) date was on 07-Feb-2019, the estimated delivery date (EDD) and corrected estimated date of delivery (CEDD) were both reported as 02-Dec-2019. The type of pregnancy was singleton.   On 01-Apr-2019, the subject underwent haemoglobin electrophoresis and no MCMs were noted.  On 16-Apr-2019, the subject underwent ultrasound and no MCMs were noted.  On 20-Jun-2019, the subject underwent ultrasound and no MCMs were noted.  On 03-Oct-2019, the subject underwent ultrasound and no MCMs were noted.  On 17-Oct-2019, at approximately 33 weeks of gestation, the subject was administered Flucelvax QIVc (Flu Vaccine Cell Subunit QIV NVD) [influenza vaccine, subunit influenza virus vaccine polyvalent, batch number: 261218, dose: 0.5 mL, route of administration, anatomical location and expiration date: not reported] (explicitly coded as 'Vaccine exposure during pregnancy') for influenza immunisation.  On 09-Nov-2019, at approximately 36.7 weeks of gestation, the subject gave live birth to a male neonate via caesarean section method. The neonate's birth weight was 2750 grams, length was 50.2 cm and head circumference was 33 cm. The appearance, pulse, grimace, activity, and respiration (APGAR) scores were 8 (one minute) and 9 (five minutes). The APGAR score for ten minutes was not reported. No MCMs were identified at the time of birth.   At the time of this report, the outcome for the event of 'premature delivery' was not reported.  The event of premature delivery' was considered as serious due to criterion of medical significance, per company.  The reporter did not provide causality assessment.  This case is linked to case number 202001701 (the corresponding baby case).  Company comment: It was reported that the male neonate was delivered via Caesarean section several weeks after vaccination. A Caesarean section in general, and in particular if conducted prior to the term, would suggest an underlying cause prompting this method over vaginal delivery. No other pregnancy complications were reported which precludes thorough assessment of causality. Based on the available information, causality for the event of premature delivery was considered unassessable. Vaccine exposure during pregnancy was assessed as unrelated to the vaccine in line with internal conventions.; Sender's Comments: It was reported that the male neonate was delivered via Caesarean section several weeks after vaccination. A Caesarean section in general, and in particular if conducted prior to the term, would suggest an underlying cause prompting this method over vaginal delivery. No other pregnancy complications were reported which precludes thorough assessment of causality. Based on the available information, causality for the event of premature delivery was considered unassessable. Vaccine exposure during pregnancy was assessed as unrelated to the vaccine in line with internal conventions.",35.0,Adults,0,1
876619,"expired dose of Menactra was given to patient/no AE; Initial information received on 14-Jul-2020 regarding an unsolicited valid non-serious case received from a nurse.  This case involves a 18 years old female patient who was vaccinated with MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] (batch number U6219BA, dosing details 0.5 ml and dosage interval: once) route and site of administration not reported on 14-Jul-2020 for prophylactic vaccination which was already expired on 16-Jun-2020 (Expired product administered).  Medical history, concomitant therapy, medical treatment(s), vaccination(s) and family history were not provided.  It was an actual medication error case due to expired vaccine used.  At the time of reporting, no adverse event was reported.    This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",18.0,Adults,0,1
908521,"No soreness, woke up next day with red arm, 4-5 inch redness on upper arm, little if no swelling, not warm to touch, no other reaction",75.0,Seniors,0,0
868871,"Adverse event; epigastric pain; pelvic pain; unspecified hyperlipidemia; acute upper respiratory tract infection; pain joint, leg/ knee pain; abdominal pain; Insomnia; Autoimmune hemolytic anemia; Information has been received from medical records, concerning a case in litigation and refers to a 58-year-old female patient (pt). Her past vaccination included Tdap on 23-JUN-2011. On 11-JAN-2012, the pt was vaccinated with zoster vaccine live (ZOSTAVAX) 0.65 mL, lot # 1253AA, expiry date was not reported but upon internal validation was established as 01-NOV-2012 (route of administration and vaccination site were not specified) for prophylaxis. On 13-MAR-2012, the pt had a hospital discharge follow-up (dates and reason for hospitalization were not reported). On 22-MAR-2012, the pt presented for hospital discharge f/u and was diagnosed with autoimmune hemolytic anemia. On 22-MAY-2012, she presented for routine general medical examination, autoimmune hemolytic anemia and unspecified insomnia. on 17-MAR-2014, she was diagnosed with abdominal pain. On 24-MAR-2014, she presented for abdominal pain. On 24-APR-2014, she had routine general medical examination and screening for diabetes mellitus. She was also diagnosed  with insomnia. On 23-JUL-2014, the pt was seen for knee pain (pain in joint). On 15-DEC-2014, she was diagnosed with acute upper respiratory tract infection and insomnia. On 25-FEB-2015, she presented with abdominal pain. On 26-MAY-2015, she was diagnosed with unspecified hyperlipidemia. On 29-AUG-2015 and 10-JUL-2015, she presented with abdominal pain. On 24-OCT-2015, she was diagnosed with abdominal pain and pelvic pain. On 06-SEP-2017, she was diagnosed with epigastric pain. On 21-SEP-2017, she was diagnosed with unspecified abdominal pain. The outcome of the events and the causality assessment were not provided.    Upon internal review, the event of autoimmune hemolytic anemia was determined to be medically significant.   All available medical records will be provided upon request.",58.0,Adults,0,0
906097,"No additional AEs reported.; Caller is a pharmacist reporting that he was informed a 20 month old received a dose of PROQUAD and VARIVAX.; This spontaneous report was received from a pharmacist, referring to 20-months-old patient, of unknown gender. The patient's pertinent medical history, current conditions, previous drug reactions or allergies and concomitant medications were not reported.   On 15-DEC-2020, the patient received a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) and varicella virus vaccine live (oka/merck) (VARIVAX) (formulations, strengths, vaccination schemes, routes of administration, anatomical sites of vaccination, lot numbers and expiration dates were not provided) (inappropriate schedule of product administration), both vaccines were administered as prophylaxis. No additional adverse events were reported.",1.67,Kids,0,1
862173,UNMONITORED TEMP FOR 63H,5.0,Kids,0,0
915626,"I am 8 weeks pregnant and my estimate delivery date is August 10, 2021 . I felt numbness on my right left and could barely walk. Some nausea, dizziness ,and fatigue .",21.0,Adults,1,0
903664,"rash on face, chest, abdomen,  warm and itchy skin blurred vision Itchy throat Took 50 Benadryl orally 2 hour post injection around 9p,.",36.0,Adults,1,0
910993,I received the vaccine around 7:55 am in my left arm. I waited  around the appropriate time then drove home. No problems until 12:30 or so. I was resting in my bed and immediate felt my heart start to race. I checked it with my pulse oximeter and my rate had shot up to 148. I got up and tried some maneuvers to try to get it down. It then went up to 152. I told my husband to call EMS. I also contact my co-worker. She is a physician and she agreed with taking some benadryl. I took 25 mgs of benadryl. EMS arrived about 10 minutes later. they monitor my blood pressure and heart rate. it did come down but remained around 100. I then went to ER by car for evaluation.,48.0,Adults,0,1
860231,Pt developed rash on forehead,59.0,Adults,1,0
912700,"Patient received Pfizer Vaccine at approximately 1430 and was in observation area. At approximately 1435  observer stated that patient started to c/o  dizziness and became pal.. Patient maintained LOC. Emergency measures implemented. Patient was place on oxygen,  vital signs taken, EMSA called. EMSA present and evaluated patient. Patient was able to leave clinic site after evaluation.",59.0,Adults,0,0
910265,"about 3 hours after injection, began feeling nauseous.  the next day at about 8 am temp went up to 102.4. took ibuprofen and temp finally broke about 4 pm that day. had injection site soreness for the first 48 hours then developed large red wheal that covered 3/4 of upper arm. still with red area when this report was filed on 12/28/2020",56.0,Adults,0,0
867259,"SINUS INFECTION; This spontaneous case (PVX2019-2224) was received from a pharmacist on 30-Aug-2019. It described an adult female consumer (between 18 to 64 age) who had sinus infection (PT: Sinusitis), after administration of Vivotif for an unknown indication.  Case report: The consumer was on therapy of Vivotif from an unknown date. After started taking Vivotif doses, she developed a sinus infection. The last dose was taken on 28-Aug-2019. On 30-Aug-2019, she went to the physician, who prescribed Keflex for treatment, but he did not have the dosing regimen as he was still deciding whether he should take it.  Action taken with Vivotif with respect to the event was unknown.  The clinical outcome of the reported event was unknown.  Company's Comment: In this case, the consumer developed a sinus infection after receiving Vivotif vaccine. Since sinus infection is an infectious condition, the causality of the event sinus infection is assessed as unlikely with Vivotif vaccine. ; Sender's Comments: Company's Comment: In this case, the consumer developed a sinus infection after receiving Vivotif vaccine. Since sinus infection is an infectious condition, the causality of the event sinus infection is assessed as unlikely with Vivotif vaccine.",,Unknown,0,1
908876,Five minutes after the shot she had trouble swallowing her saliva.  Dry Cough Tight Lungs,69.0,Seniors,0,0
893572,"Patient returned to clinic after 30 min, complaining of dizzines, nausea and facial swelling. Assed patients heart and lungs. Breathe sounds clear to ausculation, no diminished breathing, wheezing or rales noted. Flushed face. Blood pressure 138/98, RR 18, oxygen 100%, HR 114. Patient with pervious anxiety about getting flu vaccine as she could not remember if she had inthe past. Discussed with patient to remain calm, no complaints of throat swelling or shortness of breath. Looked for swellingon her facial but could only find mild redness from where she wore the mask on her face. Airway patent, no swlling of throat or tonsils. Had patient sit for 5 mings, gave her water and a sucker as she could not remember the last time she had something to eat or drink, in several hours. After 5 min HR 98, blood pressure 128/82, RR 18, oxygen 100% , airway still patent. Had patient sit in the clinic in a lounged position for another 10 mints. Reviewed side effects of medication, given VIS sheet. Upon leaving the clinic blood pressure 118/72, RR 18, HR 62, oxygen 100 %. Color returned to face and patient reports that she felt much better, able to talk in complete sentence, aireway patent. Reviewed signs and symptoms of an allergic reaction and when to call 911.",30.0,Adults,0,0
913146,Injection site pain 4-36 hours after dose. Headache 12-36 hours after dose. Joint pain 12-36 hours after dose. Fatigue 12-36 hours after dose. Chest tickle 24-36 hours after dose. Tooth ache 4-36 hours after dose.,23.0,Adults,1,0
910737,"Received the vaccine and 8 hours after had nausea.  Was scheduled to work and by the time I got inside I also had chills, fever, muscle aches and fatigue. I was sent home. I took Tylenol and went home and went to sleep. The next day the fever was gone but I still had some fatigue and a sore arm at injection site. The next day I only had a sore arm at injection site.  No other symptoms after that day.",49.0,Adults,0,0
868795,"MISSED TO TAKE THIRD DOSE ON DUE DATE; This case (PVX2019-2158) was received from a pharmacist on 23-Aug-2019. It described a 33-year-old male consumer who ""missed to take third dose on due date"" (PT: Product dose omission), while being on Vivotif for an unknown indication  Case report: The consumer missed to take the third dose of Vivotif that was due on 21-Aug-2019.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event ""missed to take third dose on due date"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""missed to take third dose on due date"" was considered as not applicable.",,Unknown,0,0
888738,No reaction at time of vaccine administration. Tried contacting parent but our calls were not answered.,16.0,Kids,0,1
891808,"Started with chills and sweating, then prg to upper left side ache (pt was afraid of the vax causing blood clots), then when pt went to walk and stand, her toes were hurting along with stiffness (like arthritis), along with slight headache and frequent urination every two hours. Headache then prg to migraine, pt took tylenol and then felt better next morning.",72.0,Seniors,0,0
893165,"Patient had a pain at the site of injection . Had to go to Dr ( PCP) who prescribed him Prednisone tab to resolve that , what MD suspected was bursitis caused by the needle. Followed up with patient second time today 10/28 . He said he has no pain and Presnisone worked. When I spoke to clinical nurse on 10/26/20 , she said that it was not allergic reaction but probably muscular tear caused by needle , leading to bursitis.",57.0,Adults,1,0
880173,"no adverse effects; Product reported as GARDASIL but lot # valid for GARDASIL 9; unspecified number of unspecified patients have been administered doses of improperly stored vaccines; This spontaneous report as received from a registered nurse, referring to a patient (gender and age not reported).  No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided.  On 27-MAR-2020 at 11:23 hours, the patinet was vaccinated with an improperly stored dose of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) with a lot # reported as 1621931 (Reporter reported Gardasil with lot # 1621931 which was not valid for Gardasil. However, lot# 1621931 is valid for Gardasil 9) at a dose of 0.5 mL intramuscularly (IM) on the right arm (RA) and with a dose of Hepatitis A Vaccine, Inactivated (VAQTA) at a dose of 0.5 mL intramuscularly (IM) on the right arm, with a lot # reported as 747P5, and an improperly stored dose of diphtheria toxoid, pertussis acellular vaccine (unspecified), tetanus toxoid, influenza virus split virion 4v vaccine inactivated (FLUZONE) and meningococcal ACYW conj vaccine (dip toxoid) (MENACTRA).  Administered doses of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) and Hepatitis A Vaccine, Inactivated (VAQTA) experienced the temperature excursion above 9 degrees Celsius (15.5C) for 4 hour and 6 minutes. Digital data logger was involved. There were no previous temperature excursions reported.  Lot # 747P5 is not a valid lot # for Hepatitis A Vaccine, Inactivated.    This is one of the several reports received from the same reporter.   This case comes from a case previously considered non-valid, but per new information received (patient identifiers) the case was splitted and determined to be valid for a specific patient. ; Sender's Comments:  US-009507513-2008USA008876: US-009507513-2008USA008890: US-009507513-2008USA008889: US-009507513-2003USA002275: US-009507513-2008USA008877: US-009507513-2008USA008875: US-009507513-2008USA008885: US-009507513-2008USA008880: US-009507513-2008USA008881: US-009507513-2008USA008883: US-009507513-2008USA008882: US-009507513-2008USA008879: US-009507513-2008USA008910: US-009507513-2008USA008911: US-009507513-2008USA008912: US-009507513-2008USA008913: US-009507513-2008USA008914: US-009507513-2008USA008915: US-009507513-2008USA008916: US-009507513-2008USA008917: US-009507513-2008USA008887: US-009507513-2008USA008918: US-009507513-2008USA008919: US-009507513-2008USA008890: US-009507513-2008USA008920: US-009507513-2008USA008904: US-009507513-2008USA008922: US-009507513-2008USA008923: US-009507513-2008USA008896: US-009507513-2008USA008925: US-009507513-2008USA008926: US-009507513-2008USA008927: US-009507513-2008USA008898: US-009507513-2008USA008928: US-009507513-2008USA008929: US-009507513-2008USA008899: US-009507513-2008USA008900: US-009507513-2008USA008930: US-009507513-2008USA008931: US-009507513-2008USA008909: US-009507513-2008USA008907: US-009507513-2008USA008906: US-009507513-2008USA008921: US-009507513-2008USA008903: US-009507513-2008USA008901: US-009507513-2008USA008933:",,Unknown,0,1
908731,"Pfizer-BioNTech COVID-19 Vaccine EUA  initial IM caused intense pain at site, then through evening into night pain radiated to shoulder and neck, experienced sweats/chills during night, site swollen but not red, recovered next day but exhausted.",57.0,Adults,0,0
858275,"Patient reported that she has experienced left shoulder pain ever since receiving her vaccine. She reports that she can not move arm without it hurting. At rest there is no pain. Patient was seen by her primary care physician's office on 1/23 and the physician assistant's exam at that time showed no erythema, no ecchymosis, no joint effusion; patient had active range of motion, full range of motion; abduction was uncomfortable; shoulder was non-tender at rest and non-tender on palpation. Patient was advised by the physician assistant to apply moist heat, followed by stretching of the shoulder, followed by fifteen minutes of ice. She was advised to report back to the office if symptoms continued or worstened.",60.0,Adults,0,0
902832,Within and hour and a half of receiving developed tinnitus in both ears lasting 6 hours. The night after receiving vaccine also developed orthostatic hypotension and started to pass out but caught myself with an assisted fall.  Fever(102 F with temporal and oral thermometer) body aches/sweats/general malaise lasting close to 24 hours after receiving vaccine. Fever/aches treated with acetaminophen.,33.0,Adults,0,0
889903,"Rash, mottled in appearance, appeared on R arm on mid-arm between elbow and shoulder about 3 inches below deltoid.  Flat, no pustules, dark pigmented, itchy.. Not accompanied by fever, chills or other rashes or symptoms.  Sore arm x 24 hrs.",73.0,Seniors,1,0
879415,No adverse event. Patient asked for meningitis vaccine and was given MMR by mistake. Patient is ok,3.17,Kids,0,1
886320,Mom states face and feet swollen as per MD's notes.,0.17,Kids,0,0
913818,"6 hours post - dizzy spells, headache, fatigue day 1 - day 6 - Nausea, vomiting, diarrhea, headache, fatigue, arm pain and redness, muscle aches day 7 - red ring around injection site and itchiness",28.0,Adults,1,0
896954,"Difficulty with range of motion, weakness in right arm, pain to injection site. All symptoms began the night of the injection and have not gone away. She was seen by her provider on 11/16/2020, X-rays ordered. Physical therapy referral was made, diclofenac prescribed.",39.0,Adults,1,0
901649,"Patient received a influenza vaccine on 11/17/2020. Patient reports that he experienced a dull pain on the arm the day afterwards that has continually worsened. Patient reports that he is having trouble lifting arm for normal day to day activities and the pain is conistent and dull. Patient reports that he saw a chiropractor approximately 2 weeks after vaccine administration. Per patient, chiropractor conducted immaging and found no abnormalities. Patient has not taken anything for pain excpet for using hot compress on the injury area. Patient stated on 12/11/2020 that he has not yet seen his primary care provider regarding this pain.",67.0,Seniors,0,0
867959,Pain arm Achy Headache Crawly skin for 5 days Reaction of bubble painful red rash when doing my 5th rapatha shot since Dec 2019 in left leg 4 days later,70.0,Seniors,1,0
870360,"Severe Pain in right upper arm. Upper Biceps, (Swollen, Pain radiated down, upper Arm to wrist-to soulder, down to Front wrist, can't raise Arm up sense this, vaccine.",57.0,Adults,0,0
865795,"meniscus torn in a skiing accident; patient did not receive the 3rd dose of vaccine yet (over 6 months since the initial dose)/she will have to delay the vaccine further due to surgery after accident; patient did not receive the 3rd dose of vaccine yet (over 6 months since the initial dose)/she will have to delay the vaccine further due to surgery after accident; This spontaneous report was received from a patient's mother and refers to a 15-year-old female patient. No information regarding the patient's medical history, concurrent conditions, drug reactions or allergies, historical drugs and concomitant medications was provided.  On an unknown dates (reported as on time), the patient received two doses of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (strength, exact doses, frequency, route of administration, lot number and expiration date were not provided) for prophylaxis. At the time of the report (reported as over 6 months since the initial dose), the patient did not receive the third dose. It was also reported that the patient torn her meniscus on an unknown date in a skiing accident and she would have to delay the vaccine further. The patient would have surgery due to torn meniscus.  The outcome of the events was unknown.  The causality assessment between torn meniscus and of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) was not provided.",,Unknown,0,1
871602,"due to no enough diulent for complete reconsititution big chunk observered which did not dissolved into diluent/No AE; patient had sent home without receiving vaccine/No AE; Initial information was received on 15-May-2020 regarding an unsolicited valid non-serious case from a pharmacist.  This case involves a 22-years-old female patient who did not received RABIES (HDC) VACCINE [IMOVAX RABIES] due to no enough diluent used for complete reconstitution and big chunk observed which did not dissolve into diluent (product dose omission and Package quantity incorrect).  Medical history, medical treatment, vaccination and family history were not provided.  On an unknown date, the vaccination was scheduled of suspect RABIES (HDC) VACCINE [vial lot: R1C85, Diluent lot: N1L47, Box lot: R1C854M and expiry date: 14-May-2021] for prophylactic vaccination for the patient.  It was a case of potential medication error due to product dose omission and Package quantity incorrect.   At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
881262,"Injection site reaction of a red, hot, very sore rash extending down from injection site to inner elbow. Rash appeared 24 hours after injection and continued to resolve over 2 days.",77.0,Seniors,1,0
916214,"After injection, had arm pain, muscle pain in neck and upper back. Woke up late this morning feeling fatigue, dizzy , lightheaded and nausea.",23.0,Adults,1,0
874403,"expired dose of Pentacel was administered to 4 month old patient, no adverse event; Initial information was received on 22-Jun-2020 regarding an unsolicited valid non-serious case from an other health professional  This case involves a 4 months old female patient who was administered an expired dose of DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL] (Expired product administered).  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included PNEUMOCOCCAL VACCINE and ROTAVIRUS VACCINE for prophylactic vaccination.  On 18-Jun-2020, the patient received a 0.5 ml dose 1 of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (diluent: Lot: UJ066ABA, ActHib Lot: UJ100AA) (expiry date 13-Jun-2020) via intramuscular route in the left thigh for prophylactic vaccination  It was a case of an actual medication error due to expired vaccine used  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",0.33,Kids,0,1
904592,"10/28/2020:  She states initially had pain at injection site. She also has had some pain radiating to left scapular area as well as down to her thumb.   She went back to her office and became nauseated /queasy and felt lightheaded x 1 hour.  3 hours post injection, she has decreased shoulder ROM Limited with flexion and abduction, external rotation, and horizontal adduction Hurts with movement. Currently, using anti-inflammatories, icing.  11/02 -Reports that shoulder is improving; however, there is pain with sleeping. Reports that if she doesn't do ROM exercises hourly, increased pain Pain with flexion, abduction, and horizontal adduction, but ROM is improved. Strength is ok.   12/14 - Shoulder continues to be bothersome - Appointment made with Ortho Plan:  Continue home exercise program          RX:  Celebrex          Recheck 2/15/2021",60.0,Adults,1,0
876527,"sore arm; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 9th February 2020, the patient received the 1st dose of Shingrix. On 9th February 2020, less than a day after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovered/resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional details were reported as follows: The patient recived Shingrix and experienced sore arm. The reporter consented to follow up. For tolerance after 2nd dose refer case US2020123381.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020123381:same reporter",69.0,Seniors,1,0
869464,"Within an hour or two - extreme pain.  Had to move the vaccinated arm with my good arm.  It was way too painful to move on its own.  I had the chills and extreme shivering.  I may have had a temperature but did not have a thermometer.  The pain lasted a week.  It would not go away.  Ended up in physical therapy for about 2 months. The inflammation from the vaccine settled in my left shoulder. The physical therapy did help, but my shoulder still hurts, but not like it did in the beginning.  I am not taking the second dose due to the adverse effects of the first one.",80.0,Seniors,0,0
909950,"Muscle aches, subjective fever, headache, sore arm",30.0,Adults,1,0
895107,"Few spots; red rectangle on arm around the injection site on left arm; itchy and broke out across forehead; welts; ear was beet red, redness on chest and underneath nose and over top lip; Ear hot/ as feeling like it was on fire; tingling on ear, chest, underneath nose and over top lip; itchy on her chest and underneath her nose and over her top lip; Initial information regarding an unsolicited valid non-serious case was received from a consumer or non-health care professional via Medical Information (Reference number- 00302631) and transmitted to Sanofi on 06-Oct-2020.  This case involves a 79-years-old female patient who experienced itchy and broke out across forehead (rash pruritic), welts (urticaria), ear was beet red, redness on chest and underneath nose and over top lip (erythema), ear hot/ as feeling like it was on fire (Feeling hot), tingling on ear, chest, underneath nose and over top lip (paraesthesia) and itchy on her chest and underneath her nose and over her top lip (pruritus), few spots (rash macular) and red rectangle on arm around the injection site on left arm (vaccination site erythema), after she received vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.  On 05-Oct-2020 at 9:00 AM, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE lot number not reported via an intramuscular route in the left arm for prophylactic vaccination.  On 05-Oct-2020 at 11:00 AM, the patient developed a non-serious itchy and broke out across forehead (rash pruritic), welts (urticaria) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  On 05-Oct-2020, the patient developed a non-serious ear was beet red, redness on chest and underneath nose and over top lip (erythema), ear hot/ as feeling like it was on fire (Feeling hot), tingling on ear, chest, underneath nose and over top lip (paraesthesia) and itchy on her chest and underneath her nose and over her top lip (pruritus) 4-5 hours following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  The patient developed a non-serious few spots (rash macular) and red rectangle on arm around the injection site on left arm (vaccination site erythema) unknown latency following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  Laboratory details were not reported.   The patient was treated with CALAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (IVAREST [CALAMINE;DIPHENHYDRAMINE HYDROCHLORIDE]), PARACETAMOL (TYLENOL) and used a cold compress.  The patient was recovering from rash pruritic, urticaria, erythema, burning sensation, paraesthesia, pruritus at the time of reporting.  The event outcome was unknown for rash macular, vaccination site erythema.  There will be no information available on the batch number for this case.",79.0,Seniors,0,0
870196,"had an outbreak of herpes; This case was reported by a other health professional and described the occurrence of herpes virus infection in a patient who received Herpes zoster (Shingrix) (batch number J3M5J, expiry date 6th February 2022) for prophylaxis.   The patient's past medical history included herpes virus infection (outbreak of Herpes on July 7 1998).   On 12th February 2020, the patient received the 1st dose of Shingrix. On 22nd February 2020, 10 days after receiving Shingrix, the patient experienced herpes virus infection. On an unknown date, the outcome of the herpes virus infection was not recovered/not resolved.   The reporter considered the herpes virus infection to be unrelated to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The batch number was reported as JRM5J, however it was changed to J3M5J as per sales sheet. The patient provided the NDC number as 5816082901. The patient received Shingrix and had an outbreak of herpes which had not stopped to date. The reporter at the time of reporting need to take the herpes medication for life. On 22nd April 2020, the patient received 2nd dose batch number H4H34, expiry date 27th November 2021 and NDC5816082801. There was no relation between the vaccine and herpes. But the reporter would like to know if there was a relationship between herpes and the vaccine.",,Unknown,0,1
860874,"Sinus infection; Took first dose of Vivotif on 11DEC2019 and third dose on 14DEC2019; Started taking Zithromax concomitantly with Vivotif on 15DEC2019; Spontaneous report received on 20DEC2019. Additional information was received on 23DEC2019 and 27DEC2019.  A nurse reported that a male consumer developed ""sinus infection"" (PT: Sinusitis) and he ""took the first dose of Vivotif on 11DEC2019 and third dose of Vivotif on 14DEC2019"" (PT: Inappropriate schedule of product administration). He was receiving Vivotif for immunisation and ""started taking Zithromax concomitantly with Vivotif on 15DEC2019"" (PT: Labelled drug-drug interaction medication error).  The consumer started Vivotif on 11DEC2019 and took his third dose on 14DEC2019. On an unknown date, he developed sinus infection and did not take the fourth dose of Vivotif. Action taken with Vivotif with respect to the event sinus infection was drug withdrawn while with respect to the event ""took the first dose of Vivotif on 11DEC2019 and second dose of Vivotif on 14DEC2019"" and ""started taking Zithromax concomitantly with Vivotif on 15DEC2019"" was not applicable. At the time of report, the event ""sinus infection"" was resolved and the clinical outcome of all of other events was unknown.  He took 4 doses of Zithromax (azithromycin) in three days as a treatment for sinus infection (from 15DEC2019 to 17DEC2019).   Consumer's medical history included benign prostate hyperplasia and had two artificial knees, which he had for about 4 years.   On 19DEC2019, he took amoxicillin for his dentist appointment as pre-medication due to his knees. Other concomitant medications included alfuzosin (5 mg daily), lisinopril (5 mg daily), amlodipine (5 mg daily) and finasteride (5 mg daily). The consumer did not know the indications of his medications. He stated that two were used for blood pressure; one was used to keep the elasticity of his bladder; one was used for his prostrate.  Company Comment: A consumer took the first dose of Vivotif on 11DEC2019 and third dose of Vivotif on 14DEC2019 (Inappropriate schedule of Vaccine administered) and also developed sinus infection for which he started taking Zithromax on 15DEC2019 (Labelled drug-drug interaction medication error). The consumer did not take the fourth dose and sinus infection was resolved with antibiotic course. Antibiotics should be taken at least three days after completing the vivotif course, and the causality of the events Inappropriate schedule of Vaccine administered, and Labelled drug-drug interaction medication error is assessed as not related to Vivotif due to the nature of the events. The causality of sinus infection is assessed as not related to Vivotif due to the infectious nature of the event.; Sender's Comments: A consumer took the first dose of Vivotif on 11DEC2019 and third dose of Vivotif on 14DEC2019 (Inappropriate schedule of Vaccine administered) and also developed sinus infection for which he started taking Zithromax on 15DEC2019 (Labelled drug-drug interaction medication error). The consumer did not take the fourth dose and sinus infection was resolved with antibiotic course. Antibiotics should be taken at least three days after completing the vivotif course, and the causality of the events Inappropriate schedule of Vaccine administered, and Labelled drug-drug interaction medication error is assessed as not related to Vivotif due to the nature of the events. The causality of sinus infection is assessed as not related to Vivotif due to the infectious nature of the event.",,Unknown,0,1
855853,"Patient stated he had blurred vision day after vaccine, symptoms were starting to clear up but patient was unsure if they were related to the vaccine, however they did start 1-2 days after the vaccine",77.0,Seniors,0,1
856308,"a four months old baby was vaccinated bynurse using a wrong diluent for Pentacel, no AE.; Initial information received on 31-Dec-2019 regarding an unsolicited valid non-serious case from a Nurse.  This case involves a four months old patient who was vaccinated using a wrong diluent for DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL] (lot number UJ020AA and expiration date 09-Oct-2020)(PT: product preparation error) via unknown route in unknown administration site on an unknown date.   The medical history and concomitant medications were not reported.  It was an actual medication error case due to product preparation error. It was reported that the nurse did not use the diluent for Pentacel and used the diluent for Merck live vaccine- as reported.   No adverse event reported at the time of reporting.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",0.33,Kids,0,1
914226,"extreme soreness/pain at injection site; This is a spontaneous report from a contactable nurse.  A 65-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EH9899), intramuscular on the left arm on 22Dec2020 06:00 at single dose COVID-19 immunisation.  The patient medical history and concomitant medications were not reported.  The patient experienced extreme soreness/pain at injection site on 22Dec2020 09:00.  The patient received no treatment. The outcome of the events was recovered on Dec2020.",65.0,Adults,0,0
860320,"Pt woke up feeling ""room was spinning"" the next morning and vertigo continued intermittently. seen by myself at clinic on 2/5/2020. Rx meclizine PRN. rest and fluids",67.0,Seniors,1,0
855463,"fibromyalgia; balance issues; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of an unknown age. The patient's concurrent conditions, medical history and concomitant medications were not reported. In or around 06-MAY-2014, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (dose, dose #, lot #, expiration date and route of administration were not provided) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). On an unknown date (reported as shortly after receiving zoster vaccine live (ZOSTAVAX)), the patient suffered fibromyalgia and balance issues. As a direct and proximate result, the zoster vaccine live (ZOSTAVAX), the patient's symptoms resulted in physical limitations not present prior to using the product. The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries, suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury, suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events was not recovered. The reporter considered the events to be related to zoster vaccine live (ZOSTAVAX).  The events fibromyalgia and balance issues were determined to be disabling.",,Unknown,0,0
880307,"Swelling at shot site, severe body aches and severe headache, red rings on right side of upper chest and beside shot site, chills (I felt as though I had a case of the flu--I couldn't get warm), shot site and right shoulder still quite sore almost 24 hours.",65.0,Adults,1,0
877981,"was more painful than the one that received/arm was sore an extra day or two longer; shot ""wasn't that bad""; She experienced some shivering/shivering feeling lasted about a day.; She had some fatigue,; This case was reported by a pharmacist via sales rep and described the occurrence of pain in arm in a 53-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis.   On 13th July 2020, the patient received the 1st dose of Shingrix and Tdap Vaccine. In July 2020, less than 3 weeks after receiving Shingrix and Tdap Vaccine, the patient experienced pain in arm, feeling abnormal, shivering and fatigue. On an unknown date, the outcome of the pain in arm, feeling abnormal, shivering and fatigue were unknown.   It was unknown if the reporter considered the pain in arm, feeling abnormal, shivering and fatigue to be related to Shingrix and Tdap Vaccine.  Additional case details were reported as follows: The patient received Shingrix shot was not that bad. The arm having received the Tdap vaccine was more painful than the one that received the Shingrix. The Shingrix arm was sore an extra day or two longer, though and experienced some shivering, which improved once she went outside to do her work instead. The shivering feeling lasted about a day. The patient had some fatigue, but it was hot and humid outside and she thought that may be attributed to the fact that The patient had run outside in the heat and humidity.",53.0,Adults,0,0
865782,"DIARRHEA; STOMACH PAIN; This spontaneous case (PVX2019-1336) report was received from a nurse on 24-May-2019. It describes a 39-year-old female consumer who had diarrhea and stomach pain, after the administration of Vivotif for typhoid prophylaxis.  Case report: The consumer took the first dose of Vivotif on 23-May-2019 at 10 pm. On 24-may-2019, she had diarrhea and stomach pain at 6 am. She reported that, at 11 am both the events were continued. She had diarrhea and vomiting in every 10 minute. The nurse reported that there was no treatment medication reported for the events and she did not report any concomitant medications. She had no medical history related to the vaccine. She did not take any unhygienic food or water. Furthermore, she did not want to take other doses of Vivotif.   Action taken with Vivotif was unknown.  The consumer had not recovered from the events.  Company's Comment: In this case, it was reported that the consumer had diarrhea and stomach pain after the administration of Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Also, diarrhoea and stomach pain are labelled as per CCDS. Hence, the causality of the events with Vivotif is assessed as possible. ; Sender's Comments: Company's Comment: In this case, it was reported that the consumer had diarrhea and stomach pain after the administration of Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Also, diarrhoea and stomach pain are labelled as per CCDS. Hence, the causality of the events with Vivotif is assessed as possible.",,Unknown,0,0
892703,"Redness, itching at injection site and down arm to bicep.  Area is warm to touch and red with slight swelling. Concern for early cellulitis Patient rx'ed Keflex but advised only to start if symptoms worsen.  Treat currently with Benadryl and ice.",21.0,Adults,0,0
903497,4:30pm pt noticed tingling & hot flash of face and neck- stiffness of jaw took 50mg of Benadryl. 530-6pm pt noticed the addition of numbness and tingling arms. Pt slept. Pt woke at 11:30pm and noticed that tingling was gone. Pt woke this morning and reports to feeling fine.,34.0,Adults,0,0
900534,"get so sick after he received his first flu shot; Initial information was received on 20-Oct-2020 regarding an unsolicited valid non-serious social media case from patient's wife.  The case was related to 2020SA297232, 2020SA297338, 2020SA297344, 2020SA297203, 2020SA297183, 2020SA297189, 2020SA297215, 2020SA297267, 2020SA297198, 2020SA297259, 2020SA297264, 2020SA297224, 2020SA297197, 2020SA297275, 2020SA297193, 2020SA297278, 2020SA297301, 2020SA295993, 2020SA290234, 2020SA273251, 2020SA285105, 2020SA289150 and 2020SA297164  This case involves a patient of unknown demographics who got sick after he received his first flu shot (illness), while the patient received INFLUENZA VACCINE.  The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided.   Concomitant medications were not reported.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer, batch number and other dosing details were not reported) for prophylactic vaccination.  On an unknown date, it was reported that the patient who got sick after he received his first flu shot (illness), (unknown latency) following the administration of INFLUENZA VACCINE. The reporter had raised a concern that the product was not of help but of hindrance and had had named the product a poison.   Details of laboratory data were not reported.  Corrective treatment was not reported.   The event outcome was unknown.  There will be no information available on the batch number for this case.",,Unknown,0,1
867262,"redness at injection site; swelling at injection site; tenderness at injection site; itch at injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 18th February 2020, the patient received the 2nd dose of Shingrix. In February 2020, less than a week after receiving Shingrix, the patient experienced injection site erythema, injection site swelling, injection site tenderness and injection site itching. On an unknown date, the outcome of the injection site erythema, injection site swelling, injection site tenderness and injection site itching were not recovered/not resolved.   It was unknown if the reporter considered the injection site erythema, injection site swelling, injection site tenderness and injection site itching to be related to Shingrix.  Additional details were received as follows: The age at vaccination was not reported. The age group was not reported but was selected as an adult as per vaccine indication. The patient received Shingrix, 3 days ago of the reporting date. Till the time of reporting, the patient was experiencing redness, swelling, tenderness and itch at the shot site.  The patient asked about treatment of these symptoms specially itching.",,Unknown,0,1
830295,"started to cry; unable to stand; feeling weak; dizzy; This spontaneous report was received from a healthcare professional on 18-AUG-2020 and refers to an 11-year-old, male patient. The patient had no known allergies, no illness at the time of vaccination and up to one month prior, and no chronic or long-standing health conditions. He had no prescriptions, over-the-counter medications, dietary supplements, or herbal remedies being taken at the time of vaccination. The patient was feeling well at first. He was not talkative and expressed being nervous about vaccines. He denied any side effects from vaccines in the past. The patient was reminded to tell father or nurse if he was not feeling well. He nodded and agreed. The patient was reminded to relax and practice deep breathing during administration of vaccines.  On 23-AUG-2019 at 10:00, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) lot # R016971, expiration date was not reported but upon internal validation established as 22-MAR-2021, intramuscularly in the right arm (dose was not reported), first dose of meningococcal acyw conj vaccine (crm197) (MENVEO) lot number amva152a, intramuscularly in the right arm (dose and expiration date were not reported), first dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot number R033656, expiration date was not reported but upon internal validation established as 20-NOV-2020, subcutaneously in the left arm (dose was not reported), the second dose of diphtheria toxoid, pertussis acellular 3-component vaccine, tetanus toxoid (BOOSTRIX) lot number 97nl3, intramuscularly in the right arm (dose and expiration date were not reported) and first dose of hepatitis a virus vaccine inactivated (HAVRIX) lot number 2gy7e, intramuscularly in the left arm (dose and expiration date were not reported), all for prophylaxis (also reported as patient was administered 3 vaccines on each arm).  On 23-AUG-2019 at 10:02, once the vaccine administration was finished, the patient was asked if he was feeling well, he shook his hand and started to cry. The patient was unable to stand. He reported feeling weak and dizzy. He was kept in an exam room to monitor symptoms. He denied eating that morning. He was given an ice pack to use on back of neck and forehead. The patient's father was with him during entire time of nurse visit. The patient stayed in clinic for at least 20 minutes to monitor symptoms. He was feeling better and was able to walk by himself. He reported feeling a lot better after resting in exam room. There were no medical tests and laboratory results related to the adverse events. The outcome of the events was reported as recovered/resolved. The relatedness between the events and the suspect therapies was not provided.  Follow-up information has been received from a registered nurse on 21-SEP-2020. It was reported that the reporter was not able to provide additional information regarding the events because of limited demographics to identify the patient. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp; devicelotnumber: R016971; expirationdate: 22-MAR-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent",11.0,Kids,0,1
811846,"hives on arms, legs and face; vaccine site was red; vaccine site was warm; vaccine site was swollen; rash; This report was obtained on request by the Company from the FDA (Agency Number 811846) under the Freedom of Information Act.   This spontaneous report was received from a nurse and refers to a 13-year-old male patient. He had no chronic or long-standing health condition, no other illnesses at the time of vaccination and up to one month prior, no prescriptions, over-the-counter medications, dietary supplements or herbal remedies and no known allergies.  On 16-APR-2019 at 17:30, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) intramuscularly in the left arm, (strength and exact dose were not reported), (lot # 1602281 verified to be valid, expiry date not reported, but upon internal validation established as 21-JUL-2021) for prophylaxis.  Approximately one hour after vaccination, the patient consumed some potato chips with dip. On the same day, at approximately 20:00, the patient complained of rash. His mother gave him diphenhydramine hydrochloride (BENADRYL) before bed and rash largely disappeared. Next morning, the patient woke up with hives on arms, legs and face and vaccine site was red, warm and swollen. He denied any difficulty breathing. The patient's parent was advised to monitor next few days to help figure what was going on and also to avoid the chips and dip until known cause. The parent was told to come in if the symptoms continue or to visit emergency room (ER) for difficulty breathing or swallowing. The patient recovered from the events on an unknown date in April 2019.   The relatedness between the events and suspect vaccine was not reported.  Follow-up information has been received from the nurse on 25-FEB-2020. The nurse was unable to identify the patient.",13.0,Kids,0,0
863283,Patient was given the Twinrix which is the adult version 18 and older. She should have received the pediatric dose.,13.0,Kids,0,0
857383,"Patient called reporting he was seen by opthamologist on 1/14/20 with dx of herpes related eye infection. He reports his symptoms started approx. 7 days after the injection of the second dose of the Shingrix. He reports being placed on Valtrex 500mg po bid and pred forte every 4 hours. At baseline, he is on atenolol and brimonidine twice a day for eye related issues followed by their office. He reports the infection has caused corneal edema of the right eye and elevated IOP and iritis of that eye. He was seen again on 1/20/20 for recheck and will follow up with them in 1 week from that date.",63.0,Adults,0,0
902372,"Headache, temp 99, muscle soreness, achey tender skin",73.0,Seniors,1,0
901027,"Patient experienced a syncope episode with lightheadedness, feeling faint and vision closing in. She was very nervous before the vaccination. 15 minutes post vaccine she developed a rash on her inner crook of her elbows and forearms, face and legs. Patient states she experiences these rashes when under extreme stress or heat conditions such as final exams, long distance running track or hot tubs. She did not experience any tingling or swelling of the face lips or tongue. She was observed in pharmacy for 1 hour and rash dissipated. Patient states that most of the rash had gone away once she got home approximately 90 minutes after vaccination.",18.0,Adults,0,0
913384,HA N/V,58.0,Adults,0,0
888545,"Patient developed fever and had 4 febrile seizures beginning the morning of October 6th, approximately 15 hours after vaccines were given.  She was first transported to a local ED, where she had another seizure and was given lorazepam.  She was then transported to the hospital via emergency transport and experienced another seizure like episode, was given another benzodiazepine.  she arrived in  ED and had an additional seizure, and was given another dose of ativan.  She was admitted toMed/Surg unit and stayed there for 2 days under observation and an EEG was also performed.",1.25,Kids,0,1
890455,Patient complains of arm pain that has worsened since the vaccination,22.0,Adults,1,0
910034,"Soreness to injection site, fatigue, fever, chills, body ache and nausea.",55.0,Adults,1,0
866153,"not feeling well after getting the shingrix vaccine; This case was reported by a other health professional via other manufacturer and described the occurrence of malaise in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included tofacitinib citrate (Xeljanz) unknown for prophylaxis.   Concurrent medical conditions included psoriatic arthritis.   On an unknown date, the patient received Shingrix at an unknown dose. On 23rd January 2019, the patient started Xeljanz (oral) 11 mg at an unknown frequency. On an unknown date, unknown after receiving Shingrix, the patient experienced malaise. The action taken with Xeljanz was unknown. On an unknown date, the outcome of the malaise was unknown.   It was unknown if the reporter considered the malaise to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The age group was not reported but was captured as adult as per vaccine indication.  The patient was not felt well after receiving Shingrix vaccine. No other information was reported.",,Unknown,0,1
862942,"Patient jerked away from syringe, causing the needle to scratch the patient's left arm and waste part of the vaccine. The scratch bled lightly and was patted with dry gauze. New Tdap vaccine drawn up and administered to patient.",11.0,Kids,0,1
879842,syncope,91.0,Seniors,0,0
887197,"After getting the flu vaccine on Monday September 14, starting that evening I began to feel multiple twitching, spasms  on my chest, and triceps. I felt chest pains on both sides of my body, I felt muscle weakness and my chest and arm felt hot.   I previously was recovering from a right arm and shoulder injury which occurred in a local bar which I was feeling discomfort and pain from, however after the flu vaccine the pain and discomfort around my right shoulder increased, with new symptoms including my neck hurting. Although several days ago the twitching and spasms stopped, I continued feeling heat around my chest and shoulder and neck discomfort which I didn?t feel before the flu vaccine.",45.0,Adults,0,0
903689,10cm X 12cm erythema on left deltoid 24 hours after vaccination,9.0,Kids,0,0
888512,"Felt little sick; This case was reported by a consumer via interactive digital media and described the occurrence of sickness in a patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis.   On an unknown date, the patient received Influenza vaccine Quadrivalent unspecified season. On an unknown date, unknown after receiving Influenza vaccine Quadrivalent unspecified season, the patient experienced sickness. On an unknown date, the outcome of the sickness was recovered/resolved.   It was unknown if the reporter considered the sickness to be related to Influenza vaccine Quadrivalent unspecified season.  Additional details were provided as follows: The age at vaccination was not reported. The patient felt little sick after receiving flu shot. Apparently it was normal. It was reported as day after, the patient felt ok.",,Unknown,0,1
905649,"The evening of 12/16 my headache begin at the next day fever of 103 stayed for 7 hrs took  administered Tylenol  exp chills, body aches, and rash on face around the eye spread to right side of nose, side went to hand area lasted from 12/17 to 12/21.The headache started effecting my neck contacted my PCP on 12/19. I went to ER on 12/19 ran tests CT scan check for clots negative, lumbar puncture and chest X-ray was fine and dint exp respiratory problems. I missed 3 days of from work 12/9 to 12/21.",37.0,Adults,0,0
886673,"turned blue; This case was reported by a consumer via interactive digital media and described the occurrence of cyanosis in a female child exposed to Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) in utero. The parent received the product for prophylaxis.   On an unknown date, the mother received Influenza vaccine Quadrivalent unspecified season. The mother's last menstrual period was on an unknown date and estimated date of delivery was on an unknown date. The child was exposed to  at an unknown time during the pregnancy. The child was diagnosed with cyanosis. On an unknown date, the outcome of the cyanosis was unknown.   It was unknown if the reporter considered the cyanosis to be related to Influenza vaccine Quadrivalent unspecified season.  Additional information was provided as follows: The patient turned blue hours after the flu vaccine, head of pediatrics said oops this did happen, they would put it in her medical file to never give it to her again. The reporter consented to follow up. This case is linked with US2020AMR192700, reported by same reporter for same patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR192700:same reporter",4.0,Kids,0,1
887971,"Patient received the flu vaccination on 10/3/2020 and called doctor on 10/4/2020 about swelling on the upper left leg, thigh felt hard, no redness, limping on the left leg 2 hours after received vaccine. Patient was seen in the office on 10/5/20 with swelling on the left thigh and limping on the left leg still.",4.0,Kids,0,1
896306,"LEFT ARM ONLY:  HOT TO TOUCH, SWELLING, PAIN GENERAL NAUSEA HIVES ITCHING",78.0,Seniors,1,0
876108,"Fever of 100.4, achy right arn, swollen lymph nodes under right arm, elevated blood pressure 150/69, stiff neck. Patient felt better after Tylenol/advil. But glands were still a little swollen when she came in 7/14/2020",57.0,Adults,0,0
872346,"The following day after vaccination, my daughter would cry and whimper from when she had woken up until she had fallen asleep.  With minimal periods through out the day where she would calm down. She refused to eat all day, only drink fluids. The second day post vaccination, still fussy through out the day however a bit easier to calm. Not much eaten. Odd eye movements and neck arching throughout the day. Times where she would just ""blank out"", for almost a minute. Awaking multiple times throughout the night. Third day, she is doing better with being put down and playing, though still having small, random bursts of fussiness. Doing better with eating but not like she was. Still doing the same odd eye movements and neck arching throughout the day and the periods of blanking out.",1.08,Kids,0,0
890806,Left thigh swelling & erythema  noted 9/9/2020. Next day erythema resolved and swelling better.,0.17,Kids,0,0
884364,"allergic reaction; throat swelling; raspy voice; flushed face; itching; fever; redness and splotchy areas on her chest; redness and swelling at injection site; swelling at injection site; redness at injection site; Based on information received on 11-Sep-2020, the report previously considered as non-valid becames valid: [events added for validity].  Initial information received on 17-Sep-2019 regarding an unsolicited non-valid non-serious case received from a consumer/non-hcp and additional information received on same date.  This case involves a 60-year-old female patient who experienced allergic reaction (hypersensitivity) with symptoms throat swelling (pharyngeal swelling), raspy voice (dysphonia), flushed face (flushing), itching (pruritus), redness and splotchy areas on her chest (rash macular) and also fever (pyrexia), redness and swelling at injection site (vaccination site inflammation with vaccination site swelling and vaccination site erythema), while she received vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].  Medical history, past medical treatment, vaccination and family history were not provided.  At the time of the event, the patient had ongoing asthma that was sulfide sensitive.  Concomitant medications included DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]); and CLARITHROMYCIN (CLARITIN [CLARITHROMYCIN]).  On an unknown date (last year), the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (single dose) (lot number and expiry date: not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious allergic reaction (hypersensitivity), throat swelling (pharyngeal swelling), raspy voice (dysphonia), flushed face (flushing), itching (pruritus), fever (pyrexia), splotchy areas on her chest (rash macular), redness and swelling at injection site (vaccination site inflammation with vaccination site swelling and vaccination site erythema), (unknown latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  Other case details: reporter requested to know if the Flublok contains sulfates, latex, nickle, or gelatin as she had a reaction for Fluzone Quad (single dose) in the past.  Details of laboratory data not reported.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome of all events was unknown.  There will be no information available on the batch number for this case.  Follow up information was received on 11-Sep-2020, from a consumer.  Case was updated from non-valid to valid. New events added. Concomitant medications were added.",,Unknown,0,0
896166,"hematoma; a purple spot; hard knot in her left arm; continues to have pain. The pain is now spreading into her chest and ribs, described as too painful to move the arm.; swelling; pain at the injection site; Initial information received on 30-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer/non-health care professional.  This case involves a 87 years old female patient who experienced hematoma (haematoma) ,purple spot (skin discolouration) ,hard knot in her left arm (nodule) ,continues to have pain and the pain was now spreading into her chest and ribs, described as too painful to move the arm (pain) ,swelling and pain at the injection site (vaccination site pain), after vaccination with INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  The patient's pain medications options were limited because she cannot take NSAIDS (Nonsteroidal anti-inflammatory drugs).  Medical treatment(s), vaccination(s), concomitants and family history were not provided.   On 13-Sep-2020, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot number and expiration date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious events hematoma (haematoma) ,purple spot (skin discolouration) ,hard knot in her left arm (nodule) , swelling and pain at the injection site (vaccination site pain) (unknown latency) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  On an unknown date, the patient developed non-serious event of pain and the pain was now spreading into her chest and ribs, described as too painful to move the arm (pain), 6 weeks following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  No laboratory data reported.  It was not reported if the patient received a corrective treatment.  At the time of reports, the outcome was not reported for all the events.  There will be no information on the batch number for this case.",,Unknown,0,0
904788,"was sick.; Initial information received on 25-Nov-2020 regarding an unsolicited valid non-serious case from a consumer via Social media.  This case involves an Adult patient who experienced was sick (illness), while the patient received INFLUENZA VACCINE [INFLUENZA VACCINE]..  Medical history, medical treatment, vaccination and family history were not provided.    On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number: not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, after started vaccine, the patient informed that every time the patient got the flu shot within 2 weeks and was sick (illness).  No laboratory data was provided.  Final diagnosis was illness.   It was not reported if the patient received a corrective treatment.  The outcome was reported as Unknown for illness.",,Unknown,0,1
898517,"Patient reported rash to left hand side of body (upper chest, back, and side of torso) beginning approximately 6 hours after vaccine and ending roughly a day after receiving vaccine. Patient has not had a reaction to vaccine in the past.",66.0,Seniors,0,0
895149,After the vaccination in the right upper arm the patient experienced pain in the muscle and and shoulder joint. The aching pain persisted for two weeks after the initial vaccination. He was evaluated on 10/26/2020 with continued pain and did have an Xray of the right shoulder that was unremarkable and was referred to physical therapy for pain of the right shoulder.,65.0,Adults,1,0
913168,"Fever; chills; body aches; headaches; malaise; chest pain in side-lying; cough; diminished appetite; This is a spontaneous report from a contactable healthcare professional. A 30-year-old male (also reported as female) patient received the first dose of BNT162B2 (Pfizer-BIONTECH Covid-19 Vaccine; Lot number: EH9899), intramuscular in the left arm on 17Dec2020 at 15:45 at a single dose for immunization. The patient had no relevant medical history. The patient din not have Covid prior to the vaccination and had no known allergies to medications, food, or other products. The patient's concomitant medications were not reported. It was reported that the patient had no other medications in two weeks and did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient experienced fever, chills, body aches, headaches, malaise, chest pain in side-lying, cough, and diminished appetite starting at 11pm (23:00) on 17Dec2020 and gradually decreasing mild symptoms still present on 22Dec2020. The patient received no treatment for the adverse events and was not tested for COVID-19 after the vaccination. The facility where the most recent COVID-19 vaccine was administered was at the hospital. The outcome of the events was recovering. The case was reported as non-serious (did not result in death, was not life-threatening, did not cause or require prolonged hospitalization, was not disabling/incapacitating, and did not result to any congenital anomaly/birth defect).",30.0,Adults,0,0
899699,"was never so sick; Initial information was received on 25-Nov-2020 regarding an unsolicited valid non-serious case received from the patient.  This case involved a male patient of unknown age who was never so sick (malaise) in his life, after receiving INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), vaccination(s), family history and concomitant medication were not reported.   The patient was ok till sitting in the hospital for vaccination.   On an unknown date (some years ago), the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number and other dosing details were not reported) for prophylactic vaccination.  On an unknown date, the patient was sick (malaise), (unknown latency) following the administration of INFLUENZA VACCINE.  It was reported that, it was 10 weeks before had strength and felt like himself again and was debating to get this vaccine in 2020.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, the event outcome was not reported.  There will be no information available on the batch number for this case.",,Unknown,0,1
863706,"elevated platelets (thrombocytosis); passed out; felt hot; flu like symptoms; pain at injection site; This case was reported by a consumer via call center representative and described the occurrence of passed out in a 66-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 9th January 2020, the patient received the 1st dose of Shingrix. On 9th January 2020, less than a day after receiving Shingrix, the patient experienced passed out (serious criteria GSK medically significant), feeling hot, influenza-like symptoms and injection site pain. On 20th January 2020, the patient experienced thrombocytosis. On 11th January 2020, the outcome of the influenza-like symptoms and injection site pain were recovered/resolved. On an unknown date, the outcome of the passed out, feeling hot and thrombocytosis were recovered/resolved.   It was unknown if the reporter considered the passed out, feeling hot, influenza-like symptoms, injection site pain and thrombocytosis to be related to Shingrix.  Additional details were reported as follows: This case was reported by the patient's wife. The patient received Shingrix vaccine in unknown arm. The patient experienced passed out, feeling hot, influenza-like symptoms and injection site pain. The patient's platelets were elevated. The patient's wife reported that her husband planned to continue follow up with his physician. The ermergency room  visit was required. The reporter consented to follow up.",66.0,Seniors,0,0
871073,"experienced pain at the injection site; This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a 69-year-old male patient who received HAV (Havrix) (batch number EK59B, expiry date 26th February 2022) for prophylaxis.   On 27th February 2020, the patient received Havrix. In February 2020, immediately after receiving Havrix, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was not recovered/not resolved.   It was unknown if the reporter considered the injection site pain to be related to Havrix.  Additional details were provided as follows: The patient received Havrix and experienced pain at the injection site since receiving the vaccine. There is discrepancy between the outcome reported in the structured field (not recovered) and the outcome reported in the source document (recovering).",69.0,Seniors,0,0
877750,"The patient was administered a properly stored but expired vaccine; This spontaneous report was received from an office manager concerning a patient of unknown age an gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.  On 24-JUL-2020, the patient was vaccinated with the first dose of a properly stored but expired pneumococcal vaccine, polyvalent (23-valent) (PNEUM OVAX23), lot number R012550 with expiration date 25-JAN-2020 for prophylaxis (route of administration was not provided). No additional information was provided and no product quality complaint (PQC) was reported.  At the reporting time, the patient's outcome was unknown. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: R012550; expirationdate: 25-JAN-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",,Unknown,0,1
860396,"body ache; weakness; dizziness; This case was reported by a physician via sales rep and described the occurrence of general body pain in a 64-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included hyperthyroidism and palpitation.   On 28th October 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 3 months after receiving Shingrix, the patient experienced general body pain, weakness and dizziness. On an unknown date, the outcome of the general body pain, weakness and dizziness were recovered/resolved.   It was unknown if the reporter considered the general body pain, weakness and dizziness to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The reporter stated that, after vaccination with 1st dose of shingrix, the patient had severe body ache, dizziness and weakness which disappeared after 2 days. The patient stated that, could not determine if Shingrix was the reason for adverse events following vaccination. The patient would likely to return for second dose",,Unknown,1,0
907098,"Patient received Moderna COVID vaccine at 1926. She completed standard 15 min observation time and was dismissed from clinic. Patient returned to clinic at 2000 with redness at injection site, itching, chills. BP 126/90 and pulse 86, patient able to speak comfortably.  Diphenhydramine 25 mg given orally. Patient observed for 36 minutes. All symptoms resolved and observed redness to left deltoid completeely resolved. No complaints of shortness of breath or difficulty breathing. Patient discharged from clinic to another facility with appropriate follow up instructions. Patient texted ahead to her preceptor that she is en route.",34.0,Adults,0,0
860676,"injection site for second dose was defiinitely more sore; had flu like symtoms for 24 hours; This case was reported by a consumer via interactive digital media and described the occurrence of influenza-like symptoms in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced influenza-like symptoms and injection site pain. On an unknown date, the outcome of the influenza-like symptoms was recovered/resolved and the outcome of the injection site pain was not recovered/not resolved.   It was unknown if the reporter considered the influenza-like symptoms and injection site pain to be related to Shingrix.  Additional case details were reported as follows: The age at vaccination was not reported. The injection site for 2nd dose was definitely more sore and had flu like symptoms for 24 hours. The localized pain at the injection site was much worse (could have been the shooter). But the flu like symptoms were not as bad. The follow up was not required. This is 1 of the 3 linked cases reported by the same reporter.",,Unknown,1,0
880270,"Swollen arm, and neck was swollen and sore on left side. 1 day 1/2 later my left side was sore and I had shallow breathing, like it was heavy and hard to take breaths.",34.0,Adults,0,0
895712,"no other AE associated with administration; an expired dose of ROTATEQ was administered; This spontaneous report was received from a nurse referring to a 2-month-old male patient. Information regarding the patient's concurrent conditions, medical history, historical drugs and concomitant therapies was not provided.   On 26-OCT-2020, the patient was vaccinated with an expired dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ), lot # 1660937, expiration date 25-OCT-2020, at a dose of 2 milliliter, orally for prophylaxis (formulation, strength, dose, frequency, route of administration, indication,  were not reported). The reporter said there were no other adverse events associated with administration.  Lot No.1660937 has been verified to be a valid lot number for rotavirus vaccine, live, oral, pentavalent (ROTATEQ).",0.17,Kids,0,1
863489,"pt received pneumo 13 injection in clinic. Had allergic reaction, hives. Given 50mg Benadryl(IM), and 40mg Depo Medrol. Pt advised to stay in clinic for one hour post injections. (Will let her go at 1130). Addendum by provider on February 20, 2020 11:31 CST (Verified) Pt departed clinic @ 1130a. Pt reported feeling okay.",35.0,Adults,0,0
900866,"it gives me the worse flu; Initial information received on 22-Oct-2020 regarding an unsolicited valid non-serious social media case from a consumer (patient).  This case involves a patient of unknown demographics who reported that it gives me the worse flu (influenza), while the patient received Influenza Vaccine.  The patient's medical history, past medical treatment(s), vaccination(s), family history and concomitant medications were not provided.   On an unknown date, the patient received an unknown dose of suspect influenza vaccine produced by unknown manufacturer (lot number, route in unknown administration site unknown) for prophylactic vaccination.  On an unknown date, the patient developed worse flu (influenza) following the administration of influenza vaccine.  No laboratory test was reported.  It was not reported if the patient received any corrective treatment.  The event outcome was reported as unknown.  There will be no information available on the batch number for this case.",,Unknown,0,1
904294,"After administration of covid vaccination, patient c/o feeling warm and diaphoretic. HR 78, pt appeared slightly pale. No other complaints. Ice pack applied to forehead. Patient reports feeling better at 1840, O2 98% RA, HR 74 regular, BP 140/96",53.0,Adults,0,0
877617,"fever; severe headache; severe myalgia; This is a spontaneous report from a contactable physician. A 16-year-old male patient received meningococcal group b rlp2086 (TRUMENBA, lot number and expiration date unknown), via an unspecified route of administration on 23Jul2020 (last Thursday) at single dose for immunization. The patient medical history and concomitant medications were not reported. The patient experienced a 'severe reaction'. The patient developed a fever the next day (on 24Jul2020) along with severe headache and severe myalgia. The fever lasted one day, but the headache had persisted along with severe myalgia and it had been 5 days. He had to take ADVIL 800 mg every 6 hours. The physician would like to know how long the severe headache and severe myalgia will last. The outcome of the event fever was recovered on 25Jul2020. The outcome of the rest events was not recovered.   No follow-up attempts are needed. Information on Lot/Batch and expiration date could not be obtained. No further information is expected.",16.0,Kids,1,0
867816,"terrible headache; tired; my temp is 100.1; feel like I have bad heartburn; This case was reported by a consumer via call center representative and described the occurrence of headache in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 6th April 2020, the patient received the 2nd dose of Shingles vaccine. On 7th April 2020, 1 days after receiving Shingles vaccine, the patient experienced headache, tiredness, fever and heartburn. On an unknown date, the outcome of the headache, tiredness, fever and heartburn were not recovered/not resolved.   It was unknown if the reporter considered the headache, tiredness, fever and heartburn to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The patient had terrible headache, was tired, their temp was 100.1 degree F, and they feel like they had bad heartburn.",,Unknown,0,0
897778,"Pt received flu vaccination to the L thigh on 11/13. Noticed blisters on the L thigh yesterday, 11/15. Today, seems to be worse. Erythematous edematous plaque on L thigh with overlying intact vesicles and bullae, erosion within.",2.0,Kids,0,0
860873,"Small raised bumps on the stomach, shoulder, back and the forearm; Scratching the bumps; Spontaneous report received on 17DEC2019.  A nurse reported that a female consumer had small raised bumps on the stomach, shoulder, back and the forearm (PT: Skin reaction) and she was scratching the bumps (PT: Pruritus), while being on oral Vivotif for typhoid fever prophylaxis. On 01DEC2019, the consumer started Vivotif and a week after completing Vivotif course she developed small raised bumps on the stomach, shoulder, back and the forearm. She started scratching the bumps that made it worse. She did not have such experience in the past. On 16DEC2019, she took one dose of Benadryl (diphenhydramine) for treatment that helped with itching and subsided some bumps. She did not eat new foods and not use any new detergent. Action taken with Vivotif with respect to the reported events was not applicable. She was recovering from the reported events at the time of report.  Medical history included eczema on her hands.  Allergy included reactions to vaccines where the reactions ""were not visible but she could feel it in her body"".  Company Comment: A consumer completed Vivotif course and after a week had had small raised bumps on the stomach, shoulder, back and the forearm (generalized skin reaction) with itching. The events were resolving with Benadryl treatment. Considering the potential of Vivotif to cause pruritus and skin reactions, the causality of both the events is assessed as possible with Vivotif.; Sender's Comments: A consumer completed Vivotif course and after a week had had small raised bumps on the stomach, shoulder, back and the forearm (generalized skin reaction) with itching. The events were resolving with Benadryl treatment. Considering the potential of Vivotif to cause pruritus and skin reactions, the causality of both the events is assessed as possible with Vivotif.",,Unknown,0,0
855646,"Redness persisted for 3 weeks; Swelling persisted for 3 weeks; Tender; Warm; This case was reported by a pharmacist via call center representative and described the occurrence of erythema in a 54-year-old female patient who received Herpes zoster (Shingrix) (batch number 3FJ59, expiry date 27th November 2021) for prophylaxis.   On 10th September 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 4 months after receiving Shingrix, the patient experienced erythema, swelling, tenderness and feeling of warmth. On an unknown date, the outcome of the erythema, swelling, tenderness and feeling of warmth were recovered/resolved.   It was unknown if the reporter considered the erythema, swelling, tenderness and feeling of warmth to be related to Shingrix.  Additional details were provided as follows: The patient experienced redness, swelling, tender and warm that persisted for 3 weeks. The reporter did not consent to follow-up.",53.0,Adults,0,0
916278,"Reported onset of sustained dizziness assoc w numbness and tingling of bilateral hands and change in sensation of thumbs 10 minutes after vaccine admin. She did not notify clinic staff, self administered Benadryl 50mg and waited until staff checked on her at 20 min mark to report. Upon assessment pt is sitting up, appears mildly anxious, denies SOB, CP or difficulty swallowing. Dizziness is persistent despite change in position and fluids, removal of N95 mask. VSS, b/p 106/68, p 68, RR 26. Pt encouraged to push fluids, recline in seat and take slow deep breaths. Hand sensation w/ mild improved but did not resolve after 10 minutes, dizziness unchanged. Pt and husband verbalized understanding of further care options. Pt and husband chose to return home and verbalized understanding of when to seek further care. Pt agrees to contact PCP for further direction prn.",33.0,Adults,0,0
908945,Metallic taste,38.0,Adults,0,0
857062,patient with a contraindication receiving a live virus vaccine (vaccine error). No actual AE has occurred at this time (<24 hours after error),39.0,Adults,0,1
881709,"developed Erythem Multiform after receiving the 1st dose of Shingrix, a Gsk flu vaccine; This case was reported by a other health professional via call center representative and described the occurrence of erythema multiform-like eruption in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis.   Concurrent medical conditions included multiple myeloma.   On an unknown date, the patient received Shingrix and Influenza vaccine Quadrivalent unspecified season. On an unknown date, unknown after receiving Shingrix and Influenza vaccine Quadrivalent unspecified season, the patient experienced erythema multiform-like eruption (serious criteria GSK medically significant). On an unknown date, the outcome of the erythema multiform-like eruption was unknown.   It was unknown if the reporter considered the erythema multiform-like eruption to be related to Shingrix and Influenza vaccine Quadrivalent unspecified season.  Additional details were provided as follows: The age at vaccination was not reported. After receiving Shingrix and Influenza vaccine, the patient experienced erythema multiform-like eruption. The patient had tested due to her medical history of Multiple myeloma not related to a vaccine. The reporter consented to follow up. This case was linked with case US2020AMR174273, reported for the same patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR174273:same patient",,Unknown,0,1
862041,"No adverse event; received an expired dose of VAQTA; This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, concomitant medications, drug reactions and allergies was provided.     On 13-FEB-2020, the patient was inadvertently vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) lot # R024008, expiration date 15-NOV-2019 (dose, route of administration and anatomical location of administration were not reported) for prophylaxis. No adverse events were reported.",,Unknown,0,1
882799,"pain in back, achy all over, no fever, started morning after immunization. pt related symptoms to how he felt when he had the flu in February 2019",47.0,Adults,1,0
868149,"DID NOT TAKE SECOND DOSE ON TIME; This spontaneous case report (PVX2019-2935) was received from a consumer on 27-Nov-2019. It described a female consumer who ""did not take second dose on time"" (PT: Product dose omission), while being on oral Vivotif (lot number: 3003297) for typhoid fever prophylaxis.  Case report: The consumer took the first dose of Vivotif on 24-Nov-2019 and then she left Vivotif unrefrigerated for 2 days after taking the first dose. She did not take the second dose which was due on 26-Nov-2019 as the vaccine was no longer good to use.  Action taken with Vivotif with respect to reported event was not applicable.  The clinical outcome of the reported event was unknown.  Company Comment: It was reported that a consumer did not take the second dose of Vivotif on due date (missed dose) as she left the Vivotif unrefrigerated for two days after taking the first dose. Considering the nature of the event, the causality of missed dose is assessed as not related to Vivotif.; Sender's Comments: It was reported that a consumer did not take the second dose of Vivotif on due date (missed dose) as she left the Vivotif unrefrigerated for two days after taking the first dose. Considering the nature of the event, the causality of missed dose is assessed as not related to Vivotif.",,Unknown,0,0
912511,"Received vaccine at 1:30 pm yesterday, noted onset of symptoms at 8:45 pm.  Numbness and tingling to mouth and bilateral upper and lower extremities, mild vision change, feeling of some swelling to bilateral eyelids.  Also swelling to lips.  She also did take zinc gluconate 50 mg last night and this morning.  Has never taken zinc 50 mg, but has taken zinc as component of multivitamin/pre-natal vitamins.   Patient was prescribed Pepcid 20 mg BID, Medrol 4 mg dose pack 21 pill taper until complete.  Also given Benadryl 25 mg - 50 mg every 4 - 6 hours for allergy symptoms.  And provided with an Epi-Pen for home.",39.0,Adults,0,1
880330,"Redness and swelling at the injection site, and warm to the touch, but reaction is localized and swelling is improving.",70.0,Seniors,0,0
908962,Tingling of face difficulty breathing with a swollen tongue,54.0,Adults,0,0
868205,"hospitalized with altered mental status, atrophy, dysarthria, ataxia and left lobe pneumonia.; hospitalized with altered mental status, atrophy, dysarthria, ataxia and left lobe pneumonia.; hospitalized with altered mental status, atrophy, dysarthria, ataxia and left lobe pneumonia.; hospitalized with altered mental status, atrophy, dysarthria, ataxia and left lobe pneumonia.; hospitalized with altered mental status, atrophy, dysarthria, ataxia and left lobe pneumonia.; severe respiratory infection; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient. Information about the patient's concurrent condition, concomitant medication or medical history was not provided.  Approximately, on 18-APR-2017, the patient was vaccinated with a dose of Zoster Vaccine Live (ZOSTAVAX) (dosage, route, lot # and expiration date were not provided) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after, the patient suffered a severe respiratory infection, and the patient was hospitalized with altered mental status, atrophy, dysarthria, ataxia and left lobe pneumonia.  As a direct and proximate result of her receipt of vaccination, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, and physical impairment and injury. At the time of the report, the patient had not recovered from the aforementioned events, and the reporter considered them to be related to Zoster Vaccine Live (ZOSTAVAX). The reporter considered the events of pneumonia, mental status changes, atrophy, dysarthria, ataxia and respiratory tract infection to be disabling.  Upon internal review, the event of pneumonia was considered medically significant.",,Unknown,0,0
893969,ALL BODY COVERED IN HIVES,55.0,Adults,0,0
889998,"PT was eating lunch today, jello, and began having an episode of shaking, upper body with more tremor movements, eyes glazed over not deviated, left leg stiffened somewhat, episode last for approx 60 seconds, no coughing or choking during episode, no incontinence, did not respond for episode but was reaching for his milk during that time, after episode did not walk immediately but did not have any postictal period, began running around, has since eaten some more , playing, acting normally, episode happened about 1 hr prior to visit, did have 2 yr WCC today, influenza and Hep A vaccines given",2.0,Kids,0,1
880113,C/o neck pain and stiffness 3 hours after vaccine. Mother gave child aleve and felt that he was improving. Suggested that possible urgent care or ER visit or doctor visit may be warranted if not improving.,13.0,Kids,0,0
873026,"Left shoulder muscle pain; Left shoulder joint pain; Creaking shoulder/the vaccine destroyed her shoulder joint; discomfort in her shoulder with muscle and joint pain/shoulder discomfort is getting worse; Range of motion difficulty/her arm is not working properly anymore; Inflammation of left shoulder; shoulder is always sore/shoulder where her bone is, there is inflammation; is not working properly; it feels like something is crawling around in her shoulder; This case was reported by a consumer via call center representative and described the occurrence of localized muscle pain in a 65-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 25th March 2020, the patient received the 2nd dose of Shingrix (intramuscular). On 1st April 2020, 7 days after receiving Shingrix, the patient experienced localized muscle pain, pain in joint involving shoulder region, shoulder injury related to vaccine administration, shoulder discomfort, movement disorder, shoulder arthritis, shoulder pain, impaired work ability and crawling sensation. On an unknown date, the outcome of the localized muscle pain, pain in joint involving shoulder region, shoulder injury related to vaccine administration, movement disorder and shoulder arthritis were not recovered/not resolved and the outcome of the shoulder discomfort, shoulder pain, impaired work ability and crawling sensation were unknown.   It was unknown if the reporter considered the localized muscle pain, pain in joint involving shoulder region, shoulder injury related to vaccine administration, shoulder discomfort, movement disorder, shoulder arthritis, shoulder pain, impaired work ability and crawling sensation to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in the left arm and did not remember what part of left arm it was administered. The patient experienced discomfort in her shoulder with muscle and joint pain in and around her left shoulder.  The patient reported that when she lifts her arm over her head, her joints are creaking and her shoulder was always sore, she stated that it was like the vaccine destroyed her shoulder joint and was killing her arm and her arm was not working properly anymore.  The patient had range of motion problems, the pain was in upper shoulder where her bone was and there was inflammation, sometimes it feels like crawling around in her shoulder even when she is laying still, she can feel something going on in her shoulder continually.  The patient did not know if the problem stems from incorrect administration or from the vaccine itself and shoulder discomfort was getting worse and not better, she wants to know if there was a way to reverse the damage to her shoulder, she stated that she was willing to be a guinea pig.  The reporter consented to follow up.",65.0,Adults,0,0
903272,Round rash (redness),73.0,Seniors,1,0
882854,"Nurse initially calling in for a temperature excursion evaluation. VARIVAX administered post temperature excursion.; This spontaneous report was received from a licensed practice nurse and refers to a patient of unknown age and gender. Information regarding the patient's concomitant therapies, concurrent conditions, drug reactions/allergies, medical history and historical drugs was not provided.  On 31-AUG-2020, the patient was vaccinated with improperly stored varicella virus vaccine live VARIVAX , 0.5 milliliter lot # S032355 and expiration date 14-OCT-2021 (route of administration not reported) for prophylaxis. The vaccine was reconstituted with properly stored sterile diluent (STERILE DILUENT).  The improperly stored dose of the suspect vaccine experienced a temperature excursion of -9 to -8 degree Celsius (C) (-2.8C) for 5 hours and 2 minutes on unknown date; no previous temperature excursion were reported.  The call was made due to a digital data logger.; Sender's Comments:  US-009507513-2009USA001227: US-009507513-2009USA001249:",,Unknown,0,1
887125,"a patient that was given an expired dose of last year's formula of FLUZONE HIGH-DOSE with no adverse event; Initial information received on 23-Sep-2020 regarding an unsolicited valid non-serious case received from an other health care professional.  This case involves a 65 years old female patient who received a 0.5 ml once dose of an expired vaccine INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE] Single-dose, prefilled syringe (lot: UJ311AB, expiry date: 30-Jun-2020), via unknown route and site, on 23-Sep-2020. (Expired product administered)  The patient's medical history, medical treatments, vaccinations and family history were not provided.  Concomitant medications were not reported.  It was an actual medication error due to expired vaccine used. It was reported that a patient was given an expired dose of Fluzone High-Dose. It was last year's formula of Fluzone High-Dose. (latency: on the same day)  At the time of reporting, the patient had no adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",65.0,Adults,0,1
865448,"Noo additional adverse effects reports; one male patient was administered improperly stored ROTATEQ; This spontaneous report was received from a vaccine coordinator and refers to a 4 month old male patient. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On 11-MAR-2020, the patient was vaccinated with improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) vial, orally, lot # 1658255, expiration date 07-FEB-2021 (dose and frequency were not provided) for prophylaxis. No additional adverse effects reported. Administered doses of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) experienced the temperature excursion below 2 Celsius degrees (C): 0.8 C for 5 hours and 9 minutes on 02-MAR-2020; 0.9 C for 11 hours on 04-MAR-2020 and -1.3 C for 9 hours and 29 minutes on 05-MAR-2020. There was previous temperature excursions reported. The administered doses of the suspect vaccine experienced the temperature excursion above 9 C: 9.3 C for 3 hours and 33 minutes on 25-FEB-2020 and below 2 C: 0.8 C for 11 hours 39 minutes on 03-MAR-2020. The digital data logger was involved to capture the temperature excursion. No adverse effects were reported. The outcome of the events was unknown.",,Unknown,0,1
882222,"Sore arm, induration about 2-3"" around injection site, mildly warmer than surrounding skin.  Headache that felt like blood vessels on the side of my head were expanding and then in spasms that came periodically in the night.  Severe shaking and chills during the night that felt like all my muscles deep inside me were in spasms, lasting about 30 seconds or so during the night;  this occurred twice.   I feel that the vaccine has more severe side effects and according to the literature that I was provided affects a significant number of recipients that the formulation should be changed to be less harmful to people, especially since it's marketed to people over 50 and they are more likely to have chronic medical problems  which my render the side effects more severe to them.",70.0,Seniors,0,0
908894,44 y F referred to clinic after allergic response to COVID vaccine this afternoon. Pt received dose of covid vaccine at 1713.  at 1723 pt c/o itching R wrist and neck.  3 small reddened areas noted.  Vaccine hypersensitivity protocol initiated; RRT initiated.  Allergic reaction to COVID vaccine-pruritic hives without angioedema-resolved with Benadryl,44.0,Adults,0,1
896492,"11/11/20 5:30pm right upper arm difficulty moving arm and painful.   6:15pm took 3 advil over the coarse of an hour. Over the next few hours area of pain and extreme discomfort spread to shoulder area .  Needed the assistance of my left arm to move the right arm.  Ice applied to site Around 8:30 pm chills and body shakes started and continued for about 3 hrs.  Temp was 101.8   Around 10:00 took 2 tylenol extra strength 500mg each. Very restless night with little sleep and lots of pain and discomfort in right arm area noted above. 11/12/20 6:30a, took 3 advil for pain and discomfort 2:15 had o.v. with my PMD Dr. Prescribed advil and ice compress Advil 3 tablets 3 times a day  11/13/20 Continuing with advil as prescribed by PMD and ice.  Less pain in right shoulder/upper arm , more mobility",66.0,Seniors,0,0
893047,"missed a week of work; pain; GI problems; This case was reported by a consumer via call center representative and described the occurrence of activities of daily living impaired in a female patient who received Hepatitis B vaccine for prophylaxis.   The patient's past medical history included chickenpox and mumps. Previously administered products included Hepatitis B vaccine with an associated reaction of pain (1st dose received in october 1995 for further tolerance refer case US2020AMR209271), Nordette (Discontinued in 2011), MMR with an associated reaction of pain (for further tolerance refer case US2020AMR209271) and Dtap with an associated reaction of erythema (for further tolerance refer case US2020AMR209271).   In May 1996, the patient received Hepatitis B vaccine. On an unknown date, more than 2 years after receiving Hepatitis B vaccine, the patient experienced activities of daily living impaired, pain and gastrointestinal disorder. Rechallenge with Hepatitis B vaccine was positive. On an unknown date, the outcome of the activities of daily living impaired, pain and gastrointestinal disorder were recovered/resolved.   It was unknown if the reporter considered the activities of daily living impaired, pain and gastrointestinal disorder to be related to Hepatitis B vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Hepatitis B vaccine experienced missed a week of work, she was in pain and had GI problems. The reporter informed that she  had a hard time with vaccine her physician  advised against Boostrix in 2005 (she did not get it) instead she wears gloves in public and keeps her hands clean. The reporter did not consented to follow up. No further information was available.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR209271:For 1st dose",,Unknown,0,0
883654,"Pt's father called pharmacy to report pt had a ""softball sized lump"" that was ""red and warm"" and ""getting bigger.""",12.0,Kids,0,0
915166,"Bones and joints pain, chills and fever, bad headache, eyes pain. Cough.; Bones and joints pain, chills and fever, bad headache, eyes pain. Cough.; Bones and joints pain, chills and fever, bad headache, eyes pain. Cough.; Bones and joints pain, chills and fever, bad headache, eyes pain. Cough.; Bones and joints pain, chills and fever, bad headache, eyes pain. Cough.; Bones and joints pain, chills and fever, bad headache, eyes pain. Cough.; Bones and joints pain, chills and fever, bad headache, eyes pain. Cough.; This is a spontaneous report from a contactable nurse (patient). A 54-year-old female patient (not pregnant) received first dose of BNT162B2 (Lot number: Pcj1685), intramuscularly in left arm on 23Dec2020 18:30 at single dose for COVID-19 immunization. Medical history included anxiety, depression, seasonal allergy all from an unknown date and unknown if ongoing. Concomitant medication included celecoxib (CELEXA), biotin, curcuma longa (TURMERIC), calcium, doxylamine. The patient previously took Levofloxacin (LEVAQUIN) and experienced allergies. The patient experienced bones and joints pain, chills and fever, bad headache, eyes pain, cough all on 24Dec2020 05:00. Treatment (Around the clock Motrin) was received for events. All events were reported as non-serious. Facility type vaccine was administered in hospital. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. The outcome of events was not resolved.",54.0,Adults,0,0
909707,"12/24/2020- morning-  noticed pain in R deltoid at site of injection (expected) and also L ankle pain not associated with any type of trauma and with no hx of injury to ankle in past.  Also noticed mild aching pain to R knee (which has had extensive surgical repair several times) 12/24/2020- by midday,  limping noted due to pain in L ankle, negative for swelling, bruising, or decreased range of motion 12/24/2020- 8pm- moderate to severe pain to L ankle, still no swelling or bruising. 12/25/2020- midday- still noticeable limp, however pain was moderate and tolerable all day 12/26/2020- increased pain in L ankle as day progressed, still no bruising, decreased ROM or swelling 12/27/2020- woke at 3 am due to pain, elevated L leg.  Swelling noted in lateral aspect of ankle by 7am,  decreased ROM and point tenderness had developed around lateral and anterior ankle joint.  Took 2 Aleve for pain.  Went to walk-in orthopaedic clinic when they opened at 9am for assessment,",48.0,Adults,1,0
885938,"1-2 minutes post vaccination, patient reported that she  felt dizzy after she got off from the seat. She was advised to take a seat. Within few minutes, she complained of blurred vision.. 'not able to see things clearly.. and 'not feeling well.' She broke out into sweat and her face started to look pale.   Her mom was at her side.  Upon obtaining permission from her mom, EMS was called to avoid patient's  condition getting worse . Cold /wet cloth was  applied to the patient's face and she was alert and responsive.  Within 5 minutes, EMS arrived.  Her vitals were normal. Patient complained of feeling nauseous and stomach cramps (she did mention that her menstrual cycle was to start soon. ).  After 20 minutes or so after EMS arrived, patient seemed to be better and decided to go home.  I followed up with the patient after few hours, patient reported of feeling fine.",21.0,Adults,0,0
872946,"Injection Tuesday, June 2 Wednesday, June 3 redness & feverish where injection was given on right arm Friday, June 5, 3:00 a.m. severe abdominal cramps, body sweats and diarrhea for 3 hours All day Friday I felt achy and diarrhea continued as did cramps.  10 a.m. I had blood in my stool and called my Dr. to talk to a nurse.  She suggested I go to ER to be checked.",61.0,Adults,1,0
872945,"elevated temp, high 102",0.33,Kids,0,0
870126,Are going to receive the second dose of Shingrix at a longer interval; The case will be considered as invalid as the patient are going to receive the second dose of Shingrix at a longer interval' hence it seems enquiry and potential medication error and reason for this delay not specified if it was due to current pandemic.,,Unknown,0,0
909379,"near syncope, hypotension, nausea/vomiting, tachycardia (120-150) within 5 minutes of administration. did not resolve and worsened within 1 hour. Pt went to ER for workups. Received IV benadryl without improvement.  Admitted to hospital overnight for continuous cardiac monitoring. Improved overnight and discharged in the afternoon 12/24/20.",28.0,Adults,1,0
892424,"10/23 8 pm: chills, mild fatigue, mild nausea 10/24 6 am: splitting/strong headache, fever, muscle aches, sore arm, dehydration, fatigue - bed ridden 10/24 rest of day: same symptoms, fever maxed out at 102.1 at 4 pm - bed ridden 10/25: 8 am: fever, chills, headache gone, sore arm and slight muscle ache remains, but currently functional",50.0,Adults,1,0
897120,Patient has experienced transient hive-like welts that resolve without treatment. They do not itch most of the time. They appear suddenly. They first appeared on 11/14 and still experiencing as of 11/17 when patient contacted pharmacy. She was instructed to take Benadryl and monitor for worsening of symptoms.,84.0,Seniors,0,0
895232,"INJECTION SITE SWELLING SORENESS FACE RED AND FLUSHED ARM FROZEN - COULD NOT LIFT PROPERLY FOR 3 DAYS CONSTANT PAIN IN ARM HAND SWOLLEN AND ""PALE""",68.0,Seniors,1,0
883285,"About 3 hours after the shot my upper arm was swollen and very sore.  The next morning I woke up with bad headache, dizziness, nausea and vomiting.  This lasted all day, the vomiting stopped by 11am.  It was so bad that I was unable to go to work.  The following morning better, but still a little headache and lightheaded.",59.0,Adults,1,0
902597,"Right sided facial/lip swelling.  Started about 0200 on 12/16/20.  Patient sometimes gets angioedema, so unsure if this is related but wanted to report",36.0,Adults,0,0
885075,Shingles appeaRed a few day following the vaccinations weRe given. No oRal medication was given - he use acycloviR cReam,68.0,Seniors,0,0
895964,"had developed shingles; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 51-year-old male patient who received Herpes zoster (Shingrix) (batch number T79D7, expiry date 31st October 2022) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, unknown after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient believes he received 1st dose of Shingrix and experienced shingles.",,Unknown,0,0
894307,"pneumonia; Information has been received from a lawyer regarding a case in litigation referring to a patient of unknown age and gender. Information about medical history, concurrent condition and concomitant medication was not reported. On or around 26-OCT-2017, the patient was inoculated with Zoster Vaccine Live (ZOSTAVAX) (strength, dose, route, lot# and expiration date unknown) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving Zoster Vaccine Live (ZOSTAVAX), suffered upper respiratory symptoms and shortness of breath requiring hospitalization. Plaintiff was diagnosed with pneumonia. As a direct and proximate result of Zoster Vaccine Live (ZOSTAVAX), the patient's symptoms have resulted in physical limitations not present prior to using Zoster Vaccine Live (ZOSTAVAX) and caused by the Zoster Vaccine Live (ZOSTAVAX). The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of Zoster Vaccine Live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of Zoster Vaccine Live (ZOSTAVAX), the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of Zoster Vaccine Live (ZOSTAVAX), the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the event pneumonia was not recovered and the reporter considered the event to be related to Zoster Vaccine Live (ZOSTAVAX).  The reporter considered the event pneumonia to be disability. Upon internal review, the event pneumonia was determined to be medically significant.",,Unknown,0,0
905461,"19 month old female patient administered expired dose of ActHib, no AE; Initial information received on 01-Dec-2020 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 19 month old female patient who was vaccinated with an expired dose of HIB (PRP/T) VACCINE [ACT-HIB] (expired product administered).  Medical history, medical treatment, vaccination and family history were not provided.  Concomitant medications included HEPATITIS A VACCINE (HEPATITIS A VACCINE) for Immunisation.  On 01-Dec-2020, the patient received a 0.5 ml dose of suspect HIB (PRP/T) VACCINE (lot UJ135ABA and expiry date: 26-Nov-2020) via an unknown route in the left thigh for prophylactic vaccination.  It was a case of actual medication error due to expired vaccine used (latency on same day).  Reporter relationship: HCP (health care professional), product used: used and still using product: no  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",1.58,Kids,0,1
886429,"Right after administration, patient developed excessive swelling and some bleeding. She was monitored for 15 mins. then she was advised to put some ice! She was contacted same evening and next day. Swelling was going away.",61.0,Adults,0,0
891249,"Proquad expired on 9/16/2020, but was administered on 10/12/2020. No adverse reactions were reported. Patient was scheduled to repeat the vaccine in 3 months. Mother verbalized understanding.",4.0,Kids,0,1
882443,"A nursing assistant reported temperature excursion for vaccines that were administered to patients after excursion occurred.; This spontaneous report was received from a nursing assistant and refers to a patient of unknown age and gender.    On 21-AUG-2020, the patient was vaccinated with a dose of varicella virus vaccine live (oka/merck)(VARIVAX) lot # T002846 with expiration date of 23-JAN-2022, for prophylaxis (route of administration was not reported), the vaccine was under temperature excursion, temperature -10.2C, time frame 1 hour and 53 minutes, with no previous temperature excursion. The call was because of a ""data logger"".         This is one of several reports received from the same source. ; Sender's Comments:  US-009507513-2008USA014798: US-009507513-2008USA014950: US-009507513-2008USA014951: US-009507513-2008USA014705:",,Unknown,0,1
911065,Tiredness at the second day of vaccination (12/23/2020) and swollen tender left axillary lymph node started (12/26/2020) and still ongoing till the date of filing the adverse event (12/28/2020).,,Unknown,0,0
889811,"patient reported reaction similar to when a patient eats chickpeas and sesame seeds; nausea; trouble swallowing/similar to when a patient eats chickpeas and sesame seeds; fatigue; This case was reported by a nurse via call center representative and described the occurrence of allergic reaction in a 67-year-old male patient who received Herpes zoster (Shingrix) (batch number C47FY, expiry date 16th September 2022) for prophylaxis.   Concurrent medical conditions included food allergy (patient had reaction to chickpeas and sesame seeds).   On 6th October 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 6th October 2020, 1 hr after receiving Shingrix, the patient experienced allergic reaction, nausea, swallowing difficult and fatigue. On 6th October 2020, the outcome of the nausea, swallowing difficult and fatigue were recovered/resolved. On an unknown date, the outcome of the allergic reaction was unknown.   It was unknown if the reporter considered the allergic reaction, nausea, swallowing difficult and fatigue to be related to Shingrix.  Additional details were reported as follows: The patient received the dose and one hour later the patient reported reaction similar to when a patient eats chickpeas and sesame seeds. Patient reported trouble swallowing, fatigue and nausea, and all symptoms were resolved within a few hours.  Patient did not need to use Epipen.",67.0,Seniors,1,0
904027,Within 30 minutes - Skin flush to hands and forearms. Denied shortness of breath or problem with swallowing. Declined Epinephrine. Monitored for 45 minutes then she was escorted back to work within the building. 15-25 minutes  later stated she was  having trouble swallowing and was jittery.  She walked herself to the Emergency room for triage.,59.0,Adults,0,0
900324,Redness and tenderness,60.0,Adults,0,0
880709,Pain at injection site Flu symptoms Nausea Sore swollen  lymph glands left underarm which resulted in bruising,64.0,Adults,1,0
908948,"Patient received vaccine at 1005 and approx. 20 minutes later reports ""tickle"" in throat feeling the urge to clear throat. and ""tingling' of lips.  Benadryl 50g given by mouth per standing order.  Monitored for additional 30 min.  30 min after administration of benadry  Patient reported no change to symptoms.  Patient was escorted to ER to  be seen.",30.0,Adults,0,1
892964,Dry/nagging cough,67.0,Seniors,0,0
892820,"hives, swelling of shoulder all the way down to elbow. itching and arm still hard from shoulder to elbow 30 days after vaccine.",62.0,Adults,0,1
869205,Myalgia & Rash,67.0,Seniors,1,0
898226,"patient experienced a ""quarter sized lump""at the injection site; Initial information received on 13-Oct-2020 regarding an unsolicited valid non-serious case (GMI reference number: US-SANOFI-00314166) received from a pharmacist.  This case involves a 32 year old male patient who experienced a quarter sized lump at the injection site (injection site mass), while he received INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].  Medical history, medical treatment, vaccination, concomitant medication, family history were not provided.   On 12-Oct-2020, the patient received a 0.5 ml dose of suspect INFLUENZA QUADRIVAL A-B VACCINE [lot UT7005MA and expiry date 30-June-2021] via an unknown route at right arm site for prophylactic vaccination.  On 12-Oct-2020, the patient developed a non-serious quarter sized lump at the injection site (vaccination site mass) on the same day following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  Final diagnosis was injection site mass.  Details of laboratory data not reported.  It was not reported if the patient received any corrective treatment.   At the time of reporting, the event outcome was reported as not resolved.",32.0,Adults,0,1
909094,"Site reaction. Red, swollen, hard and warm. Fever. Severe body aches, chills, shaking, cough, SOA, headache, fatigue.",39.0,Adults,1,0
862330,UNMONITORED TEMP FOR 63H,7.0,Kids,0,0
891247,"Arm hurt a lot, arm numb",25.0,Adults,0,0
856998,"upset stomach; This case was reported by a pharmacist via call center representative and described the occurrence of upset stomach in a 72-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 9th November 2019, the patient received the 1st dose of Shingrix (intramuscular). On 10th November 2019, 1 days after receiving Shingrix, the patient experienced upset stomach. On an unknown date, the outcome of the upset stomach was recovered/resolved.   It was unknown if the reporter considered the upset stomach to be related to Shingrix.  Additional details were provided as follows: The patient experienced upset stomach 24 hours after receiving 1st dose of Shingrix. The upset stomach lasted for approximately 3-4 days. No other information was provided. Consent to follow up was provided.",72.0,Seniors,0,0
912729,"EE developed tingling in left arm, tingling of tongue and roof of mouth, started feeling like her tongue/mouth was swelling.  Was given 50 mg of Benadryl PO at 1255. Symptoms continued to worsen, to Emergency Dept at 1300.  Was given IV solumedrol and Pepcid.  Oral Zyrtec and discharged home.  OK to RTW with out restrictions.  Upon f/u EE did report a hive like rash on the right side of her body but this has since resolved as well.",34.0,Adults,1,0
880508,"shingles; Information has been received from a lawyer, regarding a case in litigation, and refers to a male patient (pt) of unknown age. No information about the pt's medical history, concurrent conditions and concomitant medications was provided. On or around 11-APR-2014, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, anatomical location, lot # and expiration date were not provided) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). On an unknown date, shortly after receiving zoster vaccine live (ZOSTAVAX), the pt suffered an outbreak of shingles. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the pt's symptoms had resulted in physical limitations not present prior to using the suspect vaccine. The pt also experienced mental and emotional distress due to resulting physical limitations and seriousness of his condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the pt sustained severe and permanent personal injuries. Further, as a tragic consequence, the pt suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result, the pt had suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the event was considered to be not recovered. The reporter considered the event of outbreak of shingles to be related to zoster vaccine live (ZOSTAVAX).  The event of outbreak of shingles was considered to be disabling.",,Unknown,0,0
913349,"Tingling, fingers, hands, mouth and lips, sore through and headache",57.0,Adults,1,0
913158,"not sure if last nights episode was an A Fib event; Woke up with a bout of tachycardia; This case was reported by a consumer and described the occurrence of atrial fibrillation in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included paroxysmal atrial fibrillation (the patient not had any A Fib symptoms since an ablation was performed last summer).   On 15th December 2020, the patient received the 1st dose of Shingrix. In December 2020, 8 hrs after receiving Shingrix, the patient experienced atrial fibrillation (serious criteria GSK medically significant) and tachycardia. On an unknown date, the outcome of the atrial fibrillation and tachycardia were recovered/resolved.   The reporter considered the atrial fibrillation and tachycardia to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected adult as per vaccine indication. The patient had paroxysmal A-Fib for which he/she was being treated. The patient received 1st dose of Shingrix and 8 hours after vaccination, the patient woke up at around midnight with a bout of tachycardia and it subsided after about 10 to 15 minutes. The patient was not sure if last night's episode was an A Fib event or just Tachycardia and was trying to confirm that with his/her cardiologist. The patient wanted to know should he/she still get the 2nd shot as required in 2 months. The patient does believe that the event was related to the vaccine.",,Unknown,0,1
901842,"Fever 102 Body aches Fatigue Nausea Headache Cough Congestion  Went to clinic, 10/8/2020. Was tested for covid.  Test was negative. Was ill with above symptoms for 5 days. Had lingering cough for 10 days. Treated at home with tylenol and delsym.",53.0,Adults,0,0
873005,contracted herpes zoster,66.0,Seniors,0,0
898412,"Chills, extreme body aches, fatigue and headaches",57.0,Adults,1,0
908026,"Received the COVID vaccine, after the 30 min observation time she left the area and returned about an hour after her administration with complains of Shortness of breath, tightness in chest, elevated BP, Flushing and rash on upper extremities and neck.",49.0,Adults,0,0
898744,Severe soreness in shoulder starting the night of getting the vaccine.  then started with muscle weakness and pains all over.  Also felt numbness in hands and feet at times.,82.0,Seniors,0,0
894500,large red swollen area that itches,84.0,Seniors,0,0
904452,"Felt an initial ""cool"" feeling all over immediately following vaccine injection, this resolved immediately as well.",50.0,Adults,0,1
881691,"vaccine in patient over the age of 45; This spontaneous report was received from a pharmacist concerning an unspecified patient over the age of 45 (unknown age and gender).    The patient's medical history, concurrent conditions and concomitant therapies were not provided.           On an unspecified date, the patient was vaccinated with a dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast)(GARDASIL 9) (dose, route, lot# and expiration date were not provided) for prophylaxis.      This is a non-valid case due to lack of patient identifier.",,Unknown,0,1
887510,"shortness of breath, out of energy",67.0,Seniors,0,0
905602,"Leg pain, back pain, chills, fever, headache. Unable to walk or stand still for more than a minute. Unable to sit upright back pain travels to mid back.",34.0,Adults,1,0
858692,"No additional adverse effects.; an unspecified two week old patient was inadvertently administered one dose of ROTATEQ along with five other unspecified GSK vaccines; This spontaneous report has been received from a physician referring to a 2 week old patient of unknown gender. Information regarding the patient's medical history, drug reactions or allergies, concurrent conditions and concomitant medications was not provided.  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent(ROTATEQ), orally (indication, strength, frequency, dose, lot # and expiration date were not provided) for prophylaxis ( product administered to patient of inappropriate age).  On the same date, the patient was vaccinated with other unspecified GSK vaccines. No additional adverse effects.",,Unknown,0,1
625949,"Viral exanthem; Small red spots began, continued in the following day spreading to most of body; Spots looked like chicken pox/ some spread and became large contagious rash; 1 year old patient received influenza vaccine; Information has been downloaded from regulatory authority (US-CHIRONMA-PHHY2016US052268US-CHIRONMA-PHHY2016US052268).  This spontaneous report was received from a other health professional and refers to a 1-year-old male patient. The patient concurrent condition included ear infection. There was no information about the patient's concomitant therapies or medical history provided. On 23-FEB-2016, the patient was vaccinated with hepatitis A vaccine, inactivated (VAQTA) (manufacturer unknown), influenza virus vaccine (unspecified) (manufacturer unknown), varicella virus vaccine live (oka/merck)(VARIVAX) (manufacturer unknown) and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (manufacturer unknown) 1 dosage form (formulation, strength, dose, frequency, route of administration, lot # and expiration date were not reported) for immunisation. On 05-MAR-2016, the patient experienced viral exanthem, small red spots began, continued in the following day spreading to most of body and spots looked like chicken pox/ some spread and became large contagious rash. The outcome of viral rash, rash vesicular and rash erythematous was reported as recovered/resolved. Causality assessment was not provided.   The events of a 1-year-old patient received influenza vaccine, viral exanthem, small red spots began, continued in the following day spreading to most of body and spots looked like chicken pox/ some spread and became large contagious rash were determined to be medically significant.; Sender's Comments:  625949:",1.0,Kids,0,0
856549,Patient reported experiencing left arm and shoulder pain since his flu shot on 10/21/19. He did not report the pain to Department of Public Health Services until 12/20/19. He stated that he believed the nurse injected the flu shot too high on his arm and caused the injury. He went to see a doctor just a few days before coming in to report it to the clinic and that he had an MRI scheduled.,55.0,Adults,0,0
888029,"localized redness, itching, pain and skin tightness;",4.0,Kids,1,0
909819,"Excessive thirst 15mins post  Heart palpation with fluttering sensations 30mins post HTN 156/96, 80hr, 1hour post  Chills 1hour post  Muscle spasms with cramping throughout body 45mins post Muscle weakness to left side 2hour post Facial twitches Treated with tylenol and Gatorade and rest. Symptoms lasted 48hours post.",49.0,Adults,0,0
884427,Severe arm pain and limited mobility. recommended otc tylenol at onset og symptoms.,80.0,Seniors,0,0
877633,Fever 18 days Diagnosed with Kawasaki on 7/29,0.5,Kids,1,0
914717,"I got the vax and they monitored me for 30 min and I was fine, returned home and I fell asleep. When I woke up I had hives on my throat, chest and face. I called my allergist Dr. to see if she told me to take all my allergy medications and she told me to take the monolukast the night before and take claritin and zyrtec for 2nd dose.  I took a full dose of hydroxizine and it worked. After a couple of hours the hives were gone.",47.0,Adults,0,0
883681,"Bell's palsy; Information has been received regarding a case in litigation from an attorney reporting on a patient (pt) of unknown age and gender. There was no information about the pt's concurrent conditions, medical history or concomitant medication.  In 2015, the pt was vaccinated with zoster vaccine live (ZOSTAVAX) as prescribed and/or administered by a healthcare provider at the office of a physician for the long-term prevention of shingles and/or zoster-related conditions (dose, route of administration, lot number and expiration date were not reported).  Subsequently to the pt vaccination with zoster vaccine live (ZOSTAVAX), on an unknown date, the pt was treated by the physician for Bell's palsy. As a direct and proximate result of pt's use of the zoster vaccine live (ZOSTAVAX)vaccine, pt had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of Bell's palsy was not provided.  Upon internal review, Bell's palsy was considered to be a medically significant event.",,Unknown,0,0
894420,"Seizure, violent shaking; chills. Diarrhea & Vomiting",69.0,Seniors,1,0
896778,"patient was given PNEUMOVAX23 that was recalled; Incorrect Product Storage; This spontaneous report as received from a medical assistant and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history, concomitant medications and drug allergies/reactions were not reported.  On 16-OCT-2020, the patient was vaccinated with recalled dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23), 0.5 milliliter (lot # S036495, expiry date 13-SEP-2021), for prophylaxis.  On 16-OCT-2020, 1 day after onset of therapy the patient experienced recalled product administered and product storage error.    The outcome of recalled product administered and product storage error is unknown.   It was also reported that the aforementioned vaccine was incorrectly stored (temperature excursion details were not reported) and administered to the patient before being recalled. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: S036495; expirationdate: 13-SEP-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",,Unknown,0,1
884487,Patient received these 3 vaccines in error. Patient has not had any reported adverse events.,12.0,Kids,0,1
875140,"shingles; Information has been received on from a lawyer, regarding a case in litigation, and refers to a patient (pt) of unknown age and gender. No information about the pt's medical history, concurrent conditions and concomitant medications was provided. On or about 11-NOV-2013, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, anatomical location, lot # and expiration date were not reported) as prescribed and/or administered by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On an unknown date, subsequent to inoculation with zoster vaccine live (ZOSTAVAX), the pt was treated by a physician for shingles. As a direct and proximate result of the pt's use of zoster vaccine live (ZOSTAVAX), the pt had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of the event was considered to be not recovered. The reporter considered the event of shingles to be related to zoster vaccine live (ZOSTAVAX).",,Unknown,0,0
884391,"Patient was sitting and was injected with the vaccine. Mother was in the room with her. Prior to the injection the mother was asked if the patient has had vaccines in the past and if there were any problems such as anaphylaxis, seizures, passing out etc. The mother stated that she got vaccines all the time at the pediatricians office with no issue. When the  injection was complete the band aid was placed and when I do this I feel for any bumps and observe the skin. She was normal, no rise in fever either. The patient said that was a ""painless"" vaccine and rotated with her mom where I gave her mom the vaccine as well. With the history of having received and no issues I sent the patients to check out to receive the prescription during which the patient seemed okay. Roughly 15-20 minutes went by and then I see the mom hurrying towards me with the patient running with her as well. I instruct them to reenter the room where the patient was sat down and the mother said the patient complained of feeling dizzy and hot then fell over in the isle. I observed patient for any signs of anaphylaxis, there was none. Then the patient started to gag so I gave her the trash can to throw up in which she did. Then I asked my technician to get me a blood pressure cuff and an soaked paper tower with an ice brick along with the thermometer because the patient was burning up.  After the patient threw up she quickly felt better and we continued to monitor. I checked her blood pressure and it was 88/66. The heat was dissipated and the patient said she no longer felt dizzy and could see. We monitored for a few minutes. At this point the scare seemed to have pass. I explained to the mother that what likely occurred is that she passed out which can occur post injections. After roughly 15 minutes the patient felt better and  the mother asked if they could walk around. I said yes just stay close to make sure she is okay. The patient had energy again and when she stood up and walked around felt fine. After a few more minutes the patient said she was okay again and the mother took her home.",10.0,Kids,0,1
913061,"10 MINUTES FOLLOWING VACCINE - SOB, COUGH, TIGHTNESS IN CHEST, THRAOT SWELLING, DIFFICULTY SWALLOWING, LIGHT HEADEDNESS, AND ELEVATED HEART RATE.  ORAL AND IM BENADRYL ADMINISTERED, 2 DOSE OF EPINEPHRINE, 2 NEB TREATMENTS, O2 PLACED. 911 CALLED AND TRANSPORTED TO EMERGENCY FOR FURTHER TREATMENT AND MONITORING. AT HOSPITAL IV STEROID ADMINISTERED. SYMPTOMS SUBSIDED WITH SECOND DOSE OF EPINEPHRINE, HOWEVER RETURNED 3 HOURS LATER AND ANOTHER DOSE OF BENADRYL ADMINISTERED. ELEVATED HEART RATE CONTINUED AND IV FLUIDS ADMINISTERED TO ATTEMPT IN BRINGING DOWN HEART RATE. IV FLUIDS WERE NOT EFFECTIVE. HEART RATE (118-120) REMAINED ELEVATED INTO THE OVERNIGHT HOURS AND SUBSIDED AROUND 1:30A ON 12/29/2020. CONTINUED HEADACHE, NAUSEA ONSET, FATIGUE, DIFFICULTY SWALLOWING AND COUGH  ON 12/29/2020.",47.0,Adults,0,0
879973,Sore arm.fever 99.9,59.0,Adults,1,0
914276,"Tingling in all four extremities, chest tightness, throat tightness, pharyngeal Edema , Nausea, lightheadedness",48.0,Adults,1,0
913880,"Headache, light headedness, cold chills, sweats, weakness, nausea",31.0,Adults,1,0
911424,"Feeling under the weather; Nausea; Headache; Muscle ache; This is a spontaneous report from a contactable other healthcare professional (HCP), who is also the patient.  This 63-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number EL0140) via an unspecified route of administration on 19Dec2020 at single dose for COVID-19 immunisation. Relevant medical history included hypertension (hypertensive for years and takes medication for that), muscle aches (she got muscle aches once in a while) and headaches (she got some headaches from wearing a mask). Concomitant medications included unspecified drugs for hypertension. On 21Dec2020, the patient experienced nausea; in Dec2020 she experienced headache and muscle ache and on 22Dec2020 she experienced feeling under the weather. The patient specified that she has had light symptoms of nausea, headache, and muscle ache. Nausea was the most prevalent symptom. She said she got some headaches from wearing a mask, and the headaches she has experienced since receiving the COVID-19 Vaccine could be related to her mask wearing, and not the vaccine. She said she was at the age where muscle aches are not uncommon, and she got muscle aches once in a while, so she was unsure if her muscle aches were from receiving the COVID-19 Vaccine. She further specified that the she had a little nausea, saying the nausea was not very noticeable. The nausea was a little heavier at the time of the report, and she had some toast and some things to help settle her stomach. She said she was feeling ""blah."" She clarified she was feeling under the weather, like she just wanted to get in bed and sleep. The patient reported that the symptoms she was experiencing could be stress, and she just wanted to get the rapid COVID test to make sure she doesn't have the virus. She would take the rapid test as a requirement for travel. Treatment: the patient took 2 Extra Strength Tylenol 500mg (Lot Number: SHA086, and Expiration Date: Jun2024). The patient had not recovered from nausea and feeling unwell; the outcome of the headache and muscle ache was unknown.",63.0,Adults,0,0
916092,"Experienced nausea at about 2230 on 12/30/20.  This resolved by midnight.  Arm injection site noted to be red, hot to touch and indurated on 12/31/20 at 0600.",28.0,Adults,1,0
888187,"Got VERY sick; This case was reported by a consumer via interactive digital media and described the occurrence of sickness in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced sickness. On an unknown date, the outcome of the sickness was unknown.   It was unknown if the reporter considered the sickness to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as adult as per the vaccine indication. The patient received Shingrix and got very sick. The patient was scared to get second shot.",,Unknown,0,1
888454,Rash at site of injection for 2 weeks,8.0,Kids,1,0
872466,"loss of skin pigmentation at the injection site; This case was reported by a pharmacist via call center representative and described the occurrence of injection site discoloration in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included estrogen nos (Oestrogens) and progesterone.   On 17th May 2020, the patient received the 2nd dose of Shingrix (intramuscular). In May 2020, less than a week after receiving Shingrix, the patient experienced injection site discoloration. On an unknown date, the outcome of the injection site discoloration was not recovered/not resolved.   It was unknown if the reporter considered the injection site discoloration to be related to Shingrix.  Additional details were provided as follows: The patient had no known drug allergies. On an unknown date between 17th May 2020 to 19th May 2020, the patient developed a loss of pigmentation about the size of a quarter at the injection site. At the time of this report the event was reported not recovered. The reporter did not consent to follow up.",50.0,Adults,0,0
886446,"dizziness, headache, appeared weak, palpitations",2.0,Kids,1,0
892334,After giving pt injection Mother instructed pt to put head between legs and mentioned to RPH that he gets dizzy sometimes. Pt stood up after about 30 seconds and moved to other chair in room. While waiting for last sibling to receive their immunization (3 siblings all receiving flu vaccine) patient fainted and convulsed for about 5 seconds. He then regained consciousness and took another 5 seconds to respond to questions. We (Mother and I) laid patient on floor and brought him water and a cold towel.   Monitored patient for additional signs of syncope for another 5-10 min.  She mentioned during this time that patient had a similar event in the past in a closed environment where he got hot and dizzy and fainted but that this was the first  vaccine related issue. Pt reported feeling better after this and mother elected to take patient home.,11.0,Kids,0,1
911703,Moderate muscle pain/soreness of left arm- started approximately 6 hours post injection and present even after 24 hours,33.0,Adults,1,0
871696,"Your child received a vaccination at our clinic during the period between February 28 and April 16, 2020. During the period between February 28th, 2020 and March 2nd, 2020, our data logger had a technical malfunction that we were not aware of and it stopped sending its temperature recordings to the system. During that period the fridge never stopped working. The temperature logs of the fridge before and after the incident were always within required range. Our fridge has been always in a perfect new condition and never had any temperature problems previously. There was no power outage in the area or inside the office during that period as well.    The CDC requires continuous temperature monitoring of all vaccines and due to lack of continuous temperature data documentation, the vaccine manufacturers have determined that the doses administered on these dates should be re-administered to ensure proper effectiveness.",0.33,Kids,0,1
871016,"The patient experienced no symptoms.; on 4/24/2020 a patient was administered a dose of improperly stored Varivax; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history, drug allergies/reactions and concomitant medications were not provided.  On 24-APR-2020, the patient was administered a dose of improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) (lot# S028920, expiration date 16-SEP-2021, strength and dose were not provided) subcutaneously for prophylaxis. The Merck sterile diluent (lot # and expiration date were unknown) used for administration was properly stored.  The improperly stored of varicella virus vaccine live (Oka/Merck) (VARIVAX) experienced a temperature of -8.1 degree Celsius for 1 hour and 30 minutes. There was no previous temperature excursion reported. The digital data logger was involved. The patient experienced no symptoms.",,Unknown,0,1
901526,"acute flaccid myelitis, transverse myelitis or acute demyelinating encephalomyelitis",15.0,Kids,0,0
856468,"shingles; Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication.   On 14-FEB-2008 the patient was vaccinated with zoster vaccine live(ZOSTAVAX) (dose, route, lot# and expiration date were unknown) for the long-term prevention of shingles and/or zoster-related conditions (for prophylaxis). Subsequent to inoculation, the patient was treated for herpes zoster .  As a direct and proximate result of patient's use of the zoster vaccine live(ZOSTAVAX) vaccine, patient has and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future.  Additional information has been requested.",,Unknown,0,0
889705,"patient explained that after the she received her shot, the following day she had a large welt and red area the size of a baseball",55.0,Adults,0,0
907967,"After she waited for 30 minutes after receiving vaccine she stated that she had generalized itching and 2 small hives on her right arm. She said it started about 3 mins after receiving the vaccine.  She was given 25mg of Benadryl syrup po. She stayed at facility another 30 minutes before being cleared to leave after she said the itching was better and no further hives formed.  12/23/20 -9:56am She was contacted by phone. She said she woke in the night and felt like ""asthma"" and had a rash at the site. She took another 25mg of Benadryl. She took another dose of Benadryl at 06:00am. As of this time, 9:56am, she states, no shortness of breath, no more rash at site, and the itching has subsided. She will follow up as needed.",34.0,Adults,0,0
880789,"concerns of liver failure; Severe rash; dark urine; yellow eyes; Severe itching; This case was reported by a nurse via sales rep and described the occurrence of liver failure in a 57-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 20th July 2020, the patient received the 1st dose of Shingrix. In July 2020, less than a week after receiving Shingrix and an unknown time after starting triamcinolone, the patient experienced pruritus. On an unknown date, the patient experienced liver failure (serious criteria GSK medically significant), rash, urine discoloration and yellow ocular coloring. The patient was treated with triamcinolone and methylprednisolone. On an unknown date, the outcome of the liver failure, pruritus, rash, urine discoloration and yellow ocular coloring were unknown.   It was unknown if the reporter considered the liver failure, pruritus, rash, urine discoloration and yellow ocular coloring to be related to Shingrix.  Additional details were provided as follows: It was reported that the patient received Shingri and on 27th July 2020 returned to office due to severe itching. The physician prescribed triamcinolone On 3rd August 2020, the patient returned to office again due to ongoing itching, the physician prescribed methylprednisolone. On 13th August 2020, the patient returned to office again due to rash and itching, the physician prescribed methylprednisolone again (to continue using triamcinolone). On 18th August 2020, the patient returned with itching but no rash, labs were checked and patient had LFTs more than 10 time upper normal limit. The patient also had dark urine and yellow eyes (concerns of liver failure).  It was unknown if it was started prior to Shingrix The patient cannot clearly identify when symptoms of itching started (pre or post Shingrix dose). The reporter consented to followup.",57.0,Adults,1,0
904011,"It's been quite some time since the shot and I am having trouble lifting and using my left arm.  I have also had pain radiating from the shoulder, muscle cramps in my arm and stomach, and an increase in trouble seeing.  I wear glasses and do not have eye diseases other than cataract.  Severe fatigue.  Stomach fluttering.  Swollen lymph glands under right arm and above right breast",50.0,Adults,1,0
893586,Aching. Significant pain in legs and lower body. Tachycardia. Trouble breathing. Numbness. Hard to stand or walk. Burning nerve pain. Headache severe,34.0,Adults,1,0
881372,"Less than 5 minutes after giving vaccines, pts mom reported pt had a rash, upon entering the room with NP, red scattered rash all over, no difficulty breathing, alert and crying , Benadryl 5 ml po given at 11:57, rash still spreading, decadron 4 mg  given at 12.07, rash has spread , pulse ox 98%, pt now scratching at rash.   At 12:15 I checked pt,   he drank some water, alert and whining, conts pulse ox on, Pulse ox 100 % and pulse 153.  tb,lpn  , AS PATIENT WAS LEAVING THE EXAM ROOM, MOM WALKED UP TO ME AND ASKED IF THE RASH HE WAS DEVELOPING ON HIS LEFT ARM WAS NORMAL. PATEINT HAD DEVELOPED WHELPS ON LEFT ARM WHERE MMR HAD BEEN INJECTED.  I HAD THE PATIENT GO BACK INTO THE EXAM ROOM.  INSTRUCTED NURSE TO GIVE 4 ML OF ORAL BENADRYL.  I WENT AND SPOKE WITH DR. AND AS I RETURNED TO EXAM ROOM THE RASH HAD SPREAD TO HEAD, SCALP,FACE, AND TORSO.  LUNGS SOUNDS CTA, NO WHEEZES, NO STRIDOR.  ORDERED NURSE TO INJECT 4 MG DECADRON IM.  PATIENT STAYED IN EXAM ROOM FOR OBSERVATION FOR A TOTAL OF 1 HR AFTER INJECTIONS.  UPON LEAVING OFFICE I NOTED HIS PULSE OX WAS STILL 100%, LUNGS CTA, PATIENT WAS ACTIVE AND ALERT, NORMAL RESPIRATIONS AND HEART SOUNDS.    TL,FNP-C",1.08,Kids,0,0
878355,"Pt came to our clinic requesting HPV vaccine. Risks benefits described. Consent forms signed. By day after receiving HPV9 #1, she felt a dull ache in her deltoid at the injection site. She called our office today 8/6/2020 to report. no fevers, no redness, no swelling. no loss of strength. No sensation changes. Reports dull ache has not improved over 3 weeks and worsens if she rolls on it in sleep or moves or palpates deltoid.  Told her probably prolonged inflammatory response in muscle, perhaps with nerve irritation. Told her to try motrim or tylenol and resting deltoid. Told her we were cancelling her #2 and #3 shots since her risk benefit calculus had shifted for an elective vaccine, and recommended other ways to limit/prevent HPV.",34.0,Adults,0,0
886011,"Fainted after vaccination - got back up and left store. Contacted wife, she said he has a history of fainting with needles / blood draws.",57.0,Adults,0,0
868416,"she started having nerve pain in the same arm that would go all the way down her arm; Uncomfortable; she was scratching her back because it itched; had red welts down along her vertebrae below her waist and above her tailbone; discovered two pox on her back /  There were also two places that looked like pox had fallen off/ After seeing the pox she realized she had shingles; started having severe pain in her back; She experiencing fever; She experiencing  shivering; She experiencing nausea; She also had pain, redness and swelling in her arm where she got the injection; She also had pain, redness and swelling in her arm where she got the injection; She also had pain, redness and swelling in her arm where she got the injection; This case was reported by a consumer via call center representative and described the occurrence of fever in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (twice).   On 16th January 2020, the patient received the 1st dose of Shingrix (intramuscular). On 15th March 2020, 59 days after receiving Shingrix, the patient experienced back pain and shingles. On 23rd March 2020, the patient experienced pruritus and erythema urticarial. On an unknown date, the patient experienced fever, shivering, nausea, injection site pain, injection site erythema, injection site swelling, nerve pain and discomfort. On an unknown date, the outcome of the fever, shivering, nausea, injection site pain, injection site erythema, injection site swelling and nerve pain were recovered/resolved and the outcome of the discomfort, pruritus and shingles were unknown and the outcome of the back pain was recovering/resolving and the outcome of the erythema urticarial was not recovered/not resolved.   It was unknown if the reporter considered the fever, shivering, nausea, injection site pain, injection site erythema, injection site swelling, nerve pain, discomfort, back pain, pruritus, erythema urticarial and shingles to be related to Shingrix.  Additional details were reported as follows: The patient received the Shingrix on an unknown arm and experienced fever, shivering and nausea for about 2-3 days after getting the vaccine. She also had pain, redness and swelling in her arm where she got the injection that lasted 1.5-2 weeks. After those symptoms resolved she started having nerve pain in the same arm that would go all the way down her arm. This nerve pain would come and go and was very uncomfortable. The nerve pain finally resolved about 1 month ago. On 15th March 2020 she started having severe pain in her back. At first she thought she had injured her back, but on 23rd March 2020 she was scratching her back because it itched and discovered two pox on her back. There were also two places that looked like pox had fallen off. She also had red welts down along her vertebrae below her waist and above her tailbone, where she was experiencing the pain. After seeing the pox she realized she had shingles, so she called her doctor and a prescription was called in for acyclovir. The welts never broke out in full blisters, but are still present. The pain has mostly resolved. She has had two previous cases of shingles, prior to getting Shingrix, and those occurred higher up on her right side from where the welts are. The previous cases of shingles were more in the location of the pox. The current welts are lower down and more central. Consented to follow up.",60.0,Adults,0,0
884926,"Under eye swollen, large itchy patch at injection site which has increased in size on day 3, long ulcer on inside cheek, itchy eyes",59.0,Adults,0,0
895458,"Pt was received only the Shingrix diluent instead of the reconstituted Shingrix vaccine. Pt was contacted and reports no adverse reaction except for a sore arm at the site of injection, no other symptoms was reported.",65.0,Adults,0,1
899274,"received  one 2 months ago in September and got one on 10NOV2020; soreness at the injection site; Initial information regarding an unsolicited valid non-serious case received via a pharmacist on 13-Nov-2020.  This case involves an unknown age male patient who experienced soreness at the injection site (injection site pain) and received one 2 months ago in september and got one on 10nov2020 (extra dose administered), while treated with influenza quadrival a-b high dose hv vaccine [Fluzone high-dose quadrivalent].  The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications were unknown.   On an unknown date in September 2020, the patient received a dose of suspect influenza quadrival a-b high dose hv vaccine (lot number: UJ540AA, expiry date: 30-Jun-2021) at an unknown dose, frequency via unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date in 2020, (unknown latency) after starting the suspect vaccine therapy the patient had soreness at the injection site (injection site pain).  On 10-Nov-2020, approximately two months after starting the suspect vaccine therapy patient got another dose (extra dose administered).  No laboratory data was reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event injection site pain was unknown.  Disclaimer: This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in directive 2001/83/ec and module VI of the good Pharmacovigilance practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,0
878950,"sensorineural hearing loss; Information has been received from a lawyer regarding a case in litigation concerning a patient (pt) (age and gender unknown). The pt's medical history, concurrent conditions and concomitant medication were not provided. On or around 23-AUG-2017, the pt was vaccinated with zoster vaccine live (ZOSTAVAX), (lot# and route unknown) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX) (date not reported), the pt suffered a sudden left-sided hearing loss and was diagnosed with sudden  onset sensorineural hearing loss. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the pt's symptoms have resulted in physical limitations not present prior to using the vaccine. The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of zoster vaccine live (ZOSTAVAX), the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the event sensorineural hearing loss was considered to be not recovered and causal relationship was assessed as related.  The reporter considered the event sensorineural hearing loss to be disability.  Upon internal review, the event sensorineural hearing loss was determined to be medically significant.",,Unknown,0,0
910540,"Reporting on behalf of staff member. She received covid vaccine on 12/24. The following day, she experienced extreme weakness/fatigue, migraine, low grade fever, body aches, and tachycardia. She went to the ER, they gave her IV fluids, pain meds and tylenol with no relief. She was monitored for awhile and then sent home to rest and recover. 3 days later (12/27) she says she feels significantly better, but still a little tired.",38.0,Adults,0,0
904317,Erythematous facial and neck rash,34.0,Adults,1,0
894242,rash = itchy and stingy on skin,20.0,Adults,1,0
895737,"flu; Initial information received on 24-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer (patient) via social media.  This case involves a patient (unknown demographics) who experienced flu (influenza), after receiving INFLUENZA VACCINE.  Past vaccinations included INFLUENZA VACCINE from which the patient got flu..  Medical history, medical treatment, concomitant medication and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number and expiry date: not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious flu (influenza), (unknown latency) following the administration of INFLUENZA VACCINE.  Details of laboratory data not reported.   It was not reported if the patient received a corrective treatment.  The outcome of the event was not reported.  There will be no information available on the batch number for this case.",,Unknown,0,1
911079,"Reported headache and twitching of right cheek. Took Tylenol and headache resolved day of vaccination; twitching resolved day of vaccination (unknown duration).  12/23/20 (day after vaccination) he reported a slight headache upon awakening that worsened as the day passed. He took 2 extra strength Tylenol at 10:00 AM (12/23/20).  Tylenol partially effective - headache lessened but still present.  12/28/20 update - chills, nausea, and fatigue from 12/23 - 12/28. Improvement in symptoms but symptoms are not completely resolved as of 12/28/20 per patient.",61.0,Adults,0,0
905758,"FATIGUE , HEADACHE,  I WOKE UP WITH A MIGRAINE . Mild headache for two days",50.0,Adults,1,0
871312,"Upon withdrawing the needle some of the vaccine leaked out; Shot hurt; This is a spontaneous case, initially received from pharmacist via Agency (reference number: SEQ19-02429) on 09-Sep-2019, concerning a 73-year-old, female patient.   The patient's medical history included unspecified cardiac issues.   The patient's concomitant medications included: oxygen, diltiazem, water pill, potassium, warfarin, propranolol and Albuterol (salbutamol); all for unknown indication.   On 03-Sep-2019, the patient was administered Fluad [influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, MF59, dose: 0.5 ml, route of administration: intramuscularly, anatomical location: deltoid, batch number: 260389, expiration date: 31-May-2020] for influenza prophylaxis. The patient stated that the shot hurt. The patient was treated with ice.  As reported, while administering the vaccine, the reporter stated that she might have backed out a little bit (also reported that half of it came out), but still administered the full dose. Upon withdrawing the needle, some of the vaccine leaked out (explicitly coded as Inappropriate dose of vaccine administered'. The reporter wanted to know if the patient should be re-vaccinated.   On 05-Sep-2019, the patient recovered from the vaccination site pain.  The reporter assessed the case as non-serious and did not provide causality assessment.  The reporter gave consent to be contacted for further follow up.  Follow up received by pharmacist on 18-Sep-2019: Reporter did not give us permission to contact the patient therefore there would be no additional information provided.  Company comment :The patient developed vaccination site pain on the same day after vaccination with the suspect product, Fluad. Chronology is plausible. Reportedly, upon withdrawing the needle some of the vaccine leaked out, which suggests incorrect dose administration. The patient recovered from the vaccination site pain two days after, as reported. Based on this information, causal relationship between the suspect product and the event vaccination site pain is assessed as related, while for incorrect dose administered as not related.; Reporter's Comments: The patient developed vaccination site pain on the same day after vaccination with the suspect product, Fluad. Chronology is plausible. Reportedly, upon withdrawing the needle some of the vaccine leaked out, which suggests incorrect dose administration. The patient recovered from the vaccination site pain two days after, as reported. Based on this information, causal relationship between the suspect product and the event vaccination site pain is assessed as related, while for incorrect dose administered as not related.",73.0,Seniors,0,0
894846,"fatigue; headaches; fever; chills; soreness; Flu-like symptoms; not being able to lift arm; This case was reported by a pharmacist via call center representative and described the occurrence of fatigue in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced fatigue, headache, fever, chills, pain, influenza-like symptoms and mobility decreased. On an unknown date, the outcome of the fatigue, headache, fever, chills, pain, influenza-like symptoms and mobility decreased were unknown.   It was unknown if the reporter considered the fatigue, headache, fever, chills, pain, influenza-like symptoms and mobility decreased to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The reporter mentioned Flu-like symptoms such as chills, fever soreness, fatigue also complaints of not being able to lift arm and headaches. The patient noticed that if the patient did not experience an adverse event after 1st dose they may have a mild case after 2nd dose. And if they have an adverse event after 1st dose they have a mild case after 2nd dose.  The Health care professional mentioned it was all patients well over 10 patients, so no PII was captured nor lot/exp. date.  The reporter consented to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR215857:same reporter US-GLAXOSMITHKLINE-US2020214762:same reporter",,Unknown,1,0
875146,"No adverse symptoms reported; the patient was inadvertently administered an expired dose of VAQTA; This spontaneous report was received from a pharmacist referring to a 72 year old patient of unknown gender. Information regarding the patient's concurrent conditions, pertinent medical history and concomitant medications was not provided.      On 30-JUN-2020, the patient was inadvertently vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) pre-filled syringe, strength, route of administration and anatomical location were not reported (Lot # S001832, expiration date 12-MAY-2020) for prophylaxis.   No adverse symptoms were reported. Product quality complaint was not involved. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: S001832; expirationdate: 12-MAY-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",72.0,Seniors,0,1
889746,"Anaphylaxed to her first dose / allergic reaction; Vaccine was given 3/20/2020 / 6 month window / has already passed; This case was reported by a physician and described the occurrence of anaphylactic reaction in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 20th March 2020, the patient received the 1st dose of Shingrix. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than 9 months after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced anaphylactic reaction (serious criteria GSK medically significant) and incomplete course of vaccination. On an unknown date, the outcome of the anaphylactic reaction and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the anaphylactic reaction to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported for 1st dose of vaccine. The age at vaccination was not applicable for 2nd dose of vaccine. The patient was anaphylaxed to her first dose of Shingrix.  The reporter planned to do allergy testing to the vaccine and then give the vaccine in an incremental challenge. The reporter inquired about the non irritating concentration of the vaccine. The reporter asked since the 6 month window for getting the 2nd vaccine has already passed whether there was need to get 2 more vaccinations. Till the time of reporting patient did not receive 2nd dose of Shingrix which led to incomplete course of vaccination.",,Unknown,0,1
874258,"shingles; Information has been received from a lawyer, regarding a case in litigation, and refers to a patient (pt) of unknown age and gender. No information about the pt's medical history, concurrent conditions and concomitant medications was provided. On or about 04-MAY-2012, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, anatomical location, lot # and expiration date were not provided) by a healthcare provider at a physician's medical office for the long-term prevention of shingles and/or zoster-related conditions. On an unknown date, subsequent to inoculation with zoster vaccine live (ZOSTAVAX), the pt was treated by a healthcare provider at a walk-in-clinic for shingles. As a direct and proximate result of the pt's use of zoster vaccine live (ZOSTAVAX), the pt had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of the event was considered to be not recovered. The reporter considered the event of shingles to be related to zoster vaccine live (ZOSTAVAX).",,Unknown,0,0
865206,"No symptoms were reported; patient was inadvertently administered one dose of VAQTA which was expired; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. Information about patient's pertinent concurrent conditions, medical history, concomitant medications and previous drug reactions and allergies were not provided.  On 12-MAR-2020, the patient was inadvertently vaccinated with an expired hepatitis a vaccine, inactivated (VAQTA) strength 50/1.0 units per milliliter (U/ml), 1 dose as prophylaxis (vaccination scheme frequency, route and anatomical location of vaccination were not reported; lot number S001360, and expiration date reported 06-MAR-2020) (expired product administered). The product had not undergone any temperature excursions and no symptoms were reported for the patient.",,Unknown,0,1
895465,"I have bee Vegan for 7 years, I do not drink soda, very rarely juice or sugar. No reason for the gain of 20 pounds. This happened after vaccination and I now have had to eat Keto to re-gain some control over my weight and I am still vegan and I also very rarely eat gluten-bread. and I only drink water/black coffee & tea. I could literally gain a pound or two overnight! I am now Insulin Resistant",58.0,Adults,0,0
878446,"PATIENT EXTREMELY FATIGUED, HAD TO LAY IN BED X24 HRS, HEADACHE",70.0,Seniors,1,0
897309,"probably polycellulitis; The whole half of the arm was really red and swollen; The whole half of the arm was really red and swollen; This is a spontaneous report from a contactable pharmacist. A patient of unspecified age and gender received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13), intramuscular on an unspecified date at single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient experienced polycellulitis, the whole half of the arm was really red and swollen on an unspecified date. The reporter mentioned that a patient developed something that the reporter thought was probably polycellulitis after shot of unknown pneumonia vaccine product; product might have been Prevnar 13 but reporter was not sure. The patient called the doctor who sent them to a clinic to be seen that day and think theirs was maybe 3 days since they had gotten the unknown pneumonia vaccine if the reporter remembered correctly. This occurred maybe 6 months ago. The reporter just remembered the whole half of the arm was really red and swollen. The outcome of the events was unknown. Lot/batch number has been requested.; Sender's Comments: A contributory role of PREVNAR 13 cannot be fully excluded in triggering the onset of probably polycellulitis with the whole half of the arm was really red and swollen.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.",,Unknown,0,1
906349,None stated.,25.0,Adults,0,0
882338,"Injection didn't hurt however within hour my shoulder was throbbing and a little swollen.  But then headache started my lower back hurt and I woke up at 1:30 am (was awake rest of night) with extreme feet and leg pain. Nothing helped - tried aspirin, did take prednisone, then felt like swollen glands in neck.  For several hours I felt horrible - after couple days has settled down except for some lingering muscular pain - which I didn't have before the vaccine.  Last year I had the Fluvent HD I think it's called.  I did have extreme swelling in my left arm which turned black, then purple then green for 3 long weeks.  I did report that reaction. But I would take that over these reactions anytime.  I think this has been worse than flu. I'll never take this vaccine again.  Last year's was very effective in that I was around my family (son, DIL, and four school age grandchildren who in January/February had many illnesses.  I escaped all of them. I think the HD vaccine was that good. This one time will tell but right now I am thinking not worth the misery.",70.0,Seniors,0,0
876283,"calling for temperature evaluation for VARIVAX and notifed it was administered to multiple patients; This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided. On 26-MAY-2020, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX)(strength, dosing schedule, lot#, expiration date and route of administration were not provided) for prophylaxis. Administered dose of vaccine was exposed to the temperature from -14 Celsius degrees to -10 Celsius degrees for 4 hours 15 minutes. There was a previous temperature excursion noted: from -9 Celsius degrees to 8 Celsius degrees for 2 hours 21 minutes, as recorded by a digital data logger.  This is one of multiple reports from the same reporter.; Sender's Comments:  US-009507513-2007USA003458: US-009507513-2007USA004416:",,Unknown,0,1
873401,"The patient did not experience any symptoms; patient was vaccinated with improperly stored varivax; This spontaneous report as received from a medical assistant refers to a 3 year old female patient. The patient's pertinent medical history and drug reactions or allergies were not reported. The patient's concomitant therapy included sterile diluent. On 27-NOV-2019, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck)(VARIVAX) for prophylaxis (strength, dose, route of administration and anatomical location were not reported) of lot # S004119 is an invalid lot number, expiry date reported as 11-FEB-2021 (product storage error). The patient did not experience any symptoms. The outcome of product storage error was unknown. The temperature excursion for varicella virus vaccine live (oka/merck) (VARIVAX) was reported as -9 degrees Celsius (C) to 8 degrees Celsius (3.3 C) for 53 hours. There was no previous temperature excursion reported. Data logger was involved. No product quality complaint (PQC) was associated with this report.  This is one of the multiple reports from the same reporter.; Sender's Comments:  US-009507513-1911USA011629:",3.0,Kids,0,1
914442,RECEIVED DOSE @ 1:30 PM. No reaction until 7:30 PM at home: red rash and itchiness on neck with some stiffness of neck. AT 8:15PM THROAT WAS TIGHT AND PAINFUL WITH SOME DIFFICULTY SWALLOWING. Notified PCP WHO ADVISED TO GO TO ER. 9:30 PM IN ER RECEIVED BENADRYL 25MG PO AND PREDNISONE 60MG PO WITH RELIEF OF SYMPTOMS. THIS AM REPORTS RELIEF WITH SOME RT SIDED THROAT TINGLING. TAKING BENADRYL q6h.,36.0,Adults,1,0
914565,"Right after vaccine I had a headache. Dry throat, I had to continue clearing my throat. My throat was burning.",38.0,Adults,0,0
902154,"After his flu shot on 11/13, he was being driven home by his brother and he started seizing. He was shaking and unresponsive and urinated in the car seat. Brother pulled the car over and shook patient who came around. He was very tired afterward, and did not remember the event. He also had a seizure after a series of immunizations as a young child, but not sure which shot caused it that time. Mom thinks flu vaccine was one of the shots given that day. We will no longer give him flu shots.",21.0,Adults,0,1
908345,"I started to feel a little dizzy at work within hours of vaccine, had not slept well the night before but dizziness continued on and off remainder of the day, felt a little ?off?.",50.0,Adults,0,0
906852,"Patient reported having a fever of 101.7 degrees with chills, abdominal cramps, pruritus (itching), vomiting, blurred vision, dizziness, laryngitis/hoarseness of voice, and headache. She described being awake intermittently throughout the night with these symptoms which continued into the next morning. She was seen at urgent care facility late that afternoon (on 11/12/20) for these symptoms and also to be tested for COVID-19 because of her fever. Rapid COVID antigen test was negative. Her fever resolved earlier that day & temperature measured 97.5 at Urgent Care. She reports Urgent Care told her to take Benedryl, which she did that evening upon reaching home. She reports feeling better a few hours after one dose of Benedryl. The following morning, 11/13/20, she reports feeling completely better with complete resolution of symptoms.",45.0,Adults,1,0
884455,"Patient received vaccine around 2pm and by about 8pm was experiencing fever, chills, and sweating. Tthoughout the night she had bad sweats and high fever. Following morning patient states she passed out.",73.0,Seniors,0,0
855944,"Patient called primary care physician, Dr. and reported generalized weakness and hypotension BP @ 112/60 mmHg (normally 124/80) 4 hours after receiving 2nd Shingrix shot. No syncope reported by office",85.0,Seniors,0,0
916494,"high heart rate, burning sensation in chest, dizziness, extreme weakness. Went to ED, had blood tests (normal), urine (normal, BP and pulse were high, EKG was normal. Once stable, CG was released home. Had doctor?s appt, provider advised against receiving the second vaccination. Still has weakness, occasional burning sensation in chest, shortness of breath with activity. I advised CG to seek medical attention if symptoms worsen or persist.",26.0,Adults,1,0
883556,"Gave pt flu shot at 11:30 am Pt came back after shot arojnd 11:45am and said Back tightened up , then said had trouble breathing , told to take mask off to help breathe better, Breathing did not improve in 5 mintues called emt. They responed in at 12:05, And took gentleman to ER .",64.0,Adults,0,1
906931,Pt experienced headache and dizziness immediately after injection. Approximately 30 mins later the patient began experiencing chest tightness. The patient received 50mg Benadryl and was transferred to the emergency department within about 20 mins.,33.0,Adults,1,0
865431,"See report submitted on first shot in series #189158. After second shot - Urinary tract infection day after shot, put on nitrofurinan for five days, infection cleared up but recurred two weeks later, on Cipro now but getting switched to nitrofurinan again as that is supposed to clear it up",65.0,Adults,0,0
855667,"the patient pulled away during the injection and did not get much/ no AE; Initial information received on 10-Dec-2019 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 57 year old female patient who received less than 0.5 mL of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV].  Medical history, medical treatments, vaccinations and family history were not provided.   On 10-Dec-2019, the patient received a dose of less than 0.5 mL suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [lot QSAA1945, expiry date: 30-JUN-2020] via unknown route in the left deltoid.   It was a case of actual medication error due to Vaccine underdose (underdose). Pharmacist stated that while administering a Flublok vaccine, the patient pulled away, just as he was pushing the plunger. She did not get much, if any of the vaccine.  At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
883378,"When injecting the vaccine, the patient pulled away and had the needle drag across her arm causing a superficial scratch. There was very minimal bleeding. The area was cleared with a cotton ball and a small bandaid was applied. The entire dose of vaccine was not able to be administered due to the patient's jerking away before it could all be pushed into the muscle.",3.0,Kids,0,1
883272,"@ 24 hr red, tender, swollen, hot 4x6 cm area to injection site  @ 48 hr bright red, tender, indurated, very swollen, hot 6x8 cm area to injection site - ice to site 4-5x/day @ 72 hr red, tender, very swollen, hot and indurated 5x8 area to injection site",51.0,Adults,0,0
912896,patient received a dose of Moderna vaccine after receiving the Pfizer vaccine.,66.0,Seniors,0,1
883939,entire shoulder and neck pain treated with ibuprofen,72.0,Seniors,1,0
869256,"This was second dose. I experienced shivering for 8 hrs,  fever (100.2-101.5), muscle aches, tiredness through day two & a half,  just tired, worn out third day, fourth day all good again.  I only experienced sore arm for first dose (February 3, 2020). My husband had Shingrix vaccination at the same times, same places, and only experienced sore arm.",64.0,Adults,1,0
893446,"zoster within 1-2 days after vaccination; This case was reported by a physician via sales rep and described the occurrence of herpes zoster in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included diabetes.   On an unknown date, the patient received the 1st dose of Shingrix .5 ml. On an unknown date, less than a week after receiving Shingrix, the patient experienced herpes zoster. The patient was treated with antivirals nos (Antiviral (Drug Name Unknown)). On an unknown date, the outcome of the herpes zoster was recovered/resolved.   It was unknown if the reporter considered the herpes zoster to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received the 1st dose of Shingrix and experienced herpes zoster which was resolved. The patient treated with antiviral therapy. A medical history that is significant for herpes zoster other than age-one patient is in the 60s with diabetes. The reporter consented to follow up. No further information wa available. This case was linked with case US2020AMR214291.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR214291:same reporter",,Unknown,0,0
908204,"Body aches, fatigue, mild headache, scratchy throat, ?foggy? feeling, sore arm",33.0,Adults,1,0
896482,"36 HOURS AFTER VACCINE - DIFFUSE ERYTHEMA ABDOMEN & CHEST LASTED 4 DAYS - HEADACHE 1 WEEK FLARE UP OF RA - INTENSE PAIN HANDS, WRISTS, R ELBOW, HIPS - SWELLING, STIFFNESS AND FATIQUE MD O/C MTX WITH RASH - RENEWED MTX WITH FLAREUP",77.0,Seniors,0,0
885281,"Patient vaccinated on September 7/ 2020 presents the day after to report redness, swelling, tenderness and erythema from the shoulder at the administration site to the elbow.  Was instructed to put ice on the affected area and if not subsides or get worse to consult her primary care physician.  On September 9/ 2020 patient returned to the pharmacy to pick up electronic prescription for Septra DS #20 take one twice a day for 10 days, after MD visit for the symptoms earlier described.  Patient contacted on September 11, 2020 11 45AM and reported significant improvement on symptoms",68.0,Seniors,0,0
914166,"PARESTECIA BOTH ARM AND FEET. SOB,DIZZINES AND CHEST PAIN. LABIAL CYANOSIS.",54.0,Adults,1,0
888755,Local hypersensitivity reactions measuring 2 inches or greater diameter of induration (swelling) constitute significant local reactions and are relative contraindications to future Influenza vaccination. This has been recorded in the allergy section of patient's chart. Please report this reaction to VAERS (Vaccine Adverse Event Reporting System),3.0,Kids,0,1
880348,patient called and said she has really bad swelling and red at injection site and warm to touch,76.0,Seniors,0,0
907262,Woke with fat lips and a body rash on torso and arms,59.0,Adults,1,0
870204,12AM twitching tingling in legs pain in thighs started 1AM shivering severe by 2AM Had to put blanket in mouth teeth were chattering so badly finally fell asleep or passed out 4AM woke up had to use bathroom light shivering but severe pain in thighs 8AM woke up pain and shivering gone,67.0,Seniors,1,0
893006,"the morning after the immunization patient experience nausea, aching, pressure in chest - 24 hours which then passed; she also experienced  pain below injection site, into elbow, difficulty lifting weight these symptoms have not resolved",72.0,Seniors,1,0
910604,"Developed vomiting, four to five times; Diarrhea; Abdominal pain; Slightly flushed face and minimum facial flowing; Numb ears/Numb body; Bleeding; Anaphylaxis; This is a spontaneous report from a contactable consumer. A 43-year-old female patient received bnt162b2, via an unspecified route of administration on 19Dec2020 at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced anaphylaxis on 20Dec2020. Clinical course: the patient received the COVID vaccine on 19Dec2020, and since then she had developed onset of vomiting after 3 o' clock this morning on 20Dec2020, four to five times, numb ears, numb body. She also had diarrhea and bleeding. She had some abdominal pain and she also complained of having slightly flushed face and the minimum facial flowing. The outcome of events was unknown.  Information for Lot/Batch number has been requested.; Sender's Comments: There is a reasonable possibility that the event anaphylaxis was related to BNT162b2 based on known drug safety profile. Based on the close temporal relationship, the association between the event bleeding with BNT162b2 can not be completely excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.",,Unknown,0,1
897200,"Symptoms started about 8pm ShAking chills, headache in temple region and top-of-head, frequent urination (approx. Q. 15-20 minutes, and loss of balance, and unsteady gait. Symptoms lasted from 8pm - approx. 7AM - fell asleep from 7AM - 11AM next morning. When I awoke, I felt better, except a little fuzzy headed.",68.0,Seniors,1,0
885940,"Within hours of receiving Kinrix and Varicella Vaccines, developed redness and warmth at the site that progressed over the following 48 hours.  No c/o pain, no itching, no fevers, acting completely normally.  No improvement with benadryl X `1 the day prior",4.0,Kids,0,0
914979,Within 5 minutes of receiving dose  I developed a bounding pulse. My heart was racing and I started sweating. It resolved on its own with no treatment in about 5 minutes.,47.0,Adults,0,0
868766,"TOOK ONE DOSE OF UNREFRIGERATED VIVOTIF; This spontaneous case report (PVX2019-1714) was received from pharmacist on 01-Jul-2019. It describes a female consumer who ""took one dose of unrefrigerated Vivotif"", while being on oral Vivotif (one dose every other day) for typhoid fever prophylaxis.  Case report: The consumer took the first two doses of Vivotif that was refrigerated. The second dose was taken on 27-Jun-2019. Then, she left Vivotif unrefrigerated for 48 hours and took the third dose on 29-Jun-2019.  Action taken with Vivotif with respect to the event was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event ""took one dose of unrefrigerated Vivotif"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took one dose of unrefrigerated Vivotif"" was considered as not applicable.",,Unknown,1,0
894697,"8 year old patient had been given with Flublok vaccine, no adverse event; Initial information received on 13-Oct-2020 regarding an unsolicited valid non-serious case received from a physician.  This case involves an 8 years old female patient who received an INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] (lot number: unknown, expiry date: unknown) via unknown route and site on unknown date for prophylactic vaccination (product administered to patient of inappropriate age).  The patient's medical history, medical treatments, concomitant therapy, vaccinations and family history were not provided.  It was an actual medication error due to Inappropriate age at vaccine administration. (latency: on the same day)  At the time of reporting, patient did not experience any adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information available on the batch number.",8.0,Kids,0,1
884782,"shingles; Information has been received from a lawyer, regarding a case in litigation, and refers to an approximately 59-year-old female patient (pt) who was 59 years old at the time of vaccination (calculated based on the suspect vaccine start date; age at vaccination reported as 56 years old, conflicting information). No information about the pt's medical history, concurrent conditions and concomitant medications was provided. On or about 21-JUL-2010, the pt was administered zoster vaccine live (ZOSTAVAX) (dose, route of administration, anatomical location, lot # and expiration date were not provided) at a county health department for the long-term prevention of shingles and zoster-related conditions. As a result of her receipt of zoster vaccine live (ZOSTAVAX), the pt was caused to suffer shingles in or about 2010, including any and all of its sequelae (also reported as subsequently (date not provided), the pt was treated by a healthcare provider for shingles, resulting from the pt's use of zoster vaccine live (ZOSTAVAX)). As a direct and proximate result of zoster vaccine live (ZOSTAVAX) manufacturing defect, the pt suffered severe and permanent physical injuries, including but not limited to shingles, as well as other severe and permanent health consequences (also reported as had been caused to suffer severe personal injuries, pain, suffering, and emotional distress, as well as to incur substantial economic damages). The pt had endured substantial pain and suffering. She had incurred significant expenses for medical care and treatment, and would continue to incur such expenses in the future. The pt had lost earnings and had suffered a loss of earning capacity. The pt had suffered and would continue to suffer economic loss, and had otherwise been physically, emotionally and economically injured. The pt's injuries and damages were permanent and would continue into the future. The outcome of the event was considered to be not recovered. The reported considered the event of shingles to be related to zoster vaccine live (ZOSTAVAX).  The event of shingles was considered to be disabling.",59.0,Adults,0,0
901582,"Got flu shot, had a little cold, but not too bad; Initial information was received on 27-Oct-2020 regarding an unsolicited valid non-serious case from a social media via consumer or non-health care professional.  This case is linked to cases 2020SA305170, 2020SA305230 and 2020SA305527.  This case involves a male patient of unknown age who had a little cold, but not too bad (nasopharyngitis), after he received INFLUENZA VACCINE.  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received an unknown dose of INFLUENZA VACCINE (produced by unknown manufacturer) [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date (unknown latency), the patient had a little cold, but not too bad (nasopharyngitis), following the administration of INFLUENZA VACCINE.  Details of laboratory data not reported.   It was not reported if the patient received a corrective treatment.  At the time of reporting, the patient was recovering from the event.  There will be no information available on lot number.",,Unknown,0,1
890957,"Patient reported arm swelling, pain and redness down to her left elbow. Self treated initially with Aleve. Pharmacist recommended ice, Tylenol and Benadryl. If symptoms worsen, to contact PCP. She did report to Dr following day, who asked her to stay on treatment recommended, and come to office if her symptoms worsen. After 6 days her arm has stabilized, symptoms improved, with minimal swelling, pain and redness.",66.0,Seniors,0,0
897472,"redness and a rash around the trunk area.; rash around the trunk area; This case was reported by a pharmacist via call center representative and described the occurrence of erythema in a 60-year-old female patient who received Herpes zoster (Shingrix) (batch number 23LD9, expiry date 2nd April 2022) for prophylaxis.   On 6th November 2020, the patient received Shingrix (intramuscular). On 7th November 2020, 1 days after receiving Shingrix, the patient experienced erythema and rash. On an unknown date, the outcome of the erythema and rash were recovering/resolving.   It was unknown if the reporter considered the erythema and rash to be related to Shingrix.  Aditional details were provided as follows: The reporter stated that after Shingrix vacciaton, the patient had redness and a rash around the trunk area. The reporter stated redness and a rash around the trunk area were still ongoing currently but had gotten better. The reporter did not consent to follow up. This was 1 of 2 linked cases, reported by same reporter for different patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020183487:same reporter",60.0,Adults,1,0
897832,"Started with shivers night of day ((Tuesday) I received the vaccine. I developed fever that night. The next day I continued with fever, developed muscle aches. On Thursday  I felt a lot better.  Still felt ok Friday morning, but things quickly went downhill. I began feeling very achy and weak. By afternoon, I developed fever, stomach pains, worse body aches, nausea, and a bad headache. By last night, I felt just awful. When I got up this AM, fever was almost gone, but I continue to feel weak, nauseous, have a headache, and have muscle aches, and stomach pain.",54.0,Adults,0,0
878172,"potassium was 5.5 from blood work results, elevated Potassium post Imovax use; Initial information received on 30-Jul-2020 regarding an unsolicited valid non-serious case from a physician.  This case involves female patient (unspecified age groups and age) who experienced an increase in potassium of about 5.5, reported from blood work results (blood potassium increased), while she received vaccine RABIES (HDC) VACCINE [IMOVAX RABIES].  The patient had no prior history.  The patient's past medical treatment, vaccination and family history were not provided.  It was not reported that the patient had concomitant medications.   The patient received two doses of suspect RABIES (HDC) VACCINE (lot number and expiration date for both the doses were not reported) via unknown route in unknown administration site for unknown indication on 20-Jul-2020 and 27-Jul-2020.  On 22-Jul-2020, the patient who had increase in potassium of about 5.5 (blood potassium increased), 2 days post RABIES (HDC) VACCINE administration.  Relevant laboratory test results included: Blood potassium - On 22-Jul-2020: 5.5; on 29-Jul-2020: 5.5; on 30-Jul-2020: 5.5 (units unspecified for all).  Final diagnosis was blood potassium increased.   It was not reported if the patient received a corrective treatment.  The outcome was reported as Unknown for the event blood potassium increased.  There will be no information on the batch number for this case.",,Unknown,0,1
908773,When I filled out visage I put the wrong brand of vaccine and need to change it.,56.0,Adults,0,1
883340,ARM SWELLED AND WAS HOT AND PAINFUL,78.0,Seniors,1,0
916551,"sore arm (2 days) fever (1 day) chills (1 day) headache (2 days) fatigue (3 days) nausea (2 days) 1st day after, in bed all day 2nd day, in bed quite a bit 3rd day, worked from home with breaks and a nap 4th day, felt great",63.0,Adults,1,0
890494,Patient had arm pain that got worse in the 48 hours after injection. Developed a hematoma and ended up being hospitalized for monitoring. Underwent some occupational physical therapy prior to going back to her apartment. She was back in her home on 10/17.,82.0,Seniors,1,0
912934,"headache, chills, temp 100.7",30.0,Adults,1,0
887860,"7cm itchy, red, warm to touch and swollen patch around the injection site within 24 hours. Has been present since date of injection on 10/01/2020. No treatment currently.",31.0,Adults,0,0
858178,"Shingrix vaccine was given subq, not IM. patient developed large, red, raised, itchy patch on arm that grew in size over a 3 day span.",63.0,Adults,0,1
908114,"Pt was lighted and dizzy about 10 mins after vaccine. Vitals were all normal and after we changed him from N95 to surgical mask, laid him down and gave him water he recovered fully.",40.0,Adults,0,1
892360,"I had a call in the pharmacy today (sunday 25th), stating pt has a large redness and mild pain...initially she had swelling and it subsided.",65.0,Adults,1,0
895903,"Within 5 minutes of administering vaccines pt had vasovagal syncope episode.  Episode lasted a few seconds. Ice applied to back of neck, pt laid flat with knees bent and pillow under knees, apple juice given. Pt stated she felt extremely tired like she just wanted to go to sleep.  We kept pt in clinic x15 minutes after episode for evaluation. Color came back to face and pt was able to walk out of office on her own. Dr. examined patient and cleared her to leave. Follow up call was done in the afternoon to check on patient with report of patient doing better with no concerns at this time.",12.0,Kids,0,1
902489,"Injection site reaction greater than 4 inches with redness, pain, and swelling. Patient called PCP and was told to monitor rash and mark with a pen. Over the course of the next few days, the injection site reaction had subsided, and the patient has since recovered.",63.0,Adults,1,0
887237,"didn't feel good; she felt fatigued; flu-ey; arm felt sore; This case was reported by a other health professional via call center representative and described the occurrence of feeling unwell in a 80-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included dermatomyositis and systemic lupus erythematosus.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced feeling unwell, fatigue, influenza-like symptoms and pain in arm. On an unknown date, the outcome of the feeling unwell, fatigue, influenza-like symptoms and pain in arm were recovered/resolved.   It was unknown if the reporter considered the feeling unwell, fatigue, influenza-like symptoms and pain in arm to be related to Shingrix.  Additional details were provided as follow: The age vaccination was not reported. The patient was vaccinated with Shingrix within the last 3 months. After vaccination patient did not feel good, felt flu, srm sore and fatigued. The symptoms were resolved within 24 hours. The reporter did not sure if the symptoms started the night of vaccination with Shingrix or the next day. The reporter consent to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020190518:same reporter US-GLAXOSMITHKLINE-US2020190557:same reporter",,Unknown,1,0
870426,"No additional adverse effects reported; Patient received improperly stored dose of VARIVAX; This spontaneous report was received from a physician referring to a patient of unknown age and gender. Information regarding his/her pertinent medical history, current conditions and previous drug reactions or allergies were not provided.     On 11-MAR-2020, the patient was vaccinated with an improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) (Strength, dose, vaccination scheme and route of administration were not provided; lot number S025609 and expiration date 18-AUG-2021) as prophylaxis. The vaccine was exposed to temperature excursion between 15 degrees Fahrenheit to 46 degrees Fahrenheit (-9 degrees celcius [C] to 8C) -5.48 C, for 7 hours (product storage error).   The vaccine was reconstituted with a sterile diluent (MERCK STERILE DILUENT) and which was stored properly. There was no previous temperature excursion and the call was due to a digital data logger. No additional adverse effects were reported.",,Unknown,0,1
907381,"Received vaccine aprox 0745 am 12/22/2020, aprox 09:00pm 12/22/2020 while at work onset tachycardia at rest 140's-150s, , chills, flushing, and light headiness. Employee continued to work through her 12 hr shift, she advised tachycardia persisted throughout the night 140s.  She reported taking Tylenol at 3am, and chills resolved. She reported to Employee Health at 0730am 12/23/2020, vitals HR 142, BP 103/72 (she advised that was her normal BP), resp 14, Temp 97.2. She denies chest pain, shortness of breath, weakness, headache, cold symptoms, n/v/d. Advised the chills, flushing and light headiness had resolved, but the tachycardia continues. Employee denies any medical history, takes no daily meds, reports recovered from COVID early November. Discussed with Employee the need to seek higher level of care, she was escorted to the ED.",35.0,Adults,0,0
903635,"Shortly after vaccine felt dizzy; nurse gave me water and a granola bar to eat.  Employee took a bite or two and then felt dizzy.  Employee sat down and blood pressure taken 170/ 80 and then 10 minutes later B/P 200/90.  Nurse manager came and recommended employee go to ER for assessment.  Blood sugar was checked and employee states ""they were not low""",49.0,Adults,0,1
856405,"Pt received 2nd dose of Shingrix vaccine at 1600. No problems prior to administration. Fine immediately post. Went to gym but did no arm exercises. At 2000 I received a all asking me, spouse, to pick him up as he was ill and unable to drive. He displayed blurry vision, ataxia and severe Lt arm pain (site of injection). Opted to take him to ED. By now, approx. 2020 he displayed rigors. Temp spiked from afebrile to 100.8 in hour and BP dropped to 90/52 which is relative hypotension for him. Fluid resuscitated with 2L of NSS. Initial Lactate was elevated to 2.6, 2nd dropped to 1.2 post fluids. Pain was temporarily relieved with .05mg of Dilaudid. He was discharged at 0130 1/3/20. Today continues with Lt arm pain (5-6/10) will see PCP regarding pain control. Tylenol is not effective and NSAIDs are out of the picture due to renal insufficiency. He did fine with the first dose, just having just an achy arm. I appears that the side effects he experienced are listed as possible but severely exacerbated in my husband. No signs of anaphylaxis.",,Unknown,0,1
891848,"No further AE; temperature excursion involving multiple lot numbers for GARDASIL 9, MMR II, ROTATEQ, and RECOMBIV AX. Many of the vaccines have been administered to patients; This spontaneous report was received from a practice manager and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On 17-SEP-2020, the patient was vaccinated with an improperly stored dose of hepatitis b vaccine (recombinant) (RECOMBIVAX HB), 1 injection, lot # S022584, expiration date: 31-OCT-2021 (injection site and route of administration were not provided) for prophylaxis.  On 04-AUG-2020, the administered dose experienced the temperature excursion of below 2 degrees Celsius (C) (1.1 C) for 27 hours and 45 minutes and above 9 degrees Celsius (9 C) for 1 hour and 15 minutes. The digital data logger was involved in recording the temperature excursion details. No previous temperature excursion had occurred. No further adverse events (AE) were reported.  This is one of multiple reports received from the same reporter. combinationproductreport: Yes; brandname: RECOMBIVAX HB SYRINGE (DEVICE); commondevicename: Hepatitis B Vaccine (Recombinant); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: S022584; expirationdate: 31-OCT-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2010USA001083:Same Reporter",,Unknown,0,1
914821,"Rash, Itching and swelling of left arm.  Progressed to tachycardia in the 150's, hypertension 200/114.  Tingling of lips, dizziness",42.0,Adults,1,0
904572,Migraine  Nausea  Dehydration  Low grade fever  Fatigue,21.0,Adults,1,0
905336,"got the flu shot and got the flu; Initial information received on 09-Dec-2020 regarding an unsolicited valid non-serious case received from a consumer (patient) via social media.  This case involved unknown demographic patient for whom got the flu shot and got the flu (Influenza) was reported, while patient received vaccine INFLUENZA VACCINE.  The patient's medical history, concomitant medication, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient for whom got the flu shot and got the flu (Influenza) was reported, latency 1 week following the administration of INFLUENZA VACCINE.  Relevant laboratory test was not reported.  Final diagnosis was got the flu shot and got the flu.  It was not reported if the patient received a corrective treatment.  The outcome was reported as Unknown for got the flu shot and got the flu.  There would be no information available on batch number for this case.",,Unknown,0,1
889843,"I have had trouble breathing,  wheezing,  headaches, nausea, muscle aches.  None of which I had the day before.  I have had to go on an inhaler the last week as I am not improving.  My breathing was fine prior to the shot and I am getting worse.",62.0,Adults,1,0
908303,"sore arm; lightheaded; This is a spontaneous report from a non-contactable consumer.  A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; Lot number: EK5730), via an unspecified route of administration on 19Dec2020 at a single dose for COVID-19 immunization.  The patient's medical history and concomitant medications were not reported.  The patient experienced sore arm and lightheaded on 19Dec2020.  The outcome of sore arm and lightheaded was recovered in Dec2020.    No follow-up attempts are possible. No further information is expected.",,Unknown,0,1
878036,Patient developed rash/ bumps along her back. She went to an urgent care facility on  8/1 and was diagnosed with shingles. She was given treatment.,57.0,Adults,1,0
885093,"vaccines that were administered to patients after excursion occurred; This spontaneous report was received from a nursing assistant, referring to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions or allergies and concomitant medications were not reported.   On 12-AUG-2020, the patient received a dose of varicella virus vaccine live (oka/merck) (VARIVAX) injection (strength, vaccination scheme, route of administration and anatomical site of vaccination were not reported; lot number T002846, expiration date reported and validated as 23-JAN-2022) for prophylaxis, that experienced a temperature excursion (product storage error). Digital Data logger was involved. The administered dose of the vaccine experienced a temperature and time frame of -10.2 degrees Celsius for 1 hour and 53 minutes. No previous temperature excursion was reported.; Sender's Comments:  US-009507513-2008USA014798: US-009507513-2008USA014950: US-009507513-2008USA014951: US-009507513-2008USA014705: US-009507513-2008USA014803:AE Case # 01697212 US-009507513-2009USA000113: US-009507513-2008USA014888: US-009507513-2008USA014697:",,Unknown,0,1
914261,"Body aches; Feeling unwell; Fever; This is a spontaneous report from a contactable consumer (patient). This consumer reported similar events for two patients (herself and her husband). This is the 1st of 2 reports. A 63-years-old female patient started to receive bnt162b2 (BNT162B2, Manufacturer Pfizer-BioNTech), via an unspecified route of administration, on an unspecified date, at single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced body aches, feeling unwell and fever all on an unspecified date with outcome of unknown.    The information on the lot/batch number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2020518044 Same reporter/event, different patient",,Unknown,0,0
904634,"First, my arm starting hurting  and is still a little sore.  That night, every bone in my body started aching. From the bones in my hands (the knuckles to the bottoms of my feet.   The next morning I got up and took a bath with alcohol, and epson salt.  Afterwhich, I felt much better.  Only my arm still hurts.",67.0,Seniors,0,0
863144,Mother called clinic this morning and report that wear child received DTaP-IPV vaccine she has a large red and swollen bump and has been lethargic since last night. Mother encouraged to see child's pediatrician or emergency clinic if symptoms persist or become worse.Mother stated she has applied a cool compress to area and given child Tylenol.  Mother stated she would take child intro health care provider as soon as possible.,4.0,Kids,0,1
904432,headache and nausea around 2am...throwing up...reso;ved by 2:30am,66.0,Seniors,1,0
862836,"I started feeling extremely weak, to the point I called my husband and told him it wasn't safe for me to drive the rest of the 10 minutes home.  Upon getting home, my husband had to help me to my bed where I passed out immediately and slept for several hours.  It took a few days to feel good again.  I felt like I was hanging onto life by a thread.  I am now too afraid to ever get a flu shot again nor do I want my kids getting a flu shot again.",35.0,Adults,0,1
914863,"fatigue, aching muscles and joints. Lasted 28 hrs.",60.0,Adults,1,0
914005,"Headache; soreness in the injection site; chills; soreness on the right side of neck; swollen lymph nodes on right side of neck; nausea; This is a spontaneous report from a contactable nurse (patient) reported for herself.  A 33-year-old female patient (not pregnant) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number EH9899), via an unspecified route of administration in left arm on 16Dec2020 16:00 at single dose for COVID-19 immunization.  The patient medical history was not reported.  The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not have COVID tested post vaccination and did not have COVID prior vaccination. The patient had no known allergies. Concomitant medication included paracetamol (TYLENOL) and birth control pills, multivitamins taken within 2 weeks of vaccination. The patient experienced headache, soreness in the injection site, chills, soreness on the right side of neck, swollen lymph nodes on right side of neck, nausea all on 17Dec2020 08:00 with outcome of not recovered. The patient did not receive treatment.",33.0,Adults,0,0
870194,"I had all your listed symptoms minus the vomiting / I have a severe reaction to it; I was bedridden for 7 days.; This case was reported by a consumer and described the occurrence of adverse event in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included type i diabetes mellitus (for 46 years).   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than 6 months after receiving Shingrix, the patient experienced adverse event and bedridden. On an unknown date, the outcome of the adverse event was unknown and the outcome of the bedridden was recovered/resolved.   The reporter considered the adverse event and bedridden to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient stated that they took their first shot over a couple of months ago. They had a severe reaction to it. They had all company listed symptoms minus the vomiting. The patient was bedridden for 7 days. The patient was due for shot 2. The patient did not know if they should or not take it. The patient was very apprehensive about it. The patient had a question are their reaction considered an allergic reaction.",,Unknown,0,0
895262,"mild fever, chills. body aches, fatigue, joint soreness. started approx. 12-16 hrs after shot and continued another 24 -36 hrs.",69.0,Seniors,1,0
913215,Runny nose headache lost taste and smell,39.0,Adults,1,0
858434,"Child presented to ER on 1/23/2020 with left arm erythema, swelling and warmth since immunizations day prior. Patient complained of pain, Motrin was given for pain/swelling. Warm compress applied. Ultrasound showed no fluid collection but concerns for cellulitis. Treated with Keflex TID x7 days. Patient is scheduled to come into office for a follow up on 1/31. Patient was followed up on after ER report, parent reported no issues at that time.",5.0,Kids,1,0
879871,"mild or small pustule; the area started as a small white center/on his left thigh; it does itch.; red inflamed tissue on his left thigh; red inflamed tissue / little red spot with a white spot / looked like a bug bite / continued to grow; something bothering him on his back; second dose of Shingrix on 8/6/2020 / diagnosed with shingles / case of shingles; having a chill; he may have had fever; This case was reported by a consumer via call center representative and described the occurrence of chills in a 65-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included heart transplant (heart transplant in February 2016) and shingles (Family History) (the patient's father had shingles). Previously administered products included Zostavax (received on an unknown date in 2015).   On 6th August 2020, the patient received the 2nd dose of Shingrix. On 6th August 2020, less than a day after receiving Shingrix, the patient experienced chills and fever. On 7th August 2020, the patient experienced pustule, skin discoloration, pruritus, shingles, soft tissue inflammation and erythema. In August 2020, the patient experienced back discomfort. The patient was treated with acetylsalicylic acid (Aspirin). On 6th August 2020, the outcome of the chills and fever were recovered/resolved. On an unknown date, the outcome of the pustule, skin discoloration, pruritus, soft tissue inflammation, erythema and back discomfort were unknown and the outcome of the shingles was not recovered/not resolved.   It was unknown if the reporter considered the chills, fever and back discomfort to be related to Shingrix. The reporter considered the pustule, skin discoloration, pruritus, shingles, soft tissue inflammation and erythema to be related to Shingrix.  Additional information was provided as follows: The patient received Shingrix at 8:30 or 9:00 AM, and later that day experienced chill. As per reporter, the patient might had a fever but he could not confirm because he did not take his temperature. The patient took one Aspirin and the incident resolved. On Friday, he noticed a a mild or small pustule, little red spot with a white spot in the middle on his left calf which was surrounded by red inflamed tissue. It was about the size of a dime and looked like a bug bite. Saturday it was the size of a nickel so he went to ER where he was told that it was a side effect of the Shingrix vaccine and that he had a mild case of shingles. He was released and they did not provide any treatment for him because he was a heart transplant patient. The patient says it does not hurt but it does itch. The patient also felt something bothering him on his back but he had not been able to look at it yet. The reporter consented to follow up.",65.0,Adults,0,0
918249,Generalized body urticaria with itching within 30 minutes Treated with steroids and antihistamine None - rash/urticaria still resolving,45.0,Adults,1,0
883900,"an expired diluent was administered with PROQUAD; This spontaneous report was received from a physician referring to a 4 years old patient of unknown gender. Information regarding the patient's concurrent conditions, medical history and historical drugs were not provided.   The reporter indicated that on 24-AUG-2020, the patient was vaccinated with a dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (Dosage regimen and route of administration not provided; lot # S017255 and expiration date: 01-DEC-2020, albumin status: rha) for prophylaxis, which was reconstituted with an expired sterile diluent (MERCK STERILE DILUENT) (lot # S018821 and expiration date 22-AUG-2020). No additional information was provided.",4.0,Kids,0,1
872771,"No patients experienced any adverse effects; Improperly stored dose of ROTATEQ; This spontaneous report was received from a physician concerning a patient of unknown age and gender. No information was provided regarding the patient's pertinent medical history, concomitant medications, or drug reactions/allergies.     On 08-MAY-2020, the patient was vaccinated with an improperly stored dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) vial (product storage error), by oral route (lot # 1660693, has been verified to be a valid lot number; expiration date 19-MAR-2021) as prophylaxis (dosage schedule and strength were not reported).   The administered dose of the vaccine experienced a multiple temperature excursions below highest temperature above 47 Fahrenheit degrees  to 66.6 Fahrenheit degrees for 2 hours and lowest temperature below 36 Fahrenheit degrees to 33.6 Fahrenheit degrees  for 45 minutes as recorded by a data logger. There was no previous temperature excursion. There was no adverse effect reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2006USA001703:",,Unknown,0,1
883292,"Pt was given injection in Left thigh with no complications.  She was speaking and walking.  Sitting in chair, Pt father said her name as nurse turned to look, observed pt slumped over to left side not responding, eyes rolled back in head.  Father stated ""I saw her going and grabbed her.""  Pt did not sustain head injury.  Nurse lowered pt to floor, she had lolli pop in her mouth jaw was clenched, body ridged, upper body shaking.  Her jaw relaxed, body still ridged, lolli pop was removed from mouth and pt was placed in rescue position on left side with nurse at head.  Blood pressure was obtained 50/36 pulse of 98  blood sugar was 77.  This activity lasted approx. 30-45 seconds.  Pt body began to loosen up, eyes opened, not responsive to commands.  After approx. 5 min pt began to recognize father.  911 was activated.  After approx. 12 min pt started to respond to name, and person.  She was able to answer simple questions.  blood pressure 70/50.  Pt was sat up on floor with nurse, given water and color began to return.  EMS arrived pt was transported via ambulance with father.",6.0,Kids,0,0
869115,"PRESENTING WITH A FEVER.  HAD SHINGRIX IMMUNIZATION ON Friday./  ARM SWELLING, ERYTHEMA, PAIN, TENDERNESS.  HAD SYSTEMIC SYMPTOMS OF FEVERS, FATIGUE, DIZZINESS, AND MALAISE.   NO COUGH, CHANGE IN BOWEL OR BLADDER HABITS. NO HEADACHE.",62.0,Adults,1,0
858053,Severe Pain in left arm beginning the night of the vaccine and continuing 2 days.  I could not move my arm. After 2 days I could move the arm slowly to pull a shirt over my head but still could not sleep on that arm. After 2 weeks the pain remains at a reduced severity .If I use the arm for lifting or sleep on it the pain intensifies.,65.0,Adults,0,0
877436,"Patient received the above vaccines on 7-20-20 along with a PPD skin test. Was fine until 7-26 when Lt upper arm became red, inflamed, waRm, sore. 4 x 4 1/2"" inch area induration. Had been outside in the heat most of the previous day. Some confusion about which arm had Bexsero - pt says Left, Nurse charted Right",18.0,Adults,0,1
897194,"The shipment of vaccine was received outside 72 hour guideline and was potentially compromised, no AE; The shipment of vaccine was received outside 72 hour guideline and was potentially compromised, no AE; Initial information regarding an unsolicited valid non-serious case was received from a other health professional via The Agency (Reference number- 00303291) and transmitted to Sanofi on 06-Oct-2020.  This case is linked to cases 2020SA310350, 2020SA310351, 2020SA310352, 2020SA310353, 2020SA310335, 2020SA310460, 2020SA310461, 2020SA310462, 2020SA310463, 2020SA310354, 2020SA310555, 2020SA310556, 2020SA310557, 2020SA310558, 2020SA310464, 2020SA310559, 2020SA310705, 2020SA310706, 2020SA310707, 2020SA310708 and 2020SA277871 (same reporter)  This case involves a patient (demographics unknown) who was administered a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] (lot UJ505AA, expiry date: 30-Jun-2021) via unknown route in unknown administration site for prophylactic vaccination on 06-Oct-2020, whose shipment was received outside the 72 hour guideline and was potentially compromised (product storage error and product distribution issue)  It was a case of an actual medication error due to incorrect product storage.  It was also a case of product shipment delay.  The shipment of vaccines was received outside the 72 hour guideline for standard shipping. It was received in 76 hours. The practice was advised not to use any remaining stock as new stock will be replenished and to return the remaining stock. It was also advised to re-vaccinate the patients who had received a dose of the potentially compromised product.  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error",,Unknown,0,1
912788,"Pt presented to receive 1st dose of Pfizer COVID Vaccine, which she received at 1130. She emailed hospital leadership to describe a reaction which is as follows: I feel the need to inform you about a likely reaction I had to the COVID vaccine I received yesterday around 11:30 am. I was feeling fine after the immunization, drove home and took some Tylenol in case of any arm pain (of which I have had none). I ate some lunch, was on the phone talking with a friend and developed sudden onset of lightheadedness, slurred speech and extreme sleepiness. No other focal deficit.  I actually got up and walked around to try to shake it off.  But I suddenly felt so tired that I could not keep my eyes open.  I called my husband and asked him to come home immediately. I laid down and tried to reassure my kids that I was fine.  I don't remember much thereafter.  Just bits and pieces.   It felt like I was under general anesthesia, trying to wake up but not able to open my eyes or move my arms/legs.  I could hear some things going on but could not talk.  There were times I would ""wake  up"" in my mind and I would check to make sure I could swallow and I was breathing ok.  I remember mumbling to my husband that I could breathe.  He says he was checking my vitals throughout this time and monitoring things.  He said my Blood pressure was initially 80/60, pulse 50,  and as he keep checking it gradually improved.    This lasted about 2 hours and then finally I was able to wake up.  I felt a little lightheaded and tired for the rest of the day,  but I feel essentially normal today.    Please note: age not provided in internal system report; unsure of person's age",,Unknown,0,0
890939,"Parent states that child began to develop a pustule/papular rash on the left side of his face about 3 hours after receiving his vaccines. He does complain of slight itching but denies any other symptoms. he does have a few papules on his neck today, as well.",11.0,Kids,0,0
914805,RESIDENT CODED AND EXPIRED,63.0,Adults,0,0
874133,Patient complained of difficulty swallowing and shortness of breath. Sent to ER from home. ER doctor notes fine red rash over trunk/arms. No Airway issues. Pt. Given Benadryl & monitored.,14.0,Kids,1,0
886940,"Sore arm; This case was reported by a other health professional via call center representative and described the occurrence of pain in arm in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 28th August 2020, the patient received the 1st dose of Shingrix. On an unknown date, less than a month after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovering/resolving.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional information was provided as follows: The patient experienced sore arm after receiving 1st dose of Shingrix. The reporter consented to follow up. This case is 1 of the 4 linked cases, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020189737:same reporter US-GLAXOSMITHKLINE-US2020189738:same reporter US-GLAXOSMITHKLINE-US2020189741:same reporter",60.0,Adults,1,0
857963,"a dose of improperly stored PROQUAD was administered to a patient; This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender. No information was provided regarding the patient's medical history, concurrent conditions, concomitant medications, drug reactions and allergies.  On 15-JAN-2020, a dose of improperly stored measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) 0.5 milliliter, with lot # S013712 and expiration date on 01-NOV-2020, for prophylaxis (dose number, route of administration and anatomical injection site were not reported) was administered to the patient. The sterile diluent used to reconstitute the vaccine was properly stored.  It was reported that on an unknown date, the vaccines were exposed to a temperature excursion below 12.2 Celsius (C) degrees for 25 minutes. There were no previous temperature excursions. The call was placed because of a Digital Data logger report.",,Unknown,0,1
864511,"Patient reports having 6 ""chicken pox"" blisters appearing 2 weeks after receiving the SHINGRIX vaccine. She said they scabbed over the next day and healed.",73.0,Seniors,0,1
866459,"a pregnant patient got VARIVAX within one month of conceiving; Information has been received from a physician referring to a female patient of unknown age. The patient's concomitant medication, pertinent medical history and drug reactions/allergies were not reported. The patient was pregnant.  On an unknown date, the patient received varicella virus vaccine live (oka/merck) (VARIVAX) (strength, dose detail, route, lot # and expiration date were not reported) within one month of conceiving for prophylaxis (exposure during pregnancy).   The last menstrual period (LMP) and the estimated date of delivery (EDD) were unknown. The pregnancy outcome was pending. The fetal outcome was unknown.",,Unknown,0,1
909318,"12/18/2020 I HAD A LOT OF BODY, MUSCLE AND JOINT PAIN. THIS LASTED ALL DAY 9:00 AM - 9PM. I WENT HOME AT 5 AND WENT TO SLEEP FOR 90 MINUTES. SYMPTOMS WERE MILDER. I STARTED TO NOTICE L UNDER ARM PAIN, INTENSIFIED OVER THE WEEKEND.  12/21/2020 CONTACTED PCP; LYMPHNODES SWELLING. PAIN LASTED UNTIL  12/22/2020, LATER EVENING THRU 12/23/2020 12/25-/12/26 NO  PAIN TELECHAT WITH PCP NOT VISIT; DR PRESCRIBED TYLENOL",47.0,Adults,0,0
878239,"Shot given approximately 10 AM, later in day while at  park & about in car seat 4 hrs later mother  noted lower legs to look bright red + now 5 hrs  after shots (L) leg clear but (R) lower leg with purplish  macular rash with few petechiae on lower leg.",0.17,Kids,1,0
914806,"Flushing, tachycardia, received IM Benadryl 25 mg and oral hydration, monitored and recovered",44.0,Adults,0,0
911098,"WITH BURNING AT SITE OF INJECTION. WITH NAUSEA AND LIGHT HEADEDNESS, STOMACH ACHE.",23.0,Adults,1,0
908316,"rash on his chest; metallic taste in mouth; light headness; shortness of breath; Initial information regarding an unsolicited valid non-serious case was received from a Consumer or non-health care professional (Patient) via Medical Information (Reference number- 00394250) on 15-Dec-2020.  This case involves a 67 years old male patient who experienced metallic taste in mouth (taste disorder), light headness (dizziness), shortness of breath (dyspnoea) and rash on his chest (rash), while he received INFLUENZA VACCINE.  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.   On 24-Sep-2020, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) [lot number not and expiry date reported] via an unknown route at an unknown administration site for prophylactic vaccination.  On 24-Sep-2020, the patient developed a non-serious metallic taste in mouth (taste disorder) 10 minutes following the administration of INFLUENZA VACCINE.  On 24-Sep-2020, the patient developed a non-serious light headness (dizziness) and shortness of breath (dyspnoea) several hours following the administration of INFLUENZA VACCINE.  It was reported that, patient went for a run later that evening and he felt better.  Before went to bed symptoms stopped.  On an unknown date, the patient developed a non-serious rash on his chest (rash) unknown latency following the administration of INFLUENZA VACCINE.  Patient was feeling fine. Rash lasted less than two days.  Details of laboratory data not reported.   It was not reported if the patient received any corrective treatment.  On an unknown date, the patient was recovered from events.  There will be no information available on the batch number for this case.",67.0,Seniors,0,0
895286,"Patient reports arthritis pain in both wrists.  No report of an associated rash.  The right wrist pain persisted for 2 to 3 weeks prior to resolving, and the left wrist pain is still persistent.  Instructed patient that this is a known ADR for up to 30 days post vaccination, and he should follow up with his doctor.",69.0,Seniors,1,0
915204,"Dizziness, feels like head is spinning BP 107/66 Pulse 88 Blood sugar 159  Onset of symptoms was 2 hours post vaccine administration.",70.0,Seniors,0,0
891989,"The weekend after receiving vaccinations, patient felt a stiffness in her neck that traveled down her spine to her lower back. Today October 22, 2020, the patient still experiencing the stiffness in her lower back along with a cluster of blisters.",61.0,Adults,0,0
900438,"Severe hives on toro, back and arms",66.0,Seniors,0,0
913285,"severe nausea and headache started about 1 minute after injection and is continuing today, I know as a nurse myself, it is just a side effect and not a problem, just wanted to report it for your statistic reports",50.0,Adults,1,0
872315,"No additional adverse events; on 5/28/2020 a 2 month old patient was administered a properly stored but expired ROTATEQ; This spontaneous report was received from a medical assistant and refers to a 2-month-old male patient. No information regarding the patient's concurrent conditions, medical history, drug reactions or allergies and concomitant medications was provided.  On 28-MAY-2020, the patient was vaccinated with properly stored but expired rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # R022221, expiration date 23-MAY-2020 (exact dose, dose number, dose site and route of administration were not provided) for prophylaxis. No additional adverse events were reported.",0.17,Kids,0,1
855633,Gradual loss of eyesight from 08/21/2019 to 09/02/2019      Total loss of eyesight on 09/03/2019     Many tests and doctors Hospitalization for 5 days with 1000 units of IV steroids      Continued steroids for weeks     Gradual improvement over 6 months-not 100%    Some permanent damage to Optic nerve,59.0,Adults,0,0
890190,"I told nurse I am allergic to neomycin. She said i would get preservative-free version. 11 days after the shot, i woke up unable to lift my arm higher than a few inches. Gives me a painful twinge when I try to use/lift my arm. This has happened to me before. When I reported it, I learned that my neomycin allergy was worth noting next time. Which I did.",63.0,Adults,1,0
869564,"syncope and collapse. started feeling faint and collapsed while sitting in car with dad. episode lasted 20-30min and she was in and out of consciousness during that time per dad. She was very pale at the time, eyes deviated back. no tonic clonic features. + emesis and dry heaving for 15-20min following the event. when she came to her underwear was wet, believe she may have lost continence of urine. no stool incontinence. Marked fatigue following the event. She did have WCC and vaccines earlier that day, Tdap, MCV, HPV. Hx of vasovagal responses to pain in the past, usually immediately following pain. did have emesis in response to pain from a bee sting in the past. No prior Hx of incontinence of urine.",11.0,Kids,0,0
899270,"received an extra dose of Fluzone Quadravalent, with no adverse event; Initial information regarding an unsolicited valid non-serious case was received from an other health care professional (Reference number- 00356778) and transmitted to Sanofi on 12-Nov-2020.  This case involves a 4-year-old male patient who received an extra dose of influenza quadrival a-b vaccine [Fluzone Qiv], with no adverse event (extra dose administered).  Medical history, concurrent conditions, vaccination(s) and family history were not provided. Concomitant medication was unknown.  On 12-Nov-2020, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE 0.5 mL (lot number: UT7065LA) via an unknown route as prophylactic vaccination.  On an unknown date, received an extra dose of Fluzone Quadravalent, with no adverse event.  It was not reported if the patient received a corrective treatment.  The event outcome was reported as not applicable for extra dose administered.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",4.0,Kids,0,1
875190,"Pt reported flu like symptoms, fever, no vomiting, full body aches, loss of appetite.",62.0,Adults,1,0
911680,1mL was given instead of 0.5mL,61.0,Adults,0,0
892053,Swelling + bleeding at time of injection consistent with hematoma x 4cm (L) deltoid. Txt with antbx prophylactically,37.0,Adults,0,0
911614,"Pfizer-BioNTech COVID-19 Vaccine  Soreness at injection site, generalized body aches and malaise, headache/neck ache, low grade fever (99.3), mild chills.",28.0,Adults,0,0
864906,"1.) WITHIN FIRST 2-3 HOURS POST INJECTION-HOT, SWOLLEN, INCREASED TENDERNESS (L) DETOID RASH 2.) @ 26 HOURS POST INJECTION - HIVES/RASH-BILATERAL UPPER EXTREMITY PROGRESSION TO CHEST, TORSO, BACK, POPLITEAL & NECK, FACE SCALP",66.0,Seniors,1,0
904171,Tingling injection side arm and face rash,54.0,Adults,1,0
900505,"arm was a little sore; Initial information received on 17-Oct-2020 regarding an unsolicited valid non-serious case from a consumer (patient) via social media.  This case is linked to case ID: 2020SA294179, 2020SA294195, 2020SA294181, 2020SA294133, 2020SA294183, 2020SA294184, 2020SA294185, 2020SA294186, 2020SA294187, 2020SA294188, 2020SA294189, 2020SA294190, 2020SA294191, 2020SA294192, 2020SA294193, 2020SA294194,  2020SA294182.  This case involves a female patient (unknown demography) with an unknown age who reported that her arm was a little sore (pain in extremity), while she received vaccine Influenza Vaccine.  Medical history, past medical treatment(s), concomitant therapy, vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, patient stated that her arm was a little sore (pain in extremity) (Unknown latency) following the administration of Influenza Vaccine. Reporter stated that she and her husband for flu shot and didn't hurt.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event was unknown.   There will be no information available on batch number for this case.",,Unknown,0,0
886726,"I got a large blood clot on the backside of my arm across from injection site.  My arm hurt within the hour of shot given and got worse over the next 2 days. I did ""chat with a doctor"" and sent him pictures. He had me take Benadryl thinking it was an allergy Weds. 9/23/2020, by that evening I could not even lift my arm. It was double in size and there was a tennis ball sized lump. I went to the ER and got a ultrasound to find I had a blood clot. I have been on enoxaparin shots and just started Pradaxa yesterday. The lump in my arm is now little marbles.",58.0,Adults,0,0
879221,"shingles; Information has been received from a lawyer and a patient of unknown age and gender regarding a case in litigation. Information about concurrent condition, medical history and concomitant medication was not reported. On or about 31-MAY-2017, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (strength, dose, lot# and route unknown) for the long-term prevention of shingles and zoster-related conditions. Subsequent to the inoculation (date not reported), the patient was treated by a physician for shingles. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient has and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of the event shingles was not recovered. The causality assessment was considered as related by the lawyer.",,Unknown,0,0
911767,"Patient felt lightheaded, flushed and nauseous.",26.0,Adults,0,0
883777,"-patients arm (upper) is swollen, red & feels heavy & in pain -stomach was upset -I had our clinic nurse  practitioner look at it - she said rest  & take ibuprofen",69.0,Seniors,1,0
889484,"lymphoma; Patient receieved it twice, on 10Jan2020 and other dose 28Sep2020 within 8 months; This is a spontaneous report from a Pfizer-sponsored program, IBCC (Inbound Call Center for HCPs). A contactable healthcare professional reported that a patient of unspecified age and gender received pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) (PREVNAR 13, lot number and expiration date unknown), a single dose on 10Jan2020, and another single dose on 28Sep2020, both via an unspecified route of administration for immunization. The patient's medical history and concomitant medications were not reported. It was reported that the patient received pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) twice, on 10Jan2020 and other dose 28Sep2020 within 8 months. The patient has lymphoma on an unspecified date but wasn't supposed to get it this close. The patient does not have symptoms. The reporter asked for any consequences. The outcome of the events was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: The association between the event lymphoma with PREVNAR 13 can not be fully excluded based on the limited information.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.",,Unknown,0,1
868187,"Patient received the vaccine in the morning. Later in the evening, I was holding her, and she flung herself backwards into a seizure. Her body stiffened, head nodding, and she was non-responsive. I took her to the emergency room after she came back to herself. The doctors checked her, and said it's possible she had a seizure, but said the only way to verify it was for sure a seizure was to do a brain scan, which they do not recommend in babies after only one seizure following a vaccine.",0.42,Kids,0,1
913306,"Soreness at injection site for 2 days. On the third day, I awoke with muscle tightness, abdominal cramping, severe headache, diarrhea, lymphadenopathy, and cough. Sunday I took my temperature and it was slightly elevated at 99 with a baseline of 97.6. Fever and headache broke on Monday, other symptoms still persisting with diarrhea improving.",39.0,Adults,1,0
899573,"Patient had HPV vaccination on 6/4/2014 had a seizure in the doctor's office. She has been hospitalized 4th times since stated by mother and has exp 9 seizures. The reporter provided the name of all tx'g facilities 1st Hospital, 2nd&3rd Hospital, 4th Hospital. Just recently in 2020 she was hospitalized in April and in October. Since being hospitalized patient has been diagnosed with epilepsy. She is currently seeing Dr. (Neurology).",12.0,Kids,0,0
873776,"received a dose of ROTATEQ following temperature excursions; no other adverse effects; This spontaneous report has been received from a nurse referring to a patient of unknown age and gender. No concurrent condition, medical history or concomitant therapy was reported.   On an unknown date, the patient was vaccinated with a 2 ml dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (lot # R033256 with expiration date of 23-JUN-2020; strength and route were not reported) following temperature excursions (product storage error), for prophylaxis. The vaccines were exposed to the highest temperature of above 47 degrees Fahrenheit (F)/ 9 degrees Celsius (C) (8.5 C) for 30 minutes. Previous temperature excursion included highest temperature above 47 F/9C (12.1 C) for 42 hours, above 47 F/9C (8.5 C) for 1 hour and above 47 F/9C (8.7 C) for 30 minutes. A data logger was involved. No other adverse effects were reported.",,Unknown,0,1
863137,Erythema and swelling to left upper arm. Started 2/25/20. Pain started at 5:00pm on 2/24/20.,65.0,Adults,1,0
896661,Sore and painful left shoulder. Weakness in entire left arm and hand. Unable to use full motion of shoulder and arm. Pain 24/7.,67.0,Seniors,1,0
880566,"Patient got the seasonal flu shot on 08/21/20 around 2:39 P.M . She called around 6:30 P.M and said she felt her arm was weakness,pain, and tingle sensation, and a little swollen comparing to other arm. Pharmacist recommended that she could take Ibuprofen and applied ice at the injection site. Pharmacist said will call patient back on Monday to check on her. Called patient today at 8:20 P.M. Patient said she is feeling much better and back almost to normal.",24.0,Adults,0,0
883838,"Labored breathing, temp fluctuating from 97-101, nauseous, awful joint pain everywhere, headache, conjunctivitis, throat sore, nodules in throat enormous...I?ve never ever ever had any adverse reactions to the annual flu shot.",60.0,Adults,0,0
868589,"WILL NOT BE  ABLE TO COMPLETE COURSE BEFORE TRAVEL; TOOK UNREFRIGERATED VIVOTIF; This spontaneous case (PVX2019-1517) was received from a consumer on 11-Jun-2019. It describes a 25-year-old adult male consumer who ""took unrefrigerated Vivotif"" and ""will not be able to complete course before travel"". He was receiving oral Vivotif (one capsule every other day) (lot no: 3003272) for typhoid prophylaxis.   Case report: The consumer left Vivotif doses outside the refrigerator, then after 6 to 7 hour, he took the first dose on 07-Jun-2019, which was good to use but then he took the second dose on 09-Jun-2019, which was unrefrigerated for 30 hours at 75 degree Fahrenheit. Also, he had a planned trip for one month on 16-Jun-2019.  Action taken with Vivotif was not applicable.  The clinical outcome of the events was unknown.  Company's Comment: The causality of the event ""took unrefrigerated Vivotif"" and ""will not be able to complete course before travel"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took unrefrigerated Vivotif"" and ""will not be able to complete course before travel"" was considered as not applicable.",,Unknown,0,0
891127,"No further AE; temperature excursion; This spontaneous report was received from a practice manager and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On 29-SEP-2020, the patient was vaccinated with an improperly stored dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 1 injection, lot # 1621931, expiration date: 26-JAN-2022 (injection site and route of administration were not provided) for prophylaxis.  On 04-AUG-2020, the administered dose experienced the temperature excursions of below 2 degrees Celsius (C) (1.1 C) for 27 hours and 45 minutes and above 9 degrees Celsius (9 C) for 1 hour and 15 minutes. The digital data logger was involved. No previous temperature excursion had occurred. No further adverse events (AE) were reported.  This is one of multiple reports received from the same reporter. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. devicelotnumber: 1621931; expirationdate: 26-JAN-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other;  followupadditionalinfo :Yes; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2010USA001083:Same Reporter",,Unknown,0,1
912059,"Hypotensive (diastolic 43, sistolic 103); neurological tingling -upper spine/between shoulder blades; felt crummy; This is a spontaneous report from a contactable consumer. A female patient of an unspecified age received 1st dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration in left arm on 21Dec2020 15:45 at single dose for Covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced hypotensive (diastolic 43,sistolic 103), neurological tingling - upper spine/between shoulder blades and generally felt crummy on 21Dec2020 at 15:45 (also reported as occurred within 5 minutes of shot). The patient underwent lab tests and procedures which included blood pressure measurement: 103/43 on 21Dec2020. Event resulted in emergency room and physician's room visit. Treatment received intravenous (IV) fluid replacement, lab tests (unspecified), 6 hour observation. The outcome of events was unknown.  Information on the lot/batch number has been requested.",,Unknown,0,1
899506,Redness and discomfort to site,56.0,Adults,0,0
910702,"Developed itching and redness to bilateral arms and face approximately 20 minutes after vx admin.  Admin Benadryl 25mg po x 1 per S.O.  1400-itching nearly resolved, redness decreased.",32.0,Adults,0,0
895546,"The day after the vaccine was administered, the patient experienced high fever (103 degrees), body aches, tiredness, and heart rate over 90 bpm.",51.0,Adults,0,0
880590,"No additional adverse events reported.; patient received VARIVAX on 8/13/2020 using a short needle (exact size unknown at time of call) on the  top of thigh.  Due to the location this is being reported as possibly administered into the muscle; possibly administered in to the muscle/it might have hit muscle; Information has been received from a registered nurse, referring to an 18 months old male patient. The patient's medical history, concurrent condition and concomitant medication was not provided.     On 13-AUG-2020, the patient received varicella virus vaccine live (oka/merck) (VARIVAX) (strength, dose, lot # and expiration date were unknown) using a short needle (exact size unknown at time of call) on the top of thigh. Due to the location this was being reported as possibly administered into the muscle (incorrect route of product administration). The reporter reported they used a subcutaneous size needle and the baby was described as ""chubby"" but since location was closer to hip, concerned it might have hit muscle (circumstance or information capable of leading to medication error). No additional adverse events were reported.",1.5,Kids,0,1
914719,Woke up this morning with a slight raspy voice and minor chest tightness. Tested positive for COVID-19.,41.0,Adults,0,0
890741,"Two days post injection of vaccine, it was noted that an area below ideal injection site was warm, red and painful to the touch. On-call provider looked at and diagnosed with cellulites. She was started on IV antibiotic Vancomycin (three doses).  Incident report started as location of the injection was in question. Per nurse who administered it, she went four finger widths below shoulder joint, and injected with one inch needle.   Location most likely not into the Deltoid, but subcutaneously due to patient arm size and placement.",51.0,Adults,0,0
886568,"Patient stated that she had excessive sneezing since the vaccination. Warm at site of vaccine. 3 inch diameter of hardness and redness around site of vaccination. Experienced dry, itchy eyes. No fever, runny nose or cough. 3 days later, redness was subsiding.",70.0,Seniors,0,0
864592,"shingles; This spontaneous report has been received from a lawyer, regarding a case in litigation and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant medications were not reported. On an unknown date in 2008, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (dose, anatomical location, route of administration, lot # and expiry date were not provided), as prescribed and/or administered by the healthcare provider at physician's office for the long-term prevention of shingles and/or zoster-related conditions. Subsequent to patient's zoster vaccine live (ZOSTAVAX) inoculation, the patient was treated by the healthcare provider for shingles. As a direct and proximate result of the patient's use of the zoster vaccine live (ZOSTAVAX) vaccine, the patient has and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of shingles was considered to be not recovered. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).",,Unknown,0,0
904352,"After 3-5 minutes after injection felt anxious, shaky, lightheaded and stated he ""felt off"". Patient in chair and notified observation staff who notified POD manager RN. Patient stated he had not eaten today, given water, peanut free snack and room temperature made cooler. At 1535, patient states all symptoms are resolved.",46.0,Adults,0,0
857969,"improperly stored dose of proquad; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's concurrent condition, medical history and concomitant therapy details were not reported.       On 23-DEC-2019, the patient was vaccinated with improperly stored measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) at a dose of 0.5 milliliter, lot # s013712, expiry date 01-NOV-2020, via unknown route for prophylaxis (product storage error). The vaccine was reconstituted with well stored sterile diluent. The vaccine was exposed to a temperature of -12.2 degree Celsius at a time frame of 25 minutes. No previous temperature excursion was reported. The call was due to digital data logger. No additional information was reported.",,Unknown,0,1
912623,"I'm not sure if it was the vaccine, I'm a chaplain at the hospital I didn't eat or drink anything before the vaccine. I had a trauma that day and after the shot my arm was tingling when I was driving home I couldn't focus I had a headache, when I got home I ate and immediately went to bed, I slept for 10 hours and the next day I was getting my son ready and I fell asleep sitting up and by lunch time I felt completely normal again.",35.0,Adults,0,0
899677,"No additional adverse events reported; dose of PROQUAD was administered to a patient on 11/18/2020 that had been involved in a temperature excursion; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's medical history, historical drugs, concurrent conditions and concomitant medications were not provided.       On 18-NOV-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA)(PROQUAD), 0.5 milliliter, lot number T015261, expiration date 31-OCT-2021 (route of administration was not provided) for prophylaxis. Sterile diluent(STERILE DILUENT) was used to reconstitute the vaccine. No additional adverse were reported.; Sender's Comments:  US-009507513-2011USA014866:",,Unknown,0,1
894317,"red, itchy area of little red bumps around 3 inches in size; red bumps around 3 inches in size near injection site; local injection site reaction that is slightly sore; red, itchy red bumps around 3 inches in size at injection site near injection site; Initial information received on 29-Sep-2020 regarding an unsolicited valid non-serious case received from a consumer.  This case involves a 54 years old female patient who experienced red, itchy area of little red bumps around 3 inches in size (pruritus), (rash erythematous), (vaccination site reaction) and local injection site reaction that is slightly sore (vaccination site pain), while she received vaccine INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED.  Patient once had an Ear infection and treated with an oral steroid. The patient's vaccination(s) included influenza vaccine for prophylactic vaccination. The patient's medical treatment(s) and family history were not provided.  Concomitant medications included DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL N).  On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED (lot number and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious red, itchy area of little red bumps around 3 inches in size (pruritus), (rash erythematous), (vaccination site reaction) and local injection site reaction that is slightly sore (vaccination site pain) around two hours following the administration of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED.  Details of laboratory data were not reported.  Patient used topical steroid.  At the time of reporting, outcome of the events were unknown.  There will be no information available on batch number for this case.",54.0,Adults,0,0
868674,"hurt when the injection was given; Patient was administered with the dose of expired vaccine; Initial information was received on 17-Apr-2020 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 45 years old male patient who experienced hurt when the injection was given (Vaccination site pain), while he received expired vaccine RABIES (HDC) VACCINE [IMOVAX RABIES] (expired product administered).  Medical history, past medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included JAPANESE ENCEPHALITIS VACCINE INACT (IXIARO) for immunisation.  On 16-Apr-2020, the patient received a 1 mL booster dose of suspect RABIES (HDC) VACCINE (lot N1L132M and expiry date 14-Nov-2019) via unknown route in the right deltoid for prophylactic vaccination  (pre-exposure prophylaxis).  On 16-Apr-2020, the patient developed a non-serious hurt when the injection was given (vaccination site pain) on same day following the administration of RABIES (HDC) VACCINE.  It was also an actual medication error case due to expired vaccine used. The response was injection of an expired or poorly stored vaccine.  No laboratory data was reported.  Final diagnosis was vaccination site pain.   It was not reported if the patient received a corrective treatment.  The outcome was unknown for the event of  vaccination site pain.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error",45.0,Adults,0,0
891836,"No other AE reported; temperature excursion; This spontaneous report was received from a medical assistant and refers to a 11-day-old male patient. There was no information about the patient's concurrent conditions, allergies, drug reactions, concomitant therapies or medical history provided. On 28-SEP-2020, the patient was vaccinated with improperly stored hepatitis b vaccine (recombinant) (RECOMBIVAX HB) via intramuscular route of administration (lot# reported as R028259 which was verified to be non valid with expiration date 20-JUN-2021 lot was also reported as #R028529 verified to be valid, expiration date: 09-JUN-2021) (exact dose, dose number, route of administration and anatomical location were not reported) for prophylaxis. Other suspect therapies included improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) via oral route of administration (lot# 1660989 was confirmed to be valid, expiration date was reported as 20-JUN-2021 and 15-MAY-2021, but upon internal validation was established as 15-APR-2021) (exact dose, dose number, anatomical location were not reported) for prophylaxis. The temperature to which the vaccines were exposed was from 43.4 (low temperature, degrees not reported) to 60.4 (high temperature) degrees of Fahrenheit (F) and the time frame was reported as 665.83 hours (first date when the product was out of proper storage range was reported as 01-AUG-2020, but noone did not know about it until the reporting time). No previous temperature excursion was reported. A digital data logger was involved. No adverse symptoms were reported.",,Unknown,0,1
860040,"Worsening left shoulder pain and decreasing range of motion in the 14 days after vaccination with influenza and HPV without signs of cellulitis, no bursitis appreciated. Possible tendon injury or possible frozen shoulder. Will be taking nonsteroidal anti-inflammatory medication and doing home physical therapy exercises. Will follow-up to assess improvement or need for further work-up/referral.",31.0,Adults,1,0
899107,"sick /soo sick.; Initial information was received on 16-Oct-2020 regarding an unsolicited valid non-serious case from a consumer/non-health care professional via social media.  This case is linked to cases 2020SA293971, 2020SA293986, 2020SA293987, 2020SA293985 and 2020SA293971.  This case involves a patient (age and gender unspecified) who was sick /soo sick. (Illness), when received vaccine INFLUENZA VACCINE.  Medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.   In 2016, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient was sick /soo sick. (Illness), (unknown latency, non-serious event) following the administration of INFLUENZA VACCINE..   No laboratory data was provided.   It was not reported if the patient received a corrective treatment.  At the time of report, the outcome of event was unknown.  There will be no information available on the batch number for this case.",,Unknown,0,1
883550,"strained muscle; shingles hurts/pain/in pain; little bumps; little bumps that look like heat rash; little bumps that look like heat rash and discolored.; can't sleep; received the second dose of Shingrix in the summer 2018 / last Thursday, 9/3/2020 he was diagnosed with shingles/ Suspected vacination failure; shingles/shingles again; This case was reported by a consumer via call center representative and described the occurrence of suspected  vaccination failure in a 66-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (experienced shingles in 2013, for 5 to 6 months with nerve pain) and nerve pain. Previously administered products included Zostavax.   On an unknown date, the patient received the 1st dose of Shingrix and the 2nd dose of Shingrix. In August 2020, unknown after receiving Shingrix and less than 2 years after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the patient experienced muscle strain, pain, swelling, heat rash, skin discoloration and sleeplessness. On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles, muscle strain, pain, swelling, heat rash, skin discoloration and sleeplessness were recovering/resolving.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix. It was unknown if the reporter considered the muscle strain, pain, swelling, heat rash, skin discoloration and sleeplessness to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient reported that he received the second dose of Shingrix in the summer 2018, in left arm.  He thought that he had a strained muscle on his side from playing golf so he saw his physician on 3rd September 2020.  The patient was diagnosed with shingles which started 8 days ago on his right side. He reported that the shingles hurts a lot with a few little bumps that look like heat rash and were discolored. The patient could not sleep at night and the area affected was from his right side going from his sternum under his right breast along his side and spine and back. He claimed that it was around his torso. In 2013, patient had a horrible case of shingles for 5 to 6 months with nerve pain on his left side. The patient reported that he did get the Zostavax vaccine after his shingles experience in 2013. This shingles experienced was not as bad as his first case of shingles. He believed that he received the Shingrix in his left arm and his condition was improving a little from last week and his pain has lessened 20 percent at the time of reporting. The patient stated that he was just frustrated. The reporter consented to follow up. This case was considered as suspected vaccination failure as details regarding vaccination schedule, time to onset for target disease and laboratory confirmation were unknown at the time of reporting.",,Unknown,0,0
890072,"Ataxia, Dizziness, Diplopia.  Diagnosed with ADEM.  Currently recovering on steroids, pending neuroimmunology evaluation",4.0,Kids,1,0
818937,"ITCHING; FULL BODY HIVES; This spontaneous case report (818937-1) was extracted through VAERS database on 27-Sep-2019. The case was reported by a consumer via health authority. The report describes a 24-year-old female consumer who experienced full body hives (PT: Urticaria) and itching on legs and head (PT: Pruritus), after administration of oral Vivotif (lot number: 3003183) for an unknown indication.  Case report: The consumer took the first dose of Vivotif either on 09-Aug-2017 or 10-Aug-2017, after getting the yellow fever vaccine on an unknown date. On 15-Aug-2017, she took the fourth dose of Vivotif and experienced itching on her legs and head. She took Benadryl (diphenhydramine) for treatment which helped, but the hives just moved to a different location such as on stomach and legs. Thus, she took another dose of Benadryl in the next morning. She was prescribed steroids and allergy medication to control it. All the hives went away slowly after 1.5 weeks.  Concomitant medications included yellow fever vaccine (injection).  Action taken with Vivotif with respect to reported events was not applicable.  The consumer had recovered from the reported events.  Company's Comment: In this case, it was reported that the consumer experienced full body hives and itching on legs and head after intake of 4th dose Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Hence, the causality of the events with Vivotif is assessed as possible. Also, itching and hives are labelled as per CCDS.; Sender's Comments: Company's Comment: In this case, it was reported that the consumer experienced full body hives and itching on legs and head after intake of 4th dose Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Hence, the causality of the events with Vivotif is assessed as possible. Also, itching and hives are labelled as per CCDS.",,Unknown,0,0
897407,"she was instructed to continue topical tretinoin cream and also obtain human papillomavirus (HPV) immunization; Literature report: Pediatric Dermatology. 2020.  This literature marketed report has been received from authors of the literature article entitled as stated above. Treatment of verruca plana was often challenging, and multiple treatment modalities, both pharmacologic and destructive, were frequently necessary to clear lesions.  This report referred to a 16-year-old girl presented to the dermatology clinic with a 2-year history of asymptomatic, flesh-colored, flat, polygonal papules of the forehead, temples and upper periorbital skin. She reported fairly rapid onset and gradual growth of papules to current size. She had previously seen another physician and had been misdiagnosed with acne vulgaris. Subsequently, she was prescribed topical 0.1% tretinoin cream, which she had used aggressively prior to dermatology evaluation. On dermatology evaluation, she was diagnosed with verruca plana. After treatment options were discussed, the patient decided to pursue photodynamic therapy (PDT) but wanted to delay her treatment for several months. In the meantime, she was instructed to continue topical tretinoin cream.  On an unknown date, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (dose, strength, route, lot# and expiration date were unknown) for verruca plana (off label use).  When the patient presented for follow-up six weeks later, she reported an approximate 50% improvement in the number of lesions and requested delay of PDT in favor of continuing current treatment. Six weeks after that, her skin had completely cleared. She had still only obtained her first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) immunization but pledged to get the second and third doses.  A copy of the published article is attached as further documentation of the patient's experience.",16.0,Kids,0,1
909001,"Patient complained about difficulty swallowing, and tongue swelling about 12 minutes after receiving vaccine.  50mg Benadryl given and  EMS called. Patient transferred to Hospital.",38.0,Adults,0,1
861128,"Patient was given today another dose of Menactra by mistake / No AE; Initial information was received on 05-Feb-2020 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves an 18 years old female patient who on 11-Jun-2018 received a first dose of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] (lot number not reported via unknown route in an unknown administration site and on 05-Feb-2020 was mistakenly given second 0.5 ml dose of same vaccine (lot U6586BA and expiry date 20-APR-2020) via intramuscular route in the left deltoid for prophylactic vaccination.     The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   It was reported that on 11-Jun-2018 patient got her initial first dose of Menactra when she was 17 years old and on 05-Feb-2020 was given another dose by mistake .   It was an actual medication error case due extra dose administered.  No adverse reaction was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  Information on the batch number was requested for first dose.",17.0,Kids,0,1
908815,Phone call,67.0,Seniors,0,0
897958,"injection site pain; bruising at injection site; injection site redness; severe chills; headaches with the vaccine; high fever of 104.3; This spontaneous report was received from a consumer, regarding herself, a female patient of unknown age. The patient's concomitant medication, pertinent medical history, drug reactions or allergies were reported as unknown.  On 10-NOV-2020, the patient was vaccinated with a single dose shot of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (lot# unknown; dose, frequency, route and expiration date were not reported) to prevent pneumonia from her pharmacy.  On the same date, the patient had some adverse experiences such as injection site pain, bruising at injection site, injection site redness, severe chills, high fever of 104.3 (unit not reported), and headaches with the vaccine pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23). She stated as of 16-NOV-2020 (reported as today), she still had these symptoms. No treatment was given for the events. The patient stated that she was going to contact her physician for follow-up. It was unknown if lab diagnostics or studies were performed. The patient did not sought medical attention. The outcomes of the events were reported as not recovered. The causality assessment between the events and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was not reported.",,Unknown,0,0
903176,"12/17/2020 patient self reported that the Shingrix vaccine of 10/9/20 left him with extremely sore and partially usable affected arm.  After initial injection site irritation and swelling, he feels that he cannot lift that arm past about 45 degrees without incurring pain.",65.0,Adults,0,0
904765,"Sore arm at injection site; Initial information received on 23-Nov-2020 regarding an unsolicited valid non-serious case received from a patient via social media.  This case involves patient (unknown demographics) who had Sore arm at injection site (Injection site pain) while he/she received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patients who had Sore arm at injection site (Injection site pain) unknown latency following the administration of INFLUENZA VACCINE.  Laboratory details were not reported.  It was not reported if the patient received a corrective treatment.  The event outcome was unknown.",,Unknown,0,0
880686,"fever, tylenol",0.33,Kids,0,0
862695,"Child has complained about pain, starting approximately five minutes after the shot was given, and still complaining two days later. Injection site has redness and swelling approximately 4-5 inches in diameter. Site is warm to touch.",5.0,Kids,1,0
901589,"patient got a sick as a dog; Initial information was received on 11-Nov-2020 regarding an unsolicited valid non-serious case from a social media (Facebook) via consumer or non-health care professional (patient).  This case involves patient (with unknown demographics) who was sick (got sick as a dog) (illness), while patient received INFLUENZA VACCINE [Flu shot].  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.    On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient got sick (got a sick as a dog) (illness) (non-serious) unknown latency following the administration of INFLUENZA VACCINE.  Details of laboratory data not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, the event outcome reported as unknown for event.  There will be no information available on the batch number for this case.",,Unknown,0,1
894965,After receiving the vaccine the patient started having trouble with his vision. He stated that his vision blurred and went black. He never lost consciousness but was very pale and sweaty. He stated that this has happened before after giving blood.  He felt back to normal after about 15 minutes.,21.0,Adults,0,1
857781,"Hives, extremely itchy first night, lump under injection site, warm to touch, swelling above and below eyes",85.0,Seniors,0,0
880344,"The morning after I received the injection, I was sitting at the table on our back porch tending to an injured bird that had hit one of our windows.  Only a minute or two after having sat down, I became extremely hot, light-headed, and nauseous.  I sat the bird down on the table, stood up, and began walking toward the patio door.  As I approached the door, my left arm (the same arm in which I received the injection) began twitching uncontrollably.  I had to reach across my body to open the door with my right hand.  Upon entering our house, I collapsed to my knees and fell forward.  I was able to catch myself from completely collapsing, but then my upper body began to convulse forward and I was unable to stop myself from slamming my head against the floor.  I was completely aware of what was happening, but I just couldn?t control my body.  After multiple convulsions, perhaps 10 ? 12, the convulsions stopped.  During the repetitive impacts with the floor, my nose was cut rather severely, and my forehead suffered a significant abrasion.  Roughly a minute after the convulsions stopped, I began to feel extremely hot and nauseous once again and then vomited.",50.0,Adults,0,0
868805,"TOOK VIVOTIF AFTER PLACING IT IN THE FREEZER; A spontaneous case report was received from a nurse on 12-Sep-2019 for two consumers.  Based on the information obtained from the nurse, two individual case safety reports PVX201909-000734 (PVX2019-2370; male) and PVX201909-000735 (PVX2019-2371; female) were created and cross-linked in the database.  This case report (PVX2019-2371) described an elderly female consumer (over 65-year-old) who ""took Vivotif after placing it in the freezer"" (PT: Product storage error), while being on oral Vivotif capsule (one capsule every other day) for typhoid prophylaxis.  Case report: The consumer took the first dose of Vivotif, which was kept in the freezer for 12 hours at unknown temperature. The remaining doses were kept in the refrigerator. The dosage dates remained unknown.  Action taken with Vivotif with respect to the event was not applicable.  The clinical outcome of the reported event was unknown.; Sender's Comments:  US-PaxVax Berna GmbH-PVX201909-000734:",,Unknown,0,0
897409,"no additional AE; expired GARDASIL 9 lhat was accidently administered to a patient today; This spontaneous report was received from a nurse and refers to a patient of an unknown age and gender. No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided. On 04-NOV-2020, the patient was vaccinated with expired first of three in series dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 0.5 ml, lot # N035032 with expiration date on 24-SEP-2020 (route of administration and anatomical location was not reported) for prophylaxis. No additional adverse event was reported.",,Unknown,0,1
913706,"muscle and joint pains, headache, chills, swelling on injection site. Finger joints swelling and pain. Dizziness.",61.0,Adults,1,0
868595,"TOOK TWO DOSES IN A ROW; This spontaneous case (PVX2019-1540) was received from a caregiver on 13-Jun-2019. It describes a 14-year-old adolescent male consumer who ""took two doses in a row"", while being on oral Vivotif (one capsule every other day) for typhoid prophylaxis.  Case report: The consumer took two doses of Vivotif in a row. The doses were taken on 12-Jun-2019 and 13-Jun-2019, respectively.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event ""took two doses in a row"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took two doses in a row"" was considered as not applicable.",,Unknown,0,0
883313,"Facial edema, initially treated with amoxicillin at Dentist for suspect tooth infection on 9/11/20, left side swelling improved and right side facial swelling when patient awoke on 9/12/20, right sided edema improving 8 hours after awakening. Started on fexofenadine OTC for reaction",90.0,Seniors,0,0
898726,By dinner time I became very tired. Went to bed about 7 PM and wasn't able to get up until nearly 4 PM the next day (the 31st). I had no energy for the remainder of the day and well into the next day (Nov 1). Periodically felt a bit nauseated and had a couple of episodes of chills that lasted  about half an hour.  Began to feel better by the evening of the 1st and by the morning of the 2nd was back to normal.,78.0,Seniors,1,0
869918,"multiple unspecified patients were vaccinated with improperly stored GARDASIL 9 or RECOMBIVAX on multiple unspecified dates.; No adverse effects reported.; This spontaneous report was received from a medical assistant referring to multiple unspecified patients of unknown age and gender. The patients pertinent medical history, concurrent conditions, drug allergies or reactions, historical and concomitant drugs were not reported.  On multiple unspecified dates, the patients were vaccinated with improperly stored doses of Hepatitis B Vaccine (Recombinant) thimerosal-free (RECOMBIVAX HB) lot numbers R013540 and R007212 with expiration dates on 21-MAR-2021 and 04-NOV-2020 respectively or HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) lot numbers N032284, R032766, and 1602284 with expiration dates on 22-SEP-2020, 31-AUG-2021, and 26-SEP-2021 respectively (dose, frequency, strength and route of administration were not reported) and all were given for prophylaxis.  Administered doses of vaccine experienced temperature excursion below 36 degrees Fahrenheit / 2 degrees Celsius (27.7degrees Fahrenheit) for 408 hours. There was no previous temperature excursion. Digital data logger was not involved. No adverse effects were reported.   As of 30-APR-2020, all telephone attempts trying to obtain additional information has been unsuccessful",,Unknown,0,1
879085,"Mild allergic response; This case was reported by a physician via call center representative and described the occurrence of allergic reaction in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced allergic reaction. On an unknown date, the outcome of the allergic reaction was unknown.   It was unknown if the reporter considered the allergic reaction to be related to Shingrix.  Additional information was received as follows: Age at vaccination was not reported but was taken as an adult as per vaccine indication. The patient received 1 dose of Shingrix without the second dose and experienced a mild allergic response and wanted to have an informed discussion regarding risks and benefits of having a second dose. The reporter consented to follow up.",,Unknown,0,1
874139,Patient developed temperature of 101*F two day after receiving Pentacel and inadvertent Trumenba.,0.5,Kids,0,0
885415,"Site swelled up and gradually increase in diameter. Approximately 4 inches wide. Area is hot, throbbing, raised, hard and arm is difficult to raise.",43.0,Adults,0,0
893399,"34-year-old female psychologist received a flu shot on 10/12/2020. She reports that the following day she started to develop redness, swelling, and pain in the Left Shoulder. She also reported a fever but did not take her temperature. Her symptoms continue to worsen through 10/15/2020 despite use of antihistamines.  She ultimately presented to the ED. She was treated with Keflex 500mg Q 6hrs for cellulitis which improved her symptoms.  She reports a significant amount of Allergies as well totaling 21 foods as well as plants and seasonal allergies. She has since completed the antibiotics and is presently reporting resolution of her symptoms. She reports an occasional itch in the area in questions but on presentation denies any further pain, redness swelling or aggravating factors.  She denies any allergies to medications and uses spironolactone for acne, she also uses Zyrtec and Allegra.",34.0,Adults,0,0
910836,"Excessive Sneezing, Sore Throat, Headache, Stuffy/Runny Nose. Symptoms started around 6:30pm and have continued through Sunday to Monday and are still on going.",21.0,Adults,1,0
882972,Patient is 50 years old and received the high dose flu vaccine.,50.0,Adults,0,1
897745,"patient got sick; it got worse every year (sick); Initial information received on 12-Nov-2020 regarding an unsolicited valid non-serious case received from a consumer or non-health care professional.   This case involves patient of unknown demographics who got sick (illness) and got worse every year (condition aggravated), while patient received vaccine INFLUENZA VACCIN [Flu shot].   The patient medical history included Hospitalisation (2 times), sick and pneumonia (six times).  Past medical treatment, past vaccination, concomitant medication and family history were not provided.   On an unknown date in Oct-2016, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination   On an unknown date, the patient developed a non-serious patient got sick (illness) and got worse every year (condition aggravated) unknown latency following the administration of INFLUENZA VACCINE.  It was reported that, patient got deathly after taking flu shot.  Details of laboratory data not reported.     It was not reported if the patient received any corrective treatment.  At the time of reporting, the event outcome reported as unknown for events.  There will be no information available on the batch number for this case.",,Unknown,0,1
865977,"Rash developed 1 week after vaccination to  bilateral arms,  no redness at site, no, sob, no elevated temperature. As of today 03/24/2020 rash to bilateral legs and stomach and itching to site . No other complaints. Treatment at home consisted of alovera and other home remedies.  Advised for patient to contact a provider in town for treatment /evaluation of rash and itching. Again no other complaints was mentioned.",36.0,Adults,1,0
883315,"Muscle soreness both arms-couldn?t lift up, fever, chills, headache , fatigue",54.0,Adults,1,0
885073,"Patient has experienced pain in the left shoulder since vaccination.  Pain comes and goes.  Patient has not received any treatment for this condition.  Patient mentioned he heard a ""weird"" noise during the vaccination that sounded like a squeegee.",70.0,Seniors,1,0
876565,"was administered Shingrix instead of HEB; was administered Shingrix instead of HEB; has been fussy; experiencing sleep regression; This case was reported by a consumer via call center representative and described the occurrence of irritability in a 2-month-old male patient who received Herpes zoster (Shingrix) (batch number MT7C9, expiry date 15th April 2022) for prophylaxis.   On 13th July 2020, the patient received Shingrix .5 ml. On 13th July 2020, unknown after receiving Shingrix, the patient experienced wrong vaccine administered and inappropriate age at vaccine administration. In July 2020, the patient experienced irritability and difficulty sleeping. On an unknown date, the outcome of the irritability was recovering/resolving and the outcome of the difficulty sleeping, wrong vaccine administered and inappropriate age at vaccine administration were unknown.   It was unknown if the reporter considered the irritability and difficulty sleeping to be related to Shingrix.  Additional details were reported as follows: A two month old baby was administered Shingrix in thigh instead of Heb vaccine at his two month visit which led to wrong vaccine administered and inappropriate age at vaccine administration. The patient was in leap two and had been fussy and experiencing sleep regression where he would not let his mother put him down to sleep. The reporter stated that she had to hold him which was not like him.  No other events were reported. The reporter consented to follow up.",0.17,Kids,0,1
898648,patient states she had pain and immobility in her shoulder.  She says that today (November 27) the pain is starting to diminish but she is still unable to lift her arm higher than her chest.,37.0,Adults,1,0
857024,"improperly stored vaccine administered; no adverse effect; This spontaneous report as received from an office manager refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.       On an unknown date, the patient was vaccinated with improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) (lot # S021925, expiry date : 15-JUL-2021) for prophylaxis. Other suspect therapies included sterile diluent(MERCK STERILE DILUENT). It was unknown if diluent used to reconstitute was stored at proper temperature.    It was reported that the vaccine experienced a temperature excursion total time in the range of 6 degrees Fahrenheit (F) to 14 degrees F (-14 degrees Celsius (C) to - 10 degrees C) for 30 minutes, 15 degrees F to 46 degrees F (-9 degrees C to 8 degrees C) for 7 hours and 47 degrees F to 77 degrees F (9 degrees C to 25 degrees C) for 9 hours (product storage error). There was no previous temperature excursion and it was reported that this call was due to a digital data logger. The patient had no adverse events. There was no product quality compliant involved.   This is one of the several reports received from the same reporter.; Sender's Comments:  US-009507513-2001USA005586:Original Case : 2001USA005586",,Unknown,0,1
884973,"ROTATEQ after 15 weeks old(4 months old).; Information has been received from a nurse practitioner referring to a 4 months old patient. The patient's historical condition, concomitant medications and drug reactions or allergies were not reported.  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent(ROTATEQ)(dose, frequency, route, lot # and expiration date were not reported) for prophylaxis(inappropriate schedule of product administration). Nurse Practitioner wanted to know if the patient should continue with the regimen or stop.",0.33,Kids,0,1
915856,"5 min after vaccine, had ""body tightness"", lightheaded, clammy, dizzy, and slight shortness of breath. Did have a seafood allergy.   BP 110/62 SPO2 99 P 69  Ate breakfast",34.0,Adults,0,1
903961,"Within 5 minutes of receipt of vaccine, reddened ears and reddened blotches on chest appeared.  No worsening after 10-15 minutes, but after 20 minutes appeared to worsen, and transport to ED via wheelchair initiated.  Pt treated in ED with epinephrine, solumedrol, Benadryl, famotidine and 1 liter of 0.9% Normal Saline IV on arrival time to ED.",39.0,Adults,0,1
858792,"Swelling in the injection site.; Redness in the injection site.; This case was reported by a pharmacist via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   In November 2019, the patient received the 1st dose of Shingrix. On an unknown date, between 1 and 3 months after receiving Shingrix, the patient experienced extensive swelling of vaccinated limb and injection site erythema. On an unknown date, the outcome of the extensive swelling of vaccinated limb and injection site erythema were recovered/resolved.   It was unknown if the reporter considered the extensive swelling of vaccinated limb and injection site erythema to be related to Shingrix.  Additional details were provided as follows: Post vaccination the patient experienced redness and swelling in the injection site of approximately 3 to 4 inches. The reporter consented to follow up.  The reporter did not provide lot number and expiration date of the first dose of Shingrix. The case is linked to case US2020AMR012680 reported for the same patient (2nd dose).",62.0,Adults,0,0
899345,"has a small quarter sized rash on this right cheek; tired; lethargic; did not sleep well; This is a spontaneous report from a contactable consumer(patient's parent). A 16-year-old male patient received meningococcal group b rlp2086 (TRUMENBA) via an unspecified route of administration on 22Nov2020 at single dose for immunization and meningococcal vaccine a/c/y/w(trade name not reported) via unspecified route on 22Nov2020 at unspecified dosage for immunization. The patient medical history and concomitant medications were not reported.  The patient received Trumenba and Meningococcal ACWY Vaccine yesterday(22Nov2020). He was very tired and lethargic and did not sleep well on 22Nov2020. He is still tired and lethargic today and has a small quarter sized rash on this right cheek on 23Nov2020. The outcome of the events ""tired"" and ""lethargic"" was not recovered and of the other events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.",16.0,Kids,0,0
890465,Fever 100.0 and headache,58.0,Adults,1,0
906326,Employee experienced nausea and headache,54.0,Adults,1,0
874274,"Wednesday morning 6/10/2020 had well visit and 1 year vaccines Wednesday night at 7pm had increased fussiness, vomited, pale, and ""lethargic,"" started to seize, upper body mostly. Called 911 and taken to hospital Temp in ER 101,  Went home that same night, seized again around midnight, went back to ER, still had a fever, therefore admitted wed through friday, fevers continued to go up and down during admission COVID negative, CT, chest xray, CBC, blood culture, urine, BMP, & EEG normal Fever free since hospital visit and without any additional symptoms.",1.0,Kids,0,0
905485,"Pfizer/BioNTech COVID 19 vaccine EUA C/O ""heart coming out of chest"", itching, and hot feeling approximately 10-15 minutes after injection. She took 25mg Benadryl PO one hour before vaccine. Was given 25 mg oral Benadryl at 1410. HR and blood pressure returned to normal and pt was released within 20  minutes of reaction.",30.0,Adults,0,1
872392,"Sciatic nerve inflammation/; Unable to walk; Permanent nerve damage; Weakness in that nerve; This case was reported by a consumer and described the occurrence of neuritis sciatic in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included Herpes zoster (Shingrix).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than 9 months after receiving Shingrix, the patient experienced neuritis sciatic, unable to walk, nerve damage and sciatic nerve injury. On an unknown date, the outcome of the neuritis sciatic, unable to walk, nerve damage and sciatic nerve injury were not recovered/not resolved.   It was unknown if the reporter considered the neuritis sciatic, unable to walk, nerve damage and sciatic nerve injury to be related to Shingrix.  Additional case details were reported as follows: The age at vaccination was not reported. The patient received Shingrix in late 2019 and experienced very severe side effect. The patient had severe inflammation in sciatic nerve and not able to walk for two months and then required cane. The patient could walk but not normally and had permanent nerve damage and still going to address weakness in that nerve. The patient would send itemized list via registered mail to corporate office. The reporter reported that if no reply was forthcoming and would engaged an attorney to assist in this matter.",,Unknown,0,0
909407,"On 12/24 @3am I started vomiting and did so on and off for the next 4 hours.  A felt very fatigued the rest of the day. On 12/25 I developed a macular pruritic rash to my chest  that progressed throughout the day that covered my torso. By 9pm on 12/25 I was experiencing fatigue, headaches, muscle aches and chills. I took Tylenol and ibuprofen and went to bed.  I current have  a headache, worse pruritic rash and upper tooth pain .",46.0,Adults,0,0
900274,"1-2 inches below injection site, small red swollen patch of skin. Warm to the touch, raised, and tender like a bruise. Size of the affected area began to grow over next 24-48 hrs, to about 3 inches in diameter.",25.0,Adults,0,0
913749,"Patient complained of feeling funny, ""prickly"" feeling in lower lip and having to force to swallow",58.0,Adults,0,0
887345,"Fever 100.8 at 10pm 10-1-20; weakness, dizziness, almost fainted 10-2-20 5pm; blood pressure at 6pm 98/55, temp 99.0.",71.0,Seniors,1,0
915592,"100.3 Fever, Cough, Congestion and Heart Palpitations",32.0,Adults,1,0
870492,"Suspected Vf; he had a case of shingles; Sick; feeling like a deep sun burn; itchy, raw; tender areas; There is also a small spot on his left breast; small spot in the area of breast; he developed some labored breathing; his first shot in his left arm in February 2020 and then received his second shot in his right arm 6 weeks later; flu like symptoms after traveling; fever; headache; fatigue that lasted a week; had pain at the injection site; had pain at the injection site and STIFFNESS  in his arm; This case was reported by a consumer via call center representative and described the occurrence of vaccination failure in a 61-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included gout (had gout in the past).   In February 2020, the patient received the 1st dose of Shingrix. In March 2020, the patient received the 2nd dose of Shingrix. In March 2020, not applicable after receiving Shingrix and less than a month after receiving Shingrix, the patient experienced influenza-like symptoms and drug dose administration interval too short. On 12th April 2020, the patient experienced labored breathing. On an unknown date, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, injection site pain, limbs stiffness, fever, headache, fatigue, sickness, burning sensation, pruritus, tenderness, spot-like rash and breast nodule. On an unknown date, the outcome of the vaccination failure, sickness, burning sensation, pruritus, tenderness, spot-like rash, breast nodule and drug dose administration interval too short were unknown and the outcome of the shingles and labored breathing were recovering/resolving and the outcome of the injection site pain, limbs stiffness, influenza-like symptoms, fever, headache and fatigue were recovered/resolved.   It was unknown if the reporter considered the vaccination failure, shingles, injection site pain and limbs stiffness to be related to Shingrix. It was unknown if the reporter considered the vaccination failure, shingles, influenza-like symptoms, labored breathing, fever, headache, fatigue, sickness, burning sensation, pruritus, tenderness, spot-like rash and breast nodule to be related to Shingrix.  Additional details were provided as follows: The patient received 1st dose of Shingrix in left arm and 2nd dose of Shingrix in right arm. The patient received 2nd dose of Shingrix 6 weeks later in the beginning of March 2020 after 1st dose, which led to shortening of vaccination schedule. After vaccination with 1st dose, the patient had pain at the injection site and stiffness in his arm  that lasted for a week. In early March, the patient, his wife and son  developed flu like symptoms after traveling and were sick with fever, headache and fatigue that lasted a week. Approximately 4 weeks ago, from the date of reporting, the patient developed some labored breathing in his right lung. The doctor stated that, the patient had case of shingles and were presented as itchy, raw, tender areas and described it asfeeling like a deep sun burn. The area affected includes right breast on nipple, under right arm and around part way on right shoulder blade.  There is also a small spot on left breast. The patient had COVID 19 test negactive. The patient did not have blisters. The reporter stated that the patient did not experienced any symptoms after 2nd dose of Shingrix. The reporter consented to follow up.",61.0,Adults,1,0
915953,All the following were severe and debilitating: fever >102.5F Chills Rigors Headache Nausea Malaise  Abdominal pain Lethargy Arthralgias Myalgias  Palpitations  Tachycardia  Injection site pain Flushing,32.0,Adults,1,0
877763,"On 29Jul2019, the patient received second dose / On 17Jul2020, the patient was diagnosed with a case of the shingles; shingles; This case was reported by a pharmacist via call center representative and described the occurrence of vaccination failure in a 73-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 4th April 2019, the patient received the 1st dose of Shingrix (intramuscular). On 29th July 2019, the patient received the 2nd dose of Shingrix (intramuscular). On 17th July 2020, 470 days after receiving Shingrix and 354 days after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. The patient was treated with antivirals nos (Antiviral (Drug Name Unknown)). On an unknown date, the outcome of the vaccination failure and shingles were not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient received 1st dose of Shingrix in the left deltoid and second dose of Shingrix in the right deltoid. On17th July 2020, the patient was diagnosed with a shingles, unknown severity and unknown location of the shingles lesions.  The patient was prescribed anti viral for treatment and started treatment on 18th July 2020. The shingles was ongoing at the time of reporting. The reporter did not consent to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020087418:same reporter US-GLAXOSMITHKLINE-US2018126864:same reporter",,Unknown,0,0
894866,"Rash started on day 4 after shingles vaccine. Red patch on neck, progressive and spread up her neck and onto the top part of her chest. She was seen in office on 11/3, rash had receded some. Per MD notes: on the midline of her neck there is a macular rash with just a faint overlying scale 5cm in width and 16cm in length. It is continuous. No other rash on any other distribution. No lesions.",62.0,Adults,0,0
896958,Patient said she became very hot and unable to sleep until roughly 4am. She called the pharmacy at 8am and said she was feeling better and asked if she could take advil due to headache from lack of sleep.,68.0,Seniors,1,0
882859,"Three children received a dose of the VARIVAX that was stored out of recommended temperature range.; Information has been received from the office manager and refers to a child patient of unknown age and gender. There was no information about patient's concurrent conditions, medical history, concomitant medications or drug reactions/allergies.  On an unknown date, the patient was vaccinated with a dose of improperly stored varicella virus vaccine live (VARIVAX) lot # R035226 and expiration date of 04-DEC-2020 (route of administration and anatomical location were not reported), for prophylaxis, which were stored in the range of 57.9 Fahrenheit degrees for 49 hours. No previous temperature excursion was reported. Unable to retreive the vial as it was disposed of after administration of vaccine.  Digital data logger was involved.  This is one of several reports from the same reporter.; Sender's Comments:  US-009507513-2009USA001660: US-009507513-2009USA001387: US-009507513-2009USA002057:",,Unknown,0,1
867410,"TOOK THE LAST DOSE OF VIVOTIF LATE; This spontaneous case (PVX2019-1021) was received from a pharmacist on 26-Apr-2019. It describes a female consumer who ""took the last dose late"", while being on oral Vivotif (one dose every other day) for typhoid fever prophylaxis.  Case report: The consumer missed to take the last dose of Vivotif, which was due on 23-Apr-2019 and took it on 26-Apr-2019.  Action taken with Vivotif was not applicable.  The clinical outcome of the event ""took the last dose of Vivotif late"" was unknown.  Company's Comment: The causality of the event ""took the last dose of Vivotif late"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took the last dose of Vivotif late"" was considered as not applicable.",,Unknown,1,0
896880,"Patient states she started having pain in her left arm at the injection site 6 hours after the injection.  Staff gave it to her on 11/11/20. At 48 hours post injection she said her left arm was hot and  red and swollen from the injection site to the elbow.  She just came in today 11/16/20 to tell me.  She states she is improving but the arm is still red and swollen.  Her primary concern is she still has some heaviness, numbness, and tingling.  She states she is afraid she has nerve damage.  She has NOT notified her doctor but was going to show him at her appt next Tuesday.  I am recommending that the calls her doctor today.",70.0,Seniors,1,0
871395,"Flucelvax QIV administered to a pregnant patient; Sore arm; This is a spontaneous case, initially reported by other non-health professional to Agency (reference number: SEQ19-06140) on 04-Nov-2019 and additional information received on the same date (being processed together), concerning a 35-year-old, pregnant female patient.   The patient's medical history was not provided.   The patient's concomitant medications were not reported.   The patient's obstetrical history included two previous pregnancies. Also, the patient had no maternal or paternal history with major congenital malformations. The patient did not have a history of offspring with congenital malformation.   The patient's last menstrual period (LMP) date was 07-Apr-2019 and estimated delivery date (EDD) was reported as 12-Jan-2019.   On 28-Oct-2019, at gestational age of 29 weeks, the patient was administered Flucelvax QIVc (influenza vaccine, subunit influenza virus vaccine polyvalent; dose: 0.5 ml, route of administration: intramuscular, anatomical location: upper right deltoid, batch number and expiry date: not reported] (explicitly coded as 'Vaccine exposure during pregnancy') for influenza prophylaxis.  On an unspecified date, an unknown amount of time after vaccination, the patient experienced sore arm.  On an unspecified date, three days after the onset, the patient recovered from sore arm.   At gestational age of approximately 39.6 weeks, the patient gave a live birth to a female neonate, delivered vaginally. It was reported that there were no problems with the delivery.  There were no problems since, and the baby was 'fat and healthy' as reported.   The reporter did not provide causality assessment to Flucelvax QIV.   Follow up information received from other non-health professional via Agency (reference number: SEQ19-06584) on 13-Feb-2020: Patient's date of birth amended. Pregnancy outcome received. Anatomical location for vaccination added. Sore arm added as new event. Hence, classification special case with no AE was removed. Stop date added and outcome changed from not reported to recovered for vaccine exposure during pregnancy. Narrative was amended accordingly.  Company comment: It is unknown when the patient developed sore arm, therefore the temporal and causal relationship between vaccination and this adverse event was considered unassessable. Vaccine exposure during pregnancy is unrelated to Flucelvax.; Sender's Comments: It is unknown when the patient developed sore arm, therefore the temporal and causal relationship between vaccination and this adverse event was considered unassessable. Vaccine exposure during pregnancy is unrelated to Flucelvax.",35.0,Adults,0,1
909353,Soreness at injection site 3/10 for 24 hrs. Soreness radiating down to elbow and up to neck and base of skull starting 3 hrs after injection lasting 11 hrs.,59.0,Adults,0,0
910618,"profound dizziness; This is a spontaneous report from a contactable nurse.  A 54-year-old female patient received BNT162B2 (lot number: EK5730), intramuscular at the right arm  on 17Dec2020 18:00 at 0.3 mL for COVID-19 immunization at a hospital. There were no medical history and concomitant medications. The patient experienced which she described as bizarre side effect  of profound dizziness, almost like vertigo, states she was having to hold onto a wall, considered medically significant by the reporter on 20Dec2020 12:00. The patient recovered from the event on 21Dec2020, 10:00.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event dizziness cannot be excluded. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.",54.0,Adults,0,0
903776,"Hives, itching, warmth on bilateral face and neck and chest. Tachycardia. Facial swelling.",45.0,Adults,0,0
904241,Morbiliform rash on torso Tiredness,40.0,Adults,1,0
871305,"Neck pain; Back [and neck] pain; Chills; Fever of 101.7 F; Nausea; Vomiting; This is a non-serious spontaneous case initially received from other health professional on 19-March-2019, concerning a 70-year-old, elderly, female patient.  On 12-Oct-2018, the patient was administered Afluria QIV (influenza vaccine, dose, route of administration, anatomical location, batch number and expiry date: not reported) for an unknown indication and on 11-Mar-2019, at 3:30 pm, the patient was also administered non-company drug glatiramer acetate.  On 11-Mar-2019, 4 months and 27 days after vaccination, at around 08:00 pm, the patient was administered glatiramer acetate and eventually experienced chills, fever of 101.7 F, nausea, vomiting, back pain and neck pain. The symptoms lasted for around 2 hours and then resolved.  The outcome of the events was recovered on 11-Mar-2019.; Reporter's Comments: A 70-year-old female patient experienced neck pain, back pain, chills, fever, nausea and vomiting, four months twenty-seven days after administration of Afluria QIV. The company assessed the causality of the events as not related to the suspect vaccine as there is no plausible temporal relationship between the events and the suspect vaccine.",70.0,Seniors,0,0
891715,"Received Afluria vaccine from local pharmacy on Sun Oct 4. Experienced chills, general fatigue, nausea, slight sore throat and reddened eyes overnight Sunday through Monday. I took aspirin Monday AM which alleviated some of the problems though I still have red eyes with some fatigue.",,Unknown,0,0
915091,"I experienced feeling  fatigue and extremely cold for a period of a few hours, I then took a NSAID and drank hot liquid and the feeling slowly subsided.",31.0,Adults,1,0
906832,"About 3 hours after vaccination, she began having hives and itching all over body.  No difficulty breathinc etc.  She went to ER that noted reaction to vaccine.  She was Administered  Benadryl 50mg PO X1 and Prednisone 60mg .  She also received one dose of Pepcid 20mg PO.   No signs of distress noted in ER.",32.0,Adults,0,1
880788,"No additional adverse effects reported; the patient was administered improperly stored PROQUAD; This spontaneous report was received from a nurse and refers to a 4-year-old male patient. No information regarding the patient's medical history, concurrent conditions, concomitant medications and previous drug reactions or allergies was reported.  On 18-AUG-2020, the patient was vaccinated with an improperly stored measles, mumps, rubella and varicella (oka-merck) virus vaccine live rHA (recombinant human albumin) (PROQUAD) subcutaneously, lot # T001187 was verified to be valid, expiration date reported and established as 11-JUL-2021 (dose and anatomical location were not provided) for prophylaxis. The vaccine was reconstituted with a properly stored sterile diluent.  The administered dose of vaccine experienced a temperature excursion of 6 to 14 Fahrenheit degrees (10.9 Fahrenheit degrees) for 2 hours and 30 minutes. There was no previous temperature excursion. Digital Data Logger was involved.  The patient did not experience any additional adverse events.",4.0,Kids,0,1
867601,"MISSED A DOSE; This spontaneous case (PVX2019-1440) was received from a pharmacist on 04-Jun-2019. It describes a male consumer who ""missed a dose"", while being on Vivotif for an unknown indication.  Case report: The consumer missed a dose of Vivotif that was due on 03-Jun-2019.  Action taken with Vivotif was not applicable.  The clinical outcome of the event ""missed a dose"" was unknown.  Company's Comment: The causality of the event ""missed a dose"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""missed a dose"" was considered as not applicable.",,Unknown,0,0
901942,"came down with it immediately after ,and she was diagnosed with Swine flu; She was sick for several weeks; Initial information received on 05-Nov-2020 regarding an unsolicited valid non-serious social media case received from a consumer.  This case is linked to case 2020SA313295.  This case involved an adult female patient who was diagnosed with Swine flu (H1N1 influenza) and was sick for several weeks (Illness), while she received(INFLUENZA VACCINE (MONOVALENT).  The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE MONOVALENT(INFLUENZA VACCINE (MONOVALENT) (Unknown)  produced by unknown manufacturer( lot number not reported) via unknown route at unknown administration site for prophylactic vaccination.  On an unknown date, immediately after the vaccination the patient was diagnosed with Swine flu (H1N1 influenza) and was sick for several weeks (Illness), (unknown latency) following the administration of INFLUENZA VACCINE MONOVALENT.  No relevant laboratory data was reported.   It was not reported if the patient received a corrective treatment.  The event outcome was unknown at the time of reporting.  There will be no information available on the batch number for this case.",,Unknown,0,1
861836,Injection site red; warm to  touch and indurated.,11.0,Kids,0,0
867454,"TOOK ONE PILL EACH DAY INSTEAD OF EVERY OTHER DAY; This spontaneous case (PVX2019-1361) was received from a physician on 28-May-2019. It describes a female consumer who ""took one pill each day instead of every other day"". The consumer was receiving Vivotif for an unknown indication.  Case report: The consumer took Vivotif doses every day instead of every other day.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event ""took one pill each day instead of every other day"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took one pill each day instead of every other day"" was considered as not applicable.",,Unknown,0,0
915536,"At 5pm on day of vaccine she noticed right arm soreness, which worsened and woke her from sleep; Noticed swollen lymph node in right axilla; Took 600mg ibuprofen and pain subsided; Felt fatigued in the morning, went to her physical therapy and during therapy developed nausea, elevated heart rate to 160-170's for 20 minutes, and near syncope - was seen in the ED, EKG and labs unremarkable",28.0,Adults,0,0
858914,"Patient stated he developed a red rash that went around to the inside part of his arm starting at the shoulder and going down to about half way down his bicep. He said it was a little bit itchy. He did say it has gotten better the last couple days, but is still slightly red.",51.0,Adults,1,0
868997,"vaccine expiration date 4/02/2022 & Dilutant 4MT3A/Exp 5/20/2022. Next morning felt achy and tired.  By 3pm, had 102 fever, disseminated rash on forehead and down arms, discreet bumps on thorax, inner left thigh, dry cough and nausea.   Patient contacted pharmacist via phone and was encouraged to call doctor and was told that they were not sure whether could receive the 2nd shot.   Rash lasted through Sunday.  Fever would spike around 100-101 at 3pm every afternoon for 12 days.   Patient took Ibuprofen but only when pain was high--took only 1 time every 3rd day.  Even now patient gets temperature spikes on afternoon periodically. It is hay fever season so it could be related to that as well. Patient has not spoken to doctor",63.0,Adults,0,0
885353,Pt stated he threw up starting the next morning and thinks it was from the vaccine- it eased up by the night time and feels fine today,67.0,Seniors,0,1
889402,"sick; Initial information was received on 07-Oct-2020 regarding an unsolicited valid non-serious case from a consumer/non-health care professional via social media.  This case involves a patient (age and gender unspecified) who was sick (malaise), when received vaccine INFLUENZA VACCINE.  Medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient was sick (malaise) (unknown latency, non-serious event) following the administration of INFLUENZA VACCINE. The patient was sick for 3 months and then 2 months   No laboratory data was provided.   It was not reported if the patient received a corrective treatment.  At the time of report, the outcome of event was unknown.  There will be no information available on the batch number for this case.",,Unknown,0,1
890036,"hard lump; itchiness; This is a spontaneous report from a contactable healthcare professional and a pharmacist. A patient of unspecified age and gender started to receive pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13), via an unspecified route of administration on 07Oct2020 at single dose for immunization. Medical history and concomitant medications were not reported. Patient experienced a hard lump and itchiness on an unspecified date. Patient was coming in to be seen by the pharmacist and sent to primary care based on recommendation. Outcome of the events was unknown.  No follow-up attempts are needed, information about lot/batch number cannot be obtained.",,Unknown,0,0
870847,"The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 6-month-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ)  (lot # S013439 with expiration date 03-MAR-2021, lot # S013436 with expiration date 30-JAN-2021, and lot # S006050 with expiration date 12-DEC-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36F/2C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36F/2C (0C) for 8 hours 30 minutes Was call because of a ""data logger""? yes  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) at a dose of 2 ml (route not provided) as prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter  This spontaneous report as received from a other health professional refers to a patient of unknown age.    On an unknown date the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S006050, 2 milliliter for prophylaxis.       On an unknown date the patient experienced product storage error and no adverse event.    The outcome of product storage error and no adverse event is unknown.   The reporter considered product storage error and no adverse event to be not assessed to Rotavirus Vaccine, Live, Oral, Pentavalent(ROTATEQ).     {Additional information has been requested. / Additional information is not expected.}; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004545: US-009507513-2005USA004950: US-009507513-2005USA004951: US-009507513-2005USA004952: US-009507513-2005USA004953: US-009507513-2005USA004954: US-009507513-2005USA004955: US-009507513-2005USA004956: US-009507513-2005USA004957: US-009507513-2005USA004958: US-009507513-2005USA004959: US-009507513-2005USA004960: US-009507513-2005USA004962: US-009507513-2005USA004963: US-009507513-2005USA004964: US-009507513-2005USA004965: US-009507513-2005USA004966: US-009507513-2005USA004967: US-009507513-2005USA004968: US-009507513-2005USA004969: US-009507513-2005USA004970: US-009507513-2005USA004971: US-009507513-2005USA004972: US-009507513-2005USA004973: US-009507513-2005USA004974: US-009507513-2005USA004975: US-009507513-2005USA004976: US-009507513-2005USA004977: US-009507513-2005USA004978: US-009507513-2005USA004979: US-009507513-2005USA004980: US-009507513-2005USA004981: US-009507513-2005USA004982: US-009507513-2005USA004983: US-009507513-2005USA004984: US-009507513-2005USA004985: US-009507513-2005USA004986: US-009507513-2005USA004987: US-009507513-2005USA004988: US-009507513-2005USA004989: US-009507513-2005USA004990: US-009507513-2005USA004991: US-009507513-2005USA004992: US-009507513-2005USA004993:",,Unknown,0,1
908642,"Progress Notes APRN (Nurse Practitioner) ? ? Nurse Practitioner Cosign Needed Expand All Collapse All    COVID VACCINE CLINIC 12/22/2020     Date:  12/22/2020                                                                                           Subjective Patient is a 34 y.o. female who was seen at COVID Vaccine Clinic today for her first dose of the COVID 19 vaccination.  She denied any history of previous adverse reactions to vaccines.  She was given the Pfizer vaccination in the left deltoid muscle.  During her 15 minute waiting period after the injection, the patient began to experience lightheadedness and confussion.  She denied rash, hives, welts, difficulty breathing, difficulty swallowing, wheezing, throat tightness, hoarseness, stridor, itching, facial swelling, lip swelling and tongue swelling.  This provider was notified of patient reaction and she was then assessed in the emergency bay area.  Monitored patient for severe reaction symptoms, including respiratory distress with stridor, wheezing, dyspnea, increased work of breathing, persistent cough and cyanosis.  Pt  Presents with lightlessness and confusion.  Blood sugar on presenting was 74.  She has a history of fibromyalgia and Migraines.  She had a gastric bypass in 2010. She was given a protein bar to eat.  Fingerstick BS done 20 minutes later was 96.  Pt was feeling better after eating.   Review of Systems  Neurological: Positive for light-headedness.  Psychiatric/Behavioral: Positive for confusion.  All other systems reviewed and are negative.     Objective   Vitals Vitals:  12/22/20 1612 12/22/20 1628 12/22/20 1639 BP: (!) 135/92 127/79 128/84 BP Location: Right arm Right arm  Patient Position: Sitting Sitting  Pulse: 98 74 88 SpO2: 98% 98% 98%    Physical Exam Vitals signs and nursing note reviewed.  Constitutional:      Appearance: Normal appearance.  HENT:     Head: Normocephalic.     Right Ear: External ear normal.     Left Ear: External ear normal.     Nose: Nose normal.     Mouth/Throat:     Mouth: Mucous membranes are moist.  Eyes:     Pupils: Pupils are equal, round, and reactive to light.  Neck:     Musculoskeletal: Normal range of motion.  Cardiovascular:     Rate and Rhythm: Normal rate and regular rhythm.     Pulses: Normal pulses.     Heart sounds: Normal heart sounds.  Pulmonary:     Effort: Pulmonary effort is normal.     Breath sounds: Normal breath sounds.  Abdominal:     General: Abdomen is flat.  Musculoskeletal: Normal range of motion.  Skin:    General: Skin is warm and dry.     Capillary Refill: Capillary refill takes less than 2 seconds.  Neurological:     Mental Status: She is alert.  Psychiatric:        Mood and Affect: Mood normal.        Behavior: Behavior normal.        Thought Content: Thought content normal.      Assessment/Plan  Treatment included: no therapy. Follow up response to treatment: no side effects. Patient discharge: Stable to go home and follow up with PCP.  Pt was released at 4:39 with no symptoms at that time.    APRN Electronically Signed 12/22/2020 4:40 PM    Division of Health       3 of 3",34.0,Adults,0,0
880643,"HAD A SEIZURE EARLY AM OF SATURDAY, 8-22 -2020 HAD A FEVER ON 8-21-2020 OF AT LEAST 105 R  BABY TURNED BLUE & STOPPED BREATHING SO MOM STARTED CPR  CALLED 911 & TAKEN BY AMBULANCE TO ER DIAGNOSIS IN ER- FEBRILE SEIZURE, DISCHARGED AND FOLLOW UP IN OFFICE 8/24/2020.",0.5,Kids,1,0
913439,"Headache, fatigue, muscle pain soreness at injection site",71.0,Seniors,1,0
916006,"I have body aches,fever and chills.Also soreness at injection site.This lasted for36 hours and resoved by taking tylenol and ibuprofen",74.0,Seniors,0,0
856801,Patient developed progressively worsening redness + swelling that encompassed entire (R) upper extremity + shortness of breath treated w/ oral steroids + Albuterol,17.0,Kids,0,0
880341,"After the shot(s) were given, she went silent from crying, threw up and got down on the floor. She crawled to the corner, sat there and zoned out staring at the corner of the wall. She wouldn't respond to anybody calling her name, you could approach her and there was no response. Like she was frozen. Wouldn't respond to any verbal or physical stimuli. The nurse ran to get the doctor and he came in and just stood there. She finally ""came to"" but did not recognize me or her father or anything. I tried to pick her up and she would push herself away, crying as if she was scared of me. After everything had happened she finally ""snapped"" out of it, came to me and said I want to go. She had a high fever for 3-4 days straight. All she remembers is throwing up and that she got a shot. Nothing afterwards.",3.0,Kids,1,0
889831,Pt accidently received a third dose of the Hepatitis A vaccine. No adverse effects. pt mother was notified about the injection. No harm expected for the patient in receiving an extra dose per PCP.,16.0,Kids,0,1
866133,"-Employee arrived at work this morning and reported the following current symptoms: Dizzy, GI upset, fatigue, nausea, soreness at injection site - VS: 98.0-125/75-93 - Left arm assessed:  full range of motion, radial pulse present and  no redness, warmth or swelling noted - Employee was dismissed from duties today and instructed to seek medical care",31.0,Adults,1,0
866957,"Swelling / goes into the axilla and has a ""formation""; Redness / erythema around the entire left upper arm where he got the injection; Pain; This case was reported by a physician via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 11-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA197A, expiry date 31st October 2020) for prophylaxis.   On 26th February 2020, the patient received the 1st dose of Menveo (intramuscular). In February 2020, less than a week after receiving Menveo, the patient experienced extensive swelling of vaccinated limb, erythema of extremities and pain. The patient was treated with benadryl (nos) (Benadryl). On an unknown date, the outcome of the extensive swelling of vaccinated limb was not recovered/not resolved and the outcome of the erythema of extremities and pain were recovering/resolving.   It was unknown if the reporter considered the extensive swelling of vaccinated limb, erythema of extremities and pain to be related to Menveo.  Additional details were reported as follows: The patient was administered his 1st dose of the Menveo vaccine 2 days prior to the reporting. The patient stated that the patient developed swelling and redness below where the vaccine was administered. The reporter stated that the patient was given Benadryl but on day of reporting, the swelling was much bigger and there was erythema around the entire left upper arm where he got the injection. The reporter stated that the area does not felt hard or like cellulitis and that the swelling got into the axilla and had a formation. The patient stated that the patient reported pain. The reporter consented to follow up.",11.0,Kids,0,0
879981,"LOW BP 111/50, WEAKNESS, SORE ARMS, HEADACHE",72.0,Seniors,1,0
881429,"Patient called the pharmacy after visiting her doctor to report that her arm was red, hot, itchy and swollen from the site of the injection down to the bend at her elbow. She had the reaction start within a few hours of the injection. She has been taking benadryl and using ice.",81.0,Seniors,0,0
914368,"Hives, hot, flushed",43.0,Adults,0,0
894921,"Pt received her 2nd Shingrix vaccine on 11/3/2020. At that time, pt reported having a rash on her neck and face following the first vaccine in August. Pt was asked to call back if she notices any unusual reactions.  Pt called the office on 11/5/2020 to report that a short while ago (~10:00am today) a rash began to appear on her face a neck. This rash is not as pronounced the rash following the first vaccine. Described as red and flat. The rash is greater on the left side than the right, and is on both sides of her neck and face near her temples. Pt denies any difficulty breathing or any swelling of her mouth, tongue, neck or cheeks.",59.0,Adults,0,0
861158,"Patient started having injection site pain that got worse by the day, with pain radiating to her back area.  She went to see her primary doctor on 2/5/20 and on 2/7/20 and they examined her, got her EKG and x-ray.  Nothing abnormal came out from  both screening tests.  She was then referred to emergency room as the primary care was unable to give further treatment for the pain.  She received muscle relaxants and pain meds (oral & topical) but stated that no medication (oral or topical) is helping to relieve pain.",54.0,Adults,1,0
894840,"Improper storage of product in use; ADMINISTERED RECALLED VACCINE; No other AE information given at this time; This spontaneous report was received from a medical assistant (also reported as certified medical assistant) referring to a patient of unknown age and gender. Information about patient's pertinent concurrent conditions, medical history, concomitant medications and previous drug reactions or allergies were not provided.  On 19-OCT-2020, the patient was vaccinated with incorrectly stored (no details of storing were provided) pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23), which was recalled, a dose was 0.5 milliliter, lot # S036495 was confirmed to be valid, expiration date 13-SEP-2021 (concentration, number of administered dose, route and anatomical location of administration were not reported), for prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: S036495; expirationdate: 13-SEP-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2010USA010843: US-009507513-2010USA010890: US-009507513-2010USA010905: US-009507513-2010USA011114: US-009507513-2010USA011126: US-009507513-2010USA011133: US-009507513-2010USA011194: US-009507513-2010USA011201: US-009507513-2010USA011364: US-009507513-2010USA011379: US-009507513-2010USA011790: US-009507513-2010USA012196: US-009507513-2011USA001141: US-009507513-2011USA001174:",,Unknown,0,1
873877,"experiencing a reaction at the site of injection; Soreness of the arm; This case was reported by a consumer via call center representative and described the occurrence of injection site reaction in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 12th December 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 6 months after receiving Shingrix, the patient experienced injection site reaction and pain in arm. On an unknown date, the outcome of the injection site reaction and pain in arm were unknown.   It was unknown if the reporter considered the injection site reaction and pain in arm to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix shot back and experiencing a reaction at the site of injection and soreness of the arm. The reporter did not consent to follow up. Not all information was available.  Unable to collect date of birth and other adverse event details because caller abruptly disconnected.",,Unknown,1,0
891313,"Day 1  Oct 15th  tiredness and a little weakness.  Day 2 Oct 16 Headache, joint pain in knees, lower back,  hips, fingers.  Had a quivering/moving halo around everything,   My heart rate also kept beating fast.  Heart rate is usually in the 70's/80's for 0ct 16th and 17th it was in the high nineties.  It would come and go through out the day.,  I kept getting waves of this awful feeling like I was extremely sick with the flu.  I felt this way through Oct 17,",52.0,Adults,1,0
885005,"expired IPOL MDV was given to the patient, no AE; Initial information was received on 31-Aug-2020 regarding an unsolicited valid non-serious case from a physician.  This case involves a 9 month old female patient who was administered an expired dose of IPV (VERO) [IPOL] (expired product administered).  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  It was unknown whether patient received concomitant medications or other vaccines.   On 28-Aug-2020, the patient received a 0.5 ml dose of suspect IPV (VERO) (lot P1A251M, expiry date: 02-May-2020, form: injection (multi dose vial)) once via intramuscular route in the left thigh for prophylactic vaccination.  It was a case of an actual medication error due to expired vaccine used (latency same day)  At the time of report, the patient had no adverse event symptoms.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",0.75,Kids,0,1
913502,"chills, headache, fatigue, runny nose, feeling unwell, joint pain, muscle aches, tingling sensation all over body at time of injection",30.0,Adults,1,0
867602,"TOOK ONE DOSE OF UNREFRIGERATED VIVOTIF; This spontaneous case (PVX2019-1473) was received from a consumer on 07-Jun-2019. It describes a female consumer who ""took one dose of unrefrigerated Vivotif"". The consumer was receiving oral Vivotif (one dose every other day) (lot no: 3003272) for typhoid fever prophylaxis.  Case report: The consumer took the first unrefrigerated dose of Vivotif on 06-Jun-2019.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event ""took one dose of unrefrigerated Vivotif"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took one dose of unrefrigerated Vivotif"" was considered as not applicable.",,Unknown,1,0
907279,"severe joint pain; extremely severe allergic reaction to Typhim Vi; Initial information regarding this unsolicited valid non-serious case received from a patient and transmitted to Sanofi on 25-Nov-2020.  This case involved a 34 year old female patient who experienced severe joint pain (arthralgia) and extremely severe allergic reaction to Typhim Vi (Allergy to vaccine), while she received vaccine TYPHOID VI POLYSACCHARIDE VACCINE [TYPHIM VI].  Relevant medical history, medical treatment, vaccination details and family history were not provided.  At the time of the event, the patient possibly had an ongoing egg allergy.  No concomitant medication was taken by the patient.   On an unknown date in 2019, the patient received a dose of suspect TYPHOID VI POLYSACCHARIDE VACCINE (lot number and expiry date not reported) via intramuscular route in the left arm prophylactic vaccination.  On an unknown date in 2019, the patient had extremely severe allergic reaction to Typhim Vi (Allergy to vaccine), unknown latency following the administration of TYPHOID VI POLYSACCHARIDE VACCINE.   On 26-Dec-2019, the patient developed a non-serious severe joint pain (arthralgia), unknown latency following the administration of TYPHOID VI POLYSACCHARIDE VACCINE.   It was reported that she had not received a flu shot for many years because she felt sick for about a week afterwards.   Relevant laboratory test was not reported.  No corrective treatment was received.  On an unknown date, the event outcome was recovered for arthralgia and unknown for allergy to vaccine.  There would be no information available on batch number for this case.  Additional information regarding this unsolicited valid non-serious case received from a patient and transmitted to Sanofi on 25-Nov-2020.  New event allergy to vaccine was added. Corresponding fields and narrative updated accordingly.",34.0,Adults,0,0
871847,"Your child received a vaccination at our clinic during the period between February 28 and April 16, 2020. During the period between February 28th, 2020 and March 2nd, 2020, our data logger had a technical malfunction that we were not aware of and it stopped sending its temperature recordings to the system.  During that period the fridge never stopped working. The temperature logs of the fridge before and after the incident were always within required range. Our fridge has been always in a perfect new condition and never had any temperature problems previously. There was no power outage in the area or inside the office during that period as well.       The CDC requires continuous temperature monitoring of all VFC vaccines and due to lack of continuous temperature data documentation, the vaccine manufacturers have determined that the doses administered on these dates should be re-administered to ensure proper effectiveness.",0.83,Kids,0,1
876189,"vomiting; This spontaneous report as received from a physician via a company representative concerning a 2-month-old patient of an unknown gender. Information regarding the patient's drug reactions or allergies, concomitant therapies and pertinent medical history was not provided. In approximately July 2019, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) vial, orally, for prophylaxis(concentration, dose, frequency, lot # and expiry date were not reported). In approximately July 2019 (reported as a week after receiving the dose), the patient experienced vomiting. No product quality complaint (PQC) involved. The outcome of vomiting was unknown. The action taken was not applicable. The causality assessment between the vomiting and rotavirus vaccine, live, oral, pentavalent (ROTATEQ) was not provided.",0.17,Kids,0,1
880761,"developed hearing loss in right ear; This case was reported by a nurse via sales rep and described the occurrence of hearing loss in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 10th August 2020, the patient received the 2nd dose of Shingrix. On 13th August 2020, 3 days after receiving Shingrix, the patient experienced hearing loss (serious criteria GSK medically significant). On an unknown date, the outcome of the hearing loss was not recovered/not resolved.   The reporter considered the hearing loss to be possibly related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient developed hearing loss in right ear that was still ongoing at the time of reporting.  The patient thought it was related to Shingrix",,Unknown,0,0
874626,"Localized reaction around the injection site. Red, warm to touch, rash like. Patient also stated feeling under the weather and achy",64.0,Adults,1,0
884772,"A 16 month old received both PROQUAD and VARICELLA at the same time; This spontaneous report was received from a nurse concerning a 16-month-old patient of unknown gender. The patient's concurrent conditions, medical history, historical drug, drug reactions/allergies and concomitant therapies were not provided.  On 09-SEP-2020, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) 0.5 mililliter and varicella virus vaccine live (oka/merck)(manufacturer unknown) (Overdose) both for prophylaxis. Dosage regimens, lot numbers and expiration dates were not provided.",1.33,Kids,0,1
863990,"SkinRash METHYLPREDNISOLONE 125 MG ONCE 125 mg/1 VIAL INTRAMUSCULAR NOW, PREDNISOLONE 20 MG EVERY DAY TAKE FOUR TABLETS BY MOUTH EVERY DAY FOR 2 DAYS, THEN THREE TABLETS BY MOUTH EVERY DAY FOR 2 DAYS, THEN TWO TABLETS BY MOUTH EVERY DAY FOR 2 DAYS, THEN ONE TABLET BY MOUTH EVERY DAY FOR 2 DAYS, TAKE WITH FOOD",71.0,Seniors,1,0
876158,"Onset of temp of 102.8 evening of vaccinations (no prior illness of vaccinations), headache, dizziness. Treatment - Tylenol and motrin, fluids, and rest",11.0,Kids,0,0
864191,Flu vaccine administered through IV instead of IM. No signs or symptoms at the time of administration. 5 hours after administration patient became SOB and had elevated temperature. MD states symptoms not from flu vaccine but from arm infection.,51.0,Adults,0,1
882852,"No adverse event; Interchange of vaccine products; This Non-valid spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions and concomitant therapies were not reported.     On 02-SEP-2019, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (dose, route of administration and lot # were not reported) for prophylaxis.  Approximately on 16-SEP-2019 (reported as 2 weeks later), the patient was vaccinated with pneumococcal 13v conj vaccine (crm197) (PREVNAR 13) (dose, route of administration, lot # and indication were not reported) due to charting mistake (interchange of vaccine products). No adverse effects reported",,Unknown,0,1
915100,"chills, extreme body aches, fever, migraine, loss of appetite all lasting about 36 hours",41.0,Adults,1,0
898014,"persistent light pink, rectangular papule 5 x 7cm. Not hot/red/tender/itchy. Started within several days & has persisted x 3 weeks. Vaccine administered at urgent care clinic. Lot number not available.",4.0,Kids,0,1
860061,"swelling of the entire arm, hand and fingers;  pain and discomfort",24.0,Adults,1,0
880061,"sore arm; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 56-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix (intramuscular). On 12th August 2020, couple of hours after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovered/resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional information was provided as follows: The patient had her first shot in February or March. She developed a sore arm several hours later but it resolved in a day or so. The reporter consented to follow up. For tolerance of 2nd dose, refer case US2020160502.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020160502:same patient",56.0,Adults,1,0
907134,6:45 pm asthma attack requiring albuterol inhaler. Attack was not triggered by any particular event. I was at rest when it started.,33.0,Adults,0,0
891299,"Patient experienced flu-like symptoms, headaches, extremity pain, and burning eyes.  Patient said the symptoms start the night after receiving the vaccine.",65.0,Adults,0,0
866942,"FELT HORRIBLE; FATIGUE; HEAD HURTING/ HORRIBLE HEADACHE; FEELING FEVERISH; MOSTLY EXTREME STOMACH PAIN/STOMACH HURTING/ INTENSE PAIN LIKE SHE DRANK DAGGERS ALMOST; NAUSEA; This spontaneous case (PVX2019-1340) was received from a consumer on 24-May-2019. It describes a female consumer who experienced the adverse events ""mostly extreme stomach pain/stomach hurting/ intense pain like she drank daggers almost/ incredible pain, nausea, felt horrible, insane pain, fatigue, head hurting/horrible headache, and feeling feverish"", after the administration of oral Vivotif (one dose every other day) for typhoid fever prophylaxis.  Case report: The consumer started experiencing extreme stomach pain and nausea, after taking a dose of Vivotif. She took the first dose of Vivotif on 21-May-2019 at 12 a.m. Then, on 22-May-2019, in the morning she ate small granola bar and a little bit of coffee, immediately she experienced, intense pain like she drank daggers. She stated that she woke up around 35 to 45 minutes before eating and she felt fine, but the moment she drank and ate, she experienced incredible pain. She reported that the adverse events were coming in waves and sometimes she felt horrible for four to five minutes and experienced head hurting, stomach hurting, nausea, and felt feverish. After the wave she again felt fine. She also experienced insane pain and fatigue, where she was not able to keep her eyes open. She stated that the fatigue she experienced was sleeping all day where she could not do anything, and she would ""sit down and pass out."" On 24-May-2019, when she woke up in the morning, she felt completely normal.   She took 2 dose of Advil (ibuprofen) for horrible headache.  She only took one dose of Vivotif and then discontinued it based on the nurse's recommendation.  She did not take any other vaccines or concomitant drugs along with Vivotif. She did not have any history of contaminated and unhygienic food or water intake.  Action taken with Vivotif was dosage discontinued.  The consumer had recovered from the reported events on 24-May-2019.  Company's Comment: In this case, it was reported that the consumer had experienced the adverse events ""mostly extreme stomach pain/stomach hurting/ intense pain like she drank daggers almost/ incredible pain, nausea, felt horrible, insane pain, fatigue, head hurting/horrible headache, and feeling feverish"", after the administration of oral Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Hence, the causality of the events with Vivotif is assessed as possible.; Sender's Comments: Company's Comment: In this case, it was reported that the consumer had experienced the adverse events ""mostly extreme stomach pain/stomach hurting/ intense pain like she drank daggers almost/ incredible pain, nausea, felt horrible, insane pain, fatigue, head hurting/horrible headache, and feeling feverish"", after the administration of oral Vivotif. There seems to be a temporal association between the intake of the vaccine and the events. Hence, the causality of the events with Vivotif is assessed as possible.",,Unknown,0,0
916120,"Slight diarrhea for the afternoon of injection, 2 events.  Next day back to normal stool.",64.0,Adults,0,0
876789,"no known adverse effects; a patient only received a partial dose of GARDASIL 9; This spontaneous report was received from a medical assistant, referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions or allergies, and concomitant medications were not reported.       On an unknown date, the patient was vaccinated with a partial dose (underdose) of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) injection (route of administration, anatomical location, and dosage regimen were not reported; lot number 1637642, which has been verified to be valid, expiration date reported and validated as 28-MAY-2022) as prophylaxis. No known adverse effects. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: 1637642; expirationdate: 28-MAY-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",,Unknown,0,1
910069,Possible Bell's Palsy Rx of Prednisone 60mg Daily x7 days Valacyclovir 1000mg TID x7 days,37.0,Adults,0,0
913156,"temperature excursion involving PROQUAD; This spontaneous report was received from a nurse refers to a patient of unknown age and gender. The patient's medical history, historical drugs, concurrent conditions and concomitant medications were not provided.     On 04-DEC-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA)(PROQUAD) 0.5 milliliter, lot number T011302 (conflicting information as it was also reported as T021302), expiration date 19-FEB-2021 (route of administration not provided) for prophylaxis.  The vaccine had a temperature excursion of -5 degrees Celsius for 20 hours. There were no previous temperature excursions. The call was due to digital data logger.  This is one of several cases reported by the same reporter.; Sender's Comments:  US-009507513-2012USA010555: US-009507513-2012USA010556: US-009507513-2012USA010579: US-009507513-2012USA010585: US-009507513-2012USA010590: US-009507513-2012USA010592: US-009507513-2012USA010652: US-009507513-2012USA010667: US-009507513-2012USA010678: US-009507513-2012USA010683: US-009507513-2012USA010686: US-009507513-2012USA010698: US-009507513-2012USA010722: US-009507513-2012USA010725: US-009507513-2012USA011227:",,Unknown,0,1
866826,"Delivery at 36.9 weeks of gestation; Vaccine exposure during pregnancy; This is an observational study case, initially received from other health professional on 25-Mar-2020, concerning a 29-year-old, female pregnant subject of body weight: 286 lbs, height: 60 inches and body mass index (BMI): 55.8   (Ethnicity: not reported) enrolled in a prospective observational safety study on pregnancy outcomes in women immunized with seasonal cell culture influenza trivalent (TIVc) or quadrivalent (QIVc) vaccine during pregnancy.  The subject's historical condition included vaginitis/bacterial vaginosis. The subject's current condition included anaemia and obesity.  The subject's past medication included Metrogel (metronidazole) for vaginitis/bacterial vaginosis, while the the subject's concomitant medications included Prenatal vitamins (unspecified vitamins and minerals) for pregnancy and ferrous sulfate for anaemia.  The subject had two previous pregnancies with full term live births, with no birth defects. The subject had no maternal or paternal history with major congenital malformation (MCM).    The subject's last menstrual period (LMP) date was 14-Mar-2019. The type of pregnancy was singleton. The subject's estimated delivery date (EDD) and corrected estimated delivery date (CEDD) were both 19-Dec-2020. The subject did not consume tobacco, alcohol or illicit drugs during pregnancy.  On 25-Jun-2019, the subject underwent cystic fibrosis mutation analysis and spinal muscular atrophy and no MCM was noted.  On 24-Jul-2019, the subject underwent ultrasound scan and panorama, and no MCM was noted.  On 24-Oct-2019, at gestational age of 32 weeks, (calculated per LMP), the subject was administered Flucelvax QIVc (Flu Vaccine Cell Subunit QIV NVD) [influenza vaccine, subunit influenza virus vaccine polyvalent, batch number: 262218, dose, route of administration, anatomical location and expiry date: not reported) (explicitly coded as Vaccine exposure during pregnancy') for an influenza immunisation. On the same day, the subject underwent ultrasound scan and no MCM was noted.  On 13-Nov-2019 and on 26-Nov-2019, the subject underwent ultrasound scan and no MCMs were noted.  Oligohydramnios was noted. On the same day, at gestational age of 36.9 weeks (as reported), the subject gave a live birth to a male neonate via caesarean method of delivery. The birth weight of the neonate was 2552 g. Head circumference was 33 cm and length 45.7 cm. Appearance, pulse, grimace, activity and respiration (APGAR) score at one minute was 8, at five minutes was 9. No data was reported for APGAR score at ten minutes. No MCM was identified at birth.   At the time of initial reporting, the outcome of event premature delivery' was not reported.  The event of premature delivery' was considered serious due to the criterion of medical significance.  The reporter did not provide the causality assessment to Flucelvax QIV.  This case is linked to case 202002629, the corresponding child case.  Company comment: The subject was administered Flucelvax QIV at approximately 32 weeks of gestational age (explicitly considered as vaccine exposure during pregnancy).  Reportedly, at gestational age of 36.9 weeks the subject gave a live birth to a male neonate via caesarean method of delivery. (coded as premature delivery). Causality may have been confounded by medical history of obesity. Considering all the above mentioned, causal relationship between the suspect product and the event of vaccine exposure during pregnancy is assessed as not related based on company's conventions, while for premature delivery is assessed as unlikely related. (defaults to ""related"" in the safety database for reporting purposes).; Sender's Comments: The subject was administered Flucelvax QIV at approximately 32 weeks of gestational age (explicitly considered as vaccine exposure during pregnancy).  Reportedly, at gestational age of 36.9 weeks the subject gave a live birth to a male neonate via caesarean method of delivery. (coded as premature delivery). Causality may have been confounded by medical history of obesity. Considering all the above mentioned, causal relationship between the suspect product and the event of vaccine exposure during pregnancy is assessed as not related based on company's conventions, while for premature delivery is assessed as unlikely related. (defaults to ""related"" in the safety database for reporting purposes).",29.0,Adults,0,1
863923,"No additional adverse event; patient received improperly stored vaccine; This spontaneous report was received from a registered nurse, referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, and previous drug allergies or reactions were not reported.      On 20-FEB-2020, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck)(VARIVAX) injection (strength, dosage regimen, route of administration, and anatomical location were not reported; and lot number S000132 has been verified to be valid, expiration date reported and validated as 02-JAN-2021) as prophylaxis (product storage error). The sterile diluent (MERCK STERILE DILUENT) used to reconstitute the vaccine was properly stored. No additional adverse event.  The temperature excursion was reported as: temperature total time in the range 6 degrees Fahrenheit to 14 degrees Fahrenheit (-14 degrees Celsius to -10 degrees Celsius) 6.7 degrees Fahrenheit. The time frame was 5 minutes. No previous temperature excursions reported. A data logger was used.  This is one of two reports received from the same reporter.; Sender's Comments:  US-009507513-2002USA010011:",,Unknown,0,1
869228,"No additional adverse effects reported; A physician states that on 04/20/2020 a patient was administered an improperly stored dose of VARIV AX.; This spontaneous report has been received from a physician, referring to a patient of unknown gender and age, Information about the patient's pertinent medical history, concurrent conditions and previous drug reactions and allergies was not provided.  On 20-APR-2020, the patient received an improperly stored dose (product storage error) of varicella virus vaccine live (oka/merck)(VARIVAX) for prophylaxis, lot number S010465 (had not been valid upon internal validation) and expiration date 20-MAY-2021 (strength, dose, frequency, route of administration and anatomical location were not provided).  The vaccine was stored at 14 Fahrenheit (F) for a timeframe of 339 minutes, with no previous temperature excursion. The call was due to a Digital Data Logger.  No additional adverse events were reported.",,Unknown,0,1
879310,"No known adverse effects; received dose of improperly stored Varivax and MMR II; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. No information regarding the patient's medical history, concurrent conditions, concomitant medications and previous drug reactions or allergies was reported.  On 05-AUG-2020, the patient was vaccinated with varicella virus vaccine live (oka/merck)(VARIVAX) lot number S015464 was verified to be valid, expiration date reported and established as 20-MAY-2020 (dose, route of administration and anatomical location were not provided) for prophylaxis. On the same day, the patient was also vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) lot number S013536 was verified to be valid, expiration date reported and established as 02-MAY-2020 (dose, route of administration and anatomical location were not provided) for prophylaxis.  The administered doses of vaccines experienced a temperature excursion of -14.3 Celsius degrees for 3 hours and 45 minutes. There was no previous temperature excursions. Digital Data Logger was involved.   The patient did not experience any additional adverse reactions.",,Unknown,0,1
855739,Patient had swelling & redness below injection site. Complained of pain when trying to raise arm. Area sensitive to touch. Patient given Keflex 500mg q 12hrs x 10 days for cellulitis. Outcome pending,58.0,Adults,1,0
886034,pt fell on floor. pt remained alert and consious. pt drank gator ade. mother sat with patient until ems arrived. pt's pulse-ox was 100%. pt left store healthy.,14.0,Kids,0,0
898849,"Patient administered MMR II and PROQUAD concurrently; This spontaneous report was received from a Nurse and refers to a 11 years old patient of unknown gender. Information regarding the patient's concomitant therapies, concurrent conditions, medical history and historical drugs was not provided.  On 10-NOV-2020,  the patient was vaccinated concurrently  with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) 0.5 milliliter for prophylaxis and measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) 0.5 milliliter for prophylaxis  (route of administration, lot number and expiration date were not reported for any suspect therapy).",11.0,Kids,0,1
889317,swelling of arm; fatigue; joint pain for months after incident; fever; brain fog; inflammation,29.0,Adults,1,0
856504,"4 hours after vaccination onset pain (L) upper arm constant, pain level 3-10/10",80.0,Seniors,1,0
874485,"extreme pain in my lower left extremities; pain goes from my left toe up to my left hip; pain goes from my left toe up to my left hip across my groin; pain / across my buttox; couldn't walk; excruciating pain; This case was reported by a consumer and described the occurrence of pain in extremity in a 83-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 19th December 2019, the patient received the 2nd dose of Shingrix. In April 2020, between 3 and 5 months after receiving Shingrix, the patient experienced pain in extremity, pain in hip, groin pain, buttock pain, unable to walk and pain. On an unknown date, the outcome of the pain in extremity, pain in hip, groin pain, buttock pain, unable to walk and pain were not recovered/not resolved.   The reporter considered the pain in extremity, pain in hip, groin pain, buttock pain, unable to walk and pain to be related to Shingrix.  Additional details were provided as follows: The age at the vaccination was not reported. The patient received Shingrix and had a very violent reaction to the shingles shot.  The patient had extreme pain in my lower left extremities and the pain goes from left toe up to left hip across groin and across buttox and been confined to a walker.  The patient could not walk and was in rehab for several weeks and still experiencing from excruciating pain. The patient had not contacted an attorney yet. But thought would call company to see if there were any cases on this. The patient was calling because feel company was responsible for pain and would be reaching out to company regarding the pain the suffering from.  The reporter consented to follow up.",,Unknown,1,0
873670,Shoulder Pain and reduced range of motion since immunization on 12/19/2019. Patient has been exercising to increase range of motion. Pain level has decreased but is still present.,71.0,Seniors,1,0
915984,Headache and diarrhea lasting 12 hours,35.0,Adults,1,0
870898,Child given vaccine that may have had temperature excursion (Data Logger Failure) with stable fridge temps before & after. DOH determine the vaccine to be at risk & advised reporting & revaccination Child had no ill effects thus far,1.5,Kids,0,1
900407,Sharp pain in upper arm that occurs on movement.  Pain has continued to present,64.0,Adults,1,0
908008,"12/19/2020 MORNING WOKE UP AT 4PM FOR WORK, HAD HIVES ALL OVER EXTREMITIES AND TRUNK. WENT TO URGENT CARE; PRESCRIBED MENTHOPREDNISONE. TAKING THE PREDNISONE AND ZYRTEC SINCE THAT DATE.  *HX 5-6 MONTHS OF HIVES.  CONSULTING WITH ALLERGIST. SEEN 12/21/2020.",24.0,Adults,0,0
883703,"Thirty five minutes following administration, patient became nauseous, dizzy, headache occipital area of head, and blurred vision. A fever developed at about 7:30pm with chills that lasted until about 4:30am the next morning.",48.0,Adults,1,0
905843,"PATIENT REPORTS RECEIVING VACCINATION AT APPROXIMATELY 830AM. SHE WAS BUSY THROUGHOUT THE DAY BUT ONCE SHE RETURNED TO HER OFFICE AROUND 120 PM, SHE STARTED TO NOTICE HER ARM IN WHICH SHE RECEIVED HER VACCINE WAS PAINFUL AND SHE WAS UNABLE TO ""LIFT IT UP"". SHE ALSO NOTICED HER TONGUE BEGAN TO FEEL ""WIERD AND TINGLY"". SHE THEN REALIZED HER TONGUE WAS PUSHED UP AGAINST HER TEETH AND COULD SEE A VISIBLE TOOTH MARK ON HER TONGUE. SHE ALSO REPORTS THAT HER BRAIN FELT ""FOGGY"" DURING THIS TIME"". ADDITIONALLY, SHE REPORTS THAT ONSENT OF ALL HER SYMPTOMS PRESENTED PROGRESSIVELY. SHE RECIEVED IM BENADRYL ONSITE PRIOR TO TRANSFER TO THE EMERGENCY ROOM FOR EVALUATION. AT THE EMERGENCY ROOM SHE WAS GIVEN THREE MEDICATIONS, SHE RECALLS ONE WAS A STERIOD AND BELIEVES ATLEAST ONE WAS AN ANTIHISTAMINE. HOWEVER, SHE IS NOT COMPELTELY CERTAIN WHAT THE OTHER MEDICATIONS WERE. SHE REPORTED IMPROVEMENT OF SYMPTOMS WITH MEDICATION. SHE WAS PRESCRIBED BENADRYL AND A MEDROL DOSE PAK AT TIME OF DISCHARGE. SHE WAS NOT ADMITTED TO THE HOSPITAL.",42.0,Adults,0,0
887672,"Soreness; This case was reported by a pharmacist via call center representative and described the occurrence of pain in a 84-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Coumadin.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced pain. On an unknown date, the outcome of the pain was recovered/resolved.   It was unknown if the reporter considered the pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. Pharmacist reported the patient experienced soreness after 1st dose of Shingrix.  The reporter consented to follow up. For tolerance in 2nd dose of Shingrix refer case US2020AMR193446.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR193446:Same patient, 2nd dose",84.0,Seniors,1,0
882520,"did not receive the second dose on time because the patient started chemotherapy.; This case was reported by a pharmacist via call center representative and described the occurrence of cancer in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 15th March 2018, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced cancer (serious criteria GSK medically significant). The patient was treated with chemotherapy, nos (Chemotherapy). On an unknown date, the outcome of the cancer was unknown.   It was unknown if the reporter considered the cancer to be related to Shingrix.  Additional details were provided as follows: Till the time of reporting, the patient did not receive the 2nd dose of Shingrix on time because the patient started chemotherapy.  The patient wanted to have the 2nd dose on the day of reporting.",64.0,Adults,0,0
891865,"The bump was measured: 6 inches long and 11 inches wide; very red,hot, hard bump on the right thigh which is swollen and growing; very red,hot, hard bump on the right thigh which is swollen and growing; very red,hot, hard bump on the right thigh which is swollen and growing; This case was reported by a other health professional via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 4-year-old female patient who received DTPa-IPV (Kinrix) (batch number D24G7, expiry date 4th June 2022) for prophylaxis.   Co-suspect products included INFLUENZA VIRUS VACCINE INACTIVATED (FLUZONE VACCINE) for prophylaxis.   On 28th September 2020, the patient received Kinrix and FLUZONE VACCINE. On an unknown date, less than 3 weeks after receiving Kinrix, the patient experienced extensive swelling of vaccinated limb, injection site erythema, injection site warmth and injection site induration. On an unknown date, the outcome of the extensive swelling of vaccinated limb, injection site erythema, injection site warmth and injection site induration were unknown.   It was unknown if the reporter considered the extensive swelling of vaccinated limb, injection site erythema, injection site warmth and injection site induration to be related to Kinrix.  Additional details were reported as follows: Reporter was medical assistant. On 28th September 2020, the patient received both Kinrix and Flu vaccine (Fluzone) on the same day, on the thigh. The patient developed a very red, hot and hard bump on the right thigh which was swollen and growing, the bump was measured 6 inches long and 11 inches wide, it goes from the top of the thigh to almost reach the knee. The reporter consented to follow up. This case had been linked with US2020203021, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020203021:same reporter",4.0,Kids,0,1
872435,"No additional adverse effects reported; improperly sotred dose of PROQUAD was administered to a patient; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, concomitant medications and drug reactions/allergies were not provided.     On 29-MAY-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) lot # S031702 with an expiration date on 06-APR-2021, for prophylaxis. Vaccine was improperly stored at a temperature of 32.7F during a time frame of 4 hours. The call was because of a data logger and no previous temperature excursions neither additional adverse effects were reported.",,Unknown,0,1
905012,"Aching in both shoulders, aching progressed all over body 2 days later, has had shingles since his 30's, outbreaks normally occur in lower back, took Valtrex medication which caused reactions to subside.",74.0,Seniors,0,0
863942,"Breech; Foetal vaccine exposure during pregnancy; This is an observational study case, initially received from other health professional on 27-Feb-2020, concerning a female foetal subject, whose mother was 26-year-old, pregnant, female subject of body weight: 141 lbs, height: 68.5 inches and body mass index (BMI): 21.1 enrolled in, a prospective observational safety study.  The mother's medical history included Chiari malformation and she was Rh negative.  The mother's concomitant medications included ferrous sulfate for anemia.  The mother did not have any previous pregnancies, nor maternal and paternal history with major congenital malformation (MCM). The mother did not consume tobacco, alcohol and illicit-drugs during pregnancy.  The mother's last menstrual period (LMP) date was 07-Apr-2019. The type of pregnancy was singleton. The mother's estimated delivery date (EDD) was 12-Jan-2020 and corrected estimated delivery date (CEDD) was not provided. The subject's mother did not consume alcohol, tobacco and illicit drugs during pregnancy. The father's age was not provided.  On 28-Jun-2019, the subject's mother underwent first sequential and nuchal translucency.  No MCM was noted.  On 26-Jul-2019, the subject's mother underwent second sequential and no MCM was noted.  On 03-Sep-2019, the subject's mother underwent targeted ultrasound and no MCM was noted.  On 21-Oct-2019, at gestational age of 28 weeks, the subject's mother was administered Afluria QIV (Flu Vaccine Egg Split QIV CSL) [influenza vaccine, batch number: P100112488, dose, route of administration, anatomical location and expiration date: not reported] for influenza immunisation (explicitly coded as 'Foetal exposure during pregnancy').  On 19-Nov-2019, 29 days after vaccination, the subject's mother developed anemia.  On an unknown date, the pregnancy was complicated with breech presentation of foetus in uterus.   At gestational age of 39.1 weeks, the subject's mother vaginally delivered a live female neonate. The neonate birth weight was 3130 grams. No data was reported for head circumference and length. Appearance, pulse, grimace, activity and respiration (APGAR) score at one minute was 6 and at five minutes was 8. No data was reported for APGAR score at ten minutes. No MCM was identified at birth.  At the time of this report, the outcome of breech presentation' was not reported.  The event of 'breech presentation' was considered serious due to the criterion of medical significance.  The reporter did not provide the causality assessment to Afluria QIV.  This case is linked to case 201907400 (the corresponding mother case).  Company comment: Reportedly, breech presentation was associated with Afluria QIV. Subject's mother was administered vaccine at approximately 28 weeks of gestation and the event was noted on an unknown date. Chronology needs more clarification. Most breech presentations seem to be chance occurrences. However, in up to 15% of cases, it may be due to foetal or uterine causes. Therefore, causal role of the suspect vaccine is assessed as not related. Foetal exposure during pregnancy is assessed as unrelated per company's conventions.; Sender's Comments: Reportedly, breech presentation was associated with Afluria QIV. Subject's mother was administered vaccine at approximately 28 weeks of gestation and the event was noted on an unknown date. Chronology needs more clarification. Most breech presentations seem to be chance occurrences. However, in up to 15% of cases, it may be due to foetal or uterine causes. Therefore, causal role of the suspect vaccine is assessed as not related. Foetal exposure during pregnancy is assessed as unrelated per company's conventions.",,Unknown,0,1
895646,"it appears injection administerd high, now increased pain with shoulder movement",26.0,Adults,1,0
916290,Mild swelling at injection site without erythema present.  Mild swelling of soft tissue of the lower axillary  area of the left upper arm.  Pain in the axillary area on lifting of the arm.  Mild tenderness on palpation of the swollen lower axillary area.,48.0,Adults,1,0
894475,Heeling hot and turned red/hives all over her upper body.,40.0,Adults,0,0
906193,"a patient has accidently administered a 2nd dose of vaccine without adverse event; Initial information regarding an unsolicited valid non-serious case was received from a consumer via Medical Information (Reference number- 00372235) and transmitted to Sanofi on 25-Nov-2020.  This case involves a 65 years old male patient who received QUADRIVALENT INFLUENZA VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT], (Extra dose administered).  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medication included pneumococcal vaccine polysacch 23V (Pneumovax 23).  The patient was given two doses of QUADRIVALENT INFLUENZA VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] (Lot numbers: UJ500AA, UJ555AA) via an unknown route for prophylactic vaccination on two separate occasions. On the first visit on 30-Sep-2020, the patient was given 0.7 ml of the product in the left deltoid. No other vaccinations or medications were given on that visit. On 19-Nov-2020, the same patient was given 0.7 ml of the product in the right deltoid. It was reported that the patient had accidently administered a 2nd dose of vaccine (Extra dose administered).   It was a case of actual medication error due to Extra dose administered.  At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
904139,"First dose:   Shingles appeared on upper chest on evening of injection.  Burned,  painful if fabric or anything touched area.  Pain lasted till next AM but evidence of rash lasted a couple weeks.  Second dose:  shingles appeared in same area as before (upper chest) but also on neck & face.  Burned. Painful if fabric or anything touched area.  Chills at night.  Next AM:   Face & eyes swollen.  By noon, day after injection,  area still red but not as painful. Swelling in face starting to go down.",78.0,Seniors,1,0
870309,"breakout on her shoulder; This case was reported by a consumer via call center representative and described the occurrence of skin breakout in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced skin breakout. On an unknown date, the outcome of the skin breakout was unknown.   It was unknown if the reporter considered the skin breakout to be related to Shingrix.  Additional details were reported as follows:  The age at vaccination was not reported. Caller was a patient reporting an adverse event on behalf of another patient.  The patient states that she was in the pharmacy and a woman in the pharmacy told her that after she received the 1st dose of Shingrix, she developed a breakout on her shoulder. Caller did not have any additional details regarding the event or patient. This case has been linked with US2020075700, reported by same reporter.",,Unknown,0,0
866529,"No adverse effects reported; The patient was administered an improperly stored dose of VARIVAX; This spontaneous report has been received from a vaccine coordinator concerning a patient of unknown age and gender.      The patient's pertinent concurrent conditions, medical history, drug/allergy reactions, and concomitant therapies were not reported.  On 23-MAR-2020, the patient was administered an improperly stored dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) (strength, dose, vaccination scheme, route of administration, and anatomical location, were not reported) with lot number (lot # S020159 (verified to be a valid lot number) expiration date reported and stablished as 30-JUN-2021) for prophylaxis. The vaccine temperature was -13.3 Celsius. The time frame was 5 hours and 5 minutes. The vaccine had a previous temperature excursion with a temperature excursion of -13.6 Celsius for 24 minutes. The call was due to a datalogger.  No additional adverse effects were reported.",,Unknown,0,1
897330,"a patient received an expired doe of FLUZONE QUADRIVALENT/ No AE; Initial information regarding an unsolicited valid non-serious case was received from a pharmacist via agency (Reference number- 00315880) and transmitted to Sanofi on 14-Oct-2020.  This case involves female patient (age unspecified) who received an expired dose of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED (Fluzone quadrivalent) [lot number and expiry date not reported] via an unknown route at an unknown administration site on an unknown date for prophylactic vaccination (expired product administered).  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.   It was an actual medication error due to expired vaccine used. (Latency: at the time of vaccination)  It was reported that, reporter wanted to know how long before patient had to wait before they could administer the correct vaccine.   At the time of reporting, patient had no adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information available on the batch number for this case.",,Unknown,0,1
891963,"At 2:57pm on Oct 22, 2020, I gave Afluria to the patient in her right arm. No swelling or adverse reaction occurred at the time of vaccination. Approximately 15 minutes later, a coworker told me that the patient lost consciousness. When I arrived with the emergency kit, the patient was sitting up and speaking. Her mother who was with her did not want us to call 911. I checked the administration site, and there was no indication of an allergic reaction. Patient said she did not have any swelling in her face or mouth. An ice pack was given to her because she hit her head on the floor when she passed out. She seemed lethargic. We helped her into a wheelchair and I advised the mother to take her to the hospital to get checked out. I asked the patient if she had eaten, and she said yes. We got her some orange juice and she drank it. While she was drinking the juice, I tried to take her blood pressure twice, but both times I had an error message ""ERR 5"", which according to the manual meant that there was ""an unacceptable difference between systolic and diastolic pressures"".  The mother wheeled her out of the store and said they were going to the hospital. I asked her to call me and keep me updated.",16.0,Kids,0,0
907767,"vomiting a lot; This is a spontaneous report from a Pfizer sponsored program . A non-contactable consumer (patient's partner) reported that a male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration in Dec2020 at single dose for covid-19 immunisation.  The patient's medical history and concomitant medications were not reported. Caller's partner received the vaccine yesterday morning and drank a lot of alcohol in the evening. In Dec2020, her partner (patient) was vomiting a lot. She was worried if this was due to the vaccine and wanted to know what else could happen. Outcome of event was unknown.   No follow-up attempts are needed. Information about lot/batch number cannot be obtained.",,Unknown,0,1
883170,Pt reports generalized muscle aches and malaise lasting about 24 hours after evening of vaccination.,65.0,Adults,0,0
891939,"Started to bother her on Friday with swelling and muscle pain which lasted about 2-3 days. Saw doctor today had no fever, no stomach pains or diarrhea, but feeling tired, some weakness and headache. Today makes seven days.",75.0,Seniors,1,0
867859,"Bronchitis; Bacterial vaginosis; Vaccine exposure during pregnancy; This is an observational study case, initially received from other health professional on 02-Jan-2020, concerning a 30-year-old female, pregnant subject, of body weight 114 lbs, height 61.2 in and body mass index (BMI) 21.4, enrolled in a prospective observational safety study on pregnancy outcomes in women immunized with Afluria QIV, a seasonal quadrivalent vaccine, during pregnancy.  The subject's relevant medical history included bacterial vaginosis.   The subject's concomitant medications included: Prenatal vitamins (unspecified vitamins and minerals) for healthy pregnancy and Metrogel (metronidazole) for bacterial vaginosis.   The subject had no previous pregnancies. The subject had no history of offspring with major congenital malformation (MCM) and no maternal or paternal history with MCM. The subject did not use tobacco, alcohol or illicit drugs during pregnancy.   The subject's last menstrual period (LMP) date was 01-Aug-2019. The subject's estimated delivery date (EDD) was reported as 07-May-2020 and corrected estimated date of delivery (CEDD) was not reported. The type of pregnancy was singleton.  On 09-Sep-2019, at approximately five weeks of gestation (calculated per LMP), the subject was administered Afluria QIV (Flu Vaccine Egg Split QIV CSL) [influenza vaccine, batch number: P100110950, dose, expiration date, route of administration and anatomical location: not reported] (explicitly coded as 'Vaccine exposure during pregnancy') for an influenza immunization.  On 07-Oct-2019, the subject underwent cystic fibrosis mutation analysis and no MCM was noted.   On 21-Oct-2019, the subject underwent first trimester screening and no MCM was noted.   On 04-Nov-2019, 1 month and 26 days after vaccination, the subject experienced recurrence of bacterial vaginosis and was treated with terconazole at dose of 0.4 %, every day, vaginally.  On 11-Nov-2019, treatment with terconazole was stopped.  On 02-Dec-2019, the subject underwent second trimester screening and no MCM was noted. On the same day, the event of bacterial vaginosis was resolved.  On an unspecified date, an unknown amount of time after vaccination, the subject developed bronchitis.  On 18-Jan-2020, the subject started treatment with Zithromax (azithromycin) for bronchitis, at dose of 250 mg, two pills first day and than one pill for four days, orally.   On 22-Jan-2020, the treatment with Zithromax was stopped.  On 03-Feb-2020, the subject underwent one hour glucola test (1HGCT) and no MCMc were noted.  On 24-Mar-2020, the subject underwent group B strep (GBS) test and no MCMc were noted.  At the time of this report, the outcome of event bronchitis was not reported.  The event of 'bronchitis bacterial' was assessed as serious, due criterion of medical significance, per company.  The reporter did not provide causality assessment to Afluria QIV.  Follow up information received from other health professional on 12-Feb-2020: Medical history was updated. Start and stop date added and outcome changed from not reported to resolved for bacterial vaginosis. Narrative was amended accordingly.  Follow up received from other health professional on 02-Apr-2020: Two lab tests were added (1HGCT and group B strep (GBS) test). Bronchitis was added as event and Zithromax was added as treatment medication. The case upgraded to serious due to bronchitis. The narrative was amended accordingly.  Company comment: The patient experienced bacterial vaginosis 1 month 26 days after receiving Flu Vaccine Egg Split QIV CSL. Chronology is unsuggestive. Moreover, patient's relevant medical history includes bacterial vaginosis. The subject also developed bronchitis, an unknown amount of time after vaccination. Chronology needs more clarification. However, causal role of the suspect vaccine cannot be excluded and is assessed as unlikely related to the event bronchitis bacterial (defaults to ""related"" in the safety database for reporting purposes). Causality is not related for bacterial vaginosis. Vaccine exposure during pregnancy assessed as not related per company's conventions.; Sender's Comments: The patient experienced bacterial vaginosis 1 month 26 days after receiving Flu Vaccine Egg Split QIV CSL. Chronology is unsuggestive. Moreover, patient's relevant medical history includes bacterial vaginosis. The subject also developed bronchitis, an unknown amount of time after vaccination. Chronology needs more clarification. However, causal role of the suspect vaccine cannot be excluded and is assessed as unlikely related to the event bronchitis bacterial (defaults to ""related"" in the safety database for reporting purposes). Causality is not related for bacterial vaginosis. Vaccine exposure during pregnancy assessed as not related per company's conventions.",30.0,Adults,0,1
911376,"Diarrhea; she could feel her stomach again; This is a spontaneous report from a contactable consumer. A 64-year-old female patient received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA Vaccine BNT162B2; lot number: EH9899), via an unspecified route of administration on 17Dec2020 at a single dose by injection once so she doesn't get COVID. The patient's medical history was not reported. There were no concomitant medications. The patient experienced diarrhea on 19Dec2020. The patient just thought about it, she had diarrhea, she had said everything is good, but she didn't think about it when answering the questions, when she eats the food, she notices, she got the COVID vaccine. She doesn't know how to change responses to the questions. She answered no to them, but this could be tied together. Every time she eats, she gets diarrhea. Patient got the COVID test. She wanted to change answers, but it wouldn't let her. Patient could feel her stomach again in Dec2019, but she hasn't eaten. This was the first time she received the vaccine. The outcome of the events was unknown.",,Unknown,0,1
899455,"two Fluzone Quadrivalent doses were given to a 21 month old child 5 days apart/ no AE; Initial information regarding an unsolicited valid non-serious case was received from a nurse via Medical Information (MI) (Reference number- 00337530 ) and transmitted to Sanofi on 29-Oct-2020.  This case involves a 21 months old male patient who received two doses of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED [FLUZONE] (strength- standard, presentation- multidose vial) 5 days apart on 24-Oct-2020 ( lot number UJ477AC expiration date: 30-Jun-2021) via intramuscular route in the right thigh and again on 29-Oct-2020 (lot number UJ452AB expiration date: 30-Jun-2021) via intramuscular route in the left thigh for prophylactic vaccination (Extra dose administered).  It was reported as the patient had received 2 doses of vaccine last year.  Medical history, medical treatments, and family history were not provided.  Concomitant therapy was reported as none on 24-Oct-2020 and Hepatitis A vaccine on 29-Oct-2020 (batch number and dosing details not reported) for prophylactic vaccination .  It was a actual medication error due to Extra dose administered.  It was reported as the patient was supposed to get only one dose this year. Reported wanted to know about to side effects if any to look for.  At the time of this reporting, patient had no adverse event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",1.75,Kids,0,1
864734,Right arm pain/hot arm starting the next day for 5 days. It was severe for 4 days. Fever 3 days 99.3-102.8. Chills with cold hands and feet for 3 days with fever. Treated with Aleve and Ibuprofen 4 days. Hot pack on 4th day to arm with moderate relief,55.0,Adults,1,0
907259,"Severe itching, irritation, took oral Benadryl, proceeded to nearest Emergency Room",57.0,Adults,0,0
899856,The patient experienced a Syncopal episode immediately after receiving these immunizations and regained consciousness without intervention,19.0,Adults,0,0
901173,"Swelling, hot to touch, redness, hard and some pain at injection site",4.0,Kids,1,0
860050,"Pain and swelling at the site of injection; Pain and swelling at the site of injection; This spontaneous report was received from a nurse referring to a 41-year-old female patient. The patient's concurrent conditions were not reported. The patient's medical history included herpes virus infection. Concomitant therapies included ethinyl estradiol, norgestimate (TRI-SPRINTEC) and valacyclovir hydrochloride. On 22-OCT-2019, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) intramuscular (dose 1, lot# R024259, expiry date: 30-MAY-2021) for prophylaxis. On 09-JAN-2020, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) intramuscular (dose 2, lot # S026372, expiry date: 01-APR-2020) for prophylaxis. On 25-JAN-2020, the patient developed pain (injection site pain) and swelling at the site of injection (injection site swelling). The patient did not receive any treatment for the event but called the nurse and sought medical attention. The outcome of injection site pain and injection site swelling was not recovered. The causality of the events was not reported with respect to suspect therapy hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9).",,Unknown,0,0
883595,"swollen arm area and red rash, low grade fever 99.5, nausea, chills,",69.0,Seniors,1,0
901177,Patient was given Kinrix . This vaccine is for 4-6 year olds.,0.5,Kids,0,1
915402,"NauseaVomiting, Syncope & SYNCOPE; FEVER; DIAPHORESIS; NAUSEA AND VOMITING",48.0,Adults,1,0
898974,"Bruising under the eye / Left eye; Flu like symptoms; This case was reported by a physician via sales rep and described the occurrence of eye contusion in a 51-year-old male patient who received Herpes zoster (Shingrix) (batch number 3L3PR, expiry date 11th December 2021) for prophylaxis.   On 14th November 2020, the patient received Shingrix. In November 2020, less than a week after receiving Shingrix, the patient experienced eye contusion and influenza-like symptoms. On an unknown date, the outcome of the eye contusion and influenza-like symptoms were unknown.   It was unknown if the reporter considered the eye contusion and influenza-like symptoms to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The batch number of Shingrix was updated from 303PR to 3L3PR, as per sales data sheet. The patient Flu like symptoms and bruising under the left eye.  No other information about the patient of vaccine available not provided.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020226582:same reporter",51.0,Adults,0,1
903913,"at 11pm started to lot of soreness, lump in armpit. Periods of feeling very hot, chills and profuse sweating. woke up at 11pm, 1am, 3am, 5am 'woke up every few hours with intervals of profuse sweating'. 12/18/2020 feels like 'never happened' other than some soreness in arm.",47.0,Adults,1,0
902710,"Pain and aching; Redness; Swelling; This spontaneous case was received on 27-Oct-2020 from other non-health professional (consumer) via Agency (reference number: SEQW20-04372) and concerned a female patient of unreported age.    The patient's medical history and concomitant medications were not reported.     On an unknown date, the patient was vaccinated with influenza virus vaccines polyvalent (brand not specified, dose, route of administration and anatomical location: not reported) for influenza prophylaxis. The batch number was not reported.    On an unknown date, an unknown amount of time after receiving influenza virus vaccines polyvalent, the patient experienced some pain, redness, swelling and aching. The patient stated the reactions were normal and thought that was expected.   On an unknown date, a day or two after the injection, the reactions disappeared and the patient recovered from the events.   The reporter did not provide causality assessment.  The reporter assessed the case as non-serious.  Case updated on 26-Nov-2020: Correction made to information received on 27-Oct-2020: Suspect product recoded from 'INN Seasonal' to 'INN Flu Vaccine Seasonal'. No changes in narrative.   Company comment:The patient developed pain, erythema and swelling on an unknown date after vaccination with the suspect product, influenza virus vaccines polyvalent. Although onset date was not provided, narrative suggested plausible temporal relationship. No information regarding concomitant medications and medical history was provided. Considering all above mentioned, causal relationship for all events is assessed as possibly related. (defaults to ''related'' in the safety database for reporting purposes).; Sender's Comments: The patient developed pain, erythema and swelling on an unknown date after vaccination with the suspect product, influenza virus vaccines polyvalent. Although onset date was not provided, narrative suggested plausible temporal relationship. No information regarding concomitant medications and medical history was provided. Considering all above mentioned, causal relationship for all events is assessed as possibly related. (defaults to ''related'' in the safety database for reporting purposes).",,Unknown,0,0
892410,"Reaction at the site of injection; swelling, redness, hot to touch",65.0,Adults,0,0
891205,"pain, muscle spasm started on left side where vaccine was administered then spreaded to top of hip, started on 10.6.2020 and patient still feel almost the same on 10.19.2020 patient has appointment with doctor",65.0,Adults,0,0
902328,"No additional AEs reported; Expired vaccine used; This spontaneous report was received from a Nurse Practitioner refers to a patient of unknown age and gender. No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided.  On 09-DEC-2020, the patient was vaccinated with a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) 0.5 ml, subcutaneously, lot # S017237 and expiration date on 01-DEC-2020 (strength, frequency and anatomical location were not provided) for prophylaxis (expired product administered). No additional adverse events reported.",,Unknown,0,1
910362,"8 hours after injection: itching, induration, pain @ injection site (left deltoid) Following morning: headache, earache & pressure,  Post nasal drip, increased pain & itching @ injection site, ping-pong sized swelling at injection site with redness. Took Motrin for symptoms with some relief.  2nd Day: improvement in pain, swelling, itching, still present. Slight headache/bilateral earache. General malaise. Took Motrin with some relief. 3rd day: left arm tender to touch, swelling/redness further decreased, intermittent itching. Malaise improved. Remnants of headache/earache.  No need for Motrin. 4th Day: arm pain/itchiness continues to decrease, no swelling now, no headache, no malaise, some ear pressure.",,Unknown,1,0
886024,"Symptoms: flu-like with aches, chills, severe shaking, headache, joint pain, no appetite, extreme fatigue that lasted 2.5 days. Had to remain in bed. Took ibuprofen for pain. Unable to work or leave home for 3 days until recovered",64.0,Adults,1,0
910647,"Autoimmune disorder, it just exacerbated when I got the shot; Autoimmune disorder, it just exacerbated when I got the shot; Joint pain; My immune system overreacted and it was like rash all over my body; This is a spontaneous report from a contactable Nurse for herself.  A 32-year-old female patient received bnt162b2 (BNT162B2; Lot #EH9899) vaccine, intramuscular on 18Dec2020 at single dose for covid-19 immunisation.  The patient medical history included autoimmune disorder.  The patient's concomitant medications were not reported.  The patient stated that she suffered from unknown autoimmune disorder, and it just exacerbated when she got the shot, and she had like rash all over her body and had joint pain. The patient was treated with steroids.; Sender's Comments: A possible contribution role of BNT162B2 to the aggravated autoimmune disorder, joint pain and rash cannot be excluded.  The case will be reassessed should additional information become available.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.",32.0,Adults,0,0
896798,"Patient states that 4 hours after her influenza vaccination on 10/05/2020 she began having a stabbing pain, with difficulty lifting her left arm over her hand, with occasional numbness in her left hand. NSAID's have helped with the patient's swelling very little. Patient is still currently having all the listed symptoms.",37.0,Adults,1,0
908779,I developed fever and chills and headach for 2 nights now  my fever was a 102.3 lasted at least 6-8 hours  had Pfizer-bioNTech COVID-19vaccine,73.0,Seniors,0,0
879879,"chills; fatigue; headache; body aches; fever was 99.8 the first time it presented; arm soreness; This case was reported by a consumer via call center representative and described the occurrence of chills in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 29th July 2020, the patient received the 2nd dose of Shingrix. On 30th July 2020, 1 days after receiving Shingrix, the patient experienced chills, fatigue, headache, general body pain, fever and pain in arm. On an unknown date, the outcome of the chills, fatigue, headache, general body pain and fever were not recovered/not resolved and the outcome of the pain in arm was recovered/resolved.   It was unknown if the reporter considered the chills, fatigue, headache, general body pain, fever and pain in arm to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix and chills, fatigue, headache, general body pain, fever was 99.8 the first time it presented.  The arm soreness resolved in one day.   All other symptoms were still present and come and go but had not resolved. The reporter consented to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020159668:Same reporter",70.0,Seniors,1,0
888757,Arm inflamed and red the following morning and doctor told her she had phlebitis. Got a prescription for bactrim ds on wednesday morning. Big red blotch on arm and heading to axilla.,68.0,Seniors,0,0
900987,redness and swelling at injection site -subsequent neck and shoulder pain,73.0,Seniors,1,0
871345,"Fever of 102F; Vaccine administered to a 7 month-old-child by mistake; This is a spontaneous case, initially received from other health professional (nurse) via Med Communications (reference number: SEQ19-04421) on 10-Oct-2019, concerning a 7-month-old female patient.  The patient's medical history and concomitant medications were not provided.  On 09-Oct-2019, the patient was administered Flucelvax QIV [influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5ml, route of administration: intramuscular, anatomical location: deltoid, batch number: 261198 (also reported as 261199), expiration date: 18-Jun-2020 (also reported as 19-Jun-2020)] (explicitly coded as Inappropriate age at vaccine administration') for an influenza prophylaxis.  On 10-Oct-2019, one day after vaccination, the patient developed fever of 102F. As reported, the patient did not receive any treatment.  At the time of initial reporting, event of fever was not resolved.  The reporter assessed the case as non-serious and did not provide causality assessment.  Non-significant follow-up reported by Med Communications (reference number: SEQ19-05258) on 22-Oct-2019: Additional Med Communications reference number added. No changes in narrative.; Sender's Comments: The patient experienced pyrexia after administration of the suspect product Flucelvax QIV to patient of inappropriate age. Chronology is plausible. No medical history, diagnostic findings and concomitant medications were reported. Causal relationship between the suspect product and product administered to patient of inappropriate age is assessed as not related per company conventions. For the event pyrexia, causal role of the suspect product is assessed as related.",0.58,Kids,0,0
880916,"Pharmacy student called in to report that a patient who was vaccinated on 05-AUG-2020 with varivax and developed a injection site skin rash on the right upper arm; This spontaneous report has been received from pharmacy student concerning a 38 year old female patient. The patient's concomitant therapies, concurrent conditions, historical drugs and medical history were not reported.    On 05-AUG-2020, the patient was vaccinated with one dose of varicella virus vaccine live (oka/merck)(VARIVAX) subcutaneous injection in the right arm Lot # S025914, expiration date 20-AUG-2021 for prophylaxis.   On 17-AUG-2020, the patient developed an injection site skin rash on the right upper arm.      It was reported that the patient did not seek medical attention and no laboratory tests or diagnostic studies were performed.  At the time of reporting, the patient had  not recovered from injection site skin rash on the right upper arm and the causal relationship between varicella virus vaccine live (oka/merck)(VARIVAX) and the injection site rash was not reported.",,Unknown,0,0
872653,"developed shingles; rash was unilateral; blistering; This case was reported by a nurse via sales rep and described the occurrence of shingles in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 19th May 2020, the patient received the 1st dose of Shingrix. On 23rd May 2020, 4 days after receiving Shingrix, the patient experienced shingles, rash and blister. On an unknown date, the outcome of the shingles, rash and blister were unknown.   It was unknown if the reporter considered the shingles, rash and blister to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. After receiving Shingrix, the patient developed shingles. The rash was unilateral and blistering. This case was linked with case US2020AMR089341, reported by the same reporter.",,Unknown,1,0
867664,"loss of taste and smell; loss of taste and smell; had first dose of Shingrix on 23SEP2020 and second dose on 02APR2020; This case was reported by a consumer via call center representative and described the occurrence of taste loss in a 74-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 23rd September 2019, the patient received the 1st dose of Shingrix (intramuscular). On 2nd April 2020, the patient received the 2nd dose of Shingrix. On 2nd April 2020, not applicable after receiving Shingrix and unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the patient experienced taste loss and loss of smell. The action taken with Shingrix was unknown. On an unknown date, the outcome of the taste loss, loss of smell and drug dose administration interval too long were unknown.   It was unknown if the reporter considered the taste loss and loss of smell to be related to Shingrix.  Additional details were provided as follows: The patient reported that around the time of the first dose vaccination, she noted that she lost sense of smell and taste, noticed that especially with food. The patient received 2nd dose of Shingrix late, which led to lengthening of vaccination schedule. The reporter consented to follow up.",74.0,Seniors,0,0
885621,"Approximately 5 hours after the injection I started having full body shaking with got progressively worse.  I vomited up my dinner twice. I was running a fever of 101.  My wife and I went to the emergency room where I was tested for COVID19. Blood was drawn, urine samples taken. I soon felt better and was sent home the Dr. rulled out food poisoning and said she didn't know what the cause was. We determined by a process of elimination the it was the flu shot.",74.0,Seniors,0,0
856269,"shingles; Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication.   On 10-OCT-2017 the patient was vaccinated with zoster vaccine live(ZOSTAVAX) (dose, route, lot# and expiration date were unknown) by a pharmacist for the long-term prevention of shingles and/or zoster-related conditions (for prophylaxis). Subsequent to inoculation, the patient was treated for shingles.  As a direct and proximate result of patient's use of the zoster vaccine live(ZOSTAVAX) vaccine, patient has and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future.  Additional information has been requested.",,Unknown,0,0
860250,"Patient given Varicella instead of MMR as requested. Patient has complaint of red, itchy sore arm.",35.0,Adults,0,0
908724,"hearing loss; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of an unknown age and gender. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On or about 2016, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot #, expiration date, dose, dose # and route not specified) for the long-term prevention of singles and zoster-related conditions. Subsequently on an unknown date, the patient was treated for hearing loss. As a direct and proximate result of the patient's receipt of zoster vaccine live (ZOSTAVAX), the patient continued suffer ongoing injuries including but not limited to mental and physical pain and suffering, medical care and treatment for these injuries; significant medical and related expenses as medical losses and costs included care for hospitalization, physical care, monitoring, treatment, medications and supplies, diminished capacity for the enjoyment of life, diminished quality of life, increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of the event was not recovered. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).  Upon internal review, the event hearing los was considered to be medically significant.",,Unknown,0,0
867835,"expired dose of Daptacel inadvertently given to patient, no AE; Initial information received on 31-Mar-2020 regarding an unsolicited valid non-serious case from a nurse.  This case involves a 17 months old female patient who inadvertently received a 0.5 ml dose of an expired DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL] (cycle series 4, lot C5367AA, expiry date: 30-Mar-2020) on 31-Mar-2020, via an intramuscular route in the left thigh  The patient's medical history, past medical treatment, past vaccination and family history were not provided.  It was an actual medication error due to expired vaccine used.  At the time of reporting, the patient did not experienced any adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",1.42,Kids,0,1
855584,"hypersensitivity reaction; hives; looked like contact dermatitis; This case was reported by a physician via call center representative and described the occurrence of hypersensitivity reaction in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 10 days after receiving Shingrix, the patient experienced hypersensitivity reaction, hives and contact dermatitis. The patient was treated with prednisone. On an unknown date, the outcome of the hypersensitivity reaction, hives and contact dermatitis were recovering/resolving.   It was unknown if the reporter considered the hypersensitivity reaction, hives and contact dermatitis to be related to Shingrix.  Additional case details were reported as follows: The age at vaccination was not reported. The reaction initially looked like contact dermatitis, then hives. It became widespread and severe so a biopsy was performed that showed it was a hypersensitivity reaction.  The patient took a couple courses of prednisone. It was at the time of reporting a couple months since he was first seen in the office and the reaction has improved a lot.  The emergency room visit required to the patient.      Lab Comments: Biopsy was performed on unknown date and that showed it was a hypersensitivity reaction",,Unknown,0,0
867273,"rash at the injection site; felt ill for a day; This case was reported by a consumer and described the occurrence of injection site rash in a 63-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of injection site rash (1st dose, refer case US2020AMR042554).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced injection site rash and feeling unwell. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the injection site rash was unknown and the outcome of the feeling unwell was recovered/resolved.   It was unknown if the reporter considered the injection site rash and feeling unwell to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient felt ill for a day and had a rash at the injection site. This case has been linked to US2020AMR042554 and US2020AMR042566, reported by the same reporter.",,Unknown,1,0
883314,"Patient states he experienced swollen lymph nodes, dizziness (which has improved), and a runny nose about 2 days after vaccine was given.  No respiratory distress or issues.",71.0,Seniors,0,0
883250,Patient said his right arm was swollen and sore. He also stated that he had red streaking lines going around arm towards armpit. I suggest that he go to an urgent care or emergency room.,47.0,Adults,0,0
915719,"Dizzy, shortness of breath, legs are numb within 5 minutes of receiving vaccine, cannot feel feet, whole body tingling, nauseated about 20 minutes after vaccine administration, redness noted in face and at injection site",32.0,Adults,0,0
893563,PT'S LEFT AREM IS STILL SORE AND PT IS UNABLR TO LIFE ARM ABOUT 90 DEGREES,79.0,Seniors,0,0
892834,"Heavy drainage, sore throat, throat swollen, eyes we're very irritated with heavy mucus production, threw up dinner, chills and shaking. Woke up with congestion and experienced fatigue throughout the day on Monday. Slept 3 hours in the afternoon. Other symptoms were absent on Monday. I don't know the name of the vaccine. The pharmacist said it was given. It was the stronger dose for seniors.",69.0,Seniors,0,0
886521,The patients said that she had chills and shaking all night long and with jerking of her left arm.,67.0,Seniors,1,0
898931,"Arm hurt; This case was reported by a consumer and described the occurrence of pain in arm in a elderly male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was unknown.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received second dose of Shingrix and reported arm hurt.",,Unknown,1,0
875487,"The unspecified patient experienced ""fever"" and ""rash"" that ""could be chickenpox"".; The unspecified patient experienced ""fever"" and ""rash"" that ""could be chickenpox"".; The unspecified patient experienced ""fever"" and ""rash"" that ""could be chickenpox"".; This spontaneous report was received from a nurse, referring to a child patient between 1 and 2-year-old of an unknown gender. The patient's pertinent medical history, previous drug reactions, allergies, or concomitant medications were unknown by the reporter.  On an unspecified date, the child was vaccinated with measles, mumps, rubella and varicella (Oka-Merck) virus vaccine live (rHA) (PROQUAD) injection, 1 dose administered subcutaneously, as ""routine vaccination"" (lot number S027459 which has been verified to be valid, expiration date reported and validated as 02-MAR-2021) (vaccination scheme and anatomical site of injection were not reported).  On an unspecified date (also reported as ""within 1-10 days of administration""), the patient experienced fever (pyrexia) and rash. According to the nurse, it could be chickenpox (varicella). The patient sought medical attention, however, no treatment was given for the events and the patient did not have any laboratory diagnostics or studies performed.   The outcome of the events pyrexia, rash and varicella was reported as recovered. The causal relationship between the abovementioned events and therapy with measles, mumps, rubella and varicella (Oka-Merck) virus vaccine live (rHA) (PROQUAD) was not reported.   This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2007USA001874: US-009507513-2007USA001872: US-009507513-2006USA008951:",,Unknown,0,0
880002,"no adverse effects; Patient have been administered doses of improperly stored vaccines; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical histories provided.  On 13-MAR-2020 at 09:33, the patient was vaccinated with an improperly stored dose of haemophilus b conjugate vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAXHIB) lot # S023219, expiration date on 03-MAR-2022, at a dose of 0.5 mL, intramuscular on the left thigh (LT). On that same day, the patient also received pneumococcal 13v conj vaccine (CRM197). Administered dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) experienced the temperature excursion above 9 degrees Celsius (15.5C) for 4 hour and 6 minutes. Digital data logger was involved. There were no previous temperature excursions reported. The outcome was provided as ""supported"". No adverse events reported.   This is one of several reports received form the same reporter.; Sender's Comments:  US-009507513-2003USA002275:Original Case : 2003USA002275 US-009507513-2008USA008889: US-009507513-2008USA008876: US-009507513-2008USA008883: US-009507513-2008USA008885: US-009507513-2008USA008875: US-009507513-2008USA008877: US-009507513-2008USA008878: US-009507513-2008USA008879: US-009507513-2008USA008880: US-009507513-2008USA008881: US-009507513-2008USA008882: US-009507513-2008USA008884: US-009507513-2008USA008886: US-009507513-2008USA008887: US-009507513-2008USA008888: US-009507513-2008USA008891: US-009507513-2008USA008892: US-009507513-2008USA008893: US-009507513-2008USA008894: US-009507513-2008USA008895: US-009507513-2008USA008896: US-009507513-2008USA008897: US-009507513-2008USA008898: US-009507513-2008USA008899: US-009507513-2008USA008900: US-009507513-2008USA008901: US-009507513-2008USA008902: US-009507513-2008USA008903: US-009507513-2008USA008904: US-009507513-2008USA008905: US-009507513-2008USA008906: US-009507513-2008USA008907: US-009507513-2008USA008908: US-009507513-2008USA008909: US-009507513-2008USA008910: US-009507513-2008USA008911: US-009507513-2008USA008912: US-009507513-2008USA008913: US-009507513-2008USA008914: US-009507513-2008USA008915: US-009507513-2008USA008916: US-009507513-2008USA008917: US-009507513-2008USA008918: US-009507513-2008USA008919: US-009507513-2008USA008920: US-009507513-2008USA008921: US-009507513-2008USA008922: US-009507513-2008USA008923: US-009507513-2008USA008924: US-009507513-2008USA008925: US-009507513-2008USA008926: US-009507513-2008USA008927: US-009507513-2008USA008928: US-009507513-2008USA008929: US-009507513-2008USA008930: US-009507513-2008USA008931: US-009507513-2008USA008932: US-009507513-2008USA008933:",,Unknown,0,1
873919,"Pt's wife has reported a significant reaction of an all-over body rash that is suspected to be varicella zoster. Awaiting confirmation with physician, however the office seems to believe this to be the diagnosis.",92.0,Seniors,1,0
903989,Perioral numbness and anxiousness starting 11 minutes after administration and terminating approximately 1 hour later soon after presenting to the emergency department.,36.0,Adults,0,0
911866,"Pfizer-biontech covid-19 vaccine eua 15 minutes after receiving shot my head became itchy. that resolved within 15 minutes. around 1430 that day i developed nausea and diarrhea, which lasted until 12/25/20 at  2130.",48.0,Adults,0,0
892558,"10/12/20 arm a little sore and late afternoon one shooting pain down arm then gone.  I was very sick from midnight on. I woke up with a very bad headache and my jaw was extremely painful like everything had swelled. I was very dizzy and disoriented and had to hold onto cabinets getting to the bathroom to remove my MAD sleep appliance & put on my jaw aligner. Had chills all night, fever and headache.  I took Advil- one of the meds advised for side effects on the list given me and it reduced fever.  Later temp went to 99 and I took advil again. No sleep at all. Temp went down, but in the morning 8am-10am I still had chills, headache and temp started to go up to 100.7.  I took more Advil, temp went to normal.  By afternoon I was okay, but tired. Everything cleared up by late afternoon around 5:00pm.",76.0,Seniors,1,0
890585,"Patient complained of numbness, heat, and inflammation of the left side of face.",49.0,Adults,0,0
887552,"Medical assistant calling to report a temperature excursion that occurred 8/14/2020 which involved the following products: GARDASIL9, PEDVAXHIB, RECOMBIVAX, ROTATEQ. Per caller, ""it would be possible that at least 100 patients have received vaccines; This spontaneous report was received from a medical assistant, concerning a 11-years-old male patient. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies or concomitant medications were not reported.  On 03-SEP-2020, the patient was vaccinated with an improperly stored dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 0.5 ml in the left upper arm for prophylaxis (lot # S023475, expiration date on 26-MAR-2022) (strength, dose, frequency and route of administration were not reported) (incorrect product storage).  The improperly stored dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) experienced a temperature excursion of 35.4 Fahrenheit degrees (F) for the time frame of 20 minutes without a previous temperature excursion. It was confirmed that a digital data logger was involved.  This is one of several cases from the same reporter. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: S023475; expirationdate: 26-MAR-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2009USA006106:",10.0,Kids,0,1
897553,Mother called in to office triage line within 30 minutes of receiving vaccines concerns with cough and rash. Patient without wheeze but mother states he did sound as if he had stridor. Rash consistent with hives based on photos that were obtained by parent at the time of the event. Mother instructed to administer Benadryl at home. By the time patient presented to the office the rash was resolved.,4.0,Kids,0,0
885902,"1) Swelling, pain, tenderness, redness of entire left arm from shoulder to wrist, fever 100.5. Physician observed and ordered Augmentin x 7 days. Symptoms slowly improved over about two weeks. 2) Tachycardia, irregular heart beat, chest pressure, shortness of breath, fatigue beginning two days after vaccine and although I feel better now, symptoms are still present at the time of this report (lasting over a month)",69.0,Seniors,0,0
890074,"Next day she had severe fatigue, hot flashes, headaches, body aches, and 3 diarrhea stools. Denies ever having a fever. (However she takes meloxicam daily due to residual dyspnea and pleuritic pain s/p covid infection )",29.0,Adults,1,0
884482,"3-years-old patient who was vaccinated with FLUZONE HIGH-DOSE QUADRIVALENT by mistake, No AE; 3-years-old patient who was vaccinated with FLUZONE HIGH-DOSE QUADRIVALENT by mistake, No AE; Initial information received on 03-Sep-2020 regarding an unsolicited valid non-serious case from a nurse.  This case is linked to cases 2020SA242184, 2020SA242186 and 2020SA242187 (same reporter).  This case involves a 3-years-old patient (gender unknown) who was vaccinated with a dose (unclear whether 0.5 mL or 0.7 mL was administered) of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] by mistake (Lot number: UJ450AB and expiration date:30-Jun-2021) via unknown route in an unknown administration site as prophylactic vaccination on an unknown date (product administered to patient of inappropriate age and overdose).  Medical history, past medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.  It was a case of an actual medication error due to inappropriate age at vaccine administration and overdose.  No adverse event reported at the time of reporting.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",3.0,Kids,0,1
882856,"VAQTA was given to a 4 month old patient; This spontaneous report was received from a nurse referring to a 4 month old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not reported.  On 01-SEP-2020, the patient was vaccinated with hepatitis a vaccine, inactivated(VAQTA) 0.5 ml, lot # T014835, expiration date on 17-JUL-2021, for prophylaxis (route  and freuqencywas not provided) (Inappropriate age at vaccine administration). combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T014835; expirationdate: 17-JUL-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",0.33,Kids,0,1
872505,"Received vaccines on 5/19. On 5/27, had seizure activity. Hospitalized, normal CBC, EEG, and MRI. Then on 5/28 developed fever x1-2 days up to 101. Fever resolved and developed full body rash on 5/30. Rash resolved in about 1 day.",1.08,Kids,0,1
883385,"PATIENT RECIEVED 2 VACCINES IN SAME (LEFT) ARM - PREVNAR 13 AND FLUZONE HD - PATIENT STATED CAME BACK ABOUT A WEEK LATER WHEN PICKING UP A PRESCRIPTION TO INFORM US ABOUT HER EXPERIENCE WITH 2 VACCINES IN ONE ARM. THERE WAS A LARGE BUMP THAT FORMED  IN THE INJECTION AREA IN THE BEGINNING THEN SLOWLY CHANGED TO A LARGE DARK BRUISE. PATIENT STATED SHE FEELS OK NOW AND IS NOT UPSET, BUT WANTED TO TELL US TO ADVISE FUTURE PATIENTS TO NOT GET IN THE SAME ARM IN THE FUTURE.",83.0,Seniors,0,1
898189,"pneumonia; neurological problems; Information has been received from a lawyer regarding a case in litigation, concerning a patient (pt) of unknown age and gender. Information regarding the pt's concurrent conditions, medical history and concomitant medications was not provided.  On an unknown date, the pt was vaccinated with zoster vaccine live(ZOSTAVAX) (dose, route of administration, anatomical location, lot number and expiration date were not reported) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster).   On an unspecified, after received zoster vaccine live(ZOSTAVAX) the pt suffered from pneumonia and serious neurological problems. As a result of these symptoms, the pt was seen and treated by medical providers. As a direct and proximate result of pt's use of the zoster vaccine live (ZOSTAVAX) vaccine, the pt had sustained severe and permanent personal injuries, including but not limited to: serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. The pt also had suffered and incurred damages, including medical related expenses, the loss of accumulations; and other economic and non-economic damages as a result of these injuries.  By the time of this report, the pt had not recovered from shingles. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).",,Unknown,0,0
889078,Pain and a decreased range of motion.,39.0,Adults,1,0
881653,Patient developed a large circular itching rash on back of left shoulder that looks like shingles.,78.0,Seniors,1,0
875915,Rash & UrticariaPruritus,68.0,Seniors,1,0
896418,"bright red knot on her arm (at injection site) the size of a baseball; bright red knot on her arm the size of a baseball; pharmacist ""made a mistake"" / by administering the Shingrix, Tdap, and flu shot all in one arm; This case was reported by a consumer via call center representative and described the occurrence of injection site induration in a 59-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis and DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis.   On an unknown date, the patient received Shingrix, Influenza vaccine Quadrivalent unspecified season and Tdap Vaccine. On an unknown date, unknown after receiving Shingrix, Influenza vaccine Quadrivalent unspecified season and Tdap Vaccine, the patient experienced injection site induration, injection site erythema and vaccine administered at inappropriate site. On an unknown date, the outcome of the injection site induration was recovered/resolved and the outcome of the injection site erythema and vaccine administered at inappropriate site were unknown.   The reporter considered the injection site induration and injection site erythema to be related to Shingrix, Influenza vaccine Quadrivalent unspecified season and Tdap Vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The patient reported that the pharmacist made a mistake by administering the Shingrix, Tdap, and flu shot all in one arm which resulted in a bright red knot on her arm (at injection site) the size of a baseball and vaccine administered at inappropriate site. The reporter was the husband and patient were the wife and provided email address but did not want to provide a personal fax number. No further information gathered and did not specify if it was the right or left arm. The reporter did not consent to follow up. The reporter did not want to provide his wife's MD contact information because says her doctor was retiring and did not yet know who new doctor would be.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020220484:same reporter (reporters case)",,Unknown,0,1
886055,"I received the following Flu Shot (FLUCELVX PFS 2020-21   INJ 0.5 ML).  That evening I started getting Hives all over my body.  I was having an extremely allergic reaction.  My Hands turned red and were extremely itchy and burning.  I was having trouble breathing.  I went to the ER and they did an ECG.  I was provided, DiphenhydrAMINE (Benadryl), Famotidine (Pepcid) and MethylPREDNI Solone sodium Succ (Solo-Medrol).  These treatments worked.  I was released from the ER approximately 4 hours after I was admitted.",60.0,Adults,0,1
905854,"Vaccine on Wednesday. Sneezing (allergies) around the time of injection. Sore arm for a day. Felt fine on Thursday and Friday. A little off on Saturday.  Myalgia, headache w temp of 99 on Sunday.  Took Tylenol at 2000 and went to bed. Did not sleep well. Temp at 0400 was 100. Took additional Tylenol.  Achnese returned at 1100 on Monday. No fever. Shaking chills but no fever from 1400-1500. Resolved but temp of 101.2.  This is where I am now.",65.0,Adults,0,0
908794,None stated.,48.0,Adults,0,0
904411,Patient became very flushed and ee stated she was not feeling well. BP: 156/96-176-96 HR: 80-98. Patient states this was not normal bp. continued to monitor pt and noted to have reddened rash on face. Patient to ED for further evaluation.,41.0,Adults,1,0
898632,9pm-2 am Severe shivering; 2 am-8 am Fever,65.0,Adults,1,0
858036,"patient was administered the Hib portion of Pentacel in his right thigh today. The Hib portion was diluted in error with sterile diluent from  Merck, no AE; Initial information received on 16-Jan-2020 regarding an unsolicited valid non-serious case received from a nurse.  This case involves a 15 months old male patient who received a 0.5 mL DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL] (lot UJ187AAA and expiry date: 16-Feb-2021) via unknown route in the right thigh, on 16-Jan-2021.  Medical history, medical treatment, vaccination and family history were not provided.  Concomitant medications included PNEUMOCOCCAL VACCINE CONJ 7V (CRM197) (PREVNAR) for Immunisation.  It was an actual medication error case due to inappropriate reconstitution technique (product preparation issue). It was reported that patient was administered the Hib portion of Pentacel in his right thigh today. The Hib portion was diluted in error with ""sterile diluent from Merck, Sharpe, and Dome Company"" further described as sterile water with no preservatives. The DTaP-IPV portion of Pentacel was not administered.  At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
904638,"Patient stated that 45 minutes after receiving the vaccine he became dizzy and foggy, requiring the individual to sit down for a period of time as they felt unsteady on their feet.  No treatment was given, patient decided to have spouse pick them up and go home.",33.0,Adults,0,1
880152,"No additional AE; PROQUAD was administered on 8/3/2020 but expired on 8/2/2020; This spontaneous report was received from a licensed practical nurse, referring to a patient of unknown age and gender. The patient's pertinent medical history, previous drug reactions or allergies, and concomitant medications were not reported.   On 03-AUG-2020, the patient was vaccinated with an expired dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) 0.5 milliliters as prophylaxis (ml) (formulation, strength, vaccination scheme, anatomical site of vaccination and route of administration were not reported; lot number S003326, expiration date reported 02-AUG-2020, which were verified to be valid). There was no previous temperature excursion. No additional events were reported.",,Unknown,0,1
870682,"no adverse event; administered an impropery stored dose of PEDVAX HIB; This spontaneous report was received from a nurse regarding a patient of unknown age and gender. Patient's pertinent medical history, concurrent conditions, past drugs, allergies and concomitant therapies were not reported. On 17-APR-2020, the patient was vaccinated with improperly stored haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (strength, dose and route were not reported) (lot number S023645 and expiration date 10-MAR-2022) for prophylaxis (product storage error). The temperature excursion was noted with a temperature of 51.5 Fahrenheit (F) for 45 minutes. There was no previous temperature excursion. No adverse effects were reported. The call was because of digital data logger. No product quality complaint was reported.  This is one of the several reports received from the same reporter.; Sender's Comments:  US-009507513-2005USA002553:",,Unknown,0,1
904927,"sick for two weeks; Initial information regarding an unsolicited valid non-serious case received from a consumer (patient) via social media on 01-Dec-2020.  This case involves a patient of unknown demographics who was sick for two weeks (illness), after receiving INFLUENZA VACCINE.  The patient's medical history, past medical treatments, past vaccinations, family history and concomitant medications were not provided.   On an unknown date in 2017 reported as 3 years ago, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number and expiration date not reported) via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient was sick for two weeks (illness), (non-serious event) (unknown latency) following the next day of administration of INFLUENZA VACCINE.  No laboratory data reported.  It was not reported if the patient received a corrective treatment.  At the time of report, the outcome was unknown for the event.  There will be no information available on the batch number for this case.",,Unknown,0,1
907295,"Lightheaded, dizziness, flushed face, sweating",,Unknown,1,0
861833,"First dose of Gardasil on June 2017/Second dose of Gardasil on October 2017/On 2020 the consumer called inquiring for the third dose administration; Consumer inquired if the patient could receive the third dose of Gardasil 9 if the patient was experiencing an ""ulcerative colitis flare up""; This spontaneous report was received from a consumer reporting on her daughter, a 21-year-old female patient. The patient's concurrent conditions included colitis ulcerative. Information regarding the patient's pertinent medical history, past drug reactions/allergies, and concomitant medications was not reported.  On an unspecified date in June 2017, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) for prophylaxis (strength, dose, route of administration, anatomical location, lot number and expiration date were not provided).  In October 2017, the patient received the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) for prophylaxis (strength, dose, route of administration, anatomical location, lot number and expiration date were not provided).   On an unspecified date in October 2017, the patient experienced ulcerative colitis flare up. The reporter wanted to know if the patient could receive a third dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (inappropriate schedule of product administration).  The outcome of colitis ulcerative was unknown.    The causality between hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) and the event occurrence was not reported.   Upon internal review, the event colitis ulcerative was determined to be medically significant.",,Unknown,0,1
893849,PATIENT WAS GIVEN A FLUZONE HD AND HAD ALREADY HAD A FLU SHOT AT HER DRS OFFICE THIS SEASON,89.0,Seniors,0,1
899426,"Expired VAQTA was administered to a patient; This spontaneous report was received from the physician's office manager, concerning a 2 year old patient of unknown gender. There was no information regarding the patient's medical history, concurrent conditions, concomitant medications or drug reactions/allergies.  On 19-NOV-2020, the patient was vaccinated with hepatitis a vaccine, inactivated(VAQTA) 0.5ml lot # S010727 with expiration date of 26-JUL-2020, for prophylaxis (frequency, route of administration and anatomical location were not provided). combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: S010727; expirationdate: 26-JUL-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",2.0,Kids,0,1
899343,"gained 10 lbs; croupy pneumonia; croupy pneumonia; upper respiratory infection,slowly getting worse and worse; severe outbreak of genital herpes/herpes outbreak/8-9 genital herpes lesions/got worse and worse; severe outbreak of genital herpes/herpes outbreak/8-9 genital herpes lesions/got worse and worse; severe herpes outbreak; This is a spontaneous report from a contactable consumer (patient). A 63-year-old female patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13, Solution for injection in pre-filled syringe, batch/lot number and expiration date not provided), via an unspecified route of administration on 04Nov2018 12:45 in upper right arm at single dose for immunization. Medical history included ongoing genital herpes lesion. There was no history of all previous immunization with the Pfizer vaccine considered as suspect (or patient age at first and subsequent immunizations if dates of birth or immunizations were not available). The patient's concomitant medications were none (other products: no). The patient previously took trimethoprim, sulfamethoxazole (SEPTRA DS) and allergy to it. There were no prior vaccinations within 4 weeks. There were no additional vaccines administered on same date of the Pfizer suspect. The patient received the Prevnar 13 vaccine at the pharmacy two years ago and a few days later developed an upper respiratory infection and a severe herpes outbreak, she had a very severe outbreak of genital herpes, along with a croupy pneumonia, shortly after receiving the Prevnar 13 vaccine in Nov2018. Vaccine was not administered at military facility. The adverse events did require a visit to emergency room or physician office. She received her Prevnar 13 vaccine on 04Nov2018 at 12:45 in the afternoon. She said both the croupy pneumonia and genital herpes outbreak started a couple days after she received the Prevnar 13 vaccination. She clarified that the side effects of the Prevnar 13 came on slowly. She said the croupy pneumonia started out slowly as an upper respiratory infection, slowly getting worse and worse. She said the genital herpes outbreak started out slowly and got worse and worse. She said she usually had only 1 genital herpes lesion, but after the Prevnar 13 vaccine, she had 8-9 genital herpes lesions. The patient stated she had a bad reaction to the Prevnar 13 vaccine in Nov2018. She said her concern was she had genital herpes, and had a very severe outbreak, along with a croupy pneumonia, saying she felt like she was near death at the time. She said her experience with the Prevnar 13 made her concerned with vaccines. She said she didn't know at the time she had the bad reaction with the Prevnar 13 vaccine that Pfizer was the Prevnar 13 manufacturer. She said she just found that Pfizer was the Prevnar 13 manufacturer and was thrilled that Pfizer was the manufacturer of the COVID vaccine. She wanted to know if she should have the COVID vaccine based on her experience with the Prevnar 13 vaccine. Her doctor told her the severe genital herpes outbreak and the croupy pneumonia weren't side effects of the Prevnar 13 vaccine. She said her doctor blew her off, so she went to her pharmacist, and her pharmacist wouldn't tell her who the manufacturer was of the Prevnar 13. She said she called the Clinic and told the Clinic her experience after she had received the Prevnar 13 vaccine, and the Clinic told her to fire her doctor and pharmacist. She said she told herself she won't take vaccines anymore, but since she survived, and now knowing that Pfizer was the COVID vaccine manufacturer, she would like to know if she should get the COVID vaccine. She also inquired whether someone with genital herpes could receive the new COVID-19 mRNA vaccine (BNT162). She said she was virology lover. she was a naturopath. The patient stated she had gained 10 lbs. since COVID Reported she received the Prevnar 13 vaccine at a pharmacy. Treatment: Declined any. She stated after she fired her doctor and pharmacist, she used Echinacea, Vicks VapoRub and chicken soup. Spring Valley Echinacea 760mg, UPC Number: 681131016193, Lot Number: 004325,  Expiration Date: Aug2020. The Spring Valley Echinacea 760mg was distributed by (Pharmacy Name) Stores, (City and state name). She said the Spring Valley Echinacea 760mg was a certified organic product of China. Vicks VapoRub UPC Number: Unknown, Lot Number: 92954354M2, Expiration Date: Sep2021. It was reported that the Vicks VapoRub was made in Mexico by (Company Name) providing number from the Vicks VapoRub product packaging. The patient needed something to see with to get the numbers off of the Vicks VapoRub product packaging. She stated she put glasses on to read the Vicks VapoRub product information, and had difficulty reading and providing the product information. She had a whole luggage full of supplements, she kept her supplements in a piece of luggage just in case she needed to take her supplements with her if she went to the hospital. She stated she told Dr. (Name)she wanted to strengthen her immune system, and asked Dr. (Name) how she should do that. She said Dr. (Name) told her that she could strengthen her immune system by immunizations. She said she told Dr. (Name) she didn't want pneumonia as an older person, and she would get the pneumonia vaccine. She said she called Dr. (Name) after she had the bad reaction to the Prevnar 13 vaccine, and she said Dr. (Name) told her ""sorry, those are not side effects of the Prevnar 13. Reported she hadn't had a vaccine since she was a kid"". She talked to someone and filled out a form for Prevnar 13. She was asked what she had used when she was trying to recover. She reported that she used echinacea and vicks vapo rub and she was asked for the lot numbers. She just caught that there was an error since she provided the lot number from her vicks vapo rub that she purchased two weeks ago. The vicks vapo rub that she had used when she had the issue two years ago with Prevnar 13 vaccine hadbeen discarded. The lot number she reported for the vicks vapo rub was null and void since it was from her recent container. The echinacea lot number she provided was the same since she still used the same bottle. There were no relevant tests and investigation assessment. Patient's Weight was 150 lbs and 68.04 kg on unknown dates. The outcome of events gained 10 lbs, severe herpes outbreak was unknown. The outcome of events croupy pneumonia, upper respiratory infection and genital herpes was not recovered.  Information about lot/batch number has been requested.",63.0,Adults,0,1
909202,"WITHIN 5-10 MINUTES OF GETTING THE VACCINE. I STARTED FEELING LIGHTHEADED WHILE SITTING ON A CHAIR.  I FELT LIKE I NEEDED TO LIE DOWN AND PUT MY FEET UP BECAUSE I FELT LIKE MY BP IS GOING UP. I TOLD SOMEBODY AND A NURSE CAME WITH A CRASH CART. I TOLD THE NURSE IF SHE COULD CHECK MY BP BECAUSE I COULD FEEL IT GETTING HIGH ( I CAN TELL IF MY BP IS HIGH BECAUSE I TAKE BP MEDS FOR MY HTN.) I TRIED TO TAKE A DEP BREATH TO CALM MYSELF. NEXT THING I KNEW, A NASAL CANNULA WAS PLACED ON MY NARES. I FELT TACHYCARDIC, AND STARTED TO FEEL PALPITATIONS CREEPING UP MY NECK AND CHEST.  THEY DID AN EKG AND FS BLOOD SUGAR ON ME. I HEARD SOMEBODY SAID, 'HER BP IS 200!"". THE DOCTORS AND NURSES WERE STARING AT ME TO ASSES ME FOR ANAPHYLACTIC REACTIONS. I SAID ""I DONT THINK IT'S ANAPHYLACTIC REACTIONS"". A DOCTOR TOLD ME THAT THEY ARE BRINGING ME TO THE ED FOR FURTHER OBSERVATION. ON THE SECOND DAY POST-VACCINATION, I FELT SO TIRED, FEVERISH AND IT'S LIKE I HAD A HANGOVER.",52.0,Adults,0,0
885629,"Day time enuresis with later having headaches (frontal headache) and aggressive behavior. Had three episodes of the day time enuresis and two episodes of headaches that self-resolved. Mom did give the first time he had a headache. All symptoms resolved by 9/22/2020. No localized erythema, swelling, calor nor point tenderness from the injection site.",5.0,Kids,1,0
890316,I don't have the lot number,71.0,Seniors,0,0
889770,Patient complained of Diarrhea on 10/14/2020.,80.0,Seniors,0,0
907774,"In the evening, the day I got the vaccine, I started feeling body aches all over. The arm that got the vaccine hurt the most, as to be expected, and there is a knot in the muscle where I got the injection. I have felt pain all over since then. It has not been touched by naproxen sodium. A cold shower gave temporary relief.",27.0,Adults,0,0
881565,"Headache, dizzy, blurry vision, chest and stomach pain, nausea, drained/no energy, muscle pain, chills, feeling of fever but none. Both times that I had the vacciine, I am 54 years of age.",54.0,Adults,1,0
901979,"flu; Initial information regarding this unsolicited valid non-serious social media case received from a consumer (patient) on 10-Nov-2020. This case involves a patient with unknown demographics who experienced flu (Influenza), when received vaccine INFLUENZA VACCINE (flu shot). Relevant medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination. On an unknown date, the patient experienced flu (Influenza), unknown latency following the administration of INFLUENZA VACCINE. Relevant laboratory test was not reported.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome was unknown for the reported events.  There will be no information available on batch number for this case.",,Unknown,0,1
875338,"No adverse symptoms reported.; Nurse reported that the patient was ""inadvertently administered an expired dose of ZOSTAVAX""; This spontaneous report was received from a registered nurse, referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions or allergies, and concomitant medications were not reported.  On 16-JUN-2020, the patient was inadvertently administered an expired dose of zoster vaccine live (ZOSTAVAX) (dose, route of administration, vaccination scheme and anatomical site of vaccination, were not reported; lot number N013274, which has been verified to be valid, expiration date reported and valid as 04-JUL-2018) as prophylaxis. No additional adverse effects were reported.",,Unknown,0,1
866767,"2nd shot yesterday-now fever; 2nd shot yesterday-now body aches /sore; nausea; This case was reported by a consumer via call center representative and described the occurrence of fever in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced fever, general body pain and nausea. On an unknown date, the outcome of the fever, general body pain and nausea were unknown.   It was unknown if the reporter considered the fever, general body pain and nausea to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group of the patient was not reported, but selected as an adult as per vaccinae indication. The reporter stated that, after vaccination had fever, general body pain and nausea. For the tolerence of 2nd dose refer case US2020AMR047393, reported by same reporter for the same patient.",,Unknown,1,0
892716,Refrigerator temp out of range. Invalid vaccination.,,Unknown,0,0
906156,Itchiness and rash on skin.,41.0,Adults,1,0
896654,"Pt complained that injection hurt when she got it. SHe felt it was given too high, and was terribly sore afterwards. Some days have been more painful than others culminating today where she was unable to lift her arm. Suggested she should see her provider at this point.",75.0,Seniors,1,0
898511,"Randomized muscle twitching, anxiety, brain fog, muscle weakness, neck pain, pressure in head",36.0,Adults,1,0
888027,"Immediately after vaccine was administered, patient reported she might have to pass out and felt nauseated. She had to breathe through her mouth and was warm to the touch. She reported not eaten anything in all day. Patient was given water, some sugar sources, and cold paper towels placed on the back of her back. After 10 minutes of staying seated, patient was fine and left the pharmacy with her family member. Patient knows the pharmacy's phone number and was encouraged to contact with any issues and/or questions.",67.0,Seniors,0,0
889755,"Patient was lying on exam table when given vaccination. He sat up after receiving it and a few seconds after stated that he felt dizzy. He laid back down then a few seconds after lying down his eyes turned toward the right and the pupils dilated then he had tremors in his arms, he was not responsive but his eyes remained opened. He had tremors approximately 30-45 seconds then became responsive. His color was pale during the unresponsive period then returned to normal when he became responsive.  Treatment: Elevated feet, cold compress to back of neck, wet cloth to forehead.  Blood pressure and pulse were taken (100/60, 60 bpm). He was oriented x3. He was given juice when he sat up. His PCP was called by his mother to notify her. This nurse spoke to nurse at PCP's office and informed of event. PCP directed mom to take him to ER to follow up.",13.0,Kids,0,0
872934,"stroke; Information has been received from a lawyer regarding a case in litigation and refers to a male patient (pt) of an unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On or about 14-FEB-2014, the pt was inoculated with zoster vaccine live (ZOSTAVAX) as prescribed and/or administered by a pharmacist at a pharmacy (strength, dose, dose number, route, anatomical site of vaccination, lot number and expiration date were not provided) for the long-term prevention of shingles and/or zoster-related conditions. On an unknown date (reported as subsequent to the pt's zoster vaccine live (ZOSTAVAX) inoculation), the pt was hospitalized and treated by a healthcare provider for stroke (cerebrovascular accident). As a direct and proximate result of pt's use of the zoster vaccine live (ZOSTAVAX) vaccine, the pt had and would continued suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. At the time of this report, the outcome of cerebrovascular accident was unknown. The reporter assessed that the event was related to zoster vaccine live (ZOSTAVAX).  Upon internal review, cerebrovascular accident was determined to be a medically significant event.",,Unknown,0,1
864362,"Patient had swelling and a bruise 1 week after injection, along with soreness. Injection site was IM Deltoid.",88.0,Seniors,0,0
887823,"The morning following the vaccine I woke with a very sore arm about 5AM.   My arm was tight and hard to lift or move behind my back as the day went on.   I used the internet to see if this was unusual, the site said you could have symptoms for up to 10 days, which was very rare, or two days following the injection.   As the days went on I have had less and less motion and more and more pain.   I cannot sleep through the night, I have a very difficult time driving, turning the wheel as well as backing up.   Yesterday, 10/4/20, I went back to the pharmacy and spoke with the pharmacist.   The pharmacist said I should file a complaint, as well as make an apt with my doctor.   The pharmacist also said this was much to long to be from the shot.   The pharmacist then asked where it hurt, when I showed her my shoulder area, she said ""that is much to high for a shot"".   When I asked if I could speak with the young man you gave me the shot, she said ""he is no longer with the pharmacy.      I have made an apt with my doctor and will know more but this is absolutely without any doubt from the shot.     I am 65 on no medications, very healthy, play golf, tennis, ski, hike.    I currently am unable to lift my arm or pull it behind me.",65.0,Adults,0,0
864332,"PT WAS GIVEN MMR V AND VARICELLA ON THE SAME DAY IN EACH ARM.  SHE WAS MEANT TO GET MMR AND VARICELLA SEPARATELY BUT ACTUALLY RECEIVED TWO DOSES OF VARICELLA.   PT MOTHER WAS NOTIFIED OF ERROR.   I ASKED PT MOTHER IF PT WAS SHOWING IN SIDE EFFECTS AND SHE STATED PATIENT WAS ENERGETIC WITH NO EVIDENCE OF RASH, FEVER OR  MALAISE.  I ADVISED HER TO WATCH PATIENT FOR 7-14 DAYS PER CDC RECCOMENDATION.  IF SHE STARTS SHOWING SIGNS OF SEVERE REACTION LISTED IN VIS SHE WAS ADVISED TO CALL 911 OR GO TO ER IMMEDIATELY.   I ALSO TOLD PT MOTHER TO CALL OUR CLINIC WITH ANY QUESTIONS SHE MIGHT HAVE.  MOTHER STATED PATIENT WAS ENERGETI C AND EVEN WENT TO STORE AND PLAYED AND ATE LIKE NORMAL.  I ADVISED PT PER CDC TO ADMINISTER ANTIPYRETICS AS NEED PER INSTRUCTIONS FOR FEVER OR PAIN. MOTHER SEEMED TO UNDERSTAND INSTRUCTIONS THAT WERE GIVEN.",4.0,Kids,1,0
879449,"Nursing was called to the lobby. Patient had been seen by a provider for a well-child visit and received three vaccines. Mother reports that while waiting for the elevator after the visit patient was nauseous. Patient and mother went to the restroom instead of getting on the elevator. Nurses found patient kneeling in front of a toilet. She appeared pale and shaky. Nursing took her back to a patient exam room by wheelchair and observed her, checked her vitals which were all within normal limits, gave her juice and graham crackers. Patient had not eaten breakfast this morning and was anxious for her vaccines today.   Provider and team manager evaluated the patient. Patient's vitals remained within normal limits and she was dismissed home with mother.",12.0,Kids,0,1
888485,Hello. Patient received both the high dose flu shot and a Shingrix vaccine in his left deltoid on 9-28-20. Patient called pharmacy 10-7-20 to say he has a red patch on left arm 3 inches long from mid bicep to tripcep that hurts in in the shower and if scratched. Patient said this has not impeded his daily living activities. He said it is getting better and he has been putting a moisturizing cream on it. He wanted to know if this reaction was normal. I told him it was not. I asked him if it seemed to be infected and he said he did not think so. He asked about getting the second Shingrix after having this reaction and I told him to ask you your opinion. I am providing you this information as it is part of pharmacys policy and procedure with reporting of adverse vaccine events. Thank you.,68.0,Seniors,0,1
874969,"Headache, chills, sever muscle ache, fatigue, redness and hardness at the site of injection for 4 days The redness at the site of injection lasted for about a week.",61.0,Adults,1,0
866557,"Shingles; Information was received from a lawyer regarding a case in litigation and refers to a currently 68 year old female patient. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On or about 09-NOV-2013 the patient was vaccinated with zoster vaccine live(ZOSTAVAX)(strength, route, dosage schedule, lot number and expiration date were not reported) for prophylaxis. As a result of her receipt of zoster vaccine live(ZOSTAVAX), in 2014, patient was caused to suffer shingles, including any and all of its sequelae. As a result of her receipt of zoster vaccine live(ZOSTAVAX), patient has been caused to suffer severe personal injuries, pain, suffering, and emotional distress, as well as to incur substantial economic damages. The outcome of herpes zoster was unknown. The reporter considered herpes zoster to be related to Zoster Vaccine Live(ZOSTAVAX).",62.0,Adults,0,0
898722,"About 2 hours after the Influenza Vaccine was administered, the first symptoms started including wheezing, hoarseness and tightness in the throat and burning eyes. Then it developed into full-blown flu symptoms, including extreme malaise, chills, fever (101+), sweats, headache and nausea.  I couldn't eat for two days due to the nausea and I couldn't sleep due to the extreme feeling of malaise and headache. This was beyond 'mild' flu-like symptoms. It was full blown - just as bad as any flu I've had, but it lasted for a shorter period of time. I will never ever have another flu shot again. It was the most miserable  days I've had since my cancer.",51.0,Adults,0,0
901595,"break out in shingles; Initial information regarding an unsolicited valid non-serious case from a consumer (patient) via social media on 07-Dec-2020.  This case involves an unknown demography patient who got INFLUENZA VACCINE and broke out in shingles (Herpes zoster).  Medical history, medical treatments, vaccinations, concomitant medications and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, (unknown latency) following vaccination patient broke out in shingles (Herpes zoster).  Case details- every time patient get the flu shot the patient broke out in Shingles, would rather had flu.  No relevant laboratory tests were reported.  It was not reported if the patient received a corrective treatment.  Event outcome was Unknown for Herpes zoster.  There will be no information available regarding batch number for the case.",,Unknown,0,1
897232,"chills, fever, aches, cold sweats, lack of appetite",73.0,Seniors,1,0
915682,"Resident received vaccine per pharmacy at the facility at 5 pm.  Approximately 6:45 resident found unresponsive and EMS contacted.  Upon EMS arrival at facility, resident went into cardiac arrest, code initiated by EMS and transported to hospital.  Resident expired at hospital at approximately 8 pm",85.0,Seniors,0,1
861953,"Foetal exposure during pregnancy; Preterm delivery at 36.7 weeks of gestation; This is an observational study case initially received from other health professional on 11-Feb-2020, concerning a neonate male subject whose  mother was 35-year-old female pregnant  of body weight 108 lbs, height 62 inches and body mass index (BMI) 19.8, enrolled in a prospective observational safety study.   The subject's mother current conditions included advanced maternal age, obsessive compulsive disorder (OCD) and anxiety.  The subject's mother concomitant medications included prenatal vitamins (unspecified vitamins and minerals) for pregnancy.  The subject's mother obstetrical history noted that the mother had two previous pregnancies of full-term live birth with no birth defects. The subject's mother had no maternal or paternal history with major congenital malformations (MCMs). The subject's mother had no history of offspring with MCM. The subject's mother did not use tobacco, alcohol or illicit drugs during pregnancy.   The subject's mother last menstrual period (LMP) date was on 07-Feb-2019. The subject's mother estimated date of delivery (EDD) and corrected estimated date of delivery (CEDD) were reported as 02-Dec-2019. The type of pregnancy was singleton. The subject's father was 37 years old.  On 01-Apr-2019, the subject's mother underwent haemoglobin electrophoresis and no MCMs were noted.  On 16-Apr-2019, the subject's mother underwent ultrasound and no MCMs were noted.  On 20-Jun-2019, the subject's mother underwent ultrasound and no MCMs were noted.  On 03-Oct-2019, the subject's mother underwent ultrasound and no MCMs were noted.  On 17-Oct-2019, at approximately 33 weeks of gestation, the subject's mother was administered (Flucelvax QIVc)  Flu Vaccine Cell Subunit QIV NVD [influenza vaccine, subunit influenza virus vaccine polyvalent, batch number: 261218, dose: 0.5 mL, route of administration, anatomical location and expiration date: not reported] (explicitly coded as 'Foetal exposure during pregnancy') for influenza immunisation.  At 36.7 weeks of gestation, the mother delivered a live male neonate via caesarean method. The characteristics of the neonate included birth weight: 2750 grams, length: 50.2 cm and head circumference: 33 cm. Appearance, pulse, grimace, activity, and respiration (APGAR) scores were 8 at one minute and 9 at five minutes. No MCMs were identified at the time of birth.   At the time of this report, the outcome for the event of premature baby' was not reported.  The event of premature baby' was considered as serious due to criterion of medical significance, per company.  The reporter did not provide causality assessment to Flucelvax QIVc.  This case is linked to case number 202001700 (corresponding mother case).  Company comment: It was reported that the male neonate was delivered via Caesarean section several weeks after vaccination. A Caesarean section in general, and in particular if conducted prior to the term, would suggest an underlying cause prompting this method over vaginal delivery. No other pregnancy complications were reported which precludes thorough assessment of causality. Based on the available information, causality for the event of premature baby was considered unassessable. Foetal exposure during pregnancy was assessed as unrelated to the vaccine in line with internal conventions.; Sender's Comments: It was reported that the male neonate was delivered via Caesarean section several weeks after vaccination. A Caesarean section in general, and in particular if conducted prior to the term, would suggest an underlying cause prompting this method over vaginal delivery. No other pregnancy complications were reported which precludes thorough assessment of causality. Based on the available information, causality for the event of premature baby was considered unassessable. Foetal exposure during pregnancy was assessed as unrelated to the vaccine in line with internal conventions.",,Unknown,0,1
883546,"felt tired; achy; She feels run down still; This case was reported by a consumer via call center representative and described the occurrence of tiredness in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 31st August 2020, the patient received the 1st dose of Shingrix. On 31st August 2020, less than a day after receiving Shingrix, the patient experienced tiredness, pain and feeling bad. On an unknown date, the outcome of the tiredness, pain and feeling bad were recovering/resolving.   It was unknown if the reporter considered the tiredness, pain and feeling bad to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as adult as per the vaccine indication. The patient received Shingrix and felt tired and achy. The reporter feels run down still but it was lessening as time goes on. The reporter did not consent to follow up.",,Unknown,0,0
885387,"Patient has a history of nervousness with vaccinations and medical care. After receiving the vaccine, patient fainted. Emergency services were called and took vitals. Parent and EMT agreed further care was not needed and it was likely nerves.",,Unknown,0,1
912500,"Body aches and weakness; Body aches and weakness; Really fatigued; Sore arm; Chills; This is a spontaneous report from a contactable consumer (patient). This 25-years-old female patient (no pregnant) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: EH9899) on 23Dec2020 02:15 PM on Right arm for COVID-19 immunization. Medical history and concomitant drug were not reported. Past drug was known allergies with pethidine hydrochloride (DEMEROL). No other vaccine in four weeks, no other medications in two weeks. It was reported that patient experienced really fatigued, sore arm, chills and slight body aches and weakness (all reported as non-serious) on 23Dec2020 08:00 PM with outcome was Recovered in an unspecific date in Dec2020. No treatment. No COVID prior vaccination. No COVID tested post vaccination. Prior to vaccination no diagnosed with COVID-19.  No follow-up attempts are possible. No further information expected.",25.0,Adults,0,0
855272,"shingles; post-herpetic neuralgia; Information has been received from a lawyer concerning a case in litigation and refers to female patient of an unknown age. No information regarding the patient's medical history, concurrent conditions and concomitant medications was reported. On an unknown date, the patient was inoculated with zoster vaccine live (ZOSTAVAX) vaccine (dose, route of administration, vaccination site, lot # and expiry date were not provided) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). On an unknown date, shortly after receiving zoster vaccine live (ZOSTAVAX), the patient suffered a shingles and post herpetic neuralgia. As a result of these symptoms, the patient was seen and treated by medical providers and was still under their care. As a direct and proximate result of the Company's defective zoster vaccine live (ZOSTAVAX) vaccine, the patient's symptoms have resulted in physical limitations not present prior to using the Company's product. The patient also experienced mental and emotional distress due to resulting physical limitations and seriousness of the patient's condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of the Company's wrongful conduct, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of the Company's conduct, the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events was not recovered. The causality was related.  The events of shingles and post herpetic neuralgia were considered to be disabling.",,Unknown,0,0
899899,"10/7/20, about 2 weeks after receiving IM seasonal flu and Shingrex vaccine she developed back pain, numbness in legs which progressed to paraplegia over the course of around 6 hours.  MRI showed GAD enhancing partial transverse myelitis.  Treated with IV corticosteroid and over the course of 2 months she has improved quite a bit, walking without use of gait aid but remains incontinent of bowel and bladder and has disabling neuropathic pain.   CSF analysis,  MRI of the brain and repeat MRI of the cord shows that she does not have multiple sclerosis.  She was negative for the MOG and AQP4 antibody in serum.    she is diagnosed with transverse myelitis and this is suspected to have been triggered in some way by the vaccination.",73.0,Seniors,0,0
886712,"12 year old female client was given TDAP, Menactra, and HPV . A few minutes after receiving immunizations, client?s lips turned pale, skin was cold, pale and clammy, and client briefly loss consciousness. Client remained seated and did not fall. Mother was with the child. Ammonia inhalant was administered. Client remained pale at this time. Oxygen 2L per minute was given via face mask. Vital signs taken and were as follows: BP=154/134, oxygen saturation=90%, pulse rate =57, respirations=18. Client was lethargic but was able to respond appropriately to questions asked. 911 was called at 11:15 am. Client was continuously monitored by nurses present. 911 responders came in at 11:23. Vital signs were taken by 911 responders and were as follows: BP= 88/58, oxygen saturation=88% on room air, pulse rate=67, respirations=20. Client stated ?I feel very tired?. Skin remained pale, cold and clammy, lips remained pale. Client taken by 911 responders to Hospital at 11:35.",12.0,Kids,0,0
899904,Pt had an episode of loss of consciousness and brief tonic clonic/seizure like activity,15.0,Kids,0,0
875410,After the patient received the 2nd dose of Shingrix we came out of the immunization room.  The patient felt faint.  I had her sit down and place her head between her legs and I got her some water.  She sat there for a few minutes and felt better.  She then walked around the store for a little bit and stated that she felt fine and could go home.,51.0,Adults,0,0
904700,Approximately 29 hours after my first dose of the Pfizer COVID 19 vaccine I started experiencing right axillary pain that was accompanied by swelling. Lymph node enlargement was not felt. Symptoms are still present at the time of filling this survey out.,27.0,Adults,0,0
906639,"Throat numbness; Lymph node swelling; Felt flush; This is a spontaneous report from a non-contactable consumer. A 28-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; Lot number: EK5730), via an unspecified route of administration in the right arm, on 17Dec2020 at 15:15 (at the age of 28-years-old) at a single dose for COVID-19 immunization. The patient had no medical history or concomitant medications. The patient was not pregnant at the time of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food, or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced throat numbness, lymph node swelling, and felt flush on 17Dec2020 at 15:15. The events were reported as non-serious. Therapeutic measures were taken as a result of the events, which included treatment with diphenhydramine hydrochloride (BENADRYL). The clinical outcome of throat numbness, lymph node swelling, and felt flush was recovering. It was also reported that since the vaccination, the patient had not been tested for COVID-19.  No follow-up attempts are possible. No further information expected.",28.0,Adults,0,1
900370,"A few days after getting the shot, I started breaking out in vesicles on my lower legs.  They were extremely itchy, had yellow fluid oozing from them. Very comparable to a chicken pox vesicle. They continued for a couple of weeks and gradually went away.   A week after I got the shot, I did go in to see an NP and she didn't seem too concerned, just to let them run their course (I was worried about them being contagious).  Fast forward to 12/2/2020, I had an appt to get the 2nd dose. I was pretty leery about getting it, worried about having another reaction. I showed the pictures to the nurse before I got the shot and she said it definitely looked like shingles. She did consult with the doctor and the pharmacist there, and after researching, the pharmacist said it is not a live virus, so it should not have been from the shot. After discussing with the nurse, I decided to wait on getting the booster.  I believe it would have been pretty coincidental to have shingles/chicken pox vesicles break out only days after getting the Shingrix vaccine.  Of note, I also have had chicken pox twice in my life.  I do have photos of the vesicles if you would like them.",51.0,Adults,0,1
915353,"Fever and intense chills, soreness in muscles and joints in legs. Took 650mg of Tylenol and the chills subsided half an hour to an hour later. Hot and cold flashes persisted throughout the night, but fever and leg pain had resolved by morning.",28.0,Adults,0,0
879275,"I have injection site pain; fatigue.; This case was reported by a consumer via interactive digital media and described the occurrence of injection site pain in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 5th August 2020, the patient received Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced injection site pain and fatigue. On an unknown date, the outcome of the injection site pain and fatigue were unknown.   It was unknown if the reporter considered the injection site pain and fatigue to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication. The patient received the Shingrix vaccine on Wednesday and In August 2020, and had injection site pain and fatigue.  The patient asked how long do the side effects last",,Unknown,0,0
895533,"headache; body ache and chills; body ache and chills; This is a spontaneous report from a contactable physician received via Pfizer Sales Representative.   An 18-year-old female patient received meningococcal group b rlp2086 (TRUMENBA) at single dose, and influenza vaccine (Quadravalent flu vaccine, Sanofi), both in right arm on 27Oct2020 for immunisation.  The patient medical history and concomitant medications were not reported. The patient previously received a dose of TRUMENBA at single dose and FLU vaccine, both in right arm in 2019 for immunization and experienced neck stiffness headache and swelling in the arm. The patient experienced headache, body ache and chills on 27Oct2020. The outcome of headache, body ache and chills were recovered after one day in Oct2020. Patient was seen on the 29Oct2020 and physician confirmed to the reporter.  No follow-up attempts are needed. Information about lot/batch number cannot be obtained.",,Unknown,0,0
885051,"Pt had rash on back of shoulder+ described the injection site as ""oozy"" next day said looked Blistered around site told pt to call oncall MD since weekend. Went to urgent care told pt to use Bacitracin oint over weekend seems to be healing 9/18",72.0,Seniors,1,0
915876,"Patient received COVID19 vaccine (moderna, 1st dose) at 3:20 PM. Approx. 3:28 PM patient reported tingly/numbness in left arm  to clinical nurse at observation station. Nurse assessed patient's strength push and pull and range of motion and deemed good. Patient was advised to call ED if symptoms worsen or for any concerns. Patients left at 4:25 PM, reporting that tingling subsided.",42.0,Adults,0,1
911347,"Arm is getting redder today and sore. Was not red or sore yesterday after the injection.; Arm is getting redder today and sore. Was not red or sore yesterday after the injection.; This is a spontaneous report from a contactable Nurse. This Nurse reported for self that the 59-year-old female patient received first dose of bnt162b2 (BNT162B2), via unspecified route of administration on Left arm on 20Dec2020 07:45 AM at single dose for covid-19 immunisation. She is not pregnant at the time of vaccination. Medical history included known allergies to medications, food, or other products: PCN, cedar, mold and Hashimotos disease. Concomitant medications included other medications the patient received within 2 weeks of vaccination:ibuprofen (ADVIL [IBUPROFEN]), Levothyroxine and ergocalciferol (VIT D). Facility type vaccine was Hospital. No other vaccine in four weeks. The patient experienced Arm is getting redder today and sore. Was not red or sore yesterday after the injection from 20Dec2020 07:45 AM. The outcome of the event was not recovered. No treatment received. No Covid prior vaccination.  Covid tested post vaccination. Covid test type post vaccination was Nasal Swab on 15Dec2020 with result of Negative. Facility where the most recent COVID-19 vaccine was administered was Hospital. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Vaccine Facility information available.  Information on the lot/batch number has been requested.",59.0,Adults,0,1
905948,"12/16-headache/abdominal pain 12/16 3am nausea/headache/dizziness 12/17 headache/dizziness 12/18 dizzy/diaphoretic  12/19 headache/dizziness/night sweats 12/20 headache that worsened at night, dizziness, night sweats 12/21 headache/dizzy-went to doctor -pulse thready EKG was performed (normal).  Dr felt I was  dehydrated and suggested drinking plenty of water and following up with him.",38.0,Adults,1,0
908745,"Palpitations with HR of 120 within 5 minutes after receiving the vaccine. Wheeled to the ER for further evaluation. Dizziness and high BP.  Was given Benadryl, Pepcid and Solu-Medrol and a liter of NS. Discharged after 2 hours with Benadryl and Prednisone prescribed for home meds.",53.0,Adults,0,0
915894,Fatigue for 12 hours Headache for 2 days off and on Injection site discomfort not pain Nausea,60.0,Adults,1,0
878238,"Right upper arm - deltoid area with erythema and streaking. edema at injection site - fever and warm to touch, tender to palpate clindamycin 150g 1 PO TID/Ibuprofen",11.0,Kids,1,0
895437,"9 patients received an expired dose of Fluzone Quadrivalent vaccine with no adverse event; Initial information received on 07-Oct-2020 regarding this unsolicited valid non-serious case from a consumer/non-healthcare professional (Practice manager)   This case involves 9 patients of an unknown demographic who received a dose of  INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT] (Lot number- UT6695KA, Expiration date- 30-Jun-2020) via an unknown route in unknown administration site (expired product administered) for prophylactic vaccination on an unknown date.  The patients medical history, medical treatments, vaccinations, concomitant drug and family history were not provided.  It was a case of an actual medication error due to expired vaccine used (Latency: Same day).  At the time of reporting, patient had no adverse event.  Reporter wanted to know if the patient should revaccinated.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",,Unknown,0,1
900065,"I feel my legs muscles to weak and a lot anxiety attacks; Initial information regarding this unsolicited valid non-serious social media case received from a consumer and transmitted to Sanofi on 18-Oct-2020.  This case is linked to cases 2020SA294157, 2020SA294158 and 2020SA294166 (same source).  This case involved a patient of unknown demographics who experienced got the INFLUENZA VACCINE patient feel my legs muscles to weak and a lot anxiety attacks (anxiety).  Relevant medical history, medical treatment, vaccination details, concomitant medications and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient patient feel my legs muscles to weak and a lot anxiety attacks (anxiety), unknown latency following the administration of INFLUENZA VACCINE.  Relevant laboratory test was not reported.  Final diagnosis was patient feel my legs muscles to weak and a lot anxiety attacks.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome was unknown for the reported event.  There will be no information available on batch number for this case.",,Unknown,0,1
898660,Red rash over whole body starting 10 days after vaccine. Seems fussy and uncomfortable,1.0,Kids,0,0
857177,"fever of 105 starting on 12/7/19, hives several days later; headache, fatigue",17.0,Kids,1,0
898571,Swelling of injection arm starting at armpit and ending at elbow. Redness and itching. Swelling subsided significantly when the patient came in on 11/25 to talk to pharmacist about it. Recommended Benadryl if itching continued. Patient said that it had improved a lot in 24 hours and didn't really itch too much anymore.,68.0,Seniors,0,0
915648,"Fever ranging from 99.1 degree to 100.1 degree, Continuous Pounding headache, weakness, Nausea and vomiting Lasting 24 hrs. deltoid down to the fingers.",54.0,Adults,1,0
910180,Employee stated that she woke up at midnight with severe nausea and started vomiting intermittently throughout the night.  She also experienced fever/chills/body aches and right arm pain.  Had to call in sick.,49.0,Adults,1,0
898151,Pt developed a fever and seizures that same day following vaccination,2.0,Kids,1,0
907850,"pain at the injection site; headache; joint pain; fatigue; chills; This is a spontaneous report from a contactable Pharmacist. A female patient of an unspecified age received BNT162B2 via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient shared information about her experience after receiving the Pfizer BioNTech COVID-19 vaccine. The patient reported pain at the injection site, headache that she treated with Naproxen, joint pain, fatigue, and chills that lasted for 72 hours. Events outcome was unknown.  Information on the Batch/Lot number has been requested.",,Unknown,0,0
886635,Patient developed diffuse body shaking that lasted for several hours.  Onset was about 8 hours after the shot.,70.0,Seniors,0,0
864306,"Pt had Pneumo 23 on 3/3/2020 24' Later 3/4 exp pain-swelling, redness 2"" area left upper inner arm-not injection site Pt took Advil 800mg & Benadryl 50mg Pt reported reaction on 3/6 - SXS resolved 90% - no apt needed",46.0,Adults,1,0
873917,"Administered an HPV vaccine on patient on her left arm. Gave apple juice prior to giving vaccine. Patient drank all of the apple juice. Once vaccine was administered, patient got up too quickly and asked if she can remain seated. She sat back down on the bed table, said she was okay. Once I walked out of the room her brother came out and she fainted and we elevated her legs. Took her blood pressure right away, and it was 131/65 Once patient laid down for a few minutes, we retook blood pressure, and it was 100/65, 88/50, 96/61. Patient was feeling nauseous and was pale, but never vomited. Mom brought her something to eat, and after she ate she felt better. Patient was able to get up and walk, felt better and left with mom. Dr said it was okay for patient to leave and will follow up with patient.",12.0,Kids,0,1
881561,"Patient was suppose to get a dose of VAQTA and was given RECOMBIV AX HB; This spontaneous report was received from a registered nurse and refers to a 15-month-old male patient. There was no information about the patient's concurrent conditions, allergies, drug reactions, concomitant therapies or medical history provided. On 27-AUG-2020, the patient was vaccinated with hepatitis b vaccine (recombinant) (RECOMBIVAX HB), 0.5 milliliter, via subcutaneous (reported as SUB Q) route (lot# 4CL44 upon internal review was established as invalid for hepatitis b vaccine (recombinant) (RECOMBIVAX HB), expiration date was reported as 24-JAN-2022) (dose number, anatomical location of administration were not reported) for prophylaxis. The patient was suppose to receive a dose of hepatitis A Vaccine, Inactivated (VAQTA).",1.25,Kids,0,1
858767,"Within the next day he was Very lethargic, went from happy smiling baby to blank. Within a month after he  no longer had eye contact. In his own world. Didn?t respond to his name. No longer waved or clapped his hands. 4 months later banging his hands and blanket into his head. Black circle bags under his eyes. Swollen like eye & seemed sick. Started showing signs of autism.",,Unknown,0,0
886306,"rash, fainting spell, double vision, ear aches, stomach irritation, fatigue.",7.0,Kids,1,0
913260,"Moderate myalgia of arms, shoulders, neck and upper back; milder myalgia of lower back and thighs. Treatment is rest, acetaminophen and massage. Outcome to be determined; symptoms still present at 48 hours.",55.0,Adults,0,0
890579,SWELLING AND DISCOMFORT AROUND INJECTION SITE.,43.0,Adults,0,0
867584,"TOOK ONLY ONE DOSE/ DID NOT COMPLETE VIVOTIF COURSE ONE-WEEK PRIOR TRAVEL; This spontaneous case (PVX2019-884) was received from a pharmacist on 15-Apr-2019. It describes a 59-year-old adult male consumer who ""took only one dose/ did not complete Vivotif course one-week prior travel"". The consumer was receiving Vivotif for international travel.  Case report: The consumer took first dose of Vivotif on 11-Apr-2019 after that did not take any more doses. The consumer had a planned trip on 22-Apr-2019 to travel internationally to another country.  Action taken with Vivotif was not applicable.  The clinical outcome of the event ""took only one dose/ did not complete Vivotif course one-week prior travel"" was unknown.  Company's Comment: The causality of the event ""took only one dose/ did not complete Vivotif course one-week prior travel"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took only one dose/ did not complete Vivotif course one-week prior travel"" was considered as not applicable.",,Unknown,0,0
881553,"muscle aches and pains, low grade fever, extremely tired for 3 days. baseball sized swelling and redness around injection site.",52.0,Adults,1,0
861176,"no adverse event; patient was administered an improperly stored dose of VARIVAX; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant medications were not reported.  On 06-FEB-2020, the patient was administered an improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) lot # S006017 (Expiration Date 27-FEB-2021), as prophylaxis  (dose, frequency, route of administration were not reported). It was incorrectly stored from minus (-) 14 Celsius degrees () to-10C (-13.5C) for 41 minutes and had no previous temperature excursion. The error was identified due to a data logger. The sterile diluent (lot# S031278 with expiration date 16-JUN-2022) was properly stored. No additional adverse event (AE) information was provided.",,Unknown,0,1
903500,"I experienced  after 40 or 50 minutes I felt funny. I felt fatigue, sleep and after that I felt a sharp pain from my neck to my upper back.",54.0,Adults,1,0
912580,0915 Generalized itching walked pt over to EMS Administered 50 mg of diphenhydramine PO,42.0,Adults,0,0
877466,"Patient turned red and became limp 5 minutes after receiving vaccines. Stats at 96%, no wheezing, no stridor. Patient was given 5ml of Claritin and oral steroid 10mL. Patient monitored for 30 minutes.",4.0,Kids,0,1
860950,"Per the patient ""36 hours after the shot, I woke up itching at my ankles/lower legs (I had assumed at the time it was just dry skin) but also in the waist area on both sides which seemed very peculiar.   I have a pinkish rash at my waist that looks like the area indicated on the shingles CDC statement for where  shingles appears on a body.   Also the itching on my legs has a bumpy rash, but it is not red.  None of it looks dramatic like I would think ""hives"" would be and I am not experiencing any of the serious symptoms of an allergic reaction.",64.0,Adults,1,0
898592,fever chills,48.0,Adults,1,0
894831,"acute cerebrovascular accident/ Severe right sided weakness/dysarthria/double vision/Vomiting/nausea; This initial spontaneous report was received from a lawyer regarding a case in litigation, referring to a patient of unknown age and gender. No information was provided regarding medical history, concurrent conditions, or concomitant medications. In or around 12-NOV-2015, the patient was inoculated with zoster vaccine live (ZOSTAVAX) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster) (strength, dose, route of administration, anatomical location, lot#, and expiration date were not reported). On an unknown date, reported as shortly after received zoster vaccine live (ZOSTAVAX), the patient suffered severe right sided weakness, dysarthria, double vision, nausea and vomiting. The patient was hospitalized and diagnosed with an acute cerebrovascular accident.  As a direct and proximate result of the patient's use of the zoster vaccine live (ZOSTAVAX) vaccine, the patient had resulted in physical limitations not presented prior to used zoster vaccine live (ZOSTAVAX). Also experienced mental and emotional distress due to resulted physical limitations and seriousness of her condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate resulted, the patient had suffered and incurred damages, included medical expenses, the loss of accumulations; and other economic and non-economic damages. The outcome of cerebrovascular accident, nausea, vomiting, diplopia, dysarthria and hemiparesis was not recovered. The reporter considered the aforementioned events to be related to Zoster Vaccine Live (ZOSTAVAX).  Upon internal review, cerebrovascular accident and hemiparesis were determined to be medically significant events.",,Unknown,0,0
862814,"pneumonia; suffered varicella type rash located throughout his body, facial swelling, difficulty swallowing and was diagnosed with autoimmune urticaria, dermatitis, cryoglobulinemia and vasculitis; suffered varicella type rash located throughout his body, facial swelling, difficulty swallowing and was diagnosed with autoimmune urticaria, dermatitis, cryoglobulinemia and vasculitis; suffered varicella type rash located throughout his body, facial swelling, difficulty swallowing and was diagnosed with autoimmune urticaria, dermatitis, cryoglobulinemia and vasculitis; suffered varicella type rash located throughout his body, facial swelling, difficulty swallowing and was diagnosed with autoimmune urticaria, dermatitis, cryoglobulinemia and vasculitis; atherosclerosis of aorta; chronic obstructive pulmonary disease; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of unknown age. Information on the patient's concurrent conditions, medical history or concomitant therapy was not reported.  On or around 27-JUN-2016, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, lot# and expiration date were not reported) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster).  On an unknown date, shortly after receiving zoster vaccine live (ZOSTAVAX), patient suffered varicella type rash located throughout his body, facial swelling, difficulty swallowing and was diagnosed with autoimmune urticaria, dermatitis, cryoglobulinemia and vasculitis. Patient also suffered and was diagnosed with pneumonia, atherosclerosis of aorta and chronic obstructive pulmonary disease.  As a direct and proximate result of zoster vaccine live (ZOSTAVAX), patient's symptoms have resulted in physical limitations not present prior to using the vaccine. Patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of his condition. As a result of using zoster vaccine live (ZOSTAVAX), patient sustained severe and permanent personal injuries. Further, as a tragic consequence of Company's wrongful conduct, patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages.  All events were considered to be disabling.  Upon internal review, cryoglobulinaemia and pneumonia were considered to be medically significant.",,Unknown,0,0
867437,"DID NOT COMPLETE DOSES ONE WEEK PRIOR TO TRAVEL; This spontaneous case (PVX2019-1202) was received from a consumer on 14-May-2019. It describes a female consumer who ""did not complete doses one week prior to travel"", while being on Vivotif for international travel.  Case report: The consumer took the first dose of Vivotif on 07-May-2019 and the last dose on 13-May-2019, respectively. She had an internationally (endemic area) planned travel on 18-May-2019.  Action taken with Vivotif was unknown.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event ""did not complete doses one week prior to travel"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""did not complete doses one week prior to travel"" was considered as not applicable.",,Unknown,0,0
907096,"Patient was okay when she came in. After getting the shot for about 15 minutes she stated that she did not feel good. She had the feeling of chest pain. The nurse got called in to monitor her blood pressure. After that about an hour or two hours, she mentioned to the supervisor that the chest pain did  not go away but it did not get worse either.",35.0,Adults,1,0
886037,"Extensive bruising, patient states bleeding down arm the day/evening of vaccine, significant swelling, fever, chills, generalized pain",68.0,Seniors,0,0
898318,Patient experiencing symptoms of Bell's Palsy,68.0,Seniors,0,0
865625,"vesicular rash, which was diagnosed as severe herpes zoster or shingles; The vaccine did not prevent shingles as intended; Information has been received from a lawyer regarding a case in litigation concerning a patient of unknown age or gender. The patient's medical history, concurrent conditions and concomitant medication use were not provided.   In 2012, the patient was vaccinated with a dose of zoster vaccine live (ZOSTAVAX) (dose, strength, administration route, anatomical location, lot number and expiration date were not reported) for routine adult health maintenance and for the long-term prevention of shingles by a physician.The reporter stated that the vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster or shingles. Later in 2013, the patient was treated in a medical center, for the onset of a vesicular rash, which was diagnosed as severe herpes zoster or shingles. As a direct and proximate result of the zoster vaccine live (ZOSTAVAX), and/or despite receiving zoster vaccine live (ZOSTAVAX) for long-term prevention of shingles. The patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and would continue to suffer significant medical expenses, and pain and suffering, and other damages.",,Unknown,0,0
885049,"On 09/19/20 woke up with severe arm pain. Persisted entire day. Next morning noticed that large (2-3"" diameter) welt near injection site. Warm to touch and very painful. Dr. recommended  Benadryl and Advil and ordered allergy panel (blood drawn 9/21). Today welt is gone, but still tender.",34.0,Adults,1,0
876359,"No additional adverse effects were reported in the patient; A patient received an expired dose of VAQTA; Information has been received from a registered nurse regarding a patient of unknown age and gender. The patient's medical history, drug allergies, previously drug reactions, concurrent conditions and concomitant medications were not reported.  On 14-JUL-2020, the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) Vial 50 (units not provided), at a dose of 1 ml for prophylaxis, (lot number S001832 with expiration date in 12-MAY-2020) (route of administration and anatomical location were not reported) (expired vaccine used).  No additional adverse effects were reported in the patient. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: S001832; expirationdate: 12-MAY-2020; deviceage and unit: 0 ; malfunction: Unknown; productavailableforevaluation: No; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent",,Unknown,0,1
865584,"Bell's palsy; This initial spontaneous report was received from a lawyer on 13-MAR-2020, regarding a case in litigation and refers to a male patient of unknown age. The patient's pertinent medical history, concurrent conditions or concomitant medications were not reported. On or about 18-JUL-2016, the patient was inoculated with zoster vaccine live (ZOSTAVAX) for routine health maintenance and for its intended purpose: the prevention of shingles. Shortly (on an unspecified date) after receiving the vaccine, the patient suffered sudden onset of facial numbness and was diagnosed with Bell's palsy. As a direct and proximate result of patient's vaccination, his symptoms resulted in physical limitations not present prior to using zoster vaccine live (ZOSTAVAX). The patient also experienced mental and emotional distress due to resulting physical limitations and seriousness of his condition. The patient sustained severe and permanent personal injuries. Further, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury.  Upon internal review, Bell's palsy was considered to be medically significant.",,Unknown,0,0
858810,There error was found during an audit,7.0,Kids,0,0
881754,The patient's entire upper arm was dark red and noticeably swollen.  He stated that he hadn't experienced any changes in his already troubled breathing and that it was just local to the site of injection,79.0,Seniors,0,0
864935,"Two shots were administered, one in each shoulder.  Once the shots were injected, patient immediately felt pain in both shoulders. This pain  has persisted for 5 straight months resulting in a visit to ER,  and visits to primary doctor..  As of this week, patient is currently taking  pain medication to deal with the pain.",73.0,Seniors,1,0
857250,"Skin itching; Slight tenderness on shoulder; Pimple-like clusters; Allergic reaction; This case was reported by a consumer and described the occurrence of itchy skin in a 64-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   In October 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 2 months after receiving Shingrix, the patient experienced itchy skin, shoulder pain, papular rash and allergic reaction. On an unknown date, the outcome of the itchy skin, shoulder pain, papular rash and allergic reaction were unknown.   It was unknown if the reporter considered the itchy skin, shoulder pain, papular rash and allergic reaction to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received 1st dose of the Shingrix vaccine about 3 months ago and for the last 6 weeks patient experienced on and off bouts of skin itching, with slight tenderness, confined to upper back (mainly on my shoulder blades). The area did not have a visible rash, only occasionally some very small pimple like clusters. The patient was doubtful that it was an allergic reaction to any new medicine, food, soap, or clothing as have not  changed any of these variables since before or after receiving the vaccine. The patient did not see delayed itching listed as a side effect for the vaccine but was wondering. If so, would this be a reason not to receive the 2nd dose.",,Unknown,0,0
861746,"""PCR stool test was completed on an unspecified date and the results showed ""rotavirus""; mucus and blood in their stool; mucus and blood in their stool; This spontaneous report was received from a nurse prescriber via a field employee, referring to a 6 weeks old male patient. The patient had no concomitant medications, no pertinent medical history and no drug reactions/allergies.  On 06-JAN-2020, the patient was vaccinated with first dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (strength, dose, frequency, lot# and expiration date were unknown) orally for prophylaxis in the series.  On 08-JAN-2020, the patient began experiencing mucus and blood in their stool within 48 hours of administration. The nurse prescriber switched the patient to a hypoallergenic formula. On an unspecified date, a polymerase chain reaction (PCR) stool test was completed and the results showed ""rotavirus"". The patient sought medical attention by seeing at nurse prescriber's office. There was no intervention to prevent serious criteria. The outcome of the events was reported as not recovered. The causality assessments between rotavirus vaccine, live, oral, pentavalent (ROTATEQ) and the events were not reported.  Upon internal review, blood in stool was determined to be medically significant.",0.08,Kids,0,1
888771,"became ""ill"" Saturday evening after getting shot on Friday afternoon - spiked fever of 100.5 with aches, very sore R arm with redness and rash at injection site size of baseball, - felt bad on Sunday with body aches and soreness",58.0,Adults,1,0
912192,"no AE; improperly stored administered vaccines; This spontaneous report was received from a nurse and refers a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On 20-NOV-2020, the patient was vaccinated with improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (recombinant human albumin) (PROQUAD), dose: 0.5 milliliter, lot# S030211, expiry date: 25-MAR-2021 (dose number, route of administration, anatomical location were not provided) for prophylaxis. Administered dose of vaccine experienced the temperature excursion of -10.8 degrees Celsius for 1 hour 30 minutes. There were previous excursions related: -12.3 degrees Celsius for 1 hour and -10.3 degrees Celsius for 10 hours and 30 minutes. Data logger was involved. No adverse events were reported.   This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2012USA003543:",,Unknown,0,1
896440,Patient developed localized redness & swelling on right thigh (siTe for Pediarix + Prevnar-13 vaccines were given) 31 hours after vaccines were given treated with ice pack & Infant's Tylenol 2.5ml every 4 hours as needed.,0.5,Kids,0,1
892539,"patient had the flu once, and it was the year the patient took the shot; Initial information received on 15-Oct-2020 regarding an unsolicited valid non-serious case from a consumer/non-health care professional via social media.  This case involves patient of unknown demography (a sixth-grade teacher) who had the flu once, and it was the year the patient took the shot (influenza), after receiving INFLUENZA VACCINE.  Medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiration date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious flu once, and it was the year the patient took the shot (influenza) (Unknown latency) following the administration of INFLUENZA VACCINE. And it was reported that teacher's immune systems build up quickly.  No laboratory data reported.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome was unknown for the event influenza.  There will be no information on the batch number for tis case.",,Unknown,0,1
907880,After leaving Clinic symptoms started within 10 minutes. Started with scratchy throat. Then tingling in my lips. Bottom lip slightly swollen.,36.0,Adults,0,0
898167,Patient stated that she ended up with welts that were itchy as well as overall itchiness. Pain at the injection site lasting 13 days after injection.,60.0,Adults,1,0
907903,"Patient reports after she received the vaccine she reported to the observation area for the 30 minute monitoring period and reported feeling her heart racing.  Patient with hx of histamine intolerance and angioedema, so carries epi pen with her.  Patient notified monitors of her symptoms and her medical hx and that she had her epi pen with her.   Patient reports ?heart racing? and recorded 130 BPM on activity tracker.  Pt endorses history of anxiety and panic attacks.  Patient reports resolution of symptoms at approximately 8:15 am, resting HR at that time 97-98 BPM.  Patient denies any other symptoms.",51.0,Adults,0,1
865682,"left cerebral hemispheric stoke; transient ischemic attack; This initial spontaneous information was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. On or about 09-FEB-2017, the patient was inoculated with zoster vaccine live (ZOSTAVAX) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after, the patient suffered left sided numbness and weakness. The patient was hospitalized and diagnosed with left cerebral hemispheric stroke and transient ischemic attack. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient's symptoms have resulted in physical limitations not present prior to using the product. The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of the Company's wrongful conduct, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of the Company's conduct, the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events was considered not recovered/not resolved. The events were considered to be related to zoster vaccine live (ZOSTAVAX).  Upon internal review, left cerebral hemispheric stroke and transient ischemic attack were considered to be medically significant. Left cerebral hemispheric stroke and transient ischemic attack were considered to be disabling.",,Unknown,0,1
868746,"TOOK ONLY THREE DOSES; A spontaneous case report was received from a nurse on 28-Feb-2019 for two consumers.  Based on the information obtained from the nurse, two individual case safety reports PVX201903-000162 (PVX2019-551; younger female) and PVX201903-000163 (PVX2019-552, elder female) were created and cross-linked in the database.  This case report describes a female consumer who ""took only three doses"". The consumer was receiving Vivotif for an unknown indication.  It was reported that the consumer took only three doses of Vivotif and forgot to take the fourth dose.  The action taken with Vivotif with respect to event ""took only three doses"" was not applicable.  The clinical outcome of the event ""took only three doses"" was unknown.  Company's Comment: The causality of the event ""took only three doses"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took only three doses"" was considered as not applicable. US-PaxVax Berna GmbH-PVX201903-000162:",,Unknown,0,0
888583,"Day after flu shot, had an upset stomach, headache, and noticeable fatigue. She then noted a rash that started on her left hand and went up her arm. Stomach upset, headache and fatigue have resolved. Rash is still there, and very itchy, but seems to be resolving. She is treating with Caladryl cream. Suggested Benedryl tabs orally if available.",78.0,Seniors,0,0
910786,"At the  36 hour I was in severe joint pain with profound myalgia, and fatigue.  The pain was an 8 to 9/10 and would have caused me to seek emergency medical care if I were not a physician capable of treating myself.  I laid in bed writhing in horrible pain and after analgesics did fall asleep.  The next day these pains continued as I had to work and had difficulty walking and maintaining professionalism.  The pain continued through Saturday at which time I took a tapering dose of steroids and it seems to finally be letting up.  I will not seek the booster injection for covid 19.",51.0,Adults,1,0
878384,"Acute onset esotropia, left cranial nerve 6 palsy. Normal MRI and lumbar puncture with normal CSF studies. No other symptoms. Being monitored.",0.67,Kids,0,0
868763,"TOOK UNREFRIGERATED VIVOTIF; This spontaneous case report (PVX2019-1658) was received from a pharmacist on 26-Jun-2019. It describes a female consumer who ""took unrefrigerated Vivotif"". She was receiving Vivotif for an unknown indication.  Case report: The consumer took three doses of Vivotif that was unrefrigerated for 6 days.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event ""took unrefrigerated Vivotif"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took unrefrigerated Vivotif"" was considered as not applicable.",,Unknown,0,0
889789,"collapsed. He awoke confused; fatigue and feeling main in his head and joints; He awoke confused; Feeling pain in his head and joints; Feeling pain in his head and joints; collapsed. He awoke confused; This case was reported by a nurse via sales rep and described the occurrence of passed out in a 16-year-old male patient who received Men B NVS (Bexsero) for prophylaxis.   On an unknown date, the patient received the 1st dose of Bexsero (unknown). On an unknown date, 5 days after receiving Bexsero, the patient experienced passed out (serious criteria GSK medically significant), circulatory collapse (serious criteria GSK medically significant), fatigue, confusion, headache and joint pain. On an unknown date, the outcome of the passed out, circulatory collapse, fatigue, confusion, headache and joint pain were recovered/resolved.   The reporter considered the passed out, circulatory collapse, fatigue, confusion, headache and joint pain to be related to Bexsero.  Additional details provided as follows: The age at vaccination was not reported, however the patient could be of 15 or 16 years old at a time of vaccination. The patient received Bexsero and experienced several adverse event. The patient was about 5 days post dose and symptoms lasted about 4 days. It started when he collapsed, he awoke confused, very fatigue and feeling main in his head and joints. The patient was unsure of the root cause of these symptoms because it was in late summer during the very intense football workout. However Nurse quickly concluded that the events were consequential to his first dose of Bexsero.",,Unknown,1,0
880483,"had blisters in his throat; and on the left lower portion of his gums.; pain on his left face/minimal pain remaining on his face; gum; pain in ear; eye; throat; scalp; This case was reported by a other health professional via call center representative and described the occurrence of throat blister in a 54-year-old male patient who received Herpes zoster (Shingrix) (batch number GB429, expiry date 5th December 2021) for prophylaxis.   On 24th July 2020, the patient received Shingrix. On 12th August 2020, 19 days after receiving Shingrix, the patient experienced throat blister (serious criteria GSK medically significant), gingival blister, facial pain, gum pain, ear pain, eye pain, throat pain and scalp pain. On an unknown date, the outcome of the throat blister, gingival blister and facial pain were recovering/resolving and the outcome of the gum pain, ear pain, eye pain, throat pain and scalp pain were not recovered/not resolved.   It was unknown if the reporter considered the throat blister, gingival blister, facial pain, gum pain, ear pain, eye pain, throat pain and scalp pain to be related to Shingrix.  Additional details were provided as follows: The patient received the dose of shingrix and developed pain on his left face, gums, ears, eye, throat, scalp and ear. In addition to the left sided pain, he had blisters in his throat and on the left lower portion of his gums.  The blisters had resolved, all except 1, per the reporter. The patient reported minimal pain remained on his face.  The reporter did not diagnose the incident as shingles, nor prescribed any medication. The reported batch number was updated from  BG429 to GB429, as per sales data sheet. The follow up consent was granted",54.0,Adults,1,0
890549,"Sever Headache, Nausea, Vomiting  Felt like a black out hangover lasting until 10/17/2020 at which time there is still some mild nausea and headache.  I didn't not have this reaction in 2010 and with this type of reaction I am very unlikely to ever recieve/accept/consent to another vaccine.",45.0,Adults,0,0
876358,"No symptoms or additional adverse effects reported.; patient received unspecified dose in PROQUAD that was improperly stored; This spontaneous report was received from a licensed practical nurse, referring to a 4-year-old patient of unknown gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions, allergies, or concomitant medications were not reported.  On 06-JUL-2020, the patient was vaccinated with an improperly stored measles, mumps, rubella and varicella (Oka-Merck) virus vaccine live (rHA) (PROQUAD) injection, as prophylaxis (lot number S021328 which has been verified to be valid, expiration date reported and validated as 05-JAN-2021) (dose, vaccination scheme, frequency, route of administration and anatomical site of injection were not reported). The vaccine was reconstituted with properly stored sterile diluent (DILUENT MRK). The administered dose of the vaccine was stored at a temperature of 67 degrees Fahrenheit, during a time frame of 17 hours, as recorded by a digital data logger. There was no previous temperature excursion. No symptoms or additional adverse effects were reported in the patient.",4.0,Kids,0,1
893206,"event -extensive swelling limited to face - down to neck, mouth and tongue numbness, warm and tingly, increased bp  treatment - Benadryl once daily, steroids twice daily for 1 week outcome - 100% improvement (took 3-4 days)",48.0,Adults,0,0
910051,"Moderna COVID- 19 Vaccine EUA Patient reported account of vaccination on 12/21/20: I received my 1st dose of the Pfizer Covid-19 vaccine yesterday afternoon and about 2 mins post injection I felt flushed, dizzy, and nauseous which disappeared quickly but then came back about 10 mins post injection and then never happened again. I felt completely normal after that and I feel fine today.",42.0,Adults,0,1
870141,"No additional adverse event; a patient was administered an expired VAQTA; This spontaneous report as received from a nurse refers to a 12-month-old patient of unknown gender. No information regarding the patient's pertinent medical history, concomitant medications, drug reactions and allergies was provided.  On 04-MAY-2020, the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) injection, lot # S002507, expiration date 04-APR-2020 (dose and route of administration were not reported) for prophylaxis. No additional adverse effects were reported.",1.0,Kids,0,1
909510,"Patient received Moderna COVID-19 vaccine IM in the Administration clinic. During the observation period, patient reported feeling flushed, warm, sweaty, with lip tingling. Vital signs 138/95, HR98, 02 Sat 98%. Proceed out call. Patient transported via wheelchair to ED for further monitoring.   In ED, monitored with resolution of tingling of the lips, cheeks still with slight flushing to them. No sob or abd pain or tongue/lip swelling, no worsening rash. Encouraged followup with working well clinic. Patient was discharged home 4 hours later.",32.0,Adults,0,0
894316,"angioedema; hives; Initial information was received on 26-Oct-2020 regarding an unsolicited valid non-serious case from a physician in the United States.  This case involves patient of unknown demography who experienced angioedema and hives (urticaria), while the patient received vaccine INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE [FLUZONE].  The patient's past vaccination(s) included INFLUENZA with no reactions and has no egg allergies. Medical history, concomitant therapy, medical treatment(s) and family history were not provided.  On 01-Oct-2020, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE (lot number and expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On 01-Oct-2020, the patient developed non-serious angioedema and hives (urticaria) 6 hours following the administration of INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE.  Details of laboratory data not reported.  It was not reported if the patient received any corrective treatment.  Patient was not recovered from both the events at the time of reporting.  There will be no information available on the batch number for this case.",,Unknown,0,1
889478,"rash looks like shingles; This case was reported by a nurse via sales rep and described the occurrence of vesicular rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced vesicular rash. On an unknown date, the outcome of the vesicular rash was unknown.   It was unknown if the reporter considered the vesicular rash to be related to Shingrix.  Additional case details were reported as follows: The patient reported case for herself. The age at vaccination was not reported. The patient had rash that developed after she got the second Shingrix dose. She did not remember when it started exactly but it was after the second dose and it looks like shingles although it did not presents pain it itches. The rash was present in the upper abdomen and upper back, right side. The reporter consented to follow up.",,Unknown,1,0
869696,"I have all of the usual side effects; This case was reported by a consumer via call center representative and described the occurrence of adverse reaction in a 71-year-old patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 21st April 2020, the patient received the 2nd dose of Shingles vaccine. In April 2020, less than a week after receiving Shingles vaccine, the patient experienced adverse reaction. On an unknown date, the outcome of the adverse reaction was unknown.   It was unknown if the reporter considered the adverse reaction to be related to Shingles vaccine.  Additional details were reported as follows:  The patient got second shingles shot the day before reporting.  The patient had all of the usual side effects.  The patient asked how long should the patient expect the side effects to last.",71.0,Seniors,0,1
848735,"patient's deltoid muscle became quite sore; Information has been received from Food and Drug Administration (FDA) (Agency number 848735) on 22-OCT-2020.  This spontaneous report was received from a health professional and refers to non-pregnant a 25-year-old White female patient. She had no chronic or long-standing health conditions, no other illnesses at the time of vaccination or up to one month prior. She was allergic to egg whites and penicillin (PCN). Her perceptions, over-the-counter medications, dietary supplements, or herbal remedies being taken at the time of vaccination included amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate (ADDERALL TABLETS), lamotrigine and acldophllus problotlcs (unspecified). She had no history of an adverse event following previous vaccinations.  On 04-NOV-2019, at 12:20, the patient was vaccinated with the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (lot # R027575 was an invalid lot number), intramuscularly in the left arm (exact dose and expiration date were not provided), and a dose of influenza virus sag 4v vaccine inactivated (mdck cell) (FLUCELVAX QUADRIVALENT) lot # reported as 261224, expiration date was not reported, intramuscularly in the right arm (exact dose was not provided); both for prophylaxis. After vaccine administration on 04-NOV-2019, at 13:30, the patient's deltoid muscle became quite sore. The soreness waned over two weeks but worsened significantly on 19-NOV-2019 and still hurt significantly on 20-NOV-2019. The patient denied swelling, redness, should joint pain, fever or chills. There were no medical tests and laboratory results related to the adverse event performed. The outcome of the event was reported as not recovered at the time of the report.  The causality assessment between the suspect therapy and the event was not provided.  Follow-up information was received from a registered nurse on 07-DEC-2020. The nurse provided a lot# R027576 with expiry date 23-JUN-2021 for hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9). The lot# R027576 has been verified to be a valid lot number for prefilled syringe formulation. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp; devicelotnumber: R027576; expirationdate: 23-JUN-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other;  followupadditionalinfo :Yes; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent",25.0,Adults,0,0
881034,"Vomitting, blood in stool.",0.17,Kids,0,0
866768,"If the person giving me the shot, pushed the medicine in slowly instead at lightening speed, would my sore arm feel better?; This case was reported by a consumer and described the occurrence of pain in arm in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was unknown.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional details were reported as follows: The case was reported by patient itself. The age at vaccination was not reported. The patient received shingrix vaccine and experienced sore arm. The patient wanted to know if the person who gave the vaccine shot, pushed the medicine in slowly instead at lightening speed, would the sore arm  would have been feel better. No other information was reported.",,Unknown,0,0
871157,Patient was given an expired immunization. Patient will return to clinic for additional dose,61.0,Adults,0,0
880178,"Incorrect product storage; no additional AE reported; This spontaneous report was received from a medical assistant and refers to a 15-months-old male patient. No information was provided regarding the patient's historical conditions, previous drug reactions, allergies, concurrent conditions or concomitant medications.  On 11-AUG-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) subcutaneous for prophylaxis (dose, frequency, and anatomical injection site were not reported; lot number was reported as T007359, and upon internal review was determined not to be valid for measles, mumps, rubella and varicella (oka-merck) virus vaccine live, expiration date was reported as 29-AUG-2021); with the first dose of diphtheria toxoid, pertussis acellular 3-component vaccine, poliovirus vaccine inactivated (Vero), tetanus toxoid (KINRIX) intramuscular (IM) (lot number 7595K with expiration date on 30-DEC-2021); with the first dose of Hib conj vaccine (tet toxoid) (ACTHIB) IM (lot number NJ165AAA with expiration date on 29-MAY-2021); with the fourth dose of pneumococcal 13v conj vaccine (CRM197) (PREVENAR 13) IM (lot number CN0615 with expiration date on April 2022); and with the first dose of diphtheria toxoid, pertussis acellular 3-component vaccine, tetanus toxoid (INFANRIX) (lot number D2KX9 with expiration date on 26-NOV-2021) (for those four vaccines doses, frequencies, indications and anatomical injection site were not reported).  On an unknown date, the mentioned vaccines had a temperature excursion in freezer. No previous temperature excursions were reported. No digital data logger was involved. No adverse reaction was noted with the patient.  This is one of six reports received from the same reporter.; Sender's Comments:  US-009507513-2008USA008314: US-009507513-2008USA009256: US-009507513-2008USA009257: US-009507513-2008USA001768: US-009507513-2008USA009259:",1.25,Kids,0,1
906611,"Phizer-BioNtech COVID-19 Vaccine EUA pain at site of infection.  Fatigue, maliaise, dizziness, nausea, low grade fevers",34.0,Adults,0,0
904911,"got a flu shot got sick; Initial information regarding an unsolicited valid non-serious case received from a consumer (patient) via Global Digital Media through social media  on 30-Nov-2020 .  This case involves an unknown age patient who got a flu shot got sick (malaise), while the patient was treated with INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), concomitant therapy, past vaccination(s) and family history were not provided.  On an unknown date in 2005 , the patient received suspect Influenza Vaccine produced by unknown manufacturer (lot number and expiry date not reported) at an unknown dose via unknown route at an unknown administration site for prophylactic vaccination.  On an unknown in 2005 after 3 days of starting the suspect vaccine therapy, the patient got a flu shot got sick (malaise)   It was reported that patient believe they used the live virus back then.   Finally patient had one this Oct-2020 after 15 years with no shots and was fine.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of the reporting , event outcome was unknown .  There will be no information available on batch number for this case .",,Unknown,0,1
856992,"headache; This case was reported by a consumer via call center representative and described the occurrence of headache in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 7th January 2020, the patient received the 2nd dose of Shingrix. In January 2020, less than a week after receiving Shingrix, the patient experienced headache. On an unknown date, the outcome of the headache was unknown.   It was unknown if the reporter considered the headache to be related to Shingrix.  Additional details were provided as follows: The age at administration was not reported. The age group was selected as adult as per vaccine indication. It was reported that the patient received 2nd dose and experienced headache. The patient knew the side effects but could not find out if the patient could take Ibuprofen for headache.",,Unknown,0,0
864440,"Fever for one night, Tylenol given, did well afterwards.",4.0,Kids,0,0
877849,"full body aches, tem spike to 103, could not get out of bed the next day..2nd day after still pain, body aches, fever but seems to be improving",58.0,Adults,1,0
886137,"no adverse event; patient received an improperly stored dose of PNEUMOVAX 23; This spontaneous report was received from a nurse, referring a patient of unknown age and gender. The patient's pertinent medical history, current conditions, previous drug reactions or allergies were not reported.  On an unspecified date in August 2020,  the patient was administered improperly stored Pneumococcal Vaccine, Polyvalent (23-valent)(PNEUMOVAX23)  (formulation, strength, dose, vaccination scheme, route of administration and anatomical site of vaccination were not reported, lot number T000702 , which has been verified to be valid, expiration date reported and validated as 01-OCT-2021), as prophylaxis (product storage error). At the reporting time, no adverse events were reported.   The vaccine administered was stored at temperatures that went from above 9 degrees Celsius (C) to 13.4C for a time frame of 51 hours and 36 minutes, as recorded by a data logger. There was no previous temperature excursion.",,Unknown,0,1
890664,"Caller states a different diluent was used to reconstitute a dose of MMR II and it was given to a patient.; This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. The patient's medical history, historical drugs, concurrent conditions and concomitant medications were not provided.  On 05-OCT-2020, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) 1 dosage form (Route of administration, lot number and expiration date were not provided) for immunization, that was reconstituted with a different diluent, rather  than sterile water.",,Unknown,0,1
873936,"adverse event(s): Myalgia, Grade 3; Fatigue, Grade 3; Headache, Grade 3;Shivering, Grade 3; Fever,  Grade 3 (101.5 degree F); GI (slight nausea)  treatment: 4 200mg advil and 5 hours sleep/rest  outcome: complete recovery",54.0,Adults,1,0
892589,"PATIENT CAME IN ON 10/23/20 WITH REDNESS AND SIGNIFICANT SWELLING FROM SHOULDER DOWN TO ELBOW, AND PAIN. HE WAS REFERRED TO URGENT CARE",77.0,Seniors,1,0
918442,Injection site - swollen arm  Muscle aches Joint pain Tingling in toes/fingernails Metal taste in mouth,,Unknown,1,0
881892,"swelling at the injection site; This case was reported by a pharmacist via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 75-year-old female patient who received Herpes zoster (Shingrix) (batch number 4X733, expiry date 8th March 2021) for prophylaxis.   On 28th July 2020, the patient received the 1st dose of Shingrix. On 28th July 2020, less than a day after receiving Shingrix, the patient experienced extensive swelling of vaccinated limb. On an unknown date, the outcome of the extensive swelling of vaccinated limb was recovered/resolved.   It was unknown if the reporter considered the extensive swelling of vaccinated limb to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient after the dose of Shingrix in the right arm experienced swelling at the injection site on the right arm that lasted 2 to 3 days, mentioned the size was about 100mm. The reporter consent to follow up.",75.0,Seniors,0,0
888802,"flu-like symptoms; This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a 55-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 28th July 2020, the patient received the 1st dose of Shingrix. In July 2020, 8 hrs after receiving Shingrix, the patient experienced influenza-like symptoms. On an unknown date, the outcome of the influenza-like symptoms was recovered/resolved.   It was unknown if the reporter considered the influenza-like symptoms to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix and experiencing flu-like symptoms beginning 8 hours after administration and lasting approximately 48 hours. Limited information was available. The reporter consented to follow up. For tolerances of 2nd dose refer case US2020197294, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020197294:same reporter",55.0,Adults,0,0
862783,"Patient called the pharmacy about 1pm on 02/04/2020 and stated that she had felt tired and had a slight fever the night of having the vaccine (02/0/3/2020). After she woke up about 4:45AM on 02/04/2020, she fainted and hit her head. Her husband called for an ambulance that took her to the hospital.",72.0,Seniors,0,0
893673,warm indurated area on upper arm with soreness / itchiness,49.0,Adults,0,0
882360,"for pneumovax injection- no pain or reaction at injection site but extensive pain on inner left arm around elbow and 6 inches up the arm.  The area was very red, hot, and swollen",83.0,Seniors,1,0
893228,"Patient was given the flu shot with her mom and little sister present.  The patient was a little nervous about getting the vaccine.  After vaccine was given, mom and children walked around the store a little but and then proceeded to walk to car to leave.  As patient got into the car, mom says she fainted.  Mom then brought her back into the store and laid her on the floor at the front of the store entrance.  By the time I got to the scene EMS had already been called and the child was laying on the floor and talking.  I asked her if she knew her name and age and she did.  There was another bystander who took her pulse and felt it was slow.  The child also looked pale.  While waiting for EMS to arrive the child was talking more and then able to sit up.  Her pulse was taken again and was getting better.  She was also given a bottle of water.  No complaints at this point of dizziness or feeling sick.  EMS arrived and checked her vitals and determined she was ok but also gave mom the choice to be taken to the hospital to be looked at.  Mom refused as she lived close to the hospital if she needed to be taken.  It was also determined that maybe the child needed to eat a snack/was hungry so she was given a bag of Doritos while EMS was still there and was able to eat.  We followed up with mother the next day and she reported that the child felt really good and went to school that day.  The mom thinks she is having a growth spurt and was probably hungry at the time of the vaccine visit and also nervous which may have contributed to the fainting.",8.0,Kids,0,0
903952,"Headache, not feeling well, slight nausea, dry throat No treatment at this time",26.0,Adults,1,0
873836,"During injecting, vaccine leaked out of needle from opposite end. Due to this, the exact dose the patient received could not be determined. Arm was cleaned with alcohol pad and patient reported no skin irritation following. ACIP and MD (Dr. per employee 2/26/20) recommended revaccination as this was most likely a sub-therapeutic dose. Patient agreed to come in for revaccination. She did not end up coming in and she was then contacted again a few times in April to come back. She did end up coming in 5/23/20 and received the revaccination. First dose of shingrix was received on 11/14/2019.",61.0,Adults,0,1
858749,"Injection site bump; Injection site erythema; injection site pruritis; This case was reported by a pharmacist via call center representative and described the occurrence of injection site swelling in a 11-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA190A, expiry date 30th September 2020) for prophylaxis.   Concomitant products included DTPa (Reduced antigen) (Boostrix) and Gardasil.   On 18th December 2019, the patient received Menveo. In December 2019, 2 days after receiving Menveo and not applicable after receiving Boostrix, the patient experienced injection site swelling, injection site erythema and injection site itching. On an unknown date, the outcome of the injection site swelling, injection site erythema and injection site itching were unknown.   It was unknown if the reporter considered the injection site swelling, injection site erythema and injection site itching to be related to Menveo.  Additional details were provided as follows: The patient received Menveo and he also received Boostrix and Gardasil at another injection site. Two days after he developed a good sized 30 mm red bump with severe itching at the Menveo injection site. The reporter consented to follow up.",11.0,Kids,0,0
857139,PT FAINTED AND FELL TO THE FLOOR AND BECAME CONCIOUS WITHIN A FEW MOMENTS. 911 WAS CALLED. PT HAD NORMAL BLOOD PRESSURE AND LEFT WITH HER MOTHER.,12.0,Kids,0,0
867386,"Shingles; Information was received from a lawyer regarding a case in litigation concerning a female patient (pt) of unknown age. No information was provided regarding the pt's medical history, concurrent conditions, previous drug reactions, allergies and concomitant medications.  On an unspecified date in 2016, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dose, route of administration, anatomical location, lot number and expiration date were not reported) for the long-term prevention of shingles and/or zoster-related conditions.  On an unspecified date (reported as ""subsequent to inoculation""), the pt was hospitalized and treated for shingles. As a direct and proximate result of zoster vaccine live (ZOSTAVAX) vaccination, the pt suffered ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment and quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. Outcome was not recovered and causality was reported as related.  Additional information has been requested.",,Unknown,0,0
874971,"Fever, upto 101.7, entire body aches. Adverse effects laste for 1 1/2 days. Woke up on morning of 7/2 and felt fine.",63.0,Adults,1,0
902879,"I got the flu; Initial information received on 21-Nov-2020 regarding an unsolicited valid non-serious case received from a consumer or non-health care professional (patient).   This case involves patient [age and gender unspecified] who got the flu (influenza), while patient received INFLUENZA VACCINE [Flu shot].  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient got the flu (influenza) (non-serious) unknown latency following the administration of INFLUENZA VACCINE.  It was reported that, every time patient taken the flu shot. Patient got the flu.   Details of laboratory data not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, the event outcome reported as unknown for event.  There will be no information available on the batch number for this case.",,Unknown,0,1
879389,"MMR II was administered to a patient that was improperly stored; no additional AE; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender.  On 05-AUG-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) lot # S015427 and expiration date 20-MAY-2021, for prophylaxis (dose, strength, frequency and route of administration were not reported).  It was reported that the vaccine had a temperature excursion of -4.1C during 45 minutes. No previous temperature excursions were reported. Digital data logger was involved.",,Unknown,0,1
888106,I believe it was the Shingles vaccine that caused bodyaches that last 48-60 hours and fever of 100.0 degrees which lasted approximately 24 hours.  3 weeks later I am experiencing the same bodyaches again but with no fever.,52.0,Adults,0,0
873949,Celllulitis,5.0,Kids,0,0
898506,"four children including my son went in with this illness; four children including my son went in with this illness/Suspected vaccination failure; This case was reported by a consumer via interactive digital media and described the occurrence of bacterial meningitis in a child patient who received Men B NVS (Meningococcal B vaccine) for prophylaxis.   On an unknown date, the patient received Meningococcal B vaccine. On an unknown date, unknown after receiving Meningococcal B vaccine, the patient experienced bacterial meningitis (serious criteria death and GSK medically significant) and vaccination failure (serious criteria GSK medically significant). On an unknown date, the outcome of the bacterial meningitis was fatal and the outcome of the vaccination failure was unknown. The reported cause of death was bacterial meningitis.   The reporter considered the bacterial meningitis and vaccination failure to be related to Meningococcal B vaccine.  Additional details were provided as follows: The age at the vaccination was not reported. The patient was given meningitis B vaccine and it did not protect from bacterial meningitis. The reporter reported children went in with this illness. The patient did not survive. This case was considered as suspected vaccination failure, since the details regarding dose number, time to onset and laboratory confirmation were not provided. This case is linked to the case US2020AMR232425, US2020AMR232424 and US2020AMR232267.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR232425:same reporter US-GLAXOSMITHKLINE-US2020AMR232424:same reporter US-GLAXOSMITHKLINE-US2020AMR232267:same reporter; Reported Cause(s) of Death: Meningitis bacterial",,Unknown,0,1
869789,"Shingles; This case was reported by a physician via call center representative and described the occurrence of shingles in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 10 weeks after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The patient experienced shingles 10 weeks after receiving the Shingrix No vaccines data was provided. The reporter consented to follow up.",,Unknown,0,1
877559,"she also has a rash on her neck and stomach; Indication: For the new symptoms of asthma; her arm that was not injected with the vaccine is experiencing pain in her bicep and tricep; Caller also stated she is not able to bend or move her arm; her arm that was not injected with the vaccine is experiencing pain in her bicep and tricep and it is a bright red; This spontaneous report was received from a consumer who refers herself, a 65-year-old female patient. Her concurrent condition included asthma, allergy to penicillin, morphine and sulfa drugs. Concomitant medication included ibandronate sodium (BONIVA) and unspecified inhaler for asthma. Medical history included morphine, penicillin and sulfa drugs.  On 06-JUL-2020, the patient was vaccinated with one dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) injection for the new symptoms of asthma and as precaution (exact dose, route of administration, lot number and expiration date were not provided).  On 07-JUL-2020, the patient's arm that was not injected with the pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) was experiencing pain in her bicep and triceps and it was a bright red. The patient was not able to bend or move her arm.  On 09-JUL-2020 (reported as yesterday), the patient noticed a rash on her neck and stomach. The patient sought for medical attention and she spoke with her primary care doctor who informed her to put ice on it. The patient went to get a second opinion and spoke with a dermatologist and she it was prescribed to her an oral steroid to use. On an unknown date in July 2020, the patient had performed computer tomography (CT) and magnetic resonance imaging (MRI) but no results were provided.  The outcome of the events was reported as not recovered. The causality assessment was not provided.",65.0,Adults,0,0
915452,pain and 4 x 4 cm edema redness and swelling at injection site myalgia x 4 days headache x 3 days sweats x 3 days fatigue that prevented work x 3 days GI upset Loose bowel movements x 2 days  loss of appetite 5 lb weight loss in 6 days,,Unknown,1,0
858259,"Vaccine fetal exposure during pregnancy; Shoulder dystocia labour complication; This is an observational study case, initially received from other health professional on 20-Jan-2020, concerning a female neonate subject, whose mother was 22-year-old, pregnant subject of body weight: 156 lbs, height: 63.6 inches and body mass index (BMI): 27.1 enrolled in a prospective observational safety study.  The mother's medical history included increased body mass index and congestion.  The mother's concomitant medications included fluticasone propionate for congestion and unspecified vitamins as obstetrics (OB) supplements.  The mother did not have any previous pregnancies, nor maternal and paternal history with major congenital malformation (MCM). The mother did not consume tobacco, alcohol and illicit-drugs during pregnancy.  The mother's last menstrual period (LMP) date was 23-Mar-2019. The mother's estimated date of delivery (EDD) was 28-Dec-2019 and corrected estimated date of delivery (CEDD) was 06-Jan-2020. The type of pregnancy was singleton. The father's age was 23.  On 30-May-2019, the subject's mother underwent ultrasound and no MCM was noted.  On 26-Jun-2019, the subject's mother underwent first trimester screen and nuchal translucency. No MCM was noted.  On 22-Jul-2019, the subject's mother underwent second trimester screen and maternal serum alpha-fetoprotein (MSAFP/serum markers). No MCM was noted.  On 12-Aug-2019, the subject's mother underwent anatomy ultrasound and no MCM was noted.  On 13-Sep-2019, at 16 weeks of gestation, the subject's mother was administered Flucelvax QIVc (Flu Vaccine Cell Subunit QIV NVD) [influenza vaccine, subunit influenza virus vaccine polyvalent; batch number: 261200, dose, route of administration, anatomical location and expiration date: not reported] (explicitly coded as 'Foetal exposure during pregnancy') for influenza immunisation.   On 10-Oct-2019, the subject's mother was administered TDAP vaccine [diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid, dose: 0.5 ml, route of administration: intramuscular, anatomical location, batch number and expiration date: not reported] for vaccination.  On 06-Jan-2020, the subject's mother had elevated blood pressure at office visit.  The subject's mother underwent labour induction and at gestational age of 40.4 weeks, the mother vaginally delivered live female neonate. The neonate birth weight was 3827 grams and no data were reported for head circumference and length. Appearance, pulse, grimace, activity and respiration (APGAR) scores at one minute was 6 and at five minutes was 9. No data was reported for APGAR score at ten minutes. The neonate experienced labour complication - shoulder dystocia.  At the time of this report, the outcome of shoulder dystocia was not reported.  Per company, the event of shoulder dystocia was considered as serious - medically significant.  The reporter did not provide causality assessment to Flucelvax QIVc.  This case is linked to case 202000562 (corresponding mother case).  Company Comment: The female neonate subject experienced shoulder dystocia after foetal exposure during pregnancy, at gestation age of 16 weeks with the suspect product Flucelvax QIVc. Chronology is plausible. Mother's medical history increased body mass index (27.1) may have contributed to development of the event. Causality is also confounded by mother's therapy with concomitant medication fluticasone propionate. Foetal exposure during pregnancy is assessed as not related per company's conventions. Causality between suspect product and the event shoulder dystocia is assessed as not related due to biological implausibility.; Sender's Comments: The female neonate subject experienced shoulder dystocia after foetal exposure during pregnancy, at gestation age of 16 weeks with the suspect product Flucelvax QIVc. Chronology is plausible. Mother's medical history increased body mass index (27.1) may have contributed to development of the event. Causality is also confounded by mother's therapy with concomitant medication fluticasone propionate. Foetal exposure during pregnancy is assessed as not related per company's conventions. Causality between suspect product and the event shoulder dystocia is assessed as not related due to biological implausibility.",,Unknown,0,1
896570,"Pt reported swelling and redness at the injection site.  It started out the day after injection as a quarter-sized welt.  By the fourth day post injection, pt reports that area of swelling has increased to a 5''x7'' area.",47.0,Adults,0,0
890268,"Swelling, redness, itching (at times), warm to the touch - Applied ice for the swelling, took Benadryl for the itching, took Tylenol for the discomfort",67.0,Seniors,0,1
887941,"Medical assistant calling to report a temperature excursion that occurred 8/14/2020 which involved the following products: GARDASIL9, PEDVAXHIB, RECOMBIVAX, ROTATEQ. Per caller, ""it would be possible that at least 100 patients have received vaccines; This spontaneous report was received from a medical assistant, concerning a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies or concomitant medications were not reported.  On 04-SEP-2020, the patient was vaccinated with an improperly stored doses of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) orally as prophylaxis (lot # 1660991 with expiration date 27-APR-2021) (strength and frequency were not reported) and with haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) 0.5 ml as prophylaxis (lot # S036821 with expiration date 21-APR-2022) (strength, frequency, route of administration and anatomical location were not reported).  The improperly stored doses of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) and haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) experienced a temperature excursion of 35.4 Fahrenheit degrees (F) for the time frame of 20 minutes without previous temperature excursions. It was confirmed that a digital data logger was involved.  This is one of several cases from the same reporter. ; Sender's Comments:  US-009507513-2009USA006106:",,Unknown,0,1
872624,"No symptoms reported; Inappropriate schedule of vaccine administered; Unspecified number of patients have recieved improperly stored ROTATEQ on unspecified dates; This spontaneous report was received from a nurse, referring to a 11 weeks old female patient. There was no information about the patient's concurrent conditions, concomitant therapies or medical histories provided.  On 25-SEP-2019, the patient was vaccinated with the first improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (lot number S004251 with expiration date: 22-SEP-2020; dose, strength and route of administration were unknown) for prophylaxis (product storage error). On 13-JAN-2020, the patient had received the second dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (strength, dose, route of administration, lot# and expiration date were not reported) (inappropriate schedule of product administration). No symptoms reported.  Administered dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) underwent temperature excursion of 46.9 degrees Fahrenheit (F) for 55 minutes. Data logger was involved. The previous temperature excursion was 34.9 F for 25 minutes and 48.6 F for 25 minutes.  This is 1 of 4 reports received from the same reporter.; Sender's Comments:  US-009507513-2005USA007560: US-009507513-2005USA007561: US-009507513-1911USA004865:",0.17,Kids,0,1
856598,"Lethargy, severe headache, no appetite, explosive diarrhea, whole body chills, injection site redness and swelling with spots around the site--most of the severe symptoms resolved about 24 hours later, energy better slightly, did not measure temperature.  Still with some injection site pain but less red.",69.0,Seniors,1,0
891489,"I had the vaccine at 3:45pm Thursday, Oct 8th, 2020.  While sleeping at about 11pm I awoke with nausea and starting to vomit. I had an bad stomach ache with bloating. I also had a very bad head ache. I do not normally get head aches. I could not fall back asleep. I tried to get up at 6am but was dizzy and unsteady. My husband helped me to the bathroom 4 feet away. Through out Friday I was dizzy, had a very bad head ache and continued to be bloated. I could not eat. Saturday I woke up feeling not as bloated but still with a mild stomach. Later in the day around 4pm I had heart palpitations while sitting out in the back yard. They only lasted about 2 minutes. On Sunday I broke out in a full body rash. Red raised splotches all over my body. I do get this reaction to a cold so I was not concerned. The rash finally started to go away on Tuesday.",70.0,Seniors,0,0
855449,"Severe chills and intense headache, nausea, body aches",66.0,Seniors,1,0
866217,"on same day as administered vaccine patient began complaining of excruciating pain at site that prompted a return to office for evaluation.  A second visit on day of report with worsening pain that radiated to L trapezius and L side of neck and distally to end of fingers.  Gripping movement of L hand associated with pain of entire L arm, L posterior shoulder and L neck.  Patient describes circumferential stocking - glove like numbness immediately distal to injection site and extending to fingers lasting a couple of hours.  exam demonstrated limited range of motion of left shoulder due pain and intact though weak strength of left are  compared to right",18.0,Adults,0,0
885947,The patient states she received vaccine at 8:30am and we she got home she had some swelling as the day moved on she had a Red Line about finger width all around her arm just below vaccine site.  Throughout the day she said she was fine but her swelling  extended from her arm up to her neck by 6:30 pm that day. She went to the emergency room and received pepcid AC and benadryl. She states she had already taken some benadryl.  She says she stayed at hospital for 2 and 1/2 hours then was sent home with a prescription for Prednisone. She says she did get dizzy and lightheaded but that passed and she did not have any discomfort only swelling on her arm. She says she is fine now but did want for someone to report her occurence. She states she had Prevnar vaccine last year with issues. Her flu vaccines have always been ok.,75.0,Seniors,0,1
863845,"something deltoid bursa or something; Initial information was received on 25-Feb-2020 regarding an unsolicited valid non-serious case from other health professional.  This case involves female patient who experienced something deltoid bursa or something (bursa disorder), while she received vaccine DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL].  Medical history, medical treatments, vaccinations and family history were not provided.  On an unknown date, the patient received a dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (lot number and expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious something deltoid bursa or something (bursa disorder) (unknown latency), following the administration of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE.  Laboratory data was not provided.  Final diagnosis was (unspecified) bursa disorder.  It was not reported if the patient received a corrective treatment.  The event outcome was unknown.  Information on batch number was requested.",,Unknown,0,1
903483,"1509 pt received imms x3 listed above as inpatient prior to discharge home 1513 moc called nurse back to bedside per MD / Rapid response note: child unresponsive, good pulses, non-responsive to sternal rub, eyes open but not tracking, heart and lung exam WNL  Narcan was administered in case related to narcotics- no change in LOC after admin Ativan was administerd in event of possible new onset seizure- no change in LOC after admin",7.0,Kids,0,0
893992,"Pt reported redness, swole , sore, ?hurts to touch? at injection site",31.0,Adults,0,0
912797,"Received vaccine 12/26/2020, by 4:45 pm 12/27/2020 started feeling a headache. On 12/28/2020 it had become a migraine with nausea. On 12/29/2020 it is still a migraine with some vomiting and nausea.",48.0,Adults,0,0
862764,"No adverse event; The patient was administered an improperly stored dose of M-M-R II; This spontaneous report was received from the Immunization official who was also a nurse concerning a 4-year-old patient of unknown gender. Information regarding the patient's pertinent medical history, concomitant medications or drug reactions/allergies was not provided.  On 11-NOV-2019, the patient was vaccinated with an improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), lot number S004118, expiration date 11-FEB-2021 for prophylaxis (dosage schedule, anatomical location and route of administration were not reported) (product storage error). The vaccine was reconstituted with sterile diluent (lot number and expiration date were not reported).  The administered dose of the vaccine experienced a temperature excursion above 9C: 10.9 C for 8 hours and 15 minutes, as recorded by a data logger. There was no adverse effect reported.",,Unknown,0,1
866018,"While I did experience chills, pain at site, malaise, and general aches the evening of the injection, several days later I also noticed a constant headache with continued malaise.  When I felt my head/skull where it hurt the most, I noticed lumps/bumps which ran upward from my upper neck along the route of my occipital nerve on the right side of my skull.   I also noted an enlarged lymph node behind my right ear. These were tender to touch and made it hard to sleep laying on my right side.  I did not have fever, chills, sore throat or other issues.  But after two weeks of  the tender bumps and headache, I became suspicious that I was actually experiencing a case of Shingles.  When I awoke on 3/24/20 with a new small vesicle on my eyelid, I became more concerned.  So I made an appt. to see my MD where she did confirm that she felt I had a case of shingles and started me on a course of cortisone and Valacyclovir.",68.0,Seniors,1,0
904533,Sore deltoid muscle starting 10 hrs after injection lasting 24 hrs.  No treatment required.   Menstrual cycle 3 days late as of today. Negative home pregnancy test. Menstrual cycle is normally very regular.,36.0,Adults,0,0
880568,"102 degree fever, severe headaches",52.0,Adults,1,0
891160,Guillain Barre Syndrome.,10.0,Kids,0,0
910793,"PT. REC'D VACCINE AT 2:18PM, WAITED RECOMMENDED 15 MIN. AND CHECKED OUT AT 2:33PM.  T/C AT 2:42 PT CALLED AND C/O TINGLING TO LEFT SIDE OF FACE AND LIPS, AND C/O  A H/A THAT PT. REPORTS COULD POSSIBLY BE D/T STRESS/ANXIETY  OF THE TINGLING SENSATION. STAYED ON THE PHONE WITH HER WHILE SHE COMPLETED HER DRIVE TO THE WORK SITE. SPOKE WITH HUSBAND AND ASKED THAT HE GET BENADRYL AND ADMINISTER ASAP AND TO CALL IF SYMPTOMS WORSEN. T/C TO PT AT 3:12PM HAS TAKEN BENADRYL AND FEELS FINE.",43.0,Adults,0,1
863542,"Child began complaining about stomach pain and no appetite along with leg soreness and fatigue. Shortly after she started to run and fever and vomited once. She continued to be very tired, no appetite, and with continued leg soreness for the following 48 hours.",2.0,Kids,1,0
890472,"I went to get a flu vaccine at my local pharmacy clinic. I asked for the flublok quadrivalent vaccine because I had read that it was better suited for people with allergies, and who are prone to have allergic reactions. However, the nurse practitioner insisted that I get the flucelvax quadrivalent flu vaccine instead. She told me that she and her children had received the same vaccine, and that they didn't have a bad reaction to it. She told me that both vaccines were very similar. I thought it was odd that she just didn't give me the vaccine I asked for, but I didn't see any reason to press the matter. So I agreed to have the flucelvac quadrivalent vaccine which she kept insisting on. After she administered the flu vaccine to me I left. I didn't live far from the store. I started to feel tingling all over my body about 30 to 45mins after I received the flu vaccine.  When this started happening I thought that I must be having a mild reaction to the vaccine. The tingling and itching lasted all day. I was still itching some the next day, but this time I noticed that my left hand, on the arm that I received the injection was really really sore, and weak. My left arm muscles also ached and felt really fatigued. The muscle ache in my left hand, and arm lasted all day. Later on that night my entire body was experiencing muscle aches, and muscle fatigue. When I went to bed that night I took a Benadryl and went  to sleep. The next day the itching I had experienced had greatly diminished, but I was still experiencing muscle aches and fatigue all over my body. I have to lift heavy things at work, and for the past few days it has been difficult to do  so because of the muscle fatigue I've been experiencing. I am writing a report today, 10/17/20, because it has been a week since I received the flu vaccine, and I am still experiencing mild itching, muscle aches, and muscle fatigue.  I have never had such a bad reaction from receiving a flu vaccine before!",34.0,Adults,0,0
902504,"Patient reports severe shoulder pain that is worse with movement even after one week after administration. Denied any erythema, edema or heat at injection site.",45.0,Adults,1,0
904492,Throat tightness,47.0,Adults,0,0
895370,"During the  first night after the shot, I awoke with pain that radiated down the left side of my body from neck all the way down.  The pain felt muscular and joint...by morning it was all over my whole body.  So much joint pain.  I developed a huge bulge at the injection site...the size of my hand.  On the day following injection, we were heading out of town for the weekend.  The pain was pretty bad all over my body.  It got a little better each day...today 11/8, i still have a huge bulge on my arm...it is still painful to touch, just not as bad as it was.  Now the injection site itches really bad...but the bulge is still there.  Body aches are better so I?m hopeful that I?m on the upswing.  I?ve taken some ibuprofen...can?t really tell if it lessened the symptoms.",53.0,Adults,1,0
881226,"Swelling wheel, burning, hot at site, radiating pain to under arm and shoulder",36.0,Adults,1,0
898715,"Sore arm with first injection on September 14, 2020. Sore arm, shivering, body aches, back and neck muscle soreness, fatigue and nausea with second injection on November 27, 2020. Symptoms for second injection started about 12-13 hours after the injection and continued through 48 hour period. Arm soreness still lingers, but diminishing.",58.0,Adults,1,0
891947,"Vaccine was administered in the Deltoid region, she called a week ago and spoke with my colleague and he suggested icing, taking tylenol and let us know in few days, she visited the pharmacy now (10/22/20) and informed that she started having pain at the ELBOW (not Shoulder) area, she said she started having the pain approximately a week or so after the vaccine.",72.0,Seniors,0,0
910573,"red splotchy itchy face; red splotchy itchy face; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration in the right arm on 17Dec2020 at 16:00 (at the age of 29-years-old) as a single dose for Covid-19 vaccination. Medical history included Premenstrual dysphoric depression syndrome from an unknown date. The patient did not have any allergies to medications, food or other products. The patient was not pregnant at the time of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient was not tested for COVID-19 post vaccination. The patient's concomitant medications included citalopram (MANUFACTURER UNKNOWN) and ibuprofen (ADVIL); all for unknown indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Dec2020 at 21:00, the patient experienced red splotchy itchy face. Therapeutic measures were taken for the red splotchy itchy face which included allergy medicine (unspecified). The clinical outcome of the events red splotchy itchy face was not recovered.  The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.",29.0,Adults,0,1
864522,The Hep A was not due until 6/9/20. The TDaP-IPV was the incorrect dose for a 15 month old.,1.25,Kids,0,0
864297,"it can not be ruled out if that unspecified patient received potential dose of PNEUMOVAX23 prior to being asthmatic/a unspecified 14 year old who has asthma may have received a dose of PNEUMOVAX23 in the past; This spontaneous report has been received from a pharmacist referring to a 14 years old female patient. Information about medical history, concurrent conditions, concomitant therapies and drug allergies was not provided.      On an unknown date, the patient might had been vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (lot #, expiration date, frequency, route and dose details were unknown) for prophylaxis.       On an unknown date, the patient experienced asthma. It could not be ruled out if that the patient received potential dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) prior to being asthmatic.      The outcome of asthma was unknown. The causality between the asthma and the pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was unknown.",,Unknown,0,1
894698,"4 or 5 year-old child received Flublok, no Adverse event; Initial information received on 16-Oct-2020 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a child patient (age reported as 4 or 5 year-old) who received an INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] (lot number: unknown, expiry date: unknown) via unknown route and site on an unknown date for prophylactic vaccination (product administered to patient of inappropriate age).  The patient's medical history, medical treatments, concomitant therapy, vaccinations and family history were not provided.  It was an actual medication error due to Inappropriate age at vaccine administration. (latency- on the same day).  At the time of reporting, patient had not experienced any adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information available on the batch number for this case.",,Unknown,0,1
910310,"throat tightness; tingling of lips; allergic reaction; felt strange; This is a spontaneous report from a contactable Other-HCP (nurse practitioner). A 43-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, NDC, lot/batch number and expiration date unknown), via an unspecified route of administration on 18Dec2020 at single dose for covid-19 immunization (She wanted to be vaccinated against COVID 19). Patient history was no. She has no other history no other history of reactions to vaccines or flu vaccines, no history of allergies noted before. She thought her weight was probably about 140. She did not have her height either, but she was about 5'4"" probably. Concomitant medication included atorvastatin (LIPITOR) and thyroid medications. It was reported that they have an employee that received the COVID 19 vaccination and experienced an allergic reaction. It had to be a brief call but it was there crazy. Patient received the vaccine and within 30 minutes she had throat tightness and tingling of lips. This happened on 18Dec2020(today) about 20-30 minutes after receiving the vaccine. The throat tightness had resolved after giving Epinephrine (Epi). She said the tingling of her lips resolved as well after Epi. She just said she felt strange but that could be from the Epi. She said it was an employee vaccination so there was no prescriber. She took Lipitor and thyroid medications. She said those were just her routine medications. She did not have a start date for the Lipitor. She had not been on anything new. It was definitely just the COVID vaccine. Outcome of the events tingling of her lips, throat tightness and allergy reaction was recovered on 18Dec2020, of other event was unknown.   Information about lot/batch number has been requested.; Sender's Comments: There is a reasonable possibility that the events allergic reaction and throat tightness were related to BNT162b2 based on known drug safety profile and close temporal relationship. Based on the close temporal relationship, the association between the event tingling of lips with BNT162b2 can not be completely excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.",43.0,Adults,0,1
873325,"Pt was given both shots on the same day, Varivax in left arm and Boostrix in right arm.. Patient fainted after second shot. Called the next day to report injection site reaction on left arm (Varivax).",27.0,Adults,0,0
879971,"Muscle pain in arm, shivering, stomach pain and nausea, all over malaise....",88.0,Seniors,1,0
856467,"a couple drops of PROQUAD splashed directly into his eye; a couple drops of PROQUAD splashed directly into his eye.; a couple drops of PROQUAD splashed directly into his eye.; This spontaneous report was received from a physician referring to a male employee of unknown age. Information about medical history, concurrent conditions and concomitant therapies was not provided.  On 07-JAN-2020, when the employee was preparing measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) (before reconstitution) to administer to a patient (dose, strength, route, lot# and expiration date were not provided) for prophylaxis, a couple drops of preparing measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) splashed directly into the employee's eye (occupational exposure to product, accidental exposure to product and exposure via eye contact). The eye was rinsed with water. Medical attention had been sought.",,Unknown,0,1
868528,"Patient called and states Friday early evening hours she had a terrible headache, fullness in her throat,  ear pain,  muscle pain, gum pain and then Saturday morning woke up with blisters in her mouth.",67.0,Seniors,1,0
908382,"Diffuse splotchy erythematous, mildly pruritic rash on arms, neck, trunk, and legs. More prominent on flexor surfaces of limbs.",37.0,Adults,1,0
2759415,"Adacel exposed to 52.6 degree Fahrenheit for seven days and administered to patient/ No AE; pregnant female patient received Adacel/no AE; Initial information was received on 20-Jul-2020 regarding an unsolicited valid non-serious case received from other health professional.  This case is linked to cases 2020SA188909, 2020SA189132, 2020SA189059 and 2020SA189085 (same reporter).  This case involves a 36 year old pregnant female patient who received 0.5 ml of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL](batch number U6638AA and expiry date 12-Apr-2022) via intramuscular route in the left arm on 15-Jul-2020 for prophylactic vaccination which was exposed at 52.6 degree Fahrenheit for seven days (exposure during pregnancy and product storage error).  Data regarding this pregnancy were received prospectively, that is before pregnancy outcome was known.   The patient received adacel vaccine at 27 Weeks of gestation.  The date of last menstrual period was reported as 03-Jan-2020.  The estimated due date is 09-Oct-2020.  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  No concomitant therapy was given.  It was an actual medication error due to incorrect product storage and was also a case of vaccine exposure during pregnancy.   Case details: It was reported that the excursion was for seven days and vaccine got exposed to 52.6 degrees Fahrenheit from 08-Jul-2020 to 15-Jul-2020 that was administered to five patients since the excursion.  The patient had no adverse reactions at the time of report.  The outcome of the pregnancy was unknown.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",36.0,Adults,0,1
856206,Left upper arm -blanching faint pink macular rash 10x 11 cm extending to medial arm,4.0,Kids,1,0
858227,"stroke; Information has been received from a lawyer regarding a case in litigation concerning a 62-year-old male patient. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication.  On 25-OCT-2017, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot number, dosage and route of administration not provided) for prophylaxis in a pharmacy. On or about 25-FEB-2018, as a result of his receipt of zoster vaccine live (ZOSTAVAX), the patient was caused to suffer a stroke, including any and all of its sequelae. As a result of his receipt of zoster vaccine live (ZOSTAVAX), the patient has been caused to suffer severe personal injuries, pain, suffering, and emotional distress, as well as to incur substantial economic damages. The outcome of the event was not reported. The event was considered to be related to zoster vaccine live (ZOSTAVAX).  Upon internal review, the event of stroke was considered to be medically significant.",62.0,Adults,0,1
893312,"rash; This case was reported by a consumer via interactive digital media and described the occurrence of rash in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as adult as per the vaccine indication. The patient received Shingrix and had rash.",,Unknown,0,0
902995,"pt developed chills, nausea and vomiting. Reports > 10 episodes of vomiting total. Went to lunch and continued to have chills and vomiting. Also developed chest pain - described as burning and heaviness. Denies any shortness of breath. CT negative for any changes.  Chest X ray normal.",37.0,Adults,1,0
866303,"local reactions in the injection site; muscle spasms/ involuntary muscle spasms; shivering; This case was reported by a pharmacist via call center representative and described the occurrence of injection site reaction in a 54-year-old female patient who received Herpes zoster (Shingrix) (batch number B4TT5, expiry date 10th April 2022) for prophylaxis.   Concurrent medical conditions included asthma. Concomitant products included cannabidiol.   On 28th February 2020, the patient received the 1st dose of Shingrix. In February 2020, 12 hrs after receiving Shingrix, the patient experienced muscle spasm and shivering. On 1st March 2020, the patient experienced injection site reaction. On an unknown date, the outcome of the injection site reaction, muscle spasm and shivering were unknown.   It was unknown if the reporter considered the injection site reaction, muscle spasm and shivering to be related to Shingrix.  Additional information was provided as follows: The health care professional provided lot number and expiration date of the vaccine. The patient received vaccine between 3 to 4 pm, that night the patient woke up in middle of the night (around 3 am)  with muscle spasms (parkinson like) and shivering.  Two days after that, the patient developed local reactions in the injection site. The health care professional was especially concerned about the muscle spasms since she did not find information about that in the prescribing information. The reporter consented to follow up.",54.0,Adults,0,0
864881,"Pt phones provider's office reporting redness to left arm. Pt states redness is ""a couple inches diameter around injection site and a spot below it"", a bump on injection site and a line under his arm. He reports temp of 99.2 F starting last night, ""went down since then"", stiff fingers and cramping in the arm. Pt denies adverse reaction/allergy to vaccine in the past. Per Dr., pt having an immune response to the vaccine as it has been within 24-48 hours from when the vaccine has been received, have pt ice area, draw a line around the reddened area and monitor it for increasing redness outside the marked line, pt can take ibuprofen as well. RN phones pt with Dr. further direction, pt verbalizes understanding and is agreeable to plan. RN advises pt to call provider if redness increases outside of line drawn, temperature increases, arm becomes warm to the touch, symptoms do not improve. Pt verbalizes agreement to do so if needed. Pt denies further questions/concerns/needs at this time.",66.0,Seniors,0,1
891838,"lnadvertenly adminstered expired vaccine; This spontaneous report was received from a nurse refers to a patient of unknown age and gender. The patient's concomitant medication, pertinent medical history and drug reactions or allergies were not reported.  On 09-OCT-2020, the patient was vaccinated with second dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II) (strength, frequency, dose and route of administration were not reported; lot # R028381, expiration date was reported as 03-OCT-2020) for prophylaxis. This was an expired measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), which was inadvertently administered to the patient (expired product administered). No previous temperature excursions. The outcome of the event was unknown.",,Unknown,0,1
861612,"refrigerator containing Fluzone went down to 29.1F. After that excursion, injections administered to patient / no AE; Initial information received on 07-Feb-2020 regarding an unsolicited valid non-serious case received from other health professional.  This case was linked to cases 2020SA032577, 2020SA038302, 2020SA038343, 2020SA038344, 2020SA038345, 2020SA038346, 2020SA038347, 2020SA038348, 2020SA038349, 2020SA038350, 2020SA038351, 2020SA038352, 2020SA038468, 2020SA038469, 2020SA038470, 2020SA038471, 2020SA038472, 2020SA038467, 2020SA038474 and 2020SA038473 (same reporter)  This case involves a 6 years old patient of unknown gender who received 0.5 ml dose of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED [FLUZONE] lot UJ254AC (Expiry date 30-Jun-2020) via unknown route in the left Deltoid for Prophylactic vaccination which was exposed to refrigerator down to 29.1F.  Medical history, medical treatment(s), concomitant therapy, vaccination(s) and family history were not provided.  It was an actual medication error case due to Product storage error temperature too low (Product storage error).  Patient did not receive any adverse event at the time of reporting.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",6.0,Kids,0,1
877949,Chronic Urticaria,62.0,Adults,0,0
903254,Patient states her jaw began tingling recently with mild pain.,52.0,Adults,1,0
907429,"injection site soreness, mild headache, fatigue, muscle aches with hear palpitations x 2 days then it started to improve  and resolved on day 3. I am also breastfeeding an infant.  There were mild heart palpitations the day prior to getting vaccine as well, which are not uncommon to patient during times of stress.",35.0,Adults,0,0
907888,"10 minutes after receiving the injection I was experiencing dizziness and lightheadedness. As I was moved to a new location I was still experiencing aforementioned symptoms in addition to feeling hot and nauseous and I vomitted. I was moved to the ER for further evaluation. I was given a COVID test, an EKG and my vitals were monitored. I was discharged home.",24.0,Adults,1,0
878345,"no additional adverse event reported; expired vaccine used; This spontaneous report as received from a other refers to a 62 year old patient. The patient's medical history, concurrent conditions and concomitant therapies were not provided.   On 28-JUL-2020 the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated(VAQTA) lot # S007265 expiration date 07-JUL-2020 (dose and route were not provided) for prophylaxis. No adverse event were reported. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; manufactureraddress:; manufacturercity:; manufacturerstate:; manufacturercountry:; devicelotnumber: S007265; expirationdate: 07-JUL-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",,Unknown,0,1
901040,"Day of vaccination, in the evening felt like i had been hit and my arm was almost immobile.  If I moved my arm, pain localized in the socket was intense.  I went to bed early because of the pain.  For the next 2 days the pain continued, my arm had to stay close to my body, with little movement.  On the 3rd day could feel the pain lessening.  The fourth day I could move it freely and finally returned to normal.  i didn?t report my problem with the vaccine but today had boil like itchy skin above the shoulder joint.  I took a picture of the skin.   With the eruption of my skin, I thought I should report it.  I?ve never had a vaccine shot that brought pain like this, and then later reaction of a boil-like itch.",75.0,Seniors,0,0
872779,"No patients experienced any adverse effects; Improperly stored dose of ROTATEQ; This spontaneous report was received from a physician concerning a patient of unknown age and gender. No information was provided regarding the patient's pertinent medical history, concomitant medications, or drug reactions/allergies.     On 19-MAY-2020, the patient was vaccinated with an improperly stored dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) vial (product storage error), by oral route (lot # 1660693, has been verified to be a valid lot number; expiration date 19-MAR-2021) as prophylaxis (dosage schedule and strength were not reported).   The administered dose of the vaccine experienced a multiple temperature excursions below highest temperature above 47 Fahrenheit degrees  to 66.6 Fahrenheit degrees for 2 hours and lowest temperature below 36 Fahrenheit degrees to 33.6 Fahrenheit degrees  for 45 minutes as recorded by a data logger. There was no previous temperature excursion. There was no adverse effect reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2006USA001703:",,Unknown,0,1
873959,"When we called him for his second vaccine in the series, he said his arm was still sore and bothering him. He said that he had an xray done and they said it was arthritis.",77.0,Seniors,0,1
899123,"flu; Initial information was received on 14-Oct-2020 regarding an unsolicited valid non-serious social media case from a consumer via social media.  This case involves patient (unknown demography) experienced flu (influenza), while the patient received INFLUENZA VACCINE.  Medical history, medical treatment, vaccination, concomitant medications and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious flu (influenza) (unknown latency) following the administration of INFLUENZA VACCINE.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  The event outcome was unknown at the time of report.  There will be no information available on the batch number for this case.   Initial information was received on 14-Oct-2020 regarding an unsolicited valid non-serious social media case from a consumer via social media.  This case involves patient (unknown demography) experienced flu (influenza), while the patient received INFLUENZA VACCINE.  Medical history, medical treatment, vaccination, concomitant medications and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious flu (influenza) (unknown latency) following the administration of INFLUENZA VACCINE.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  The event outcome was unknown at the time of report.  There will be no information available on the batch number for this case.",,Unknown,0,1
915068,"I started to feel poorly about 10pm the evening of the shot. I had a fever and body aches along with a headache that started in the night. As time went on, my fever got worse and it felt like ibuprofen and acetaminophen did. It help the aches and headache much.",49.0,Adults,1,0
885968,"patient husband called on 9/25 and said patients arm was red, swollen and her bottom lip had started swelling up.  I told him he should contact her primary care doctor about the swollen lip.  Patients husband came to pharmacy on 9/26 and said her top lip had started swelling today.  He had contacted the doctor on 9/25 and he advised pt to take Benadryl, Pepcid and to not get the second dose of Shingrix",69.0,Seniors,0,0
888054,"herpes zoster; Information has been received from a lawyer concerning a case in litigation and refers to a patient of an unknown age and gender. No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided. On or about 03-OCT-2017, the patient was inoculated with zoster vaccine live (ZOSTAVAX) vaccine (dose, route of administration, vaccination site, lot # and expiry date were not specified) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). On an unknown date, after receiving zoster vaccine live (ZOSTAVAX) vaccine, the patient suffered from herpes zoster. As a result of these symptoms, the patient was seen and treated by medical providers. As a direct and proximate result of the Company's defective zoster vaccine live (ZOSTAVAX) vaccine, the patient's symptoms have resulted in physical limitations not present prior to using the Company's product. The patient also experienced mental and emotional distress due to resulting physical limitations and seriousness of his condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of the Company's wrongful conduct, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of the Company's conduct, the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the event was not recovered. The causality was related.   The event of shingles was considered to be disabling.    This spontaneous report as received from a lawyer refers to a patient of unknown age with routine health maintenance.    On 03-OCT-2017 the patient was vaccinated with zoster vaccine live(ZOSTAVAX), unknown for routine health maintenance and prophylaxis.       On an unknown date the patient experienced herpes zoster (disability).    The outcome of herpes zoster was reported as not recovered/not resolved.   The reporter considered herpes zoster to be related to Zoster Vaccine Live(ZOSTAVAX).     {Additional information has been requested. / Additional information is not expected.}",,Unknown,0,0
2759416,"patient received a dose of Adacel which was exposed to 52.6 degrees Fahrenheit for seven days,No AE; A pregnant female received a dose of ADACEL,No AE; Initial information was received on 20-Jul-2020 regarding an unsolicited valid non-serious case from the other health care professional.  This case is linked to cases 2020SA188909, 2020SA189132 ,2020SA189059 and 2020SA189112 (same reporter).  This case involves a 30 years old pregnant female patient who on 15-Jul-2020 at 28 weeks of gestation received a 0.5 mL dose of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] (lot number: U6638AA and expiry date 12-Apr-2022) via intramuscular route in the left arm for prophylactic vaccination and that vaccine was exposed to 52.6 degrees Fahrenheit for seven days (exposure during pregnancy and product storage error)  Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known.   The patient received Adacel vaccine at 28 Weeks of gestation.  The date of last menstrual period was reported as 01-Jan-2020.  The estimated due date is 07-Oct-2020.  Medical history, past medical treatment, vaccination and family history were not provided.  No other concomitant medications were reported.   It was an actual medication error due to incorrect product storage and was also a case of vaccine exposure during pregnancy.    Case details: It was reported that the excursion was for seven days and vaccine got exposed to 52.6 degrees Fahrenheit from 08-Jul-2020 to 15-Jul-2020 that was administered to five patients since the excursion. Reporter wanted to know about the possible side effects.  Laboratory details were not reported.  The patient had no adverse reactions at the time of report.   Additionally, at time of reporting, the outcome of the pregnancy was unknown.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",30.0,Adults,0,1
901721,"Patient received vaccination the morning of 11/11/2020, and the evening of the same day, patient stated he developed fever (101), upset stomach, muscle weakness, muscle aching, and fatigue.  No diarrhea, difficulty breathing or rash was reported.  Patient went to ER the next morning after vaccination due to his symptoms and possible concern about COVID.  COVID test came back negative.  Patient was in ER for about 8 hours and started feeling better and was completely symptom free by the evening of the same day.",76.0,Seniors,1,0
879575,"Day of the vaccines (08/13) he had a low grade temperature - highest it got was 99.6. No redness, no swelling, wasn?t hot to the touch.   08/14 - had a little visible redness that was ?localized? to the shot location, and a bit of swelling. He had a low grade temperature all day long, and complained of a headache. He laid around most of the day, didn?t play much, and said he was tired.   08/15 - swelling is down to just below his elbow, very visible redness, and is VERY warm to the touch. We?ve been applying ice to the area to combat the swelling, but not much happened. I drew around the red areas and nothing seemed to get ?bigger? in terms of redness but the swelling is very visible. He says his arm is sore and doesn?t want anyone to touch it.   We have been applying bentonite clay to the shot area and taking warm Epsom salt baths.",5.0,Kids,0,0
862160,"Foetal exposure during pregnancy; Preterm birth at 32.7 weeks of gestational age; This is an observational study case, initially received from other health professional on 12-Feb-2020, concerning a female neonate subject, whose mother was 38-year-old, female subject of body weight 263 lbs, height 67 inches and body mass index (BMI) 41.2 enrolled in a prospective observational safety study.  The mother's current conditions included increased BMI, hypertension, pain and pregnancy with advanced maternal age and superimposed pre-eclampsia.  The mother's concomitant medications included Prenatal vitamins (unspecified vitamins and minerals) for pregnancy, Tylenol (paracetamol) for pain, labetalol and Procardia (nifedipine) both for hypertension.  The subject's mother had one previous preterm live birth pregnancy. The subject's mother had no maternal or paternal history with major congenital malformations (MCMs) and had no history of offspring with MCM. The subject's mother did not use tobacco, alcohol or illicit drugs during pregnancy.  The mother's last menstrual period (LMP) date was 30-May-2019, the estimated delivery date (EDD) and corrected estimated date of delivery (CEDD) were reported as 06-Mar-2020. The type of pregnancy was singleton. The subject's father was 59-year-old.  On 12-Aug-2019, the subject's mother had an ultrasound scan and no MCMs were noted.  On 24-Sep-2019, at approximately 16 weeks of gestation, the subject's mother was administered Afluria QIV (Flu Vaccine Egg Split QIV CSL) [Influenza vaccine, batch number: P100118566, dose, route of administration, anatomical location and expiration date: not reported] (explicitly coded as Foetal exposure during pregnancy') for an influenza immunisation.  At approximately 32.7 weeks of gestation, the subject's mother delivered a live birth male neonate via caesarean method. The neonate's birth weight was 2693 g, length was 48.3 cm and head circumference was 32.5 cm. The appearance, pulse, grimace, activity, and respiration (APGAR) scores were 5 (one minute), 6 (five minutes) and 9 (ten minutes). No MCM was identified at birth.   At the time of this report, the outcome of the event 'premature birth' was not reported.  The event of 'premature birth' was considered serious due to criterion of medical significance, per company.  The reporter did not provide causality assessment.  This case is linked to the case 202001708 (the corresponding mother case).  Company Comment: A female neonate subject was delivered as premature baby after maternal receipt of Afluria Quadrivalent vaccine at approximately 16 weeks of gestation (considered as foetal exposure during pregnancy). Chronology is incompatible due to very long onset latency over three months. Mother's current conditions of obesity (body mass index 41.2), hypertension, advanced maternal age and superimposed pre-eclampsia may provide more plausible alternative aetiology. Foetal exposure during pregnancy assessed as not related per company's conventions. Considering all the above mentioned, causality between suspect product and the event premature baby is assessed as not related.; Sender's Comments: A female neonate subject was delivered as premature baby after maternal receipt of Afluria Quadrivalent vaccine at approximately 16 weeks of gestation (considered as foetal exposure during pregnancy). Chronology is incompatible due to very long onset latency over three months. Mother's current conditions of obesity (body mass index 41.2), hypertension, advanced maternal age and superimposed pre-eclampsia may provide more plausible alternative aetiology. Foetal exposure during pregnancy assessed as not related per company's conventions. Considering all the above mentioned, causality between suspect product and the event premature baby is assessed as not related.",,Unknown,0,0
894362,"Refer to continuation page. Within hours after my vaccination I began feeling slightly detached from what was going on around me, more like I was observing life rather than participating- - although I was active. This feeling continued and was more noticeable the second day before starting to recede. Right after that I began to discover that I had developed both a lack of recall (names, words) and lack of concentration. I would walk across the kitchen, reach a cupboard and could not remember what I went there to get. Or I would unthinkingly open the wrong cupboard or drawer. Also, I would walk off in the middle of doing something and forget about it until I passed by again and saw my unfinished project.  I began making an effort to remind myself of the names of flowers, trees, etc. in our yard. I looked up names of relatives in our family tree (my husband is the youngest of 11 children). Most of that re-learning has stuck with me, but sometimes not until after repeated times of reminding myself. Some problems have toned down but are still with me. Others still happen repeatedly such as misplacing my cell phone. Occasionally I forget to feed our feral outdoors cat until reminded, or I forget a load of dry clothes in the dryer for a day or two. While I don't require entering a senior eldercare facility, these side effects of the Shingrix vaccine have been a real nuisance.",78.0,Seniors,0,1
905962,"approximately 30 minutes after receiving the vaccine, patient reported development of symptoms including increased HR, chest tightness and mild shortness of breath.  She presented to the ED and was evaluated.  She was given diphenhydramine 25 mg IV x 1 1629, famotidine 40 mg iv x 1 @ 1630, methylprednisolone 125 mg iv x 1 at 1629.  patient was observed for 90 minutes. She was without further symptoms, VSS and she was discharge to home in stable condition at 1800",35.0,Adults,0,1
906544,"Hypertensive to 190/80; shaking; chills; after 30 minutes, BP reduced 159/80; sent to ER; monitored; sent home; resolved, per follow-up call following day.",59.0,Adults,1,0
885152,"mother of Patient brought Patient on 09/21/2020 stating Patient had vomiting and seizure at 9:30pm, 09/18/2020. Seizure lasted about  1 1/2 minute.",8.0,Kids,0,0
861399,"At approximately 3:00 PM, patient was waiting in clinic lobby as instructed for 15 min. post immunization, when she started shaking, loss of pinkness to skin and lips, slow to respond to conversation, unable to sit upright in chair. Patient was carried to exam room and laid down with feet elevated and ice pack applied to back of neck. At 3:25 PM Vital signs taken: BP 75/45, HR 50, Spo2 % 98. After rest, snack, and drink, patient returned to baseline. At 3:50 PM Vitals retaken: BP 85/56, HR 62, Spo2% 100.",11.0,Kids,0,0
864084,"Intrauterine growth restriction; Foetal exposure during pregnancy; This is an observational study case from, initially received from other health professional on 27-Feb-2020, concerning a foetus subject of unknown gender, whose mother was a 21-year-old female, of body weight 154 lbs, height 61 inches and body mass index (BMI) 29.1, enrolled in, a prospective observational safety study.  The subject's mother's past medical history included chlamydia infection. The subject's mother's current medical history included Rh negative, body mass index hight (29.1), nausea and vomiting and gastroesophageal reflux disease (GERD).   The subject's mother's concomitant medications included Prenatal gummy (unspecified vitamins and minerals) for pregnancy, Zantac (ranitidine hydrochloride) for GERD, Unisom (doxylamine succinate) and pyridoxine for nausea and vomiting and Rhogam (anti-d immunoglobulin) for Rh negative.   The subject's mother had no previous pregnancies. The subject's mother had no maternal or paternal history with major congenital malformations (MCMs). The  subject's mother did not use tobacco, alcohol or illicit drugs during pregnancy.   The subject's mother's last menstrual period (LMP) was on 06-Aug-2019. Type of pregnancy was singleton. The estimated delivery date (EDD) of subject's mother was reported as 18-May-2020 and corrected estimated date of delivery (CEDD) was reported as 18-Apr-2020. The subject's father age were not reported.  On 15-Oct-2019, the subject's mother underwent ultrasound and non-invasive prenatal testing (NIPT), and no MCM was noted.   On 21-Nov-2019, the subject's mother underwent maternal serum alpha-fetoprotein screening, and no MCM was noted.   On 03-Dec-2019, the subject's mother underwent 20 week anatomy ultrasound, and no MCM was noted.  On 31-Dec-2019, at approximately 21 weeks of gestation, the mother was administered Afluria QIV (Flu Vaccine Egg Split QIV CSL) [influenza vaccine, batch number: P100112488, dose, route of administration, anatomical location and expiration date: not reported] (explicitly coded as Foetal exposure during pregnancy') for an influenza immunization.   On an unknown date, the pregnancy status was collected and intrauterine growth restriction (IUGR) was noted.  At the time of initial reporting, the outcome of the event fetal growth restriction' was not reported.  The event of  fetal growth restriction' was considered serious due to the criterion of medical significance, per company.  The reporter did not provide causality assessment.  This case is linked to 202001962 (the corresponding mother case).  Company comment: Foetal growth restriction was noted in neonate subject with foetal exposure Afluria QIV. Subject's mother was administered vaccine at approximately 21 weeks of gestation. The event was noted on an unknown date, therefore chronology needs more clarification. With information available, causal role of the suspect vaccine cannot be excluded and is assessed as unlikely related (defaults to ""related"" in the safety database for reporting purposes). Foetal exposure during pregnancy are assessed as unrelated per company's conventions.; Sender's Comments: Foetal growth restriction was noted in neonate subject with foetal exposure Afluria QIV. Subject's mother was administered vaccine at approximately 21 weeks of gestation. The event was noted on an unknown date, therefore chronology needs more clarification. With information available, causal role of the suspect vaccine cannot be excluded and is assessed as unlikely related (defaults to ""related"" in the safety database for reporting purposes). Foetal exposure during pregnancy are assessed as unrelated per company's conventions.",,Unknown,0,0
898202,"a patient was administered two doses of FLUZONE High Dose Quadrivalent after 10 days by mistake from 2 different nurses with no AE; Initial information was received on 09-Oct-2020 regarding an unsolicited valid non-serious case received from a pharmacist via Medical Information (MI) (Reference number- 00309495).   This case involves a 93 years old male patient who was vaccinated with two 0.7 mL doses of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] (lot number: UJ470AB expiry date 30-JUN-2021) via an unknown route and left deltoid administration site on 29-Sep-2020 and left deltoid administration site on 08-Oct-2020 for prophylactic vaccination (extra dose administered) respectively by 2 different nurse.  Medical history, medical treatment, vaccination, family history were not provided.   Concomitant medications included DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID (TDAP) in arm.  It was a case of an actual medication error due to extra dose administered (latency unknown).  At the time of report, no adverse event reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.",93.0,Seniors,0,1
867391,"FORGOT TO TAKE THIRD AND FOURTH DOSE OF VIVOTIF ON TIME; A spontaneous case report was received from a pharmacist on 17-May-2019 for two consumers.  Based on the information obtained from the pharmacist, two individual case safety reports PVX201905-000389 (PVX2019-1238; wife) and PVX201905-000390 (PVX2019-1239, husband) were created and cross-linked in the database.  This case describes a female consumer who ""forgot to take third and fourth dose of Vivotif on time"". The consumer was receiving oral Vivotif (one dose every other day) for typhoid fever prophylaxis.  Case report: The consumer took two doses of Vivotif on 10-May-2019 and 12-May-2019, respectively. Then, she forgot to take the remaining doses.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event ""forgot to take third and fourth dose of Vivotif on time"" was considered as not applicable. ; Sender's Comments: Company's Comment: The causality of the event ""forgot to take third and fourth dose of Vivotif on time"" was considered as not applicable. US-PaxVax Berna GmbH-PVX201905-000390:",,Unknown,1,0
868173,Rash,49.0,Adults,1,0
904232,"high fever, chills, swollen arm, fatigue, nausea",27.0,Adults,1,0
884412,Hives fevers about 4 weeks from when immunization was administered,4.0,Kids,1,0
873579,Started with numbness and tingling from left forearm to fingers approximately 5 minutes post injection. Treatment includes ice pack to injection site and rest on left arm for 15 minutes. Instructed to replace ice pack in 20-30 minutes.,22.0,Adults,0,0
890390,1. Local reaction on injection site 2. Facial redness 3. Lethargy,47.0,Adults,0,0
861358,SWELLING AT INJECTION SITE AND REDNESS ON ARM PROGRESSIVELY WORSENED AFTER FIRST 24-48 HOURS.  NO TREATMENT UP TO NOW. WILL RECOMMEND ICING AND ANTI-INFLAMMATORY MEDICATION.,63.0,Adults,0,0
908777,"Physician called to report an adverse reaction to the COVID-19 vaccine.  Patient  had a 6.5 cm x 6.5 cm reaction at her injection site.   This included erythema, warmth, and swelling.    The patient also reported chills.    Patient's O2 saturation measured at 80% a few hours after the vaccination.   Patient received a liter of oxygen on Saturday and Sunday.    Patient was tested for COVID-19 and had a negative result.    On Monday and Tuesday, patient was given 25mg of oral diphenhydramine as the injection site had not improved.     Patient has a mild history of asthma, but is not currently taking any medications for that condition.",75.0,Seniors,0,0
873352,"4"" area of erythema Inj site",,Unknown,0,0
863214,"Shoulder pain, itching at site.",71.0,Seniors,1,0
890952,"10/16- report of sudden onset of right sided facial and eye drooping, declined to go to ER for evaluation .  Symptoms persisted over the weekend, seen by physician this morning, prescribed  60 mg oral prednisone.",94.0,Seniors,0,0
899434,"extreme exhaustion; This case was reported by a consumer via interactive digital media and described the occurrence of exhaustion in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced exhaustion. On an unknown date, the outcome of the exhaustion was recovered/resolved.   It was unknown if the reporter considered the exhaustion to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as per the vaccine indication. After received the 2nd dose of Shingrix the patient experienced extreme exhaustion which lasted almost 2 days. The patient asked was this part of the side effects.",,Unknown,0,1
884705,"Roughly 3 hours after vaccination I developed chills, body aches, and a measured fever of 39.1 C. The fever lasted roughly 6 hours; remaining symptoms largely resolved 12 hours after onset.",34.0,Adults,1,0
883311,"Patient received vaccination on 9/10 and reported feeling symptoms shortly after receiving vaccine. She reported extreme fatigue, dizziness, nausea, and vomiting. Her arm showed a 3inx3in bruised area, with the surrounding tissue being red and inflamed. Patient reported never having reactions to vaccines in the past. Symptoms continued throughout the next day (9/11) and resolved on their own by 9/12. The arm is still bruised on 9/12 but patient states no other symptoms present, and cannot even feel the bruise. Advised patient to use OTC pain relief and ice packs for the pain.",69.0,Seniors,0,0
873875,"SEVERE HEADACHE; JOINT PAIN; NAUSEA; VOMITING; FEVER; This case was reported by a nurse via call center representative and described the occurrence of headache in a 17-year-old female patient who received Men B NVS (Bexsero) for prophylaxis.   On 9th June 2020, the patient received Bexsero. In June 2020, less than a week after receiving Bexsero, the patient experienced headache, joint pain, nausea, vomiting and fever. On an unknown date, the outcome of the headache, joint pain, nausea, vomiting and fever were not recovered/not resolved.   It was unknown if the reporter considered the headache, joint pain, nausea, vomiting and fever to be related to Bexsero.  Additional details were provided as follows: The reporter was the patient's grandmother who was also a nurse.  The patient received Bexsero and had severe headache, joint pain, nausea, vomiting and fever. The patient was experiencing all the symptoms after receiving this vaccine and not certain when the symptoms presented.   The reporter was concerned about patient symptoms which had not resolved. The reporter did not consent to follow up.",17.0,Kids,0,0
865035,"had a lot of pain after the first injection; This case was reported by a nurse and described the occurrence of pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced pain. On an unknown date, the outcome of the pain was recovered/resolved.   It was unknown if the reporter considered the pain to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient received 1st dose of vaccine and experienced lot of pain. The patient also received 2nd dose and wanted to administered tylenol but immunization coordinator who administered the vaccine told that if she receive tylenol before the pain in her arm  started, the strength of the vaccine would be weakened",,Unknown,0,0
903110,"Suspected Vaccination failure; sore shoulder; blister; shingles blister; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis, PNEUMOCOCCAL PNEUMONIA VACCINE for prophylaxis and PNEUMOCOCCAL VACCINE (PNEUMOCOCCAL PNEUMONIA VACCINE) for prophylaxis.   On an unknown date, the patient received Shingles vaccine, Influenza vaccine Quadrivalent unspecified season, PNEUMOCOCCAL PNEUMONIA VACCINE and PNEUMOCOCCAL PNEUMONIA VACCINE. On an unknown date, unknown after receiving Shingles vaccine and not applicable after receiving Influenza vaccine Quadrivalent unspecified season, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, shoulder soreness and blister. On an unknown date, the outcome of the vaccination failure and shoulder soreness were unknown and the outcome of the shingles and blister were recovered/resolved.   It was unknown if the reporter considered the vaccination failure, shingles, shoulder soreness and blister to be related to Shingles vaccine. It was unknown if the reporter considered the shingles, shoulder soreness and blister to be related to Influenza vaccine Quadrivalent unspecified season.  Additional details were received as follows: The age at vaccination was not reported. The patient received flu vaccine, shingles vaccine, both kinds of pneumonia vaccine, and had sore shoulder. Also one shingles blister which lasted 2 days and went away. This case was considered as suspected vaccination failure as completion of primary vaccination schedule, time to onset and laboratory confirmation test were unknown at the time of reporting.  It was unknown if the reporter considered the shingles, shoulder soreness and blister to be related to Pneumococcal vaccine.",,Unknown,0,1
910658,"the following morning after receving the vaccination at around 0300 the patient developed Fv TMax 101.8 F along with chils, body aches, nausea and diarrhea. These symptoms lasted around 36 hours with the patient taking acetaminophen regularly.",64.0,Adults,1,0
870804,"Wed 5/13/20: around midnight, ~13-15 hrs after late 4-mo shot series was given at age 6 mos 1 day, he woke w/an emesis, mom felt tactile temp, checked him & had a mild temp of 101. Gave Tylenol & slept. Thursday 5/14/20: Tmax 101.8, controlled w/Tylenol. Afeb off Tylenol by evening of 5/14 w/temp 98 around 1800 hrs Thursday, 5/14. Friday 5/15/20 around 1400 hrs: was being fed when mom noted arms out akimbo w/shaking in a vibratory manor of arms, less so in bilateral legs, & eyes rolled up & was unresponsive for ~45 secs. No gagging or emesis prior to sz & no cyanosis of perioral area.  Sz activity stopped, eyes were closed but tried to feed again. After a few secs had recurrent seizure type, but just lasted 5-10 secs. Slept thereafter for 10-20 mins & has been fine since as of parent calling me at ~1530 hrs. Told to take to Immediate Care for recurrent fever over 100.4, or a recurrent seizure of >=60 secs.",0.5,Kids,0,1
878657,"I had 99.5F on 7/31/2020. 0n 8/1/2020, my fever spiked to 101.5F. I went to Urgent Care. The prescribed Keflex and Doxycycline and Tylenol. My fever came down but the swelling in my arm got worse. It was about the diameter of a baseball and red and hot. I contacted my PCP on 8/3/2020 and she told me to continue the antibiotics. The fever dropped but the redness and swelling continued. By 8/6, I had more red patches appearing near the injection site. The original site grew as well. Mt PCP took me off of the antibiotics and now has me on Prednisone and Benadryl since last night. By this morning it faded a little bit.",54.0,Adults,0,0
912467,"rash; This is a spontaneous report from a contactable pharmacist. A patient of unspecified age and gender received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient experienced rash after first vaccine on an unspecified date with outcome of unknown.    Information on the lot/batch number has been requested.",,Unknown,0,0
885821,"Shortly after receiving vaccine patient experienced redness, warmth & aches at injection site. This last a couple of days before a welt developed down the arm towards bicep area. This also was very warm. Patient iced areas and it all resolve 3 days after injection. Patient also experienced nausea.",67.0,Seniors,0,0
915483,"Fatigue, paresthesia in the lower extremity, muscle aches. Of note did have COVID within 35 days of receiving the vaccine but working in a Nursing home.",33.0,Adults,0,0
879498,"Patient presented with complaints that 3 days after she received the vaccine her arm became red, warm to the touch and itchy and has not improved. At todays visit her left arm exhibited redness for about 2/3 of the area from the shoulder to the elbow.    Patient was prescribed : cephalexin 500mg tablet take 1 tablet by mouth every 12 hours for 10 days Benadryl 25 mg capsules take 2 capsules by mouth every 4-6 hours as needed for 3 days",72.0,Seniors,0,1
891871,PATIENT RECEIVED HER FIRST FLU SHOT (FLUAD QUAD) ON 9/25/20. SHE THEN CAME IN SIX DAYS LATER AND ASKED FOR HER FLU SHOT. SHE RECEIVED TWO DOSE OF THE FLUAD QUAD IMMUNIZATION. PATIENT DID NOT EXPERIENCE ANY ADVERSE REACTIONS FROM EITHER IMMUNIZATION. DOCTORS OFFICE WAS NOTIFIED.,82.0,Seniors,0,1
858175,Patient says she still feels the pain at the injection site after 3 month.,62.0,Adults,1,0
863371,Patient started experiencing pain in the vaccinated arm as well as redness below the injection site on the left upper arm.,73.0,Seniors,1,0
872921,rash and bluish feet the evening of  vaccines.  Rash gone in 15 minutes. No fever baby acting normally,0.33,Kids,0,0
897638,aching and tireness on Tuesday up to Thrusday. Itchy throat starting 11/18th and got worse on 11/19,59.0,Adults,0,0
894766,Patient came on 11/02/2020 telling that his arm was red and a little sored. I asked if it was hot and he answered it was a little hot. He said the symptoms developed the day after the vaccination. I suggested him to go to his doctor for an examination of the area.,68.0,Seniors,0,0
867587,"TOOK ONLY ONE DOSE; TOOK DOXYCYCLINE WHILE ON VIVOTIF; This spontaneous case (PVX2019-905) was received from a nurse on 16-Apr-2019. It describes a 71-year-old elderly male consumer who ""took only one dose"" and ""took doxycycline while on Vivotif"". The consumer was receiving Vivotif for an unknown indication and doxycycline for Lyme disease exposure.   Case report: The consumer took a dose of Vivotif about 2.5 weeks ago from the date of report and then after few days (not more than two days), he had an exposure to Lyme disease. As a prophylaxis, he took doxycycline for 2 weeks.   Action taken with Vivotif and doxycycline was not applicable.  The clinical outcome of the events ""took only one dose"" and ""took doxycycline while on Vivotif"" was unknown.   Company's Comment: The causality of the event ""took only one dose"" and ""took doxycycline while on Vivotif"" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event ""took only one dose"" and ""took doxycycline while on Vivotif"" was considered as not applicable.",,Unknown,0,0
890684,"sore in the injection site; This case was reported by a physician via call center representative and described the occurrence of injection site pain in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, less than 2 months after receiving Shingrix, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was recovered/resolved.   It was unknown if the reporter considered the injection site pain to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient received the 1st dose and experienced sore in the injection site.  The reporter did not consent to followup.  This case has been linked with US2020204752 and US2020AMR206445 reported by same reporter. For tolerance of 2nd dose refer case US2020AMR206625.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020204752:same reporter (reporters case)",,Unknown,1,0
865447,"pneumonia; vitreous floaters; blepharitis; shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. On or about 21-APR-2012, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (dose, route, lot # and expiration date not provided) as recommended for routine adult health maintenance and for the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX), patient suffered a rash and visual impairment and was diagnosed with shingles, vitreous floaters and blepharitis. In the weeks following these diagnoses, patient additionally suffered and was diagnosed with pneumonia. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), patient's symptoms have resulted in physical limitations not present prior to using the vaccine. Plaintiff also experiences mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), patient sustained severe and permanent personal injuries. Further, as a tragic consequence of wrongful conduct, patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events was not recovered. Causality assessment between the events and zoster vaccine live (ZOSTAVAX) was related.  Upon internal review, pneumonia was considered to be medically significant.",,Unknown,0,0
913059,"Vaccine date 17, migraine headache 18th, followed by a week of body aches, sweating, fatigue, headache. Loss of smell not sure when was the exact date but Christmas when I 100% noticed so smell. Tested 26 and results received today the 29th",28.0,Adults,0,0
865215,"No additional adverse effect reported; patient received a dose of improperly stored ROTATEQ; This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender. Information about patient's pertinent concurrent conditions, medical history, concomitant medications and previous drug reactions and allergies was not reported.  On 04-MAR-2020, the patient was vaccinated with an improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) 1 dose, orally (concentration  and vaccination scheme frequency were not reported; lot number 1660942 and expiration date 06-FEB-2021) as prophylaxis. No adverse effects were reported for the patient.  According to the reporter, the multiple temperature excursion was below 2 degrees Celsius (1.28 degrees Celsius) for a time frame of 2 hours and 30 minutes on an unspecified date (product storage error), without any previous temperature excursion; which was detected by a digital data logger.",,Unknown,0,1
890726,"approximately 6 cm wheal on left upper arm at vaccine site hives on torso, legs, chest, back treatment: prednisone, diphenhydramine, Reglan, cetirizine",59.0,Adults,0,1
891858,"fever of 100.8 degrees; diarrhea; body aches; This case was reported by a consumer via call center representative and described the occurrence of fever in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of pain (1st dose received on an unknown date, refer case US2020205665).   On 11th October 2020, the patient received the 2nd dose of Shingrix. In October 2020, 12 hrs after receiving Shingrix, the patient experienced fever, diarrhea and general body pain. Rechallenge with Shingrix was positive. In October 2020, the outcome of the fever, diarrhea and general body pain were recovered/resolved.   It was unknown if the reporter considered the fever, diarrhea and general body pain to be related to Shingrix.  Additional details were provided as follows: It was reported that on 12th October 2020, 12 hours after the 2nd dose ,the patient experienced fever of 100.8 degrees and experienced diarrhea.  The reporter did not consent to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020205665:same reporter",69.0,Seniors,1,0
906076,"About 1-2 hours after receiving the vaccine, I began to have tongue Hb and throat swelling?mild to moderate. About 3-4 hours later, I had one episode of diarrhea, followed by chills and palpitations. I took Benadryl and Zantac around 8P.  When I woke up in the morning, I still had tongue and throat swelling (no trouble breathing), so went to the ER and was treated for an allergic reaction with IV Benadryl, Solumedrol, and Pepcid.",38.0,Adults,0,0
900095,"Individual stated that during the time of vaccination, the vaccinator had difficulty getting the medication injected through the needle to the skin. Individual stated that the vaccine was cold which could have caused the pain and discomfort. Individual has not been able to really use her arm, has a lot of pain, throbbing, and discomfort, the pain is worse at night time and keeps her up because of it. Individual stated that it hurts worse at night. Individual did have physical therapist check it out but nothing was resolved. Flu Shot Coordinator suggested seeing PCP.",83.0,Seniors,0,0
913339,"I took the vaccine on 12/23/20 and the next day I was woken up around 4:30 am by a horrible dizziness, I felt weak, nauseous, and on later days had diarrhea for a day and headaches while the dizziness continued, I decided to go to an urgent care spot facility on 12/29/20 where the doctor prescribed me meclizine 12.5 mg and rest. I still feel dizzy but not as bad as the first day.",30.0,Adults,0,0
909572,Chest pain associated with flare up of SLE (lupus)  Hospitalized 9/25/20.  Advised not to get 2nd vaccine shot.,77.0,Seniors,0,0
872727,"Headache began within 20miutes, Gradually increasing in pain over 2 hours. Dizzyness began around 2 hours. Pain in shoulder and neck became excruciating and 2 Extra Strength Tylenol were taken for pain at 9 PM to little effect. At 11 PM shivering began in back muscles, quickly ramped up to full body uncontrollable seizures which caused my back to bend backwards and made walking and arm use impossible and breathing difficult. This lasted for THREE HOURS. Finally subsided back to normal shivering. Fever of 100.3 was noted at 5AM on 6/04. ALL joints painful, eyes and mouth very dry, long bones in legs and arms hurt to touch. Headache very bad and shoulder of injection site and neck felt like broken glass. Joint pain and headache very bad all day. Fever stayed up until 5pm on  6/05,  and then subsided to 99.8. On 5AM of 6/05 fever and headache was gone but joint pain and residual stiffness and pain in spine and joints remain to this day.",65.0,Adults,0,1
875874,"no adverse side effects; one month old patient received 2 doses of Recombivax in the hospital; This spontaneous report was received from a medical assistant and refers to an 1-month-old patient of unknown gender. The patient's pertinent medical history, drug reactions, allergies and concomitant therapies were not reported. On 23-JUN-2020, the patient was in the hospital and received 2 doses of hepatitis b vaccine (recombinant) (RECOMBIVAX HB) (for both lot #, expiration date, strength, dose, site and route of administration were not provided) for prophylaxis (extra dose administered). No adverse side effect was reported.",0.08,Kids,0,1
867441,"TOOK AN UNREFRIGERATED DOSE OF VIVOTIF; This spontaneous case (PVX2019-1252) was received from a caregiver on 20-May-2019. It describes a 17-year-old female consumer who ""took an unrefrigerated dose of Vivotif"". The consumer was receiving oral Vivotif (one dose every other day) for typhoid fever prophylaxis.  Case report: The consumer did not refrigerate Vivotif doses for several weeks and then she took the first dose on 19-May-2019.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event ""took an unrefrigerated dose of Vivotif"" was considered as not applicable. ; Sender's Comments: Company's Comment: The causality of the event ""took an unrefrigerated dose of Vivotif"" was considered as not applicable.",,Unknown,1,0
902577,"get sick; Initial information received on 20-Nov-2020 regarding an unsolicited valid non-serious case received from a consumer (patient) via social media.  This case involves a patient (unknown demographics) who got sick (illness), when received INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer batch number and expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient got sick (illness) (unknown latency) following the administration of INFLUENZA VACCINE.  It was reported that he/she will not get the flu vaccine because he/she  get sick from the flu shot, yes and do have problems with the flu vaccine. Every year that patient don't get the flu shot, don't get sick and every year when the patient gets the flu vaccine gets sick.  Laboratory details were not reported.   It was not reported if the patient received a corrective treatment.  The event outcome was unknown for illness.  There will be no information available on the batch number for this case.",,Unknown,0,1
903605,"Headache and increased HR followed by dizziness (room spinning), and throat tightening. Evaluation  in vaccination clinic revealed tachycardia and elevated BP. Brought to ER to monitor throat tightening. Upon trip to ER (roughly one minute), experienced nausea. Experienced chest pain after being admitted to ER, roughly 20 minutes after vaccination. Chest tightness and throat swelling lasted for roughly about 30 minutes. All symptoms subsided with the exception of the headache about an hour after injection.  Discharged from ER and went back to work. Headache continued into the afternoon, along with general weakness.",23.0,Adults,1,0
874901,Menveo powder was mixed with sterile water diluent instead of provided diluent by healthcare worker in the facility.  No adverse reaction or response occurred while patient in the office.  We called GlaxoSmithKline and notified of error.  Representative that took information states that no adverse reaction should occur and replacement Menveo needs to be given.  This can be given at anytime and is not time sensitive based on dose given today.,11.0,Kids,0,0
904406,"Recurrence of the exact symptoms I had when I had COVID in March, 2020, but less intense and for only one day.  These were severe fatigue and wet cough.  No fever. It was like deja vu, but only lasted 24 hours.  No other new symptoms.",71.0,Seniors,1,0
894233,62 YOM who had his first shingrix vaccine 2 months ago (8/13/2020). The following day developed hearing loss in his right ear which recovered after 3 days. He has normal hearing now.,62.0,Adults,0,1
885791,"Rash, warm to the touch, minor swelling",79.0,Seniors,1,0
903539,"Injection site reaction. Mild localized redness and swelling. Reaction occurred on 12/15, the day after receiving 1st dose of Pfizer covid vaccine. Day 4 12/18 injection site is circular redness, approx 2.5 inches in diameter. Mild discomfort, not painful not itchy. Have been applying over the counter 1% hydrocortisone cream with some relief.",28.0,Adults,0,0
888285,"Administration of an expired PNEUMOVAX 23 vaccine; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's medical history, historical drugs, previous drug reactions, allergies, concurrent conditions, and concomitant therapies were not reported.  On 30-SEP-2020, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) 1 injection form, lot # R034248, expiration date on 07-AUG-2020 (Expired vaccine used) for prophylaxis (strength, frequency, route of administration, and anatomical location were not reported).  combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: R034248; expirationdate: 07-AUG-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",,Unknown,0,1
914737,"Fever of 101.6 and 100.3 the next day, tired muscle aches, chills.  Ibuprofen helped (span of two days)",61.0,Adults,1,0
879569,"Patient states that area where the vaccine was given started off being very sore. She states that on 8/15/20 hives began on the area that she had received the vaccine. She states today (8/16/20) that the hives have subsided and the area is slightly swollen, has larger red patches around the vaccine site, and is warm to the touch. She states the adverse effects are not bothersome.",61.0,Adults,0,1
877062,"On 7/18, he had redness and swelling, warm to touch around injection site. 7/19 increased in size, arm painful and stiff neck.  Warmth and erythema increased to 3x5in. Did not increase in size after Zyrtec. 7/20, redness and swelling almost all gone, injection site still firm and warm. c/o left side neck pain with movement 7/19-7/20, mostly hurting when moving and turning to left. Some nausea, no vomiting.",12.0,Kids,1,0
871275,"an unspecified patient was administered the third dose of ROTATEQ at age 8 and a half months old on an unspecified date.; This spontaneous report was received from a physician referring to an 8 and a half month years old patient of unknown gender. The patient's concurrent condition, pertinent medical history, concomitant medication, drug reactions or allergies were not reported.   On an unknown date, the patient was administered the third dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (strength, dose, route, batch/lot# and expiration date were not reported) for prophylaxis (inappropriate age at vaccine administration). The physician was in another country . The physician was warm conferenced to Merck.",,Unknown,0,1
914702,She claims that she felt a swelling in her throat approximately 10 minutes after receiving her COVI-19 vaccine.,47.0,Adults,0,1
893153,"large red area and hard knot; large red area and hard knot; knot; This case was reported by a pharmacist via call center representative and described the occurrence of erythema in an unspecified number of patients who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced erythema, induration and mass. On an unknown date, the outcome of the erythema, induration and mass were recovered/resolved.   It was unknown if the reporter considered the erythema, induration and mass to be related to Shingrix.  Additional deatils were provided as follows: The age at vaccination was not applicable to this report. The unknown number of patients were vaccinated with 1st dose of Shingrix. After vaccination patients experienced large red area and hard knot. The symptoms were started day or day after vaccination and lasted about 3 days. No further details available. This was 1 of 4 cases reported by same reporter. The reporter consent to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020209432:same reporter US-GLAXOSMITHKLINE-US2020209416:same reporter US-GLAXOSMITHKLINE-US2020209436:same reporter",,Unknown,0,0
902347,"patient got it and been sicker then crap for 2 weeks; Initial information received on 13-Nov-2020 regarding an unsolicited valid non-serious social media case received from a consumer.  This case involves a patient who got sicker then crap for 2 weeks (illness), while she received INFLUENZA VACCINE.  The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided.   Concomitant medications were unknown.  On an unknown date,the patient received a dose  of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, patient got sicker then crap for 2 weeks (illness) (Unknown latency) following the administration of INFLUENZA VACCINE and been isolating for at least that long no call back for covid test so taking it as negative.  Relevant laboratory data was not reported.  It was not reported if the patient received any corrective treatment.  The outcome was unknown for event.  There will be no information available on the batch number for this case.",,Unknown,0,1
901445,"Patient had no AE to the 1st Shingrix.  Patient AE started 2 hours after injection.  Dry heaves, diarrhea, hands wouldn't stop shaking, body aches all over, excessive sneezing, could hardly walk. Patient referred to Dr. Advised to take Tylenol. Patient slept. Patient feels a little better each day except joints hurt.",87.0,Seniors,0,1
856462,"shingles; This spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient (pt) of an unknown age. The pt's concurrent conditions, medical history and concomitant medications were not reported. On an unknown date in 2013, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (exact dose, site and route of administration, lot# and expiration date were not provided) as prescribed and/or administered by a pharmacist for long-term prevention of shingles and/or zoster-related conditions. Subsequent to the pt's zoster vaccine live (ZOSTAVAX) inoculation, she was treated by a healthcare provider for shingles. As a direct and proximate result of the pt's use of zoster vaccine live (ZOSTAVAX) vaccine, she had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of the event was not recovered. the relatedness between the event and zoster vaccine live (ZOSTAVAX) was related.",,Unknown,0,0
897680,"improperly stored PEDVAX HIB, GARDASIL, GARDASIL 9 and MMR II; No additional AE/PQCS reported.; This spontaneous non-valid report was received from a nurse and refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical histories provided. On unknown dates, the patients were vaccinated with improperly stored doses of: - haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) lot # T000883, expiration date 28-MAY-2022 (dose and route of administration were not reported), administered doses of vaccines experienced the temperature excursion of below 36 (35.2) degrees Fahrenheit for 14 minutes; - quadrivalent human papillomavirus (types 6,11,16,18) recomb. Vaccine (GARDASIL) (lot number, expiration date, dose and route of administration were not reported), administered doses of vaccines experienced the temperature excursion of below 36 (35.2) degrees Fahrenheit for 14 minutes; - hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), lot # 1637648, expiration date 19-JUN-2022 (dose and route of administration were not reported), administered doses of vaccines experienced the temperature excursion of below 36 (35.2) degrees Fahrenheit for 14 minutes; - measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), lot # S015428, expiration date 20-MAY-2021, albumin status recombinant Human albumin (rHA) (dose and route of administration were not reported), administered doses of vaccines experienced the temperature excursion of minus 58 and plus 46 (35.2) degrees Fahrenheit for 14 minutes. There was no adverse effect reported. Data logger was involved. There were no previous excursions reported. This case is non-valid due to non of patients' identifier provided. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: 1637648; expirationdate: 19-JUN-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability",,Unknown,0,1
897857,"Patient states that after a few  days after receiving the shot she had the area swollen. That it became red ,hot and very inflamed as days went by. She states that she has had MRI studies, Doppler studies as well as been on morphine and steroid shots and the pain is still severe and getting worse. They are thinking that she had an allergic reaction to the fluzone hd shot.",87.0,Seniors,1,0
869523,"Fever, chills, body aches for 10 hours, headache, tiredness, swelling of lips/gums/fingers/toes for 3 hours, mild nausea",58.0,Adults,1,0
899639,"Patient presents with prolonged injection site pain that spreads to her left upper arm/shoulder/neck area. The pain comes and goes away through out the day. The pain gets worse when she lifts her arm, and /or puts on clothes. She hasn't taken any medications or seen a doctor to help treat the pain. She has only been watching-waiting the pain hoping that it goes away.",58.0,Adults,1,0
903119,"Around 1 am dov, I started trembling very bad. Was weak and couldnt lift my head off the pillow. Then an hour later, I started feeling like I was getting a fever. I checked my temp, and I did have a fever. Trembling lasted a couple of hours.  I had extreme fatigue, had to lay down and stay home from work for 2 days cause of me being so weak and fatigue. Fever lasted on and off for a little over 24hrs.  Then after I got pass the fever, I have a really bad headache. I still have a headache. I took tylenol for the fever. Then last night, I took some Benadryl to calm the reactions.  My upper arm is still  a little swollen and is still sore.",53.0,Adults,0,0
